assay_id,doc_id,description,assay_type,assay_test_type,assay_category,assay_organism,assay_tax_id,assay_strain,assay_tissue,assay_cell_type,assay_subcellular_fraction,tid,relationship_type,confidence_score,curated_by,src_id,src_assay_id,chembl_id,cell_id,bao_format,tissue_id,variant_id
1,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615117,,BAO_0000019,,
2,684,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615118,,BAO_0000219,,
3,15453,,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615119,,BAO_0000019,,
4,17841,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,B,,,Bos taurus,9913.0,,,,,104729,H,4,Autocuration,1,,CHEMBL615120,,BAO_0000249,,
5,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615121,163.0,BAO_0000219,,
6,17430,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615122,163.0,BAO_0000219,,
7,13799,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,F,,,Mus musculus,10090.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615123,163.0,BAO_0000219,,
8,17774,In vitro cell cytotoxicity was determined against 143B cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615124,163.0,BAO_0000219,,
9,3801,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615125,163.0,BAO_0000219,,
10,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615126,163.0,BAO_0000219,,
11,17430,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Intermediate,1,,CHEMBL615127,163.0,BAO_0000219,,
12,17774,In vitro cell cytotoxicity was determined against 143B-LTK cell line,F,,,Homo sapiens,9606.0,,,143B,,80001,N,1,Expert,1,,CHEMBL615128,163.0,BAO_0000219,,
13,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL857900,,BAO_0000218,,
14,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615129,,BAO_0000218,,
15,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615130,,BAO_0000218,,
16,11324,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",F,,,Staphylococcus aureus,1280.0,,,,,50185,N,1,Intermediate,1,,CHEMBL615131,,BAO_0000218,,
17,11347,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100122,D,9,Expert,1,,CHEMBL884521,,BAO_0000357,,
18,16474,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615132,,BAO_0000357,,
19,10091,Inhibition of partially purified 15-lipoxygenase from human leukocytes,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615133,,BAO_0000019,,
20,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615134,,BAO_0000357,,
21,16474,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615135,,BAO_0000357,,
22,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615136,,BAO_0000357,,
23,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615137,,BAO_0000357,,
24,16474,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,B,,,,,,,,,12054,H,8,Autocuration,1,,CHEMBL615138,,BAO_0000357,,
25,14352,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL836324,,BAO_0000219,,
26,5646,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615139,,BAO_0000357,,
27,5646,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),B,,,Oryctolagus cuniculus,9986.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615140,,BAO_0000357,,
28,10997,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12426,H,8,Autocuration,1,,CHEMBL615141,,BAO_0000219,,
29,6309,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,B,,,soya bean,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615142,,BAO_0000357,,
30,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615143,,BAO_0000357,,
31,167,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615144,,BAO_0000357,,
32,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL872867,,BAO_0000357,,
33,11087,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615145,,BAO_0000357,,
34,13622,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615146,,BAO_0000357,,
35,13622,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL615147,,BAO_0000357,,
36,11347,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615148,,BAO_0000019,,
37,5926,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,B,,,Escherichia coli,562.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615149,,BAO_0000019,,
38,4567,Dissociation constant with dimeric 16S rRNA RNA construct B,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615150,,BAO_0000019,,
39,3782,Dissociation constant towards 16S rRNA construct A,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615151,,BAO_0000225,,
40,3782,Dissociation constant towards 16S rRNA construct B,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615152,,BAO_0000225,,
41,4466,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615153,,BAO_0000225,,
42,6592,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,B,,,Escherichia coli,562.0,,,,,100263,M,3,Expert,1,,CHEMBL615154,,BAO_0000225,,
43,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615155,,BAO_0000019,,
44,898,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL615156,,BAO_0000019,,
45,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615157,,BAO_0000019,,
46,13163,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,B,,,Homo sapiens,9606.0,,,,,20001,H,8,Autocuration,1,,CHEMBL615158,,BAO_0000019,,
47,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615159,,BAO_0000019,,
48,10691,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615172,,BAO_0000019,,
49,10691,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615173,,BAO_0000019,,
50,10691,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",B,,,Rattus norvegicus,10116.0,,,,,12971,D,9,Expert,1,,CHEMBL615174,,BAO_0000019,,
51,898,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),B,,,,,,,,,13053,H,8,Autocuration,1,,CHEMBL884518,,BAO_0000019,,
52,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615175,,BAO_0000357,,
53,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615176,,BAO_0000357,,
54,912,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,B,,,,,,,,,11512,H,8,Autocuration,1,,CHEMBL615177,,BAO_0000357,,
55,15103,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104740,D,5,Autocuration,1,,CHEMBL615178,,BAO_0000249,,
56,5116,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615179,506.0,BAO_0000219,,
57,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104835,D,7,Autocuration,1,,CHEMBL615180,,BAO_0000219,,
58,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104821,D,7,Autocuration,1,,CHEMBL615181,,BAO_0000219,,
59,14578,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,F,,,Rattus norvegicus,10116.0,,,Oocytes,,104848,D,7,Autocuration,1,,CHEMBL615182,,BAO_0000219,,
60,4787,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615183,506.0,BAO_0000219,,
61,4787,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615184,506.0,BAO_0000219,,
62,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615185,506.0,BAO_0000219,,
63,3547,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615186,506.0,BAO_0000219,,
64,6726,Effective dose of compound against replication of 1A9 cell line was evaluated,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615187,506.0,BAO_0000219,,
65,3455,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL885343,506.0,BAO_0000219,,
66,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615188,506.0,BAO_0000219,,
67,5726,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615189,506.0,BAO_0000219,,
68,5726,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615190,506.0,BAO_0000219,,
69,3395,Inhibitory activity against Taxol resistant 1A9 cell lines,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615191,506.0,BAO_0000219,,
70,3415,Cytotoxicity against human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615192,506.0,BAO_0000219,,
71,3415,Percentage inhibition of human ovarian cancer (1A9) cell lines.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL827083,506.0,BAO_0000219,,
72,17099,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Expert,1,,CHEMBL615193,506.0,BAO_0000219,,
73,17099,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615194,506.0,BAO_0000219,,
74,17099,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615195,506.0,BAO_0000219,,
75,17099,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,F,,,Homo sapiens,9606.0,,,1A9,,80002,N,1,Intermediate,1,,CHEMBL615196,506.0,BAO_0000219,,
76,17721,Inhibitory concentration against Jurkat cells,F,,,Homo sapiens,9606.0,,,Jurkat,,81072,N,1,Intermediate,1,,CHEMBL615197,503.0,BAO_0000219,,
77,1229,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615198,,BAO_0000019,,
78,11347,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,A,,,Rattus norvegicus,10116.0,,,,,100121,D,9,Expert,1,,CHEMBL615199,,BAO_0000357,,
79,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615200,,BAO_0000357,,
80,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615201,,BAO_0000357,,
81,17117,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",B,,,,,,,,,11231,H,8,Expert,1,,CHEMBL615202,,BAO_0000357,,
82,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615203,,BAO_0000251,,
83,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",B,,,Candida albicans,5476.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615204,,BAO_0000251,,
84,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615205,,BAO_0000251,,
85,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",B,,,Saccharomyces cerevisiae,4932.0,,,,Microsomes,11231,H,8,Autocuration,1,,CHEMBL615206,,BAO_0000251,,
86,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",B,,,Sus scrofa,9823.0,,Liver,,Microsomes,12083,H,8,Autocuration,1,,CHEMBL615207,,BAO_0000251,2107.0,
87,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL827084,,BAO_0000019,,
88,791,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615208,,BAO_0000019,,
89,791,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",B,,,Rattus norvegicus,10116.0,,,,,11231,H,8,Autocuration,1,,CHEMBL615209,,BAO_0000019,,
90,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615210,,BAO_0000251,2107.0,
91,11375,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615211,,BAO_0000251,2107.0,
92,153,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12083,D,9,Autocuration,1,,CHEMBL615212,,BAO_0000251,2107.0,
93,8269,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615213,,BAO_0000357,,
94,8269,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,B,,,,,,,,,11377,H,8,Expert,1,,CHEMBL615273,,BAO_0000357,,
95,17653,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Expert,1,,CHEMBL615274,726.0,BAO_0000219,,
96,14277,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615275,726.0,BAO_0000219,,
97,1717,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615276,726.0,BAO_0000219,,
98,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615277,726.0,BAO_0000219,,
99,14091,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615326,726.0,BAO_0000219,,
100,17653,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,F,,,Hepatitis B virus,10407.0,,,,,50606,N,1,Expert,1,,CHEMBL883130,,BAO_0000218,,
101,13105,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL884519,726.0,BAO_0000219,,
102,1717,Concentration required to inhibit 50% of 2.2.15 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615327,726.0,BAO_0000219,,
103,13105,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,A,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615328,726.0,BAO_0000219,,
104,13600,Cytotoxic activity of compound against uninfected 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615329,,BAO_0000218,,
105,13467,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615330,,BAO_0000218,,
106,17477,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",F,,,Hepatitis B virus,10407.0,,,2.2.15,,50606,N,1,Expert,1,,CHEMBL615331,,BAO_0000218,,
107,1593,In vitro anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615332,,BAO_0000218,,
108,1593,In vitro anti-HBV activity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615333,,BAO_0000218,,
109,15089,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615334,,BAO_0000218,,
110,15089,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615335,,BAO_0000218,,
111,1593,Cytotoxicity in 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615336,,BAO_0000218,,
112,1593,Cytotoxicity in 2.2.15 cells; Not determined,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615337,,BAO_0000218,,
113,13600,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615338,,BAO_0000218,,
114,13467,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615339,,BAO_0000218,,
115,13467,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,F,,,Homo sapiens,9606.0,,,2.2.15,,50587,N,1,Intermediate,1,,CHEMBL615340,,BAO_0000218,,
116,14764,Antiviral activity against HBV was determined in 2.215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615341,726.0,BAO_0000219,,
117,6531,Inhibition of 20-HETE synthesis in human renal microsomes,B,,,Homo sapiens,9606.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL615342,,BAO_0000251,,
118,17322,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615343,,BAO_0000019,,
119,17072,Inhibitory concentration against 2008 (ovarian) cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615344,388.0,BAO_0000219,,
120,16936,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615345,388.0,BAO_0000219,,
121,16936,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615346,388.0,BAO_0000219,,
122,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615347,388.0,BAO_0000219,,
123,17146,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,F,,,Homo sapiens,9606.0,,,2008,,80612,N,1,Intermediate,1,,CHEMBL615348,388.0,BAO_0000219,,
124,10797,In vitro inhibition of 2008/R ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL827085,561.0,BAO_0000219,,
125,10797,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/R,,80613,N,1,Intermediate,1,,CHEMBL615349,561.0,BAO_0000219,,
126,10797,In vitro inhibition of 2008/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615350,389.0,BAO_0000219,,
127,10797,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,F,,,Homo sapiens,9606.0,,,2008/S,,80614,N,1,Intermediate,1,,CHEMBL615351,389.0,BAO_0000219,,
128,4823,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Expert,1,,CHEMBL615352,,BAO_0000220,,
129,12912,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,B,,,Homo sapiens,9606.0,,,,,100256,S,2,Intermediate,1,,CHEMBL615353,,BAO_0000220,,
130,2957,Inhibition of chymotrypsin-like activity of 20S proteasome,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615354,,BAO_0000220,,
131,2957,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,B,,,,,,,,,100256,S,2,Expert,1,,CHEMBL615355,,BAO_0000220,,
132,3260,Inhibitory activity against 20S proteosome,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615356,,BAO_0000220,,
133,3451,Compound was tested for inhibitory activity against tryptase,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615357,,BAO_0000019,,
134,13885,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL615358,726.0,BAO_0000219,,
135,13885,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,F,,,Homo sapiens,9606.0,,,HepG2,,81020,N,1,Intermediate,1,,CHEMBL827086,726.0,BAO_0000219,,
136,3676,Compound was tested for the inhibition of Alpha-glucosidase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615359,,BAO_0000019,,
137,6043,Inhibitory concentration against human neutrophil elastase (HNE),B,,,,,,,,,235,H,8,Autocuration,1,,CHEMBL615360,,BAO_0000357,,
138,11140,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,F,,,Rattus norvegicus,10116.0,,Heart,,,22226,U,0,Autocuration,1,,CHEMBL615361,,BAO_0000218,948.0,
139,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615362,,BAO_0000019,,
140,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615363,,BAO_0000019,,
141,10543,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,B,,,,,,,,,19640,H,8,Autocuration,1,,CHEMBL615364,,BAO_0000357,,
142,10543,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,F,,,,,,,,,19640,H,8,Expert,1,,CHEMBL615365,,BAO_0000019,,
143,11365,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615366,524.0,BAO_0000219,,
144,11365,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,F,,,Mus musculus,10090.0,,,P338,,80360,N,1,Intermediate,1,,CHEMBL615367,524.0,BAO_0000219,,
145,11803,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,F,,,Homo sapiens,9606.0,,,PBL,,80384,N,1,Intermediate,1,,CHEMBL615368,554.0,BAO_0000219,,
146,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615369,,BAO_0000019,,
147,11803,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,F,,,Ovis aries,9940.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615370,,BAO_0000019,,
148,12278,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),B,,,,,,,,,191,H,8,Autocuration,1,,CHEMBL615673,,BAO_0000357,,
149,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615674,,BAO_0000019,,
150,8249,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615675,,BAO_0000019,,
151,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615676,635.0,BAO_0000219,,
152,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615677,635.0,BAO_0000219,,
153,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615678,635.0,BAO_0000219,,
154,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,F,,,Homo sapiens,9606.0,,,CCRF-CEM,,22226,U,0,Autocuration,1,,CHEMBL615679,635.0,BAO_0000219,,
155,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615680,,BAO_0000019,,
156,8249,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615681,,BAO_0000019,,
157,16992,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,B,,,,,,,,,104290,H,6,Autocuration,1,,CHEMBL857972,,BAO_0000249,,
158,10543,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,F,,,Streptococcus pyogenes,1314.0,,,,,50264,N,1,Intermediate,1,,CHEMBL857899,,BAO_0000218,,
159,17833,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),F,,,Human herpesvirus 3,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615371,,BAO_0000218,,
160,17290,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,F,,,vericilla zoster virus,10335.0,,,HEL,,50527,N,1,Expert,1,,CHEMBL615372,468.0,BAO_0000218,,
161,17290,Antiviral activity against 07/1 strain of VZV; ND: No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615373,,BAO_0000218,,
162,17290,Antiviral activity against 07/1 strain of VZV; ND=No data,F,,,vericilla zoster virus,10335.0,,,,,50527,N,1,Intermediate,1,,CHEMBL615374,,BAO_0000218,,
163,10932,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",F,,,escherichia cloac,561.0,,,,,50145,N,1,Intermediate,1,,CHEMBL615375,,BAO_0000218,,
164,9707,Ratio of Ki at A2 to Ki at A1 receptors,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615376,,BAO_0000019,,
165,2346,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",B,,,Candida albicans,5476.0,,,,,11143,H,8,Expert,1,,CHEMBL615377,,BAO_0000249,,
166,2205,"Inhibition of 1,3-beta-glucan synthase",B,,,Candida glabrata CBS 138,284593.0,,,,,18077,H,8,Expert,1,,CHEMBL615378,,BAO_0000357,,
167,11900,Inhibition of growth of 1-87 human tumor cell line,F,,,Homo sapiens,9606.0,,,1-87 tumor cell line,,80609,N,1,Intermediate,1,,CHEMBL615379,832.0,BAO_0000219,,
168,14864,Inhibition of 1-lipoxygenase (LOX)in RBL cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615380,,BAO_0000219,,
169,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615381,,BAO_0000357,,
170,16474,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615382,,BAO_0000357,,
171,16474,% inhibition against soybean 1-lipoxygenase (SLO),B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615383,,BAO_0000357,,
172,16474,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615384,,BAO_0000357,,
173,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615385,,BAO_0000357,,
174,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615386,,BAO_0000357,,
175,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615387,,BAO_0000357,,
176,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615388,,BAO_0000357,,
177,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615214,,BAO_0000357,,
178,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL827087,,BAO_0000357,,
179,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615215,,BAO_0000357,,
180,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615216,,BAO_0000357,,
181,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615217,,BAO_0000357,,
182,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615218,,BAO_0000357,,
183,3094,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,B,,,Glycine max,3847.0,,,,,100171,D,9,Autocuration,1,,CHEMBL615219,,BAO_0000357,,
184,10413,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615220,,BAO_0000019,,
185,16929,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),F,,,Mus musculus,10090.0,,,C3H 10T1/2,,80049,N,1,Intermediate,1,,CHEMBL615221,294.0,BAO_0000219,,
186,1229,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL615222,,BAO_0000019,,
187,16587,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615223,,BAO_0000357,,
188,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615224,,BAO_0000357,,
189,16587,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615225,,BAO_0000357,,
190,16587,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,B,,,,,,,,,11489,H,8,Autocuration,1,,CHEMBL615226,,BAO_0000357,,
191,16587,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,B,,,,,,,,,11862,H,8,Autocuration,1,,CHEMBL615227,,BAO_0000357,,
192,8058,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,F,,,Bos taurus,9913.0,,,,,12347,D,9,Expert,1,,CHEMBL615228,,BAO_0000019,,
193,9065,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615229,,BAO_0000357,,
194,8865,Inhibition of 11 beta-hydroxylase from rat adrenal gland,B,,,Rattus norvegicus,10116.0,,Adrenal gland,,,100120,D,9,Expert,1,,CHEMBL615230,,BAO_0000357,2369.0,
195,9066,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615231,,BAO_0000357,,
196,8394,Inhibition of rat adrenal 11-beta-hydroxylase,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL884520,,BAO_0000357,,
197,8394,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,B,,,Rattus norvegicus,10116.0,,,,,100120,D,9,Expert,1,,CHEMBL615232,,BAO_0000357,,
198,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,B,,,,,,,,,10328,H,8,Autocuration,1,,CHEMBL615233,,BAO_0000019,,
199,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL827088,,BAO_0000357,,
200,6431,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,B,,,,,,,,,11490,H,8,Autocuration,1,,CHEMBL615234,,BAO_0000357,,
201,9295,Compound was tested for the percent of inhibition against 12-LO at 10 uM,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615235,,BAO_0000019,,
202,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615236,,BAO_0000019,,
203,13622,Compound was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615237,,BAO_0000019,,
204,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615238,,BAO_0000019,,
205,13622,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615239,,BAO_0000019,,
206,12079,Inhibitory concentration against human platelet 12-lipoxygenase,F,,,Homo sapiens,9606.0,,,,,11134,D,9,Autocuration,1,,CHEMBL615240,,BAO_0000019,,
207,13500,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,B,,,,,,,,,11835,H,8,Expert,1,,CHEMBL615241,,BAO_0000019,,
208,13723,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,B,,,,,,,,,11601,H,8,Expert,1,,CHEMBL615242,,BAO_0000357,,
209,16474,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615243,,BAO_0000019,,
210,1630,Inhibitory activity against human platelet 12-lipoxygenase,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615244,,BAO_0000019,,
211,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615245,,BAO_0000019,,
212,16474,% inhibition against human platelet 12-lipoxygenase (12-HLO),B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615246,,BAO_0000019,,
213,167,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615247,,BAO_0000019,,
214,16474,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,B,,,,,,,,,11134,H,8,Autocuration,1,,CHEMBL615248,,BAO_0000019,,
215,10091,Inhibitory activity towards porcine 12-lipoxygenase,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615249,,BAO_0000357,,
216,11966,Tested for inhibition against porcine 12-LO,B,,,,,,,,,11601,H,8,Autocuration,1,,CHEMBL615250,,BAO_0000357,,
217,951,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615251,,BAO_0000019,,
218,10997,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615252,,BAO_0000019,,
219,10193,In vitro inhibition of rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Expert,1,,CHEMBL828340,,BAO_0000019,,
220,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615253,,BAO_0000019,,
221,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615254,,BAO_0000019,,
222,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615255,,BAO_0000019,,
223,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615256,,BAO_0000019,,
224,10193,In vitro inhibitory activity against rat platelet 12-lipoxygenase,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615257,,BAO_0000019,,
225,11087,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,B,,,,,,,,,12052,H,8,Autocuration,1,,CHEMBL615258,,BAO_0000019,,
226,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615259,621.0,BAO_0000219,,
227,12989,In vitro antitumor activity against 41M cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615260,621.0,BAO_0000219,,
228,16745,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615261,621.0,BAO_0000219,,
229,15569,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615262,621.0,BAO_0000219,,
230,12989,In vitro antitumor activity against 41McisR cell line.,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL615263,621.0,BAO_0000219,,
231,12989,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Expert,1,,CHEMBL838393,621.0,BAO_0000219,,
232,16745,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,41M,,80007,N,1,Intermediate,1,,CHEMBL615264,621.0,BAO_0000219,,
233,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),B,,,Homo sapiens,9606.0,,,,,84,D,9,Expert,1,,CHEMBL615265,,BAO_0000357,,
234,6210,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,Homo sapiens,9606.0,,,,,68,D,9,Expert,1,,CHEMBL615266,,BAO_0000357,,
235,6226,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),B,,,,,,,,,68,H,8,Expert,1,,CHEMBL615267,,BAO_0000357,,
236,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615268,,BAO_0000357,,
237,17855,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615269,,BAO_0000357,,
238,17855,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,B,,,,,,,,,10201,H,8,Expert,1,,CHEMBL615270,,BAO_0000357,,
239,10413,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615271,,BAO_0000357,,
240,10413,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615272,,BAO_0000357,,
241,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615103,,BAO_0000357,,
242,10413,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",B,,,Escherichia coli,562.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615104,,BAO_0000357,,
243,10413,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL615105,,BAO_0000357,,
244,10413,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",B,,,,,,,,,12220,H,8,Autocuration,1,,CHEMBL872866,,BAO_0000357,,
245,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615106,,BAO_0000357,,
246,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615107,,BAO_0000019,,
247,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615108,,BAO_0000357,,
248,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615109,,BAO_0000357,,
249,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615110,,BAO_0000357,,
250,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL840105,,BAO_0000019,,
251,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615111,,BAO_0000019,,
252,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615112,,BAO_0000019,,
253,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615113,,BAO_0000019,,
254,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615114,,BAO_0000019,,
255,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615115,,BAO_0000357,,
256,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,11303,H,8,Autocuration,1,,CHEMBL615116,,BAO_0000019,,
257,7323,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",B,,,,,,,,,11303,H,8,Autocuration,1,,CHEMBL615698,,BAO_0000357,,
258,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615699,,BAO_0000019,,
259,7587,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",B,,,Sus scrofa,9823.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615700,,BAO_0000019,,
260,13750,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,B,,,Saccharomyces cerevisiae,4932.0,,,,,100249,H,8,Expert,1,,CHEMBL615701,,BAO_0000357,,
261,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615702,,BAO_0000019,,
262,7662,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615703,,BAO_0000019,,
263,7662,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615704,,BAO_0000019,,
264,12211,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615705,,BAO_0000019,,
265,12211,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL615706,,BAO_0000019,,
266,12211,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615707,,BAO_0000221,2116.0,
267,12211,Stimulatory activity of intragastric pressure was tested in the rat,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL615708,,BAO_0000019,,
268,15453,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,B,,,,,,,,,121,H,8,Autocuration,1,,CHEMBL615709,,BAO_0000357,,
269,11884,Dose to reduce neuronal firing against 5-HT cells in rats (iv),F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615710,,BAO_0000218,,
270,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL615711,,BAO_0000019,,
271,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL615712,,BAO_0000357,,
272,6876,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,B,,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL836325,,BAO_0000357,,
273,11863,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615713,,BAO_0000019,,
274,11863,Inhibition constant of high-affinity 5-HT uptake,B,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615714,,BAO_0000357,,
275,11863,Michaelis-Menten constant was reported for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615715,,BAO_0000019,,
276,11863,Maximum rate was determined for high affinity transport of 5-HT,F,,,,,,,,,12198,H,8,Autocuration,1,,CHEMBL615716,,BAO_0000019,,
277,4639,Compound was tested for agonistic activity against 5-HT uptake,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL615717,,BAO_0000019,,
278,15796,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL881818,,BAO_0000019,,
279,15796,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL884540,,BAO_0000357,,
280,12801,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615718,,BAO_0000224,,
281,12801,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615719,,BAO_0000224,,
282,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615720,,BAO_0000249,,
283,12120,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615721,,BAO_0000249,,
284,11963,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615722,,BAO_0000019,,
285,11701,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615723,,BAO_0000019,,
286,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615724,,BAO_0000221,10000000.0,
287,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615725,,BAO_0000221,10000000.0,
288,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615726,,BAO_0000221,10000000.0,
289,16394,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615727,,BAO_0000218,,
290,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL615728,,BAO_0000019,,
291,15779,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL857971,449.0,BAO_0000219,,
292,15363,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL615729,,BAO_0000357,,
293,15363,Efficacy against 5-hydroxytryptamine 2A receptor,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL615730,,BAO_0000019,,
294,15329,Intrinsic activity towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615731,,BAO_0000019,,
295,15329,Relative potency towards 5-HT2A receptor of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615732,,BAO_0000019,,
296,15329,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615733,,BAO_0000019,,
297,15329,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615734,,BAO_0000019,,
298,15329,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL615735,,BAO_0000019,,
299,15329,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Expert,1,,CHEMBL615736,,BAO_0000019,,
300,273,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615737,,BAO_0000221,2116.0,
301,273,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615738,,BAO_0000221,2116.0,
302,273,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL615739,,BAO_0000221,2116.0,
303,12092,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL615278,,BAO_0000357,,
304,1317,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL615279,,BAO_0000019,,
305,12409,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL615280,,BAO_0000357,,
306,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,B,,,Gallus gallus,9031.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615281,,BAO_0000019,,
307,11126,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615282,,BAO_0000019,,
308,11126,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615283,,BAO_0000019,,
309,11126,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,B,,,Homo sapiens,9606.0,,,HL-60,,80156,N,1,Autocuration,1,,CHEMBL615284,649.0,BAO_0000219,,
310,11126,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615285,,BAO_0000019,,
311,11126,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615286,,BAO_0000019,,
312,17807,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,B,,,Homo sapiens,9606.0,,,Oocytes,,104703,D,7,Autocuration,1,,CHEMBL615287,,BAO_0000219,,
313,16575,Chymotryptic inhibitory activity against 26S proteasome,F,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615288,,BAO_0000220,,
314,15407,Inhibitory activity against 26S proteasome degradation of IkB,B,,,,,,,,,100256,S,2,Intermediate,1,,CHEMBL615289,,BAO_0000220,,
315,10797,In vitro inhibition of 2780/DOX ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL615290,478.0,BAO_0000219,,
316,10797,In vitro inhibition of 2780/S ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884522,478.0,BAO_0000219,,
317,3469,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615291,,BAO_0000019,,
318,16037,Association constant for binding to AATT 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615292,,BAO_0000225,,
319,16037,Kinetically Defined Association Constant for 28-mer AATT hairpin.,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615293,,BAO_0000225,,
320,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615294,,BAO_0000225,,
321,16037,Reaction Rate Parameter for 28-mer AATT hairpin,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL615295,,BAO_0000225,,
322,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL825021,,BAO_0000019,,
323,16524,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615296,,BAO_0000019,,
324,16524,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615297,,BAO_0000019,,
325,16758,Cytotoxicity against cell line 2SC/20 determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615298,,BAO_0000019,,
326,16758,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615299,,BAO_0000019,,
327,16758,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,F,,,Cricetulus griseus,10029.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615300,,BAO_0000019,,
328,14360,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,B,,,,,,,,,241,H,8,Autocuration,1,,CHEMBL615301,,BAO_0000357,,
329,14360,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,B,,,Homo sapiens,9606.0,,,,,241,D,9,Expert,1,,CHEMBL615302,,BAO_0000357,,
330,9964,Selectivity ratio of ID50 in liver and heart,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615303,,BAO_0000019,,
331,9964,"Selectivity, ratio of relative ID50 in liver and heart",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615304,,BAO_0000019,,
332,9964,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615305,,BAO_0000019,,
333,9964,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615306,,BAO_0000218,,
334,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615307,,BAO_0000218,,
335,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615308,,BAO_0000218,,
336,9964,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",F,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615309,,BAO_0000218,,
337,9964,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615310,,BAO_0000019,,
338,9964,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615311,,BAO_0000019,,
339,9964,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615312,,BAO_0000019,,
340,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615313,,BAO_0000019,,
341,9964,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615314,,BAO_0000019,,
342,9964,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615315,,BAO_0000019,,
343,9964,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615316,,BAO_0000218,,
344,9964,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,B,In vivo,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615317,,BAO_0000218,,
345,9964,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615318,,BAO_0000218,,
346,9964,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615319,,BAO_0000218,,
347,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",B,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615320,,BAO_0000019,,
348,9964,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",F,,,,,,,,,12132,H,8,Autocuration,1,,CHEMBL615321,,BAO_0000019,,
349,3796,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615322,,BAO_0000019,,
350,4251,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615323,,BAO_0000357,,
351,4251,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615407,,BAO_0000357,,
352,4251,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL857267,,BAO_0000357,,
353,4251,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,B,,,Escherichia coli,562.0,,,,,19690,H,8,Autocuration,1,,CHEMBL615408,,BAO_0000357,,
354,166,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615409,,BAO_0000357,,
355,17861,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615410,,BAO_0000357,,
356,166,Inhibition constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615411,,BAO_0000357,,
357,166,Association rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615412,,BAO_0000357,,
358,166,Rate constant against 3-dehydroquinate synthase,B,,,,,,,,,19690,H,8,Autocuration,1,,CHEMBL615413,,BAO_0000357,,
359,3548,Inhibitory activity against fuc-TVII,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615414,,BAO_0000019,,
360,9877,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615415,,BAO_0000251,2107.0,
361,9877,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615416,,BAO_0000251,2107.0,
362,9877,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615417,,BAO_0000251,2107.0,
363,9877,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615418,,BAO_0000251,2107.0,
364,9877,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615419,,BAO_0000251,2107.0,
365,9877,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615420,,BAO_0000251,2107.0,
366,9877,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615421,,BAO_0000251,2107.0,
367,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615422,,BAO_0000251,2107.0,
368,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615423,,BAO_0000251,2107.0,
369,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL872868,,BAO_0000251,2107.0,
370,9877,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,12236,D,9,Autocuration,1,,CHEMBL615424,,BAO_0000251,2107.0,
371,3003,Inhibitory activity against 3-phosphoglycerate kinase.,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL825022,,BAO_0000224,,
372,3003,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615425,,BAO_0000224,,
373,3003,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",B,,,,,,,,,104832,H,4,Autocuration,1,,CHEMBL615426,,BAO_0000224,,
374,17185,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,B,,,Homo sapiens,9606.0,,,,,10612,D,9,Expert,1,,CHEMBL615427,,BAO_0000357,,
375,6072,Cytotoxicity on 3677 melanoma cells,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615428,844.0,BAO_0000219,,
376,6072,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,F,,,Homo sapiens,9606.0,,,3677 melanoma cell line,,80616,N,1,Intermediate,1,,CHEMBL615429,844.0,BAO_0000219,,
377,5018,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,F,,,Mus musculus,10090.0,,,MC-38,,80617,N,1,Intermediate,1,,CHEMBL615430,700.0,BAO_0000219,,
378,2852,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL615431,,BAO_0000019,,
379,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615432,798.0,BAO_0000218,,
380,8663,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,F,,,,,,,B16,,22226,U,0,Autocuration,1,,CHEMBL615433,798.0,BAO_0000218,,
381,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615434,,BAO_0000019,,
382,3245,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,F,,,Human rhinovirus sp.,169066.0,,,,,50085,N,1,Intermediate,1,,CHEMBL615435,,BAO_0000218,,
383,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615436,,BAO_0000218,,
384,3877,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,F,,,human rhinovirus type 14,169066.0,,,,,50679,N,1,Intermediate,1,,CHEMBL615437,,BAO_0000218,,
385,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615438,,BAO_0000019,,
386,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615439,,BAO_0000019,,
387,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615440,,BAO_0000019,,
388,5861,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,F,,,Human rhinovirus 14,12131.0,,,,,12464,D,9,Expert,1,,CHEMBL615441,,BAO_0000019,,
389,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615641,,BAO_0000218,,
390,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL872065,,BAO_0000218,,
391,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL825023,,BAO_0000218,,
392,13748,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,F,,,Enterovirus,12059.0,,,,,50665,N,1,Intermediate,1,,CHEMBL615642,,BAO_0000218,,
393,13748,Inhibition of human rhinovirus 3C protease,B,,,Human rhinovirus B,147712.0,,,,,12464,H,8,Expert,1,,CHEMBL615643,,BAO_0000357,,
394,17699,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,B,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615644,,BAO_0000019,,
395,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615645,833.0,BAO_0000218,,
396,7145,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615646,833.0,BAO_0000218,,
397,7145,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615647,833.0,BAO_0000218,,
398,7145,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615648,833.0,BAO_0000218,,
399,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615649,833.0,BAO_0000218,,
400,7145,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,F,,,Mus musculus,10090.0,,,3EM 37,,80619,N,1,Intermediate,1,,CHEMBL615650,833.0,BAO_0000218,,
401,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615651,847.0,BAO_0000218,,
402,5325,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615652,847.0,BAO_0000218,,
403,5325,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Expert,1,,CHEMBL615653,847.0,BAO_0000218,,
404,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615654,847.0,BAO_0000219,,
405,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615655,847.0,BAO_0000219,,
406,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL825024,847.0,BAO_0000219,,
407,16169,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615656,847.0,BAO_0000219,,
408,16169,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615657,847.0,BAO_0000219,,
409,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615658,847.0,BAO_0000219,,
410,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615659,847.0,BAO_0000219,,
411,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615660,847.0,BAO_0000219,,
412,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615661,847.0,BAO_0000219,,
413,16169,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615662,847.0,BAO_0000219,,
414,16169,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615663,847.0,BAO_0000219,,
415,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615664,847.0,BAO_0000219,,
416,16169,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615665,847.0,BAO_0000219,,
417,16169,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615666,847.0,BAO_0000219,,
418,16169,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615667,847.0,BAO_0000219,,
419,16169,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615668,847.0,BAO_0000219,,
420,16169,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615669,847.0,BAO_0000219,,
421,16169,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615670,847.0,BAO_0000219,,
422,16169,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL836739,847.0,BAO_0000219,,
423,16169,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615671,847.0,BAO_0000219,,
424,16169,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615672,847.0,BAO_0000219,,
425,16169,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615791,847.0,BAO_0000219,,
426,16169,spermine levels in 3LL cells after the treatment of 1 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615792,847.0,BAO_0000219,,
427,16169,spermine levels in 3LL cells after the treatment of 10 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615793,847.0,BAO_0000219,,
428,16169,spermine levels in 3LL cells after the treatment of 250 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615794,847.0,BAO_0000219,,
429,16169,spermine levels in 3LL cells after the treatment of 50 uM of Compound,F,,,Mus musculus,10090.0,,,3LL cell line,,80620,N,1,Intermediate,1,,CHEMBL615795,847.0,BAO_0000219,,
430,15547,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,F,,,Homo sapiens,9606.0,,,3LLD122,,80621,N,1,Intermediate,1,,CHEMBL615590,971.0,BAO_0000219,,
431,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615591,,BAO_0000218,,
432,8663,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615592,,BAO_0000218,,
433,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615593,,BAO_0000218,,
434,8663,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615594,,BAO_0000218,,
435,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615595,723.0,BAO_0000219,,
436,4504,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615596,723.0,BAO_0000219,,
437,12695,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,F,,,,,,,NIH3T3,,11169,H,8,Expert,1,,CHEMBL615597,723.0,BAO_0000219,,
438,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615598,723.0,BAO_0000219,,
439,12695,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615599,723.0,BAO_0000219,,
440,17642,Effective dose against murine 3T3 fibroblasts cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615600,723.0,BAO_0000219,,
441,17642,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615601,723.0,BAO_0000219,,
442,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615602,723.0,BAO_0000219,,
443,12340,Cytotoxic effect on 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615603,723.0,BAO_0000219,,
444,12716,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615604,723.0,BAO_0000219,,
445,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615605,723.0,BAO_0000219,,
446,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615606,723.0,BAO_0000219,,
447,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL884526,723.0,BAO_0000219,,
448,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615607,723.0,BAO_0000219,,
449,6277,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615608,723.0,BAO_0000219,,
450,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615609,723.0,BAO_0000219,,
451,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615682,723.0,BAO_0000219,,
452,6277,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615683,723.0,BAO_0000219,,
453,17780,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615684,723.0,BAO_0000218,,
454,12751,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,F,,,Mus musculus,10090.0,,,,,104860,D,7,Autocuration,1,,CHEMBL615685,,BAO_0000219,,
455,12380,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615686,723.0,BAO_0000219,,
456,14892,Inhibitory activity against 3T3 cell line,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615687,723.0,BAO_0000219,,
457,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL884523,723.0,BAO_0000219,,
458,12695,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615688,,BAO_0000019,,
459,12695,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615689,723.0,BAO_0000219,,
460,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615690,723.0,BAO_0000219,,
461,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615691,,BAO_0000019,,
462,12695,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,F,,,,,,,,,11169,H,8,Expert,1,,CHEMBL615692,,BAO_0000019,,
463,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615693,723.0,BAO_0000219,,
464,6277,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615324,723.0,BAO_0000219,,
465,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615325,723.0,BAO_0000219,,
466,4959,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,9,D,9,Expert,1,,CHEMBL615490,723.0,BAO_0000219,,
467,4959,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615491,723.0,BAO_0000219,,
468,4959,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),F,,,Homo sapiens,9606.0,,,NIH3T3,,188,D,9,Expert,1,,CHEMBL615492,723.0,BAO_0000219,,
469,12082,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615493,723.0,BAO_0000219,,
470,12082,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615494,723.0,BAO_0000219,,
471,12082,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615495,723.0,BAO_0000219,,
472,12082,Inhibitory concentration was calculated on 3T3 cells by using growth assay,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615496,723.0,BAO_0000219,,
473,2643,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615497,723.0,BAO_0000219,,
474,11926,Inhibition of Swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615498,723.0,BAO_0000219,,
475,15204,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,A,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615499,723.0,BAO_0000219,,
476,15992,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL835522,723.0,BAO_0000219,,
477,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615500,723.0,BAO_0000219,,
478,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615501,723.0,BAO_0000219,,
479,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615502,723.0,BAO_0000219,,
480,16279,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615503,723.0,BAO_0000219,,
481,16279,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615504,723.0,BAO_0000219,,
482,16279,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615505,723.0,BAO_0000219,,
483,12831,Inhibition of swiss 3T3 mouse fibroblast proliferation,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Expert,1,,CHEMBL615506,723.0,BAO_0000219,,
484,13497,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,F,,,Mus musculus,10090.0,,,NIH3T3,,80951,N,1,Intermediate,1,,CHEMBL615507,723.0,BAO_0000219,,
485,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615508,620.0,BAO_0000218,,
486,13618,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615509,620.0,BAO_0000219,,
487,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615510,620.0,BAO_0000219,,
488,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615511,620.0,BAO_0000219,,
489,11902,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615512,620.0,BAO_0000219,,
490,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615513,620.0,BAO_0000218,,
491,14840,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615514,620.0,BAO_0000218,,
492,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615515,620.0,BAO_0000219,,
493,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615516,620.0,BAO_0000219,,
494,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615517,620.0,BAO_0000219,,
495,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615518,620.0,BAO_0000219,,
496,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615519,620.0,BAO_0000219,,
497,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615520,620.0,BAO_0000218,,
498,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615521,620.0,BAO_0000218,,
499,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615522,620.0,BAO_0000218,,
500,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615523,620.0,BAO_0000218,,
501,13715,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615524,620.0,BAO_0000218,,
502,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615525,620.0,BAO_0000218,,
503,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615526,620.0,BAO_0000218,,
504,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615527,620.0,BAO_0000218,,
505,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615528,620.0,BAO_0000218,,
506,13715,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615529,620.0,BAO_0000218,,
507,13715,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615530,620.0,BAO_0000218,,
508,13715,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615531,620.0,BAO_0000218,,
509,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615532,620.0,BAO_0000219,,
510,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615533,620.0,BAO_0000219,,
511,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615534,620.0,BAO_0000219,,
512,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615535,620.0,BAO_0000218,,
513,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615536,620.0,BAO_0000218,,
514,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615537,620.0,BAO_0000218,,
515,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615538,620.0,BAO_0000218,,
516,13715,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,F,,,,,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL836166,620.0,BAO_0000218,,
517,6411,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615539,620.0,BAO_0000219,,
518,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615540,620.0,BAO_0000219,,
519,6411,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,F,,,,,,,3T3-L1,,11214,H,8,Expert,1,,CHEMBL615541,620.0,BAO_0000219,,
520,3966,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615542,620.0,BAO_0000219,,
521,3966,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Intermediate,1,,CHEMBL615543,620.0,BAO_0000219,,
522,15556,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615544,620.0,BAO_0000219,,
523,5845,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615545,620.0,BAO_0000219,,
524,14422,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615546,620.0,BAO_0000219,,
525,5845,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615547,620.0,BAO_0000219,,
526,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615548,620.0,BAO_0000219,,
527,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615549,620.0,BAO_0000219,,
528,14508,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,F,,,Mus musculus,10090.0,,,3T3-L1,,80006,N,1,Expert,1,,CHEMBL615550,620.0,BAO_0000219,,
529,6349,Inhibitory activity against rat fibroblast (3Y1) cell line,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615551,1118.0,BAO_0000219,,
530,15899,Mean concentration causing inhibition of cell growth in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615552,1118.0,BAO_0000219,,
531,15899,Cytotoxicity in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615553,1118.0,BAO_0000219,,
532,15899,Cytostatic effect in 3Y1 cells.,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615554,1118.0,BAO_0000219,,
533,15899,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Intermediate,1,,CHEMBL615555,1118.0,BAO_0000219,,
534,17038,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,F,,,Rattus norvegicus,10116.0,,,3Y1 cell line,,80622,N,1,Expert,1,,CHEMBL615556,1118.0,BAO_0000219,,
535,12421,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615557,,BAO_0000019,,
536,12947,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615558,,BAO_0000019,,
537,12947,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL872066,,BAO_0000019,,
538,4896,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615559,,BAO_0000019,,
539,6148,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615560,,BAO_0000019,,
540,16432,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615561,,BAO_0000019,,
541,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL857062,,BAO_0000019,,
542,4978,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),B,,,,,,,,,11607,H,8,Expert,1,,CHEMBL615562,,BAO_0000019,,
543,3723,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615563,,BAO_0000019,,
544,3518,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615564,,BAO_0000357,,
545,4164,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615565,,BAO_0000019,,
546,3518,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615566,,BAO_0000019,,
547,4164,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,B,,,Sus scrofa,9823.0,,,,,11607,D,9,Expert,1,,CHEMBL615567,,BAO_0000019,,
548,3518,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615568,,BAO_0000019,,
549,3518,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615569,,BAO_0000357,,
550,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615570,,BAO_0000019,,
551,4978,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),B,,,,,,,,,11607,H,8,Autocuration,1,,CHEMBL615571,,BAO_0000019,,
552,6455,Binding affinity against melatonin (MT1) receptor (pC1),B,,,,,,,,,104733,H,4,Autocuration,1,,CHEMBL615572,,BAO_0000224,,
553,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615573,,BAO_0000019,,
554,13020,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615574,,BAO_0000019,,
555,13021,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615575,,BAO_0000019,,
556,14532,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615576,,BAO_0000357,,
557,14118,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10619,H,8,Autocuration,1,,CHEMBL615577,,BAO_0000357,,
558,11884,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615578,,BAO_0000221,10000000.0,
559,13969,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615579,,BAO_0000357,,
560,13392,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615580,,BAO_0000357,,
561,14430,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615581,,BAO_0000019,,
562,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615582,,BAO_0000221,10000000.0,
563,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615583,,BAO_0000221,10000000.0,
564,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615584,,BAO_0000221,10000000.0,
565,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL833691,,BAO_0000221,10000000.0,
566,9995,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615585,,BAO_0000221,10000000.0,
567,9995,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615586,,BAO_0000221,10000000.0,
568,9995,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL884524,,BAO_0000221,10000000.0,
569,12249,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615587,,BAO_0000221,10000000.0,
570,11799,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615588,,BAO_0000221,10000000.0,
571,14331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615589,,BAO_0000249,,
572,11884,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,B,,,Bos taurus,9913.0,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615442,,BAO_0000221,10000000.0,
573,14331,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615443,,BAO_0000221,10000000.0,
574,11701,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615444,,BAO_0000221,10000000.0,
575,11701,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615445,,BAO_0000221,10000000.0,
576,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615446,,BAO_0000221,10000000.0,
577,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615447,449.0,BAO_0000219,,
578,12248,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615448,,BAO_0000221,10000000.0,
579,12249,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615449,,BAO_0000221,10000000.0,
580,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615450,449.0,BAO_0000219,,
581,11799,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615451,,BAO_0000221,10000000.0,
582,634,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615452,,BAO_0000357,,
583,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615453,,BAO_0000221,10000000.0,
584,9995,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615454,,BAO_0000221,10000000.0,
585,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615455,,BAO_0000221,10000000.0,
586,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615456,,BAO_0000221,10000000.0,
587,9995,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615457,,BAO_0000221,10000000.0,
588,12210,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615458,,BAO_0000218,10000000.0,
589,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Expert,1,,CHEMBL615459,,BAO_0000221,10000000.0,
590,2331,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615460,449.0,BAO_0000219,,
591,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615461,,BAO_0000019,,
592,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,F,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615462,,BAO_0000019,,
593,11574,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,F,,,Cavia porcellus,10141.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL615463,,BAO_0000221,10000000.0,
594,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615464,,BAO_0000221,2116.0,
595,12867,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615465,,BAO_0000221,2116.0,
596,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615466,,BAO_0000221,2116.0,
597,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615467,,BAO_0000221,2116.0,
598,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615468,,BAO_0000221,2116.0,
599,12867,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,B,,,Cavia porcellus,10141.0,,Ileum,,,51,H,8,Autocuration,1,,CHEMBL615469,,BAO_0000221,2116.0,
600,11574,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615470,,BAO_0000357,,
601,13114,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615471,,BAO_0000357,,
602,13181,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,B,,,Cavia porcellus,10141.0,,,,,51,H,8,Autocuration,1,,CHEMBL615472,,BAO_0000357,,
603,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,B,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL883242,,BAO_0000221,10000000.0,
604,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,F,,,Cavia porcellus,10141.0,,Hippocampus,,,106,H,8,Autocuration,1,,CHEMBL615473,,BAO_0000221,10000000.0,
605,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,Cricetulus griseus,10029.0,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL615474,449.0,BAO_0000218,,
606,17785,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615475,,BAO_0000357,,
607,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615476,308.0,BAO_0000219,,
608,1558,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,F,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615477,308.0,BAO_0000219,,
609,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615478,,BAO_0000019,,
610,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615160,449.0,BAO_0000219,,
611,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615161,449.0,BAO_0000219,,
612,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615162,449.0,BAO_0000219,,
613,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615163,449.0,BAO_0000219,,
614,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615164,449.0,BAO_0000219,,
615,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615165,449.0,BAO_0000219,,
616,17624,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615166,449.0,BAO_0000219,,
617,14256,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615167,,BAO_0000219,,
618,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615168,308.0,BAO_0000219,,
619,3445,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL615169,308.0,BAO_0000219,,
620,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615170,449.0,BAO_0000219,,
621,17200,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615171,449.0,BAO_0000219,,
622,15180,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615694,,BAO_0000019,,
623,15180,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615695,,BAO_0000019,,
624,16026,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615696,,BAO_0000019,,
625,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615697,449.0,BAO_0000219,,
626,2759,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL859410,449.0,BAO_0000219,,
627,2759,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615841,449.0,BAO_0000219,,
628,2759,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615842,449.0,BAO_0000219,,
629,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL835003,449.0,BAO_0000219,,
630,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615843,449.0,BAO_0000219,,
631,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615979,449.0,BAO_0000219,,
632,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615980,449.0,BAO_0000219,,
633,2759,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615981,449.0,BAO_0000219,,
634,3445,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615982,,BAO_0000019,,
635,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615983,,BAO_0000019,,
636,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615984,,BAO_0000019,,
637,5272,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615985,,BAO_0000019,,
638,17624,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615986,449.0,BAO_0000219,,
639,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615987,449.0,BAO_0000219,,
640,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615988,449.0,BAO_0000219,,
641,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615989,449.0,BAO_0000219,,
642,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615990,449.0,BAO_0000219,,
643,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615991,449.0,BAO_0000219,,
644,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615992,449.0,BAO_0000219,,
645,17624,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615993,449.0,BAO_0000219,,
646,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615994,449.0,BAO_0000219,,
647,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615995,449.0,BAO_0000219,,
648,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615996,449.0,BAO_0000219,,
649,17624,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615997,449.0,BAO_0000219,,
650,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615998,,BAO_0000019,,
651,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615999,,BAO_0000019,,
652,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616000,,BAO_0000019,,
653,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616001,722.0,BAO_0000219,,
654,6876,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616002,,BAO_0000019,,
655,6876,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616003,,BAO_0000019,,
656,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616004,,BAO_0000019,,
657,5272,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616005,,BAO_0000019,,
658,5548,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616006,,BAO_0000019,,
659,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616007,,BAO_0000019,,
660,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616008,,BAO_0000019,,
661,5548,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616009,,BAO_0000019,,
662,5929,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616010,,BAO_0000019,,
663,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616011,,BAO_0000019,,
664,5929,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615740,,BAO_0000019,,
665,16245,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615741,,BAO_0000019,,
666,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615742,,BAO_0000019,,
667,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615743,,BAO_0000019,,
668,14509,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615744,449.0,BAO_0000219,,
669,14509,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,F,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615745,449.0,BAO_0000219,,
670,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615746,,BAO_0000357,,
671,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615747,,BAO_0000357,,
672,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615748,,BAO_0000019,,
673,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615749,,BAO_0000019,,
674,6563,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615750,,BAO_0000019,,
675,6563,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616259,,BAO_0000019,,
676,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616260,,BAO_0000019,,
677,5272,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616261,,BAO_0000019,,
678,5272,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616262,,BAO_0000019,,
679,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616263,,BAO_0000019,,
680,5272,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616264,,BAO_0000019,,
681,5272,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616265,,BAO_0000019,,
682,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616266,,BAO_0000019,,
683,5272,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616267,,BAO_0000019,,
684,5272,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616268,,BAO_0000019,,
685,16146,Inhibition of human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616269,,BAO_0000357,,
686,17624,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL884528,449.0,BAO_0000219,,
687,13706,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,B,,,,,,,HEK293,,105,D,9,Expert,1,,CHEMBL616270,722.0,BAO_0000219,,
688,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616271,449.0,BAO_0000219,,
689,17624,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616272,449.0,BAO_0000219,,
690,6861,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616273,,BAO_0000357,,
691,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616274,,BAO_0000357,,
692,17624,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616275,449.0,BAO_0000219,,
693,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616276,449.0,BAO_0000219,,
694,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616277,,BAO_0000218,,
695,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616278,,BAO_0000218,,
696,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616279,,BAO_0000218,,
697,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616280,,BAO_0000218,,
698,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616281,,BAO_0000218,,
699,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616282,,BAO_0000218,,
700,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616283,,BAO_0000218,,
701,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616284,,BAO_0000218,,
702,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616285,,BAO_0000218,,
703,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616286,,BAO_0000218,,
704,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616287,,BAO_0000218,,
705,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616288,,BAO_0000218,,
706,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL616289,,BAO_0000218,,
707,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615610,,BAO_0000218,,
708,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615611,,BAO_0000218,,
709,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615612,,BAO_0000218,,
710,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615613,,BAO_0000218,,
711,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615614,,BAO_0000218,,
712,12058,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615615,,BAO_0000218,,
713,11440,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,B,,,,,,,,,105093,H,4,Autocuration,1,,CHEMBL615616,,BAO_0000019,,
714,6238,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,B,,,,,,Hypothalamus,,,11923,H,8,Autocuration,1,,CHEMBL615617,,BAO_0000249,1898.0,
715,10046,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615618,,BAO_0000019,,
716,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL615619,,BAO_0000019,,
717,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL615620,,BAO_0000019,,
718,167,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615621,,BAO_0000357,,
719,167,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615622,,BAO_0000357,,
720,11520,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615623,,BAO_0000019,,
721,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615624,,BAO_0000019,,
722,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615625,,BAO_0000019,,
723,11520,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL767045,,BAO_0000019,,
724,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615626,,BAO_0000019,,
725,135,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615627,,BAO_0000019,,
726,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615628,,BAO_0000019,,
727,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL615629,,BAO_0000357,,
728,12281,Inhibitory concentration against 5-lipoxygenase from human whole blood,B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL615630,,BAO_0000357,,
729,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL615631,,BAO_0000219,,
730,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615632,,BAO_0000218,,
731,12281,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615633,,BAO_0000357,,
732,12576,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,F,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL615634,,BAO_0000218,,
733,11089,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Expert,1,,CHEMBL615635,,BAO_0000019,,
734,11006,In vitro inhibition of rat 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL615636,,BAO_0000357,,
735,11481,Inhibitory activity against 5-Lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL615637,,BAO_0000357,,
736,10864,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL615638,702.0,BAO_0000219,,
737,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615639,702.0,BAO_0000219,,
738,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615640,702.0,BAO_0000219,,
739,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615796,,BAO_0000019,,
740,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615845,,BAO_0000219,,
741,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615846,,BAO_0000357,,
742,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL615847,702.0,BAO_0000219,,
743,11311,The compound was tested for inhibition of isolated 5-Lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615848,,BAO_0000357,,
744,11481,Ratio of IC50 against 5-LO and COX,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615849,,BAO_0000019,,
745,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615850,,BAO_0000357,,
746,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615851,,BAO_0000357,,
747,11311,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615852,,BAO_0000219,,
748,11006,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL615853,,BAO_0000019,,
749,4288,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,B,,,,,,Prostate gland,,,120,H,8,Autocuration,1,,CHEMBL884527,,BAO_0000357,2367.0,
750,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL872871,,BAO_0000019,,
751,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615854,,BAO_0000019,,
752,7587,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,B,,,Columba livia,8932.0,,,,,22226,U,0,Autocuration,1,,CHEMBL767046,,BAO_0000019,,
753,11249,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,B,,,,,,,,,10732,H,8,Autocuration,1,,CHEMBL615855,,BAO_0000357,,
754,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615856,,BAO_0000019,,
755,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615857,,BAO_0000019,,
756,8003,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),F,,,Rattus norvegicus,10116.0,,,,,12198,D,9,Expert,1,,CHEMBL615858,,BAO_0000019,,
757,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615859,,BAO_0000221,10000000.0,
758,16293,Binding affinity towards human 5-hydroxytryptamine 1 receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615860,,BAO_0000357,,
759,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615861,,BAO_0000019,,
760,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615862,,BAO_0000019,,
761,13047,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615863,,BAO_0000019,,
762,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615864,,BAO_0000019,,
763,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615865,,BAO_0000221,10000000.0,
764,10085,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615866,,BAO_0000221,10000000.0,
765,10085,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615867,,BAO_0000221,10000000.0,
766,9841,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104744,H,4,Autocuration,1,,CHEMBL615868,,BAO_0000249,,
767,8822,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615869,,BAO_0000249,,
768,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615870,,BAO_0000019,,
769,9806,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615871,,BAO_0000019,,
770,8868,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615872,,BAO_0000224,,
771,9036,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL833492,,BAO_0000221,10000000.0,
772,11374,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,B,,,,,,Hippocampus,,,104744,H,4,Autocuration,1,,CHEMBL615873,,BAO_0000221,10000000.0,
773,10881,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615479,,BAO_0000224,,
774,8822,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615480,,BAO_0000019,,
775,9806,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615481,,BAO_0000249,,
776,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL872869,,BAO_0000019,,
777,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615482,,BAO_0000019,,
778,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615483,,BAO_0000221,955.0,
779,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615484,,BAO_0000221,955.0,
780,8569,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615485,,BAO_0000019,,
781,10062,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615486,,BAO_0000224,,
782,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615487,,BAO_0000224,,
783,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615488,,BAO_0000224,,
784,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615489,,BAO_0000224,,
785,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615389,,BAO_0000224,,
786,15463,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615390,,BAO_0000019,,
787,15463,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615391,,BAO_0000019,,
788,9098,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615392,,BAO_0000224,,
789,3070,Affinity for 5-hydroxytryptamine 1 receptor,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615393,,BAO_0000019,,
790,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615394,,BAO_0000221,955.0,
791,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615395,,BAO_0000221,955.0,
792,6398,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615396,,BAO_0000224,,
793,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615397,,BAO_0000221,955.0,
794,11963,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615398,,BAO_0000019,,
795,8908,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615399,,BAO_0000019,,
796,9098,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615400,,BAO_0000019,,
797,8841,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,B,,,Rattus norvegicus,10116.0,,,,,104744,D,5,Autocuration,1,,CHEMBL615401,,BAO_0000019,,
798,8814,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL615402,,BAO_0000019,,
799,11752,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615403,,BAO_0000019,,
800,11642,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615404,,BAO_0000221,955.0,
801,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,B,,,,,,,,,104744,H,4,Autocuration,1,,CHEMBL615781,,BAO_0000019,,
802,9231,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615782,,BAO_0000220,955.0,
803,11351,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104744,H,4,Autocuration,1,,CHEMBL615783,,BAO_0000221,955.0,
804,4639,Compound was tested for binding affinity against 5-HT1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL873481,,BAO_0000019,,
805,1205,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL615784,,BAO_0000019,,
806,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615785,,BAO_0000357,,
807,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615786,,BAO_0000249,,
808,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615787,,BAO_0000218,,
809,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615788,,BAO_0000218,,
810,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL767044,,BAO_0000019,,
811,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615789,,BAO_0000218,,
812,16245,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615790,,BAO_0000218,,
813,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615813,,BAO_0000019,,
814,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615814,,BAO_0000219,,
815,15535,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL615815,,BAO_0000219,,
816,15535,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615816,,BAO_0000219,,
817,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615817,,BAO_0000249,,
818,10085,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615818,,BAO_0000221,10000000.0,
819,10085,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615819,,BAO_0000221,10000000.0,
820,17331,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615820,,BAO_0000249,,
821,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615821,,BAO_0000221,10000000.0,
822,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615822,,BAO_0000221,10000000.0,
823,10845,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615823,,BAO_0000221,10000000.0,
824,10845,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615824,,BAO_0000221,10000000.0,
825,10845,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615825,,BAO_0000221,10000000.0,
826,13730,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615826,,BAO_0000357,,
827,13508,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615827,,BAO_0000249,,
828,13508,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615828,,BAO_0000249,10000000.0,
829,12073,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615829,,BAO_0000221,10000000.0,
830,4671,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615830,,BAO_0000221,10000000.0,
831,13631,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615831,,BAO_0000221,10000000.0,
832,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615832,,BAO_0000357,,
833,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615833,,BAO_0000019,,
834,10483,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615834,,BAO_0000221,10000000.0,
835,12352,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL615835,,BAO_0000249,,
836,14732,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615836,,BAO_0000249,10000000.0,
837,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615837,,BAO_0000019,,
838,11049,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615838,,BAO_0000019,,
839,13657,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615839,,BAO_0000249,,
840,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL884525,,BAO_0000019,,
841,2014,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615840,,BAO_0000249,,
842,3086,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615405,,BAO_0000221,10000000.0,
843,15854,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615406,,BAO_0000019,,
844,10922,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615900,,BAO_0000221,10000000.0,
845,13346,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615901,,BAO_0000221,10000000.0,
846,15311,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615902,,BAO_0000357,,
847,10922,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615903,,BAO_0000221,10000000.0,
848,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615904,,BAO_0000357,,
849,10025,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615905,,BAO_0000357,,
850,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615906,,BAO_0000019,,
851,9742,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615907,,BAO_0000019,,
852,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615908,,BAO_0000019,,
853,15789,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615909,,BAO_0000221,10000000.0,
854,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615910,,BAO_0000019,,
855,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615911,,BAO_0000019,,
856,9912,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615912,,BAO_0000019,,
857,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615913,,BAO_0000019,,
858,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615914,,BAO_0000357,,
859,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615915,,BAO_0000221,10000000.0,
860,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615916,,BAO_0000357,,
861,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615917,,BAO_0000357,,
862,13830,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615918,,BAO_0000357,,
863,14286,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615919,,BAO_0000249,10000000.0,
864,14356,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615920,,BAO_0000221,10000000.0,
865,15306,Inhibition concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615921,,BAO_0000357,,
866,15306,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615922,,BAO_0000357,,
867,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL881290,,BAO_0000249,,
868,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615923,,BAO_0000221,10000000.0,
869,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615924,,BAO_0000221,10000000.0,
870,14331,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,F,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615925,,BAO_0000221,10000000.0,
871,14178,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615926,,BAO_0000357,,
872,10639,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615927,,BAO_0000019,,
873,12306,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615928,,BAO_0000221,10000000.0,
874,1348,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615929,,BAO_0000357,,
875,13605,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615930,,BAO_0000221,10000000.0,
876,17624,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615931,449.0,BAO_0000219,,
877,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615932,449.0,BAO_0000219,,
878,17624,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615933,449.0,BAO_0000219,,
879,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615934,,BAO_0000357,,
880,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615935,,BAO_0000357,,
881,6563,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615936,,BAO_0000019,,
882,4751,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615937,449.0,BAO_0000219,,
883,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615938,,BAO_0000357,,
884,3805,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615797,,BAO_0000357,,
885,5640,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615798,,BAO_0000357,,
886,6563,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872870,,BAO_0000357,,
887,5548,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615799,,BAO_0000357,,
888,6347,Percent binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615800,,BAO_0000357,,
889,17296,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL615801,722.0,BAO_0000219,,
890,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615802,,BAO_0000019,,
891,15740,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615803,,BAO_0000357,,
892,5640,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL835002,,BAO_0000019,,
893,5640,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615804,,BAO_0000019,,
894,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615805,308.0,BAO_0000219,,
895,4751,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615806,449.0,BAO_0000219,,
896,6491,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615807,,BAO_0000357,,
897,4707,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615808,,BAO_0000357,,
898,13910,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615809,,BAO_0000357,,
899,16190,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL615810,308.0,BAO_0000219,,
900,16633,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615811,,BAO_0000357,,
901,11898,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615812,449.0,BAO_0000219,,
902,11898,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615751,449.0,BAO_0000219,,
903,14331,Binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615752,,BAO_0000357,,
904,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL615753,449.0,BAO_0000219,,
905,17624,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL615754,449.0,BAO_0000219,,
906,3307,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615755,,BAO_0000357,,
907,6563,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615756,449.0,BAO_0000219,,
908,14165,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615757,,BAO_0000019,,
909,5732,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615758,,BAO_0000357,,
910,13366,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615759,,BAO_0000357,,
911,17626,Binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615760,,BAO_0000357,,
912,6588,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL615761,308.0,BAO_0000219,,
913,16209,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872104,,BAO_0000357,,
914,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615762,,BAO_0000357,,
915,15463,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615763,,BAO_0000357,,
916,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615764,,BAO_0000357,,
917,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),B,,,,,,,Cell line,,51,H,8,Autocuration,1,,CHEMBL615765,1167.0,BAO_0000219,,
918,16245,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615766,,BAO_0000019,,
919,5548,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615767,,BAO_0000357,,
920,5548,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615768,,BAO_0000357,,
921,5548,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615769,,BAO_0000357,,
922,6876,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615770,,BAO_0000357,,
923,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615771,,BAO_0000357,,
924,17785,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615772,,BAO_0000357,,
925,6013,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615773,,BAO_0000357,,
926,5929,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615774,,BAO_0000357,,
927,16633,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615775,,BAO_0000357,,
928,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615776,,BAO_0000357,,
929,16026,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL615777,,BAO_0000357,,
930,12469,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615778,,BAO_0000219,,
931,15874,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL615779,,BAO_0000357,,
932,15874,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL615780,,BAO_0000357,,
933,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616298,,BAO_0000357,,
934,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616299,,BAO_0000357,,
935,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,51,H,8,Autocuration,1,,CHEMBL616300,485.0,BAO_0000219,,
936,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,51,H,8,Expert,1,,CHEMBL616301,485.0,BAO_0000219,,
937,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616302,,BAO_0000019,,
938,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616117,,BAO_0000019,,
939,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616118,,BAO_0000019,,
940,15413,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616119,,BAO_0000019,,
941,3445,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616120,308.0,BAO_0000219,,
942,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616121,,BAO_0000357,,
943,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616122,,BAO_0000357,,
944,17626,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616123,,BAO_0000357,,
945,4234,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616124,,BAO_0000357,,
946,5640,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616125,,BAO_0000357,,
947,5272,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Expert,1,,CHEMBL616126,,BAO_0000357,,
948,4622,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616127,449.0,BAO_0000219,,
949,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616128,,BAO_0000019,,
950,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616129,,BAO_0000357,,
951,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616130,,BAO_0000357,,
952,15267,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616131,,BAO_0000357,,
953,17158,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616132,308.0,BAO_0000219,,
954,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616133,308.0,BAO_0000219,,
955,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616134,,BAO_0000357,,
956,16532,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616135,,BAO_0000357,,
957,2391,Affinity for 5-hydroxytryptamine 1A receptor subtype,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616136,,BAO_0000357,,
958,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616137,,BAO_0000019,,
959,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL872105,,BAO_0000019,,
960,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616138,,BAO_0000357,,
961,13051,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616139,,BAO_0000357,,
962,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616140,,BAO_0000019,,
963,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616141,,BAO_0000019,,
964,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616142,,BAO_0000357,,
965,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616143,,BAO_0000357,,
966,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616144,308.0,BAO_0000219,,
967,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616145,308.0,BAO_0000219,,
968,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616012,308.0,BAO_0000219,,
969,17211,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,B,,,,,,,HeLa,,51,H,8,Autocuration,1,,CHEMBL616013,308.0,BAO_0000219,,
970,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616014,,BAO_0000019,,
971,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616015,,BAO_0000019,,
972,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616016,,BAO_0000019,,
973,16394,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,F,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616017,,BAO_0000218,,
974,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616018,,BAO_0000019,,
975,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616019,,BAO_0000019,,
976,15740,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616020,,BAO_0000019,,
977,15740,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL858018,,BAO_0000357,,
978,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616021,722.0,BAO_0000219,,
979,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616022,,BAO_0000019,,
980,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616023,,BAO_0000019,,
981,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616024,,BAO_0000019,,
982,5640,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616025,,BAO_0000019,,
983,2759,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616026,449.0,BAO_0000219,,
984,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616027,,BAO_0000019,,
985,16394,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616028,,BAO_0000019,,
986,3445,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616029,,BAO_0000019,,
987,4316,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,B,,,,,,,CHO,,51,H,8,Expert,1,,CHEMBL616030,449.0,BAO_0000219,,
988,4316,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616031,,BAO_0000019,,
989,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616032,,BAO_0000019,,
990,15180,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616033,,BAO_0000019,,
991,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616034,,BAO_0000019,,
992,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616035,,BAO_0000019,,
993,15042,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616036,,BAO_0000019,,
994,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616037,,BAO_0000019,,
995,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616038,,BAO_0000019,,
996,15042,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616039,,BAO_0000019,,
997,15042,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616040,,BAO_0000019,,
998,15180,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616041,308.0,BAO_0000219,,
999,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616042,308.0,BAO_0000219,,
1000,15180,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,F,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616043,308.0,BAO_0000219,,
1001,16245,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616044,,BAO_0000019,,
1002,16026,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616045,,BAO_0000019,,
1003,17296,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,F,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616046,722.0,BAO_0000219,,
1004,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616047,449.0,BAO_0000219,,
1005,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616048,449.0,BAO_0000219,,
1006,2759,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),F,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616049,449.0,BAO_0000219,,
1007,2759,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),F,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616050,449.0,BAO_0000219,,
1008,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,F,,,,,,,,,51,H,8,Expert,1,,CHEMBL616051,,BAO_0000219,,
1009,15419,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616212,,BAO_0000219,,
1010,16026,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616213,,BAO_0000019,,
1011,1414,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616214,,BAO_0000219,,
1012,1414,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,B,In vitro,,,,,,,,51,H,8,Expert,1,,CHEMBL616215,,BAO_0000219,,
1013,12861,Binding activity radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616216,,BAO_0000357,,
1014,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616217,,BAO_0000019,,
1015,5104,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616218,,BAO_0000357,,
1016,5105,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616219,,BAO_0000357,,
1017,16312,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616220,,BAO_0000357,,
1018,15180,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL833493,,BAO_0000357,,
1019,5033,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616221,,BAO_0000357,,
1020,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL616222,449.0,BAO_0000219,,
1021,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616223,,BAO_0000019,,
1022,2590,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,F,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616224,,BAO_0000019,,
1023,16394,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616225,,BAO_0000019,,
1024,4540,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,51,D,9,Expert,1,,CHEMBL616226,722.0,BAO_0000219,,
1025,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616227,722.0,BAO_0000219,,
1026,17296,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616228,722.0,BAO_0000219,,
1027,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616229,722.0,BAO_0000219,,
1028,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616230,722.0,BAO_0000219,,
1029,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616231,722.0,BAO_0000219,,
1030,6166,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616232,,BAO_0000357,,
1031,15779,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616233,722.0,BAO_0000219,,
1032,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL857973,722.0,BAO_0000219,,
1033,15316,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616234,,BAO_0000219,,
1034,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616235,,BAO_0000357,,
1035,14727,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,HeLa,,51,H,8,Expert,1,,CHEMBL616236,308.0,BAO_0000219,,
1036,14727,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616237,,BAO_0000019,,
1037,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616238,722.0,BAO_0000219,,
1038,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616239,722.0,BAO_0000219,,
1039,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616240,,BAO_0000219,,
1040,15042,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,B,,,Homo sapiens,9606.0,,,HeLa,,51,D,9,Expert,1,,CHEMBL616241,308.0,BAO_0000219,,
1041,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616242,722.0,BAO_0000219,,
1042,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",B,,,,,,,HEK293,,51,H,8,Autocuration,1,,CHEMBL616243,722.0,BAO_0000219,,
1043,17200,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,D,9,Expert,1,,CHEMBL616244,,BAO_0000357,,
1044,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,B,,,Homo sapiens,9606.0,,,,,51,D,9,Autocuration,1,,CHEMBL616245,,BAO_0000357,,
1045,5486,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616246,,BAO_0000357,,
1046,5254,Binding affinity against 5-HT1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616247,,BAO_0000357,,
1047,5254,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616248,,BAO_0000357,,
1048,15331,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL616249,,BAO_0000357,,
1049,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL616250,,BAO_0000357,,
1050,15267,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616251,,BAO_0000357,,
1051,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616252,,BAO_0000218,,
1052,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616253,,BAO_0000218,,
1053,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,F,In vivo,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616254,,BAO_0000218,,
1054,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616255,,BAO_0000218,,
1055,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL832872,,BAO_0000218,,
1056,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616256,,BAO_0000218,,
1057,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616257,,BAO_0000218,,
1058,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616258,,BAO_0000218,,
1059,16616,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,F,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616384,,BAO_0000218,,
1060,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616385,,BAO_0000221,10000000.0,
1061,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,B,,,,,,,,,11863,H,8,Expert,1,,CHEMBL616386,,BAO_0000357,,
1062,10297,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616387,,BAO_0000221,10000000.0,
1063,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616388,,BAO_0000221,10000000.0,
1064,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616389,,BAO_0000221,10000000.0,
1065,10297,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,B,,,,,,Hippocampus,,,11863,H,8,Autocuration,1,,CHEMBL616390,,BAO_0000221,10000000.0,
1066,217,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616391,,BAO_0000357,,
1067,10297,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,B,,,Mus musculus,10090.0,,Hippocampus,,,11863,D,9,Expert,1,,CHEMBL616392,,BAO_0000221,10000000.0,
1068,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616393,,BAO_0000357,,
1069,4921,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616394,,BAO_0000357,,
1070,4996,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616395,,BAO_0000019,,
1071,12918,Compound was evaluated for the binding affinity at 5- HT1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616396,,BAO_0000357,,
1072,5333,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL872907,,BAO_0000019,,
1073,4437,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616397,,BAO_0000019,,
1074,1742,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616398,,BAO_0000019,,
1075,16688,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616399,,BAO_0000357,,
1076,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL857065,,BAO_0000357,,
1077,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616400,,BAO_0000019,,
1078,12861,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616401,,BAO_0000019,,
1079,12490,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL616402,,BAO_0000019,,
1080,11828,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,B,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616403,,BAO_0000019,,
1081,11866,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,B,,,Sus scrofa,9823.0,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616404,,BAO_0000221,10000000.0,
1082,12827,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616405,,BAO_0000249,,
1083,12918,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,B,,,Sus scrofa,9823.0,,,,,51,H,8,Autocuration,1,,CHEMBL616406,,BAO_0000019,,
1084,12919,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,F,,,Sus scrofa,9823.0,,,,,51,H,8,Expert,1,,CHEMBL616407,,BAO_0000019,,
1085,13047,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,B,,,Oryctolagus cuniculus,9986.0,,,,,51,H,8,Autocuration,1,,CHEMBL616408,,BAO_0000019,,
1086,15796,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616409,,BAO_0000249,,
1087,3651,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616410,,BAO_0000221,10000000.0,
1088,188,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616411,,BAO_0000357,,
1089,16616,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616412,,BAO_0000249,,
1090,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616413,,BAO_0000249,10000000.0,
1091,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616414,,BAO_0000221,10000000.0,
1092,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616415,,BAO_0000221,10000000.0,
1093,14776,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616416,,BAO_0000019,,
1094,12158,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616417,,BAO_0000357,,
1095,13481,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616418,,BAO_0000357,,
1096,13427,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616419,,BAO_0000219,,
1097,10210,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616420,,BAO_0000357,,
1098,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616421,,BAO_0000249,,
1099,10205,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,B,,,,,,,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616422,,BAO_0000249,,
1100,10205,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL616423,,BAO_0000249,,
1101,12280,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616424,,BAO_0000357,,
1102,17386,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616425,,BAO_0000357,,
1103,13654,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616426,,BAO_0000357,,
1104,14423,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616427,,BAO_0000221,10000000.0,
1105,15412,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616428,,BAO_0000221,10000000.0,
1106,12073,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616290,,BAO_0000221,10000000.0,
1107,4101,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616052,,BAO_0000357,,
1108,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616053,,BAO_0000357,,
1109,6238,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616054,,BAO_0000249,,
1110,16273,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616055,,BAO_0000357,,
1111,11139,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616056,,BAO_0000357,,
1112,16796,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616057,,BAO_0000019,,
1113,9548,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,10576,D,9,Expert,1,,CHEMBL616058,,BAO_0000221,955.0,
1114,10381,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616059,,BAO_0000221,955.0,
1115,13408,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616060,,BAO_0000249,,
1116,13825,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616061,,BAO_0000221,10000000.0,
1117,11147,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616062,,BAO_0000221,10000000.0,
1118,10552,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616063,,BAO_0000249,,
1119,10552,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,,10576,H,8,Autocuration,1,,CHEMBL616064,,BAO_0000249,2435.0,
1120,17136,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616065,,BAO_0000249,,
1121,5778,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616066,,BAO_0000249,,
1122,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616067,,BAO_0000221,10000000.0,
1123,13481,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616068,,BAO_0000221,10000000.0,
1124,13630,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616069,,BAO_0000221,10000000.0,
1125,16245,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616070,,BAO_0000249,,
1126,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616071,,BAO_0000221,10000000.0,
1127,14509,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616072,,BAO_0000221,10000000.0,
1128,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616073,,BAO_0000221,10000000.0,
1129,14509,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616074,,BAO_0000221,10000000.0,
1130,14256,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616075,,BAO_0000019,,
1131,11139,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616076,,BAO_0000357,,
1132,11047,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616077,,BAO_0000019,,
1133,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616078,,BAO_0000019,,
1134,11047,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616079,,BAO_0000019,,
1135,2395,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL616080,485.0,BAO_0000219,,
1136,9699,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616081,,BAO_0000357,,
1137,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616082,,BAO_0000221,10000000.0,
1138,12028,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616083,,BAO_0000221,10000000.0,
1139,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616084,,BAO_0000019,,
1140,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616085,,BAO_0000019,,
1141,5815,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616086,,BAO_0000019,,
1142,2761,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616087,,BAO_0000221,10000000.0,
1143,13133,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616088,,BAO_0000357,,
1144,10444,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616089,,BAO_0000019,,
1145,13278,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616090,,BAO_0000357,,
1146,15874,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616091,,BAO_0000357,,
1147,10552,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",B,,,,,,Striatum,,Membranes,10576,H,8,Autocuration,1,,CHEMBL616092,,BAO_0000249,2435.0,
1148,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616093,,BAO_0000357,,
1149,11130,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),B,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616094,,BAO_0000218,,
1150,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616095,,BAO_0000221,955.0,
1151,13670,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616096,,BAO_0000357,,
1152,9888,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616097,,BAO_0000249,,
1153,3678,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616098,,BAO_0000249,,
1154,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616099,,BAO_0000221,10000000.0,
1155,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616100,,BAO_0000221,10000000.0,
1156,1185,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616101,,BAO_0000357,,
1157,2014,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616102,,BAO_0000249,,
1158,1185,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616103,,BAO_0000357,,
1159,14429,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616104,,BAO_0000019,,
1160,16288,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616105,,BAO_0000019,,
1161,5432,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616106,,BAO_0000019,,
1162,14429,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616107,,BAO_0000019,,
1163,13672,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616108,,BAO_0000357,,
1164,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616109,,BAO_0000221,10000000.0,
1165,11296,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616110,,BAO_0000357,,
1166,14749,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616111,449.0,BAO_0000219,,
1167,15086,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616112,,BAO_0000019,,
1168,13462,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616113,,BAO_0000221,10000000.0,
1169,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616114,,BAO_0000019,,
1170,15363,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616115,,BAO_0000019,,
1171,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616116,,BAO_0000357,,
1172,12816,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615844,,BAO_0000221,955.0,
1173,13542,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615939,,BAO_0000221,10000000.0,
1174,13308,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615940,,BAO_0000019,,
1175,13541,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL615941,,BAO_0000221,10000000.0,
1176,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615942,,BAO_0000221,10000000.0,
1177,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615943,,BAO_0000221,10000000.0,
1178,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615944,,BAO_0000221,10000000.0,
1179,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615945,,BAO_0000221,10000000.0,
1180,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615946,,BAO_0000221,10000000.0,
1181,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615947,,BAO_0000221,10000000.0,
1182,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615948,,BAO_0000221,10000000.0,
1183,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615949,,BAO_0000221,10000000.0,
1184,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615950,,BAO_0000221,10000000.0,
1185,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615951,,BAO_0000221,10000000.0,
1186,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615952,,BAO_0000221,10000000.0,
1187,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615953,,BAO_0000221,10000000.0,
1188,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615954,,BAO_0000221,10000000.0,
1189,10058,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL615955,,BAO_0000221,10000000.0,
1190,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615956,,BAO_0000221,10000000.0,
1191,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL615957,,BAO_0000221,10000000.0,
1192,12879,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615958,,BAO_0000019,,
1193,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615959,,BAO_0000019,,
1194,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615960,,BAO_0000019,,
1195,11964,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615961,,BAO_0000019,,
1196,9548,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL615962,,BAO_0000221,955.0,
1197,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615963,,BAO_0000019,,
1198,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615964,,BAO_0000019,,
1199,9098,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615965,,BAO_0000019,,
1200,13248,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL615966,449.0,BAO_0000219,,
1201,3147,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615967,,BAO_0000249,,
1202,13949,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615968,,BAO_0000019,,
1203,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL615969,449.0,BAO_0000218,,
1204,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615970,,BAO_0000218,,
1205,11883,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615971,,BAO_0000357,,
1206,15535,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10576,H,8,Expert,1,,CHEMBL615972,,BAO_0000249,,
1207,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615973,,BAO_0000249,,
1208,15535,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615974,,BAO_0000249,,
1209,16372,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL615975,449.0,BAO_0000219,,
1210,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615976,,BAO_0000249,,
1211,4795,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL872106,,BAO_0000221,10000000.0,
1212,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615977,,BAO_0000357,,
1213,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615978,,BAO_0000357,,
1214,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616166,,BAO_0000357,,
1215,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616167,,BAO_0000357,,
1216,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616168,,BAO_0000357,,
1217,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616169,,BAO_0000357,,
1218,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616170,,BAO_0000357,,
1219,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616171,,BAO_0000357,,
1220,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616172,,BAO_0000357,,
1221,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616173,,BAO_0000357,,
1222,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616174,,BAO_0000357,,
1223,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616175,,BAO_0000357,,
1224,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616176,,BAO_0000357,,
1225,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616177,,BAO_0000357,,
1226,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616178,,BAO_0000357,,
1227,9742,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616179,,BAO_0000019,,
1228,12073,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616180,,BAO_0000357,,
1229,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616181,,BAO_0000357,,
1230,15360,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616182,,BAO_0000019,,
1231,11576,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616183,,BAO_0000221,10000000.0,
1232,5834,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615874,,BAO_0000019,,
1233,2395,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,10576,D,9,Expert,1,,CHEMBL615875,485.0,BAO_0000219,,
1234,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615876,,BAO_0000019,,
1235,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615877,,BAO_0000019,,
1236,3967,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615878,,BAO_0000357,,
1237,12884,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615879,,BAO_0000357,,
1238,2343,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL615880,,BAO_0000357,,
1239,11511,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615881,,BAO_0000019,,
1240,11511,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL615882,,BAO_0000019,,
1241,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615883,,BAO_0000218,,
1242,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615884,,BAO_0000218,,
1243,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615885,,BAO_0000218,,
1244,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615886,,BAO_0000218,,
1245,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615887,,BAO_0000218,,
1246,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615888,,BAO_0000218,,
1247,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615889,,BAO_0000218,,
1248,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615890,,BAO_0000218,,
1249,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615891,,BAO_0000218,,
1250,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615892,,BAO_0000218,,
1251,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615893,,BAO_0000218,,
1252,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615894,,BAO_0000218,,
1253,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615895,,BAO_0000218,,
1254,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615896,,BAO_0000218,,
1255,16394,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,F,In vivo,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615897,,BAO_0000218,,
1256,16616,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL615898,,BAO_0000249,,
1257,16796,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL615899,,BAO_0000019,,
1258,16796,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616291,,BAO_0000019,,
1259,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616292,,BAO_0000357,,
1260,13241,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616293,,BAO_0000249,,
1261,12073,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616294,,BAO_0000221,10000000.0,
1262,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616295,,BAO_0000249,10000000.0,
1263,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616296,,BAO_0000221,955.0,
1264,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616297,,BAO_0000019,,
1265,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616605,,BAO_0000019,,
1266,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616606,,BAO_0000019,,
1267,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616607,,BAO_0000019,,
1268,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616608,,BAO_0000019,,
1269,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616609,,BAO_0000019,,
1270,13630,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616610,,BAO_0000019,,
1271,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616611,,BAO_0000019,,
1272,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616612,,BAO_0000019,,
1273,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616613,,BAO_0000019,,
1274,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616614,,BAO_0000019,,
1275,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616615,,BAO_0000019,,
1276,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616616,,BAO_0000019,,
1277,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616617,,BAO_0000019,,
1278,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616618,,BAO_0000019,,
1279,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616619,,BAO_0000019,,
1280,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616620,,BAO_0000019,,
1281,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616621,,BAO_0000019,,
1282,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616622,,BAO_0000019,,
1283,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616146,,BAO_0000019,,
1284,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832873,,BAO_0000019,,
1285,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616147,,BAO_0000019,,
1286,13630,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL872872,,BAO_0000019,,
1287,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616148,,BAO_0000019,,
1288,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616149,,BAO_0000221,10000000.0,
1289,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616150,,BAO_0000221,10000000.0,
1290,14331,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616151,,BAO_0000249,,
1291,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL872873,,BAO_0000221,10000000.0,
1292,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616670,,BAO_0000221,10000000.0,
1293,15260,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616671,,BAO_0000221,10000000.0,
1294,16616,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",F,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL884861,,BAO_0000249,,
1295,15629,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616672,,BAO_0000357,,
1296,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616673,,BAO_0000019,,
1297,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616674,,BAO_0000019,,
1298,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616675,,BAO_0000357,,
1299,14608,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616676,,BAO_0000221,10000000.0,
1300,12306,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616677,,BAO_0000221,10000000.0,
1301,12306,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616678,,BAO_0000221,10000000.0,
1302,15247,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616679,,BAO_0000357,,
1303,17529,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616680,,BAO_0000221,10000000.0,
1304,14826,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616681,,BAO_0000221,10000000.0,
1305,14826,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616682,,BAO_0000221,10000000.0,
1306,13241,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616683,,BAO_0000221,10000000.0,
1307,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616684,,BAO_0000221,10000000.0,
1308,14093,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616685,,BAO_0000221,10000000.0,
1309,14442,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616686,,BAO_0000221,955.0,
1310,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616687,,BAO_0000357,,
1311,9919,Affinity for 5-hydroxytryptamine 1A receptor site,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616688,,BAO_0000357,,
1312,11440,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616689,,BAO_0000221,10000000.0,
1313,11257,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616690,,BAO_0000357,,
1314,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616691,,BAO_0000357,,
1315,17331,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616692,,BAO_0000221,10000000.0,
1316,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616693,,BAO_0000249,,
1317,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616694,,BAO_0000019,,
1318,9699,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616695,,BAO_0000221,10000000.0,
1319,9547,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616696,,BAO_0000357,,
1320,10330,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616697,,BAO_0000357,,
1321,14331,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616698,,BAO_0000357,,
1322,14060,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616949,,BAO_0000019,,
1323,14744,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616950,,BAO_0000221,10000000.0,
1324,13506,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL832875,,BAO_0000357,,
1325,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616951,,BAO_0000221,955.0,
1326,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Expert,1,,CHEMBL616952,,BAO_0000221,955.0,
1327,10062,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616953,,BAO_0000357,,
1328,12073,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616954,,BAO_0000357,,
1329,14875,GTPgammaS radioligand binding assay,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616955,,BAO_0000357,,
1330,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616956,,BAO_0000357,,
1331,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616957,,BAO_0000019,,
1332,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616958,,BAO_0000019,,
1333,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616959,,BAO_0000357,,
1334,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616960,,BAO_0000357,,
1335,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616961,,BAO_0000019,,
1336,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,B,,,,,,,HeLa,,106,H,8,Expert,1,,CHEMBL616962,308.0,BAO_0000219,,
1337,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616963,308.0,BAO_0000219,,
1338,6491,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616524,,BAO_0000357,,
1339,16190,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616525,449.0,BAO_0000219,,
1340,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL872908,,BAO_0000019,,
1341,14165,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616526,,BAO_0000019,,
1342,4234,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616527,,BAO_0000357,,
1343,6328,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616528,,BAO_0000219,,
1344,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616529,,BAO_0000357,,
1345,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616530,,BAO_0000357,,
1346,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616531,,BAO_0000357,,
1347,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616532,,BAO_0000357,,
1348,6013,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616533,,BAO_0000357,,
1349,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616534,,BAO_0000357,,
1350,14454,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616535,,BAO_0000357,,
1351,16209,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616536,,BAO_0000357,,
1352,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616537,,BAO_0000357,,
1353,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616538,485.0,BAO_0000219,,
1354,14251,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616539,,BAO_0000019,,
1355,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616540,,BAO_0000019,,
1356,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616429,,BAO_0000357,,
1357,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616430,,BAO_0000357,,
1358,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616431,,BAO_0000219,,
1359,3804,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616432,,BAO_0000357,,
1360,2391,Affinity for 5-hydroxytryptamine 1B receptor subtype,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616433,,BAO_0000357,,
1361,4175,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616434,,BAO_0000357,,
1362,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616435,449.0,BAO_0000219,,
1363,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616436,,BAO_0000019,,
1364,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616437,308.0,BAO_0000219,,
1365,17211,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616438,308.0,BAO_0000219,,
1366,17211,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,B,,,,,,,HeLa,,106,H,8,Autocuration,1,,CHEMBL616439,308.0,BAO_0000219,,
1367,15926,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616440,,BAO_0000357,,
1368,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616441,485.0,BAO_0000219,,
1369,5843,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL616442,,BAO_0000357,,
1370,5843,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616443,,BAO_0000357,,
1371,16312,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616444,485.0,BAO_0000219,,
1372,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616445,,BAO_0000357,,
1373,15926,Binding activity against human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616446,,BAO_0000357,,
1374,4540,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616447,449.0,BAO_0000219,,
1375,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616448,,BAO_0000357,,
1376,17296,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616449,449.0,BAO_0000219,,
1377,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616450,449.0,BAO_0000219,,
1378,17296,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL857974,449.0,BAO_0000219,,
1379,15779,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616451,449.0,BAO_0000219,,
1380,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616452,449.0,BAO_0000219,,
1381,15779,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616453,449.0,BAO_0000219,,
1382,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616454,449.0,BAO_0000219,,
1383,14875,Binding affinity for human 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616455,,BAO_0000357,,
1384,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616456,449.0,BAO_0000219,,
1385,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616457,,BAO_0000357,,
1386,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616458,449.0,BAO_0000219,,
1387,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616459,449.0,BAO_0000219,,
1388,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616460,,BAO_0000019,,
1389,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616461,,BAO_0000019,,
1390,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616462,449.0,BAO_0000219,,
1391,14875,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616463,449.0,BAO_0000219,,
1392,15250,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616464,,BAO_0000019,,
1393,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616465,449.0,BAO_0000219,,
1394,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,17105,H,8,Autocuration,1,,CHEMBL832874,,BAO_0000357,,
1395,3025,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,F,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616184,,BAO_0000019,,
1396,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616185,,BAO_0000019,,
1397,14998,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Intermediate,1,,CHEMBL616186,,BAO_0000019,,
1398,14998,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616187,,BAO_0000019,,
1399,13969,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616188,,BAO_0000357,,
1400,13392,Binding affinity for 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,D,9,Intermediate,1,,CHEMBL873475,,BAO_0000357,,
1401,3651,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,B,,,Rattus norvegicus,10116.0,,Striatum,,,10577,D,9,Expert,1,,CHEMBL616189,,BAO_0000019,2435.0,
1402,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616190,,BAO_0000357,,
1403,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616191,,BAO_0000357,,
1404,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616192,,BAO_0000357,,
1405,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616193,,BAO_0000357,,
1406,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616194,,BAO_0000357,,
1407,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616195,,BAO_0000357,,
1408,13863,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616196,,BAO_0000357,,
1409,4622,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616197,,BAO_0000249,10000000.0,
1410,14911,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616198,,BAO_0000019,,
1411,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616199,,BAO_0000221,10000000.0,
1412,12678,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616200,,BAO_0000221,10000000.0,
1413,14235,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616201,,BAO_0000221,10000000.0,
1414,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616202,,BAO_0000221,10000000.0,
1415,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616203,,BAO_0000221,10000000.0,
1416,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616204,,BAO_0000221,10000000.0,
1417,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616205,,BAO_0000221,10000000.0,
1418,14949,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616206,,BAO_0000221,10000000.0,
1419,16118,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616207,,BAO_0000249,,
1420,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616208,,BAO_0000249,,
1421,3268,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616209,,BAO_0000249,,
1422,16117,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616210,,BAO_0000357,,
1423,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616211,,BAO_0000221,10000000.0,
1424,9783,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616504,,BAO_0000221,10000000.0,
1425,14356,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616505,,BAO_0000221,10000000.0,
1426,15740,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616506,,BAO_0000019,,
1427,12306,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872107,,BAO_0000221,10000000.0,
1428,13348,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616507,,BAO_0000221,10000000.0,
1429,10394,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616303,,BAO_0000249,,
1430,15260,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616304,,BAO_0000221,10000000.0,
1431,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616305,,BAO_0000221,10000000.0,
1432,15260,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,F,,,,,,Hippocampus,,,10576,H,8,Intermediate,1,,CHEMBL616306,,BAO_0000221,10000000.0,
1433,12851,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616307,,BAO_0000357,,
1434,2148,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL881829,,BAO_0000221,10000000.0,
1435,13134,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616308,,BAO_0000357,,
1436,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616309,,BAO_0000019,,
1437,12462,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616310,,BAO_0000019,,
1438,12462,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,B,,,,,,,CHO,,10576,H,8,Autocuration,1,,CHEMBL616311,449.0,BAO_0000219,,
1439,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616312,,BAO_0000357,,
1440,11933,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616313,,BAO_0000357,,
1441,403,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616314,,BAO_0000221,10000000.0,
1442,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616315,,BAO_0000221,10000000.0,
1443,15538,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616567,,BAO_0000221,10000000.0,
1444,15538,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616568,,BAO_0000221,10000000.0,
1445,12464,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,B,,,,,,,,,10576,H,8,Intermediate,1,,CHEMBL616569,,BAO_0000019,,
1446,1455,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616570,,BAO_0000357,,
1447,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616571,,BAO_0000357,,
1448,12639,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616572,,BAO_0000221,10000000.0,
1449,13949,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616573,,BAO_0000249,,
1450,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616574,,BAO_0000357,,
1451,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616575,,BAO_0000221,10000000.0,
1452,14829,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL872108,,BAO_0000221,10000000.0,
1453,12092,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616576,,BAO_0000357,,
1454,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616577,,BAO_0000249,,
1455,403,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616578,,BAO_0000249,,
1456,3967,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616579,,BAO_0000357,,
1457,12771,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616580,,BAO_0000019,,
1458,15086,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616581,,BAO_0000019,,
1459,14909,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616582,,BAO_0000221,10000000.0,
1460,14949,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616583,,BAO_0000221,10000000.0,
1461,2309,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616584,,BAO_0000221,10000000.0,
1462,4170,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616585,,BAO_0000357,,
1463,11642,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616586,,BAO_0000221,10000000.0,
1464,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616587,,BAO_0000221,10000000.0,
1465,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616588,,BAO_0000221,10000000.0,
1466,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616589,,BAO_0000221,10000000.0,
1467,12953,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616590,,BAO_0000221,10000000.0,
1468,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",B,,,,,,,CHO,,10576,H,8,Expert,1,,CHEMBL616591,449.0,BAO_0000219,,
1469,12536,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616592,,BAO_0000357,,
1470,10058,The inhibition activity of 5-HT1A at 1 uM,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616593,,BAO_0000357,,
1471,12902,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",B,,,,,,,CHO-K1,,10576,H,8,Expert,1,,CHEMBL616594,485.0,BAO_0000219,,
1472,14057,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616595,,BAO_0000249,,
1473,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616596,,BAO_0000357,,
1474,11296,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616597,,BAO_0000221,10000000.0,
1475,11296,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Expert,1,,CHEMBL616598,,BAO_0000221,10000000.0,
1476,16616,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,F,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616599,,BAO_0000249,,
1477,16616,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",F,,,Rattus norvegicus,10116.0,,Hippocampus,,Membranes,10576,D,9,Expert,1,,CHEMBL616600,,BAO_0000249,10000000.0,
1478,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616601,,BAO_0000019,,
1479,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616602,,BAO_0000019,,
1480,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616603,,BAO_0000019,,
1481,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616604,,BAO_0000019,,
1482,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616316,,BAO_0000249,,
1483,17136,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616317,,BAO_0000249,,
1484,16616,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616318,,BAO_0000019,,
1485,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616319,,BAO_0000221,10000000.0,
1486,17331,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616320,,BAO_0000221,10000000.0,
1487,17167,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616321,,BAO_0000221,10000000.0,
1488,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616322,,BAO_0000019,,
1489,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616323,,BAO_0000019,,
1490,4671,Ratio of binding affinity to 5-HT 1A and D2 receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616324,,BAO_0000357,,
1491,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616325,,BAO_0000221,10000000.0,
1492,10058,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616326,,BAO_0000221,10000000.0,
1493,10058,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616327,,BAO_0000221,10000000.0,
1494,12073,Percentage inhibition against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616328,,BAO_0000357,,
1495,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL858110,,BAO_0000249,,
1496,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616329,,BAO_0000249,,
1497,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616330,,BAO_0000249,,
1498,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616331,,BAO_0000249,,
1499,2759,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616332,,BAO_0000249,,
1500,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL857063,,BAO_0000249,955.0,
1501,9737,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616333,,BAO_0000019,,
1502,5717,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,F,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616334,,BAO_0000019,,
1503,12253,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616335,,BAO_0000221,10000000.0,
1504,14025,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616336,,BAO_0000019,,
1505,10425,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616337,,BAO_0000249,,
1506,14998,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616338,,BAO_0000019,,
1507,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616339,,BAO_0000221,10000000.0,
1508,13694,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616340,,BAO_0000221,10000000.0,
1509,4342,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616341,,BAO_0000357,,
1510,12936,Binding affinity against rat 5-hydroxytryptamine 1A receptor,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616342,,BAO_0000357,,
1511,13144,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,B,,,Rattus norvegicus,10116.0,,,,,10576,D,9,Expert,1,,CHEMBL616343,,BAO_0000019,,
1512,13343,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616344,,BAO_0000019,,
1513,12132,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616345,,BAO_0000357,,
1514,15419,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616346,,BAO_0000019,,
1515,1479,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616347,,BAO_0000221,10000000.0,
1516,14287,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616348,,BAO_0000019,,
1517,13116,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616349,,BAO_0000357,,
1518,2759,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,10576,D,9,Expert,1,,CHEMBL616152,,BAO_0000249,,
1519,2759,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616153,,BAO_0000249,,
1520,14748,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616154,,BAO_0000019,,
1521,12304,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616155,,BAO_0000019,,
1522,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616156,,BAO_0000221,10000000.0,
1523,12409,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,10576,D,9,Expert,1,,CHEMBL616157,,BAO_0000221,10000000.0,
1524,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL616158,,BAO_0000221,10000000.0,
1525,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616159,,BAO_0000357,,
1526,14256,pKi value against rat 5-hydroxytryptamine 1A receptor.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL616160,,BAO_0000357,,
1527,16567,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616161,,BAO_0000019,,
1528,15740,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616162,,BAO_0000019,,
1529,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL616163,,BAO_0000357,,
1530,1970,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,B,,,,,,,,Membranes,10626,H,8,Expert,1,,CHEMBL616164,,BAO_0000249,,
1531,10034,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616165,,BAO_0000221,955.0,
1532,13348,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,B,,,Rattus norvegicus,10116.0,,,,,51,H,8,Autocuration,1,,CHEMBL616355,,BAO_0000019,,
1533,13630,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,F,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616356,,BAO_0000019,,
1534,10862,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,B,,,,,,Brain,,,10576,H,8,Autocuration,1,,CHEMBL616357,,BAO_0000221,955.0,
1535,12058,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL616358,,BAO_0000019,,
1536,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616359,,BAO_0000357,,
1537,15453,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616360,,BAO_0000357,,
1538,4820,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616361,,BAO_0000357,,
1539,1089,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616362,,BAO_0000357,,
1540,386,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,B,,,,,,,,Brain membranes,51,H,8,Autocuration,1,,CHEMBL616363,,BAO_0000249,,
1541,6011,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616364,,BAO_0000357,,
1542,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616365,,BAO_0000357,,
1543,4402,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616366,,BAO_0000357,,
1544,17066,Binding affinity towards 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL872906,,BAO_0000357,,
1545,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616367,,BAO_0000357,,
1546,2474,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616368,,BAO_0000357,,
1547,4775,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616369,,BAO_0000357,,
1548,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616370,,BAO_0000357,,
1549,14294,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,B,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL616371,,BAO_0000357,,
1550,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,51,H,8,Autocuration,1,,CHEMBL616372,449.0,BAO_0000219,,
1551,11376,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL616373,,BAO_0000219,,
1552,2474,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,B,In vivo,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616374,,BAO_0000218,,
1553,13311,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,B,,,,,,Hippocampus,,,51,H,8,Autocuration,1,,CHEMBL616375,,BAO_0000221,10000000.0,
1554,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616376,,BAO_0000357,,
1555,1633,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,B,,,,,,,,,51,H,8,Expert,1,,CHEMBL857064,,BAO_0000357,,
1556,11866,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616377,,BAO_0000357,,
1557,4373,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616378,,BAO_0000357,,
1558,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616379,,BAO_0000357,,
1559,16946,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616380,,BAO_0000357,,
1560,13291,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616381,,BAO_0000357,,
1561,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616382,,BAO_0000357,,
1562,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616383,,BAO_0000357,,
1563,3032,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,11863,D,9,Expert,1,,CHEMBL616350,449.0,BAO_0000219,,
1564,16655,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616351,,BAO_0000357,,
1565,14532,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616352,,BAO_0000357,,
1566,13944,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616353,,BAO_0000357,,
1567,13033,Binding affinity against serotonergic 5-HT1a receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616354,,BAO_0000357,,
1568,10321,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616508,,BAO_0000357,,
1569,2968,Binding affinity for 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616559,,BAO_0000357,,
1570,13964,Binding affinity at 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616560,,BAO_0000357,,
1571,15527,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616561,,BAO_0000357,,
1572,12248,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616562,449.0,BAO_0000219,,
1573,12249,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,B,,,,,,,CHO,,11863,H,8,Autocuration,1,,CHEMBL616563,449.0,BAO_0000219,,
1574,15120,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616564,,BAO_0000357,,
1575,13313,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616565,,BAO_0000357,,
1576,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616566,,BAO_0000218,,
1577,16700,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616989,,BAO_0000357,,
1578,2201,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL857975,,BAO_0000357,,
1579,1274,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,Mus musculus,10090.0,,,,,11863,D,9,Expert,1,,CHEMBL616990,,BAO_0000357,,
1580,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616991,,BAO_0000357,,
1581,12146,Tested against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616992,,BAO_0000357,,
1582,14059,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,11863,H,8,Autocuration,1,,CHEMBL616993,,BAO_0000357,,
1583,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Expert,1,,CHEMBL616994,,BAO_0000019,,
1584,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616995,,BAO_0000019,,
1585,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105571,D,9,Intermediate,1,,CHEMBL616996,722.0,BAO_0000219,,
1586,3025,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616997,,BAO_0000218,,
1587,3025,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,F,In vivo,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616998,,BAO_0000218,,
1588,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL616999,,BAO_0000019,,
1589,15329,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617000,,BAO_0000019,,
1590,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL617001,,BAO_0000019,,
1591,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,106,H,8,Autocuration,1,,CHEMBL858111,,BAO_0000019,,
1592,14165,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617002,,BAO_0000019,,
1593,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617003,,BAO_0000019,,
1594,14214,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617004,,BAO_0000019,,
1595,14214,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,F,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL617005,,BAO_0000019,,
1596,13729,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,F,,,Homo sapiens,9606.0,,,CHO-K1,,106,D,9,Expert,1,,CHEMBL616623,485.0,BAO_0000219,,
1597,3025,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616624,449.0,BAO_0000219,,
1598,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL883243,,BAO_0000357,,
1599,2391,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616625,,BAO_0000019,,
1600,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",F,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616626,449.0,BAO_0000219,,
1601,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616627,449.0,BAO_0000219,,
1602,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616628,449.0,BAO_0000219,,
1603,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616629,449.0,BAO_0000219,,
1604,2598,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,F,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616630,449.0,BAO_0000219,,
1605,14956,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Expert,1,,CHEMBL616631,,BAO_0000019,,
1606,14956,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616632,,BAO_0000019,,
1607,14214,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL616633,,BAO_0000357,,
1608,3463,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616634,449.0,BAO_0000219,,
1609,15331,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616635,,BAO_0000357,,
1610,16146,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,Homo sapiens,9606.0,,,,,106,D,9,Expert,1,,CHEMBL885358,,BAO_0000357,,
1611,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,106,D,9,Expert,1,,CHEMBL616636,449.0,BAO_0000219,,
1612,14158,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616637,449.0,BAO_0000219,,
1613,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616638,,BAO_0000357,,
1614,15250,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616639,449.0,BAO_0000219,,
1615,15250,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616640,449.0,BAO_0000219,,
1616,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616641,449.0,BAO_0000219,,
1617,15332,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616642,449.0,BAO_0000219,,
1618,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616643,449.0,BAO_0000219,,
1619,3805,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616644,,BAO_0000357,,
1620,14875,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616645,,BAO_0000357,,
1621,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616646,,BAO_0000019,,
1622,14454,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),F,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL616647,,BAO_0000019,,
1623,16288,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616509,,BAO_0000357,,
1624,16288,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616510,,BAO_0000357,,
1625,16312,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616511,,BAO_0000357,,
1626,1348,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616512,,BAO_0000357,,
1627,5834,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616513,,BAO_0000357,,
1628,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616514,,BAO_0000019,2435.0,
1629,1414,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,B,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616515,,BAO_0000357,,
1630,14998,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616516,,BAO_0000019,,
1631,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616517,,BAO_0000357,,
1632,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616518,,BAO_0000357,,
1633,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616519,,BAO_0000357,,
1634,10639,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616520,,BAO_0000357,,
1635,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616521,,BAO_0000357,,
1636,1375,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616522,,BAO_0000357,,
1637,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL884531,,BAO_0000357,,
1638,11147,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616523,,BAO_0000357,,
1639,13366,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,B,,,Bos taurus,9913.0,,Striatum,,,105,H,8,Autocuration,1,,CHEMBL616731,,BAO_0000019,2435.0,
1640,10444,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616732,,BAO_0000019,,
1641,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616733,,BAO_0000357,,
1642,16532,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616734,,BAO_0000357,,
1643,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616735,,BAO_0000249,,
1644,12827,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616736,,BAO_0000249,,
1645,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616737,,BAO_0000019,,
1646,14025,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,B,,,Bos taurus,9913.0,,,,,105,H,8,Autocuration,1,,CHEMBL616738,,BAO_0000019,,
1647,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616739,,BAO_0000019,,
1648,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616740,,BAO_0000019,,
1649,12919,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,F,,,Bos taurus,9913.0,,,,,105,H,8,Expert,1,,CHEMBL616741,,BAO_0000019,,
1650,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,B,,,Gorilla gorilla,9593.0,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616742,722.0,BAO_0000219,,
1651,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616743,,BAO_0000019,,
1652,1375,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616744,,BAO_0000019,,
1653,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616745,,BAO_0000019,,
1654,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616746,,BAO_0000019,,
1655,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616747,,BAO_0000019,,
1656,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616748,,BAO_0000019,,
1657,12409,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616648,,BAO_0000019,,
1658,11574,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616649,,BAO_0000357,,
1659,1558,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616650,,BAO_0000357,,
1660,12409,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616651,,BAO_0000218,,
1661,12409,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616652,,BAO_0000218,,
1662,12409,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616653,,BAO_0000218,,
1663,12409,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,F,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616654,,BAO_0000218,,
1664,12253,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616655,,BAO_0000019,,
1665,12936,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616656,,BAO_0000357,,
1666,13181,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,B,,,Cavia porcellus,10141.0,,,,,105,H,8,Autocuration,1,,CHEMBL616657,,BAO_0000019,,
1667,12409,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,B,,,Cavia porcellus,10141.0,,Striatum,,,105570,D,9,Intermediate,1,,CHEMBL616658,,BAO_0000357,2435.0,
1668,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,B,,,Cavia porcellus,10141.0,,,,,105570,D,9,Intermediate,1,,CHEMBL616659,,BAO_0000357,,
1669,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL616660,,BAO_0000357,,
1670,13051,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616661,,BAO_0000357,,
1671,3463,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616662,,BAO_0000019,,
1672,15315,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616663,,BAO_0000019,,
1673,6011,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616664,,BAO_0000019,,
1674,14159,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL881820,449.0,BAO_0000219,,
1675,14159,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616665,449.0,BAO_0000219,,
1676,15250,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616666,449.0,BAO_0000219,,
1677,15250,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616667,449.0,BAO_0000219,,
1678,15331,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616668,449.0,BAO_0000219,,
1679,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616669,449.0,BAO_0000219,,
1680,15332,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617040,449.0,BAO_0000219,,
1681,3294,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL617041,449.0,BAO_0000219,,
1682,14158,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617042,449.0,BAO_0000219,,
1683,14956,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617043,449.0,BAO_0000219,,
1684,12469,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617044,,BAO_0000019,,
1685,3463,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,F,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617045,449.0,BAO_0000219,,
1686,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617046,449.0,BAO_0000219,,
1687,15250,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL617047,449.0,BAO_0000219,,
1688,14956,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",F,,,,,,,,,105,H,8,Expert,1,,CHEMBL617048,,BAO_0000019,,
1689,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616897,,BAO_0000019,,
1690,14159,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",F,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616898,,BAO_0000019,,
1691,14499,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,F,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL858201,449.0,BAO_0000219,,
1692,15315,Intrinsic activity for 5-hydroxytryptamine 1D receptor,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616899,,BAO_0000019,,
1693,3294,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),B,In vitro,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616900,,BAO_0000219,,
1694,3463,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616901,449.0,BAO_0000219,,
1695,15331,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616902,,BAO_0000357,,
1696,14159,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616903,449.0,BAO_0000219,,
1697,14158,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616904,449.0,BAO_0000219,,
1698,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616905,,BAO_0000357,,
1699,15250,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616906,449.0,BAO_0000219,,
1700,15250,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616907,449.0,BAO_0000219,,
1701,15331,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616908,449.0,BAO_0000219,,
1702,15332,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616909,449.0,BAO_0000219,,
1703,14499,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616910,449.0,BAO_0000219,,
1704,15332,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616911,449.0,BAO_0000219,,
1705,14956,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL616912,449.0,BAO_0000219,,
1706,3805,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616913,,BAO_0000357,,
1707,6011,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616914,449.0,BAO_0000219,,
1708,16190,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616915,449.0,BAO_0000219,,
1709,14165,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616916,,BAO_0000019,,
1710,4234,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616917,,BAO_0000357,,
1711,15527,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616918,,BAO_0000357,,
1712,6328,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616919,,BAO_0000219,,
1713,16209,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616920,,BAO_0000357,,
1714,14770,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872914,,BAO_0000357,,
1715,2598,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616921,,BAO_0000357,,
1716,6897,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616922,,BAO_0000357,,
1717,6013,Binding affinity towards 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616923,,BAO_0000357,,
1718,5843,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616924,,BAO_0000357,,
1719,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL875909,,BAO_0000357,,
1720,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616925,,BAO_0000357,,
1721,14454,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616926,,BAO_0000357,,
1722,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616927,,BAO_0000357,,
1723,13729,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,F,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616928,485.0,BAO_0000219,,
1724,6011,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),B,In vitro,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616929,,BAO_0000219,,
1725,4234,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616930,,BAO_0000357,,
1726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616931,,BAO_0000019,,
1727,3025,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616932,,BAO_0000357,,
1728,15315,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616933,,BAO_0000357,,
1729,14214,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616934,,BAO_0000219,,
1730,3804,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616935,,BAO_0000357,,
1731,16700,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616936,,BAO_0000357,,
1732,2391,Affinity for 5-hydroxytryptamine 1D receptor subtype,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616937,,BAO_0000357,,
1733,4175,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616938,,BAO_0000357,,
1734,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616939,,BAO_0000019,,
1735,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616940,,BAO_0000019,,
1736,15926,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616941,,BAO_0000357,,
1737,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616942,485.0,BAO_0000219,,
1738,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616943,485.0,BAO_0000219,,
1739,14956,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,B,,,,,,,CHO,,104802,H,4,Autocuration,1,,CHEMBL616944,449.0,BAO_0000219,,
1740,3294,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616945,,BAO_0000019,,
1741,12861,Binding activity radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616946,,BAO_0000357,,
1742,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616947,,BAO_0000019,,
1743,16312,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL616948,485.0,BAO_0000219,,
1744,5104,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616851,,BAO_0000357,,
1745,5105,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616852,,BAO_0000357,,
1746,14499,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616853,,BAO_0000357,,
1747,15926,Binding activity against human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616854,,BAO_0000357,,
1748,4540,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,B,,,Homo sapiens,9606.0,,,CHO,,105,D,9,Expert,1,,CHEMBL616855,449.0,BAO_0000219,,
1749,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616856,449.0,BAO_0000219,,
1750,15779,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616857,449.0,BAO_0000219,,
1751,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616858,,BAO_0000357,,
1752,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616859,449.0,BAO_0000219,,
1753,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616860,449.0,BAO_0000219,,
1754,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616861,722.0,BAO_0000219,,
1755,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616541,722.0,BAO_0000219,,
1756,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL616542,722.0,BAO_0000219,,
1757,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616543,449.0,BAO_0000219,,
1758,14875,Binding affinity for human 5-hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL616544,,BAO_0000357,,
1759,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616545,449.0,BAO_0000219,,
1760,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616546,,BAO_0000357,,
1761,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616547,449.0,BAO_0000219,,
1762,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Autocuration,1,,CHEMBL616548,449.0,BAO_0000219,,
1763,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616549,,BAO_0000019,,
1764,14454,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,F,,,,,,,,,105,H,8,Expert,1,,CHEMBL616550,,BAO_0000019,,
1765,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL857066,,BAO_0000357,,
1766,5254,Binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616551,,BAO_0000357,,
1767,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616552,,BAO_0000357,,
1768,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,F,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL832876,,BAO_0000019,,
1769,12352,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616553,,BAO_0000019,,
1770,9098,Binding affinity towards 5-HT1B was determined,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616554,,BAO_0000357,,
1771,14430,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616555,,BAO_0000019,,
1772,13657,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616556,,BAO_0000019,,
1773,13657,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616557,,BAO_0000019,,
1774,15854,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616558,,BAO_0000019,,
1775,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616749,,BAO_0000019,,
1776,10025,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616750,,BAO_0000357,,
1777,10025,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616751,,BAO_0000357,,
1778,14286,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616752,,BAO_0000249,,
1779,3651,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616753,,BAO_0000019,2435.0,
1780,14178,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616754,,BAO_0000357,,
1781,10639,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616755,,BAO_0000019,,
1782,13605,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616756,,BAO_0000019,2435.0,
1783,5834,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616757,,BAO_0000019,2435.0,
1784,10922,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616758,,BAO_0000357,2435.0,
1785,14286,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616759,,BAO_0000249,,
1786,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616760,,BAO_0000357,,
1787,14826,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616761,,BAO_0000019,2435.0,
1788,9699,Binding affinity against 5-HT1B serotonin receptor in rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616762,,BAO_0000019,2435.0,
1789,14423,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616763,,BAO_0000019,,
1790,10062,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL872909,,BAO_0000357,,
1791,10062,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616764,,BAO_0000357,,
1792,12280,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616765,,BAO_0000357,,
1793,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616766,,BAO_0000357,2435.0,
1794,15412,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616767,,BAO_0000357,2435.0,
1795,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616768,,BAO_0000357,,
1796,11147,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616769,,BAO_0000357,,
1797,9547,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616770,,BAO_0000019,,
1798,10444,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616771,,BAO_0000019,,
1799,12469,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,B,,,,,,Striatum,,,10577,H,8,Autocuration,1,,CHEMBL616772,,BAO_0000019,2435.0,
1800,9098,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616773,,BAO_0000019,,
1801,9098,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616774,,BAO_0000019,,
1802,9699,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616775,,BAO_0000357,,
1803,10394,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616776,,BAO_0000249,,
1804,12092,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616777,,BAO_0000357,,
1805,16700,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616778,,BAO_0000357,,
1806,403,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616779,,BAO_0000249,,
1807,12771,Binding affinity towards 5-hydroxytryptamine 1B receptor,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616780,,BAO_0000357,,
1808,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616781,,BAO_0000019,,
1809,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616782,,BAO_0000357,,
1810,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616783,,BAO_0000357,,
1811,12953,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,B,,,,,,Striatum,,,10577,H,8,Expert,1,,CHEMBL616784,,BAO_0000019,2435.0,
1812,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616785,,BAO_0000357,,
1813,9737,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL857067,,BAO_0000249,955.0,
1814,9737,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616786,,BAO_0000019,,
1815,9737,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,10577,H,8,Autocuration,1,,CHEMBL616787,,BAO_0000249,955.0,
1816,12827,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616788,,BAO_0000357,,
1817,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616789,,BAO_0000357,,
1818,9786,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616790,,BAO_0000019,,
1819,13116,Binding affinity at 5-hydroxytryptamine 1B receptor,B,,,,,,,,,10577,H,8,Expert,1,,CHEMBL616791,,BAO_0000357,,
1820,16429,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616792,,BAO_0000019,,
1821,12409,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,B,,,Rattus norvegicus,10116.0,,,,,10577,D,9,Expert,1,,CHEMBL616793,,BAO_0000249,,
1822,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616794,,BAO_0000357,,
1823,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL616795,,BAO_0000357,,
1824,5486,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616796,,BAO_0000019,,
1825,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616797,,BAO_0000357,,
1826,386,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,B,,,,,,,,Brain membranes,106,H,8,Autocuration,1,,CHEMBL616798,,BAO_0000249,,
1827,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616799,,BAO_0000357,,
1828,6011,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616800,,BAO_0000357,,
1829,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616801,,BAO_0000357,,
1830,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616802,,BAO_0000357,,
1831,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616803,,BAO_0000357,,
1832,1633,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,B,,,,,,,,,106,H,8,Expert,1,,CHEMBL857068,,BAO_0000357,,
1833,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616804,,BAO_0000357,,
1834,4373,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616805,,BAO_0000357,,
1835,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616806,,BAO_0000357,,
1836,11574,Binding affinity against 5-hydroxytryptamine 1B receptor,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616807,,BAO_0000357,,
1837,10321,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616808,,BAO_0000357,,
1838,15527,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616809,,BAO_0000357,,
1839,17200,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616810,,BAO_0000357,,
1840,14423,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,104802,H,4,Autocuration,1,,CHEMBL616811,,BAO_0000224,,
1841,5834,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL616812,,BAO_0000357,,
1842,11473,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616813,,BAO_0000357,,
1843,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616814,,BAO_0000357,,
1844,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616815,,BAO_0000357,,
1845,10639,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616816,,BAO_0000357,,
1846,14331,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616817,,BAO_0000357,,
1847,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616818,,BAO_0000357,,
1848,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616819,,BAO_0000357,,
1849,14331,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616820,,BAO_0000357,,
1850,11828,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL616821,,BAO_0000019,,
1851,11866,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL616822,,BAO_0000357,,
1852,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,108,H,8,Autocuration,1,,CHEMBL616823,,BAO_0000019,,
1853,188,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616824,,BAO_0000357,,
1854,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616825,,BAO_0000357,,
1855,11825,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616826,,BAO_0000357,,
1856,11624,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616827,,BAO_0000019,,
1857,11139,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616828,,BAO_0000357,,
1858,11147,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616829,,BAO_0000357,,
1859,10444,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616830,,BAO_0000019,,
1860,11624,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616831,,BAO_0000357,,
1861,11662,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616832,,BAO_0000019,,
1862,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616833,,BAO_0000019,,
1863,11662,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL616834,,BAO_0000019,,
1864,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL829595,,BAO_0000019,,
1865,9098,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616835,,BAO_0000357,,
1866,10394,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL872910,,BAO_0000249,,
1867,11933,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL616836,,BAO_0000357,,
1868,12092,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616837,,BAO_0000357,,
1869,12253,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Autocuration,1,,CHEMBL616466,,BAO_0000019,,
1870,12253,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,B,,,Rattus norvegicus,10116.0,,,HEK293,,12689,D,9,Autocuration,1,,CHEMBL616467,722.0,BAO_0000219,,
1871,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616468,,BAO_0000357,,
1872,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616469,,BAO_0000357,,
1873,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL616470,,BAO_0000357,,
1874,11574,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616471,,BAO_0000357,,
1875,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616472,,BAO_0000357,,
1876,13944,Binding affinity against 5-hydroxytryptamine 1C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616473,,BAO_0000357,,
1877,13033,Binding affinity against serotonergic 5-HT1c receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616474,,BAO_0000357,,
1878,10321,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616475,,BAO_0000357,,
1879,11866,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL616476,,BAO_0000357,,
1880,14454,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL616477,,BAO_0000019,,
1881,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616478,,BAO_0000224,,
1882,11574,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616479,,BAO_0000224,,
1883,13631,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616480,,BAO_0000019,,
1884,9630,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616481,,BAO_0000019,,
1885,8822,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616482,,BAO_0000249,,
1886,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL884713,,BAO_0000221,955.0,
1887,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616483,,BAO_0000224,,
1888,9064,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616484,,BAO_0000224,,
1889,9806,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616485,,BAO_0000019,,
1890,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616486,,BAO_0000224,,
1891,8868,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616487,,BAO_0000224,,
1892,12765,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616488,,BAO_0000224,,
1893,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616489,,BAO_0000019,,
1894,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616490,,BAO_0000019,,
1895,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616491,,BAO_0000019,,
1896,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616492,,BAO_0000019,,
1897,11049,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616493,,BAO_0000019,,
1898,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616494,,BAO_0000019,,
1899,11473,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616495,,BAO_0000019,,
1900,3086,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616496,,BAO_0000019,,
1901,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616497,,BAO_0000019,,
1902,11049,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616498,,BAO_0000019,,
1903,10639,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616499,,BAO_0000019,,
1904,10922,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616500,,BAO_0000019,,
1905,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL616501,,BAO_0000221,955.0,
1906,10748,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL616502,,BAO_0000221,955.0,
1907,11614,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL884529,,BAO_0000249,,
1908,11615,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616503,,BAO_0000249,,
1909,11615,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616964,,BAO_0000224,,
1910,11614,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616965,,BAO_0000249,,
1911,11702,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616966,,BAO_0000224,,
1912,11702,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616967,,BAO_0000224,,
1913,11702,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616968,,BAO_0000224,,
1914,11702,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616969,,BAO_0000224,,
1915,13346,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL884530,,BAO_0000019,,
1916,10025,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616970,,BAO_0000224,,
1917,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616971,,BAO_0000224,,
1918,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616972,,BAO_0000224,,
1919,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616973,,BAO_0000224,,
1920,9036,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616974,,BAO_0000224,,
1921,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616975,,BAO_0000019,,
1922,12304,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616976,,BAO_0000019,,
1923,13276,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616977,,BAO_0000224,,
1924,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616978,,BAO_0000224,,
1925,12443,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616979,,BAO_0000224,,
1926,13830,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616980,,BAO_0000224,,
1927,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616981,,BAO_0000249,,
1928,9592,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL616982,,BAO_0000249,,
1929,10881,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616983,,BAO_0000224,,
1930,13605,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616984,,BAO_0000019,,
1931,11624,Inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL616985,,BAO_0000224,,
1932,4101,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616986,,BAO_0000224,,
1933,4101,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616987,,BAO_0000224,,
1934,15360,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL616988,,BAO_0000019,,
1935,11576,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617243,,BAO_0000019,,
1936,5834,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617244,,BAO_0000019,,
1937,2395,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617245,485.0,BAO_0000219,,
1938,11965,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617246,,BAO_0000249,,
1939,3967,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617546,,BAO_0000224,,
1940,11130,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),B,,,,,,,,Brain membranes,104686,H,4,Autocuration,1,,CHEMBL617547,,BAO_0000249,,
1941,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617548,,BAO_0000219,,
1942,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617549,,BAO_0000224,,
1943,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617550,,BAO_0000224,,
1944,11825,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617551,,BAO_0000224,,
1945,12120,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617552,,BAO_0000249,,
1946,12120,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617553,,BAO_0000249,,
1947,11963,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,F,,,,,,Thoracic aorta,,,104686,H,4,Autocuration,1,,CHEMBL617554,,BAO_0000019,1515.0,
1948,9069,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617555,,BAO_0000019,,
1949,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617556,,BAO_0000224,,
1950,17200,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617557,,BAO_0000357,,
1951,17200,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL617558,,BAO_0000357,,
1952,13969,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617559,,BAO_0000357,,
1953,13392,Binding affinity for 5-hydroxytryptamine 1D receptor,B,,,,,,,,,17106,D,9,Expert,1,,CHEMBL617560,,BAO_0000357,,
1954,1742,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617561,,BAO_0000249,,
1955,1742,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617562,,BAO_0000249,,
1956,14331,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,B,,,,,,Striatum,,,17106,H,8,Autocuration,1,,CHEMBL617563,,BAO_0000357,2435.0,
1957,12861,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,F,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617564,,BAO_0000019,,
1958,12861,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617565,,BAO_0000019,,
1959,12861,Binding activity radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL856076,,BAO_0000357,,
1960,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617566,,BAO_0000019,,
1961,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL875911,,BAO_0000019,,
1962,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617567,,BAO_0000019,,
1963,675,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617568,,BAO_0000249,,
1964,12490,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617569,,BAO_0000019,,
1965,11828,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,B,,,,,,,,,17106,H,8,Expert,1,,CHEMBL617570,,BAO_0000249,,
1966,11866,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617571,,BAO_0000357,,
1967,773,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,B,,,Sus scrofa,9823.0,,,,,105,H,8,Autocuration,1,,CHEMBL617572,,BAO_0000357,,
1968,13047,The compound was tested for intrinsic activity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617573,,BAO_0000357,,
1969,13047,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617574,,BAO_0000019,,
1970,13047,The compound was tested for binding affinity against 5-HT1D receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Expert,1,,CHEMBL617575,,BAO_0000357,,
1971,188,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617576,,BAO_0000357,,
1972,10639,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617577,,BAO_0000019,,
1973,12438,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,F,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617578,,BAO_0000019,,
1974,12438,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617579,,BAO_0000357,,
1975,15854,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617580,,BAO_0000019,,
1976,10394,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617581,,BAO_0000249,,
1977,12092,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,B,,,,,,,,,10578,H,8,Autocuration,1,,CHEMBL617582,,BAO_0000357,,
1978,3389,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,B,,,,,,,,,10578,H,8,Expert,1,,CHEMBL617583,,BAO_0000019,,
1979,6011,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617584,,BAO_0000357,,
1980,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617585,,BAO_0000357,,
1981,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL875912,,BAO_0000357,,
1982,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617586,,BAO_0000357,,
1983,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617587,,BAO_0000357,,
1984,11866,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617588,,BAO_0000357,,
1985,4687,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL857980,,BAO_0000357,,
1986,12146,Tested against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617589,,BAO_0000357,,
1987,10321,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617590,,BAO_0000357,,
1988,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617591,722.0,BAO_0000219,,
1989,1274,Binding affinity against 5-Hydroxytryptamine 1D receptor,B,,,Homo sapiens,9606.0,,,,,105,D,9,Expert,1,,CHEMBL617592,,BAO_0000357,,
1990,15250,,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617593,,BAO_0000357,,
1991,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL617594,485.0,BAO_0000219,,
1992,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617595,485.0,BAO_0000219,,
1993,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617596,722.0,BAO_0000219,,
1994,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,105,H,8,Autocuration,1,,CHEMBL617597,722.0,BAO_0000219,,
1995,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617598,,BAO_0000019,,
1996,13366,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL872916,,BAO_0000357,,
1997,13366,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617599,,BAO_0000357,,
1998,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617091,,BAO_0000357,,
1999,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",B,,,,,,,CHO-K1,,105,H,8,Expert,1,,CHEMBL617092,485.0,BAO_0000219,,
2000,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL617093,485.0,BAO_0000219,,
2001,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617094,,BAO_0000019,,
2002,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617095,,BAO_0000019,,
2003,14251,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617096,,BAO_0000019,,
2004,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617097,,BAO_0000019,,
2005,14251,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,F,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617098,,BAO_0000019,,
2006,13313,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617301,,BAO_0000357,,
2007,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617302,,BAO_0000357,,
2008,13366,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617303,,BAO_0000357,,
2009,13051,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617304,,BAO_0000357,,
2010,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,105,H,8,Expert,1,,CHEMBL617305,449.0,BAO_0000219,,
2011,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,B,,,Homo sapiens,9606.0,,,,,105,D,9,Autocuration,1,,CHEMBL617306,,BAO_0000219,,
2012,5619,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL617307,,BAO_0000357,,
2013,13047,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,105,H,8,Autocuration,1,,CHEMBL617308,,BAO_0000019,,
2014,16633,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617309,,BAO_0000357,,
2015,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617310,,BAO_0000357,,
2016,16633,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617311,,BAO_0000357,,
2017,16633,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617312,,BAO_0000357,,
2018,3269,Affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL617313,,BAO_0000357,,
2019,12409,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL617314,,BAO_0000357,,
2020,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617315,,BAO_0000019,,
2021,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617316,722.0,BAO_0000219,,
2022,13706,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,B,,,,,,,HEK293,,106,H,8,Autocuration,1,,CHEMBL617317,722.0,BAO_0000219,,
2023,12903,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL617318,449.0,BAO_0000219,,
2024,13047,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL617319,,BAO_0000019,,
2025,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617320,,BAO_0000357,,
2026,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617321,,BAO_0000357,,
2027,13366,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,106,D,9,Expert,1,,CHEMBL617322,,BAO_0000357,,
2028,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616862,,BAO_0000357,,
2029,13366,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616863,,BAO_0000357,,
2030,12469,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,B,,,,,,,CHO,,106,H,8,Autocuration,1,,CHEMBL616864,449.0,BAO_0000219,,
2031,13706,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616865,485.0,BAO_0000219,,
2032,13706,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,106,H,8,Autocuration,1,,CHEMBL616866,485.0,BAO_0000219,,
2033,13706,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,F,,,,,,,,,106,H,8,Autocuration,1,,CHEMBL616867,,BAO_0000019,,
2034,12902,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",B,,,,,,,CHO-K1,,106,H,8,Expert,1,,CHEMBL616868,485.0,BAO_0000219,,
2035,13051,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL616869,,BAO_0000357,,
2036,12903,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",B,,,,,,,CHO,,106,H,8,Expert,1,,CHEMBL616870,449.0,BAO_0000219,,
2037,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616871,485.0,BAO_0000219,,
2038,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616872,485.0,BAO_0000219,,
2039,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616873,485.0,BAO_0000219,,
2040,1558,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,F,,,,,,,CHO-K1,,105,H,8,Autocuration,1,,CHEMBL616838,485.0,BAO_0000219,,
2041,1558,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616839,,BAO_0000357,,
2042,13047,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,106,H,8,Autocuration,1,,CHEMBL616840,,BAO_0000019,,
2043,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616841,,BAO_0000357,,
2044,13313,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL616842,,BAO_0000357,,
2045,12409,Binding affinity against 5-hydroxytryptamine 1D receptor beta,B,,,,,,,,,105,H,8,Expert,1,,CHEMBL857976,,BAO_0000357,,
2046,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616843,449.0,BAO_0000219,,
2047,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616844,,BAO_0000357,,
2048,1348,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616845,,BAO_0000357,,
2049,4234,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,B,,,Homo sapiens,9606.0,,,,,10618,D,9,Expert,1,,CHEMBL616846,,BAO_0000357,,
2050,16209,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616847,,BAO_0000357,,
2051,10444,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616848,,BAO_0000019,,
2052,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616849,,BAO_0000357,,
2053,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL872911,,BAO_0000357,,
2054,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616850,,BAO_0000019,,
2055,12936,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,10618,D,9,Expert,1,,CHEMBL616699,449.0,BAO_0000219,,
2056,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616700,,BAO_0000357,,
2057,15779,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616701,449.0,BAO_0000219,,
2058,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616702,449.0,BAO_0000219,,
2059,15779,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616703,449.0,BAO_0000219,,
2060,13181,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616704,,BAO_0000357,,
2061,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616705,449.0,BAO_0000219,,
2062,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616706,,BAO_0000357,,
2063,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616707,449.0,BAO_0000219,,
2064,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616708,,BAO_0000357,,
2065,12146,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616709,,BAO_0000357,,
2066,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616710,449.0,BAO_0000219,,
2067,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616711,449.0,BAO_0000219,,
2068,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,10618,H,8,Autocuration,1,,CHEMBL616712,449.0,BAO_0000219,,
2069,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616713,,BAO_0000357,,
2070,4373,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616714,,BAO_0000357,,
2071,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616715,,BAO_0000357,,
2072,16633,Binding affinity towards 5-hydroxytryptamine 1E receptor,B,,,,,,,,,10618,H,8,Autocuration,1,,CHEMBL616716,,BAO_0000357,,
2073,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616717,,BAO_0000019,,
2074,17085,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616718,,BAO_0000019,,
2075,16209,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL875905,,BAO_0000019,,
2076,16209,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,F,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616719,,BAO_0000019,,
2077,17085,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",F,,,,,,,,,279,H,8,Expert,1,,CHEMBL616720,,BAO_0000019,,
2078,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616721,,BAO_0000357,,
2079,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616722,449.0,BAO_0000219,,
2080,3805,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616723,,BAO_0000357,,
2081,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL616724,449.0,BAO_0000219,,
2082,16190,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616725,,BAO_0000357,,
2083,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616726,,BAO_0000357,,
2084,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616727,,BAO_0000357,,
2085,16209,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616728,,BAO_0000357,,
2086,6866,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL616729,,BAO_0000357,,
2087,17085,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Expert,1,,CHEMBL616730,,BAO_0000019,,
2088,16312,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617125,,BAO_0000357,,
2089,6166,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL857977,,BAO_0000357,,
2090,15779,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617126,449.0,BAO_0000219,,
2091,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617127,449.0,BAO_0000219,,
2092,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617128,,BAO_0000357,,
2093,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617129,449.0,BAO_0000219,,
2094,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617130,,BAO_0000357,,
2095,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617131,449.0,BAO_0000219,,
2096,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617132,449.0,BAO_0000219,,
2097,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",B,,,,,,,CHO,,279,H,8,Autocuration,1,,CHEMBL617133,449.0,BAO_0000219,,
2098,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617134,,BAO_0000357,,
2099,4373,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617135,,BAO_0000357,,
2100,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,B,,,,,,,,,279,H,8,Autocuration,1,,CHEMBL617136,,BAO_0000357,,
2101,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617137,,BAO_0000019,,
2102,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617138,,BAO_0000019,,
2103,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617139,,BAO_0000019,,
2104,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617140,,BAO_0000019,,
2105,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617141,,BAO_0000218,,
2106,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858112,,BAO_0000019,,
2107,12352,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,B,,,,,,,,,17005,H,8,Intermediate,1,,CHEMBL617142,,BAO_0000019,,
2108,13657,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617143,,BAO_0000019,,
2109,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617144,,BAO_0000019,,
2110,14331,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,B,,,Bos taurus,9913.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617145,,BAO_0000019,,
2111,14331,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617146,,BAO_0000019,,
2112,12685,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617147,,BAO_0000019,,
2113,14389,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617148,,BAO_0000019,,
2114,14386,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,B,,,Cavia porcellus,10141.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617149,,BAO_0000019,,
2115,5732,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617150,,BAO_0000224,,
2116,16293,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617151,,BAO_0000224,,
2117,2078,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617201,,BAO_0000224,,
2118,5486,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL617202,,BAO_0000357,,
2119,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617203,,BAO_0000218,,
2120,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617204,,BAO_0000019,,
2121,13704,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617205,,BAO_0000224,,
2122,10297,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617206,,BAO_0000019,,
2123,11820,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,B,In vivo,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617207,,BAO_0000218,,
2124,10297,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617208,,BAO_0000019,,
2125,11555,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617209,,BAO_0000224,,
2126,11555,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617210,,BAO_0000224,,
2127,11555,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617211,,BAO_0000224,,
2128,10297,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,B,,,Mus musculus,10090.0,,,,,104826,D,5,Autocuration,1,,CHEMBL617212,,BAO_0000019,,
2129,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617213,,BAO_0000224,,
2130,16688,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,B,,,Sus scrofa,9823.0,,,,,104784,H,4,Autocuration,1,,CHEMBL617214,,BAO_0000224,,
2131,5333,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617215,,BAO_0000221,,
2132,4437,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617216,,BAO_0000221,,
2133,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,B,,,Sus scrofa,9823.0,,,,,17005,H,8,Autocuration,1,,CHEMBL617217,,BAO_0000357,,
2134,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617218,,BAO_0000019,,
2135,15267,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872913,,BAO_0000019,,
2136,11820,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,B,,,,,,,,,104826,H,4,Autocuration,1,,CHEMBL617219,,BAO_0000019,,
2137,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL873482,,BAO_0000224,,
2138,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617220,,BAO_0000019,,
2139,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617221,,BAO_0000019,,
2140,9162,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617222,,BAO_0000019,,
2141,10428,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL875906,,BAO_0000019,,
2142,9628,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617223,,BAO_0000019,,
2143,12704,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617224,,BAO_0000224,,
2144,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617225,,BAO_0000224,,
2145,188,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617226,,BAO_0000224,,
2146,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617227,,BAO_0000224,,
2147,10349,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617228,,BAO_0000224,,
2148,8868,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617229,,BAO_0000224,,
2149,10025,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617230,,BAO_0000224,,
2150,10025,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617231,,BAO_0000224,,
2151,11702,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617232,,BAO_0000224,,
2152,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617233,,BAO_0000224,,
2153,11702,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617234,,BAO_0000224,,
2154,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617235,,BAO_0000019,,
2155,11702,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617236,,BAO_0000019,,
2156,10085,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617237,,BAO_0000221,10000000.0,
2157,10085,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,B,,,,,,Hippocampus,,,104686,H,4,Autocuration,1,,CHEMBL617238,,BAO_0000221,10000000.0,
2158,9630,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617239,,BAO_0000221,955.0,
2159,11070,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617240,,BAO_0000019,,
2160,9841,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL617241,,BAO_0000249,,
2161,9841,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,B,,,,,,,,Membranes,104686,H,4,Autocuration,1,,CHEMBL875907,,BAO_0000249,,
2162,13291,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617242,,BAO_0000019,,
2163,10590,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617152,,BAO_0000019,,
2164,9064,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,B,,,Rattus norvegicus,10116.0,,Brain,,,104686,D,5,Autocuration,1,,CHEMBL617153,,BAO_0000221,955.0,
2165,12268,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104686,D,5,Autocuration,1,,CHEMBL617154,,BAO_0000249,,
2166,13508,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617155,,BAO_0000221,955.0,
2167,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617156,,BAO_0000019,,
2168,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617157,,BAO_0000019,,
2169,11200,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617158,,BAO_0000019,,
2170,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617159,,BAO_0000019,,
2171,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617160,,BAO_0000019,,
2172,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL858113,,BAO_0000019,,
2173,9231,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617247,,BAO_0000220,955.0,
2174,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617248,,BAO_0000019,,
2175,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617249,,BAO_0000249,955.0,
2176,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617250,,BAO_0000019,,
2177,9737,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617251,,BAO_0000019,,
2178,11828,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617252,,BAO_0000019,,
2179,12253,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617006,,BAO_0000019,,
2180,12253,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617007,,BAO_0000019,,
2181,11279,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617008,,BAO_0000019,,
2182,11866,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617009,,BAO_0000019,,
2183,14424,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617010,,BAO_0000224,,
2184,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL857978,,BAO_0000019,,
2185,15180,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617011,,BAO_0000019,,
2186,9786,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617012,,BAO_0000019,,
2187,12132,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617013,,BAO_0000224,,
2188,5486,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617014,,BAO_0000249,,
2189,15316,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617015,,BAO_0000019,,
2190,16429,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617016,,BAO_0000019,,
2191,14617,pKi value for 5-hydroxytryptamine 2 receptor binding site,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617017,,BAO_0000224,,
2192,11351,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617018,,BAO_0000221,955.0,
2193,11279,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617019,,BAO_0000019,,
2194,9523,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617020,,BAO_0000019,,
2195,9523,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617021,,BAO_0000019,,
2196,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617022,,BAO_0000019,,
2197,9523,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617023,,BAO_0000019,,
2198,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617024,,BAO_0000019,,
2199,9523,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617025,,BAO_0000019,,
2200,9523,Hill coefficient of compound was determined,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617026,,BAO_0000224,,
2201,4771,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617027,,BAO_0000019,,
2202,5033,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617028,,BAO_0000019,,
2203,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617029,,BAO_0000019,,
2204,10845,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL875908,,BAO_0000019,,
2205,16288,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617030,,BAO_0000357,,
2206,16288,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617031,,BAO_0000019,,
2207,16190,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617032,,BAO_0000019,,
2208,12463,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617033,,BAO_0000224,,
2209,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617034,,BAO_0000224,,
2210,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617035,,BAO_0000224,,
2211,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617036,,BAO_0000019,,
2212,1205,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617037,,BAO_0000224,,
2213,11376,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617038,,BAO_0000219,,
2214,11376,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617039,,BAO_0000219,,
2215,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617161,,BAO_0000224,,
2216,2222,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617162,,BAO_0000224,,
2217,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617163,,BAO_0000224,,
2218,1089,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617164,,BAO_0000224,,
2219,386,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,B,,,,,,,,Brain membranes,104784,H,4,Autocuration,1,,CHEMBL617165,,BAO_0000249,,
2220,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617166,,BAO_0000224,,
2221,17066,Binding affinity towards 5-HT2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617167,,BAO_0000224,,
2222,959,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL872912,,BAO_0000224,,
2223,6398,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617168,,BAO_0000224,,
2224,11889,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617169,,BAO_0000224,,
2225,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617170,,BAO_0000224,,
2226,11026,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617171,,BAO_0000224,,
2227,11866,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617172,,BAO_0000224,,
2228,4221,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617173,,BAO_0000224,,
2229,13950,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL617174,,BAO_0000019,,
2230,1263,5-hydroxytryptamine 2 receptor binding affinity,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617175,,BAO_0000224,,
2231,13291,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617176,,BAO_0000357,,
2232,10812,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617177,,BAO_0000357,,
2233,13020,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617178,,BAO_0000224,,
2234,13021,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617179,,BAO_0000224,,
2235,13020,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617180,,BAO_0000224,,
2236,14532,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617181,,BAO_0000357,,
2237,13944,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617182,,BAO_0000357,,
2238,14331,Binding affinity against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617183,,BAO_0000357,,
2239,14118,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617184,,BAO_0000357,,
2240,13033,Binding affinity against serotonergic 5-HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617185,,BAO_0000357,,
2241,10321,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617186,,BAO_0000357,,
2242,12918,Compound was evaluated for the binding affinity at 5- HT2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617187,,BAO_0000357,,
2243,15120,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617188,,BAO_0000357,,
2244,2613,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617189,,BAO_0000218,,
2245,13378,Inhibitory activity against cloned human 5-HT2 receptor,B,,,Homo sapiens,9606.0,,,,,104784,D,5,Autocuration,1,,CHEMBL617190,,BAO_0000224,,
2246,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617191,449.0,BAO_0000219,,
2247,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617192,449.0,BAO_0000219,,
2248,2331,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617193,449.0,BAO_0000219,,
2249,2331,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",B,,,Homo sapiens,9606.0,,,CHO,,104784,D,5,Autocuration,1,,CHEMBL617194,449.0,BAO_0000219,,
2250,4170,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL617195,,BAO_0000224,,
2251,15453,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,B,,,,,,,,,104784,H,4,Autocuration,1,,CHEMBL881830,,BAO_0000224,,
2252,1479,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,17005,H,8,Autocuration,1,,CHEMBL617196,,BAO_0000357,,
2253,11139,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617197,,BAO_0000224,,
2254,13969,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617198,,BAO_0000357,,
2255,13392,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL873476,,BAO_0000357,,
2256,14430,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,B,,,,,,,,,17005,H,8,Expert,1,,CHEMBL617199,,BAO_0000019,,
2257,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,107,H,8,Autocuration,1,,CHEMBL617200,,BAO_0000357,,
2258,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617484,,BAO_0000357,,
2259,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617485,,BAO_0000357,,
2260,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617486,,BAO_0000357,,
2261,13463,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL858022,,BAO_0000357,,
2262,6347,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617049,449.0,BAO_0000219,,
2263,6857,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617050,449.0,BAO_0000219,,
2264,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617051,,BAO_0000219,,
2265,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617052,,BAO_0000219,,
2266,4176,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617053,,BAO_0000219,,
2267,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617054,449.0,BAO_0000219,,
2268,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617055,449.0,BAO_0000219,,
2269,15331,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL882924,,BAO_0000357,,
2270,16146,Inhibition of human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617056,,BAO_0000357,,
2271,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617057,449.0,BAO_0000219,,
2272,13631,Inhibitory concentration against human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617058,,BAO_0000219,,
2273,3805,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617059,,BAO_0000357,,
2274,4011,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617060,449.0,BAO_0000219,,
2275,4012,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617061,449.0,BAO_0000219,,
2276,6366,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617062,307.0,BAO_0000219,,
2277,15949,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617063,449.0,BAO_0000219,,
2278,14093,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617064,,BAO_0000019,,
2279,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617065,,BAO_0000019,,
2280,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617066,449.0,BAO_0000219,,
2281,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,B,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617067,449.0,BAO_0000219,,
2282,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617068,,BAO_0000019,,
2283,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617069,,BAO_0000019,,
2284,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617070,,BAO_0000019,,
2285,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617071,,BAO_0000357,,
2286,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL872915,,BAO_0000357,,
2287,14755,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617072,,BAO_0000357,,
2288,16441,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617073,,BAO_0000357,,
2289,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617074,,BAO_0000357,,
2290,16659,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617075,449.0,BAO_0000219,,
2291,3307,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617076,,BAO_0000357,,
2292,6857,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617077,,BAO_0000019,,
2293,5635,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617078,,BAO_0000357,,
2294,4234,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617079,,BAO_0000357,,
2295,15527,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617080,,BAO_0000357,,
2296,6588,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,107,H,8,Expert,1,,CHEMBL617081,449.0,BAO_0000219,,
2297,13631,Binding affinity towards human 5-HT2A receptor in BEK cells,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617082,,BAO_0000219,,
2298,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617083,,BAO_0000357,,
2299,14770,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617084,,BAO_0000357,,
2300,16293,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617085,,BAO_0000357,,
2301,16209,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617086,,BAO_0000357,,
2302,12469,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617087,,BAO_0000219,,
2303,15363,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617088,,BAO_0000357,,
2304,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617089,,BAO_0000357,,
2305,16441,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617090,,BAO_0000019,,
2306,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617513,,BAO_0000357,,
2307,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617514,722.0,BAO_0000219,,
2308,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617515,,BAO_0000019,,
2309,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617516,,BAO_0000357,,
2310,17200,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617517,,BAO_0000357,,
2311,4013,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617518,449.0,BAO_0000219,,
2312,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617519,,BAO_0000357,,
2313,5088,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617520,,BAO_0000357,,
2314,5088,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617521,,BAO_0000357,,
2315,5088,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617522,,BAO_0000357,,
2316,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617523,,BAO_0000357,,
2317,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617524,,BAO_0000357,,
2318,9786,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617525,,BAO_0000019,,
2319,9205,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617526,,BAO_0000019,,
2320,11257,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617527,,BAO_0000224,,
2321,9362,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617528,,BAO_0000019,,
2322,9362,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617529,,BAO_0000019,,
2323,10590,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617530,,BAO_0000224,,
2324,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617531,,BAO_0000019,,
2325,13050,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617532,,BAO_0000019,,
2326,11624,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617533,,BAO_0000019,,
2327,10468,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617534,,BAO_0000019,,
2328,10330,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617535,,BAO_0000224,,
2329,10062,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617536,,BAO_0000224,,
2330,11642,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617537,,BAO_0000224,,
2331,10062,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617538,,BAO_0000224,,
2332,13427,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,B,In vitro,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617539,,BAO_0000219,,
2333,12280,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617540,,BAO_0000224,,
2334,4101,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617541,,BAO_0000224,,
2335,10062,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617542,,BAO_0000224,,
2336,11147,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617543,,BAO_0000224,,
2337,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617544,485.0,BAO_0000219,,
2338,2395,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,B,,,Rattus norvegicus,10116.0,,,CHO-K1,,104686,D,5,Autocuration,1,,CHEMBL617545,485.0,BAO_0000219,,
2339,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617413,,BAO_0000019,,
2340,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617414,,BAO_0000019,,
2341,9098,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617415,,BAO_0000019,,
2342,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617416,,BAO_0000224,,
2343,9443,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617417,,BAO_0000224,,
2344,9699,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617418,,BAO_0000019,,
2345,9699,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617419,,BAO_0000019,,
2346,9098,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617420,,BAO_0000224,,
2347,3070,Affinity for 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617421,,BAO_0000224,,
2348,9547,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617422,,BAO_0000224,,
2349,10444,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617423,,BAO_0000019,,
2350,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617424,,BAO_0000019,,
2351,14617,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617425,,BAO_0000019,,
2352,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617426,,BAO_0000224,,
2353,11130,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),B,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617427,,BAO_0000218,,
2354,14542,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617428,,BAO_0000221,955.0,
2355,2797,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617429,,BAO_0000224,,
2356,11332,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617430,,BAO_0000019,,
2357,11332,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617431,,BAO_0000019,,
2358,10752,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,B,,,,,,Frontal cortex,,,104686,H,4,Autocuration,1,,CHEMBL617432,,BAO_0000019,1870.0,
2359,1185,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617433,,BAO_0000224,,
2360,1185,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617434,,BAO_0000224,,
2361,11624,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617435,,BAO_0000224,,
2362,1344,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617436,,BAO_0000019,,
2363,15453,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,B,,,Rattus norvegicus,10116.0,,Striatum,,,104686,D,5,Autocuration,1,,CHEMBL617437,,BAO_0000019,2435.0,
2364,11662,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617438,,BAO_0000019,,
2365,11662,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617439,,BAO_0000019,,
2366,10796,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617440,,BAO_0000224,,
2367,9069,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617441,,BAO_0000224,,
2368,8814,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL872918,,BAO_0000019,,
2369,8908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617442,,BAO_0000019,,
2370,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617443,,BAO_0000019,,
2371,9098,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617444,,BAO_0000019,,
2372,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617445,,BAO_0000019,,
2373,9098,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617446,,BAO_0000019,,
2374,9098,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617447,,BAO_0000249,,
2375,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617448,,BAO_0000019,,
2376,9098,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617449,,BAO_0000019,,
2377,9161,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617450,,BAO_0000019,,
2378,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617451,,BAO_0000019,,
2379,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617452,,BAO_0000019,,
2380,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617453,,BAO_0000019,,
2381,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617660,,BAO_0000019,,
2382,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617661,,BAO_0000019,,
2383,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617662,,BAO_0000019,,
2384,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL872919,,BAO_0000019,,
2385,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617663,,BAO_0000019,,
2386,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617664,,BAO_0000019,,
2387,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617665,,BAO_0000019,,
2388,9161,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617666,,BAO_0000019,,
2389,12094,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617667,,BAO_0000019,,
2390,12018,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617668,,BAO_0000249,,
2391,10394,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617669,,BAO_0000249,,
2392,15260,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617670,,BAO_0000224,,
2393,11624,Inhibitory constant against 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617671,,BAO_0000224,,
2394,13654,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617672,,BAO_0000224,,
2395,9541,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617673,,BAO_0000019,,
2396,11933,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617674,,BAO_0000224,,
2397,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617675,,BAO_0000019,,
2398,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617676,,BAO_0000019,,
2399,15538,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617677,,BAO_0000019,,
2400,8841,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,D,5,Autocuration,1,,CHEMBL617678,,BAO_0000019,,
2401,1455,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617679,,BAO_0000224,,
2402,1455,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617680,,BAO_0000224,,
2403,11752,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617681,,BAO_0000019,,
2404,11642,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,B,,,,,,Brain,,,104686,H,4,Autocuration,1,,CHEMBL617682,,BAO_0000221,955.0,
2405,12092,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617683,,BAO_0000224,,
2406,3967,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617684,,BAO_0000224,,
2407,12771,Binding affinity towards 5-hydroxytryptamine 2 receptor,B,,,Rattus norvegicus,10116.0,,,,,104686,D,5,Autocuration,1,,CHEMBL617685,,BAO_0000224,,
2408,11642,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617686,,BAO_0000019,,
2409,11628,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617687,,BAO_0000224,,
2410,13654,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,B,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617688,,BAO_0000224,,
2411,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617689,,BAO_0000019,,
2412,11200,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,F,,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617690,,BAO_0000019,,
2413,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617691,,BAO_0000218,,
2414,11200,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617692,,BAO_0000218,,
2415,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617693,,BAO_0000218,,
2416,11200,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",F,In vivo,,,,,,,,104686,H,4,Autocuration,1,,CHEMBL617694,,BAO_0000218,,
2417,15436,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,B,,,,,,Brain,,,12687,H,8,Expert,1,,CHEMBL857985,,BAO_0000221,955.0,
2418,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617695,,BAO_0000019,,
2419,14025,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617696,,BAO_0000019,,
2420,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617697,,BAO_0000357,,
2421,13735,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617257,,BAO_0000019,,
2422,5816,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617258,,BAO_0000357,,
2423,14287,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617259,,BAO_0000019,,
2424,15738,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617260,,BAO_0000357,,
2425,15738,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617261,,BAO_0000357,,
2426,15026,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617262,,BAO_0000019,,
2427,16647,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617263,,BAO_0000019,,
2428,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617264,,BAO_0000019,,
2429,13345,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617265,,BAO_0000019,,
2430,1543,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,B,,,,,,,,Membranes,12687,H,8,Autocuration,1,,CHEMBL617266,,BAO_0000249,,
2431,12444,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617267,,BAO_0000019,,
2432,16404,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617268,,BAO_0000019,,
2433,16404,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617269,449.0,BAO_0000219,,
2434,15577,Kinetic inhibition constant evaluated by measuring serotonergic activity,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617323,,BAO_0000357,,
2435,15577,Serotonergic activity of the compound.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617324,,BAO_0000357,,
2436,2495,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617325,,BAO_0000249,,
2437,15042,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617326,,BAO_0000019,,
2438,15026,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617327,,BAO_0000249,,
2439,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617328,,BAO_0000019,,
2440,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617329,,BAO_0000019,,
2441,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617330,,BAO_0000019,,
2442,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617331,,BAO_0000357,,
2443,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617332,,BAO_0000357,,
2444,4820,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617333,,BAO_0000357,,
2445,6736,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617334,,BAO_0000357,,
2446,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617335,,BAO_0000357,,
2447,5163,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617336,,BAO_0000357,,
2448,6011,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617337,,BAO_0000357,,
2449,14294,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617338,,BAO_0000357,,
2450,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617339,,BAO_0000357,,
2451,17066,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617340,,BAO_0000357,,
2452,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617341,,BAO_0000357,,
2453,6736,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617342,,BAO_0000357,,
2454,5163,Affinity for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617343,,BAO_0000357,,
2455,16911,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL617344,723.0,BAO_0000219,,
2456,6841,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617345,,BAO_0000357,,
2457,6119,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617346,,BAO_0000357,,
2458,3962,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617347,,BAO_0000357,,
2459,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617348,,BAO_0000357,,
2460,4373,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617349,,BAO_0000357,,
2461,3962,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,F,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617350,,BAO_0000019,,
2462,1633,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL872339,,BAO_0000357,,
2463,4373,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617351,,BAO_0000357,,
2464,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617352,,BAO_0000357,,
2465,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617353,,BAO_0000357,,
2466,16946,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617354,,BAO_0000357,,
2467,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617355,,BAO_0000357,,
2468,3032,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,B,,,Mus musculus,10090.0,,,CHO,,107,H,8,Expert,1,,CHEMBL617356,449.0,BAO_0000219,,
2469,16655,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617357,,BAO_0000357,,
2470,13964,Binding affinity at 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617358,,BAO_0000357,,
2471,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617359,,BAO_0000357,,
2472,16117,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617360,,BAO_0000357,,
2473,16700,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL875913,,BAO_0000357,,
2474,3269,Affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617361,,BAO_0000357,,
2475,1274,Binding affinity against 5-Hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL617362,,BAO_0000357,,
2476,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617363,,BAO_0000357,,
2477,12146,Tested against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617364,,BAO_0000357,,
2478,12652,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617365,,BAO_0000224,,
2479,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617366,,BAO_0000224,,
2480,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617367,,BAO_0000224,,
2481,12652,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,B,,,,,,,,,105075,H,4,Autocuration,1,,CHEMBL617368,,BAO_0000224,,
2482,16647,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617369,,BAO_0000357,,
2483,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617370,722.0,BAO_0000219,,
2484,6857,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617371,449.0,BAO_0000219,,
2485,3805,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617372,,BAO_0000357,,
2486,6491,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617373,,BAO_0000357,,
2487,14093,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617374,,BAO_0000019,,
2488,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617375,,BAO_0000019,,
2489,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617376,,BAO_0000019,,
2490,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617377,,BAO_0000019,,
2491,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617378,,BAO_0000019,,
2492,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,F,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617379,,BAO_0000019,,
2493,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617380,,BAO_0000357,,
2494,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617381,,BAO_0000357,,
2495,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617382,,BAO_0000357,,
2496,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617383,,BAO_0000357,,
2497,12369,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617384,,BAO_0000357,,
2498,12369,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617385,,BAO_0000357,,
2499,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617386,,BAO_0000019,,
2500,14447,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617387,,BAO_0000019,,
2501,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL617388,723.0,BAO_0000219,,
2502,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,,,,,CHO,,107,H,8,Autocuration,1,,CHEMBL617389,449.0,BAO_0000219,,
2503,6857,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL617390,449.0,BAO_0000219,,
2504,5635,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,104817,H,4,Autocuration,1,,CHEMBL617391,,BAO_0000224,,
2505,12861,Binding activity radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617392,,BAO_0000357,,
2506,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617393,,BAO_0000019,,
2507,5105,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617394,307.0,BAO_0000219,,
2508,5104,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617395,307.0,BAO_0000219,,
2509,5105,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,B,,,,,,,L929,,107,H,8,Expert,1,,CHEMBL617396,307.0,BAO_0000219,,
2510,5105,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,B,,,,,,,L929,,107,H,8,Autocuration,1,,CHEMBL617397,307.0,BAO_0000219,,
2511,5254,Binding affinity against 5-HT2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617398,,BAO_0000357,,
2512,5254,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,107,H,8,Autocuration,1,,CHEMBL617399,,BAO_0000357,,
2513,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617400,722.0,BAO_0000219,,
2514,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617401,722.0,BAO_0000219,,
2515,14157,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617402,722.0,BAO_0000219,,
2516,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617403,722.0,BAO_0000219,,
2517,14068,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617404,,BAO_0000357,,
2518,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL857981,722.0,BAO_0000219,,
2519,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617405,722.0,BAO_0000219,,
2520,4540,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL617253,722.0,BAO_0000219,,
2521,6166,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,B,,,,,,,,,107,H,8,Expert,1,,CHEMBL617254,,BAO_0000357,,
2522,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617255,722.0,BAO_0000219,,
2523,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL617256,722.0,BAO_0000219,,
2524,17296,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616874,722.0,BAO_0000219,,
2525,15779,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616875,722.0,BAO_0000219,,
2526,14391,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616876,722.0,BAO_0000219,,
2527,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616877,722.0,BAO_0000219,,
2528,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616878,722.0,BAO_0000219,,
2529,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616879,722.0,BAO_0000219,,
2530,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,B,,,,,,,HEK293,,107,H,8,Expert,1,,CHEMBL616880,722.0,BAO_0000219,,
2531,12936,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,B,,,Homo sapiens,9606.0,,,HEK293,,107,D,9,Expert,1,,CHEMBL616881,722.0,BAO_0000219,,
2532,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616882,723.0,BAO_0000219,,
2533,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616883,723.0,BAO_0000219,,
2534,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,107,H,8,Autocuration,1,,CHEMBL616884,723.0,BAO_0000219,,
2535,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616885,722.0,BAO_0000219,,
2536,1883,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,B,,,,,,,CHO-K1,,107,H,8,Autocuration,1,,CHEMBL616886,485.0,BAO_0000219,,
2537,1883,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,B,,,,,,,CHO-K1,,107,H,8,Expert,1,,CHEMBL616887,485.0,BAO_0000219,,
2538,14875,Binding affinity for human 5-hydroxytryptamine 2A receptor,B,,,Homo sapiens,9606.0,,,,,107,D,9,Expert,1,,CHEMBL616888,,BAO_0000357,,
2539,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616889,722.0,BAO_0000219,,
2540,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616890,722.0,BAO_0000219,,
2541,16404,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,B,,,Homo sapiens,9606.0,,,CHO,,107,D,9,Expert,1,,CHEMBL616891,449.0,BAO_0000219,,
2542,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616892,722.0,BAO_0000219,,
2543,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",B,,,,,,,HEK293,,107,H,8,Autocuration,1,,CHEMBL616893,722.0,BAO_0000219,,
2544,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,F,,,,,,,NIH3T3,,10620,H,8,Autocuration,1,,CHEMBL616894,723.0,BAO_0000219,,
2545,4682,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,B,,,,,,,NIH3T3,,107,H,8,Expert,1,,CHEMBL616895,723.0,BAO_0000219,,
2546,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,F,,,,,,,,,10620,H,8,Autocuration,1,,CHEMBL616896,,BAO_0000019,,
2547,4921,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617099,,BAO_0000357,,
2548,4921,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,B,,,,,,,,,10621,H,8,Autocuration,1,,CHEMBL617100,,BAO_0000357,,
2549,16312,Binding affinity against rabbit aorta 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL884532,,BAO_0000357,,
2550,14998,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617101,,BAO_0000357,,
2551,14025,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617102,,BAO_0000357,,
2552,13047,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Autocuration,1,,CHEMBL617103,,BAO_0000019,,
2553,13047,The compound was tested for binding affinity against 5-HT2A receptor,B,,,Oryctolagus cuniculus,9986.0,,,,,107,H,8,Expert,1,,CHEMBL617104,,BAO_0000357,,
2554,1883,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,10576,H,8,Autocuration,1,,CHEMBL857979,485.0,BAO_0000219,,
2555,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857502,,BAO_0000019,,
2556,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617105,,BAO_0000019,,
2557,13463,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,B,,,,,,Stomach,,,12687,H,8,Autocuration,1,,CHEMBL858021,,BAO_0000019,945.0,
2558,13463,Binding affinity for 5-HT 2A in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12687,D,9,Expert,1,,CHEMBL875910,,BAO_0000019,945.0,
2559,13463,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617106,,BAO_0000019,,
2560,16326,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617107,723.0,BAO_0000219,,
2561,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617108,,BAO_0000019,,
2562,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617109,,BAO_0000019,,
2563,15740,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617110,,BAO_0000357,,
2564,16633,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617111,,BAO_0000357,,
2565,17200,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617112,,BAO_0000019,,
2566,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617113,,BAO_0000357,,
2567,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617114,,BAO_0000357,,
2568,17133,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617115,,BAO_0000357,,
2569,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617116,,BAO_0000219,,
2570,15363,Efficacy at 5-hydroxytryptamine 2A receptor,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617117,,BAO_0000019,,
2571,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617118,,BAO_0000357,,
2572,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617119,,BAO_0000357,,
2573,17200,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617120,,BAO_0000357,,
2574,17200,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617121,,BAO_0000219,,
2575,17200,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617122,,BAO_0000219,,
2576,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617123,,BAO_0000019,,
2577,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617124,,BAO_0000019,,
2578,13565,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617600,,BAO_0000249,,
2579,13730,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617601,,BAO_0000357,,
2580,12416,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL882923,,BAO_0000019,,
2581,15295,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617602,,BAO_0000357,,
2582,1742,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617603,,BAO_0000019,,
2583,15295,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617604,,BAO_0000357,,
2584,14970,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617605,,BAO_0000019,,
2585,16693,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617606,,BAO_0000019,,
2586,14776,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617607,,BAO_0000019,,
2587,14286,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617455,,BAO_0000249,,
2588,17200,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617456,,BAO_0000019,,
2589,15306,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617457,,BAO_0000357,,
2590,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617458,,BAO_0000357,,
2591,14229,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617459,,BAO_0000019,,
2592,12884,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617460,,BAO_0000357,,
2593,13149,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617461,,BAO_0000357,,
2594,15295,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617462,,BAO_0000019,,
2595,15740,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617463,,BAO_0000357,,
2596,15185,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617464,,BAO_0000019,,
2597,15185,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617465,,BAO_0000019,,
2598,17529,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617466,,BAO_0000019,,
2599,14826,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617467,,BAO_0000019,,
2600,17211,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617468,,BAO_0000019,,
2601,14826,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617469,,BAO_0000019,,
2602,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617470,,BAO_0000019,,
2603,14093,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617471,,BAO_0000019,,
2604,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617472,723.0,BAO_0000219,,
2605,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617473,,BAO_0000357,,
2606,15436,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617474,,BAO_0000019,,
2607,15436,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617475,,BAO_0000019,,
2608,14442,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617476,,BAO_0000221,955.0,
2609,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617477,,BAO_0000357,,
2610,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL617478,723.0,BAO_0000219,,
2611,14755,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617479,,BAO_0000221,,
2612,4707,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617480,,BAO_0000357,,
2613,13297,Binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617481,,BAO_0000357,,
2614,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617482,,BAO_0000019,,
2615,4664,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617483,,BAO_0000019,,
2616,16633,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621528,,BAO_0000357,,
2617,4664,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,NIH3T3,,12687,D,9,Expert,1,,CHEMBL621529,723.0,BAO_0000219,,
2618,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621530,,BAO_0000357,,
2619,16133,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621531,,BAO_0000357,,
2620,14060,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621532,,BAO_0000019,,
2621,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621533,,BAO_0000357,,
2622,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,B,,,,,,,CHO,,12687,H,8,Expert,1,,CHEMBL621534,449.0,BAO_0000219,,
2623,14776,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621535,,BAO_0000019,,
2624,13481,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621536,,BAO_0000357,,
2625,17386,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621537,,BAO_0000357,,
2626,6611,Binding affinity for 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621538,,BAO_0000357,,
2627,14423,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621539,,BAO_0000019,,
2628,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621540,,BAO_0000019,,
2629,15412,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621541,,BAO_0000019,,
2630,6238,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621542,,BAO_0000019,,
2631,6648,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621543,,BAO_0000357,,
2632,5667,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL621544,,BAO_0000357,,
2633,6611,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL621545,,BAO_0000357,,
2634,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621546,,BAO_0000357,,
2635,13481,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL621547,,BAO_0000357,,
2636,15558,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618692,723.0,BAO_0000219,,
2637,6013,Binding affinity towards 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618693,,BAO_0000357,,
2638,16633,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872922,,BAO_0000357,,
2639,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618694,,BAO_0000357,,
2640,6013,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618695,,BAO_0000357,,
2641,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618696,,BAO_0000357,,
2642,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL618697,,BAO_0000357,,
2643,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618892,,BAO_0000357,,
2644,6013,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618893,,BAO_0000357,,
2645,16293,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618894,,BAO_0000357,,
2646,17175,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618895,723.0,BAO_0000219,,
2647,13278,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL618896,,BAO_0000357,,
2648,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12687,H,8,Autocuration,1,,CHEMBL618897,,BAO_0000019,5383.0,
2649,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618898,,BAO_0000357,,
2650,2014,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618899,,BAO_0000357,,
2651,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618900,,BAO_0000357,,
2652,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618901,,BAO_0000019,,
2653,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618902,,BAO_0000357,,
2654,5432,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,Hippocampus,,,12687,D,9,Expert,1,,CHEMBL618903,,BAO_0000221,10000000.0,
2655,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618904,,BAO_0000357,,
2656,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618905,,BAO_0000357,,
2657,13672,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618906,,BAO_0000357,,
2658,14749,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,B,,,,,,,NIH3T3,,12687,H,8,Expert,1,,CHEMBL618907,723.0,BAO_0000219,,
2659,13462,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL618908,,BAO_0000019,,
2660,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617909,,BAO_0000357,,
2661,16647,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617910,,BAO_0000019,,
2662,13345,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,B,,,,,,Brain,,,12687,H,8,Autocuration,1,,CHEMBL617911,,BAO_0000221,955.0,
2663,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL872923,,BAO_0000249,,
2664,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617912,,BAO_0000249,,
2665,15535,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617913,,BAO_0000019,,
2666,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617914,,BAO_0000249,,
2667,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617915,,BAO_0000249,,
2668,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617916,,BAO_0000249,,
2669,4795,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617917,,BAO_0000019,,
2670,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617918,,BAO_0000019,,
2671,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617919,,BAO_0000019,,
2672,17200,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617920,,BAO_0000019,,
2673,2148,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617921,,BAO_0000019,,
2674,13345,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",B,,,Rattus norvegicus,10116.0,,,,,105102,D,5,Expert,1,,CHEMBL617922,,BAO_0000224,,
2675,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617923,,BAO_0000357,,
2676,5088,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617924,,BAO_0000357,,
2677,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617925,,BAO_0000357,,
2678,17133,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617926,,BAO_0000357,,
2679,16532,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617927,,BAO_0000357,,
2680,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617928,,BAO_0000357,,
2681,2309,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,B,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617929,,BAO_0000019,,
2682,12953,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617930,,BAO_0000019,,
2683,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617931,,BAO_0000019,,
2684,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617932,,BAO_0000019,,
2685,16659,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,B,,,,,,,CHO,,12687,H,8,Autocuration,1,,CHEMBL617933,449.0,BAO_0000219,,
2686,16740,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617934,,BAO_0000019,,
2687,16740,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617935,,BAO_0000019,,
2688,17133,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617936,,BAO_0000357,,
2689,17211,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617937,,BAO_0000019,,
2690,17331,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617938,,BAO_0000019,,
2691,16633,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617939,,BAO_0000218,,
2692,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617940,,BAO_0000218,,
2693,16633,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617941,,BAO_0000218,,
2694,15026,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617942,,BAO_0000357,,
2695,15026,Ratio of pKi of 5-HT2A to that of D2 receptor,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617943,,BAO_0000357,,
2696,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617944,,BAO_0000224,,
2697,16404,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,B,,,,,,,,,105093,H,4,Expert,1,,CHEMBL617945,,BAO_0000224,,
2698,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,105075,H,4,Expert,1,,CHEMBL617946,,BAO_0000224,,
2699,16404,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617947,,BAO_0000357,,
2700,16326,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617948,,BAO_0000357,,
2701,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL858116,,BAO_0000019,,
2702,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617949,,BAO_0000019,,
2703,15329,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,F,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617950,,BAO_0000019,,
2704,16404,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617951,,BAO_0000019,1515.0,
2705,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,F,,,,,,Thoracic aorta,,,12687,H,8,Expert,1,,CHEMBL617952,,BAO_0000019,1515.0,
2706,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,F,,,,,,Thoracic aorta,,,12687,H,8,Autocuration,1,,CHEMBL617953,,BAO_0000019,1515.0,
2707,12861,Binding activity radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617954,,BAO_0000357,,
2708,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617955,,BAO_0000019,,
2709,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL857071,,BAO_0000019,,
2710,12490,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,B,,,,,,,,,12687,H,8,Expert,1,,CHEMBL617270,,BAO_0000019,,
2711,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617271,339.0,BAO_0000219,,
2712,12827,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,B,,,,,,,N1E-115,,12687,H,8,Autocuration,1,,CHEMBL617272,339.0,BAO_0000219,,
2713,12918,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617273,,BAO_0000019,,
2714,12919,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,F,,,Rattus norvegicus,10116.0,,,,,12687,D,9,Expert,1,,CHEMBL617274,,BAO_0000019,,
2715,17723,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617275,,BAO_0000357,,
2716,6013,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617276,,BAO_0000357,,
2717,16293,Binding affinity towards human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617277,,BAO_0000357,,
2718,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617278,,BAO_0000019,,
2719,3857,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617279,,BAO_0000019,,
2720,3857,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617280,,BAO_0000019,,
2721,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617281,,BAO_0000357,,
2722,15363,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617282,,BAO_0000357,,
2723,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617283,,BAO_0000019,,
2724,16441,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617284,,BAO_0000019,,
2725,4176,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617285,722.0,BAO_0000219,,
2726,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617286,,BAO_0000019,,
2727,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617287,,BAO_0000357,,
2728,5088,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617288,,BAO_0000357,,
2729,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617289,,BAO_0000357,,
2730,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL872917,,BAO_0000357,,
2731,5088,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617290,,BAO_0000357,,
2732,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617291,449.0,BAO_0000219,,
2733,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617292,449.0,BAO_0000219,,
2734,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617293,723.0,BAO_0000219,,
2735,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617294,449.0,BAO_0000219,,
2736,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617295,,BAO_0000019,,
2737,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617296,,BAO_0000357,,
2738,12861,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617297,,BAO_0000019,,
2739,5104,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617298,449.0,BAO_0000219,,
2740,5105,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617299,449.0,BAO_0000219,,
2741,5105,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617300,449.0,BAO_0000219,,
2742,5254,Binding affinity against 5-HT2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617454,,BAO_0000357,,
2743,13267,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617505,722.0,BAO_0000219,,
2744,14157,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617506,722.0,BAO_0000219,,
2745,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617507,722.0,BAO_0000219,,
2746,14068,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617508,,BAO_0000357,,
2747,12936,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL857982,722.0,BAO_0000219,,
2748,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617509,722.0,BAO_0000219,,
2749,4540,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617510,722.0,BAO_0000219,,
2750,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617511,,BAO_0000357,,
2751,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617512,722.0,BAO_0000219,,
2752,17296,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617749,722.0,BAO_0000219,,
2753,15779,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617750,722.0,BAO_0000219,,
2754,15779,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617751,722.0,BAO_0000219,,
2755,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617752,722.0,BAO_0000219,,
2756,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617753,722.0,BAO_0000219,,
2757,15851,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617754,722.0,BAO_0000219,,
2758,15851,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,108,D,9,Expert,1,,CHEMBL617755,722.0,BAO_0000219,,
2759,15779,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617756,722.0,BAO_0000219,,
2760,3832,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617757,722.0,BAO_0000219,,
2761,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,B,,,,,,,HEK293,,108,H,8,Expert,1,,CHEMBL617758,722.0,BAO_0000219,,
2762,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,B,,,,,,,NIH3T3,,108,H,8,Autocuration,1,,CHEMBL617759,723.0,BAO_0000219,,
2763,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617760,722.0,BAO_0000219,,
2764,1883,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,108,H,8,Expert,1,,CHEMBL617761,485.0,BAO_0000219,,
2765,4321,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617762,,BAO_0000357,,
2766,14875,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617763,,BAO_0000357,,
2767,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL857983,722.0,BAO_0000219,,
2768,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617764,722.0,BAO_0000219,,
2769,16404,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,B,,,,,,,HeLa,,108,H,8,Autocuration,1,,CHEMBL617765,308.0,BAO_0000219,,
2770,13267,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617766,,BAO_0000019,,
2771,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,F,,,,,,Hippocampus,,,108,H,8,Autocuration,1,,CHEMBL617767,,BAO_0000221,10000000.0,
2772,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617768,722.0,BAO_0000219,,
2773,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",B,,,,,,,HEK293,,108,H,8,Autocuration,1,,CHEMBL617769,722.0,BAO_0000219,,
2774,13463,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,B,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL858023,,BAO_0000357,,
2775,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617770,,BAO_0000019,945.0,
2776,13463,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,B,,,,,,Stomach,,,11864,H,8,Autocuration,1,,CHEMBL617771,,BAO_0000019,945.0,
2777,12652,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,F,,,,,,,A9,,11864,H,8,Autocuration,1,,CHEMBL617772,625.0,BAO_0000219,,
2778,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617773,723.0,BAO_0000219,,
2779,4682,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617850,723.0,BAO_0000219,,
2780,4682,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,B,,,,,,,NIH3T3,,11864,H,8,Autocuration,1,,CHEMBL617851,723.0,BAO_0000219,,
2781,12652,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,F,,,,,,,,,11864,H,8,Autocuration,1,,CHEMBL617852,,BAO_0000019,,
2782,13463,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,B,,,Mus musculus,10090.0,,Stomach,,,12689,H,8,Autocuration,1,,CHEMBL858024,,BAO_0000019,945.0,
2783,13463,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12689,D,9,Expert,1,,CHEMBL617853,,BAO_0000019,945.0,
2784,13969,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617854,,BAO_0000357,,
2785,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL873477,,BAO_0000357,,
2786,13392,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617855,,BAO_0000357,,
2787,14430,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617856,,BAO_0000019,,
2788,1742,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617857,,BAO_0000019,,
2789,14286,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617858,,BAO_0000249,,
2790,5619,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617859,,BAO_0000357,,
2791,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617860,,BAO_0000357,,
2792,12861,Binding activity radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617861,,BAO_0000357,,
2793,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617862,,BAO_0000019,,
2794,12861,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617863,,BAO_0000019,,
2795,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617864,,BAO_0000249,,
2796,12827,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617649,,BAO_0000249,,
2797,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617650,,BAO_0000019,,
2798,12919,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,F,,,Sus scrofa,9823.0,,,,,108,H,8,Expert,1,,CHEMBL617651,,BAO_0000019,,
2799,16429,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617652,,BAO_0000357,,
2800,773,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL857072,,BAO_0000019,,
2801,5033,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,B,,,Sus scrofa,9823.0,,,,,108,H,8,Autocuration,1,,CHEMBL617653,,BAO_0000357,,
2802,12861,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,B,,,,,,,,,12687,H,8,Autocuration,1,,CHEMBL617654,,BAO_0000019,,
2803,14093,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617655,,BAO_0000019,,
2804,14970,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617656,,BAO_0000357,,
2805,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617657,,BAO_0000357,,
2806,14970,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617658,,BAO_0000357,,
2807,14178,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617659,,BAO_0000357,,
2808,14178,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617838,,BAO_0000357,,
2809,14229,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12689,D,9,Expert,1,,CHEMBL617839,,BAO_0000249,,
2810,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617840,,BAO_0000357,,
2811,14826,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617841,,BAO_0000019,,
2812,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL875915,,BAO_0000019,,
2813,17211,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL617842,,BAO_0000219,,
2814,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617843,723.0,BAO_0000219,,
2815,13246,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617844,,BAO_0000357,,
2816,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617845,,BAO_0000357,,
2817,12457,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,B,,,,,,,NIH3T3,,12689,H,8,Expert,1,,CHEMBL617846,723.0,BAO_0000219,,
2818,4707,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617847,,BAO_0000357,,
2819,13297,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617848,,BAO_0000357,,
2820,16633,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617849,,BAO_0000357,,
2821,16133,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621507,,BAO_0000357,,
2822,16326,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621508,,BAO_0000357,,
2823,14423,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621509,,BAO_0000019,,
2824,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621510,,BAO_0000019,,
2825,15412,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621511,,BAO_0000019,,
2826,15558,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,B,,,,,,,A9,,12689,H,8,Expert,1,,CHEMBL621512,625.0,BAO_0000219,,
2827,16633,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621513,,BAO_0000357,,
2828,6013,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621514,,BAO_0000357,,
2829,17175,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,B,In vitro,,,,,,,,12689,H,8,Expert,1,,CHEMBL621515,,BAO_0000219,,
2830,12469,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621516,,BAO_0000219,,
2831,3682,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,B,,,,,,Caudate-putamen,,,12689,H,8,Autocuration,1,,CHEMBL621517,,BAO_0000019,5383.0,
2832,4932,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621518,,BAO_0000357,,
2833,4932,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621519,,BAO_0000019,,
2834,3935,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621520,,BAO_0000357,,
2835,15818,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621521,,BAO_0000357,,
2836,15818,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621522,,BAO_0000357,,
2837,14749,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621523,,BAO_0000219,,
2838,15740,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621524,,BAO_0000357,,
2839,17133,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL621525,,BAO_0000357,,
2840,16532,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL872921,,BAO_0000357,,
2841,12369,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL621526,,BAO_0000357,,
2842,12369,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL621527,,BAO_0000219,,
2843,2309,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617865,,BAO_0000019,,
2844,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617866,,BAO_0000357,,
2845,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617867,,BAO_0000019,,
2846,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617487,,BAO_0000357,,
2847,12953,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,12689,H,8,Expert,1,,CHEMBL617488,,BAO_0000357,,
2848,17133,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617489,,BAO_0000357,,
2849,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617490,,BAO_0000019,,
2850,17211,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617491,,BAO_0000019,,
2851,14025,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617492,,BAO_0000019,,
2852,14998,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617493,,BAO_0000019,,
2853,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617494,,BAO_0000357,,
2854,13735,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,B,,,Rattus norvegicus,10116.0,,,,,12689,D,9,Expert,1,,CHEMBL617495,,BAO_0000019,,
2855,13181,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617496,,BAO_0000357,,
2856,1883,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,B,,,,,,,CHO-K1,,12689,H,8,Autocuration,1,,CHEMBL617497,485.0,BAO_0000219,,
2857,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617498,,BAO_0000357,,
2858,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,B,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617499,,BAO_0000357,,
2859,14579,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,F,,,,,,,,,12689,H,8,Autocuration,1,,CHEMBL617500,,BAO_0000019,,
2860,4639,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617501,,BAO_0000357,,
2861,4820,Binding affinity towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617502,,BAO_0000357,,
2862,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617503,,BAO_0000357,,
2863,14755,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617504,,BAO_0000357,,
2864,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617406,,BAO_0000357,,
2865,6857,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617407,,BAO_0000019,,
2866,16209,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617408,,BAO_0000357,,
2867,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617409,,BAO_0000357,,
2868,15363,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617410,,BAO_0000357,,
2869,15363,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617411,,BAO_0000357,,
2870,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617412,,BAO_0000019,,
2871,17200,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,B,,,Homo sapiens,9606.0,,,,,227,D,9,Expert,1,,CHEMBL617774,,BAO_0000357,,
2872,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617775,722.0,BAO_0000219,,
2873,15851,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617776,722.0,BAO_0000219,,
2874,6857,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617777,449.0,BAO_0000219,,
2875,6857,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,F,,,Homo sapiens,9606.0,,,CHO,,227,D,9,Expert,1,,CHEMBL617778,449.0,BAO_0000219,,
2876,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617779,722.0,BAO_0000219,,
2877,15851,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617780,722.0,BAO_0000219,,
2878,15779,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617781,722.0,BAO_0000219,,
2879,14157,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617782,722.0,BAO_0000219,,
2880,4540,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617783,722.0,BAO_0000219,,
2881,6166,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617784,,BAO_0000357,,
2882,15779,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617785,722.0,BAO_0000219,,
2883,14391,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL857984,722.0,BAO_0000219,,
2884,3832,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617786,722.0,BAO_0000219,,
2885,3833,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,B,,,,,,,HEK293,,227,H,8,Expert,1,,CHEMBL617787,722.0,BAO_0000219,,
2886,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617788,722.0,BAO_0000219,,
2887,15851,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,B,,,Homo sapiens,9606.0,,,HEK293,,227,D,9,Expert,1,,CHEMBL617789,722.0,BAO_0000219,,
2888,4199,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617790,722.0,BAO_0000219,,
2889,1883,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,B,,,,,,,CHO-K1,,227,H,8,Expert,1,,CHEMBL617791,485.0,BAO_0000219,,
2890,4321,Binding affinity against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Expert,1,,CHEMBL617608,,BAO_0000357,,
2891,15146,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617609,722.0,BAO_0000219,,
2892,5213,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617610,722.0,BAO_0000219,,
2893,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617611,722.0,BAO_0000219,,
2894,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617612,722.0,BAO_0000219,,
2895,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",B,,,,,,,HEK293,,227,H,8,Autocuration,1,,CHEMBL617613,722.0,BAO_0000219,,
2896,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,227,H,8,Autocuration,1,,CHEMBL617614,,BAO_0000019,,
2897,13463,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617615,,BAO_0000019,945.0,
2898,7259,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL858114,,BAO_0000357,945.0,
2899,7259,Affinity against serotonergic receptor in the isolated rat stomach fundus,B,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617616,,BAO_0000357,945.0,
2900,7185,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617617,,BAO_0000019,945.0,
2901,7185,Antagonistic against 5-hydroxytryptamine 2B receptor,F,,,Rattus norvegicus,10116.0,,,,,12688,D,9,Expert,1,,CHEMBL875914,,BAO_0000019,,
2902,13267,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617618,,BAO_0000019,945.0,
2903,13735,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617619,,BAO_0000357,945.0,
2904,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617620,,BAO_0000019,,
2905,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617621,,BAO_0000019,,
2906,15738,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,F,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617622,,BAO_0000019,,
2907,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617623,,BAO_0000357,945.0,
2908,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617624,,BAO_0000357,945.0,
2909,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617625,,BAO_0000357,945.0,
2910,12936,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,B,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617626,,BAO_0000357,945.0,
2911,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617627,,BAO_0000019,945.0,
2912,16404,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,,,,Stomach,,,12688,H,8,Expert,1,,CHEMBL617628,,BAO_0000019,945.0,
2913,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL617629,,BAO_0000019,945.0,
2914,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,F,,,,,,Stomach,,,12688,H,8,Autocuration,1,,CHEMBL858115,,BAO_0000019,945.0,
2915,16404,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Expert,1,,CHEMBL617630,,BAO_0000019,945.0,
2916,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,F,,,,,,Thoracic aorta,,,12688,H,8,Autocuration,1,,CHEMBL617631,,BAO_0000019,1515.0,
2917,7483,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617632,,BAO_0000357,,
2918,7483,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,B,,,,,,,,,12688,H,8,Expert,1,,CHEMBL617633,,BAO_0000357,,
2919,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617634,,BAO_0000357,,
2920,7483,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,B,,,,,,,,,12688,H,8,Autocuration,1,,CHEMBL617635,,BAO_0000357,,
2922,16404,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,F,,,Rattus norvegicus,10116.0,,Stomach,,,12688,D,9,Autocuration,1,,CHEMBL617637,,BAO_0000019,945.0,
2923,6347,Binding affinity against 5-hydroxytryptamine 1A receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617638,,BAO_0000357,,
2924,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617639,,BAO_0000357,,
2925,4373,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617640,,BAO_0000357,,
2926,4687,Evaluated for the binding affinity to 5-HT 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617641,,BAO_0000357,,
2927,16946,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617642,,BAO_0000357,,
2928,16633,Binding affinities against 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617643,,BAO_0000357,,
2929,16633,Binding affinities towards 5-hydroxytryptamine 2B receptor,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617644,,BAO_0000357,,
2930,16633,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,B,,,,,,,,,227,H,8,Autocuration,1,,CHEMBL617645,,BAO_0000357,,
2931,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL617646,,BAO_0000357,,
2932,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617647,,BAO_0000357,,
2933,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617648,,BAO_0000357,,
2934,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617875,,BAO_0000357,,
2935,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617876,,BAO_0000357,,
2936,16404,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617877,,BAO_0000357,,
2937,15026,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,B,,,Bos taurus,9913.0,,,,,108,H,8,Expert,1,,CHEMBL617878,,BAO_0000357,,
2938,15738,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,B,,,Bos taurus,9913.0,,,,,108,H,8,Autocuration,1,,CHEMBL617879,,BAO_0000357,,
2939,16312,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,,,108,H,8,Autocuration,1,,CHEMBL617880,,BAO_0000019,,
2940,5486,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617881,,BAO_0000357,2435.0,
2941,5254,Binding affinity against 5-HT1A receptor,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL857073,,BAO_0000357,,
2942,3857,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,F,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617882,449.0,BAO_0000219,,
2943,6857,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,F,,,Homo sapiens,9606.0,,,CHO,,108,D,9,Expert,1,,CHEMBL617883,449.0,BAO_0000219,,
2944,4176,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617884,,BAO_0000219,,
2945,6347,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617885,449.0,BAO_0000219,,
2946,6347,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617886,449.0,BAO_0000219,,
2947,16146,Inhibition of human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617887,,BAO_0000357,,
2948,3805,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617888,,BAO_0000357,,
2949,3857,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617889,,BAO_0000019,,
2950,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617890,,BAO_0000357,,
2951,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617891,,BAO_0000357,,
2952,5635,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617892,,BAO_0000357,,
2953,4012,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617893,449.0,BAO_0000219,,
2954,6366,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617894,449.0,BAO_0000219,,
2955,15949,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL617895,449.0,BAO_0000219,,
2956,17211,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,B,,,,,,,CHO,,108,H,8,Autocuration,1,,CHEMBL617896,449.0,BAO_0000219,,
2957,6491,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL617897,,BAO_0000357,,
2958,14093,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617898,,BAO_0000019,,
2959,13481,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617899,,BAO_0000019,,
2960,6347,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,B,,,Rattus norvegicus,10116.0,,,CHO,,108,H,8,Expert,1,,CHEMBL617900,449.0,BAO_0000219,,
2961,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617901,,BAO_0000019,,
2962,14093,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617902,,BAO_0000019,,
2963,13481,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,F,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617903,,BAO_0000019,,
2964,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617904,,BAO_0000357,,
2965,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617905,,BAO_0000357,,
2966,14442,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617906,,BAO_0000357,,
2967,14755,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617907,,BAO_0000357,,
2968,14744,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL617908,,BAO_0000357,,
2969,16659,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,B,,,,,,,CHO,,108,H,8,Expert,1,,CHEMBL620617,449.0,BAO_0000219,,
2970,6857,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620618,,BAO_0000019,,
2971,5635,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620619,,BAO_0000357,,
2972,4234,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL620620,,BAO_0000357,,
2973,16209,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620621,,BAO_0000357,,
2974,5778,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,104698,D,7,Autocuration,1,,CHEMBL872920,,BAO_0000249,,
2975,5094,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620622,,BAO_0000223,,
2976,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620623,,BAO_0000019,,
2977,1578,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620624,,BAO_0000019,,
2978,809,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620625,,BAO_0000019,,
2979,12469,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620626,,BAO_0000219,,
2980,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621307,,BAO_0000019,,
2981,14290,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621308,,BAO_0000019,,
2982,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621309,,BAO_0000223,,
2983,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621310,,BAO_0000223,,
2984,10609,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621311,,BAO_0000223,,
2985,15253,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621502,,BAO_0000249,,
2986,15253,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621503,,BAO_0000249,,
2987,11683,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL621504,,BAO_0000249,,
2988,12092,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621505,,BAO_0000223,,
2989,1946,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL621506,,BAO_0000019,,
2990,11623,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619781,,BAO_0000223,,
2991,11623,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619782,,BAO_0000223,,
2992,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619783,,BAO_0000019,,
2993,5432,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619784,,BAO_0000019,,
2994,14826,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619785,,BAO_0000249,,
2995,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619786,,BAO_0000223,,
2996,11963,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619787,,BAO_0000019,,
2997,14145,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872925,,BAO_0000019,,
2998,17819,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619788,,BAO_0000019,,
2999,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619789,,BAO_0000249,,
3000,10394,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619790,,BAO_0000249,,
3001,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619791,,BAO_0000019,,
3002,691,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619792,,BAO_0000019,,
3003,12092,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL619793,,BAO_0000249,,
3004,11752,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619794,,BAO_0000223,,
3005,11752,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL619795,,BAO_0000221,955.0,
3006,301,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619796,,BAO_0000019,,
3007,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620448,,BAO_0000223,,
3008,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620449,,BAO_0000223,,
3009,12092,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620450,,BAO_0000223,,
3010,11684,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620451,,BAO_0000223,,
3011,11684,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620631,,BAO_0000223,,
3012,12953,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620632,,BAO_0000019,,
3013,12953,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620633,,BAO_0000019,,
3014,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620634,,BAO_0000223,,
3015,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620635,,BAO_0000019,,
3016,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620636,,BAO_0000218,,
3017,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620637,,BAO_0000218,,
3018,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620638,,BAO_0000218,,
3019,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620639,,BAO_0000218,,
3020,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620640,,BAO_0000218,,
3021,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620641,,BAO_0000218,,
3022,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620642,,BAO_0000218,,
3023,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620643,,BAO_0000218,,
3024,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620644,,BAO_0000218,,
3025,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620645,,BAO_0000218,,
3026,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620646,,BAO_0000218,,
3027,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620647,,BAO_0000218,,
3028,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620648,,BAO_0000218,,
3029,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620649,,BAO_0000218,,
3030,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620650,,BAO_0000218,,
3031,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620651,,BAO_0000218,,
3032,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872875,,BAO_0000218,,
3033,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620652,,BAO_0000218,,
3034,10609,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620653,,BAO_0000019,,
3035,12861,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL857076,,BAO_0000019,,
3036,12861,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL620654,,BAO_0000019,,
3037,12861,Binding activity radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620655,,BAO_0000223,,
3038,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620656,,BAO_0000249,,
3039,10728,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620657,,BAO_0000249,,
3040,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620658,,BAO_0000357,,
3041,5163,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620659,,BAO_0000357,,
3042,6011,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620660,,BAO_0000357,,
3043,5014,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620661,,BAO_0000357,,
3044,5635,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620662,,BAO_0000357,,
3045,5163,Affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620663,,BAO_0000357,,
3046,6841,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620664,,BAO_0000357,,
3047,6119,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620665,,BAO_0000357,,
3048,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620666,,BAO_0000357,,
3049,1633,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620667,,BAO_0000357,,
3050,1633,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620668,,BAO_0000357,,
3051,4373,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620669,,BAO_0000357,,
3052,6576,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL620670,,BAO_0000357,,
3053,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620671,,BAO_0000357,,
3054,12146,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620672,,BAO_0000357,,
3055,12146,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620673,,BAO_0000357,,
3056,16946,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620674,,BAO_0000357,,
3057,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620675,,BAO_0000357,,
3058,16700,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL620676,,BAO_0000357,,
3059,3269,Affinity against 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621382,,BAO_0000357,,
3060,1274,Binding affinity against 5-hydroxytryptamine 2C receptor,B,,,Homo sapiens,9606.0,,,,,108,D,9,Expert,1,,CHEMBL621383,,BAO_0000357,,
3061,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL621384,,BAO_0000357,,
3062,5834,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL621385,,BAO_0000357,,
3063,11147,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,B,,,Bos taurus,9913.0,,,,,144,H,8,Autocuration,1,,CHEMBL617989,,BAO_0000357,,
3064,14145,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Expert,1,,CHEMBL617990,,BAO_0000019,,
3065,10561,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL875085,,BAO_0000221,2116.0,
3066,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617991,,BAO_0000019,,
3067,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617992,,BAO_0000019,,
3068,10561,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617993,,BAO_0000221,2116.0,
3069,11454,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617994,,BAO_0000221,2116.0,
3070,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617995,,BAO_0000019,,
3071,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617996,,BAO_0000019,,
3072,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617997,,BAO_0000019,,
3073,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617998,,BAO_0000019,,
3074,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617999,,BAO_0000019,,
3075,4639,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618000,,BAO_0000019,,
3076,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617815,,BAO_0000221,2116.0,
3077,15253,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617816,,BAO_0000221,2116.0,
3078,11963,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617817,,BAO_0000221,2116.0,
3079,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617818,,BAO_0000221,2116.0,
3080,1946,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617819,,BAO_0000221,2116.0,
3081,12045,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,B,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617820,,BAO_0000223,,
3082,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617821,,BAO_0000221,2116.0,
3083,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617822,,BAO_0000221,2116.0,
3084,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617823,,BAO_0000221,2116.0,
3085,188,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617824,,BAO_0000221,2116.0,
3086,12919,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617825,,BAO_0000221,2116.0,
3087,12918,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617826,,BAO_0000221,2116.0,
3088,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617827,,BAO_0000221,2116.0,
3089,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617828,,BAO_0000221,2116.0,
3090,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617829,,BAO_0000221,2116.0,
3091,1559,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617830,,BAO_0000221,2116.0,
3092,1559,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617831,,BAO_0000221,2116.0,
3093,14424,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617832,,BAO_0000221,2116.0,
3094,13181,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,B,,,Cavia porcellus,10141.0,,,,,22226,U,0,Autocuration,1,,CHEMBL617833,,BAO_0000019,,
3095,5486,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,B,,,,,,,,,51,H,8,Autocuration,1,,CHEMBL617834,,BAO_0000357,,
3096,6491,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,104714,D,5,Expert,1,,CHEMBL617835,,BAO_0000223,,
3097,6013,Binding affinity towards 5-HT3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617836,,BAO_0000223,,
3098,12861,Binding activity radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL617837,,BAO_0000223,,
3099,12861,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620392,,BAO_0000019,,
3100,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620393,,BAO_0000223,,
3101,5105,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620394,,BAO_0000223,,
3102,5104,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620395,,BAO_0000223,,
3103,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620396,,BAO_0000019,,
3104,13657,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,B,,,,,,,NG108-15,,105030,H,4,Expert,1,,CHEMBL620582,433.0,BAO_0000219,,
3105,10369,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",B,In vivo,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620583,,BAO_0000218,,
3106,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620584,,BAO_0000019,,
3107,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620585,,BAO_0000224,,
3108,12918,Compound was evaluated for the binding affinity at 5- HT3 receptor,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620586,,BAO_0000224,,
3109,10369,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620587,,BAO_0000019,,
3110,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620588,,BAO_0000019,,
3111,12918,5-hydroxytryptamine 3 receptor agonism in mouse,F,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620589,,BAO_0000218,,
3112,10561,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL620590,,BAO_0000219,,
3113,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617956,,BAO_0000019,,
3114,12827,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617957,,BAO_0000019,,
3115,12918,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617958,,BAO_0000224,,
3116,273,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617959,,BAO_0000219,,
3117,273,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617960,,BAO_0000219,,
3118,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617961,,BAO_0000224,,
3119,5033,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,B,In vitro,,,,,,,,105030,H,4,Autocuration,1,,CHEMBL617962,,BAO_0000219,,
3120,16429,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,B,,,,,,,N1E-115,,105030,H,4,Autocuration,1,,CHEMBL617963,339.0,BAO_0000219,,
3121,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617964,,BAO_0000019,,
3122,14331,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,B,,,,,,,,,11765,H,8,Autocuration,1,,CHEMBL617965,,BAO_0000219,,
3123,13462,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,B,,,Mus musculus,10090.0,,,,,10630,D,9,Autocuration,1,,CHEMBL617966,,BAO_0000357,,
3124,12861,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,B,,,,,,,,,17106,H,8,Autocuration,1,,CHEMBL857074,,BAO_0000019,,
3125,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617967,,BAO_0000357,,
3126,12861,Binding activity radioligand.,B,,,Sus scrofa,9823.0,,,,,144,H,8,Autocuration,1,,CHEMBL617968,,BAO_0000357,,
3127,10561,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617969,,BAO_0000223,,
3128,10561,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617970,,BAO_0000223,,
3129,10561,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617971,,BAO_0000223,,
3130,10561,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617972,,BAO_0000019,,
3131,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617973,,BAO_0000019,,
3132,273,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617974,,BAO_0000019,,
3133,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),F,,,Oryctolagus cuniculus,9986.0,,Ileum,,,104714,H,4,Autocuration,1,,CHEMBL617975,,BAO_0000221,2116.0,
3134,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617976,,BAO_0000019,,
3135,273,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617977,,BAO_0000019,,
3136,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617978,,BAO_0000019,,
3137,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),F,,,Oryctolagus cuniculus,9986.0,,,,,104714,H,4,Autocuration,1,,CHEMBL617979,,BAO_0000019,,
3138,13047,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,B,,,Oryctolagus cuniculus,9986.0,,,CHO,,104714,H,4,Autocuration,1,,CHEMBL617980,449.0,BAO_0000219,,
3139,1650,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617981,,BAO_0000019,,
3140,16288,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617982,,BAO_0000019,,
3141,16288,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL617983,,BAO_0000357,,
3142,10254,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617984,,BAO_0000019,,
3143,14532,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617985,,BAO_0000019,,
3144,13392,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,In vivo,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617986,,BAO_0000218,948.0,
3145,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617987,,BAO_0000019,948.0,
3146,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617988,,BAO_0000019,948.0,
3147,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617792,,BAO_0000019,948.0,
3148,13392,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",F,,,,,,Heart,,,104698,H,6,Autocuration,1,,CHEMBL617793,,BAO_0000019,948.0,
3149,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617794,,BAO_0000019,,
3150,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617795,,BAO_0000019,,
3151,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617796,,BAO_0000019,,
3152,13392,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617797,,BAO_0000019,,
3153,1089,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617798,,BAO_0000218,,
3154,1089,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617799,,BAO_0000218,,
3155,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617800,,BAO_0000218,,
3156,11454,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617801,,BAO_0000019,,
3157,12205,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617802,,BAO_0000218,,
3158,1089,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617803,,BAO_0000019,,
3159,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617804,,BAO_0000019,,
3160,2622,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617805,,BAO_0000019,,
3161,245,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617806,,BAO_0000223,,
3162,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617807,,BAO_0000019,,
3163,14788,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617808,,BAO_0000019,,
3164,3020,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617809,,BAO_0000249,,
3165,1742,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617810,,BAO_0000019,,
3166,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617811,,BAO_0000249,955.0,
3167,17394,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,B,,,,,,Brain,,,104698,H,6,Autocuration,1,,CHEMBL617812,,BAO_0000221,955.0,
3168,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617813,,BAO_0000249,,
3169,14286,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617814,,BAO_0000249,,
3170,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617698,,BAO_0000019,,
3171,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617699,,BAO_0000019,,
3172,14178,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617700,,BAO_0000019,,
3173,14178,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617701,,BAO_0000223,,
3174,15034,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617702,,BAO_0000019,,
3175,1089,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",B,,,,,,,,Membranes,104698,H,6,Autocuration,1,,CHEMBL617703,,BAO_0000249,,
3176,1089,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617704,,BAO_0000019,,
3177,16532,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617705,,BAO_0000223,,
3178,12801,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617706,,BAO_0000223,,
3179,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617707,433.0,BAO_0000219,,
3180,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,B,,,,,,,NG108-15,,104698,H,6,Autocuration,1,,CHEMBL617708,433.0,BAO_0000219,,
3181,15194,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617709,,BAO_0000019,,
3182,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617710,,BAO_0000019,,
3183,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL882925,,BAO_0000019,,
3184,15194,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617711,,BAO_0000019,,
3185,10610,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617712,,BAO_0000019,,
3186,10355,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,F,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617713,,BAO_0000019,,
3187,691,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617714,,BAO_0000019,,
3188,10611,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617715,,BAO_0000218,,
3189,12801,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617716,,BAO_0000218,,
3190,10609,Inhibition of 5-HT evoked reflex bradycardia in rat.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617717,,BAO_0000218,,
3191,11454,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617718,,BAO_0000218,,
3192,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617719,,BAO_0000218,,
3193,11454,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617720,,BAO_0000218,,
3194,11454,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL617721,,BAO_0000218,,
3195,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617722,,BAO_0000218,,
3196,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617723,,BAO_0000218,,
3197,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617724,,BAO_0000218,,
3198,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617725,,BAO_0000218,,
3199,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617726,,BAO_0000218,,
3200,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617727,,BAO_0000218,,
3201,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617728,,BAO_0000218,,
3202,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617729,,BAO_0000218,,
3203,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617730,,BAO_0000218,,
3204,11454,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617731,,BAO_0000218,,
3205,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617732,,BAO_0000218,,
3206,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617733,,BAO_0000218,,
3207,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617734,,BAO_0000218,,
3208,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL872874,,BAO_0000218,,
3209,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617735,,BAO_0000218,,
3210,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617736,,BAO_0000218,,
3211,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617737,,BAO_0000218,,
3212,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617738,,BAO_0000218,,
3213,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617739,,BAO_0000218,,
3214,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617740,,BAO_0000218,,
3215,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617741,,BAO_0000218,,
3216,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617742,,BAO_0000218,,
3217,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617743,,BAO_0000218,,
3218,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617744,,BAO_0000218,,
3219,11454,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617745,,BAO_0000218,,
3220,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617746,,BAO_0000218,,
3221,670,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617747,,BAO_0000218,,
3222,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL617748,,BAO_0000218,,
3223,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618909,,BAO_0000218,,
3224,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618910,,BAO_0000218,,
3225,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618911,,BAO_0000218,,
3226,10321,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618912,,BAO_0000218,,
3227,10322,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),F,In vivo,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618913,,BAO_0000218,,
3228,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618914,,BAO_0000019,,
3229,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618915,,BAO_0000019,,
3230,15412,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618916,,BAO_0000223,,
3231,15412,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618917,,BAO_0000019,,
3232,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,B,,,,,,Hippocampus,,,104698,D,7,Intermediate,1,,CHEMBL618918,,BAO_0000221,10000000.0,
3233,15412,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618919,,BAO_0000019,,
3234,17394,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL618920,,BAO_0000019,,
3235,12457,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618921,,BAO_0000223,,
3236,12457,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618922,,BAO_0000019,,
3237,12205,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618923,,BAO_0000019,,
3238,14532,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618924,,BAO_0000019,,
3239,1122,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618925,,BAO_0000019,,
3240,5094,Binding affinity towards 5-HT3 receptor in rat was evaluated,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618926,,BAO_0000019,,
3241,809,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618927,,BAO_0000221,2116.0,
3242,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618928,,BAO_0000221,2116.0,
3243,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618929,,BAO_0000221,2116.0,
3244,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618930,,BAO_0000221,2116.0,
3245,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL618931,,BAO_0000221,2116.0,
3246,14290,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619594,,BAO_0000221,2116.0,
3247,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619595,,BAO_0000221,2116.0,
3248,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619596,,BAO_0000221,2116.0,
3249,13961,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619755,,BAO_0000221,2116.0,
3250,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619756,,BAO_0000221,2116.0,
3251,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619757,,BAO_0000221,2116.0,
3252,809,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619758,,BAO_0000221,2116.0,
3253,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619759,,BAO_0000221,2116.0,
3254,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619760,,BAO_0000221,2116.0,
3255,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619761,,BAO_0000221,2116.0,
3256,14290,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619762,,BAO_0000221,2116.0,
3257,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619763,,BAO_0000221,2116.0,
3258,14290,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL617868,,BAO_0000221,2116.0,
3259,15034,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL617869,,BAO_0000357,,
3260,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL882926,,BAO_0000249,2435.0,
3261,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617870,,BAO_0000249,2435.0,
3262,5399,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617871,,BAO_0000357,2435.0,
3263,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617872,,BAO_0000357,2435.0,
3264,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617873,,BAO_0000357,2435.0,
3265,17394,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL617874,,BAO_0000357,2435.0,
3266,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619067,,BAO_0000221,2116.0,
3267,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619068,,BAO_0000221,2116.0,
3268,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619069,,BAO_0000221,2116.0,
3269,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619070,,BAO_0000357,,
3270,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619071,,BAO_0000357,,
3271,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619072,,BAO_0000019,,
3272,15034,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619073,,BAO_0000019,,
3273,12918,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619074,,BAO_0000019,,
3274,16946,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619075,,BAO_0000357,,
3275,17394,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619076,,BAO_0000357,2435.0,
3276,15034,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619077,,BAO_0000357,2435.0,
3277,5094,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619078,,BAO_0000249,2435.0,
3278,5094,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619079,,BAO_0000249,2435.0,
3279,17358,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619080,,BAO_0000221,2116.0,
3280,12953,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Expert,1,,CHEMBL619081,,BAO_0000357,,
3281,12953,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619082,,BAO_0000357,,
3282,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619083,,BAO_0000357,,
3283,12953,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619084,,BAO_0000357,,
3284,273,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL859397,,BAO_0000221,2116.0,
3285,12918,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619085,,BAO_0000221,2116.0,
3286,12919,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619086,,BAO_0000221,2116.0,
3287,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619087,,BAO_0000221,2116.0,
3288,273,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619088,,BAO_0000221,2116.0,
3289,13181,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619089,,BAO_0000357,,
3290,13181,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,B,,,Cavia porcellus,10141.0,,,,,168,H,8,Autocuration,1,,CHEMBL619090,,BAO_0000357,,
3291,15034,Antagonistic activity against 5-hydroxytryptamine 4 receptor,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619091,,BAO_0000019,,
3292,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619092,,BAO_0000357,,
3293,1980,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619093,,BAO_0000019,,
3294,13181,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,B,,,Cavia porcellus,10141.0,,,HEK293,,168,H,8,Autocuration,1,,CHEMBL619094,722.0,BAO_0000219,,
3295,14287,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619095,,BAO_0000019,,
3296,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL857988,,BAO_0000357,,
3297,15316,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619096,,BAO_0000357,,
3298,16429,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,B,,,Cavia porcellus,10141.0,,Striatum,,,20033,D,9,Intermediate,1,,CHEMBL619097,,BAO_0000357,2435.0,
3299,14818,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,B,,,Cavia porcellus,10141.0,,Hippocampus,,,20033,D,9,Intermediate,1,,CHEMBL619098,,BAO_0000221,10000000.0,
3300,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619751,,BAO_0000357,,
3301,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619752,,BAO_0000357,,
3302,13961,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL875096,,BAO_0000221,2116.0,
3303,5486,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,B,,,,,,,,,108,H,8,Autocuration,1,,CHEMBL619004,,BAO_0000357,,
3304,16209,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619005,,BAO_0000357,,
3305,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619006,,BAO_0000019,,
3306,4199,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619007,308.0,BAO_0000219,,
3307,15146,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619008,,BAO_0000357,,
3308,5213,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL619009,,BAO_0000357,,
3309,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",B,,,,,,,HeLa,,168,H,8,Autocuration,1,,CHEMBL619010,308.0,BAO_0000219,,
3310,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619011,,BAO_0000357,,
3311,17358,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619012,,BAO_0000357,,
3312,16946,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619013,,BAO_0000219,,
3313,17358,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,B,,,,,,,,,10622,H,8,Autocuration,1,,CHEMBL619014,,BAO_0000357,,
3314,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL857503,,BAO_0000019,2081.0,
3315,268,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,F,,,,,,Cardiac atrium,,,11249,H,8,Autocuration,1,,CHEMBL619015,,BAO_0000019,2081.0,
3316,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,11249,H,8,Autocuration,1,,CHEMBL619016,,BAO_0000357,,
3317,14875,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,B,,,,,,Hippocampus,,,11249,H,8,Autocuration,1,,CHEMBL619017,,BAO_0000221,10000000.0,
3318,13267,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,B,,,Sus scrofa,9823.0,,Hippocampus,,,168,H,8,Autocuration,1,,CHEMBL619018,,BAO_0000221,10000000.0,
3319,13047,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,B,,,Oryctolagus cuniculus,9986.0,,,,,168,H,8,Autocuration,1,,CHEMBL619019,,BAO_0000019,,
3320,1650,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619020,,BAO_0000357,,
3321,567,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619021,,BAO_0000019,,
3322,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619022,,BAO_0000357,,
3323,188,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619023,,BAO_0000357,,
3324,670,lntrinsic activity relative to 5-HT receptor,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619024,,BAO_0000019,,
3325,204,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619025,,BAO_0000019,,
3326,1946,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619026,,BAO_0000019,,
3327,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619027,,BAO_0000019,,
3328,6398,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619028,,BAO_0000019,,
3329,17358,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619029,,BAO_0000019,,
3330,6398,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619030,,BAO_0000019,,
3331,11752,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619031,,BAO_0000357,,
3332,809,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619032,,BAO_0000019,,
3333,14178,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619033,,BAO_0000357,,
3334,567,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619034,,BAO_0000357,,
3335,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619035,,BAO_0000357,,
3336,1946,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619036,,BAO_0000357,,
3337,13961,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL619037,,BAO_0000019,,
3338,6238,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619038,,BAO_0000249,2435.0,
3339,14290,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,B,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619039,,BAO_0000249,,
3340,14290,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619040,,BAO_0000249,,
3341,809,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,Rattus norvegicus,10116.0,,Striatum,,,10623,D,9,Expert,1,,CHEMBL619041,,BAO_0000019,2435.0,
3342,1578,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,B,,,,,,Striatum,,,10623,H,8,Autocuration,1,,CHEMBL619042,,BAO_0000019,2435.0,
3343,16709,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619043,,BAO_0000249,2435.0,
3344,1946,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619044,,BAO_0000019,2435.0,
3345,15253,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619045,,BAO_0000249,2435.0,
3346,4535,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL619046,,BAO_0000249,2435.0,
3347,13961,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,B,,,,,,,,,10623,H,8,Expert,1,,CHEMBL619047,,BAO_0000249,,
3348,17358,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,F,,,,,,Brain,,,10623,H,8,Autocuration,1,,CHEMBL619048,,BAO_0000221,955.0,
3349,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL859398,,BAO_0000019,,
3350,15847,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619049,,BAO_0000019,,
3351,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL857886,,BAO_0000019,,
3352,670,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL619050,,BAO_0000019,,
3353,1317,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620591,,BAO_0000019,,
3354,12936,Binding affinity against rat 5-hydroxytryptamine 4 receptor,B,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620592,,BAO_0000357,,
3355,4535,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,B,,,,,,Striatum,,,10623,H,8,Expert,1,,CHEMBL620593,,BAO_0000249,2435.0,
3356,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620594,,BAO_0000019,,
3357,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL875079,,BAO_0000019,,
3358,14424,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620595,,BAO_0000019,,
3359,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,F,,,Rattus norvegicus,10116.0,,,,,10623,D,9,Expert,1,,CHEMBL620596,,BAO_0000019,,
3360,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620597,,BAO_0000019,,
3361,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620598,,BAO_0000019,,
3362,14424,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),F,,,,,,,,,10623,H,8,Expert,1,,CHEMBL620599,,BAO_0000218,,
3363,14424,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,F,,,,,,,,,10623,H,8,Autocuration,1,,CHEMBL620600,,BAO_0000019,,
3364,1980,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,F,,,Rattus norvegicus,10116.0,,,,,168,H,8,Autocuration,1,,CHEMBL620601,,BAO_0000019,,
3365,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620602,,BAO_0000019,,
3366,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620603,,BAO_0000357,,
3367,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620604,,BAO_0000357,,
3368,17358,Compound was tested for 5-hydroxytryptamine 4 binding affinity,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620605,,BAO_0000357,,
3369,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620606,,BAO_0000357,,
3370,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620607,,BAO_0000019,,
3371,16117,In vitro binding affinity towards 5-HT4 receptor was determined,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620608,,BAO_0000357,,
3372,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620609,,BAO_0000019,,
3373,17358,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620610,,BAO_0000019,,
3374,17358,Tested for selectivity for 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620611,,BAO_0000357,,
3375,17358,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620612,,BAO_0000357,,
3376,17358,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620613,,BAO_0000357,,
3377,17358,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620614,,BAO_0000357,,
3378,1274,Binding affinity against 5-Hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620615,,BAO_0000357,,
3379,10728,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL857075,,BAO_0000249,,
3380,11695,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL620616,,BAO_0000249,,
3381,11695,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,B,,,,,,,,Brain membranes,104698,H,6,Autocuration,1,,CHEMBL619411,,BAO_0000249,,
3382,12490,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619412,,BAO_0000019,,
3383,11828,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619413,,BAO_0000019,,
3384,12253,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,B,,,,,,Hippocampus,,,104698,H,6,Autocuration,1,,CHEMBL619414,,BAO_0000221,10000000.0,
3385,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619415,,BAO_0000019,,
3386,10561,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619416,,BAO_0000019,,
3387,14432,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619417,,BAO_0000019,,
3388,12936,Binding affinity against rat 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619418,,BAO_0000223,,
3389,1274,Binding affinity against 5-Hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619419,,BAO_0000223,,
3390,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619420,,BAO_0000019,,
3391,670,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619421,,BAO_0000249,,
3392,968,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619422,,BAO_0000019,,
3393,14287,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619423,,BAO_0000019,,
3394,567,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL875080,,BAO_0000019,,
3395,13267,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619424,,BAO_0000019,,
3396,14826,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619425,,BAO_0000249,,
3397,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619426,,BAO_0000223,,
3398,15194,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL619427,,BAO_0000223,,
3399,10394,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,B,,,Rattus norvegicus,10116.0,,,,,104698,D,7,Autocuration,1,,CHEMBL619645,,BAO_0000223,,
3400,13657,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",B,,,,,,,,,10576,D,9,Expert,1,,CHEMBL619646,,BAO_0000249,,
3401,1879,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,F,,,,,,Brain,,,12020,H,8,Autocuration,1,,CHEMBL619647,,BAO_0000221,955.0,
3402,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619648,,BAO_0000019,,
3403,1879,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,F,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL619165,,BAO_0000019,,
3404,204,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,F,In vivo,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620719,,BAO_0000218,,
3405,1879,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL872924,,BAO_0000019,,
3406,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620720,,BAO_0000357,,
3407,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620721,,BAO_0000019,,
3408,1879,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620722,,BAO_0000019,,
3409,10641,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620723,,BAO_0000019,,
3410,773,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,B,,,,,,,,,12020,H,8,Autocuration,1,,CHEMBL620724,,BAO_0000019,,
3411,11952,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL620725,,BAO_0000249,,
3412,14145,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,F,,,Rattus norvegicus,10116.0,,,,,12020,D,9,Autocuration,1,,CHEMBL620726,,BAO_0000019,,
3413,17066,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Expert,1,,CHEMBL620727,,BAO_0000357,,
3414,6398,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620728,,BAO_0000223,,
3415,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620729,,BAO_0000019,,
3416,511,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL858288,,BAO_0000019,,
3417,4639,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620730,,BAO_0000223,,
3418,4639,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL620731,,BAO_0000223,,
3419,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL620732,,BAO_0000019,,
3420,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618042,,BAO_0000019,,
3421,4639,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618043,,BAO_0000019,,
3422,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618044,,BAO_0000223,,
3423,268,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618045,,BAO_0000019,,
3424,2474,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618046,,BAO_0000223,,
3425,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618047,,BAO_0000019,,
3426,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875084,,BAO_0000019,,
3427,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618048,,BAO_0000019,,
3428,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618049,,BAO_0000223,,
3429,5067,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619764,,BAO_0000019,,
3430,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619765,,BAO_0000019,,
3431,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619766,,BAO_0000019,,
3432,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619767,,BAO_0000223,,
3433,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619768,,BAO_0000223,,
3434,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619769,,BAO_0000019,,
3435,5067,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619770,,BAO_0000223,,
3436,5067,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619771,,BAO_0000223,,
3437,14331,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619772,,BAO_0000219,,
3438,5067,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619773,,BAO_0000223,,
3439,6179,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL619774,433.0,BAO_0000219,,
3440,4265,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL875083,,BAO_0000019,,
3441,4265,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,B,,,,,,,NG108-15,,104714,H,4,Autocuration,1,,CHEMBL620718,433.0,BAO_0000219,,
3442,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618127,,BAO_0000223,,
3443,17358,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618128,,BAO_0000223,,
3444,13628,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,B,In vitro,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618129,,BAO_0000219,,
3445,4612,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618130,,BAO_0000223,,
3446,17358,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,F,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618131,,BAO_0000019,,
3447,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618132,,BAO_0000019,,
3448,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618133,,BAO_0000019,,
3449,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618134,,BAO_0000019,,
3450,4639,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618135,,BAO_0000019,,
3451,511,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618136,,BAO_0000223,,
3452,1479,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618137,,BAO_0000223,,
3453,1317,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618138,,BAO_0000223,,
3454,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618139,,BAO_0000223,,
3455,12146,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618140,,BAO_0000223,,
3456,13969,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618141,,BAO_0000223,,
3457,13392,Binding affinity for 5-hydroxytryptamine 2C receptor,B,,,,,,,,,108,H,8,Expert,1,,CHEMBL873478,,BAO_0000357,,
3458,13392,Binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618142,,BAO_0000223,,
3459,14159,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618143,,BAO_0000357,,
3460,1558,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618144,,BAO_0000357,,
3461,16655,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618145,,BAO_0000357,,
3462,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618146,,BAO_0000223,,
3463,13021,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618147,,BAO_0000223,,
3464,13020,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618148,,BAO_0000223,,
3465,10321,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618149,,BAO_0000019,,
3466,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL872927,,BAO_0000357,,
3467,15818,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618150,,BAO_0000357,,
3468,17358,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618151,,BAO_0000357,,
3469,2222,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL875094,,BAO_0000357,,
3470,10322,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618152,,BAO_0000019,,
3471,16117,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618153,,BAO_0000357,,
3472,17200,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618888,,BAO_0000357,,
3473,17358,Tested for 5-hydroxytryptamine 3 receptor agonist activity,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618889,,BAO_0000019,,
3474,16700,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618890,,BAO_0000357,,
3475,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL618891,,BAO_0000019,,
3476,1980,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619054,,BAO_0000019,,
3477,12409,Binding affinity against the 5-hydroxytryptamine 3 receptor,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL619055,,BAO_0000223,,
3478,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619056,,BAO_0000357,,
3479,4365,Percent efficacy against 5-hydroxytryptamine 3A receptor,F,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619057,,BAO_0000019,,
3480,4365,Binding affinity against human 5-hydroxytryptamine 3A receptor,B,,,,,,,,,144,H,8,Autocuration,1,,CHEMBL619058,,BAO_0000357,,
3481,6769,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619059,,BAO_0000219,,
3482,6769,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL619060,,BAO_0000219,,
3483,6769,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,F,,,Rattus norvegicus,10116.0,,,Oocytes,,12020,D,9,Expert,1,,CHEMBL875095,,BAO_0000219,,
3484,809,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619061,,BAO_0000221,2116.0,
3485,809,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619062,,BAO_0000221,2116.0,
3486,14290,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,F,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619063,,BAO_0000019,,
3487,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619064,,BAO_0000221,2116.0,
3488,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL619065,,BAO_0000357,,
3489,17358,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,B,,,Cavia porcellus,10141.0,,Ileum,,,20033,D,9,Intermediate,1,,CHEMBL619066,,BAO_0000221,2116.0,
3490,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619775,,BAO_0000221,2116.0,
3491,3269,Affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619776,,BAO_0000357,,
3492,7721,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619777,,BAO_0000224,,
3493,7721,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619778,,BAO_0000224,,
3494,9117,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,B,,,Cavia porcellus,10141.0,,Ileum,,,104841,H,4,Autocuration,1,,CHEMBL619779,,BAO_0000221,2116.0,
3495,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619780,,BAO_0000224,,
3496,7721,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",B,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619166,,BAO_0000224,,
3497,15796,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619167,,BAO_0000019,,
3498,15796,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,F,,,Cavia porcellus,10141.0,,,,,104841,H,4,Autocuration,1,,CHEMBL619168,,BAO_0000019,,
3499,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619169,,BAO_0000219,2081.0,
3500,15650,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,B,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619170,,BAO_0000219,2081.0,
3501,6866,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",F,,,Homo sapiens,9606.0,,,,,104841,D,5,Autocuration,1,,CHEMBL619171,,BAO_0000019,,
3502,15650,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",F,,,Homo sapiens,9606.0,,Cardiac atrium,,,168,D,9,Expert,1,,CHEMBL619172,,BAO_0000219,2081.0,
3503,10063,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619173,,BAO_0000019,,
3504,12665,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,B,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619174,,BAO_0000019,,
3505,7504,5-hydroxytryptamine receptor binding affinity was determined in rats,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619175,,BAO_0000019,,
3506,7504,Binding affinity at rat 5-hydroxytryptamine receptor.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619176,,BAO_0000224,,
3507,7038,Affinity against 5-hydroxytryptamine receptors in rat fundus model,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619177,,BAO_0000019,,
3508,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619178,,BAO_0000224,,
3509,7626,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619179,,BAO_0000224,,
3510,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619180,,BAO_0000019,945.0,
3511,7185,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,F,,,,,,Stomach,,,104705,H,4,Autocuration,1,,CHEMBL619181,,BAO_0000019,945.0,
3512,7185,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,F,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619182,,BAO_0000019,,
3513,6960,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619183,,BAO_0000224,,
3514,6960,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619184,,BAO_0000224,,
3515,12416,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619185,,BAO_0000221,10000000.0,
3516,15753,Binding affinity for rat 5-hydroxytryptamine transporter.,B,,,,,,,,,12198,H,8,Expert,1,,CHEMBL619186,,BAO_0000357,,
3517,8062,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,B,,,,,,,,,104705,H,4,Autocuration,1,,CHEMBL619187,,BAO_0000019,,
3518,9036,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619188,,BAO_0000019,,
3519,15067,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619189,,BAO_0000224,,
3520,15753,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,F,,,Rattus norvegicus,10116.0,,Brain,,,12198,D,9,Expert,1,,CHEMBL619190,,BAO_0000019,955.0,
3521,15753,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,F,,,Rattus norvegicus,10116.0,,Cerebellum,,,12198,D,9,Expert,1,,CHEMBL619191,,BAO_0000221,2037.0,
3522,15295,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619192,,BAO_0000019,,
3523,6347,Percent binding affinity against 5-hydroxytryptamine receptor,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619193,,BAO_0000224,,
3524,6763,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL619194,,BAO_0000019,,
3525,12092,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619195,,BAO_0000224,,
3526,1579,Affinity against 5-hydroxytryptamine receptor was determined,B,,,Rattus norvegicus,10116.0,,,,,104705,D,5,Autocuration,1,,CHEMBL619196,,BAO_0000224,,
3527,1579,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,B,,,Rattus norvegicus,10116.0,,Stomach,,,104705,D,5,Autocuration,1,,CHEMBL619197,,BAO_0000019,945.0,
3528,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL619198,,BAO_0000219,,
3529,5963,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,B,In vitro,,Homo sapiens,9606.0,,,,,121,D,9,Expert,1,,CHEMBL875081,,BAO_0000219,,
3530,5030,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,B,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL884712,,BAO_0000357,,
3531,15796,Inhibition of 5-hydroxytryptamine reuptake,B,,,,,,,,,121,H,8,Expert,1,,CHEMBL884710,,BAO_0000357,,
3532,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619199,,BAO_0000019,,
3533,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619200,,BAO_0000019,,
3534,15413,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619201,,BAO_0000019,,
3535,12409,Tested for 5-hydroxytryptamine receptor uptake,F,,,,,,,,,18065,H,8,Autocuration,1,,CHEMBL619202,,BAO_0000019,,
3536,16909,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,B,,,Homo sapiens,9606.0,,,CHO,,51,D,9,Expert,1,,CHEMBL619203,449.0,BAO_0000219,,
3537,16909,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,F,,,Homo sapiens,9606.0,,,,,51,D,9,Expert,1,,CHEMBL619204,,BAO_0000019,,
3538,15629,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,B,,,Homo sapiens,9606.0,,,,,10576,H,8,Autocuration,1,,CHEMBL619205,,BAO_0000249,,
3539,15629,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,B,,,,,,,,,10576,H,8,Autocuration,1,,CHEMBL619206,,BAO_0000357,,
3540,15629,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,B,,,,,,,,,10576,H,8,Expert,1,,CHEMBL619207,,BAO_0000249,,
3541,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619208,,BAO_0000019,2435.0,
3542,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619209,,BAO_0000019,2435.0,
3543,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619210,,BAO_0000019,2435.0,
3544,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619211,,BAO_0000019,2435.0,
3545,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL619212,,BAO_0000019,2435.0,
3546,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620681,,BAO_0000019,2435.0,
3547,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620682,,BAO_0000019,2435.0,
3548,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620683,,BAO_0000019,2435.0,
3549,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620684,,BAO_0000019,2435.0,
3550,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620685,,BAO_0000019,2435.0,
3551,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,F,,,,,,Striatum,,,10825,H,8,Autocuration,1,,CHEMBL620686,,BAO_0000019,2435.0,
3552,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620687,,BAO_0000019,349.0,
3553,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620688,,BAO_0000019,349.0,
3554,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620689,,BAO_0000019,349.0,
3555,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620690,,BAO_0000019,349.0,
3556,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620691,,BAO_0000019,349.0,
3557,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620692,,BAO_0000019,349.0,
3558,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL620693,,BAO_0000019,349.0,
3559,1274,Binding affinity against 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620694,,BAO_0000357,,
3560,17358,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,F,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL857986,,BAO_0000019,,
3561,14532,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620695,,BAO_0000357,,
3562,16989,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Expert,1,,CHEMBL620696,,BAO_0000357,,
3563,17200,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620697,,BAO_0000357,,
3564,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620698,,BAO_0000357,,
3565,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620699,,BAO_0000357,,
3566,15779,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,B,,,,,,,,,168,H,8,Autocuration,1,,CHEMBL620700,,BAO_0000357,,
3567,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620701,643.0,BAO_0000219,,
3568,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL875082,643.0,BAO_0000219,,
3569,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620702,643.0,BAO_0000219,,
3570,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,B,,,,,,,COS-7,,168,H,8,Autocuration,1,,CHEMBL620703,643.0,BAO_0000219,,
3571,17046,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Autocuration,1,,CHEMBL620704,673.0,BAO_0000219,,
3572,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620705,673.0,BAO_0000219,,
3573,15650,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620706,673.0,BAO_0000219,,
3574,17046,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,B,,,,,,,C6,,168,H,8,Expert,1,,CHEMBL620707,673.0,BAO_0000219,,
3575,17066,Binding affinity towards 5-hydroxytryptamine 5 receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620708,,BAO_0000357,,
3576,17200,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,B,,,,,,,,,105,H,8,Autocuration,1,,CHEMBL620709,,BAO_0000357,,
3577,16146,Binding affinity against 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620710,,BAO_0000357,,
3578,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,B,,,,,,,CHO,,10624,H,8,Autocuration,1,,CHEMBL620711,449.0,BAO_0000219,,
3579,6491,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620712,,BAO_0000357,,
3580,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620713,,BAO_0000357,,
3581,17066,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620714,,BAO_0000357,,
3582,4234,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL620715,,BAO_0000357,,
3583,6013,Binding affinity towards 5-HT5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL620716,,BAO_0000357,,
3584,17175,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL620717,,BAO_0000357,,
3585,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618072,,BAO_0000357,,
3586,6166,Binding affinity towards cloned human 5-HT5A receptor was determined,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL857987,,BAO_0000357,,
3587,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618073,722.0,BAO_0000219,,
3588,15779,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618074,722.0,BAO_0000219,,
3589,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),B,,,,,,,HEK293,,10624,H,8,Autocuration,1,,CHEMBL618075,722.0,BAO_0000219,,
3590,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618076,,BAO_0000357,,
3591,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618077,,BAO_0000357,,
3592,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618078,,BAO_0000357,,
3593,17066,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL881821,,BAO_0000357,,
3594,17066,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,B,,,Mus musculus,10090.0,,,,,10625,D,9,Expert,1,,CHEMBL618079,,BAO_0000357,,
3595,17175,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,B,,,,,,,,,10625,H,8,Expert,1,,CHEMBL618080,,BAO_0000357,,
3596,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10576,H,8,Autocuration,1,,CHEMBL618081,722.0,BAO_0000219,,
3597,16190,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,B,,,,,,,HEK293,,10626,H,8,Autocuration,1,,CHEMBL618082,722.0,BAO_0000219,,
3598,4820,Binding affinity towards 5-HT5a receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618083,,BAO_0000357,,
3599,17066,Binding affinity towards 5-hydroxytryptamine 5A receptor,B,,,Homo sapiens,9606.0,,,,,10624,D,9,Expert,1,,CHEMBL618084,,BAO_0000357,,
3600,17066,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618085,,BAO_0000357,,
3601,17175,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,B,,,,,,,,,10624,H,8,Expert,1,,CHEMBL618086,,BAO_0000357,,
3602,16633,Binding affinities against 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL875092,,BAO_0000357,,
3603,16633,Binding affinities towards 5-hydroxytryptamine 5A receptor,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL618087,,BAO_0000357,,
3604,16700,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,B,,,,,,,,,10624,H,8,Autocuration,1,,CHEMBL872926,,BAO_0000357,,
3605,4639,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,F,,,Cavia porcellus,10141.0,,,,,104714,H,4,Autocuration,1,,CHEMBL618088,,BAO_0000019,,
3606,5486,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,B,,,,,,,,,104714,H,4,Autocuration,1,,CHEMBL618089,,BAO_0000223,,
3607,16146,Inhibition of human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618090,,BAO_0000357,,
3608,17273,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618091,,BAO_0000357,,
3609,17687,Inhibition against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618092,,BAO_0000357,,
3610,6491,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618093,,BAO_0000357,,
3611,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL618094,308.0,BAO_0000219,,
3612,17066,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618095,,BAO_0000357,,
3613,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL875093,,BAO_0000357,,
3614,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618096,,BAO_0000357,,
3615,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618118,,BAO_0000357,,
3616,3555,Binding affinity against 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618119,,BAO_0000357,,
3617,5808,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618120,,BAO_0000357,,
3618,6013,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618121,,BAO_0000357,,
3619,15818,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618122,722.0,BAO_0000219,,
3620,16209,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618123,,BAO_0000357,,
3621,3935,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,B,,,,,,,HEK293,,10627,H,8,Expert,1,,CHEMBL618124,722.0,BAO_0000219,,
3622,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618125,,BAO_0000357,,
3623,3805,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,Homo sapiens,9606.0,,,HEK293,,10627,D,9,Expert,1,,CHEMBL618126,722.0,BAO_0000219,,
3624,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618236,,BAO_0000019,,
3625,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL618237,,BAO_0000019,,
3626,6786,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,B,,,,,,,COS-7,,10627,H,8,Expert,1,,CHEMBL618238,643.0,BAO_0000219,,
3627,4234,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL618239,,BAO_0000357,,
3628,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618240,,BAO_0000019,,
3629,17200,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618241,,BAO_0000357,,
3630,17451,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL859399,722.0,BAO_0000219,,
3631,3935,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,F,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL618242,,BAO_0000019,,
3632,5033,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857991,,BAO_0000357,,
3633,4540,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL619951,,BAO_0000357,,
3634,4540,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619952,308.0,BAO_0000219,,
3635,4540,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Expert,1,,CHEMBL619953,308.0,BAO_0000219,,
3636,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619954,308.0,BAO_0000219,,
3637,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619955,308.0,BAO_0000219,,
3638,17296,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL619956,308.0,BAO_0000219,,
3639,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,B,,,,,,,CHO,,10627,H,8,Autocuration,1,,CHEMBL619957,449.0,BAO_0000219,,
3640,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL619958,722.0,BAO_0000219,,
3641,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620627,722.0,BAO_0000219,,
3642,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,B,,,,,,,HEK293,,10627,H,8,Autocuration,1,,CHEMBL620628,722.0,BAO_0000219,,
3643,15779,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620629,308.0,BAO_0000219,,
3644,6166,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620630,,BAO_0000357,,
3645,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620782,308.0,BAO_0000219,,
3646,15316,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620783,,BAO_0000357,,
3647,4199,Binding affinity against human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620784,,BAO_0000357,,
3648,15146,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,B,,,,,,,HeLa,,10627,H,8,Expert,1,,CHEMBL620785,308.0,BAO_0000219,,
3649,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL857992,,BAO_0000357,,
3650,16429,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620786,,BAO_0000219,,
3651,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620787,308.0,BAO_0000219,,
3652,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620788,308.0,BAO_0000219,,
3653,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620789,308.0,BAO_0000219,,
3654,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",B,,,,,,,HeLa,,10627,H,8,Autocuration,1,,CHEMBL620790,308.0,BAO_0000219,,
3655,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,B,,,,,,,CHO,,10628,H,8,Autocuration,1,,CHEMBL620791,449.0,BAO_0000219,,
3656,14423,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620792,,BAO_0000019,,
3657,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620793,,BAO_0000357,,
3658,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10628,H,8,Autocuration,1,,CHEMBL620794,,BAO_0000357,,
3659,16190,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,B,,,Homo sapiens,9606.0,,,HeLa,,10627,D,9,Autocuration,1,,CHEMBL620795,308.0,BAO_0000219,,
3660,4820,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620796,,BAO_0000357,,
3661,4639,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620797,,BAO_0000357,,
3662,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620798,,BAO_0000019,,
3663,6011,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620799,,BAO_0000357,,
3664,17066,Binding affinity towards human 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620800,,BAO_0000357,,
3665,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620801,,BAO_0000357,,
3666,5014,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL875100,,BAO_0000357,,
3667,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620802,,BAO_0000357,,
3668,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620803,,BAO_0000019,,
3669,17066,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,F,,,,,,,,,10627,H,8,Expert,1,,CHEMBL620804,,BAO_0000019,,
3670,4373,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620805,,BAO_0000357,,
3671,4687,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620806,,BAO_0000357,,
3672,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620807,,BAO_0000357,,
3673,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620808,,BAO_0000357,,
3674,16633,Binding affinities against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620809,,BAO_0000357,,
3675,16633,Binding affinities towards 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620810,,BAO_0000357,,
3676,17066,Binding affinity towards 5-hydroxytryptamine 6 receptor,B,,,Homo sapiens,9606.0,,,,,10627,D,9,Expert,1,,CHEMBL620811,,BAO_0000357,,
3677,16700,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620812,,BAO_0000357,,
3678,3269,Affinity against 5-hydroxytryptamine 6 receptor,B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620813,,BAO_0000357,,
3679,5486,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],B,,,,,,,,,10627,H,8,Autocuration,1,,CHEMBL620814,,BAO_0000357,,
3680,16146,Inhibition of human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620815,,BAO_0000357,,
3681,5014,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620816,722.0,BAO_0000219,,
3682,15463,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620817,,BAO_0000357,,
3683,3805,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620818,,BAO_0000357,,
3684,5014,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620819,722.0,BAO_0000219,,
3685,6491,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620820,,BAO_0000357,,
3686,16190,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL620821,449.0,BAO_0000219,,
3687,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620822,,BAO_0000357,,
3688,17066,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620823,,BAO_0000357,,
3689,3555,Binding affinity against 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL620824,,BAO_0000357,,
3690,6588,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,B,,,,,,,CHO,,10209,H,8,Expert,1,,CHEMBL620825,449.0,BAO_0000219,,
3691,15463,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872930,,BAO_0000357,,
3692,6013,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620826,,BAO_0000357,,
3693,16209,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620827,,BAO_0000357,,
3694,3935,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620828,,BAO_0000357,,
3695,15818,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL620829,,BAO_0000357,,
3696,5014,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL620830,722.0,BAO_0000219,,
3697,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620831,,BAO_0000019,,
3698,16441,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL620832,,BAO_0000019,,
3699,4234,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL621548,,BAO_0000357,,
3700,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621549,,BAO_0000019,,
3701,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621550,,BAO_0000357,,
3702,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL621551,449.0,BAO_0000219,,
3703,17085,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL621552,,BAO_0000019,,
3704,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL857077,,BAO_0000357,,
3705,5104,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618158,,BAO_0000357,,
3706,5033,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,Homo sapiens,9606.0,,,COS-7,,10209,D,9,Expert,1,,CHEMBL618159,643.0,BAO_0000219,,
3707,5486,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL875101,643.0,BAO_0000219,,
3708,4540,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL618160,722.0,BAO_0000219,,
3709,6166,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618161,,BAO_0000357,,
3710,17342,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL618162,722.0,BAO_0000219,,
3711,17342,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618163,,BAO_0000357,,
3712,17296,Binding affinity against 5-hydroxytryptamine 7 human receptors,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL618164,,BAO_0000357,,
3713,16429,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL618165,,BAO_0000219,,
3714,15779,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL618166,722.0,BAO_0000219,,
3715,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL857989,722.0,BAO_0000219,,
3716,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619888,722.0,BAO_0000219,,
3717,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619889,722.0,BAO_0000219,,
3718,15779,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619890,722.0,BAO_0000219,,
3719,17451,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,B,,,,,,,CHO,,10209,H,8,Autocuration,1,,CHEMBL619891,449.0,BAO_0000219,,
3720,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619892,722.0,BAO_0000219,,
3721,4199,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,B,,,,,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619893,722.0,BAO_0000219,,
3722,4199,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619894,722.0,BAO_0000219,,
3723,3680,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,B,,,,,,,HEK293,,10209,D,9,Intermediate,1,,CHEMBL619895,722.0,BAO_0000219,,
3724,3680,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,B,,,,,,,,,10209,D,9,Intermediate,1,,CHEMBL619896,,BAO_0000357,,
3725,15316,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,B,,,,,,,COS-7,,10209,H,8,Autocuration,1,,CHEMBL619897,643.0,BAO_0000219,,
3726,15146,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619898,722.0,BAO_0000219,,
3727,5213,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,B,,,,,,,HEK293,,10209,H,8,Expert,1,,CHEMBL619899,722.0,BAO_0000219,,
3728,5213,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL619900,722.0,BAO_0000219,,
3729,14818,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,B,,,Homo sapiens,9606.0,,,HEK293,,10209,D,9,Expert,1,,CHEMBL619901,722.0,BAO_0000219,,
3730,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620580,722.0,BAO_0000219,,
3731,14818,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620581,722.0,BAO_0000219,,
3732,4829,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",B,,,,,,,HEK293,,10209,H,8,Autocuration,1,,CHEMBL620733,722.0,BAO_0000219,,
3733,17200,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Autocuration,1,,CHEMBL620734,,BAO_0000357,,
3734,17066,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Mus musculus,10090.0,,,,,10022,D,9,Expert,1,,CHEMBL620735,,BAO_0000357,,
3735,14025,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,B,,,Oryctolagus cuniculus,9986.0,,,,,10209,H,8,Autocuration,1,,CHEMBL620736,,BAO_0000019,,
3736,15250,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620737,449.0,BAO_0000219,,
3737,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620738,449.0,BAO_0000219,,
3738,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620739,449.0,BAO_0000219,,
3739,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620740,449.0,BAO_0000219,,
3740,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620741,449.0,BAO_0000219,,
3741,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620742,449.0,BAO_0000219,,
3742,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620743,449.0,BAO_0000219,,
3743,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620744,449.0,BAO_0000219,,
3744,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620745,449.0,BAO_0000219,,
3745,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620746,449.0,BAO_0000219,,
3746,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620747,449.0,BAO_0000219,,
3747,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620748,449.0,BAO_0000219,,
3748,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620749,449.0,BAO_0000219,,
3749,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620750,,BAO_0000357,,
3750,17066,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620751,,BAO_0000357,,
3751,17386,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620752,,BAO_0000357,,
3752,14423,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL872929,,BAO_0000019,,
3753,15874,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620753,,BAO_0000357,,
3754,15874,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,B,,,Rattus norvegicus,10116.0,,,,,11923,D,9,Expert,1,,CHEMBL620754,,BAO_0000357,,
3755,16372,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,B,,,Rattus norvegicus,10116.0,,,CHO,,11923,D,9,Expert,1,,CHEMBL620755,449.0,BAO_0000219,,
3756,4622,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620756,,BAO_0000357,,
3757,15086,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620757,,BAO_0000357,,
3758,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620758,449.0,BAO_0000219,,
3759,16372,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620759,449.0,BAO_0000219,,
3760,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620760,449.0,BAO_0000219,,
3761,16372,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,B,,,,,,,CHO,,11923,H,8,Autocuration,1,,CHEMBL620761,449.0,BAO_0000219,,
3762,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620762,,BAO_0000221,2116.0,
3763,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620763,,BAO_0000221,2116.0,
3764,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,F,,,,,,Ileum,,,11923,H,8,Autocuration,1,,CHEMBL620764,,BAO_0000221,2116.0,
3765,5831,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,B,,,Rattus norvegicus,10116.0,,,,Membranes,11923,D,9,Expert,1,,CHEMBL857990,,BAO_0000249,,
3766,4342,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620765,,BAO_0000357,,
3767,17319,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL620766,,BAO_0000357,,
3768,17342,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL620767,,BAO_0000019,1898.0,
3769,17342,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,B,,,,,,,,,11923,H,8,Autocuration,1,,CHEMBL620768,,BAO_0000357,,
3770,3680,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,B,,,,,,Hypothalamus,,,11923,H,8,Expert,1,,CHEMBL619051,,BAO_0000249,1898.0,
3771,3680,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,11923,H,8,Expert,1,,CHEMBL619052,,BAO_0000357,,
3772,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619053,722.0,BAO_0000219,,
3773,17319,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Expert,1,,CHEMBL619703,722.0,BAO_0000219,,
3774,17319,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,F,,,Rattus norvegicus,10116.0,,,HEK293,,11923,D,9,Autocuration,1,,CHEMBL619704,722.0,BAO_0000219,,
3775,4820,Binding affinity towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619851,,BAO_0000357,,
3776,4639,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619852,,BAO_0000357,,
3777,6011,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619853,,BAO_0000357,,
3778,17066,Binding affinity towards human 5-hydroxytryptamine 7 receptor,B,,,Homo sapiens,9606.0,,,,,10209,D,9,Expert,1,,CHEMBL619854,,BAO_0000357,,
3779,17066,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619855,,BAO_0000357,,
3780,17515,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619856,,BAO_0000357,,
3781,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619857,,BAO_0000357,,
3782,17066,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,F,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619858,,BAO_0000019,,
3783,4373,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619859,,BAO_0000357,,
3784,4373,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619860,,BAO_0000357,,
3785,4687,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619861,,BAO_0000357,,
3786,17342,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619862,,BAO_0000357,,
3787,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619863,,BAO_0000357,,
3788,16946,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619864,,BAO_0000357,,
3789,16633,Binding affinities against 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL872928,,BAO_0000357,,
3790,16633,Binding affinities towards 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619865,,BAO_0000357,,
3791,17066,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,B,,,,,,,,,10209,H,8,Expert,1,,CHEMBL619866,,BAO_0000357,,
3792,16700,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,B,,,,,,,,,10209,H,8,Autocuration,1,,CHEMBL619867,,BAO_0000357,,
3793,17386,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,B,,,,,,Ileum,,,10209,H,8,Autocuration,1,,CHEMBL619868,,BAO_0000221,2116.0,
3794,14080,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619869,,BAO_0000019,,
3795,14080,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619870,,BAO_0000019,,
3796,409,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619871,,BAO_0000357,,
3797,409,In vitro inhibition of human recombinant lipoxygenase enzyme,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619872,,BAO_0000357,,
3798,409,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619873,,BAO_0000357,,
3799,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619874,,BAO_0000357,178.0,
3800,11090,Inhibition of 5-lipoxygenase in human whole blood.,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL619875,,BAO_0000357,178.0,
3801,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619876,,BAO_0000357,,
3802,948,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619877,,BAO_0000357,,
3803,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL619878,,BAO_0000219,,
3804,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619879,,BAO_0000019,178.0,
3805,9637,In vitro inhibition of 5-lipoxygenase from human polymorphs,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619880,,BAO_0000357,,
3806,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619881,,BAO_0000357,,
3807,11320,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL619882,,BAO_0000357,,
3808,6838,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619883,,BAO_0000357,,
3809,17667,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),B,,,Homo sapiens,9606.0,,Blood,,,55,D,9,Expert,1,,CHEMBL619884,,BAO_0000357,178.0,
3810,12703,In vitro potency against human 5-Lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL619885,,BAO_0000357,,
3811,14312,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,F,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL619886,,BAO_0000019,,
3812,14312,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619887,,BAO_0000019,178.0,
3813,5364,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875097,,BAO_0000019,,
3814,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618001,,BAO_0000219,,
3815,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618002,,BAO_0000219,,
3816,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618003,,BAO_0000219,,
3817,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618004,,BAO_0000219,,
3818,12365,Inhibition of human 5-lipoxygenase in human cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618005,,BAO_0000219,,
3819,10603,Inhibition of human neutrophil 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618006,,BAO_0000357,,
3820,10501,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875086,,BAO_0000019,,
3821,12281,Inhibition of 5-lipoxygenase from human whole blood,B,,,,,,Blood,,,55,H,8,Expert,1,,CHEMBL618007,,BAO_0000357,178.0,
3822,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618008,,BAO_0000357,,
3823,2567,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618009,,BAO_0000219,,
3824,10193,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618010,,BAO_0000357,,
3825,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618011,,BAO_0000357,,
3826,13623,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618012,,BAO_0000357,,
3827,12780,Tested against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL882927,,BAO_0000357,,
3828,12780,Tested for activity against 5-Lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618013,,BAO_0000357,,
3829,12780,Tested for activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618014,,BAO_0000357,,
3830,11966,Tested for inhibition of 5-HPETE production by human 5-LO,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618015,,BAO_0000357,,
3831,5364,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618016,,BAO_0000019,,
3832,13165,Inhibition of Human 5-lipoxygenase,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618017,,BAO_0000357,,
3833,5364,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618018,,BAO_0000019,,
3834,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875087,,BAO_0000219,,
3835,11311,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618019,,BAO_0000219,,
3836,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618020,,BAO_0000019,,
3837,14863,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618021,,BAO_0000019,,
3838,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),B,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL618022,,BAO_0000357,178.0,
3839,455,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618023,,BAO_0000357,,
3840,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618024,,BAO_0000357,,
3841,10319,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL873950,,BAO_0000019,,
3842,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618025,,BAO_0000357,,
3843,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618026,,BAO_0000219,,
3844,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618027,,BAO_0000219,,
3845,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618028,,BAO_0000219,,
3846,951,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618029,,BAO_0000219,,
3847,9859,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618030,,BAO_0000357,,
3848,9859,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618031,,BAO_0000357,,
3849,9859,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618032,,BAO_0000357,,
3850,2567,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618033,,BAO_0000357,,
3851,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618034,,BAO_0000357,,
3852,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL875088,,BAO_0000357,,
3853,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618035,,BAO_0000019,,
3854,949,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618036,,BAO_0000019,,
3855,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618037,,BAO_0000357,,
3856,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618038,,BAO_0000357,,
3857,10603,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,F,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618761,,BAO_0000019,,
3858,10603,Inhibition of lipoxygenase at the concentration of 0.1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618762,,BAO_0000357,,
3859,10603,Inhibition of lipoxygenase at the concentration of 1 uM,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618763,,BAO_0000357,,
3860,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618764,,BAO_0000357,,
3861,14580,Inhibition of 5-Lipoxygenase (5-LOX),B,,,Homo sapiens,9606.0,,,,,55,D,9,Expert,1,,CHEMBL618765,,BAO_0000357,,
3862,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618766,,BAO_0000357,,
3863,11090,Inhibition of 5-lipoxygenase in mouse macrophages.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL618767,,BAO_0000357,,
3864,6339,Inhibitory activity against lipoxygenase-2 in mice,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619380,,BAO_0000357,,
3865,6339,Inhibitory activity against murine lipoxygenase-2.,B,,,,,,,,,17087,H,8,Expert,1,,CHEMBL619381,,BAO_0000357,,
3866,12281,Inhibition of 5-lipoxygenase from mouse macrophage,B,,,Mus musculus,10090.0,,,,,17087,D,9,Expert,1,,CHEMBL619382,,BAO_0000357,,
3867,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,B,,,,,,,,,17087,H,8,Autocuration,1,,CHEMBL619383,,BAO_0000357,,
3868,11089,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619384,,BAO_0000019,,
3869,10091,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,B,,,Sus scrofa,9823.0,,,,,55,H,8,Autocuration,1,,CHEMBL619385,,BAO_0000019,,
3870,14352,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,B,,,Oryctolagus cuniculus,9986.0,,,,,55,H,8,Autocuration,1,,CHEMBL882928,,BAO_0000019,,
3871,13329,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619386,,BAO_0000019,,
3872,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619387,,BAO_0000019,,
3873,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619388,,BAO_0000019,,
3874,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619389,,BAO_0000019,,
3875,13329,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619390,,BAO_0000019,,
3876,13329,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619391,,BAO_0000019,,
3877,13329,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619392,,BAO_0000019,,
3878,11311,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619393,,BAO_0000019,,
3879,11311,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619394,,BAO_0000019,,
3880,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619395,702.0,BAO_0000219,,
3881,105,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619396,702.0,BAO_0000219,,
3882,9138,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619397,,BAO_0000357,,
3883,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619398,,BAO_0000357,,
3884,9138,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619399,,BAO_0000357,,
3885,14427,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619400,,BAO_0000357,,
3886,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619401,,BAO_0000019,,
3887,13329,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619402,,BAO_0000019,,
3888,14427,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,B,,,Rattus norvegicus,10116.0,,,RBL-2H3,,12166,D,9,Expert,1,,CHEMBL619403,663.0,BAO_0000219,,
3889,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619404,,BAO_0000357,,
3890,14427,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619405,,BAO_0000357,,
3891,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619406,702.0,BAO_0000219,,
3892,338,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL619407,702.0,BAO_0000219,,
3893,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619408,,BAO_0000357,,
3894,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619409,702.0,BAO_0000219,,
3895,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619410,702.0,BAO_0000219,,
3896,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619753,702.0,BAO_0000219,,
3897,137,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619754,702.0,BAO_0000219,,
3898,11481,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619903,,BAO_0000357,,
3899,11481,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619904,,BAO_0000357,,
3900,9029,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619905,,BAO_0000357,,
3901,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619906,,BAO_0000019,,
3902,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619907,,BAO_0000019,,
3903,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619908,,BAO_0000019,,
3904,1701,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619909,,BAO_0000019,,
3905,13358,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619910,702.0,BAO_0000219,,
3906,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL882929,702.0,BAO_0000219,,
3907,8797,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619911,702.0,BAO_0000219,,
3908,8797,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619912,,BAO_0000019,,
3909,577,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619913,,BAO_0000357,,
3910,9295,In vitro inhibitory activity against RBL-1 5-LO,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619914,702.0,BAO_0000219,,
3911,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619915,702.0,BAO_0000219,,
3912,9295,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619916,702.0,BAO_0000219,,
3913,9295,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619917,,BAO_0000218,,
3914,9295,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619918,,BAO_0000357,,
3915,216,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619919,,BAO_0000218,,
3916,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883710,702.0,BAO_0000219,,
3917,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,B,,,,,,Blood,,,12166,H,8,Autocuration,1,,CHEMBL619920,,BAO_0000019,178.0,
3918,10091,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619921,,BAO_0000357,,
3919,10274,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619922,,BAO_0000019,,
3920,13622,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619923,,BAO_0000219,,
3921,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619924,702.0,BAO_0000219,,
3922,12576,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619925,,BAO_0000357,,
3923,9546,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619926,702.0,BAO_0000219,,
3924,9521,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619927,702.0,BAO_0000219,,
3925,10626,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619928,702.0,BAO_0000219,,
3926,9225,In vitro inhibition of RBL-1 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619929,702.0,BAO_0000219,,
3927,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875089,702.0,BAO_0000219,,
3928,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619930,702.0,BAO_0000219,,
3929,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619931,702.0,BAO_0000219,,
3930,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619932,702.0,BAO_0000219,,
3931,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619933,702.0,BAO_0000219,,
3932,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619934,702.0,BAO_0000219,,
3933,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619935,702.0,BAO_0000219,,
3934,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619936,702.0,BAO_0000219,,
3935,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619937,702.0,BAO_0000219,,
3936,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619938,702.0,BAO_0000219,,
3937,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619939,702.0,BAO_0000219,,
3938,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619940,702.0,BAO_0000219,,
3939,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875090,702.0,BAO_0000219,,
3940,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619941,702.0,BAO_0000219,,
3941,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619942,702.0,BAO_0000219,,
3942,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883711,702.0,BAO_0000219,,
3943,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619943,702.0,BAO_0000219,,
3944,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619944,702.0,BAO_0000219,,
3945,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619945,702.0,BAO_0000219,,
3946,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619946,702.0,BAO_0000219,,
3947,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619947,702.0,BAO_0000219,,
3948,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619948,702.0,BAO_0000219,,
3949,9225,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619949,702.0,BAO_0000219,,
3950,9401,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619950,,BAO_0000019,,
3951,10325,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618050,,BAO_0000019,,
3952,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL875091,663.0,BAO_0000219,,
3953,1556,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,F,,,,,,,RBL-2H3,,12166,H,8,Expert,1,,CHEMBL618051,663.0,BAO_0000219,,
3954,961,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618052,702.0,BAO_0000219,,
3955,6838,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618053,,BAO_0000019,,
3956,10325,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL618054,,BAO_0000019,,
3957,9209,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618055,702.0,BAO_0000219,,
3958,11520,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618056,702.0,BAO_0000219,,
3959,137,In vitro inhibitory activity against 5-lipoxygenase was determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618057,,BAO_0000357,,
3960,4717,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618058,702.0,BAO_0000219,,
3961,10636,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618059,702.0,BAO_0000219,,
3962,14312,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL618060,,BAO_0000019,,
3963,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618061,702.0,BAO_0000219,,
3964,1203,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618062,,BAO_0000019,,
3965,13622,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618063,702.0,BAO_0000219,,
3966,9793,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618064,,BAO_0000357,,
3967,1143,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618065,702.0,BAO_0000219,,
3968,11854,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618066,702.0,BAO_0000219,,
3969,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618067,702.0,BAO_0000219,,
3970,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618068,702.0,BAO_0000219,,
3971,10501,Inhibition of 5-lipoxygenase in rat RBL-1 cells,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618069,702.0,BAO_0000219,,
3972,12526,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618070,702.0,BAO_0000219,,
3973,10034,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL618071,,BAO_0000019,349.0,
3974,10034,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,F,,,,,,Limbic system,,,10825,H,8,Autocuration,1,,CHEMBL619247,,BAO_0000019,349.0,
3975,10034,Approximate dose levels for a half maximal reduction of 5-HTP levels,F,,,,,,,,,10825,H,8,Autocuration,1,,CHEMBL619248,,BAO_0000019,,
3976,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619249,,BAO_0000221,10000000.0,
3977,10046,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,B,,,,,,Hippocampus,,,10576,H,8,Autocuration,1,,CHEMBL619250,,BAO_0000221,10000000.0,
3978,10046,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL619251,,BAO_0000019,,
3979,12079,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,F,,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619252,,BAO_0000019,178.0,
3980,12079,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,F,,,,,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619253,,BAO_0000019,178.0,
3981,11311,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619254,,BAO_0000219,,
3982,12338,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619255,,BAO_0000219,,
3983,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619256,,BAO_0000219,,
3984,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL875418,,BAO_0000219,,
3985,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619257,,BAO_0000219,,
3986,12143,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,B,,,,,,,,,17140,H,8,Autocuration,1,,CHEMBL619258,,BAO_0000219,,
3987,12365,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619259,,BAO_0000357,,
3988,13500,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,B,,,,,,,,,17140,H,8,Expert,1,,CHEMBL619260,,BAO_0000357,,
3989,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619261,,BAO_0000218,178.0,
3990,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619263,,BAO_0000218,178.0,
3991,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619264,,BAO_0000218,178.0,
3992,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619265,,BAO_0000218,178.0,
3993,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619266,,BAO_0000218,178.0,
3994,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619902,,BAO_0000218,178.0,
3995,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620058,,BAO_0000218,178.0,
3996,12832,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620059,,BAO_0000218,178.0,
3997,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620060,,BAO_0000218,178.0,
3998,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620061,,BAO_0000218,178.0,
3999,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620062,,BAO_0000218,178.0,
4000,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620063,,BAO_0000218,178.0,
4001,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620064,,BAO_0000218,178.0,
4002,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620065,,BAO_0000218,178.0,
4003,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620066,,BAO_0000218,178.0,
4004,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620067,,BAO_0000218,178.0,
4005,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620068,,BAO_0000218,178.0,
4006,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620069,,BAO_0000218,178.0,
4007,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620070,,BAO_0000218,178.0,
4008,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620071,,BAO_0000218,178.0,
4009,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620072,,BAO_0000218,178.0,
4010,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620036,,BAO_0000218,178.0,
4011,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857702,,BAO_0000218,178.0,
4012,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620037,,BAO_0000218,178.0,
4013,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620038,,BAO_0000218,178.0,
4014,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620039,,BAO_0000218,178.0,
4015,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620040,,BAO_0000218,178.0,
4016,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620041,,BAO_0000218,178.0,
4017,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620042,,BAO_0000218,178.0,
4018,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620043,,BAO_0000218,178.0,
4019,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620044,,BAO_0000218,178.0,
4020,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620045,,BAO_0000218,178.0,
4021,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620046,,BAO_0000218,178.0,
4022,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620047,,BAO_0000218,178.0,
4023,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620048,,BAO_0000218,178.0,
4024,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL857703,,BAO_0000218,178.0,
4025,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620049,,BAO_0000218,178.0,
4026,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620050,,BAO_0000218,178.0,
4027,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620051,,BAO_0000218,178.0,
4028,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619213,,BAO_0000218,178.0,
4029,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619214,,BAO_0000218,178.0,
4030,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619804,,BAO_0000218,178.0,
4031,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619805,,BAO_0000218,178.0,
4032,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619806,,BAO_0000218,178.0,
4033,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619807,,BAO_0000218,178.0,
4034,12832,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",F,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL619808,,BAO_0000218,178.0,
4035,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619809,,BAO_0000218,,
4036,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619810,,BAO_0000218,,
4037,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL619811,,BAO_0000218,,
4038,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620769,,BAO_0000218,,
4039,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620770,,BAO_0000218,,
4040,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620771,,BAO_0000218,,
4041,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620772,,BAO_0000218,,
4042,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,B,,,Canis lupus familiaris,9615.0,,,,,55,H,8,Autocuration,1,,CHEMBL620773,,BAO_0000218,,
4043,9203,Ability to inhibit 5-lipoxygenase in guinea pig,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620774,,BAO_0000357,,
4044,82,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL620775,,BAO_0000357,,
4045,11090,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620776,,BAO_0000357,,
4046,12832,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",B,,,Cavia porcellus,10141.0,,Blood,,,55,H,8,Autocuration,1,,CHEMBL620777,,BAO_0000218,178.0,
4047,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620778,,BAO_0000357,,
4048,1065,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL620779,,BAO_0000357,,
4049,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621500,,BAO_0000019,,
4050,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL621501,,BAO_0000019,,
4051,12832,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618098,,BAO_0000019,,
4052,10504,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618099,,BAO_0000019,,
4053,7788,Inhibitory activity against 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618100,,BAO_0000357,,
4054,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618101,,BAO_0000357,,
4055,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618102,,BAO_0000357,,
4056,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618103,,BAO_0000357,,
4057,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618104,,BAO_0000357,,
4058,969,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL883712,,BAO_0000219,,
4059,10001,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618105,,BAO_0000357,,
4060,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618106,,BAO_0000357,,
4061,10001,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618107,,BAO_0000357,,
4062,10193,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618108,,BAO_0000357,,
4063,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618109,,BAO_0000357,,
4064,13243,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618110,,BAO_0000357,,
4065,13243,Inhibitory activity uM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Expert,1,,CHEMBL618111,,BAO_0000357,,
4066,13243,Inhibitory activity uM,F,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618112,,BAO_0000019,,
4067,10504,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618113,,BAO_0000019,,
4068,7788,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,B,,,Cavia porcellus,10141.0,,,,,55,H,8,Autocuration,1,,CHEMBL618114,,BAO_0000357,,
4069,10546,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,F,,,Cavia porcellus,10141.0,,Ileum,,,55,H,8,Expert,1,,CHEMBL620871,,BAO_0000221,2116.0,
4070,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620872,,BAO_0000357,,
4071,13183,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620873,,BAO_0000357,,
4072,2578,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL620874,,BAO_0000357,,
4073,12780,In vitro inhibition of human 5-Lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL620875,,BAO_0000357,,
4074,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620876,,BAO_0000251,2107.0,
4075,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620877,,BAO_0000251,2107.0,
4076,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857854,,BAO_0000251,2107.0,
4077,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620878,,BAO_0000251,2107.0,
4078,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620879,,BAO_0000251,2107.0,
4079,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620880,,BAO_0000251,2107.0,
4080,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620881,,BAO_0000251,2107.0,
4081,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620882,,BAO_0000251,2107.0,
4082,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620883,,BAO_0000251,2107.0,
4083,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620884,,BAO_0000251,2107.0,
4084,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620885,,BAO_0000251,2107.0,
4085,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620886,,BAO_0000251,2107.0,
4086,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620887,,BAO_0000251,2107.0,
4087,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618039,,BAO_0000251,2107.0,
4088,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618040,,BAO_0000251,2107.0,
4089,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618041,,BAO_0000251,2107.0,
4090,7411,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618216,,BAO_0000251,2107.0,
4091,7411,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618217,,BAO_0000251,2107.0,
4092,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618218,,BAO_0000251,2107.0,
4093,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618219,,BAO_0000251,2107.0,
4094,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618220,,BAO_0000251,2107.0,
4095,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618221,,BAO_0000251,2107.0,
4096,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618222,,BAO_0000251,2107.0,
4097,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618223,,BAO_0000251,2107.0,
4098,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618224,,BAO_0000251,2107.0,
4099,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618225,,BAO_0000251,2107.0,
4100,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618226,,BAO_0000251,2107.0,
4101,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618227,,BAO_0000251,2107.0,
4102,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618228,,BAO_0000251,2107.0,
4103,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618229,,BAO_0000251,2107.0,
4104,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618230,,BAO_0000251,2107.0,
4105,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618231,,BAO_0000251,2107.0,
4106,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618232,,BAO_0000251,2107.0,
4107,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618233,,BAO_0000251,2107.0,
4108,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618234,,BAO_0000251,2107.0,
4109,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618235,,BAO_0000251,2107.0,
4110,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618115,,BAO_0000251,2107.0,
4111,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618116,,BAO_0000251,2107.0,
4112,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL618117,,BAO_0000251,2107.0,
4113,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619968,,BAO_0000251,2107.0,
4114,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619969,,BAO_0000251,2107.0,
4115,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619970,,BAO_0000251,2107.0,
4116,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619971,,BAO_0000251,2107.0,
4117,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619972,,BAO_0000251,2107.0,
4118,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619973,,BAO_0000251,2107.0,
4119,7411,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619974,,BAO_0000251,2107.0,
4120,7411,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619975,,BAO_0000251,2107.0,
4121,7411,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619976,,BAO_0000251,,
4122,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619977,,BAO_0000251,2107.0,
4123,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619978,,BAO_0000251,2107.0,
4124,7411,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619979,,BAO_0000251,2107.0,
4125,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619980,,BAO_0000251,2107.0,
4126,7411,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619981,,BAO_0000251,2107.0,
4127,10797,In vitro inhibition of 7226/S myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619982,741.0,BAO_0000219,,
4128,6881,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),F,,,Homo sapiens,9606.0,,,BEL-7404 tumor cell line,,80698,N,1,Intermediate,1,,CHEMBL619983,993.0,BAO_0000219,,
4129,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620031,391.0,BAO_0000219,,
4130,3838,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL620032,391.0,BAO_0000219,,
4131,12981,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620033,505.0,BAO_0000219,,
4132,12981,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,F,,,Cricetulus griseus,10029.0,,,V79,,81264,N,1,Expert,1,,CHEMBL620034,505.0,BAO_0000219,,
4133,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL620035,1119.0,BAO_0000219,,
4134,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618318,1119.0,BAO_0000219,,
4135,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618319,1119.0,BAO_0000219,,
4136,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618320,1119.0,BAO_0000219,,
4137,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL618321,1119.0,BAO_0000219,,
4138,7653,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,F,,,Rattus norvegicus,10116.0,,,7800C1 cell line,,80635,N,1,Intermediate,1,,CHEMBL883118,1119.0,BAO_0000219,,
4139,17229,In vitro antitumor activity against renal 786-0 tumor cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883795,391.0,BAO_0000219,,
4140,12858,Cytotoxic activity against 786-0 Renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618322,391.0,BAO_0000219,,
4141,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618323,391.0,BAO_0000219,,
4142,16325,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618324,391.0,BAO_0000219,,
4143,5858,In vitro antitumor activity against human renal 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618325,391.0,BAO_0000219,,
4144,16325,Inhibition of Renal cancer in 786-0 cancer cell lines,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL875416,391.0,BAO_0000219,,
4145,14696,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618326,391.0,BAO_0000219,,
4146,3786,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL618327,391.0,BAO_0000219,,
4147,14696,inhibition of the growth of renal cancer(786-0) cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619215,391.0,BAO_0000219,,
4148,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619216,391.0,BAO_0000219,,
4149,15354,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619217,391.0,BAO_0000219,,
4150,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619218,391.0,BAO_0000219,,
4151,14255,The IC50 value was measured on 786-0 cell line in ovarian tumor t,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619219,391.0,BAO_0000219,,
4152,14255,The IC50 value was measured on 786-0 cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619220,391.0,BAO_0000219,,
4153,14696,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619221,391.0,BAO_0000219,,
4154,12016,Tested for cytotoxic activity against renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619222,391.0,BAO_0000219,,
4155,2597,Compound was tested for growth inhibitory activity against 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857454,391.0,BAO_0000219,,
4156,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619223,702.0,BAO_0000219,,
4157,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619224,702.0,BAO_0000219,,
4158,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619225,,BAO_0000019,,
4159,3595,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619226,702.0,BAO_0000219,,
4160,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619227,702.0,BAO_0000219,,
4161,12767,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619228,,BAO_0000357,,
4162,10997,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619229,,BAO_0000219,,
4163,11388,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619230,702.0,BAO_0000219,,
4164,167,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619231,,BAO_0000357,,
4165,167,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619232,,BAO_0000357,,
4166,13744,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619233,,BAO_0000357,,
4167,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619234,,BAO_0000357,,
4168,1630,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619235,,BAO_0000357,,
4169,969,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL619236,,BAO_0000019,,
4170,13621,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619237,702.0,BAO_0000219,,
4171,10089,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619238,,BAO_0000357,,
4172,10193,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619239,,BAO_0000357,,
4173,11966,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619240,,BAO_0000357,,
4174,12251,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875417,,BAO_0000019,,
4175,211,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619241,702.0,BAO_0000219,,
4176,12251,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,F,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619242,,BAO_0000019,,
4177,12495,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL883796,702.0,BAO_0000219,,
4178,414,Tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619243,,BAO_0000357,,
4179,414,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619244,,BAO_0000357,,
4180,10325,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619245,,BAO_0000019,,
4181,11966,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619246,,BAO_0000019,,
4182,165,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619984,702.0,BAO_0000219,,
4183,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619985,702.0,BAO_0000219,,
4184,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619986,702.0,BAO_0000219,,
4185,165,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL619987,702.0,BAO_0000219,,
4186,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619988,,BAO_0000218,,
4187,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619989,702.0,BAO_0000219,,
4188,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL619990,702.0,BAO_0000219,,
4189,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619991,,BAO_0000219,,
4190,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619992,,BAO_0000219,,
4191,11311,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),B,In vivo,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619993,,BAO_0000218,,
4192,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619994,663.0,BAO_0000219,,
4193,11311,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL619995,663.0,BAO_0000219,,
4194,11311,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619996,,BAO_0000019,,
4195,11732,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619997,,BAO_0000019,,
4196,11732,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619998,,BAO_0000019,,
4197,11087,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL619999,,BAO_0000019,,
4198,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620000,,BAO_0000019,,
4199,11087,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620001,702.0,BAO_0000219,,
4200,11087,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620002,,BAO_0000357,,
4201,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620003,702.0,BAO_0000219,,
4202,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,F,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620004,702.0,BAO_0000219,,
4203,11520,Compound was evaluated for the inhibition of 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL874063,,BAO_0000357,,
4204,10293,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620005,702.0,BAO_0000219,,
4205,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620006,702.0,BAO_0000219,,
4206,303,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620007,702.0,BAO_0000219,,
4207,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620008,702.0,BAO_0000219,,
4208,9247,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620009,702.0,BAO_0000219,,
4209,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620010,702.0,BAO_0000219,,
4210,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620011,702.0,BAO_0000219,,
4211,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620677,702.0,BAO_0000219,,
4212,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620678,702.0,BAO_0000219,,
4213,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620679,702.0,BAO_0000219,,
4214,9247,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620680,702.0,BAO_0000219,,
4215,11481,Inhibitory activity against 5-lipoxygenase at 10 uM,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620838,,BAO_0000357,,
4216,105,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620839,,BAO_0000357,,
4217,9029,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620840,,BAO_0000357,,
4218,1175,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL620841,702.0,BAO_0000219,,
4219,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620842,702.0,BAO_0000219,,
4220,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620843,702.0,BAO_0000219,,
4221,12118,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620844,702.0,BAO_0000219,,
4222,9225,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620845,702.0,BAO_0000219,,
4223,9401,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620846,,BAO_0000019,,
4224,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873951,,BAO_0000357,,
4225,137,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620847,,BAO_0000357,,
4226,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620848,702.0,BAO_0000219,,
4227,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620849,702.0,BAO_0000219,,
4228,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620850,702.0,BAO_0000219,,
4229,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620851,702.0,BAO_0000219,,
4230,10501,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620852,702.0,BAO_0000219,,
4231,12526,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875098,702.0,BAO_0000219,,
4232,14799,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL620853,702.0,BAO_0000219,,
4233,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620854,,BAO_0000019,,
4234,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620855,702.0,BAO_0000219,,
4235,3595,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL839884,702.0,BAO_0000219,,
4236,12526,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620856,702.0,BAO_0000219,,
4237,12526,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620857,702.0,BAO_0000219,,
4238,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620858,,BAO_0000019,,
4239,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620859,,BAO_0000019,,
4240,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620860,,BAO_0000019,,
4241,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620861,,BAO_0000019,,
4242,9138,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),B,,,,,,,,,12166,H,8,Expert,1,,CHEMBL620862,,BAO_0000357,,
4243,9138,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620863,,BAO_0000357,,
4244,11966,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620864,,BAO_0000019,,
4245,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620865,702.0,BAO_0000219,,
4246,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620866,702.0,BAO_0000219,,
4247,11311,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620867,663.0,BAO_0000219,,
4248,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,B,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620868,663.0,BAO_0000219,,
4249,11311,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620869,663.0,BAO_0000219,,
4250,11311,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,F,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL873952,,BAO_0000019,,
4251,11311,The compound was tested for inhibition of isolated 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL875099,,BAO_0000357,,
4252,11311,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,F,,,,,,,RBL-2H3,,12166,H,8,Autocuration,1,,CHEMBL620870,663.0,BAO_0000219,,
4253,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618261,,BAO_0000019,,
4254,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618262,,BAO_0000019,,
4255,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619428,,BAO_0000019,,
4256,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619429,,BAO_0000019,,
4257,11087,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL619430,,BAO_0000019,,
4258,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620017,702.0,BAO_0000219,,
4259,496,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620018,702.0,BAO_0000219,,
4260,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620019,702.0,BAO_0000219,,
4261,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620020,702.0,BAO_0000219,,
4262,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620021,702.0,BAO_0000219,,
4263,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620022,702.0,BAO_0000219,,
4264,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620023,702.0,BAO_0000219,,
4265,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620024,702.0,BAO_0000219,,
4266,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620025,702.0,BAO_0000219,,
4267,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620026,702.0,BAO_0000219,,
4268,13986,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,F,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL620027,702.0,BAO_0000219,,
4269,13986,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,F,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Expert,1,,CHEMBL620028,,BAO_0000019,,
4270,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620029,,BAO_0000357,,
4271,9295,Compound was tested for the percent of inhibition against 5-LO at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL620030,,BAO_0000357,,
4272,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL875415,702.0,BAO_0000219,,
4273,4717,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618256,702.0,BAO_0000219,,
4274,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618257,702.0,BAO_0000219,,
4275,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618258,702.0,BAO_0000219,,
4276,11854,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618259,702.0,BAO_0000219,,
4277,10193,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618260,,BAO_0000019,,
4278,9295,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618215,702.0,BAO_0000219,,
4279,9295,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618390,702.0,BAO_0000219,,
4280,9295,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618391,702.0,BAO_0000219,,
4281,9295,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618392,702.0,BAO_0000219,,
4282,165,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618393,702.0,BAO_0000219,,
4283,11311,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618394,,BAO_0000219,,
4284,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Homo sapiens,9606.0,,,RBL-1,,12166,H,8,Expert,1,,CHEMBL618395,702.0,BAO_0000219,,
4285,10489,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL618396,702.0,BAO_0000219,,
4286,10489,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),B,,,Rattus norvegicus,10116.0,,,RBL-1,,12166,D,9,Expert,1,,CHEMBL858253,702.0,BAO_0000219,,
4287,14799,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,B,,,Rattus norvegicus,10116.0,,,,,12166,D,9,Autocuration,1,,CHEMBL618397,,BAO_0000019,,
4288,9295,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),B,,,Glycine max,3847.0,,,,,12054,H,8,Autocuration,1,,CHEMBL618398,,BAO_0000357,,
4289,16811,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618399,,BAO_0000019,,
4290,168,In vitro inhibition of 5-Lipoxygenase; Inactive.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618400,,BAO_0000357,,
4291,6309,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618401,,BAO_0000357,,
4292,6309,Inhibitory concentration against 5-lipoxygenase; No inhibition,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618402,,BAO_0000357,,
4293,3092,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,B,,,,,,,RBL-1,,55,H,8,Autocuration,1,,CHEMBL876400,702.0,BAO_0000219,,
4294,168,Inhibitory activity against 5-lipoxygenase.,B,,,,,,,,,55,H,8,Expert,1,,CHEMBL618403,,BAO_0000357,,
4295,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618404,,BAO_0000357,,
4296,168,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618405,,BAO_0000357,,
4297,168,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618406,,BAO_0000357,,
4298,12338,Inhibitory concentration against arachidonic acid 5-lipoxygenation,F,,,,,,,,,55,H,8,Expert,1,,CHEMBL618407,,BAO_0000019,,
4299,4501,Tested for the inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618408,,BAO_0000357,,
4300,1132,Compound was tested for its inhibitory activity against 5-lipoxygenase,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618409,,BAO_0000357,,
4301,2117,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618410,,BAO_0000357,,
4302,168,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618411,,BAO_0000357,,
4303,168,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,B,,,,,,,,,55,H,8,Autocuration,1,,CHEMBL618412,,BAO_0000357,,
4304,13575,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,B,,,,,,,RBL-1,,12166,H,8,Autocuration,1,,CHEMBL618413,702.0,BAO_0000219,,
4305,11089,,B,,,,,,,,,12166,H,8,Autocuration,1,,CHEMBL618414,,BAO_0000357,,
4306,216,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618415,,BAO_0000357,,
4307,13165,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618416,,BAO_0000019,,
4308,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL876401,,BAO_0000357,,
4309,3278,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,B,,,,,,,,,10102,H,8,Expert,1,,CHEMBL618417,,BAO_0000357,,
4310,11966,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618418,,BAO_0000357,,
4311,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618419,,BAO_0000357,,
4312,175,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618420,,BAO_0000357,,
4313,13449,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,B,,,,,,,,,10102,H,8,Autocuration,1,,CHEMBL618421,,BAO_0000357,,
4314,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618422,,BAO_0000019,,
4315,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618423,,BAO_0000019,,
4316,12014,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),B,,,,,,,,,11238,H,8,Autocuration,1,,CHEMBL618424,,BAO_0000019,,
4317,99,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,B,,,,,,,,,100284,S,2,Intermediate,1,,CHEMBL618425,,BAO_0000220,,
4318,4349,The dark toxicity against 543 human galactophore carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL618426,,BAO_0000019,,
4319,4071,Tested in vitro for cytotoxicity against 56 human tumor cell lines,F,,,Homo sapiens,9606.0,,,Panel (56 tumour cell lines),,80623,N,1,Expert,1,,CHEMBL618427,390.0,BAO_0000219,,
4320,17589,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618428,345.0,BAO_0000219,,
4321,15002,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618429,345.0,BAO_0000219,,
4322,13958,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618430,345.0,BAO_0000219,,
4323,17589,Growth inhibition against human 5637 cell lines,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL618431,345.0,BAO_0000219,,
4324,16748,Antitumor activity against human bladder carcinoma 5637 cells.,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Expert,1,,CHEMBL883799,345.0,BAO_0000219,,
4325,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618432,345.0,BAO_0000219,,
4326,16747,Antitumor activity against human bladder carcinoma 5637 cells,F,,,Homo sapiens,9606.0,,,5637,,80008,N,1,Intermediate,1,,CHEMBL618433,345.0,BAO_0000219,,
4327,15285,In vitro inhibition of bovine trypsin(Trp).,B,,,Bos taurus,9913.0,,,,,10443,D,9,Expert,1,,CHEMBL618434,,BAO_0000357,,
4328,3726,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,B,,,Cercopithecidae,9527.0,,,CV-1,,240,H,8,Expert,1,,CHEMBL618435,407.0,BAO_0000219,,
4329,5033,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,B,,,,,,,,,10577,H,8,Autocuration,1,,CHEMBL876402,,BAO_0000357,,
4330,11756,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,F,,,,,,,,,104698,H,6,Autocuration,1,,CHEMBL618436,,BAO_0000019,,
4331,11953,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,F,In vivo,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL618437,,BAO_0000218,,
4332,5033,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,B,,,Cavia porcellus,10141.0,,,,,20033,D,9,Intermediate,1,,CHEMBL618438,,BAO_0000357,,
4333,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL883800,,BAO_0000251,,
4334,11347,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,Microsomes,17045,H,8,Expert,1,,CHEMBL618439,,BAO_0000251,,
4335,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618440,,BAO_0000019,,
4336,1229,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL618441,,BAO_0000019,,
4337,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Expert,1,,CHEMBL618442,,BAO_0000019,,
4338,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,B,,,Trypanosoma brucei,5691.0,,,,,11938,H,8,Autocuration,1,,CHEMBL618443,,BAO_0000019,,
4339,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,B,,,Ovis aries,9940.0,,,,,11938,H,8,Expert,1,,CHEMBL619158,,BAO_0000019,,
4340,17588,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,B,,,Ovis aries,9940.0,,,,,11938,H,8,Autocuration,1,,CHEMBL620974,,BAO_0000019,,
4341,16485,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,B,,,,,,,,,11938,H,8,Autocuration,1,,CHEMBL620975,,BAO_0000357,,
4342,4337,Average inhibitory concentration against 60 human cell lines was reported,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Intermediate,1,,CHEMBL620976,,BAO_0000019,,
4343,4112,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Expert,1,,CHEMBL620977,,BAO_0000019,,
4344,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620978,542.0,BAO_0000219,,
4345,16160,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,F,,,Homo sapiens,9606.0,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Intermediate,1,,CHEMBL620979,542.0,BAO_0000219,,
4346,17376,In vitro mean growth inhibitory activity against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620980,542.0,BAO_0000219,,
4347,17376,In vitro mean growth lethal concentration against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620981,542.0,BAO_0000219,,
4348,17376,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620982,542.0,BAO_0000219,,
4349,17376,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,F,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,80315,N,1,Expert,1,,CHEMBL620983,542.0,BAO_0000219,,
4350,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620984,,BAO_0000019,,
4351,3241,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,F,,,,,,,,,104775,H,4,Autocuration,1,,CHEMBL620985,,BAO_0000019,,
4352,3725,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,B,,,,,,,,,275,H,8,Expert,1,,CHEMBL620986,,BAO_0000357,,
4353,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620987,,BAO_0000218,,
4354,10805,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620988,,BAO_0000218,,
4355,10805,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620989,,BAO_0000218,,
4356,10805,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Expert,1,,CHEMBL620990,,BAO_0000218,,
4357,10805,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,F,,,Plasmodium falciparum,5833.0,,,,,50425,N,1,Intermediate,1,,CHEMBL620991,,BAO_0000218,,
4358,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620992,850.0,BAO_0000218,,
4359,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620993,850.0,BAO_0000218,,
4360,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620994,850.0,BAO_0000218,,
4361,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620995,850.0,BAO_0000218,,
4362,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL620996,850.0,BAO_0000218,,
4363,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL875581,850.0,BAO_0000218,,
4364,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620997,,BAO_0000218,,
4365,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620998,,BAO_0000218,,
4366,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620999,,BAO_0000218,,
4367,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621000,,BAO_0000218,,
4368,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621001,,BAO_0000218,,
4369,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621002,,BAO_0000218,,
4370,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621003,,BAO_0000218,,
4371,10685,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621004,,BAO_0000218,,
4372,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621005,,BAO_0000218,,
4373,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621006,,BAO_0000218,,
4374,10685,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,F,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621007,,BAO_0000218,,
4375,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621008,,BAO_0000218,,
4376,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621009,,BAO_0000218,,
4377,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL857705,,BAO_0000218,,
4378,10144,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619828,,BAO_0000218,,
4379,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619829,,BAO_0000218,,
4380,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619830,,BAO_0000218,,
4381,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619831,,BAO_0000218,,
4382,10685,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619832,,BAO_0000218,,
4383,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619833,,BAO_0000218,,
4384,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619834,,BAO_0000218,,
4385,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619835,,BAO_0000218,,
4386,10685,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,A,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619836,,BAO_0000218,,
4387,8831,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619837,850.0,BAO_0000218,,
4388,11704,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619838,,BAO_0000218,,
4389,11704,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619839,,BAO_0000218,,
4390,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619840,850.0,BAO_0000218,,
4391,10685,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,F,In vivo,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619841,850.0,BAO_0000218,,
4392,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL857704,850.0,BAO_0000218,,
4393,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Intermediate,1,,CHEMBL619842,850.0,BAO_0000218,,
4394,11368,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),F,,,Mus musculus,10090.0,,,6C3HED,,80628,N,1,Expert,1,,CHEMBL619843,850.0,BAO_0000218,,
4395,17763,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",B,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619844,,BAO_0000019,,
4396,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL857855,,BAO_0000251,2107.0,
4397,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619845,,BAO_0000251,2107.0,
4398,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619846,,BAO_0000251,2107.0,
4399,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619847,,BAO_0000251,2107.0,
4400,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL619848,,BAO_0000251,2107.0,
4401,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620893,,BAO_0000251,2107.0,
4402,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620894,,BAO_0000251,2107.0,
4403,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620895,,BAO_0000251,2107.0,
4404,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620896,,BAO_0000251,2107.0,
4405,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620897,,BAO_0000251,2107.0,
4406,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620898,,BAO_0000251,2107.0,
4407,7411,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,B,,,Rattus norvegicus,10116.0,,Liver,,Microsomes,22226,U,0,Autocuration,1,,CHEMBL620899,,BAO_0000251,2107.0,
4408,347,The apparent total plasma clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620900,,BAO_0000218,1969.0,
4409,3341,Compound was evaluated for Hepatic clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620901,,BAO_0000218,,
4410,17853,Lower clearance in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620902,,BAO_0000218,,
4411,4514,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620903,,BAO_0000218,,
4412,6062,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620904,,BAO_0000218,,
4413,6821,Plasma clearance of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620905,,BAO_0000218,,
4414,6057,Plasma clearance was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620906,,BAO_0000218,,
4415,5145,Plasma clearance in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875420,,BAO_0000218,,
4416,6641,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620907,,BAO_0000218,,
4417,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620908,,BAO_0000218,,
4418,4257,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620909,,BAO_0000218,,
4419,5546,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620910,,BAO_0000218,,
4420,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620911,,BAO_0000218,,
4421,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620912,,BAO_0000218,,
4422,17509,Cmax 24 hr after 2 mg/kg oral administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620913,,BAO_0000218,,
4423,6535,Cmax in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620914,,BAO_0000218,,
4424,5668,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620915,,BAO_0000218,,
4425,5922,Cmax in cynomolgus monkey by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620916,,BAO_0000218,,
4426,5922,Cmax in cynomolgus monkey by po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620917,,BAO_0000218,,
4427,6078,Cmax value evaluated in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620918,,BAO_0000218,,
4428,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620919,,BAO_0000218,,
4429,3249,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620920,,BAO_0000218,1969.0,
4430,3249,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620921,,BAO_0000218,1969.0,
4431,5553,Maximal plasma concentration in squirrel monkeys,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620922,,BAO_0000218,1969.0,
4432,1916,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620923,,BAO_0000218,,
4433,6227,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620924,,BAO_0000218,1969.0,
4434,4809,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620925,,BAO_0000218,,
4435,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620926,,BAO_0000218,,
4436,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620927,,BAO_0000218,,
4437,5355,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620928,,BAO_0000218,,
4438,5355,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620929,,BAO_0000218,,
4439,6221,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620930,,BAO_0000218,1969.0,
4440,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620931,,BAO_0000218,,
4441,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620932,,BAO_0000218,,
4442,4257,Absolute bioavailability was evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620933,,BAO_0000218,,
4443,6221,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620934,,BAO_0000218,,
4444,17667,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620935,,BAO_0000218,,
4445,17267,Bioavailability of compound was determined in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620936,,BAO_0000218,,
4446,4256,Bioavailability determined after oral administration in marmoset,A,In vivo,,marmosets,38020.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620937,,BAO_0000218,,
4447,4256,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620938,,BAO_0000218,,
4448,17853,Bioavailability in monkey (p.o.) at 2.0 mpk,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620939,,BAO_0000218,,
4449,16365,Bioavailability was evaluated after oral administration in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620940,,BAO_0000218,,
4450,1916,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620941,,BAO_0000218,,
4451,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620942,,BAO_0000218,,
4452,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620943,,BAO_0000218,,
4453,17592,Bioavailability of the compound was determined in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620944,,BAO_0000218,,
4454,1399,Bioavailability in squirrel monkey (dose 5 mg/kg),A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620945,,BAO_0000218,,
4455,4809,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620946,,BAO_0000218,,
4456,3341,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620947,,BAO_0000218,,
4457,64,Compound was tested for bioavailability in squirrel monkey,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620948,,BAO_0000218,,
4458,5005,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620949,,BAO_0000218,,
4459,5005,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620950,,BAO_0000218,,
4460,5237,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620951,,BAO_0000218,,
4461,5237,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620952,,BAO_0000218,,
4462,5302,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875421,,BAO_0000218,,
4463,17667,Oral bioavailability of compound at 5 mg/kg in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620953,,BAO_0000218,,
4464,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873491,,BAO_0000218,,
4465,6161,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620954,,BAO_0000218,,
4466,3854,Plasma half life determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620955,,BAO_0000218,1969.0,
4467,993,Plasma half life in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618097,,BAO_0000218,1969.0,
4468,4514,Plasma half-life in Beagle dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618268,,BAO_0000218,1969.0,
4469,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618269,,BAO_0000218,1969.0,
4470,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618270,,BAO_0000218,1969.0,
4471,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618271,,BAO_0000218,,
4472,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873493,,BAO_0000218,,
4473,5313,Tested for the half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621031,,BAO_0000218,,
4474,5313,Tested for the half life period in dog at dosage of 10 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621032,,BAO_0000218,,
4475,3880,The compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621033,,BAO_0000218,,
4476,3639,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621034,,BAO_0000218,1969.0,
4477,3880,The half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621035,,BAO_0000218,,
4478,3918,The plasma half-life in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621036,,BAO_0000218,1969.0,
4479,16452,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621037,,BAO_0000218,1969.0,
4480,17796,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619812,,BAO_0000218,,
4481,5983,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619813,,BAO_0000218,,
4482,1466,tmax upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873335,,BAO_0000218,,
4483,16456,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619814,,BAO_0000218,,
4484,6113,Cmax in ferrets after 30 mg/kg oral dose,A,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619815,,BAO_0000218,,
4485,6113,Emesis in ferrets at 30 mg/kg oral dose,F,In vivo,,Mustela putorius furo,9669.0,,,,,50506,N,1,Expert,1,,CHEMBL619816,,BAO_0000218,,
4486,17796,Bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619817,,BAO_0000218,,
4487,17796,Volume of distribution in cynomolgus,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL619818,,BAO_0000218,,
4488,5308,AUC tested in guinea pig when 3 mg/kg dose was given perorally,A,,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619819,,BAO_0000218,1969.0,
4489,4877,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619820,,BAO_0000218,,
4490,4876,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875419,,BAO_0000218,,
4491,4878,AUC in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619821,,BAO_0000218,1969.0,
4492,5308,Bioavailability in guinea pig was tested,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619822,,BAO_0000218,,
4493,4877,Tested for oral bioavailability in guinea pig at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619823,,BAO_0000218,,
4494,4876,Tested for the oral bioavailability of the compound,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619824,,BAO_0000218,,
4495,4876,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619825,,BAO_0000218,,
4496,5308,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619826,,BAO_0000218,,
4497,4877,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,A,In vivo,,Cavia porcellus,10141.0,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL619827,,BAO_0000218,2048.0,
4498,4878,Cmax in guinea pig after 3mg/kg oral dose,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618167,,BAO_0000218,,
4499,5689,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618168,,BAO_0000019,178.0,
4500,5689,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL618169,,BAO_0000019,955.0,
4501,5689,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618170,,BAO_0000019,,
4502,5689,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Intestine,,,22224,U,0,Autocuration,1,,CHEMBL618171,,BAO_0000019,160.0,
4503,5689,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL618172,,BAO_0000019,2113.0,
4504,5689,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL618173,,BAO_0000019,2107.0,
4505,5689,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618174,,BAO_0000019,,
4506,5689,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,A,,,Cavia porcellus,10141.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875408,,BAO_0000019,2106.0,
4507,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL839827,,BAO_0000218,,
4508,5689,Partition coefficient was measured as -log (counts per min ),A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618175,,BAO_0000019,,
4509,611,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618176,,BAO_0000218,,
4510,611,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618177,,BAO_0000218,,
4511,14465,Elimination T1/2 in Guinea pig (PO dose),A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618178,,BAO_0000218,,
4512,4876,"Tested for the half life period of the compound, intravenously",A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618179,,BAO_0000218,,
4513,5689,Half-life was measured,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873489,,BAO_0000019,,
4514,7515,The time required for onset of inotropy after addition of a single dose of delta F75,A,,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618180,,BAO_0000019,,
4515,17667,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618181,,BAO_0000218,,
4516,17667,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618182,,BAO_0000218,,
4517,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618183,,BAO_0000218,,
4518,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618184,,BAO_0000218,,
4519,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618185,,BAO_0000218,,
4520,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618186,,BAO_0000218,,
4521,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618187,,BAO_0000218,,
4522,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618188,,BAO_0000218,,
4523,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875409,,BAO_0000218,,
4524,10107,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618189,,BAO_0000218,,
4525,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618190,,BAO_0000218,178.0,
4526,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618191,,BAO_0000218,178.0,
4527,3655,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL618192,,BAO_0000218,178.0,
4528,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618193,,BAO_0000218,10000001.0,
4529,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618194,,BAO_0000218,10000001.0,
4530,3655,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL618195,,BAO_0000218,10000001.0,
4531,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618196,,BAO_0000218,955.0,
4532,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618197,,BAO_0000218,955.0,
4533,3655,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618198,,BAO_0000218,955.0,
4534,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618199,,BAO_0000218,948.0,
4535,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618200,,BAO_0000218,948.0,
4536,3655,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL618201,,BAO_0000218,948.0,
4537,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618202,,BAO_0000218,160.0,
4538,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618203,,BAO_0000218,160.0,
4539,3655,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL618204,,BAO_0000218,160.0,
4540,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618205,,BAO_0000218,2113.0,
4541,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618206,,BAO_0000218,2113.0,
4542,3655,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618207,,BAO_0000218,2113.0,
4543,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618208,,BAO_0000218,2107.0,
4544,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618932,,BAO_0000218,2107.0,
4545,3655,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618933,,BAO_0000218,2107.0,
4546,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618934,,BAO_0000218,2048.0,
4547,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618935,,BAO_0000218,2048.0,
4548,3655,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618936,,BAO_0000218,2048.0,
4549,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618937,,BAO_0000218,2385.0,
4550,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618938,,BAO_0000218,2385.0,
4551,3655,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL619104,,BAO_0000218,2385.0,
4552,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619105,,BAO_0000218,2106.0,
4553,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619106,,BAO_0000218,2106.0,
4554,3655,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL619107,,BAO_0000218,2106.0,
4555,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL875410,,BAO_0000218,945.0,
4556,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619108,,BAO_0000218,945.0,
4557,3655,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL619109,,BAO_0000218,945.0,
4558,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619110,,BAO_0000218,,
4559,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619111,,BAO_0000218,,
4560,16597,MRT value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619112,,BAO_0000218,,
4561,16597,MRT value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619113,,BAO_0000218,,
4562,17764,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619114,,BAO_0000218,,
4563,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619115,,BAO_0000218,,
4564,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619116,478.0,BAO_0000219,,
4565,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619117,478.0,BAO_0000219,,
4566,2040,Compound was evaluated for cytotoxicity against A2780 cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619118,478.0,BAO_0000219,,
4567,15684,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619119,478.0,BAO_0000219,,
4568,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619120,478.0,BAO_0000219,,
4569,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619121,478.0,BAO_0000219,,
4570,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619122,478.0,BAO_0000219,,
4571,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619123,478.0,BAO_0000219,,
4572,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619124,478.0,BAO_0000219,,
4573,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619125,478.0,BAO_0000219,,
4574,5618,In vitro inhibitory activity against human tumor cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875411,478.0,BAO_0000219,,
4575,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619126,478.0,BAO_0000219,,
4576,15684,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619127,478.0,BAO_0000219,,
4577,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619128,478.0,BAO_0000219,,
4578,15684,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619129,478.0,BAO_0000219,,
4579,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619130,478.0,BAO_0000219,,
4580,2113,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619131,478.0,BAO_0000219,,
4581,16745,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619132,478.0,BAO_0000219,,
4582,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619133,478.0,BAO_0000218,,
4583,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619134,478.0,BAO_0000219,,
4584,15684,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619135,478.0,BAO_0000219,,
4585,2040,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619136,478.0,BAO_0000219,,
4586,2040,Relative resistance factor in A2780 cisplatin-resistant line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619137,478.0,BAO_0000219,,
4587,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883713,478.0,BAO_0000219,,
4588,16165,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875412,478.0,BAO_0000219,,
4589,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619138,478.0,BAO_0000218,,
4590,16597,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619262,478.0,BAO_0000218,,
4591,3992,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619139,478.0,BAO_0000219,,
4592,10553,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619140,478.0,BAO_0000219,,
4593,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619141,478.0,BAO_0000219,,
4594,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619142,478.0,BAO_0000219,,
4595,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619143,478.0,BAO_0000219,,
4596,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619144,478.0,BAO_0000219,,
4597,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619145,478.0,BAO_0000219,,
4598,15608,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619146,478.0,BAO_0000219,,
4599,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619147,478.0,BAO_0000219,,
4600,17420,Antiproliferative effect of compound on A2780/DX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619148,478.0,BAO_0000219,,
4601,17420,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619149,478.0,BAO_0000219,,
4602,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619150,478.0,BAO_0000219,,
4603,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619151,478.0,BAO_0000219,,
4604,17672,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL883794,478.0,BAO_0000219,,
4605,17672,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619152,478.0,BAO_0000219,,
4606,17270,In vitro cytotoxicity against A2780ADR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619153,478.0,BAO_0000219,,
4607,17270,In vitro cytotoxicity against A2780CIS cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619154,478.0,BAO_0000219,,
4608,5574,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619155,478.0,BAO_0000219,,
4609,2113,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619156,478.0,BAO_0000219,,
4610,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619157,478.0,BAO_0000219,,
4611,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619797,478.0,BAO_0000219,,
4612,17839,Oral bioavailability of compound in rhesus macaques,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619798,,BAO_0000218,,
4613,6821,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619799,,BAO_0000218,,
4614,6078,Oral bioavailability evaluated in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619800,,BAO_0000218,,
4615,6535,Oral bioavailability in monkey (dose 1 mg/kg p.o.),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619801,,BAO_0000218,,
4616,4449,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619802,,BAO_0000218,,
4617,6057,Oral bioavailability was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619803,,BAO_0000218,,
4618,5922,Oral bioavailability in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619965,,BAO_0000218,,
4619,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619966,,BAO_0000218,,
4620,6265,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619967,,BAO_0000218,,
4621,6265,Oral bioavailability in monkey (dose 1 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620073,,BAO_0000218,,
4622,6265,Oral bioavailability in monkey (dose 5 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620074,,BAO_0000218,,
4623,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620075,,BAO_0000218,,
4624,5940,Oral bioavailability in monkey,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620076,,BAO_0000218,,
4625,4514,Oral bioavailability in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620077,,BAO_0000218,,
4626,5546,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620078,,BAO_0000218,,
4627,5553,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,A,In vivo,,Saimiri sciureus,9521.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620079,,BAO_0000218,,
4628,6641,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620080,,BAO_0000218,,
4629,5472,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620081,,BAO_0000218,,
4630,5668,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620082,,BAO_0000218,,
4631,5711,Oral bioavailability in monkey at 10 mg/kg of the compound,A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620083,,BAO_0000218,,
4632,5145,Bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620084,,BAO_0000218,,
4633,3443,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620085,,BAO_0000218,,
4634,3443,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874595,,BAO_0000218,,
4635,3249,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873352,,BAO_0000218,,
4636,3249,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620086,,BAO_0000218,,
4637,5355,Mean residence time was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620087,,BAO_0000218,,
4638,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620088,,BAO_0000218,,
4639,5355,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620089,,BAO_0000218,,
4640,4809,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620090,,BAO_0000218,,
4641,4809,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620091,,BAO_0000218,,
4642,14294,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620092,,BAO_0000251,,
4643,14294,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620093,,BAO_0000251,,
4644,14294,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620094,,BAO_0000251,,
4645,14294,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),A,,,Cercopithecidae,9527.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620095,,BAO_0000251,,
4646,3443,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620096,,BAO_0000218,,
4647,3443,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620097,,BAO_0000218,,
4648,11271,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620098,,BAO_0000019,,
4649,3443,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620099,,BAO_0000218,,
4650,3443,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620100,,BAO_0000218,,
4651,6821,Elimination Half-life of compound was determined in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620101,,BAO_0000019,,
4652,17267,Half life of compound was determined in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620102,,BAO_0000019,,
4653,5819,Half life in monkey plasma,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620103,,BAO_0000366,1969.0,
4654,5819,Half life in monkey plasma; Not detected,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620104,,BAO_0000366,1969.0,
4655,1916,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874596,,BAO_0000218,,
4656,17509,Half-life 24 hr after 2 mg/kg iv administration in monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873490,,BAO_0000218,,
4657,1399,Terminal half life of the compound.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620105,,BAO_0000019,,
4658,1916,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620780,,BAO_0000218,,
4659,4809,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620781,,BAO_0000218,,
4660,5546,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620956,,BAO_0000218,,
4661,3443,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620957,,BAO_0000218,1088.0,
4662,3443,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620958,,BAO_0000218,1088.0,
4663,4257,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620959,,BAO_0000218,,
4664,6221,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620960,,BAO_0000218,,
4665,5472,Volume of distribution was evaluated in rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620961,,BAO_0000218,,
4666,4727,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620962,,BAO_0000218,,
4667,4727,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620963,,BAO_0000218,,
4668,4727,Bioavailability in hamster was determined,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620964,,BAO_0000218,,
4669,4727,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620965,,BAO_0000218,,
4670,4727,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,A,In vivo,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620966,,BAO_0000218,,
4671,4727,Half life of compound was determined in hamster blood,A,,,Cricetulus griseus,10029.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620967,,BAO_0000221,178.0,
4672,1452,Michaelis-Menten constant of the compound.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620968,,BAO_0000019,,
4673,1452,Vmax value was measured at 0 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874597,,BAO_0000019,,
4674,1452,Vmax value was measured at 10 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620969,,BAO_0000019,,
4675,1452,Vmax value was measured at 5 uM concentration of silyl ether.,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620970,,BAO_0000019,,
4676,11706,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,B,,,Homo sapiens,9606.0,,,,,235,D,9,Expert,1,,CHEMBL620971,,BAO_0000357,,
4677,1916,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620972,,BAO_0000218,,
4678,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620973,,BAO_0000019,,
4679,7766,Active metabolite of ifosfamide determined in humans; A-Active,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618243,,BAO_0000019,,
4680,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618244,,BAO_0000019,,
4681,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618245,,BAO_0000019,,
4682,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618246,,BAO_0000019,,
4683,6567,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618247,,BAO_0000019,,
4684,17791,Compound was evaluated for oral bioavailability in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618248,,BAO_0000218,,
4685,7766,Metabolite of ifosfamide determined in urine; NF-Not found,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618249,,BAO_0000019,1088.0,
4686,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618250,,BAO_0000019,,
4687,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874598,,BAO_0000019,,
4688,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618251,,BAO_0000019,,
4689,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618252,,BAO_0000019,,
4690,6852,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618253,,BAO_0000019,,
4691,6852,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618254,,BAO_0000019,,
4692,6852,Percent of compound in healthy individuals (Group D),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618255,,BAO_0000019,,
4693,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618983,,BAO_0000251,2107.0,
4694,17409,Binding towards human plasma protein at 10 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618984,,BAO_0000019,,
4695,17409,Binding towards human plasma protein at 100 uM,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618985,,BAO_0000019,,
4696,17176,Human plasma protein binding activity was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618986,,BAO_0000019,,
4697,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618987,,BAO_0000019,,
4698,17267,Percent binding of compound towards human plasma protein was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618988,,BAO_0000019,,
4699,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618989,,BAO_0000251,2107.0,
4700,5668,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618990,,BAO_0000251,2107.0,
4701,5669,In vitro intrinsic clearance in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618991,,BAO_0000251,2107.0,
4702,5041,In vitro microsome metabolism clearance in human was determined,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL876725,,BAO_0000251,,
4703,5041,In vitro microsome metabolism clearance in human was determined; High,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618992,,BAO_0000251,,
4704,5041,In vitro microsome metabolism clearance in human was determined; ND denotes no data,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618993,,BAO_0000251,,
4705,5676,Pharmacokinetic property (clearance) in human liver microsome,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618994,,BAO_0000251,2107.0,
4706,5944,Plasma clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618995,,BAO_0000251,2107.0,
4707,17538,In vitro clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618996,,BAO_0000251,2107.0,
4708,6331,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618997,,BAO_0000251,2107.0,
4709,5948,Intrinsic clearance in human liver microsomes was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618998,,BAO_0000251,2107.0,
4710,5965,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618999,,BAO_0000218,,
4711,1916,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620223,,BAO_0000218,,
4712,5965,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620224,,BAO_0000218,,
4713,1299,Stability in human plasma 2 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620225,,BAO_0000019,,
4714,1299,Stability in human plasma 4 hr after incubation expressed as percent concentration,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620226,,BAO_0000019,,
4715,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620227,,BAO_0000019,1088.0,
4716,7766,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876726,,BAO_0000019,1088.0,
4717,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620228,,BAO_0000019,1088.0,
4718,7766,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL620229,,BAO_0000019,1088.0,
4719,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620230,,BAO_0000218,,
4720,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620231,,BAO_0000218,,
4721,17764,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620232,,BAO_0000218,,
4722,17764,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620233,,BAO_0000218,,
4723,14294,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620234,,BAO_0000218,,
4724,14294,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620235,,BAO_0000218,,
4725,14294,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620236,,BAO_0000218,,
4726,6251,In vitro metabolic potential in mouse liver microsomes,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL620237,,BAO_0000218,2107.0,
4727,17582,Ability of compound to bind to plasma protein was evaluated in HSA cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620238,,BAO_0000218,,
4728,17811,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Adrenal gland,,,50594,N,1,Intermediate,1,,CHEMBL620239,,BAO_0000218,2369.0,
4729,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620240,,BAO_0000218,955.0,
4730,17811,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL620241,,BAO_0000218,955.0,
4731,17811,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876727,,BAO_0000218,,
4732,17811,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620242,,BAO_0000218,2113.0,
4733,17811,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620243,,BAO_0000218,,
4734,5288,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620244,,BAO_0000218,,
4735,2717,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620245,,BAO_0000218,1977.0,
4736,2717,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620246,,BAO_0000218,1977.0,
4737,2717,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL620247,,BAO_0000218,1977.0,
4738,17753,Half life of compound was determined in plasma of mice at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620248,,BAO_0000218,1969.0,
4739,17753,Half life of compound was determined in plasma of mice at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL873497,,BAO_0000218,1969.0,
4740,17753,Half life of compound was determined in plasma of mice at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL620249,,BAO_0000218,1969.0,
4741,17764,Half life after intraperitoneal administration in mice at 18 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620250,,BAO_0000218,,
4742,17764,Half life after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620251,,BAO_0000218,,
4743,17764,Half life after intraperitoneal administration in mice at 25 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620252,,BAO_0000218,,
4744,17764,Half life after intraperitoneal administration in mice at 26 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620253,,BAO_0000218,,
4745,17764,Half life after intravenous administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620254,,BAO_0000218,,
4746,17764,Half life after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620255,,BAO_0000218,,
4747,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620256,,BAO_0000218,,
4748,2675,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876728,,BAO_0000218,,
4749,2675,Maximum time required to reach Cp max was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620257,,BAO_0000218,,
4750,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620258,,BAO_0000218,,
4751,4890,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620259,,BAO_0000218,,
4752,429,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620260,,BAO_0000218,,
4753,17837,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620261,,BAO_0000218,178.0,
4754,16597,Half life at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620262,,BAO_0000218,,
4755,16597,Half life at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620263,,BAO_0000218,,
4756,6619,Half life in ob/ob mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620264,,BAO_0000218,,
4757,4066,Half-life at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620265,,BAO_0000218,,
4758,4239,Half-life was measured in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620266,,BAO_0000218,,
4759,5969,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620267,,BAO_0000218,,
4760,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619364,,BAO_0000218,,
4761,8999,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619365,,BAO_0000218,,
4762,17641,T2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL619366,,BAO_0000218,955.0,
4763,17641,T2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL619367,,BAO_0000218,2113.0,
4764,17641,T2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619368,,BAO_0000218,2107.0,
4765,17641,T2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL619369,,BAO_0000218,2048.0,
4766,17641,T2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876729,,BAO_0000218,2106.0,
4767,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619370,,BAO_0000218,,
4768,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619371,,BAO_0000218,,
4769,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619372,,BAO_0000218,,
4770,429,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620012,,BAO_0000218,,
4771,5969,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620013,,BAO_0000218,,
4772,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620014,478.0,BAO_0000219,,
4773,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL620015,478.0,BAO_0000219,,
4774,16913,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621010,478.0,BAO_0000219,,
4775,16913,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621011,478.0,BAO_0000219,,
4776,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621012,478.0,BAO_0000219,,
4777,16913,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621013,478.0,BAO_0000219,,
4778,17270,In vitro cytotoxicity against A2780TAX cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621014,478.0,BAO_0000219,,
4779,5618,In vitro inhibitory activity against human tumor cell line A2780cis,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618154,481.0,BAO_0000219,,
4780,17777,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618155,478.0,BAO_0000219,,
4781,16112,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618156,481.0,BAO_0000219,,
4782,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618157,481.0,BAO_0000219,,
4783,6633,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618328,478.0,BAO_0000219,,
4784,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618329,478.0,BAO_0000219,,
4785,17496,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618330,478.0,BAO_0000219,,
4786,12989,In vitro antitumor activity against A2780cisR cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618331,478.0,BAO_0000219,,
4787,4840,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618332,478.0,BAO_0000219,,
4788,12989,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618333,478.0,BAO_0000219,,
4789,16745,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,F,,,Homo sapiens,9606.0,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618334,481.0,BAO_0000219,,
4790,16597,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618335,478.0,BAO_0000219,,
4791,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,B,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618336,,BAO_0000019,,
4792,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,,,,,,,11736,H,8,Expert,1,,CHEMBL618337,,BAO_0000019,,
4793,16547,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),F,,,Rattus norvegicus,10116.0,,,,,11736,D,9,Expert,1,,CHEMBL618338,,BAO_0000019,,
4794,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618339,722.0,BAO_0000219,,
4795,15856,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,F,,,Homo sapiens,9606.0,,,HEK293,,278,D,9,Expert,1,,CHEMBL618340,722.0,BAO_0000219,,
4796,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,B,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618341,,BAO_0000019,,
4797,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,,,,,,,11831,H,8,Expert,1,,CHEMBL618342,,BAO_0000019,,
4798,16547,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),F,,,Mus musculus,10090.0,,,,,11831,D,9,Expert,1,,CHEMBL618343,,BAO_0000019,,
4799,17402,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,B,,,,,,,,,280,H,8,Expert,1,,CHEMBL621038,,BAO_0000357,,
4800,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621039,574.0,BAO_0000219,,
4801,11746,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,F,,,Homo sapiens,9606.0,,,T-cells,,22226,U,0,Autocuration,1,,CHEMBL621040,574.0,BAO_0000219,,
4802,5455,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621041,455.0,BAO_0000219,,
4803,2068,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621042,455.0,BAO_0000219,,
4804,2683,In vitro antitumor activity against A375cell line extracted form melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621043,455.0,BAO_0000219,,
4805,15313,Inhibition of cell growth in (A375) melan cell line,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Expert,1,,CHEMBL621044,455.0,BAO_0000219,,
4806,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621045,455.0,BAO_0000219,,
4807,13739,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621046,455.0,BAO_0000219,,
4808,14750,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL621047,455.0,BAO_0000219,,
4809,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621048,797.0,BAO_0000219,,
4810,14777,Antiproliferative activity measured against A427 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL883798,797.0,BAO_0000219,,
4811,17672,Cytotoxicity against lung carcinoma A427 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621049,797.0,BAO_0000219,,
4812,14368,Inhibition of large cell lung carcinoma (A427),F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621050,797.0,BAO_0000219,,
4813,14368,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621051,797.0,BAO_0000219,,
4814,13866,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621052,797.0,BAO_0000219,,
4815,2545,Inhibitory concentration in human lung carcinoma A427 cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621053,797.0,BAO_0000219,,
4816,2545,Inhibitory concentration in human lung carcinoma A427/VCR cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL621054,797.0,BAO_0000219,,
4817,6062,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621055,,BAO_0000218,,
4818,4578,Tested for volume of distribution upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876398,,BAO_0000218,,
4819,17592,Volume of distribution in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621056,,BAO_0000218,,
4820,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621057,,BAO_0000218,,
4821,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621058,,BAO_0000218,,
4822,5922,Pharmacokinetic property(Vdss) in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621059,,BAO_0000218,,
4823,5355,The distribution volume after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621060,,BAO_0000218,,
4824,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621061,,BAO_0000218,,
4825,5355,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621062,,BAO_0000218,,
4826,6057,Volume displacement was calculated in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621063,,BAO_0000218,,
4827,5145,Volume of distribution in steady state was determined in rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621064,,BAO_0000218,,
4828,6821,Volume of distribution of compound was determined in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621065,,BAO_0000218,,
4829,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621066,,BAO_0000218,,
4830,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621067,,BAO_0000218,,
4831,6641,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621068,,BAO_0000218,,
4832,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876399,,BAO_0000218,,
4833,6535,Volume distribution in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621069,,BAO_0000218,,
4834,4809,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621070,,BAO_0000218,,
4835,6062,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621071,,BAO_0000218,,
4836,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621072,,BAO_0000218,,
4837,4578,Oral systemic bioavailability upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618209,,BAO_0000218,,
4838,4809,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618210,,BAO_0000218,,
4839,11271,Baboon plasma free fraction. ,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618211,,BAO_0000019,,
4840,6057,Area under the curve was calculated in rhesus monkey after iv administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618212,,BAO_0000218,,
4841,6057,Area under the curve was calculated in rhesus monkey after peroral administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618213,,BAO_0000019,,
4842,17853,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618214,,BAO_0000019,,
4843,5302,Half life period in monkey after 5 mg/kg dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873492,,BAO_0000218,,
4844,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618272,,BAO_0000218,,
4845,4257,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618273,,BAO_0000218,,
4846,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618274,,BAO_0000218,1969.0,
4847,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618275,,BAO_0000218,,
4848,2661,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618276,,BAO_0000218,,
4849,3341,Compound was evaluated for terminal half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618277,,BAO_0000019,,
4850,3045,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618278,,BAO_0000218,,
4851,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618279,,BAO_0000218,1969.0,
4852,4847,Half life of compound was determined in squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618280,,BAO_0000019,,
4853,4256,Half life after iv administration in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618281,,BAO_0000218,,
4854,6535,Half life in monkey plasma after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618282,,BAO_0000218,1969.0,
4855,6057,Half life was calculated in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618283,,BAO_0000019,,
4856,17592,Half life in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618284,,BAO_0000019,,
4857,6641,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618285,,BAO_0000218,,
4858,5472,Half life was evaluated in rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618286,,BAO_0000019,,
4859,6221,Half life period after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618287,,BAO_0000218,,
4860,5668,Half life period was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618288,,BAO_0000218,,
4861,4809,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876393,,BAO_0000218,,
4862,5546,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618289,,BAO_0000218,,
4863,5553,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618290,,BAO_0000218,,
4864,6078,Half-life was calculated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618291,,BAO_0000019,,
4865,5147,Half-life in Squirrel monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618292,,BAO_0000019,,
4866,5145,Half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618293,,BAO_0000019,,
4867,6062,Half-life was measured in monkey after an iv dose of 1 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618294,,BAO_0000218,,
4868,5355,Half-life period after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618295,,BAO_0000218,,
4869,5355,Half-life period after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618296,,BAO_0000218,,
4870,5355,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618297,,BAO_0000218,,
4871,7766,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618298,,BAO_0000019,1088.0,
4872,7766,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618299,,BAO_0000019,1088.0,
4873,7766,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618300,,BAO_0000019,1088.0,
4874,7766,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618301,,BAO_0000019,1088.0,
4875,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618302,,BAO_0000019,1088.0,
4876,7766,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL876394,,BAO_0000019,1088.0,
4877,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618303,,BAO_0000019,1088.0,
4878,7766,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618304,,BAO_0000019,1088.0,
4879,1916,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618305,,BAO_0000218,,
4880,16643,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618306,,BAO_0000218,,
4881,17248,Compound was tested for human plasma protein binding,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618307,,BAO_0000019,,
4882,17248,Compound was tested for human plasma protein binding; Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618308,,BAO_0000019,,
4883,6241,Protein binding activity of compound in human plasma; % Free,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618309,,BAO_0000019,,
4884,17716,Unbound fraction (plasma),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618310,,BAO_0000019,,
4885,17605,Half life for the hydrolysis of compound in human blood serum,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873353,,BAO_0000366,1969.0,
4886,17625,Half life period in human plasma using phosphate buffer (0.08 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618311,,BAO_0000366,1969.0,
4887,17625,Half life period in human plasma using phosphate buffer (0.1 M),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618312,,BAO_0000366,1969.0,
4888,17747,Half-life in human plasma was determined,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618313,,BAO_0000366,1969.0,
4889,15613,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618314,,BAO_0000019,,
4890,354,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618315,,BAO_0000019,,
4891,3741,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618316,,BAO_0000019,,
4892,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618317,,BAO_0000019,,
4893,3741,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620138,,BAO_0000019,,
4894,17599,Partition coefficient (logP),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL858280,,BAO_0000019,,
4895,5486,In vitro metabolic stability in human was measured as pmol/min/mg/protein,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620139,,BAO_0000019,,
4896,5600,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620140,,BAO_0000251,,
4897,14294,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620141,,BAO_0000019,,
4898,14294,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620142,,BAO_0000019,,
4899,14294,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620143,,BAO_0000019,,
4900,14294,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620144,,BAO_0000251,,
4901,14294,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620145,,BAO_0000251,,
4902,14294,Metabolism of compound in human microsomes; Trace,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620146,,BAO_0000251,,
4903,6260,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620147,,BAO_0000251,2107.0,
4904,6187,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,A,,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620148,,BAO_0000251,,
4905,6251,In vitro metabolic potential in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL620149,,BAO_0000251,2107.0,
4906,3246,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876412,,BAO_0000019,,
4907,17313,Tested for human plasma protein binding of the compound; Not tested,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619352,,BAO_0000019,,
4908,6227,Compound was tested for percent protein binding (PB) in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619353,,BAO_0000019,,
4909,5530,Protein binding in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619354,,BAO_0000019,1969.0,
4910,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619355,,BAO_0000019,,
4911,6108,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619356,,BAO_0000019,,
4912,2774,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619357,,BAO_0000019,,
4913,16643,In vitro rate of absorption observed as Caco-2 permeability in humans,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619358,,BAO_0000019,,
4914,17582,Cellular permeability of compound was determined in Caco-2 cells; High,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619359,495.0,BAO_0000219,,
4915,6838,Permeability in Caco-2 cells of compound,A,,,Homo sapiens,9606.0,,,Caco-2,,22224,U,0,Autocuration,1,,CHEMBL619360,495.0,BAO_0000219,,
4916,6108,Permeability coefficient (A to B) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619361,,BAO_0000019,,
4917,6108,Permeability coefficient (B to A) in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619362,,BAO_0000019,,
4918,6108,Permeability coefficient (Papp) (Caco-2 cell monolayer),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619363,,BAO_0000019,,
4919,2146,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618942,,BAO_0000019,,
4920,4514,Compound was tested for protein binding in human plasma,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618943,,BAO_0000019,,
4921,6108,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618944,,BAO_0000019,,
4922,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL618945,,BAO_0000019,1088.0,
4923,5969,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618946,,BAO_0000218,,
4924,3277,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876413,,BAO_0000218,,
4925,3802,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618947,,BAO_0000218,,
4926,2862,Time taken to reach maximum concentration in plasma upon oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618948,,BAO_0000218,1969.0,
4927,6348,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL618949,,BAO_0000218,1969.0,
4928,17764,Tmax after intraperitoneal administration in mice at 23 uM/kg,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618950,,BAO_0000218,,
4929,5781,Tmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618951,,BAO_0000218,,
4930,17764,Tmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618952,,BAO_0000218,,
4931,4066,Tmax at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618953,,BAO_0000218,,
4932,17641,Tmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618954,,BAO_0000218,955.0,
4933,17641,Tmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618955,,BAO_0000218,2113.0,
4934,17641,Tmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618956,,BAO_0000218,2107.0,
4935,17641,Tmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL618957,,BAO_0000218,2048.0,
4936,17764,Tmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618958,,BAO_0000218,,
4937,17764,Tmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618959,,BAO_0000218,,
4938,17764,Tmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618960,,BAO_0000218,,
4939,17764,Tmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876723,,BAO_0000218,,
4940,17641,Tmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618961,,BAO_0000218,2106.0,
4941,16597,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618962,,BAO_0000218,,
4942,16597,Tmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618963,,BAO_0000218,,
4943,5951,Tmax value in IRC mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618964,,BAO_0000218,,
4944,5506,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618965,,BAO_0000218,,
4945,5506,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618966,,BAO_0000218,,
4946,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618967,,BAO_0000218,1088.0,
4947,429,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618968,,BAO_0000218,1088.0,
4948,4066,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL618969,,BAO_0000218,1088.0,
4949,17734,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618970,,BAO_0000218,,
4950,17734,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618971,,BAO_0000218,,
4951,6062,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618972,,BAO_0000218,,
4952,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618973,,BAO_0000218,,
4953,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618974,,BAO_0000218,,
4954,5969,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618975,,BAO_0000218,,
4955,5980,Vd in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618976,,BAO_0000218,,
4956,17592,Volume of distribution in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618977,,BAO_0000218,,
4957,6348,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876724,,BAO_0000218,,
4958,17753,Volume of distribution of compound in plasma was determined at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618978,,BAO_0000218,,
4959,17753,Volume of distribution of compound in plasma was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618979,,BAO_0000218,,
4960,17753,Volume of distribution of compound in plasma was determined at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618980,,BAO_0000218,,
4961,4239,Pharmacokinetic property (vdss) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618981,,BAO_0000218,,
4962,2862,Value distribution upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618982,,BAO_0000218,,
4963,17734,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620150,,BAO_0000218,,
4964,2675,Volume of distribution was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620151,,BAO_0000218,,
4965,2675,Volume of distribution was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620152,,BAO_0000218,,
4966,17837,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620153,,BAO_0000218,,
4967,5727,Steady state volume of distribution was determined in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876395,,BAO_0000218,,
4968,17852,Volume distribution (steady state) of compound was determined in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620154,,BAO_0000218,,
4969,17764,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620155,,BAO_0000218,,
4970,16597,Vss value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620156,,BAO_0000218,,
4971,6062,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620157,,BAO_0000218,,
4972,16438,Biodistribution of compound (oxidized form) in in kidney tissue,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL620158,,BAO_0000218,2113.0,
4973,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620159,,BAO_0000218,178.0,
4974,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620160,,BAO_0000218,178.0,
4975,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620161,,BAO_0000218,178.0,
4976,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL620162,797.0,BAO_0000219,,
4977,16597,Inhibition of A431 human squamous cell carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620163,500.0,BAO_0000219,,
4978,16062,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620833,500.0,BAO_0000219,,
4979,16062,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876396,500.0,BAO_0000219,,
4980,16958,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620834,500.0,BAO_0000219,,
4981,6700,Inhibition of A431 human carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620835,500.0,BAO_0000219,,
4982,17226,In vitro inhibition of A431 (human carcinoma) cell basal growth.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL620836,500.0,BAO_0000219,,
4983,6828,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL620837,500.0,BAO_0000219,,
4984,12314,In vitro cytotoxicity against epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621017,500.0,BAO_0000219,,
4985,13412,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621018,500.0,BAO_0000218,,
4986,13299,Antiproliferative activity of compound was measured on human tumor cell line A431.,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621019,500.0,BAO_0000219,,
4987,17420,Antiproliferative effect of compound on A431 cell line expressing mutant p53,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621020,500.0,BAO_0000219,,
4988,13678,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621021,500.0,BAO_0000219,,
4989,14171,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621022,500.0,BAO_0000219,,
4990,6333,Tested for antiproliferative activity against human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621023,500.0,BAO_0000219,,
4991,2356,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621024,500.0,BAO_0000219,,
4992,15578,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621025,500.0,BAO_0000219,,
4993,5126,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621026,500.0,BAO_0000219,,
4994,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621027,500.0,BAO_0000219,,
4995,6844,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL876397,500.0,BAO_0000219,,
4996,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL883797,500.0,BAO_0000219,,
4997,4925,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621028,500.0,BAO_0000219,,
4998,13978,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621029,500.0,BAO_0000219,,
4999,16786,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621030,500.0,BAO_0000219,,
5000,13412,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621147,500.0,BAO_0000219,,
5001,17824,In vivo antiproliferative activity against A431 cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621148,500.0,BAO_0000218,,
5002,12751,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621149,500.0,BAO_0000219,,
5003,12380,Inhibition of A431 human epidermoid carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621150,500.0,BAO_0000219,,
5004,4959,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621151,500.0,BAO_0000219,,
5005,6333,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621152,500.0,BAO_0000219,,
5006,6333,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621153,500.0,BAO_0000219,,
5007,6333,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL884000,500.0,BAO_0000219,,
5008,5296,Inhibition of EGFR overexpressing A431 cell proliferation,F,,,Homo sapiens,9606.0,,,,,9,D,9,Expert,1,,CHEMBL621154,,BAO_0000019,,
5009,12624,Inhibition of A431 cell proliferation,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL621155,500.0,BAO_0000219,,
5010,14926,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621156,500.0,BAO_0000219,,
5011,14926,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621157,500.0,BAO_0000219,,
5012,14926,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL621158,500.0,BAO_0000219,,
5013,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621159,500.0,BAO_0000219,,
5014,15144,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621160,500.0,BAO_0000219,,
5015,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621161,500.0,BAO_0000219,,
5016,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621162,500.0,BAO_0000219,,
5017,5245,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621163,500.0,BAO_0000219,,
5018,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621164,500.0,BAO_0000219,,
5019,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621165,500.0,BAO_0000219,,
5020,5922,Half-life period in cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619159,,BAO_0000019,,
5021,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",A,In vitro,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619160,,BAO_0000366,1969.0,
5022,17853,Longer half-life in monkey (i.v.) at 0.5 mpk,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619161,,BAO_0000218,,
5023,993,Plasma half life in monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619162,,BAO_0000366,1969.0,
5024,4514,Plasma half-life in rhesus monkey,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619163,,BAO_0000366,1969.0,
5025,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619164,,BAO_0000218,1969.0,
5026,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619320,,BAO_0000218,1969.0,
5027,4578,Tested for half life upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619321,,BAO_0000218,,
5028,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873336,,BAO_0000218,,
5029,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619322,,BAO_0000218,,
5030,5355,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619323,,BAO_0000218,,
5031,5355,The time for peak concentration value after oral administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619324,,BAO_0000218,,
5032,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619325,,BAO_0000019,,
5033,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876411,,BAO_0000019,,
5034,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619326,,BAO_0000019,,
5035,11271,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619327,,BAO_0000019,,
5036,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619328,,BAO_0000019,,
5037,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619329,,BAO_0000019,,
5038,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619330,,BAO_0000019,,
5039,11271,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619331,,BAO_0000019,,
5040,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619332,,BAO_0000019,,
5041,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619333,,BAO_0000019,,
5042,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619334,,BAO_0000019,,
5043,11271,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619335,,BAO_0000019,,
5044,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619336,,BAO_0000019,,
5045,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619337,,BAO_0000019,,
5046,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619338,,BAO_0000019,,
5047,11271,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619339,,BAO_0000019,,
5048,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619340,,BAO_0000218,,
5049,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873496,,BAO_0000218,1969.0,
5050,3546,AUC value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619341,,BAO_0000218,1969.0,
5051,3546,AUC value in rat after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL619342,,BAO_0000218,1969.0,
5052,3546,Cmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619343,,BAO_0000218,,
5053,3546,Bioavailability in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619344,,BAO_0000218,,
5054,3546,Tmax value in rat after oral administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619345,,BAO_0000218,,
5055,3546,Vc value in rat after IV administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619346,,BAO_0000218,,
5056,3546,Half life period in rat after IV administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619347,,BAO_0000218,,
5057,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619348,,BAO_0000019,,
5058,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619349,,BAO_0000019,,
5059,10625,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619350,,BAO_0000019,,
5060,10625,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619351,,BAO_0000019,,
5061,10625,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875953,,BAO_0000019,,
5062,10625,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621716,,BAO_0000019,,
5063,10625,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621717,,BAO_0000019,,
5064,10625,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,A,,,Papio hamadryas,9557.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621718,,BAO_0000019,,
5065,3510,Area under curve after 1 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621719,,BAO_0000019,,
5066,3510,Area under curve after 2 mpk peroral administration to beagles,A,,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621720,,BAO_0000019,,
5067,3510,Cmax value after 1 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621721,,BAO_0000218,,
5068,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621722,,BAO_0000019,1088.0,
5069,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621723,,BAO_0000019,1088.0,
5070,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL621724,,BAO_0000019,1088.0,
5071,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623443,,BAO_0000019,1088.0,
5072,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623444,,BAO_0000019,1088.0,
5073,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623445,,BAO_0000019,1088.0,
5074,7766,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,A,,,Homo sapiens,9606.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623446,,BAO_0000019,1088.0,
5075,16643,Metabolic stability observed at 30 min after administration in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623447,,BAO_0000251,2107.0,
5076,6852,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623448,,BAO_0000019,,
5077,6852,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623449,,BAO_0000019,,
5078,6852,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623450,,BAO_0000019,,
5079,6567,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623451,,BAO_0000251,2107.0,
5080,6570,Metabolic stability (% remaining at 30 mins) in human S9.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623452,,BAO_0000019,,
5081,6570,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623453,,BAO_0000019,,
5082,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623454,,BAO_0000251,2107.0,
5083,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL623455,,BAO_0000251,2107.0,
5084,5237,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624371,,BAO_0000251,2107.0,
5085,5202,First pass metabolism and metabolic bioavailability using human hepatic microsomes,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624372,,BAO_0000218,,
5086,5481,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624373,,BAO_0000019,,
5087,5481,Percent remaining in human plasma after incubation for 60 min at 37 C.,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624374,,BAO_0000019,,
5088,3956,The percent remaining in human plasma after 30 min was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624556,,BAO_0000019,,
5089,5074,Conversion rate of the prodrug in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624557,,BAO_0000366,1969.0,
5090,5074,Conversion rate of the prodrug in human plasma; ND means no data,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624558,,BAO_0000366,1969.0,
5091,4727,Half life of compound was determined in human blood,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624559,,BAO_0000221,178.0,
5092,5965,Half life of compound was determined in man with once daily dosing,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624560,,BAO_0000019,,
5093,5732,Half life in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624561,,BAO_0000251,,
5094,5819,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624562,,BAO_0000366,1969.0,
5095,5819,Half life in human plasma; Not detected,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624563,,BAO_0000366,1969.0,
5096,1916,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624564,,BAO_0000218,,
5097,6597,Half-life for oxidative metabolic stability was determined using rat liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624565,,BAO_0000251,2107.0,
5098,5229,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875152,,BAO_0000366,1969.0,
5099,5229,Half-life of the parent prodrug in plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624566,,BAO_0000366,1969.0,
5100,2192,In vitro half life in human plasma was determined,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873805,,BAO_0000366,1969.0,
5101,3032,The compound was tested In Vitro for half life in human liver microsomes.,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624567,,BAO_0000251,2107.0,
5102,1916,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624568,,BAO_0000218,,
5103,17716,Observed volume of distribution,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624569,,BAO_0000218,,
5104,15778,Oral bioavailability in human,A,In vivo,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624570,,BAO_0000218,,
5105,17313,Tested for human plasma protein binding of the compound,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624571,,BAO_0000019,,
5106,4231,"First order rate constant, k was determined in human plasma",A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624572,,BAO_0000019,,
5107,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624573,,BAO_0000019,,
5108,4755,Observed rate constant in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875153,,BAO_0000019,,
5109,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624574,,BAO_0000251,2107.0,
5110,10839,The compound was tested for the plasma binding in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624575,,BAO_0000019,,
5111,10839,Plasma protein binding (human),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624576,,BAO_0000019,,
5112,3199,Compound was evaluated for half-life in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL624577,,BAO_0000251,2107.0,
5113,1345,Half life measured in vitro for its stability in human blood,A,In vitro,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624578,,BAO_0000221,178.0,
5114,4297,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622796,,BAO_0000019,1977.0,
5115,4297,Half life in human serum; ND=not determined,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL622797,,BAO_0000019,1977.0,
5116,4297,Half life were determined in CEM-SS cell extract in decomposition step 1,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622798,,BAO_0000019,,
5117,4297,Half life were determined in CEM-SS cell extract in decomposition step 2,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622799,,BAO_0000019,,
5118,4231,Half life of the in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622800,,BAO_0000366,1969.0,
5119,5633,Half life period in human hepatic S9 fraction was determined,A,In vitro,,Homo sapiens,9606.0,,,,S9,22224,U,0,Autocuration,1,,CHEMBL622801,,BAO_0000220,,
5120,5633,Half life period in human liver microsome was determined,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL622802,,BAO_0000251,2107.0,
5121,17791,Half life period was determined; 6-7,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622803,,BAO_0000019,,
5122,17791,Half life period was evaluated in human,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875154,,BAO_0000019,,
5123,3160,Half life time in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622804,,BAO_0000366,1969.0,
5124,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622805,,BAO_0000218,955.0,
5125,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622611,,BAO_0000218,948.0,
5126,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622612,,BAO_0000218,948.0,
5127,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL875160,,BAO_0000218,2113.0,
5128,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622613,,BAO_0000218,2113.0,
5129,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622614,,BAO_0000218,2113.0,
5130,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622615,,BAO_0000218,2107.0,
5131,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622616,,BAO_0000218,2107.0,
5132,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622617,,BAO_0000218,2107.0,
5133,16438,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622618,,BAO_0000218,2106.0,
5134,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622619,,BAO_0000218,2106.0,
5135,16438,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622620,,BAO_0000218,2106.0,
5136,16438,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622621,,BAO_0000218,955.0,
5137,16438,Biodistribution of compound (oxidized form) in blood tissue,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622622,,BAO_0000218,178.0,
5138,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622623,,BAO_0000218,178.0,
5139,16438,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622624,,BAO_0000218,178.0,
5140,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622625,,BAO_0000218,178.0,
5141,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622626,,BAO_0000218,178.0,
5142,16438,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622627,,BAO_0000218,178.0,
5143,16438,Biodistribution of compound (oxidized form) in brain tissue of mice,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622628,,BAO_0000218,955.0,
5144,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622629,,BAO_0000218,955.0,
5145,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622630,,BAO_0000218,955.0,
5146,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622631,,BAO_0000218,955.0,
5147,16438,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622632,,BAO_0000218,955.0,
5148,16438,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622633,,BAO_0000218,955.0,
5149,16438,Biodistribution of compound (oxidized form) in heart tissue of mice,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622634,,BAO_0000218,948.0,
5150,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622635,,BAO_0000218,948.0,
5151,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL875161,,BAO_0000218,948.0,
5152,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622636,,BAO_0000218,948.0,
5153,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623335,,BAO_0000218,948.0,
5154,16438,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623336,,BAO_0000218,948.0,
5155,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623337,,BAO_0000218,2113.0,
5156,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623338,,BAO_0000218,2113.0,
5157,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623339,,BAO_0000218,2113.0,
5158,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623524,,BAO_0000218,2113.0,
5159,16438,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623525,,BAO_0000218,2113.0,
5160,16438,Biodistribution of compound (oxidized form) in liver tissue,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623526,,BAO_0000218,2107.0,
5161,16438,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623527,,BAO_0000218,2107.0,
5162,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623528,,BAO_0000218,2107.0,
5163,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL624615,500.0,BAO_0000219,,
5164,5245,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621672,500.0,BAO_0000219,,
5165,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621673,500.0,BAO_0000218,,
5166,16289,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621674,500.0,BAO_0000218,,
5167,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL884002,500.0,BAO_0000219,,
5168,16825,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621850,500.0,BAO_0000219,,
5169,4848,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL621851,500.0,BAO_0000219,,
5170,14827,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621852,500.0,BAO_0000219,,
5171,14827,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL621853,500.0,BAO_0000219,,
5172,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621854,500.0,BAO_0000218,,
5173,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL621855,500.0,BAO_0000218,,
5174,16289,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623724,500.0,BAO_0000218,,
5175,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623725,500.0,BAO_0000218,,
5176,16289,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623726,500.0,BAO_0000218,,
5177,16289,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL623727,500.0,BAO_0000219,,
5178,16289,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,F,,,,,,,A-431,,9,H,8,Expert,1,,CHEMBL623728,500.0,BAO_0000219,,
5179,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623729,500.0,BAO_0000218,,
5180,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623730,500.0,BAO_0000218,,
5181,16289,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",F,,,,,,,A-431,,80852,N,1,Expert,1,,CHEMBL623731,500.0,BAO_0000218,,
5182,14555,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623732,500.0,BAO_0000218,,
5183,14555,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623733,500.0,BAO_0000218,,
5184,14555,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623734,500.0,BAO_0000218,,
5185,14555,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",F,,,Mus musculus,10090.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623735,500.0,BAO_0000218,,
5186,1937,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL623736,500.0,BAO_0000219,,
5187,13739,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623737,500.0,BAO_0000219,,
5188,3558,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL623738,500.0,BAO_0000219,,
5189,3558,Dose giving a 50% decrease in the living cell number (A437 cells),F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Intermediate,1,,CHEMBL875168,500.0,BAO_0000219,,
5190,17686,In vitro inhibitory concentration against proliferation of A459 cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623739,646.0,BAO_0000219,,
5191,5305,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623740,646.0,BAO_0000219,,
5192,3614,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624424,646.0,BAO_0000219,,
5193,17229,In vitro antitumor activity against renal A498 tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624425,624.0,BAO_0000219,,
5194,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624426,624.0,BAO_0000219,,
5195,15935,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624427,624.0,BAO_0000219,,
5196,15560,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624428,624.0,BAO_0000219,,
5197,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624429,624.0,BAO_0000219,,
5198,13891,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624620,624.0,BAO_0000219,,
5199,13788,Cytotoxicity on kidney carcinoma (A-498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624621,624.0,BAO_0000219,,
5200,15403,Compound was evaluated against Human cell line renal A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624622,624.0,BAO_0000219,,
5201,1009,Compound was tested for inhibition of A498 human renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624623,624.0,BAO_0000219,,
5202,1043,Growth inhibitory activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL874365,624.0,BAO_0000219,,
5203,5858,In vitro antitumor activity against human renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624624,624.0,BAO_0000219,,
5204,5958,In vitro cytotoxic activity against renal (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624625,624.0,BAO_0000219,,
5205,5506,In vitro cytotoxic activity against human renal cancer (A498) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624626,624.0,BAO_0000219,,
5206,12781,Tested for cytostatic activity against renal A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624627,624.0,BAO_0000219,,
5207,14399,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883157,624.0,BAO_0000219,,
5208,5958,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL624628,624.0,BAO_0000219,,
5209,3510,Cmax value after 2 mpk peroral administration to beagles,A,In vivo,,beagle,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624629,,BAO_0000218,,
5210,3510,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623551,,BAO_0000218,,
5211,3510,Bioavailability after 1 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623552,,BAO_0000218,,
5212,3510,Bioavailability after 2 mpk peroral administration to beagles,A,In vivo,,Canis lupus familiaris,9615.0,beagle,,,,22224,U,0,Autocuration,1,,CHEMBL623553,,BAO_0000218,,
5213,3085,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623554,,BAO_0000019,,
5214,3085,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623555,,BAO_0000019,,
5215,3085,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623556,,BAO_0000019,,
5216,9372,Solubility against bovine alpha-chymotrypsin,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623557,,BAO_0000019,,
5217,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623558,,BAO_0000019,,
5218,3085,Rate constant of the bovine serum albumin catalyzed reaction of the compound,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623559,,BAO_0000019,,
5219,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623560,,BAO_0000221,2106.0,
5220,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623561,,BAO_0000019,,
5221,4297,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623562,,BAO_0000019,,
5222,17585,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623563,,BAO_0000019,,
5223,1336,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,A,,,Bos taurus,9913.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL623564,,BAO_0000221,2106.0,
5224,3085,Half life in presence of 2 mg/mL BSA at pH 8.8,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873806,,BAO_0000019,,
5225,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623565,,BAO_0000019,,
5226,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623566,,BAO_0000019,,
5227,2857,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623567,,BAO_0000019,,
5228,1540,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),A,,,Bos taurus,9913.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623568,,BAO_0000019,,
5229,6316,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623569,,BAO_0000218,1969.0,
5230,17594,AUC after administration at 100 mg/kg/day in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623570,,BAO_0000218,1969.0,
5231,4953,AUC in dog at 0-24 hr by peroral administration at 3 mpk,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624254,,BAO_0000218,1969.0,
5232,16907,AUC value after 15 mg/kg iv dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624255,,BAO_0000218,1969.0,
5233,16907,AUC value after 30 mg/kg po dose in Dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624256,,BAO_0000218,1969.0,
5234,2959,AUC value after administration of 4 mg/Kg oral dose in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624257,,BAO_0000218,1969.0,
5235,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624258,,BAO_0000218,1969.0,
5236,5356,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875277,,BAO_0000218,,
5237,16807,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622667,,BAO_0000218,,
5238,4527,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622668,,BAO_0000218,,
5239,4527,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622669,,BAO_0000218,,
5240,15660,Area under curve determined in dogs after intravenous administration of 3 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622670,,BAO_0000218,,
5241,15660,Area under curve determined in dogs after oral administration of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622671,,BAO_0000218,,
5242,5802,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622672,,BAO_0000218,,
5243,3598,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622673,,BAO_0000218,,
5244,3598,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL622674,,BAO_0000218,,
5245,5944,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622675,,BAO_0000218,,
5246,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622676,,BAO_0000218,,
5247,5944,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622677,,BAO_0000218,,
5248,5944,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622678,,BAO_0000218,,
5249,4186,Area under curve in dog after administration of 20 mg/kg dose through peroral route,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622679,,BAO_0000218,,
5250,5007,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622680,,BAO_0000218,,
5251,5668,Area under curve was determine after peroral administration at 10 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622681,,BAO_0000218,,
5252,5668,Area under curve was determine after peroral administration at 5 mpk in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875278,,BAO_0000218,,
5253,5006,Area under curve was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622682,,BAO_0000218,,
5254,5006,Area under curve in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622683,,BAO_0000218,,
5255,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622684,,BAO_0000218,,
5256,3771,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622685,,BAO_0000218,,
5257,3771,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622686,,BAO_0000218,,
5258,1916,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618344,,BAO_0000218,,
5259,5302,Area under curve value in dog at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875582,,BAO_0000218,,
5260,5600,Area under curve was determined after 0.1 mg/kg iv administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618345,,BAO_0000218,,
5261,5600,Area under curve was determined after 0.3 mg/kg po administration in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618346,,BAO_0000218,,
5262,17764,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618347,,BAO_0000218,,
5263,4368,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618348,,BAO_0000218,,
5264,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618349,,BAO_0000019,,
5265,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618350,,BAO_0000019,,
5266,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618351,,BAO_0000019,,
5267,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618352,,BAO_0000019,,
5268,14518,Time taken to reduce 50% of the concentration of compound in blood plasma,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL873494,,BAO_0000221,178.0,
5269,2209,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618353,,BAO_0000366,1969.0,
5270,6787,Half life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618354,,BAO_0000366,1969.0,
5271,4898,Half life in human plasma was reported,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875583,,BAO_0000366,1969.0,
5272,6072,Half life in human serum,A,,,Homo sapiens,9606.0,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL618355,,BAO_0000019,1977.0,
5273,16907,Half life upon exposure to human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618356,,BAO_0000366,1969.0,
5274,5656,t1/2 in human microsomes,A,In vitro,,Homo sapiens,9606.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618357,,BAO_0000251,,
5275,4755,Half life period in 80% human plasma at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618358,,BAO_0000366,1969.0,
5276,17503,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),A,,,Homo sapiens,9606.0,,Zone of skin,,,22224,U,0,Autocuration,1,,CHEMBL618359,,BAO_0000221,14.0,
5277,12357,Half-life measured in in vitro Cathepsin B assay in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618360,,BAO_0000366,1969.0,
5278,3076,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618361,,BAO_0000019,,
5279,6410,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618362,,BAO_0000251,2107.0,
5280,3741,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618363,,BAO_0000366,1969.0,
5281,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618364,,BAO_0000366,1969.0,
5282,3741,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875584,,BAO_0000366,1969.0,
5283,1540,Half-life in the CEM cell extracts,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618365,,BAO_0000019,,
5284,2905,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL873495,,BAO_0000366,1969.0,
5285,2905,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618366,,BAO_0000366,1969.0,
5286,5523,Half-life was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618367,,BAO_0000019,,
5287,1499,Half-life (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618368,,BAO_0000221,178.0,
5288,1499,Half-life (human blood stability); no data,A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618369,,BAO_0000221,178.0,
5289,17065,Half-life in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618370,,BAO_0000366,1969.0,
5290,6861,CYP3A4 metabolism half-life (t1/2),A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618371,,BAO_0000019,,
5291,1499,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),A,,,Homo sapiens,9606.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL618372,,BAO_0000221,178.0,
5292,530,In vitro half life in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618373,,BAO_0000366,1969.0,
5293,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618374,,BAO_0000366,1969.0,
5294,6695,In vitro hydrolysis in human plasma,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618375,,BAO_0000366,1969.0,
5295,6695,In vitro hydrolysis in human plasma; no data,A,In vitro,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618376,,BAO_0000366,1969.0,
5296,10,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL618377,,BAO_0000251,2107.0,
5297,993,Plasma half life in human,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618378,,BAO_0000366,1969.0,
5298,15429,Stability after incubation with human plasma (at 37 degree C),A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618379,,BAO_0000366,1969.0,
5299,1675,T1/2 was evaluated in human plasma,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618380,,BAO_0000366,1969.0,
5300,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618381,,BAO_0000366,1969.0,
5301,2209,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL618382,,BAO_0000366,1969.0,
5302,5318,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618383,,BAO_0000019,,
5303,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618384,,BAO_0000019,,
5304,2412,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,A,In vitro,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618385,,BAO_0000019,,
5305,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619099,,BAO_0000366,1969.0,
5306,2906,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619100,,BAO_0000366,1969.0,
5307,5495,Time taken for 50% to be consumed by serum PON1 was determined,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619101,,BAO_0000019,,
5308,5495,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,A,,,Homo sapiens,9606.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619102,,BAO_0000019,,
5309,4397,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL619103,,BAO_0000251,2107.0,
5310,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619268,,BAO_0000218,,
5311,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619269,,BAO_0000218,,
5312,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619270,,BAO_0000218,,
5313,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619271,,BAO_0000218,,
5314,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875585,,BAO_0000218,,
5315,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL619272,,BAO_0000218,,
5316,6058,Compound tested for growth inhibition of renal cancer cell line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619273,391.0,BAO_0000219,,
5317,17708,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619274,391.0,BAO_0000219,,
5318,14017,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619275,391.0,BAO_0000219,,
5319,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619276,391.0,BAO_0000219,,
5320,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619277,391.0,BAO_0000219,,
5321,16818,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619278,391.0,BAO_0000219,,
5322,11970,Tested for cytotoxicity against 786-0 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619279,391.0,BAO_0000219,,
5323,12400,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL858458,391.0,BAO_0000219,,
5324,12888,Cytotoxic effect on renal cancer line 786-0,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Expert,1,,CHEMBL619280,391.0,BAO_0000219,,
5325,15300,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619281,391.0,BAO_0000219,,
5326,14769,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619282,391.0,BAO_0000219,,
5327,15895,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619283,391.0,BAO_0000219,,
5328,17376,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619284,391.0,BAO_0000219,,
5329,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619285,391.0,BAO_0000219,,
5330,14882,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619286,391.0,BAO_0000219,,
5331,15176,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619287,391.0,BAO_0000219,,
5332,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL857455,391.0,BAO_0000219,,
5333,2496,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL883801,391.0,BAO_0000219,,
5334,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619288,972.0,BAO_0000219,,
5335,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619289,972.0,BAO_0000219,,
5336,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619290,972.0,BAO_0000219,,
5337,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619291,972.0,BAO_0000219,,
5338,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619292,972.0,BAO_0000219,,
5339,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619293,972.0,BAO_0000219,,
5340,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619294,972.0,BAO_0000219,,
5341,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619295,972.0,BAO_0000219,,
5342,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619296,972.0,BAO_0000219,,
5343,11831,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,F,,,Homo sapiens,9606.0,,,791T cell line,,80641,N,1,Intermediate,1,,CHEMBL619297,972.0,BAO_0000219,,
5344,12782,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,F,,,Homo sapiens,9606.0,,,786-0,,80640,N,1,Intermediate,1,,CHEMBL619298,391.0,BAO_0000219,,
5345,1229,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL619299,,BAO_0000019,,
5346,15313,Inhibition of cell growth in drug resistant 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619300,741.0,BAO_0000219,,
5347,15313,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL619301,741.0,BAO_0000219,,
5348,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619302,741.0,BAO_0000219,,
5349,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619303,741.0,BAO_0000219,,
5350,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619304,741.0,BAO_0000219,,
5351,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL857706,741.0,BAO_0000219,,
5352,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619305,741.0,BAO_0000219,,
5353,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619306,741.0,BAO_0000219,,
5354,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619307,741.0,BAO_0000219,,
5355,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619308,741.0,BAO_0000219,,
5356,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619309,741.0,BAO_0000219,,
5357,9424,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL619310,741.0,BAO_0000219,,
5358,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619311,624.0,BAO_0000219,,
5359,15354,Compound was tested for the growth inhibition of A498 renal tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619312,624.0,BAO_0000219,,
5360,17445,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619313,624.0,BAO_0000219,,
5361,4337,In vitro inhibitory concentration against renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619314,624.0,BAO_0000219,,
5362,15277,Cytotoxicity against A 498 tumor cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619959,624.0,BAO_0000219,,
5363,4812,In vitro antitumor activity against A498 human cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619960,624.0,BAO_0000219,,
5364,4812,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619961,624.0,BAO_0000219,,
5365,4995,Inhibitory dose required against A498 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619962,624.0,BAO_0000219,,
5366,5847,Anticancer activity against one renal cancer (A498 cell line),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL875586,624.0,BAO_0000219,,
5367,6557,In vitro cytotoxicity against melanoma A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619963,624.0,BAO_0000219,,
5368,2597,Compound was tested for growth inhibitory activity against A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619964,624.0,BAO_0000219,,
5369,6058,Compound tested for growth inhibition of renal cancer cell line A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620108,624.0,BAO_0000219,,
5370,17708,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620109,624.0,BAO_0000219,,
5371,15176,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620110,624.0,BAO_0000219,,
5372,15300,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620111,624.0,BAO_0000219,,
5373,11970,Tested for cytotoxicity against A498 cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620112,624.0,BAO_0000219,,
5374,12400,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620113,624.0,BAO_0000219,,
5375,12888,Cytotoxic effect on renal cancer lines A498,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620114,624.0,BAO_0000219,,
5376,3030,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620115,624.0,BAO_0000219,,
5377,14769,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620116,624.0,BAO_0000219,,
5378,17376,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620117,624.0,BAO_0000219,,
5379,16558,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620118,624.0,BAO_0000219,,
5380,5194,Cytotoxicity against human kidney carcinoma cell lines A4982LM,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620119,624.0,BAO_0000219,,
5381,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL620120,624.0,BAO_0000219,,
5382,16880,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620121,646.0,BAO_0000219,,
5383,10196,Antitumor activity against A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620122,646.0,BAO_0000219,,
5384,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620123,646.0,BAO_0000219,,
5385,10196,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620124,646.0,BAO_0000219,,
5386,12083,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620125,646.0,BAO_0000219,,
5387,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620126,646.0,BAO_0000219,,
5388,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL883027,646.0,BAO_0000219,,
5389,16470,In vitro cytotoxic activity against human lung A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620127,646.0,BAO_0000219,,
5390,16470,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620128,646.0,BAO_0000219,,
5391,16470,In vitro cytotoxic activity against human lung A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620129,646.0,BAO_0000219,,
5392,16470,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620130,646.0,BAO_0000219,,
5393,16582,In vitro cytotoxicity against human non small-cell-lung cell line A549.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620131,646.0,BAO_0000219,,
5394,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620132,646.0,BAO_0000219,,
5395,15935,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620133,646.0,BAO_0000219,,
5396,16597,Inhibition of A549 human lung carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620134,646.0,BAO_0000219,,
5397,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620135,646.0,BAO_0000219,,
5398,16496,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620136,646.0,BAO_0000219,,
5399,16152,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620137,646.0,BAO_0000219,,
5400,16152,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620268,646.0,BAO_0000219,,
5401,16464,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620269,646.0,BAO_0000219,,
5402,2288,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620270,646.0,BAO_0000219,,
5403,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620271,646.0,BAO_0000219,,
5404,4090,Inhibition of A549 cancer cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620272,646.0,BAO_0000219,,
5405,4090,Inhibition of A549 cancer cell proliferation (Not tested),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620273,646.0,BAO_0000219,,
5406,17350,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620274,646.0,BAO_0000219,,
5407,4197,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620275,646.0,BAO_0000219,,
5408,17072,Antiproliferative potency determined as inhibitory concentration against A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620276,646.0,BAO_0000219,,
5409,17072,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620277,646.0,BAO_0000219,,
5410,5194,Cytotoxicity against Renal cell lines A549 was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620278,646.0,BAO_0000219,,
5411,4257,Area under curve was determined in dog after a 3 mg/kg of oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620279,,BAO_0000218,,
5412,6123,Area under curve was determined in dog after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620280,,BAO_0000218,,
5413,1337,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620281,,BAO_0000218,,
5414,1337,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620282,,BAO_0000218,,
5415,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621134,,BAO_0000218,,
5416,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621135,,BAO_0000218,,
5417,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621136,,BAO_0000218,,
5418,8833,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621137,,BAO_0000218,,
5419,17657,Area under plasma concentration time curve in dog upon oral administration,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621138,,BAO_0000218,1969.0,
5420,17650,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875587,,BAO_0000218,1969.0,
5421,1977,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621139,,BAO_0000218,,
5422,1977,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621140,,BAO_0000218,,
5423,3132,Area under the curve for the compound was obtained when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621141,,BAO_0000218,,
5424,5473,Area under the curve at a dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621142,,BAO_0000218,,
5425,5474,Area under the curve at a dose of 1 mg/kg (oral),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621143,,BAO_0000218,,
5426,5474,Area under the curve at i.v. dose of 0.2 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621144,,BAO_0000218,,
5427,6062,Area under the curve was measured in dog after an iv dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621145,,BAO_0000218,,
5428,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621146,,BAO_0000218,,
5429,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622567,,BAO_0000218,,
5430,2652,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622568,,BAO_0000218,,
5431,2877,Compound was evaluated for area under the curve in dog blood.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622569,,BAO_0000218,,
5432,5444,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622570,,BAO_0000218,,
5433,5130,AUC in dog after oral dose (1 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622571,,BAO_0000218,1969.0,
5434,6265,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622572,,BAO_0000218,,
5435,4657,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622573,,BAO_0000218,,
5436,16367,Pharmacokinetic parameter AUC after intravenous administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622574,,BAO_0000218,,
5437,16367,Pharmacokinetic parameter AUC after oral administration to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622575,,BAO_0000218,,
5438,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622576,,BAO_0000218,,
5439,9579,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622577,,BAO_0000218,,
5440,5983,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622578,,BAO_0000218,,
5441,6241,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622579,,BAO_0000218,,
5442,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622580,,BAO_0000218,,
5443,5313,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622581,,BAO_0000218,,
5444,6642,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622582,,BAO_0000218,,
5445,6642,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622583,,BAO_0000218,,
5446,6641,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622584,,BAO_0000218,,
5447,6642,Oral AUCN in dog (dosed at 0.5 mpk iv ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622585,,BAO_0000218,,
5448,17791,Compound was evaluated for oral bioavailability in dog; 90-100,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622586,,BAO_0000218,,
5449,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623281,,BAO_0000218,,
5450,17655,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623282,,BAO_0000218,,
5451,6596,PAPP (membrane permeability) in dog kidney cell monolayer assay,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623283,,BAO_0000218,,
5452,3880,Oral bioavailability in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623284,,BAO_0000218,,
5453,16367,Bioavailability administered orally at a dose of 10 mg/kg to dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623285,,BAO_0000218,,
5454,17409,Plasma protein binding towards dog plasma at 10 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623463,,BAO_0000218,1969.0,
5455,17409,Plasma protein binding towards dog plasma at 100 uM,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875952,,BAO_0000218,1969.0,
5456,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621705,,BAO_0000218,,
5457,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621706,,BAO_0000218,,
5458,4527,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621707,,BAO_0000218,,
5459,15145,Bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621708,,BAO_0000218,,
5460,4219,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621709,,BAO_0000218,,
5461,17538,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621710,,BAO_0000218,,
5462,17538,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621711,,BAO_0000218,,
5463,1466,Bioavailability in dog (dose 10.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621712,,BAO_0000218,,
5464,17650,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621713,,BAO_0000218,,
5465,3132,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621714,,BAO_0000218,,
5466,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621715,,BAO_0000218,,
5467,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623717,,BAO_0000218,2107.0,
5468,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623718,,BAO_0000218,2107.0,
5469,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623719,,BAO_0000218,2107.0,
5470,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623720,,BAO_0000218,,
5471,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623721,,BAO_0000218,,
5472,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623722,,BAO_0000218,2385.0,
5473,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL623723,,BAO_0000218,2385.0,
5474,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL618543,,BAO_0000218,2385.0,
5475,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL618544,,BAO_0000218,2106.0,
5476,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL875155,,BAO_0000218,2106.0,
5477,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618545,,BAO_0000218,,
5478,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618546,,BAO_0000218,,
5479,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623529,,BAO_0000218,,
5480,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623530,,BAO_0000218,,
5481,2413,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,A,,,Mus sp.,10095.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621764,,BAO_0000218,,
5482,17827,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621765,,BAO_0000019,,
5483,17827,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621766,,BAO_0000019,2037.0,
5484,17827,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621767,,BAO_0000019,1870.0,
5485,17827,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621768,,BAO_0000019,,
5486,17827,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621769,,BAO_0000019,2435.0,
5487,17827,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621770,,BAO_0000019,,
5488,17827,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Cerebellum,,,22224,U,0,Autocuration,1,,CHEMBL621771,,BAO_0000019,2037.0,
5489,17827,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Frontal cortex,,,22224,U,0,Autocuration,1,,CHEMBL621772,,BAO_0000019,1870.0,
5490,17827,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621773,,BAO_0000019,,
5491,17827,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),A,,,Cercopithecidae,9527.0,,Striatum,,,22224,U,0,Autocuration,1,,CHEMBL621774,,BAO_0000019,2435.0,
5492,17791,Compound was evaluated for oral bioavailability in rats,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621775,,BAO_0000218,,
5493,17667,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,A,In vivo,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621776,,BAO_0000218,1969.0,
5494,17791,Half life period was evaluated in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621777,,BAO_0000019,,
5495,110,Half-life in rhesus monkeys by intravenous administration of dose,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875162,,BAO_0000218,,
5496,5781,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621778,,BAO_0000218,1969.0,
5497,17734,AUC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621779,,BAO_0000218,1969.0,
5498,17718,AUC value was determined after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622479,,BAO_0000218,1969.0,
5499,4573,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622480,,BAO_0000218,,
5500,3277,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622481,,BAO_0000218,,
5501,2862,Area under curve by ioral administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622482,,BAO_0000218,,
5502,2862,Area under curve by iv administration in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622483,,BAO_0000218,,
5503,5951,Area under curve at 0-8 hr in IRC mice after peroral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622484,,BAO_0000218,,
5504,17729,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622641,,BAO_0000218,,
5505,17728,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622642,,BAO_0000218,,
5506,17728,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622643,,BAO_0000218,,
5507,17729,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622644,,BAO_0000218,,
5508,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622645,741.0,BAO_0000219,,
5509,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL622646,741.0,BAO_0000219,,
5510,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621238,741.0,BAO_0000219,,
5511,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621239,741.0,BAO_0000219,,
5512,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621240,741.0,BAO_0000219,,
5513,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621241,741.0,BAO_0000219,,
5514,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL621242,741.0,BAO_0000219,,
5515,9424,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620350,741.0,BAO_0000219,,
5516,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620351,741.0,BAO_0000219,,
5517,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620352,741.0,BAO_0000219,,
5518,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620353,741.0,BAO_0000219,,
5519,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620354,741.0,BAO_0000219,,
5520,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620355,741.0,BAO_0000219,,
5521,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620356,741.0,BAO_0000219,,
5522,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620357,741.0,BAO_0000219,,
5523,9424,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620358,741.0,BAO_0000219,,
5524,9424,In vitro inhibition of human 8226 myeloma tumor cell line growth.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Expert,1,,CHEMBL620359,741.0,BAO_0000219,,
5525,11544,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620360,741.0,BAO_0000219,,
5526,17378,Cytotoxicity of compound against 8226/DOX1V cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620361,741.0,BAO_0000219,,
5527,17378,Cytotoxicity of compound against 8226/S cells,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620362,741.0,BAO_0000219,,
5528,17079,Inhibitory concentration against 8226 myeloma cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620363,741.0,BAO_0000219,,
5529,17079,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,F,,,Homo sapiens,9606.0,,,RPMI-8226,,80433,N,1,Intermediate,1,,CHEMBL620364,741.0,BAO_0000219,,
5530,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K).,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620365,854.0,BAO_0000219,,
5531,13466,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620366,854.0,BAO_0000219,,
5532,2392,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Expert,1,,CHEMBL620367,854.0,BAO_0000219,,
5533,2392,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,F,,,Homo sapiens,9606.0,,,833K,,80647,N,1,Intermediate,1,,CHEMBL620368,854.0,BAO_0000219,,
5534,6608,Inhibitory activity against caspase-1,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620369,,BAO_0000019,,
5535,10199,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,B,,,Enterococcus faecalis,1351.0,,,,,45,H,8,Autocuration,1,,CHEMBL620370,,BAO_0000357,,
5536,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620371,705.0,BAO_0000219,,
5537,17749,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,F,,,Homo sapiens,9606.0,,,8701-BC,,80648,N,1,Intermediate,1,,CHEMBL620372,705.0,BAO_0000219,,
5538,1229,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL876492,,BAO_0000019,,
5539,1229,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620373,,BAO_0000019,,
5540,1229,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,F,,,,,,,,,22226,U,0,Intermediate,1,,CHEMBL620374,,BAO_0000019,,
5541,6390,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,B,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620375,,BAO_0000019,,
5542,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL857902,,BAO_0000019,,
5543,16219,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,F,,,Streptococcus pyogenes,1314.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620376,,BAO_0000019,,
5544,17043,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,B,,,,,,,,,11922,H,8,Autocuration,1,,CHEMBL620377,,BAO_0000357,,
5545,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,F,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620378,324.0,BAO_0000219,,
5546,6929,Tested for in vitro cytotoxic potency of compound in 9KB assay,A,,,Homo sapiens,9606.0,,,KB ,,81115,N,1,Intermediate,1,,CHEMBL620379,324.0,BAO_0000219,,
5547,7083,In vitro cytotoxicity of compound was tested against 9KB cells.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620380,,BAO_0000219,,
5548,12446,Cytotoxic concentration against 9L cells was determined on day 3,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Intermediate,1,,CHEMBL884006,392.0,BAO_0000219,,
5549,15345,Tested in vitro for anticancer activity against 9L cells,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620381,392.0,BAO_0000219,,
5550,15345,Tested in vitro for anticancer activity against 9L cells; Not determined,F,,,Rattus norvegicus,10116.0,,,9L,,80653,N,1,Expert,1,,CHEMBL620382,392.0,BAO_0000219,,
5551,6301,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620383,646.0,BAO_0000219,,
5552,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876493,646.0,BAO_0000219,,
5553,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620384,646.0,BAO_0000219,,
5554,4833,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620385,646.0,BAO_0000219,,
5555,13330,Cytotoxicity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620386,646.0,BAO_0000219,,
5556,17517,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL620387,646.0,BAO_0000219,,
5557,17517,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",F,,,Homo sapiens,9606.0,,,A549,,25,D,9,Expert,1,,CHEMBL621404,646.0,BAO_0000219,,
5558,14425,"In vitro growth inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621405,646.0,BAO_0000219,,
5559,14425,"In vitro growth inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621406,646.0,BAO_0000219,,
5560,5228,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621407,646.0,BAO_0000219,,
5561,5351,Cytotoxic activity against human lung cancer A549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621408,646.0,BAO_0000219,,
5562,12198,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885345,646.0,BAO_0000219,,
5563,13891,Cytotoxicity concentration against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621409,646.0,BAO_0000219,,
5564,5677,Cytotoxicity in A549 (human carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL876034,646.0,BAO_0000219,,
5565,13788,Cytotoxicity on lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621410,646.0,BAO_0000219,,
5566,13384,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621411,646.0,BAO_0000219,,
5567,6726,Effective dose of compound against replication of A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621412,646.0,BAO_0000219,,
5568,3455,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621413,646.0,BAO_0000219,,
5569,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621414,646.0,BAO_0000219,,
5570,5726,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621415,646.0,BAO_0000219,,
5571,3936,The compound was evaluated for antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621416,646.0,BAO_0000219,,
5572,14991,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621417,646.0,BAO_0000219,,
5573,5243,Concentration required for growth inhibition of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621418,646.0,BAO_0000219,,
5574,12858,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621419,646.0,BAO_0000219,,
5575,6776,Growth inhibition against A549 cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621420,646.0,BAO_0000219,,
5576,16558,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875823,646.0,BAO_0000219,,
5577,4583,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621421,646.0,BAO_0000219,,
5578,13514,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621422,646.0,BAO_0000219,,
5579,15166,Chemosensitivity against DT-diaphorase rich A549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884014,646.0,BAO_0000219,,
5580,13873,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621423,646.0,BAO_0000219,,
5581,6447,In vitro cytotoxicity against human A549 (lung cancer) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621424,646.0,BAO_0000219,,
5582,2068,In vitro antitumor activity against A549 (lung) human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621425,646.0,BAO_0000219,,
5583,1863,In vitro cytotoxic activity against human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621426,646.0,BAO_0000219,,
5584,13873,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621427,646.0,BAO_0000219,,
5585,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621428,646.0,BAO_0000219,,
5586,13873,Tested against A549 lung carcinoma in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621429,646.0,BAO_0000219,,
5587,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621430,646.0,BAO_0000219,,
5588,579,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621431,646.0,BAO_0000219,,
5589,4584,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621432,646.0,BAO_0000219,,
5590,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621433,646.0,BAO_0000219,,
5591,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL875824,646.0,BAO_0000219,,
5592,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621434,646.0,BAO_0000219,,
5593,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621435,646.0,BAO_0000219,,
5594,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621436,646.0,BAO_0000219,,
5595,14188,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621437,646.0,BAO_0000219,,
5596,15354,Compound was tested for the growth inhibition of A549 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621438,646.0,BAO_0000219,,
5597,14253,Growth inhibition of human non-small-lung carcinoma (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621439,646.0,BAO_0000219,,
5598,13873,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621440,646.0,BAO_0000219,,
5599,3043,Oral bioavailability in dog (conscious),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621441,,BAO_0000218,,
5600,3045,Compound was evaluated for the oral bioavailability after oral administration in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621442,,BAO_0000218,,
5601,3022,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621443,,BAO_0000218,,
5602,4453,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621444,,BAO_0000218,,
5603,1696,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625133,,BAO_0000218,,
5604,5045,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625134,,BAO_0000218,,
5605,5356,Oral bioavailability in dog (fasted),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625135,,BAO_0000218,,
5606,17764,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625136,,BAO_0000218,,
5607,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625137,,BAO_0000218,,
5608,1475,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625138,,BAO_0000218,,
5609,3788,Percent bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625139,,BAO_0000218,,
5610,3639,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872264,,BAO_0000218,,
5611,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625140,,BAO_0000218,,
5612,2137,The compound was evaluated for bioavailability in dogs; 34-44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624436,,BAO_0000218,,
5613,2959,Bioavailability in dog (dose 4 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624437,,BAO_0000218,,
5614,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872261,,BAO_0000218,,
5615,6084,8 hour trough Blood level in dog was measured after administration of compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624438,,BAO_0000218,,
5616,3639,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624439,,BAO_0000218,1969.0,
5617,6316,C24 after oral administration at 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624440,,BAO_0000218,,
5618,5238,Clearance after oral and iv dosing in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624441,,BAO_0000218,,
5619,17796,Clearance of the drug was measured in the plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624442,,BAO_0000218,1969.0,
5620,2652,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624443,,BAO_0000218,,
5621,5654,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624444,,BAO_0000218,,
5622,6621,Clearance of compound was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624445,,BAO_0000218,,
5623,6505,Clearance on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624446,,BAO_0000218,,
5624,5802,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624447,,BAO_0000218,,
5625,17267,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624448,,BAO_0000218,,
5626,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624449,,BAO_0000218,,
5627,6535,Plasma clearance in dog after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624450,,BAO_0000218,,
5628,6535,Plasma clearance in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875942,,BAO_0000218,,
5629,6535,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624451,,BAO_0000218,,
5630,5542,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624452,,BAO_0000218,,
5631,5199,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624453,,BAO_0000218,,
5632,16907,Plasma clearance after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624454,,BAO_0000218,,
5633,16907,Plasma clearance after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624455,,BAO_0000218,,
5634,16367,Plasma administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624456,,BAO_0000218,,
5635,5505,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624457,,BAO_0000218,,
5636,6215,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624458,,BAO_0000218,,
5637,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624459,,BAO_0000218,,
5638,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624460,,BAO_0000251,2107.0,
5639,5007,Intrinsic clearance in human liver microsomes,A,In vitro,,Homo sapiens,9606.0,,Liver,,Microsomes,102164,S,2,Intermediate,1,,CHEMBL624461,,BAO_0000251,2107.0,
5640,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875943,,BAO_0000218,,
5641,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624462,,BAO_0000218,,
5642,16452,Clearance in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624463,,BAO_0000218,,
5643,6221,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624464,,BAO_0000218,,
5644,5007,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624465,,BAO_0000218,,
5645,5668,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624466,,BAO_0000218,,
5646,5668,Plasma clearance after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624467,,BAO_0000218,,
5647,5668,Plasma clearance after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624468,,BAO_0000218,,
5648,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624469,,BAO_0000218,,
5649,15660,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624470,,BAO_0000218,,
5650,5983,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624471,,BAO_0000218,,
5651,5600,Total clearance was determined after 0.1 mg/kg iv administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624472,,BAO_0000218,,
5652,17764,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622775,,BAO_0000218,,
5653,6039,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622776,,BAO_0000218,,
5654,6039,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622777,,BAO_0000218,,
5655,6039,Clearance after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622778,,BAO_0000218,,
5656,4368,Clearance by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622779,,BAO_0000218,,
5657,4305,Clearance by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622780,,BAO_0000218,,
5658,1918,Clearance value was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622781,,BAO_0000218,1969.0,
5659,6005,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622782,,BAO_0000218,,
5660,4839,Compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622783,,BAO_0000218,1969.0,
5661,4239,Pharmacokinetic property (Plasma clearance) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622784,,BAO_0000218,,
5662,17729,Area under curve when injected perorally in mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622785,,BAO_0000218,,
5663,17728,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622786,,BAO_0000218,,
5664,5302,Area under curve value in mouse at a dose of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622787,,BAO_0000218,,
5665,5506,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875949,,BAO_0000218,,
5666,5506,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622788,,BAO_0000218,,
5667,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622789,,BAO_0000218,,
5668,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622790,,BAO_0000218,,
5669,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622791,,BAO_0000218,,
5670,17764,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622792,,BAO_0000218,,
5671,17764,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622793,,BAO_0000218,,
5672,17753,Area under curve was determined for the compound at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622794,,BAO_0000218,,
5673,17753,Area under curve was determined for the compound at 40 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622795,,BAO_0000218,,
5674,17753,Area under curve was determined for the compound at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621803,,BAO_0000218,,
5675,3132,Area under the curve for the compound is obtained at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621804,,BAO_0000218,,
5676,3132,Area under the curve for the compound was obtained when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621805,,BAO_0000218,,
5677,17837,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621806,,BAO_0000218,,
5678,17837,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621807,,BAO_0000218,,
5679,6062,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621808,,BAO_0000218,,
5680,4066,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621809,,BAO_0000218,,
5681,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621810,,BAO_0000218,,
5682,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875164,,BAO_0000218,,
5683,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621811,,BAO_0000218,,
5684,4890,"Compound was evaluated for the pharmacokinetic parameter, area under curve",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621812,,BAO_0000218,,
5685,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621813,,BAO_0000218,,
5686,429,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621814,,BAO_0000218,,
5687,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621815,,BAO_0000218,,
5688,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621816,,BAO_0000218,,
5689,5969,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621817,,BAO_0000218,,
5690,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621818,,BAO_0000218,,
5691,6091,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621819,,BAO_0000218,,
5692,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621820,,BAO_0000218,,
5693,6091,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621821,,BAO_0000218,,
5694,6178,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621822,,BAO_0000218,,
5695,6178,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619474,,BAO_0000218,,
5696,6619,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619475,,BAO_0000218,,
5697,6619,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619476,,BAO_0000218,,
5698,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619477,,BAO_0000218,,
5699,3760,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619478,,BAO_0000218,,
5700,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619479,,BAO_0000218,,
5701,3760,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619480,,BAO_0000218,,
5702,3192,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619481,,BAO_0000218,,
5703,3192,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619482,,BAO_0000218,,
5704,2675,Area under the curve was evaluated in mice after intravenous administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619483,,BAO_0000218,,
5705,2675,Area under the curve was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619484,,BAO_0000218,,
5706,16597,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619485,,BAO_0000218,1969.0,
5707,16597,AUC total value at a dose of 10 mg/kg peroral administration in mice.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL619486,,BAO_0000218,1969.0,
5708,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619487,,BAO_0000218,,
5709,17734,AUMC after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619488,,BAO_0000218,,
5710,7767,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL620106,,BAO_0000218,178.0,
5711,15345,The compound was tested in vitro for anticancer activity against 9L cells,F,,,,,,,9L,,80653,N,1,Intermediate,1,,CHEMBL620107,392.0,BAO_0000219,,
5712,2181,Anti proliferation activity determined; Weak effect,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620283,,BAO_0000019,,
5713,2181,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL875176,,BAO_0000219,,
5714,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620284,,BAO_0000219,,
5715,2181,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623515,,BAO_0000219,,
5716,10486,The cytotoxic activity was in vitro tested by 9PS assay method,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623516,,BAO_0000019,,
5717,10486,The cytotoxic activity was in vitro tested by 9PS assay method.,F,,,Mus musculus,10090.0,,,,,22226,U,0,Autocuration,1,,CHEMBL623517,,BAO_0000019,,
5718,15508,Partition coefficient (logD6.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857878,,BAO_0000019,,
5719,5242,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623518,478.0,BAO_0000219,,
5720,16167,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624195,455.0,BAO_0000219,,
5721,4782,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL624196,500.0,BAO_0000219,,
5722,16093,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,F,,,Homo sapiens,9606.0,,,A-431,,9,D,9,Expert,1,,CHEMBL624197,500.0,BAO_0000219,,
5723,2596,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL624198,624.0,BAO_0000219,,
5724,2596,in vitro cytotoxicity against A 498 cancer cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621287,624.0,BAO_0000219,,
5725,3239,In vitro cytotoxic activity against renal (A 498) cancer cell line.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621288,624.0,BAO_0000219,,
5726,1847,Cytotoxic activity against A 498 renal cancer cell lines.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL876496,624.0,BAO_0000219,,
5727,10553,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL621289,624.0,BAO_0000219,,
5728,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621290,,BAO_0000019,,
5729,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621291,,BAO_0000019,,
5730,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621292,,BAO_0000019,,
5731,16219,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,F,,,Staphylococcus aureus,1280.0,,,,,22226,U,0,Autocuration,1,,CHEMBL621293,,BAO_0000019,,
5732,4782,Inhibitory concentration required against A 549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621294,646.0,BAO_0000219,,
5733,11805,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621295,646.0,BAO_0000219,,
5734,11805,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884007,646.0,BAO_0000219,,
5735,2007,In vitro cytotoxicity against lung cancer A 549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621296,646.0,BAO_0000219,,
5736,4594,Compound was tested for its cytotoxicity against A 549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621297,646.0,BAO_0000219,,
5737,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839828,646.0,BAO_0000219,,
5738,6018,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620397,646.0,BAO_0000219,,
5739,3599,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620398,646.0,BAO_0000219,,
5740,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620399,646.0,BAO_0000219,,
5741,16132,In vitro inhibition of A549 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620400,646.0,BAO_0000219,,
5742,16132,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620401,646.0,BAO_0000219,,
5743,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620402,646.0,BAO_0000219,,
5744,2551,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620403,646.0,BAO_0000219,,
5745,11913,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,F,,,,,,,,,22226,U,0,Autocuration,1,,CHEMBL620404,,BAO_0000218,,
5746,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620405,,BAO_0000218,,
5747,12621,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620406,,BAO_0000218,,
5748,12621,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620407,,BAO_0000218,,
5749,12621,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620408,,BAO_0000218,,
5750,12621,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,F,In vivo,,,,,,,,104694,H,4,Autocuration,1,,CHEMBL620409,,BAO_0000218,,
5751,3600,Inhibition of A-498 human Renal cell proliferation,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL620410,624.0,BAO_0000219,,
5752,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620411,,BAO_0000019,,
5753,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620412,,BAO_0000019,,
5754,1796,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL876596,,BAO_0000019,,
5755,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL620413,622.0,BAO_0000219,,
5756,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620414,622.0,BAO_0000219,,
5757,16464,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL620415,622.0,BAO_0000219,,
5758,13617,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620416,646.0,BAO_0000219,,
5759,4584,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620417,646.0,BAO_0000219,,
5760,13799,Cytotoxic activity evaluated against A549 tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620418,646.0,BAO_0000219,,
5761,16726,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620419,646.0,BAO_0000219,,
5762,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620420,646.0,BAO_0000219,,
5763,16109,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620421,646.0,BAO_0000219,,
5764,15474,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620422,646.0,BAO_0000219,,
5765,6851,Cytotoxicity of compound against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620423,646.0,BAO_0000219,,
5766,17534,Cytotoxicity against human lung cell carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620424,646.0,BAO_0000219,,
5767,2621,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620425,646.0,BAO_0000219,,
5768,830,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620426,646.0,BAO_0000219,,
5769,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620427,646.0,BAO_0000219,,
5770,14255,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620428,646.0,BAO_0000219,,
5771,1590,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620429,646.0,BAO_0000219,,
5772,6146,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620430,646.0,BAO_0000219,,
5773,17427,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839887,646.0,BAO_0000219,,
5774,5280,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620431,646.0,BAO_0000219,,
5775,16786,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884010,646.0,BAO_0000219,,
5776,5895,In vitro cytotoxicity against A549 (human lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620538,646.0,BAO_0000219,,
5777,14297,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620539,646.0,BAO_0000219,,
5778,17824,In vivo antiproliferative activity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623373,646.0,BAO_0000218,,
5779,14368,Inhibition of non-small-cell lung adenocarcinoma (A549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623374,646.0,BAO_0000219,,
5780,14368,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623375,646.0,BAO_0000219,,
5781,14254,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623376,646.0,BAO_0000219,,
5782,15897,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623377,646.0,BAO_0000219,,
5783,13866,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623378,646.0,BAO_0000219,,
5784,13370,Inhibitory activity of compound against human A549 lung carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623379,646.0,BAO_0000219,,
5785,4862,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623380,646.0,BAO_0000219,,
5786,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623381,646.0,BAO_0000219,,
5787,4862,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623382,646.0,BAO_0000219,,
5788,15970,Inhibitory concentration against A549 (lung cancer) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623383,646.0,BAO_0000219,,
5789,17713,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623384,646.0,BAO_0000219,,
5790,4833,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623385,646.0,BAO_0000219,,
5791,13736,Activity against A549 cancer cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL623386,646.0,BAO_0000219,,
5792,4312,The compound was evaluated for cytotoxicity against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884105,646.0,BAO_0000219,,
5793,5421,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623387,646.0,BAO_0000219,,
5794,5421,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621568,646.0,BAO_0000219,,
5795,14717,Growth inhibitory activity was measured for human A549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621569,646.0,BAO_0000219,,
5796,4634,Inhibitory activity against A549 lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621570,646.0,BAO_0000219,,
5797,1149,Inhibitory activity against A549 cell line; inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621571,646.0,BAO_0000219,,
5798,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621572,646.0,BAO_0000219,,
5799,5421,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621573,646.0,BAO_0000219,,
5800,5421,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621574,646.0,BAO_0000219,,
5801,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621575,646.0,BAO_0000219,,
5802,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621576,646.0,BAO_0000219,,
5803,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621577,646.0,BAO_0000219,,
5804,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621578,646.0,BAO_0000219,,
5805,3320,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621579,646.0,BAO_0000219,,
5806,5726,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621580,646.0,BAO_0000219,,
5807,17800,Plasma clearance (in vivo) in mongrel dogs was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621581,,BAO_0000218,,
5808,5985,Plasma clearance was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621582,,BAO_0000218,,
5809,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621583,,BAO_0000218,,
5810,5530,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621584,,BAO_0000218,,
5811,4839,Tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621585,,BAO_0000218,1969.0,
5812,3639,The compound was tested for clearance in dog plasma.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621586,,BAO_0000218,,
5813,4838,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875835,,BAO_0000218,,
5814,4137,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621587,,BAO_0000218,,
5815,5017,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621588,,BAO_0000218,1969.0,
5816,17538,In vitro clearance in dog liver microsomes,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL621589,,BAO_0000218,2107.0,
5817,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621590,,BAO_0000218,,
5818,6161,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621591,,BAO_0000218,,
5819,1696,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621592,,BAO_0000218,,
5820,6762,Clearance rate in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621593,,BAO_0000218,,
5821,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621594,,BAO_0000218,1969.0,
5822,6305,Clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621595,,BAO_0000218,,
5823,4942,Plasma clearance in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621596,,BAO_0000218,,
5824,4219,Plasma clearance was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621597,,BAO_0000218,,
5825,17853,Lower clearance in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621598,,BAO_0000218,,
5826,4514,Plasma clearance in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621599,,BAO_0000218,,
5827,6448,Plasma clearance (Clp) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875836,,BAO_0000218,,
5828,6227,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621600,,BAO_0000218,,
5829,6227,Plasma clearance (pharmacokinetic parameter) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621601,,BAO_0000218,,
5830,6062,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618474,,BAO_0000218,,
5831,6821,Plasma clearance of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618475,,BAO_0000218,,
5832,4709,Plasma clearance after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624524,,BAO_0000218,,
5833,4521,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624525,,BAO_0000218,,
5834,5374,Plasma clearance in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624526,,BAO_0000218,,
5835,6057,Plasma clearance was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624527,,BAO_0000218,,
5836,4727,Plasma clearance at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624528,,BAO_0000218,,
5837,5145,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624529,,BAO_0000218,,
5838,17657,Plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624530,,BAO_0000218,,
5839,17657,Plasma clearance in dog; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624531,,BAO_0000218,,
5840,5145,Plasma clearance in rhesus monkey,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624532,,BAO_0000218,,
5841,6642,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624533,,BAO_0000218,,
5842,6641,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624534,,BAO_0000218,,
5843,6642,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624535,,BAO_0000218,,
5844,5472,Plasma clearance was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624536,,BAO_0000218,,
5845,5472,Plasma clearance was evaluated in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624537,,BAO_0000218,,
5846,5472,Plasma clearance was evaluated in rhesus,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624538,,BAO_0000218,,
5847,5472,Plasma clearance was evaluated in rhesus; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624539,,BAO_0000218,,
5848,4257,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624540,,BAO_0000218,,
5849,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624541,,BAO_0000218,,
5850,5546,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624542,,BAO_0000218,,
5851,6348,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624543,,BAO_0000218,,
5852,5474,Clearance value at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624544,,BAO_0000218,,
5853,6316,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624545,,BAO_0000218,1969.0,
5854,17594,Cmax after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624546,,BAO_0000218,,
5855,17594,Cmax after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875957,,BAO_0000218,,
5856,5802,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624547,,BAO_0000218,,
5857,6535,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624548,,BAO_0000218,,
5858,6535,Cmax in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624549,,BAO_0000218,,
5859,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624550,,BAO_0000218,1969.0,
5860,6505,Cmax on p.o. administration of 10 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621613,,BAO_0000218,,
5861,5668,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621614,,BAO_0000218,,
5862,5668,Cmax was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623431,,BAO_0000218,,
5863,5668,Cmax was determine after peroral administration at 5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623432,,BAO_0000218,,
5864,5600,Cmax after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623433,,BAO_0000218,,
5865,17764,Cmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623434,,BAO_0000218,,
5866,6123,Cmax in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623435,,BAO_0000218,,
5867,6123,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623436,,BAO_0000218,,
5868,6757,Cmax upon oral administration in male Beagle dog at 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875958,,BAO_0000218,,
5869,16907,Cmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623437,,BAO_0000218,,
5870,7767,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623438,,BAO_0000218,178.0,
5871,7767,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623439,,BAO_0000218,178.0,
5872,7767,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623440,,BAO_0000218,10000001.0,
5873,7767,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623441,,BAO_0000218,10000001.0,
5874,7767,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL623442,,BAO_0000218,10000001.0,
5875,7767,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623469,,BAO_0000218,,
5876,7767,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623470,,BAO_0000218,,
5877,7767,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623471,,BAO_0000218,,
5878,7767,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623472,,BAO_0000218,948.0,
5879,7767,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623473,,BAO_0000218,948.0,
5880,7767,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL623474,,BAO_0000218,948.0,
5881,7767,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623475,,BAO_0000218,2113.0,
5882,7767,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623476,,BAO_0000218,2113.0,
5883,7767,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623477,,BAO_0000218,2113.0,
5884,7767,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621896,,BAO_0000218,160.0,
5885,7767,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621897,,BAO_0000218,160.0,
5886,7767,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL621898,,BAO_0000218,160.0,
5887,7767,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621899,,BAO_0000218,2107.0,
5888,7767,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621900,,BAO_0000218,2107.0,
5889,7767,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621901,,BAO_0000218,2107.0,
5890,7767,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621902,,BAO_0000218,2048.0,
5891,7767,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL621903,,BAO_0000218,2048.0,
5892,7767,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622587,,BAO_0000218,2048.0,
5893,7767,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620285,,BAO_0000218,2385.0,
5894,7767,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875285,,BAO_0000218,2385.0,
5895,7767,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL620286,,BAO_0000218,2385.0,
5896,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620287,,BAO_0000218,,
5897,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620288,,BAO_0000218,,
5898,7767,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620289,,BAO_0000218,,
5899,7767,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620290,,BAO_0000218,160.0,
5900,7767,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620291,,BAO_0000218,160.0,
5901,7767,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL620292,,BAO_0000218,160.0,
5902,7767,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620293,,BAO_0000218,2106.0,
5903,7767,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL620294,,BAO_0000218,2106.0,
5904,7767,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618614,,BAO_0000218,2106.0,
5905,7767,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618615,,BAO_0000218,945.0,
5906,7767,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL618616,,BAO_0000218,945.0,
5907,2036,Cytotoxicity against A-172 human tumor cell lines,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL618617,622.0,BAO_0000219,,
5908,2357,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL618618,622.0,BAO_0000219,,
5909,1457,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Intermediate,1,,CHEMBL618619,623.0,BAO_0000219,,
5910,4379,Tested for antiproliferative activity against A-2780 tumoral cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618620,478.0,BAO_0000219,,
5911,1093,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618621,455.0,BAO_0000219,,
5912,12152,Tested in vitro against A-375 cell line human melanoma,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL618622,455.0,BAO_0000219,,
5913,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618623,797.0,BAO_0000219,,
5914,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618624,797.0,BAO_0000219,,
5915,16582,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618625,797.0,BAO_0000219,,
5916,16464,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618626,797.0,BAO_0000219,,
5917,10413,Antitumor activity on A-427 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618627,797.0,BAO_0000219,,
5918,6418,Cytotoxic activity against human A-427 lung tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618628,797.0,BAO_0000219,,
5919,17134,In vitro antitumor effects against human A-427 cell lines.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618629,797.0,BAO_0000219,,
5920,16132,In vitro inhibition of A-427 (human lung cancer) cell growth.,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Expert,1,,CHEMBL618630,797.0,BAO_0000219,,
5921,16132,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618631,797.0,BAO_0000219,,
5922,16780,Cytotoxic activity of compound against A-427 lung human tumor cell line,F,,,Homo sapiens,9606.0,,,A-427,,80019,N,1,Intermediate,1,,CHEMBL618632,797.0,BAO_0000219,,
5923,4085,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,F,,,Homo sapiens,9606.0,,,A-431,,80852,N,1,Expert,1,,CHEMBL618633,500.0,BAO_0000219,,
5924,1276,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619315,624.0,BAO_0000219,,
5925,3498,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Expert,1,,CHEMBL619316,624.0,BAO_0000219,,
5926,1169,Cytotoxicity against human kidney carcinoma A-498cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619317,624.0,BAO_0000219,,
5927,4450,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619318,624.0,BAO_0000219,,
5928,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619319,624.0,BAO_0000219,,
5929,4461,Antitumor cytotoxic activity against A-498 cell line was determined,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619739,624.0,BAO_0000219,,
5930,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619740,624.0,BAO_0000219,,
5931,3311,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL883158,624.0,BAO_0000219,,
5932,1457,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL884012,624.0,BAO_0000219,,
5933,3664,In vitro inhibitory activity against A-498 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619741,624.0,BAO_0000219,,
5934,15895,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",F,,,Homo sapiens,9606.0,,,A498,,80021,N,1,Intermediate,1,,CHEMBL619742,624.0,BAO_0000219,,
5935,11843,Inhibition of growth lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876610,646.0,BAO_0000219,,
5936,11843,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619743,646.0,BAO_0000219,,
5937,17705,In vitro antiproliferative activity against human A-549 NSCL cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619744,646.0,BAO_0000219,,
5938,17705,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619745,646.0,BAO_0000219,,
5939,4369,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619746,646.0,BAO_0000219,,
5940,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619747,646.0,BAO_0000219,,
5941,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619748,646.0,BAO_0000219,,
5942,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619749,646.0,BAO_0000219,,
5943,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619750,646.0,BAO_0000219,,
5944,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624014,646.0,BAO_0000219,,
5945,4369,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624015,646.0,BAO_0000219,,
5946,4787,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL885344,646.0,BAO_0000219,,
5947,4787,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623224,646.0,BAO_0000219,,
5948,6513,Cytotoxic activity against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL623225,646.0,BAO_0000219,,
5949,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622698,646.0,BAO_0000219,,
5950,6690,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622699,646.0,BAO_0000219,,
5951,12263,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622700,646.0,BAO_0000219,,
5952,1054,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622701,646.0,BAO_0000219,,
5953,1359,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622702,646.0,BAO_0000219,,
5954,3547,Cytotoxic activity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622703,646.0,BAO_0000219,,
5955,5771,Cytotoxic activity towards A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622704,646.0,BAO_0000219,,
5956,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622705,646.0,BAO_0000219,,
5957,14425,"In vitro percent inhibition of A549, lung carcinoma",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622706,646.0,BAO_0000219,,
5958,14425,"In vitro percent inhibition of A549, lung carcinoma.",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622707,646.0,BAO_0000219,,
5959,14425,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622708,646.0,BAO_0000219,,
5960,5280,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622709,646.0,BAO_0000219,,
5961,15176,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622710,646.0,BAO_0000219,,
5962,15300,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622711,646.0,BAO_0000219,,
5963,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622712,646.0,BAO_0000218,,
5964,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622713,646.0,BAO_0000218,,
5965,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622714,646.0,BAO_0000218,,
5966,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622715,646.0,BAO_0000218,,
5967,17824,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622716,646.0,BAO_0000218,,
5968,17824,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622717,646.0,BAO_0000219,,
5969,17528,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622718,646.0,BAO_0000218,,
5970,6870,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL622719,646.0,BAO_0000219,,
5971,6870,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622720,646.0,BAO_0000219,,
5972,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622721,646.0,BAO_0000219,,
5973,6870,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622722,646.0,BAO_0000219,,
5974,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876030,646.0,BAO_0000219,,
5975,6170,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620206,646.0,BAO_0000219,,
5976,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620207,646.0,BAO_0000219,,
5977,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620208,646.0,BAO_0000219,,
5978,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620209,646.0,BAO_0000219,,
5979,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620210,646.0,BAO_0000219,,
5980,6583,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621639,646.0,BAO_0000219,,
5981,17321,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621640,646.0,BAO_0000219,,
5982,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621641,646.0,BAO_0000219,,
5983,12888,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL621642,646.0,BAO_0000219,,
5984,4312,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621643,646.0,BAO_0000219,,
5985,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621644,646.0,BAO_0000219,,
5986,4312,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621645,646.0,BAO_0000219,,
5987,17737,In vitro antiproliferative activity against A549 cell line,F,,,Mus musculus,10090.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621646,646.0,BAO_0000219,,
5988,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621647,646.0,BAO_0000219,,
5989,6630,Synergism with tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621648,646.0,BAO_0000219,,
5990,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621649,646.0,BAO_0000219,,
5991,6630,Antagonism of indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621650,646.0,BAO_0000219,,
5992,6630,Antagonism of sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621651,646.0,BAO_0000219,,
5993,6630,Antagonism of tolmetin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621652,646.0,BAO_0000219,,
5994,6630,Synergism with indomethacin in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621653,646.0,BAO_0000219,,
5995,6630,Synergism with sulindac in A549 cells,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621654,646.0,BAO_0000219,,
5996,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL621655,646.0,BAO_0000219,,
5997,16907,Cmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621656,,BAO_0000218,,
5998,5944,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621657,,BAO_0000218,,
5999,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621658,,BAO_0000218,,
6000,5944,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621659,,BAO_0000218,,
6001,5944,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621660,,BAO_0000218,,
6002,2959,Cmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621661,,BAO_0000218,,
6003,6241,Cmax value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621662,,BAO_0000218,,
6004,6241,Cmax value in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621663,,BAO_0000218,,
6005,2652,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621664,,BAO_0000218,,
6006,1806,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621665,,BAO_0000218,1969.0,
6007,1806,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621666,,BAO_0000218,1969.0,
6008,1021,Concentration maxima after oral dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621667,,BAO_0000218,,
6009,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876738,,BAO_0000218,,
6010,1021,Concentration maxima after oral dosing in dogs; not available,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621668,,BAO_0000218,,
6011,5444,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621669,,BAO_0000218,,
6012,5444,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621670,,BAO_0000218,,
6013,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621671,,BAO_0000218,,
6014,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622360,,BAO_0000218,,
6015,5444,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622361,,BAO_0000218,,
6016,5130,Cmax in dog plasma after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622362,,BAO_0000218,1969.0,
6017,3249,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622363,,BAO_0000218,1969.0,
6018,5473,Maximal plasma concentration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622364,,BAO_0000218,1969.0,
6019,5474,Maximal plasma concentration at a dose of 1 mg/kg (oral),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622365,,BAO_0000218,1969.0,
6020,4657,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622533,,BAO_0000218,1969.0,
6021,3031,Maximum concentration of compound in dog was evaluated.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622534,,BAO_0000218,,
6022,4527,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622535,,BAO_0000218,,
6023,4186,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876739,,BAO_0000218,,
6024,5007,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622536,,BAO_0000218,,
6025,3132,Maximum concentration obtained in dog plasma was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622537,,BAO_0000218,1969.0,
6026,5006,Maximum concentration was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622538,,BAO_0000218,,
6027,4727,Maximum concentration at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627867,,BAO_0000218,,
6028,1916,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627868,,BAO_0000218,,
6029,1918,Maximum concentration was evaluated in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627869,,BAO_0000218,1969.0,
6030,3045,Maximum concentration was evaluated after 75 min after administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627870,,BAO_0000218,,
6031,9579,Maximum plasma concentration determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627871,,BAO_0000218,1969.0,
6032,9579,Maximum plasma concentration determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627872,,BAO_0000218,1969.0,
6033,933,Maximum plasma concentration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627873,,BAO_0000218,1969.0,
6034,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627874,,BAO_0000218,1969.0,
6035,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627875,,BAO_0000218,1969.0,
6036,17839,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627876,,BAO_0000218,1969.0,
6037,17839,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627877,,BAO_0000218,1969.0,
6038,6348,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627878,,BAO_0000218,1969.0,
6039,16367,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627879,,BAO_0000218,1969.0,
6040,1337,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL875355,,BAO_0000218,1969.0,
6041,1337,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627880,,BAO_0000218,1969.0,
6042,5199,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627881,,BAO_0000218,1969.0,
6043,17650,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627882,,BAO_0000218,1969.0,
6044,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627883,,BAO_0000218,1969.0,
6045,5356,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628526,,BAO_0000218,1969.0,
6046,5356,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628527,,BAO_0000218,1969.0,
6047,6227,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628528,,BAO_0000218,1969.0,
6048,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628529,,BAO_0000218,1969.0,
6049,6227,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628530,,BAO_0000218,1969.0,
6050,6227,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625243,,BAO_0000218,1969.0,
6051,3598,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL625244,,BAO_0000218,1969.0,
6052,4368,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625245,,BAO_0000218,,
6053,6265,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625246,,BAO_0000218,,
6054,7767,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL625247,,BAO_0000218,945.0,
6055,7767,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625248,,BAO_0000218,1088.0,
6056,7767,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625249,,BAO_0000218,1088.0,
6057,7767,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,A,In vivo,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625250,,BAO_0000218,1088.0,
6058,17811,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625251,,BAO_0000218,,
6059,17811,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875356,,BAO_0000218,,
6060,17827,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625252,,BAO_0000218,,
6061,17827,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625253,,BAO_0000218,178.0,
6062,17827,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625254,,BAO_0000218,,
6063,17827,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625255,,BAO_0000218,,
6064,17827,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625256,,BAO_0000218,,
6065,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625257,,BAO_0000218,178.0,
6066,17827,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625258,,BAO_0000218,178.0,
6067,17827,Compound was evaluated for washout rate in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625259,,BAO_0000218,,
6068,17827,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625260,,BAO_0000218,,
6069,17827,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625261,,BAO_0000218,,
6070,17827,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625262,,BAO_0000218,,
6071,17827,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622639,,BAO_0000218,,
6072,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622640,,BAO_0000218,,
6073,17257,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622812,,BAO_0000218,,
6074,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622813,,BAO_0000218,,
6075,17257,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622814,,BAO_0000218,,
6076,17827,Time at maximum activity in mice (Radiolabeled compound),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622815,,BAO_0000218,,
6077,3760,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625342,,BAO_0000218,,
6078,3760,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625343,,BAO_0000218,,
6079,17409,Binding towards mouse plasma protein at 10 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877591,,BAO_0000218,,
6080,17409,Binding towards mouse plasma protein at 100 uM,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625344,,BAO_0000218,,
6081,2675,Bioavailability was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625345,,BAO_0000218,,
6082,2675,Bioavailability was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625346,,BAO_0000218,,
6083,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625347,,BAO_0000218,,
6084,3132,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625348,,BAO_0000218,,
6085,16597,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625349,,BAO_0000218,,
6086,2862,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625350,,BAO_0000218,,
6087,17764,Oral bioavailability after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL882952,,BAO_0000218,,
6088,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625351,,BAO_0000218,955.0,
6089,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625352,,BAO_0000218,955.0,
6090,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL877592,,BAO_0000218,955.0,
6091,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625353,,BAO_0000218,955.0,
6092,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625354,,BAO_0000218,955.0,
6093,846,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626019,,BAO_0000218,955.0,
6094,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626020,,BAO_0000218,948.0,
6095,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626021,,BAO_0000218,948.0,
6096,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626022,,BAO_0000218,948.0,
6097,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL626192,,BAO_0000218,948.0,
6098,1276,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626193,646.0,BAO_0000219,,
6099,3498,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL626194,646.0,BAO_0000219,,
6100,1169,Cytotoxicity against human lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626195,646.0,BAO_0000219,,
6101,4450,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626196,646.0,BAO_0000219,,
6102,358,In vitro cytotoxicity against human lung carcinoma cell line A-549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626197,646.0,BAO_0000219,,
6103,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626198,646.0,BAO_0000219,,
6104,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626199,646.0,BAO_0000219,,
6105,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626200,646.0,BAO_0000219,,
6106,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626201,646.0,BAO_0000219,,
6107,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626202,646.0,BAO_0000219,,
6108,358,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626203,646.0,BAO_0000219,,
6109,15167,In vitro cytotoxicity against A-549 human lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL626204,646.0,BAO_0000219,,
6110,4139,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624701,646.0,BAO_0000219,,
6111,833,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624702,646.0,BAO_0000219,,
6112,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624703,646.0,BAO_0000219,,
6113,12373,Tested in vitro for cytotoxicity against A-549 lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624704,646.0,BAO_0000219,,
6114,637,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624705,646.0,BAO_0000219,,
6115,14867,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624706,646.0,BAO_0000219,,
6116,4461,Antitumor cytotoxic activity against A-549 cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624707,646.0,BAO_0000219,,
6117,5406,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624708,646.0,BAO_0000219,,
6118,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624709,646.0,BAO_0000219,,
6119,1386,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL884107,646.0,BAO_0000219,,
6120,3265,Antitumoral activity was assayed against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624710,646.0,BAO_0000219,,
6121,2359,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624711,646.0,BAO_0000219,,
6122,4457,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624712,646.0,BAO_0000219,,
6123,12454,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624713,646.0,BAO_0000219,,
6124,1481,Compound was tested for inhibition of cell growth of A-549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624714,646.0,BAO_0000219,,
6125,1750,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624715,646.0,BAO_0000219,,
6126,5065,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624716,646.0,BAO_0000219,,
6127,808,In vitro cytotoxicity against A549-human lung carcinoma cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619505,646.0,BAO_0000219,,
6128,16364,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619506,646.0,BAO_0000219,,
6129,1847,Cytotoxic activity against A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619507,646.0,BAO_0000219,,
6130,1747,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619508,646.0,BAO_0000219,,
6131,1003,Cytotoxicity against human A549 non small cell lung cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619509,646.0,BAO_0000219,,
6132,15313,Inhibition of cell growth in (A-549) lung cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619510,646.0,BAO_0000219,,
6133,3122,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619511,646.0,BAO_0000219,,
6134,16049,In vitro antitumor activity against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619512,646.0,BAO_0000219,,
6135,17134,In vitro antitumor effects against human A-549 cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619513,646.0,BAO_0000219,,
6136,6406,In vitro cytotoxic activity of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619514,646.0,BAO_0000219,,
6137,627,In vitro cytotoxicity against human lung carcinoma A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619515,646.0,BAO_0000219,,
6138,12307,In vitro cytotoxicity against human non-small cell lung carcinoma A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619516,646.0,BAO_0000219,,
6139,17861,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884005,646.0,BAO_0000219,,
6140,6682,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619517,646.0,BAO_0000219,,
6141,6663,Inhibitory concentration of compound against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619518,646.0,BAO_0000219,,
6142,2454,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619519,646.0,BAO_0000219,,
6143,14709,cytotoxic activity against leukemia (A-549) cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876489,646.0,BAO_0000219,,
6144,15718,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619520,646.0,BAO_0000219,,
6145,15718,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619521,646.0,BAO_0000219,,
6146,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619522,646.0,BAO_0000219,,
6147,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619523,646.0,BAO_0000219,,
6148,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619524,646.0,BAO_0000219,,
6149,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619525,646.0,BAO_0000219,,
6150,6630,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,F,,,,,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619526,646.0,BAO_0000219,,
6151,16726,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619527,646.0,BAO_0000219,,
6152,17846,Cytotoxicity against A549 cells; No cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619528,646.0,BAO_0000219,,
6153,3415,Cytotoxicity against human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619529,646.0,BAO_0000219,,
6154,3415,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619530,646.0,BAO_0000219,,
6155,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876490,646.0,BAO_0000219,,
6156,17206,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619531,646.0,BAO_0000219,,
6157,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619532,646.0,BAO_0000219,,
6158,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619533,646.0,BAO_0000219,,
6159,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619534,646.0,BAO_0000219,,
6160,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620164,646.0,BAO_0000219,,
6161,17206,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620165,646.0,BAO_0000219,,
6162,16295,Inhibition of A549 human lung tumor cell proliferation,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620166,646.0,BAO_0000219,,
6163,16825,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620167,646.0,BAO_0000219,,
6164,3439,In vitro cytotoxicity against human tumor cell line A549,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL620168,646.0,BAO_0000219,,
6165,10870,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620338,646.0,BAO_0000219,,
6166,4845,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620339,646.0,BAO_0000219,,
6167,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620340,646.0,BAO_0000219,,
6168,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620341,646.0,BAO_0000219,,
6169,5822,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876491,646.0,BAO_0000219,,
6170,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620342,646.0,BAO_0000219,,
6171,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620343,646.0,BAO_0000219,,
6172,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620344,646.0,BAO_0000219,,
6173,5609,In vitro anticancer activity against human lung (A549) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620345,646.0,BAO_0000219,,
6174,4644,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620346,646.0,BAO_0000219,,
6175,4644,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620347,646.0,BAO_0000219,,
6176,4644,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620348,646.0,BAO_0000219,,
6177,4644,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620349,646.0,BAO_0000219,,
6178,5822,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618667,646.0,BAO_0000219,,
6179,3415,Percentage inhibition of human lung carcinoma (A549) cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL618668,646.0,BAO_0000219,,
6180,16726,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876031,646.0,BAO_0000219,,
6181,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618759,646.0,BAO_0000219,,
6182,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL618760,646.0,BAO_0000219,,
6183,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619000,646.0,BAO_0000219,,
6184,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619001,646.0,BAO_0000219,,
6185,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619002,646.0,BAO_0000219,,
6186,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619003,646.0,BAO_0000219,,
6187,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619597,646.0,BAO_0000219,,
6188,17206,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619598,646.0,BAO_0000219,,
6189,17206,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619599,646.0,BAO_0000219,,
6190,17206,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619600,646.0,BAO_0000219,,
6191,16726,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619601,646.0,BAO_0000219,,
6192,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619602,646.0,BAO_0000219,,
6193,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619603,646.0,BAO_0000219,,
6194,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619604,646.0,BAO_0000219,,
6195,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619605,646.0,BAO_0000219,,
6196,6084,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619606,,BAO_0000218,,
6197,6084,Pharmacokinetic activity (Cmax) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876032,,BAO_0000218,,
6198,4809,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619607,,BAO_0000218,,
6199,5983,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619608,,BAO_0000218,,
6200,6251,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619609,,BAO_0000218,,
6201,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619610,,BAO_0000218,1969.0,
6202,4273,Tested for the peak blood level in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619611,,BAO_0000218,178.0,
6203,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619612,,BAO_0000218,,
6204,5313,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619613,,BAO_0000218,,
6205,6221,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619614,,BAO_0000218,178.0,
6206,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619615,,BAO_0000218,,
6207,167,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619616,,BAO_0000218,,
6208,6241,Final plasma concentration in dogs after oral administration at 1 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619617,,BAO_0000218,1969.0,
6209,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619618,,BAO_0000218,,
6210,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876033,,BAO_0000218,,
6211,344,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619619,,BAO_0000218,,
6212,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619620,,BAO_0000218,,
6213,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619621,,BAO_0000218,1088.0,
6214,2189,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL619622,,BAO_0000218,1088.0,
6215,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL618874,,BAO_0000218,1088.0,
6216,4257,Absolute bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618875,,BAO_0000218,,
6217,6221,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618876,,BAO_0000218,,
6218,6215,Bioavailability after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618877,,BAO_0000218,,
6219,17267,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618878,,BAO_0000218,,
6220,6621,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618879,,BAO_0000218,,
6221,3854,Bioavailability after intravenous administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618880,,BAO_0000218,,
6222,3854,Bioavailability after peroral administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618881,,BAO_0000218,,
6223,5007,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618882,,BAO_0000218,,
6224,4333,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624226,,BAO_0000218,,
6225,4333,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624227,,BAO_0000218,1969.0,
6226,5006,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624228,,BAO_0000218,,
6227,5199,Bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624229,,BAO_0000218,,
6228,4368,Bioavailability by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624230,,BAO_0000218,,
6229,3771,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624231,,BAO_0000218,,
6230,4953,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624232,,BAO_0000218,,
6231,5064,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625127,,BAO_0000218,,
6232,17657,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625128,,BAO_0000218,,
6233,17796,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621675,,BAO_0000218,,
6234,17853,Bioavailability in dog (p.o.) at 2.0 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621676,,BAO_0000218,,
6235,4521,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621677,,BAO_0000218,,
6236,4521,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621678,,BAO_0000218,,
6237,5006,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621679,,BAO_0000218,,
6238,16365,Bioavailability was evaluated after oral administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621680,,BAO_0000218,,
6239,1916,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621681,,BAO_0000218,,
6240,1918,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876740,,BAO_0000218,,
6241,4239,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621682,,BAO_0000218,,
6242,6505,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621683,,BAO_0000218,,
6243,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621684,,BAO_0000218,,
6244,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621685,,BAO_0000218,,
6245,4809,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621686,,BAO_0000218,,
6246,6348,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621687,,BAO_0000218,,
6247,6005,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621688,,BAO_0000218,,
6248,17804,Bioavailability of compound in dog was determined after peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621689,,BAO_0000218,,
6249,3184,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621690,,BAO_0000218,,
6250,1806,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621691,,BAO_0000218,,
6251,1806,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875941,,BAO_0000218,,
6252,1806,Compound was evaluated for oral bioavailability in dogs; 37-38 %,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621692,,BAO_0000218,,
6253,4839,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621693,,BAO_0000218,,
6254,5017,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621694,,BAO_0000218,,
6255,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621695,,BAO_0000218,948.0,
6256,846,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621696,,BAO_0000218,948.0,
6257,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621697,,BAO_0000218,2113.0,
6258,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621698,,BAO_0000218,2113.0,
6259,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623420,,BAO_0000218,2113.0,
6260,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623421,,BAO_0000218,2113.0,
6261,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623422,,BAO_0000218,2113.0,
6262,846,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623423,,BAO_0000218,2113.0,
6263,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623424,,BAO_0000218,2107.0,
6264,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623425,,BAO_0000218,2107.0,
6265,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623426,,BAO_0000218,2107.0,
6266,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623427,,BAO_0000218,2107.0,
6267,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623428,,BAO_0000218,2107.0,
6268,846,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL875947,,BAO_0000218,2107.0,
6269,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623429,,BAO_0000218,2048.0,
6270,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623430,,BAO_0000218,2048.0,
6271,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622588,,BAO_0000218,2048.0,
6272,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622589,,BAO_0000218,2048.0,
6273,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622751,,BAO_0000218,2048.0,
6274,846,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL622752,,BAO_0000218,2048.0,
6275,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622753,42.0,BAO_0000218,,
6276,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622647,42.0,BAO_0000218,,
6277,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875163,42.0,BAO_0000218,,
6278,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622648,42.0,BAO_0000218,,
6279,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622649,42.0,BAO_0000218,,
6280,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622650,42.0,BAO_0000218,955.0,
6281,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622651,42.0,BAO_0000218,955.0,
6282,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622652,42.0,BAO_0000218,955.0,
6283,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622653,42.0,BAO_0000218,955.0,
6284,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Brain,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622654,42.0,BAO_0000218,955.0,
6285,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622655,42.0,BAO_0000218,948.0,
6286,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622656,42.0,BAO_0000218,948.0,
6287,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622657,42.0,BAO_0000218,948.0,
6288,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622658,42.0,BAO_0000218,948.0,
6289,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL622659,42.0,BAO_0000218,948.0,
6290,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624630,42.0,BAO_0000218,2113.0,
6291,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624631,42.0,BAO_0000218,2113.0,
6292,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624632,42.0,BAO_0000218,2113.0,
6293,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624633,646.0,BAO_0000219,,
6294,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624634,646.0,BAO_0000219,,
6295,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624635,646.0,BAO_0000219,,
6296,17130,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624636,646.0,BAO_0000219,,
6297,3263,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL857055,646.0,BAO_0000219,,
6298,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624637,646.0,BAO_0000219,,
6299,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624638,646.0,BAO_0000219,,
6300,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL874366,646.0,BAO_0000219,,
6301,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624639,646.0,BAO_0000219,,
6302,6663,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL624640,646.0,BAO_0000219,,
6303,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624641,646.0,BAO_0000219,,
6304,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624642,646.0,BAO_0000219,,
6305,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624643,646.0,BAO_0000219,,
6306,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624644,646.0,BAO_0000219,,
6307,6663,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL624645,646.0,BAO_0000219,,
6308,3983,The compound was evaluated for its cytotoxic potency against A-549 cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619445,646.0,BAO_0000219,,
6309,11141,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL839886,646.0,BAO_0000219,,
6310,5076,Cytotoxic activity of compound against A-549 tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619446,646.0,BAO_0000219,,
6311,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619447,646.0,BAO_0000219,,
6312,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619448,646.0,BAO_0000219,,
6313,3311,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619449,646.0,BAO_0000219,,
6314,5076,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619450,646.0,BAO_0000219,,
6315,4150,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619451,646.0,BAO_0000219,,
6316,2150,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619452,646.0,BAO_0000219,,
6317,4644,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619453,646.0,BAO_0000219,,
6318,263,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL874367,646.0,BAO_0000219,,
6319,11333,Cytotoxic concentration against A-549 tumor cells.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619454,646.0,BAO_0000219,,
6320,11333,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619455,646.0,BAO_0000219,,
6321,15895,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619456,646.0,BAO_0000219,,
6322,16677,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,F,,,Acinetobacter baumannii,470.0,,,,,50191,N,1,Expert,1,,CHEMBL619457,,BAO_0000218,,
6323,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL619458,,BAO_0000218,,
6324,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619459,,BAO_0000218,,
6325,16717,In vitro antifungal activity against Aspergillus flavus CM74,F,,,Aspergillus flavus,5059.0,,,,,50274,N,1,Expert,1,,CHEMBL619460,,BAO_0000218,,
6326,5513,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619461,,BAO_0000218,,
6327,15962,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL619462,,BAO_0000218,,
6328,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620388,,BAO_0000218,,
6329,15962,Antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620389,,BAO_0000218,,
6330,15962,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Intermediate,1,,CHEMBL620390,,BAO_0000218,,
6331,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL620391,,BAO_0000218,,
6332,16717,In vitro antifungal activity against Aspergillus fumigatus 48238E,F,,,Aspergillus fumigatus,746128.0,,,,,50416,N,1,Expert,1,,CHEMBL621073,,BAO_0000218,,
6333,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL621074,,BAO_0000218,,
6334,8117,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL621075,,BAO_0000218,,
6335,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619554,,BAO_0000218,,
6336,15472,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL619555,,BAO_0000218,,
6337,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619556,,BAO_0000218,,
6338,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619557,,BAO_0000218,,
6339,16443,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,F,,,Aggregatibacter actinomycetemcomitans,714.0,,,,,50169,N,1,Intermediate,1,,CHEMBL619558,,BAO_0000218,,
6340,17206,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619559,646.0,BAO_0000219,,
6341,17206,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619560,646.0,BAO_0000219,,
6342,16381,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619561,646.0,BAO_0000219,,
6343,16381,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619562,646.0,BAO_0000219,,
6344,16381,% inhibition against A549 cells (lung cancer) at 4 ug/mL,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619563,646.0,BAO_0000219,,
6345,16381,GI values against A549 cells (lung cancer),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL857457,646.0,BAO_0000219,,
6346,17206,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619564,646.0,BAO_0000219,,
6347,16325,Inhibitory activity against A549 human adenocarcinoma,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619565,646.0,BAO_0000219,,
6348,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619566,646.0,BAO_0000218,,
6349,10708,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619567,646.0,BAO_0000218,,
6350,17376,Inhibitory activity against A549 lung adenocarcinoma cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619568,646.0,BAO_0000219,,
6351,17376,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619569,646.0,BAO_0000219,,
6352,17488,Cytotoxicity against human A549 lung cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619570,646.0,BAO_0000219,,
6353,17404,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619571,646.0,BAO_0000218,,
6354,10958,Growth inhibition of A549 (human lung carcinoma) cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619572,646.0,BAO_0000219,,
6355,17099,Effective dose required for inhibitory activity against A549 human tumor cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619573,646.0,BAO_0000219,,
6356,17099,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619574,646.0,BAO_0000219,,
6357,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619575,646.0,BAO_0000219,,
6358,4096,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL619576,646.0,BAO_0000219,,
6359,4096,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619577,646.0,BAO_0000219,,
6360,2525,In vitro inhibitory activity against A549 tumor cell culture,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619578,646.0,BAO_0000219,,
6361,2525,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884009,646.0,BAO_0000219,,
6362,5302,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619579,646.0,BAO_0000219,,
6363,16325,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619580,646.0,BAO_0000219,,
6364,16939,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619581,646.0,BAO_0000219,,
6365,17229,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619582,646.0,BAO_0000219,,
6366,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619583,646.0,BAO_0000219,,
6367,17380,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL876502,646.0,BAO_0000219,,
6368,1903,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619584,646.0,BAO_0000219,,
6369,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619585,646.0,BAO_0000219,,
6370,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619586,646.0,BAO_0000219,,
6371,3838,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619587,646.0,BAO_0000219,,
6372,1522,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619588,646.0,BAO_0000219,,
6373,12400,Tested in vitro for cytotoxicity in A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619589,646.0,BAO_0000219,,
6374,14696,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619590,646.0,BAO_0000219,,
6375,14769,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619591,646.0,BAO_0000219,,
6376,14696,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619592,646.0,BAO_0000219,,
6377,1888,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL619593,646.0,BAO_0000219,,
6378,12016,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620217,646.0,BAO_0000219,,
6379,6058,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620218,646.0,BAO_0000219,,
6380,17708,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620219,646.0,BAO_0000219,,
6381,12301,Antitumor activity against A549/ATCC cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL620220,646.0,BAO_0000219,,
6382,11970,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625141,646.0,BAO_0000219,,
6383,11818,In vitro cytotoxicity against A549/ATCC cell line.,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Expert,1,,CHEMBL625142,646.0,BAO_0000219,,
6384,12400,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625143,646.0,BAO_0000219,,
6385,3381,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL625144,646.0,BAO_0000219,,
6386,17376,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL622474,646.0,BAO_0000219,,
6387,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A549,,80682,N,1,Intermediate,1,,CHEMBL884104,646.0,BAO_0000219,,
6388,2964,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL622475,,BAO_0000219,,
6389,5005,Compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Intermediate,1,,CHEMBL622476,,BAO_0000218,,
6390,6229,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875831,,BAO_0000218,,
6391,6229,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622477,,BAO_0000218,,
6392,5374,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622478,,BAO_0000218,,
6393,5374,Compound was tested for the oral bioavailability in dog; No availability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623172,,BAO_0000218,,
6394,6265,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623173,,BAO_0000218,,
6395,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623174,,BAO_0000218,,
6396,5654,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623175,,BAO_0000218,,
6397,16456,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623340,,BAO_0000218,,
6398,5302,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623341,,BAO_0000218,,
6399,3624,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623342,,BAO_0000218,,
6400,16452,Oral bioavailability of active FTIs in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623343,,BAO_0000218,,
6401,5802,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623344,,BAO_0000218,,
6402,3598,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623345,,BAO_0000218,,
6403,17839,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875832,,BAO_0000218,,
6404,6762,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623346,,BAO_0000218,,
6405,6821,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623347,,BAO_0000218,,
6406,6821,Oral bioavailability of compound was determined in dog; Not tested,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623348,,BAO_0000218,,
6407,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623349,,BAO_0000218,,
6408,6227,Oral bioavailability (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623350,,BAO_0000218,,
6409,761,Oral bioavailability,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623351,,BAO_0000218,,
6410,761,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623352,,BAO_0000218,,
6411,761,Oral bioavailability administered in solution in rats,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623353,,BAO_0000218,,
6412,16907,Oral bioavailability after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875833,,BAO_0000218,,
6413,5474,Oral bioavailability at a dose of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623354,,BAO_0000218,,
6414,6535,Oral bioavailability in dog (dose 1 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623355,,BAO_0000218,,
6415,6535,Oral bioavailability in Dog; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623356,,BAO_0000218,,
6416,3352,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623357,,BAO_0000218,,
6417,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623358,,BAO_0000218,,
6418,5988,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623359,,BAO_0000218,,
6419,4942,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623360,,BAO_0000218,,
6420,4942,Oral bioavailability in dogs; No data,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623361,,BAO_0000218,,
6421,14541,Oral bioavailability measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623362,,BAO_0000218,,
6422,4449,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623363,,BAO_0000218,,
6423,6057,Oral bioavailability was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623364,,BAO_0000218,,
6424,5600,Oral bioavailability after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875834,,BAO_0000218,,
6425,5542,Oral bioavailability in dog (i.v. dosing),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623365,,BAO_0000218,,
6426,5542,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623366,,BAO_0000218,,
6427,5546,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623367,,BAO_0000218,,
6428,4514,Oral bioavailability in Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623368,,BAO_0000218,,
6429,3624,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623369,,BAO_0000218,,
6430,3854,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623370,,BAO_0000218,,
6431,5836,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623371,,BAO_0000218,,
6432,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623372,,BAO_0000218,,
6433,6168,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621351,,BAO_0000218,,
6434,6227,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621352,,BAO_0000218,,
6435,6251,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621353,,BAO_0000218,,
6436,6448,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621354,,BAO_0000218,,
6437,6647,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621355,,BAO_0000218,,
6438,5940,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621356,,BAO_0000218,,
6439,933,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621357,,BAO_0000218,,
6440,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621358,,BAO_0000218,,
6441,6642,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621359,,BAO_0000218,,
6442,6641,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621360,,BAO_0000218,,
6443,6642,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621361,,BAO_0000218,,
6444,5472,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621362,,BAO_0000218,,
6445,5985,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621363,,BAO_0000218,,
6446,15660,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621364,,BAO_0000218,,
6447,5530,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621166,,BAO_0000218,,
6448,5530,Oral bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621167,,BAO_0000218,,
6449,6305,Oral bioavailability (F) in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621168,,BAO_0000218,,
6450,5210,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621169,,BAO_0000218,,
6451,5238,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875950,,BAO_0000218,,
6452,5668,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621170,,BAO_0000218,,
6453,5668,Oral bioavailability after peroral administration at 5 mpk in Dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621171,,BAO_0000218,,
6454,5668,Oral bioavailability in dog (dose 5 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621172,,BAO_0000218,,
6455,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621173,,BAO_0000218,,
6456,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621174,42.0,BAO_0000218,2113.0,
6457,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Kidney,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621175,42.0,BAO_0000218,2113.0,
6458,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621176,42.0,BAO_0000218,2107.0,
6459,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621177,42.0,BAO_0000218,2107.0,
6460,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621178,42.0,BAO_0000218,2107.0,
6461,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621179,42.0,BAO_0000218,2107.0,
6462,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621180,42.0,BAO_0000218,2107.0,
6463,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875951,42.0,BAO_0000218,2048.0,
6464,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621181,42.0,BAO_0000218,2048.0,
6465,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621182,42.0,BAO_0000218,2048.0,
6466,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621183,42.0,BAO_0000218,2048.0,
6467,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621184,42.0,BAO_0000218,2048.0,
6468,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621185,42.0,BAO_0000218,,
6469,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621186,42.0,BAO_0000218,,
6470,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621187,42.0,BAO_0000218,,
6471,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621188,42.0,BAO_0000218,,
6472,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621189,42.0,BAO_0000218,,
6473,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621190,42.0,BAO_0000218,2106.0,
6474,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL618520,42.0,BAO_0000218,2106.0,
6475,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621739,42.0,BAO_0000218,2106.0,
6476,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621740,42.0,BAO_0000218,2106.0,
6477,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Spleen,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621741,42.0,BAO_0000218,2106.0,
6478,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621742,42.0,BAO_0000218,,
6479,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621743,42.0,BAO_0000218,,
6480,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621744,42.0,BAO_0000218,,
6481,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621745,42.0,BAO_0000218,,
6482,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621746,42.0,BAO_0000218,,
6483,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621747,42.0,BAO_0000218,,
6484,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621748,42.0,BAO_0000218,,
6485,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621749,42.0,BAO_0000218,,
6486,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621750,42.0,BAO_0000218,,
6487,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621751,42.0,BAO_0000218,,
6488,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621752,42.0,BAO_0000218,948.0,
6489,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621753,42.0,BAO_0000218,948.0,
6490,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL875955,42.0,BAO_0000218,948.0,
6491,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621754,42.0,BAO_0000218,948.0,
6492,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Heart,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621755,42.0,BAO_0000218,948.0,
6493,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL621756,42.0,BAO_0000218,2107.0,
6494,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624199,42.0,BAO_0000218,2107.0,
6495,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624200,42.0,BAO_0000218,2107.0,
6496,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624375,42.0,BAO_0000218,2107.0,
6497,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Liver,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624376,42.0,BAO_0000218,2107.0,
6498,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624377,42.0,BAO_0000218,2048.0,
6499,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624378,42.0,BAO_0000218,2048.0,
6500,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL857901,,BAO_0000218,,
6501,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL875274,,BAO_0000218,,
6502,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,Acinetobacter calcoaceticus subsp. anitratus,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624379,,BAO_0000218,,
6503,12269,Compound tested for the antimicrobial activity against Acinetobacter anitratus,F,,,aeinetobacter anitrotap,107673.0,,,,,50067,N,1,Intermediate,1,,CHEMBL624380,,BAO_0000218,,
6504,10624,Activity against Acinetobacter calcoaceticus (AC54),F,,,Acinetobacter calcoaceticus,471.0,,,,,50192,N,1,Intermediate,1,,CHEMBL624381,,BAO_0000218,,
6505,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624382,,BAO_0000218,,
6506,17216,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,F,,,Anolis carolinensis,28377.0,,,,,50714,N,1,Intermediate,1,,CHEMBL624383,,BAO_0000218,,
6507,9560,Chlorohexidine coefficient for Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624384,,BAO_0000218,,
6508,9560,Chlorohexidine coefficient for Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624385,,BAO_0000218,,
6509,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624386,,BAO_0000218,,
6510,9560,Chlorohexidine coefficient for Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624387,,BAO_0000218,,
6511,9560,Plaque bactericidal index against Actinomyces naeslundii 631,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624388,,BAO_0000218,,
6512,9560,Plaque bactericidal index against Actinomyces naeslundii N/9,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624389,,BAO_0000218,,
6513,9560,Plaque bactericidal index against Actinomyces naeslundii B74,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL624390,,BAO_0000218,,
6514,9560,Plaque bactericidal index against Actinomyces naeslundii N/3,F,,,Actinomyces naeslundii,1655.0,,,,,50296,N,1,Intermediate,1,,CHEMBL875275,,BAO_0000218,,
6515,114,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL624391,,BAO_0000218,,
6516,114,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",F,,,Artemia salina,85549.0,,,,,50056,N,1,Intermediate,1,,CHEMBL623636,,BAO_0000218,,
6517,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623637,,BAO_0000218,,
6518,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623638,,BAO_0000218,,
6519,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623639,,BAO_0000218,,
6520,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623640,,BAO_0000218,,
6521,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623641,,BAO_0000218,,
6522,10841,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623642,,BAO_0000218,,
6523,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623643,,BAO_0000218,,
6524,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623644,,BAO_0000218,,
6525,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623645,,BAO_0000218,,
6526,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623646,,BAO_0000218,,
6527,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623647,,BAO_0000218,,
6528,10841,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,F,,,Ascaris suum,6253.0,,,,,50532,N,1,Intermediate,1,,CHEMBL623648,,BAO_0000218,,
6529,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623649,,BAO_0000218,,
6530,8117,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623650,,BAO_0000218,,
6531,9560,Chlorohexidine coefficient for Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623651,,BAO_0000218,,
6532,9560,Chlorohexidine coefficient for Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623652,,BAO_0000218,,
6533,9560,Chlorohexidine coefficient for Actinomyces viscosus M-626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623653,,BAO_0000218,,
6534,9560,Chlorohexidine coefficient for Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623654,,BAO_0000218,,
6535,9560,Plaque bactericidal index against Actinomyces viscosus 8A06,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623655,,BAO_0000218,,
6536,9560,Plaque bactericidal index against Actinomyces viscosus M-100,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623656,,BAO_0000218,,
6537,9560,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Expert,1,,CHEMBL623657,,BAO_0000218,,
6538,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623658,,BAO_0000218,,
6539,9560,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623659,,BAO_0000218,,
6540,9560,Plaque bactericidal index against Actinomyces viscosus 626,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623660,,BAO_0000218,,
6541,9560,Plaque bactericidal index against Actinomyces viscosus T14V,F,,,Actinomyces viscosus,1656.0,,,,,50366,N,1,Intermediate,1,,CHEMBL623661,,BAO_0000218,,
6542,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL875281,,BAO_0000218,,
6543,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623662,,BAO_0000218,,
6544,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623663,,BAO_0000218,,
6545,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623664,,BAO_0000218,,
6546,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL623665,,BAO_0000218,,
6547,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A673,,80023,N,1,Intermediate,1,,CHEMBL621856,165.0,BAO_0000219,,
6548,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A704,,80661,N,1,Intermediate,1,,CHEMBL620432,645.0,BAO_0000219,,
6549,416,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,F,,,Rattus norvegicus,10116.0,,,,,22226,U,0,Autocuration,1,,CHEMBL620433,,BAO_0000219,,
6550,14354,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620434,625.0,BAO_0000219,,
6551,14354,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620435,625.0,BAO_0000219,,
6552,5116,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL620436,625.0,BAO_0000219,,
6553,5116,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,F,,,Homo sapiens,9606.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL876597,625.0,BAO_0000219,,
6554,15694,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,F,,,Homo sapiens,9606.0,,,Human ovarian carcinoma cell line,,81037,N,1,Expert,1,,CHEMBL620437,874.0,BAO_0000219,,
6555,13038,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620438,625.0,BAO_0000219,,
6556,13038,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL620439,625.0,BAO_0000219,,
6557,10923,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Expert,1,,CHEMBL619657,625.0,BAO_0000219,,
6558,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619658,625.0,BAO_0000219,,
6559,10923,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619659,625.0,BAO_0000219,,
6560,10923,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",F,,,,,,,,,10649,H,8,Expert,1,,CHEMBL619660,,BAO_0000019,,
6561,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619661,625.0,BAO_0000219,,
6562,10923,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,F,,,Mus musculus,10090.0,,,A9,,80024,N,1,Intermediate,1,,CHEMBL619662,625.0,BAO_0000219,,
6563,8158,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,F,,,Cricetulus griseus,10029.0,,,AA6,,80663,N,1,Intermediate,1,,CHEMBL619663,975.0,BAO_0000219,,
6564,15494,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619664,,BAO_0000219,,
6565,15494,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",F,,,Homo sapiens,9606.0,,,,,22226,U,0,Autocuration,1,,CHEMBL619665,,BAO_0000219,,
6566,12348,Anti -HIV activity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL883244,974.0,BAO_0000219,,
6567,12348,Cytotoxicity was measured against AA5/HIV-1(IIIB),F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL884011,974.0,BAO_0000219,,
6568,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,F,,,Homo sapiens,9606.0,,,AA5,,80662,N,1,Intermediate,1,,CHEMBL619666,974.0,BAO_0000219,,
6569,2726,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,F,,,Homo sapiens,9606.0,,,U-937,,80566,N,1,Intermediate,1,,CHEMBL619667,379.0,BAO_0000219,,
6570,10747,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,F,,,Cricetulus griseus,10029.0,,,UV4,,80578,N,1,Intermediate,1,,CHEMBL619668,274.0,BAO_0000219,,
6571,11005,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619669,185.0,BAO_0000219,,
6572,12687,Average intracellular compound concentration when the hypoxic SER=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL876608,185.0,BAO_0000219,,
6573,12687,Average intracellular compound concentration when the hypoxic SER=1.6.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619670,185.0,BAO_0000219,,
6574,12687,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619671,185.0,BAO_0000219,,
6575,12687,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619672,185.0,BAO_0000219,,
6576,12687,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619673,185.0,BAO_0000219,,
6577,13436,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619674,185.0,BAO_0000219,,
6578,13435,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619675,185.0,BAO_0000219,,
6579,13302,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619676,185.0,BAO_0000219,,
6580,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619677,185.0,BAO_0000219,,
6581,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619678,185.0,BAO_0000219,,
6582,12687,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL619679,185.0,BAO_0000219,,
6583,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL619680,185.0,BAO_0000219,,
6584,12878,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621457,185.0,BAO_0000219,,
6585,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL876609,185.0,BAO_0000219,,
6586,14367,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL621458,185.0,BAO_0000219,,
6587,12398,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621459,185.0,BAO_0000219,,
6588,12878,Aerobic growth inhibition in Chinese hamster cell line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621460,185.0,BAO_0000219,,
6589,13820,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621461,185.0,BAO_0000219,,
6590,13436,Inhibition of growth under aerobic conditions in AA8 cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL621462,185.0,BAO_0000219,,
6591,6084,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621463,,BAO_0000218,,
6592,5711,Oral bioavailability in dog at 10 mg/kg of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621464,,BAO_0000218,,
6593,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621465,,BAO_0000218,,
6594,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621466,,BAO_0000218,,
6595,17800,Oral bioavailability in dog (mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621467,,BAO_0000218,,
6596,3994,Oral bioavailability in dog (dose 10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621468,,BAO_0000218,,
6597,3994,Oral bioavailability in dog (dose 10 mg/kg),F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876734,,BAO_0000218,,
6598,5145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618476,,BAO_0000218,,
6599,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618477,,BAO_0000218,,
6600,16452,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618478,,BAO_0000218,,
6601,5983,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618479,,BAO_0000218,,
6602,4273,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618480,,BAO_0000218,,
6603,12500,Bioavailability in dog (dose 3-10 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618481,,BAO_0000218,,
6604,12500,The compound was tested for bioavailability of compound in plasma of dog; Complete,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618482,,BAO_0000218,1969.0,
6605,3639,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618483,,BAO_0000218,,
6606,3880,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618484,,BAO_0000218,,
6607,4838,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618485,,BAO_0000218,,
6608,15600,oral bioavailability was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618486,,BAO_0000218,,
6609,17248,Compound was tested for plasma protein binding in dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618487,,BAO_0000218,,
6610,17248,Compound was tested for plasma protein binding of dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618488,,BAO_0000218,,
6611,17248,Compound was tested for plasma protein binding of dog; Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876735,,BAO_0000218,,
6612,17443,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618489,,BAO_0000218,,
6613,4186,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618490,,BAO_0000218,,
6614,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618491,,BAO_0000218,,
6615,3249,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618492,,BAO_0000218,,
6616,3022,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873354,,BAO_0000218,,
6617,3749,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618493,,BAO_0000218,,
6618,2517,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618494,,BAO_0000218,,
6619,2517,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Heart,,,50588,N,1,Intermediate,1,,CHEMBL618495,,BAO_0000218,948.0,
6620,2517,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Kidney,,,50588,N,1,Intermediate,1,,CHEMBL618496,,BAO_0000218,2113.0,
6621,2517,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618497,,BAO_0000218,2107.0,
6622,2517,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL618498,,BAO_0000218,2048.0,
6623,2517,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),A,In vivo,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL618499,,BAO_0000218,2106.0,
6624,3639,LogP in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876736,,BAO_0000218,,
6625,6227,Partition coefficient (logP),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618500,,BAO_0000218,,
6626,6227,Partition coefficient in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL857831,,BAO_0000218,,
6627,17764,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618501,,BAO_0000218,,
6628,4809,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618502,,BAO_0000218,,
6629,5600,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618503,,BAO_0000218,,
6630,14294,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618504,,BAO_0000218,,
6631,14294,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618505,,BAO_0000218,,
6632,14294,Metabolism of compound in dog S9 microsomes; Trace,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618506,,BAO_0000218,,
6633,6251,In vitro metabolic potential in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL618507,,BAO_0000218,2107.0,
6634,3748,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876737,,BAO_0000218,,
6635,2713,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618508,,BAO_0000218,,
6636,6512,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618509,,BAO_0000218,,
6637,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618510,,BAO_0000218,,
6638,3749,The compound was tested for bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618511,,BAO_0000218,,
6639,3749,The compound was tested for oral bioavailability in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618512,,BAO_0000218,,
6640,6742,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618513,,BAO_0000218,,
6641,6227,Compound was tested for percent protein binding (PB) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618514,,BAO_0000218,,
6642,6874,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620052,,BAO_0000218,,
6643,2877,Compound was evaluated for plasma clearance.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620053,,BAO_0000218,1969.0,
6644,12500,The compound was tested for plasma clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620054,,BAO_0000218,1969.0,
6645,12500,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620055,,BAO_0000218,1969.0,
6646,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620056,,BAO_0000218,,
6647,5542,In vitro relative rate of metabolism was determined in dog liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL620057,,BAO_0000218,2107.0,
6648,17594,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618939,,BAO_0000218,,
6649,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618940,,BAO_0000218,,
6650,17764,Half life after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618941,,BAO_0000218,,
6651,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624473,42.0,BAO_0000218,2048.0,
6652,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624474,42.0,BAO_0000218,2048.0,
6653,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,Lung,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624475,42.0,BAO_0000218,2048.0,
6654,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL624476,42.0,BAO_0000218,,
6655,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623478,42.0,BAO_0000218,,
6656,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623479,42.0,BAO_0000218,,
6657,6599,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623480,42.0,BAO_0000218,,
6658,6599,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,A,,,Mus musculus,10090.0,,,CCRF S-180,,50594,N,1,Intermediate,1,,CHEMBL623481,42.0,BAO_0000218,,
6659,17641,C2 in brain of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623482,,BAO_0000218,955.0,
6660,17641,C2 in kidney of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623483,,BAO_0000218,2113.0,
6661,17641,C2 in liver of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623484,,BAO_0000218,2107.0,
6662,17641,C2 in lungs of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623485,,BAO_0000218,2048.0,
6663,17641,C2 in spleen of mice at the oral dose of 50 mg/kg,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623486,,BAO_0000218,2106.0,
6664,17852,Plasma clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623487,,BAO_0000218,,
6665,17764,Clearance of compound after intravenous administration in mice at 24 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623488,,BAO_0000218,,
6666,17837,Clearance from mouse blood following i.v. administration of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623489,,BAO_0000218,,
6667,2675,Clearance was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875157,,BAO_0000218,,
6668,2675,Clearance was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623490,,BAO_0000218,,
6669,4239,Pharmacokinetic property (Plasma clearance) was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623491,,BAO_0000218,,
6670,17753,Plasma clearance of compound was determined at 40 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623492,,BAO_0000218,,
6671,17753,Plasma clearance of at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623493,,BAO_0000218,,
6672,17753,Plasma clearance at 24 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623494,,BAO_0000218,,
6673,17753,Plasma clearance at 5 mg/Kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623495,,BAO_0000218,,
6674,5727,Plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623496,,BAO_0000218,,
6675,2862,Plasma clearance value upon iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623497,,BAO_0000218,,
6676,5980,Total plasma clearance in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623498,,BAO_0000218,1969.0,
6677,17592,Clearance in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623499,,BAO_0000218,,
6678,17718,Clearance value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623500,,BAO_0000218,,
6679,16597,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623501,,BAO_0000218,,
6680,17384,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL875158,,BAO_0000100,,
6681,6062,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623502,,BAO_0000218,,
6682,17734,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623503,,BAO_0000218,,
6683,6348,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623504,,BAO_0000218,,
6684,5969,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623505,,BAO_0000218,,
6685,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623506,,BAO_0000218,,
6686,5969,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623507,,BAO_0000218,,
6687,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623508,,BAO_0000218,,
6688,5781,Cmax after oral administration at 30 mg/kg in ICR mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623509,,BAO_0000218,,
6689,17764,Cmax after peroral administration in mice at 2.4 uM/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875159,,BAO_0000218,,
6690,17641,Cmax in brain of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL623510,,BAO_0000218,955.0,
6691,17641,Cmax in kidney of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL623511,,BAO_0000218,2113.0,
6692,17641,Cmax in liver of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623512,,BAO_0000218,2107.0,
6693,17641,Cmax in lungs of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623513,,BAO_0000218,2048.0,
6694,17764,Cmax in mice at 18 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623514,,BAO_0000218,,
6695,17764,Cmax in mice at 23 uM/kg i.v. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622609,,BAO_0000218,,
6696,17764,Cmax in mice at 24 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622610,,BAO_0000218,,
6697,17764,Cmax in mice at 25 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621823,,BAO_0000218,,
6698,17764,Cmax in mice at 26 uM/kg i.p. administration,F,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621824,,BAO_0000218,,
6699,17641,Cmax in spleen of mice at the oral dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621825,,BAO_0000218,2106.0,
6700,16597,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621826,,BAO_0000218,,
6701,16597,Cmax value at a dose of 10 mg/kg peroral administration in mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621827,,BAO_0000218,,
6702,5727,Cmax value was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621828,,BAO_0000218,,
6703,5951,Cmax value in IRC mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621829,,BAO_0000218,,
6704,5506,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621830,,BAO_0000218,,
6705,5506,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621831,,BAO_0000218,,
6706,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621832,,BAO_0000218,1969.0,
6707,4890,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL624579,,BAO_0000218,1969.0,
6708,429,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624580,,BAO_0000218,,
6709,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624581,,BAO_0000218,,
6710,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624582,,BAO_0000218,,
6711,10986,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,F,,,Acanthocheilonema viteae,6277.0,,,,,50535,N,1,Intermediate,1,,CHEMBL624583,,BAO_0000218,,
6712,13227,Inhibitory activity against human tumor cell line A0375 melanoma.,F,,,Homo sapiens,9606.0,,,A-375,,80018,N,1,Intermediate,1,,CHEMBL624584,455.0,BAO_0000219,,
6713,4481,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,B,,,Rattus norvegicus,10116.0,,,,Brain membranes,12512,D,9,Expert,1,,CHEMBL624585,,BAO_0000249,,
6714,16931,Forskolin-induced cAMP production at human A1 adenosine receptor,F,,,Homo sapiens,9606.0,,,,,114,D,9,Expert,1,,CHEMBL875165,,BAO_0000019,,
6715,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619490,449.0,BAO_0000219,,
6716,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619491,449.0,BAO_0000219,,
6717,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619492,449.0,BAO_0000219,,
6718,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619493,449.0,BAO_0000219,,
6719,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619494,449.0,BAO_0000219,,
6720,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619495,449.0,BAO_0000219,,
6721,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619496,449.0,BAO_0000219,,
6722,3850,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,F,,,Homo sapiens,9606.0,,,CHO,,114,D,9,Expert,1,,CHEMBL619497,449.0,BAO_0000219,,
6723,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619498,449.0,BAO_0000219,,
6724,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619499,449.0,BAO_0000219,,
6725,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619500,449.0,BAO_0000219,,
6726,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619501,449.0,BAO_0000219,,
6727,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL619502,449.0,BAO_0000219,,
6728,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619503,449.0,BAO_0000219,,
6729,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL619504,449.0,BAO_0000219,,
6730,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621298,449.0,BAO_0000219,,
6731,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621299,449.0,BAO_0000219,,
6732,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621300,449.0,BAO_0000219,,
6733,3850,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,F,,,,,,,CHO,,114,H,8,Autocuration,1,,CHEMBL621301,449.0,BAO_0000219,,
6734,3850,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,F,,,,,,,CHO,,114,H,8,Expert,1,,CHEMBL621302,449.0,BAO_0000219,,
6735,12680,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,F,,,Oryctolagus cuniculus,9986.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621303,164.0,BAO_0000219,,
6736,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621304,164.0,BAO_0000219,,
6737,1313,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,F,,,Rattus norvegicus,10116.0,,,A10,,22226,U,0,Autocuration,1,,CHEMBL621305,164.0,BAO_0000219,,
6738,17567,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL621306,164.0,BAO_0000219,,
6739,17567,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618444,164.0,BAO_0000219,,
6740,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL618445,164.0,BAO_0000219,,
6741,13436,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618446,185.0,BAO_0000219,,
6742,12687,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618447,185.0,BAO_0000219,,
6743,12651,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618448,185.0,BAO_0000219,,
6744,13300,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618449,185.0,BAO_0000219,,
6745,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618637,185.0,BAO_0000219,,
6746,15328,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618638,185.0,BAO_0000219,,
6747,13302,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618639,185.0,BAO_0000219,,
6748,14367,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618640,185.0,BAO_0000219,,
6749,17002,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618641,185.0,BAO_0000219,,
6750,13436,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618642,185.0,BAO_0000219,,
6751,13435,Inhibitory activity against aerobic growth of AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL618643,185.0,BAO_0000219,,
6752,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL884013,185.0,BAO_0000219,,
6753,10503,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622723,185.0,BAO_0000219,,
6754,10503,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622724,185.0,BAO_0000219,,
6755,15090,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622725,185.0,BAO_0000219,,
6756,10368,Cytotoxicity against AA8 cell line,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622726,185.0,BAO_0000219,,
6757,12651,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622727,185.0,BAO_0000219,,
6758,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622728,185.0,BAO_0000219,,
6759,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622729,185.0,BAO_0000219,,
6760,12687,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622730,185.0,BAO_0000219,,
6761,1890,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622731,185.0,BAO_0000219,,
6762,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622732,185.0,BAO_0000219,,
6763,10747,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Intermediate,1,,CHEMBL622733,185.0,BAO_0000219,,
6764,11616,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622734,,BAO_0000218,,
6765,11616,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL622735,185.0,BAO_0000219,,
6766,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618746,185.0,BAO_0000219,,
6767,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618747,185.0,BAO_0000219,,
6768,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620540,185.0,BAO_0000219,,
6769,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620541,185.0,BAO_0000219,,
6770,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620542,185.0,BAO_0000219,,
6771,3471,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL620543,185.0,BAO_0000219,,
6772,3471,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618832,185.0,BAO_0000219,,
6773,11616,Concentration required to reduce AA8 cell survival by 10%,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL618833,185.0,BAO_0000219,,
6774,2656,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618834,185.0,BAO_0000219,,
6775,10518,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618835,185.0,BAO_0000219,,
6776,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618836,185.0,BAO_0000219,,
6777,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618837,185.0,BAO_0000219,,
6778,10518,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618838,185.0,BAO_0000219,,
6779,16156,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618839,185.0,BAO_0000219,,
6780,2656,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618840,185.0,BAO_0000219,,
6781,11005,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618841,,BAO_0000019,,
6782,11942,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618842,185.0,BAO_0000219,,
6783,2128,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL618843,185.0,BAO_0000219,,
6784,16907,Half life period after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618844,,BAO_0000218,,
6785,16907,Half life period after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618845,,BAO_0000218,,
6786,9579,Half life was measured after oral 2b administration (tested in 6 dogs),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618846,,BAO_0000218,,
6787,9579,Half life was measured in dog after oral 17b administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618847,,BAO_0000218,,
6788,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618848,,BAO_0000218,,
6789,9579,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618849,,BAO_0000218,,
6790,16907,Tmax value after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618850,,BAO_0000218,,
6791,16907,Tmax value after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618851,,BAO_0000218,,
6792,3184,Compound was evaluated for its half life when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873815,,BAO_0000218,,
6793,5017,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618852,,BAO_0000218,1969.0,
6794,6821,Elimination Half-life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618853,,BAO_0000218,,
6795,17839,Half life of compound in dog following oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618854,,BAO_0000218,,
6796,17267,Half life of compound was determined in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618855,,BAO_0000218,,
6797,4727,Half life of compound was determined in dog blood,A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618856,,BAO_0000218,178.0,
6798,5238,Half life after oral and iv dosing in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875827,,BAO_0000218,,
6799,4942,Half life in dogs in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618857,,BAO_0000218,,
6800,6505,Half life on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618858,,BAO_0000218,,
6801,5130,t1/2 in dog after oral dose (1 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618859,,BAO_0000218,,
6802,1475,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618860,,BAO_0000218,,
6803,17804,Half life period of compound was determined after intravenous administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618861,,BAO_0000218,,
6804,17804,Half life period of compound was determined after peroral administration at 2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622539,,BAO_0000218,,
6805,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622540,,BAO_0000218,,
6806,6084,Half life period (10 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873803,,BAO_0000218,,
6807,5542,Half life period by iv administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873804,,BAO_0000218,,
6808,5542,Half life period by po administration in dog at a dose of 0.3 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624311,,BAO_0000218,,
6809,6084,Half life period in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624312,,BAO_0000218,,
6810,6241,Half life period in dogs after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624313,,BAO_0000218,,
6811,1916,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624314,,BAO_0000218,,
6812,6621,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624315,,BAO_0000218,,
6813,1696,Half-life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624316,,BAO_0000218,1969.0,
6814,17800,Half-life in mongrel dogs was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624317,,BAO_0000218,,
6815,17657,Half-life in dog upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624318,,BAO_0000218,,
6816,17657,Half-life in dog upon oral administration; Unable to calculate,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624319,,BAO_0000218,,
6817,4239,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624496,,BAO_0000218,,
6818,5985,Half-life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624497,,BAO_0000218,,
6819,9932,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624498,,BAO_0000218,,
6820,5199,Oral half life was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624499,,BAO_0000218,,
6821,5199,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624500,,BAO_0000218,1969.0,
6822,1475,Plasma half life was evaluated,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL624501,,BAO_0000218,1969.0,
6823,1475,Plasma half life was evaluated in Dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623666,,BAO_0000218,1969.0,
6824,1475,Plasma half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623667,,BAO_0000218,1969.0,
6825,6316,T1/2 (Half-life) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623668,,BAO_0000218,,
6826,4883,Tested for the half life value in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623669,,BAO_0000218,,
6827,4727,Maximum time at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623670,,BAO_0000218,,
6828,1916,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623671,,BAO_0000218,,
6829,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL875945,,BAO_0000218,178.0,
6830,1337,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL623672,,BAO_0000218,178.0,
6831,6265,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623673,,BAO_0000218,,
6832,4809,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623674,,BAO_0000218,,
6833,5983,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623675,,BAO_0000218,,
6834,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872526,,BAO_0000218,,
6835,5313,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623676,,BAO_0000218,,
6836,17650,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623677,,BAO_0000218,1969.0,
6837,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623678,,BAO_0000218,1969.0,
6838,933,Time taken for maximum plasma concentration in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623679,,BAO_0000218,1969.0,
6839,16367,Time to reach Cmax after oral administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623680,,BAO_0000218,,
6840,6348,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623681,,BAO_0000218,1969.0,
6841,6316,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623682,,BAO_0000218,,
6842,6215,Tmax after peroral administration (1 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623683,,BAO_0000218,,
6843,3598,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL623684,,BAO_0000218,,
6844,4527,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622745,,BAO_0000218,,
6845,17764,Tmax after peroral administration in dogs at 2.4 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622746,,BAO_0000218,,
6846,5969,In vivo Cmax in mice at dose of 100 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622747,,BAO_0000218,,
6847,5969,In vivo Cmax in mice at dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622748,,BAO_0000218,,
6848,4573,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622749,,BAO_0000218,,
6849,3277,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622750,,BAO_0000218,1969.0,
6850,17734,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623411,,BAO_0000218,1969.0,
6851,3132,Maximum concentration obtained in mouse plasma was determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL875946,,BAO_0000218,1969.0,
6852,3132,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623412,,BAO_0000218,1969.0,
6853,6348,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623413,,BAO_0000218,1969.0,
6854,17729,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623414,,BAO_0000218,1969.0,
6855,17729,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623415,,BAO_0000218,1969.0,
6856,17729,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623416,,BAO_0000218,1969.0,
6857,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623417,,BAO_0000218,1969.0,
6858,17728,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623418,,BAO_0000218,1969.0,
6859,17728,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623419,,BAO_0000218,1969.0,
6860,4066,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622816,,BAO_0000218,,
6861,6178,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623313,,BAO_0000218,,
6862,6178,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623314,,BAO_0000218,,
6863,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876788,,BAO_0000218,,
6864,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623315,,BAO_0000218,,
6865,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623316,,BAO_0000218,,
6866,3760,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623317,,BAO_0000218,,
6868,5961,Cmax in male mice after 2 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623319,,BAO_0000218,,
6869,6137,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623320,,BAO_0000218,,
6870,3802,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623321,,BAO_0000218,,
6871,3535,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623322,,BAO_0000218,,
6872,3535,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623323,,BAO_0000218,,
6873,3535,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623324,,BAO_0000218,,
6874,3535,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623325,,BAO_0000218,,
6875,3535,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623326,,BAO_0000218,,
6876,3535,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623327,,BAO_0000218,,
6877,2862,Maximum concentration in plasma upon oral administration in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623328,,BAO_0000218,1969.0,
6878,2675,Maximum plasma concentration was evaluated in mice after oral administration,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623329,,BAO_0000218,1969.0,
6879,2675,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623330,,BAO_0000218,1969.0,
6880,5399,Dose at which the compound induced fecal excretion in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876789,,BAO_0000218,,
6893,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623333,164.0,BAO_0000219,,
6894,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL623334,164.0,BAO_0000219,,
6895,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627536,164.0,BAO_0000219,,
6896,11819,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Expert,1,,CHEMBL627537,164.0,BAO_0000219,,
6897,16361,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),F,,,Rattus norvegicus,10116.0,,,A10,,80013,N,1,Intermediate,1,,CHEMBL627538,164.0,BAO_0000219,,
6898,2288,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL884106,393.0,BAO_0000219,,
6899,10404,Anticancer activity against human ovarian carcinoma A121 cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625294,393.0,BAO_0000219,,
6900,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625295,393.0,BAO_0000219,,
6901,14790,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625296,393.0,BAO_0000219,,
6902,14253,Growth inhibition of human ovarian carcinoma (A121) cell line,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625297,393.0,BAO_0000219,,
6903,13617,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Expert,1,,CHEMBL625298,393.0,BAO_0000219,,
6904,1003,Cytotoxicity against human A121 ovarian cells,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625960,393.0,BAO_0000219,,
6905,830,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625961,393.0,BAO_0000219,,
6906,12307,In vitro cytotoxicity against human ovarian carcinoma A21,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL625962,393.0,BAO_0000219,,
6907,14254,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624717,393.0,BAO_0000219,,
6908,13370,Inhibitory activity of compound against human A121 ovarian cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624718,393.0,BAO_0000219,,
6909,14790,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624719,393.0,BAO_0000219,,
6910,3614,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,F,,,Homo sapiens,9606.0,,,A121,,80655,N,1,Intermediate,1,,CHEMBL624720,393.0,BAO_0000219,,
6911,2664,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624721,622.0,BAO_0000219,,
6912,2037,In vitro cytotoxicity against A172 human tumor cell lines.,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Expert,1,,CHEMBL624722,622.0,BAO_0000219,,
6913,14539,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL877597,622.0,BAO_0000219,,
6914,2836,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624723,622.0,BAO_0000219,,
6915,10708,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,F,,,Homo sapiens,9606.0,,,A 172,,80012,N,1,Intermediate,1,,CHEMBL624724,622.0,BAO_0000219,,
6916,8975,Association constant against A2 adenosine receptor,B,,,Canis lupus familiaris,9615.0,,,,,104729,H,4,Autocuration,1,,CHEMBL624725,,BAO_0000224,,
6917,7645,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,F,,,fish,,,,A2,,80656,N,1,Intermediate,1,,CHEMBL624726,1085.0,BAO_0000219,,
6918,11377,Ratio of Ki for adenosine A2 and A1 receptor binding,B,,,Rattus norvegicus,10116.0,,,,,104713,D,5,Autocuration,1,,CHEMBL857535,,BAO_0000224,,
6919,13528,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624727,623.0,BAO_0000219,,
6920,10160,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,F,,,Homo sapiens,9606.0,,,A204,,80014,N,1,Expert,1,,CHEMBL624728,623.0,BAO_0000219,,
6921,15144,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2058,,80015,N,1,Intermediate,1,,CHEMBL624729,404.0,BAO_0000219,,
6922,13160,Growth inhibition against Human squamous cell line(A 253),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624730,973.0,BAO_0000219,,
6923,12898,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624731,973.0,BAO_0000219,,
6924,13069,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624732,973.0,BAO_0000219,,
6925,15984,Growth inhibition of A253 cell lines.,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL883245,973.0,BAO_0000219,,
6926,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624733,973.0,BAO_0000219,,
6927,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624734,973.0,BAO_0000219,,
6928,15564,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,F,,,Homo sapiens,9606.0,,,A253 cell line,,80657,N,1,Intermediate,1,,CHEMBL624735,973.0,BAO_0000219,,
6929,4720,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621780,478.0,BAO_0000219,,
6930,16112,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL877598,478.0,BAO_0000219,,
6931,16597,Cytotoxic activity against A2780 human ovarian carcinoma cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621781,478.0,BAO_0000219,,
6932,16378,Cytotoxicity against human cancer cell lines A2780 (ovarian),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621782,478.0,BAO_0000219,,
6933,16085,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621783,478.0,BAO_0000219,,
6934,16317,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621784,478.0,BAO_0000219,,
6935,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621785,478.0,BAO_0000219,,
6936,16597,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621968,478.0,BAO_0000219,,
6937,16597,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621969,478.0,BAO_0000219,,
6938,16597,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621970,478.0,BAO_0000219,,
6939,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621971,478.0,BAO_0000219,,
6940,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621972,478.0,BAO_0000219,,
6941,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884108,478.0,BAO_0000219,,
6942,15296,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623826,,BAO_0000019,,
6943,10251,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,A,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623827,185.0,BAO_0000219,,
6944,10251,Evaluated for growth inhibition of AA8 cells under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623828,185.0,BAO_0000219,,
6945,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623829,185.0,BAO_0000219,,
6946,10251,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623830,185.0,BAO_0000219,,
6947,11858,Growth inhibition against CHO-derived cell line AA8,F,,,Cricetulus griseus,10029.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623831,,BAO_0000019,,
6948,11858,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623832,185.0,BAO_0000219,,
6949,11616,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,F,,,hampster,36483.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623833,185.0,BAO_0000219,,
6950,11616,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623834,185.0,BAO_0000219,,
6951,10518,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623835,185.0,BAO_0000219,,
6952,11396,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623836,185.0,BAO_0000219,,
6953,10518,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,22224,U,0,Autocuration,1,,CHEMBL623837,185.0,BAO_0000219,,
6954,11616,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,F,,,Cricetulus griseus,10029.0,,,CHO-AA8,,80089,N,1,Expert,1,,CHEMBL623838,185.0,BAO_0000219,,
6955,14837,compound was evaluated for association constant (Ka) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623839,,BAO_0000019,,
6956,14837,Number of binding sites (n) of isolated serum protein AAG,F,,,,,,,,,12675,H,8,Autocuration,1,,CHEMBL623840,,BAO_0000019,,
6957,16037,Association constant for binding to AATT duplex,B,,,,,,,,,22222,M,3,Intermediate,1,,CHEMBL623841,,BAO_0000225,,
6958,16597,Inhibition of ABAE human fibroblast cell proliferation,F,,,Homo sapiens,9606.0,,,ABAE,,100090,N,1,Expert,1,,CHEMBL623842,416.0,BAO_0000219,,
6959,8831,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",F,,,Mus musculus,10090.0,,,AC755,,80668,N,1,Intermediate,1,,CHEMBL623843,1064.0,BAO_0000218,,
6960,13419,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,F,,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618669,,BAO_0000218,,
6961,13419,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,F,In vivo,,Oryctolagus cuniculus,9986.0,,,,,102444,D,9,Expert,1,,CHEMBL618670,,BAO_0000218,,
6962,15778,Inhibitory activity against angiotensin-converting enzyme (ACE).,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618671,,BAO_0000357,,
6963,15778,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,B,,,,,,,,,69,H,8,Autocuration,1,,CHEMBL618672,,BAO_0000357,,
6964,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618673,978.0,BAO_0000219,,
6965,12988,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Homo sapiens,9606.0,,,ACH-2 cell line,,80669,N,1,Intermediate,1,,CHEMBL618674,978.0,BAO_0000219,,
6966,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618675,998.0,BAO_0000219,,
6967,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618676,998.0,BAO_0000219,,
6968,12988,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),F,,,Human immunodeficiency virus 1,11676.0,,,T cell line,,22224,U,0,Autocuration,1,,CHEMBL618677,998.0,BAO_0000219,,
6969,11843,Inhibition of growth of renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618678,626.0,BAO_0000219,,
6970,16939,Inhibition of growth of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618679,626.0,BAO_0000219,,
6971,4782,Inhibitory concentration required against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618680,626.0,BAO_0000219,,
6972,6310,Concentration required to inhibit growth of human renal (ACHN) cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618681,626.0,BAO_0000219,,
6973,6310,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618682,626.0,BAO_0000219,,
6974,12858,Cytotoxic activity against ACHN Renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618683,626.0,BAO_0000219,,
6975,17380,Cytotoxicity evaluation against ACHN renal cancer cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618684,626.0,BAO_0000219,,
6976,5858,In vitro antitumor activity against human renal ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618685,626.0,BAO_0000219,,
6977,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL876499,626.0,BAO_0000219,,
6978,3838,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618686,626.0,BAO_0000219,,
6979,5406,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618687,626.0,BAO_0000219,,
6980,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618688,626.0,BAO_0000219,,
6981,4071,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL618689,626.0,BAO_0000219,,
6982,4071,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618690,626.0,BAO_0000219,,
6983,15002,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL618691,626.0,BAO_0000219,,
6984,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619373,626.0,BAO_0000219,,
6985,13958,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL884008,626.0,BAO_0000219,,
6986,1665,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619374,626.0,BAO_0000219,,
6987,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619375,626.0,BAO_0000219,,
6988,15354,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619376,626.0,BAO_0000219,,
6989,13978,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619377,626.0,BAO_0000219,,
6990,6798,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL619378,626.0,BAO_0000219,,
6991,2959,Tmax value after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872527,,BAO_0000218,,
6992,9932,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876500,,BAO_0000218,,
6993,5546,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619379,,BAO_0000218,,
6994,16907,Volume distribution after 15 mg/kg iv dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619538,,BAO_0000218,,
6995,16907,Volume distribution after 30 mg/kg po dose in Dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619539,,BAO_0000218,,
6996,4257,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619540,,BAO_0000218,,
6997,4305,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619541,,BAO_0000218,,
6998,5472,Volume of distribution was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619542,,BAO_0000218,,
6999,6062,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619543,,BAO_0000218,,
7000,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL619544,,BAO_0000218,,
7001,12500,The compound was tested for volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619545,,BAO_0000218,,
7002,12500,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619546,,BAO_0000218,,
7003,6227,Vd (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619547,,BAO_0000218,,
7004,6227,Vd in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619548,,BAO_0000218,,
7005,4219,Volume distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619549,,BAO_0000218,,
7006,1696,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619550,,BAO_0000218,,
7007,5542,Volume of distribution by as 4 fold increase by iv administration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876501,,BAO_0000218,,
7008,5199,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619551,,BAO_0000218,,
7009,6348,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619552,,BAO_0000218,,
7010,4727,Volume distribution at the dose of 2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619553,,BAO_0000218,,
7011,16367,Steady state volume of distribution was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618722,,BAO_0000218,,
7012,2652,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618723,,BAO_0000218,,
7013,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618724,,BAO_0000218,,
7014,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618725,,BAO_0000218,,
7015,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618726,,BAO_0000218,,
7016,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618727,,BAO_0000218,,
7017,4239,Pharmacokinetic property (vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624233,,BAO_0000218,,
7018,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624234,,BAO_0000218,,
7019,5600,Vdss was determined after iv 0.1 mg/kg administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624235,,BAO_0000218,,
7020,6057,Volume displacement was calculated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624236,,BAO_0000218,,
7021,5654,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624237,,BAO_0000218,,
7022,5505,Volume distribution constant was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624238,,BAO_0000218,,
7023,4527,Volume distribution at a dose of 1 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624239,,BAO_0000218,,
7024,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875829,,BAO_0000218,,
7025,4521,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624240,,BAO_0000218,,
7026,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624241,,BAO_0000218,,
7027,15660,Volume distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624242,,BAO_0000218,,
7028,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624243,,BAO_0000218,,
7029,5145,Volume of distribution in steady state was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624244,,BAO_0000218,,
7030,6821,Volume of distribution of compound was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624245,,BAO_0000218,,
7031,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624246,,BAO_0000218,,
7032,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624247,,BAO_0000218,,
7033,15660,Volume of distribution (Vdss) was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624248,,BAO_0000218,,
7034,6642,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624249,,BAO_0000218,,
7035,6641,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624250,,BAO_0000218,,
7036,6642,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624251,,BAO_0000218,,
7037,11659,Maximum rate of depolarization of the upstroke of the action potential,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624252,,BAO_0000218,,
7038,6448,Steady state volume distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624253,,BAO_0000218,,
7039,5474,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624950,,BAO_0000218,,
7040,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624951,,BAO_0000218,,
7041,6535,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875830,,BAO_0000218,,
7042,6535,Volume distribution in dog after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624952,,BAO_0000218,,
7043,17764,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624953,,BAO_0000218,,
7044,6215,Vss after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624954,,BAO_0000218,,
7045,6505,Vss on i.v. administration of 2 mg/kg was measured in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624955,,BAO_0000218,,
7046,3639,Vss was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624956,,BAO_0000218,,
7047,3639,Vss in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625129,,BAO_0000218,,
7048,6062,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625130,,BAO_0000218,,
7049,4942,Volume distribution in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625131,,BAO_0000218,,
7050,17796,Volume of distribution in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625132,,BAO_0000218,,
7051,4883,Tested for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL872263,,BAO_0000218,,
7060,17837,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624336,,BAO_0000218,,
7061,17729,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624337,,BAO_0000218,,
7062,17729,Bioavailability after peroral administration of 50 mg/kg of dose in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624338,,BAO_0000218,,
7063,4239,Bioavailability was measured in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624339,,BAO_0000218,,
7064,17592,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624340,,BAO_0000218,,
7065,6348,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624341,,BAO_0000218,,
7066,2801,Bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624342,,BAO_0000218,,
7067,2801,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624343,,BAO_0000218,,
7068,17718,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624344,,BAO_0000218,,
7069,5727,Oral availability at 50 mg/kg po in male mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624345,,BAO_0000218,,
7070,5302,Oral bioavailability in mouse (dose 10 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624346,,BAO_0000218,,
7071,3598,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Expert,1,,CHEMBL624347,,BAO_0000218,,
7072,5961,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624348,,BAO_0000218,,
7074,6091,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622754,,BAO_0000218,,
7075,6091,Oral bioavailability in vivo in mice;ND=Not determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622755,,BAO_0000218,,
7076,5711,Oral bioavailability in mouse at 10 mg/kg of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622756,,BAO_0000218,,
7077,17728,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622757,,BAO_0000218,,
7078,17728,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622758,,BAO_0000218,,
7079,3802,Tested for bioavailability of the compound,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622759,,BAO_0000218,,
7080,3802,Tested for half life at the dose of 10 mg/kg when administered intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622760,,BAO_0000218,,
7081,14029,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622761,,BAO_0000218,1969.0,
7082,14029,The plasma half life of compound was determined on heparin prepared by human plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622762,,BAO_0000218,1969.0,
7083,14029,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622763,,BAO_0000218,1969.0,
7084,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622764,,BAO_0000218,1969.0,
7085,14029,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622765,,BAO_0000218,1969.0,
7086,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,F,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622766,,BAO_0000218,,
7087,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622767,,BAO_0000218,,
7088,17753,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622768,,BAO_0000218,,
7089,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL875948,,BAO_0000218,178.0,
7090,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622769,,BAO_0000218,178.0,
7091,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622770,,BAO_0000218,178.0,
7092,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622771,,BAO_0000218,178.0,
7093,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622772,,BAO_0000218,178.0,
7094,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622773,,BAO_0000218,178.0,
7095,10107,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622774,,BAO_0000218,178.0,
7096,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621725,,BAO_0000218,10000001.0,
7097,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL621726,,BAO_0000218,10000001.0,
7098,15608,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621727,478.0,BAO_0000219,,
7099,3290,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622413,478.0,BAO_0000219,,
7100,2859,Compound was evaluated for cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622414,478.0,BAO_0000219,,
7101,15688,Inhibition of A2780 cell clonogenic assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622415,478.0,BAO_0000219,,
7102,5642,Cytotoxic effect on ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL884001,478.0,BAO_0000219,,
7103,6633,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622416,478.0,BAO_0000219,,
7104,3906,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622417,478.0,BAO_0000219,,
7105,6788,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622590,478.0,BAO_0000219,,
7106,17582,Antiproliferative activity against human A2780 cells,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622591,478.0,BAO_0000219,,
7107,17764,Inhibition of human A2780 cell proliferation,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622592,478.0,BAO_0000219,,
7108,17764,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622593,478.0,BAO_0000219,,
7109,17764,Inhibition of human A2780 cell proliferation (No data),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622594,478.0,BAO_0000219,,
7110,2815,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622595,478.0,BAO_0000219,,
7111,16930,Compound was evaluated against human Ovarian carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622596,478.0,BAO_0000219,,
7112,17777,Growth inhibition against A2780 wild-type ovarian cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622597,478.0,BAO_0000219,,
7113,17777,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622598,478.0,BAO_0000219,,
7114,16936,Inhibition of tubulin polymerization in human ovarian cancer cell lines,F,,,Homo sapiens,9606.0,,,,,104766,D,5,Autocuration,1,,CHEMBL622599,,BAO_0000019,,
7115,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622600,478.0,BAO_0000219,,
7116,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622601,478.0,BAO_0000219,,
7117,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622602,478.0,BAO_0000219,,
7118,13759,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622603,478.0,BAO_0000219,,
7119,15292,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622604,478.0,BAO_0000219,,
7120,15292,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622605,478.0,BAO_0000219,,
7121,15069,In vitro inhibition of human ovarian cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL622606,478.0,BAO_0000219,,
7122,15069,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619463,478.0,BAO_0000219,,
7123,14073,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619464,478.0,BAO_0000219,,
7124,14553,Concentration required to inhibit A2780-cell growth by 50%,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619465,478.0,BAO_0000219,,
7125,13040,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619466,478.0,BAO_0000219,,
7126,6891,Cytotoxic effect on human ovarian (A2780) cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619467,478.0,BAO_0000219,,
7127,15569,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619468,478.0,BAO_0000219,,
7128,14190,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619469,478.0,BAO_0000219,,
7129,15014,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL619470,478.0,BAO_0000219,,
7130,15014,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619471,478.0,BAO_0000219,,
7131,17496,Cytotoxicity against human ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619472,478.0,BAO_0000219,,
7132,13617,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL619473,478.0,BAO_0000219,,
7133,13617,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL874368,478.0,BAO_0000219,,
7134,13617,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884003,478.0,BAO_0000219,,
7135,13617,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622690,478.0,BAO_0000219,,
7136,17672,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622691,478.0,BAO_0000219,,
7137,4544,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL622692,478.0,BAO_0000219,,
7138,4544,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623406,478.0,BAO_0000219,,
7139,16317,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL884004,478.0,BAO_0000219,,
7140,15099,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623407,478.0,BAO_0000219,,
7141,13978,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623408,478.0,BAO_0000219,,
7142,12989,In vitro antitumor activity against A2780 cell line.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623409,478.0,BAO_0000219,,
7143,5574,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL623410,478.0,BAO_0000219,,
7144,13528,In vitro cytotoxicity against A2780 human ovarian cancer cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL623576,478.0,BAO_0000219,,
7145,12782,Inhibitory activity against kidney A-CHN tumor cell growth in culture,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623577,626.0,BAO_0000219,,
7146,14255,The IC50 value was measured on ACHN cell line in renal tumor type.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623578,626.0,BAO_0000219,,
7147,16364,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623579,626.0,BAO_0000219,,
7148,17376,In vitro lethal concentration against most sensitive ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623580,626.0,BAO_0000219,,
7149,12016,Tested for cytotoxic activity against renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623581,626.0,BAO_0000219,,
7150,6058,Compound tested for growth inhibition of renal cancer cell line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL857456,626.0,BAO_0000219,,
7151,17708,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623582,626.0,BAO_0000219,,
7152,15176,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623583,626.0,BAO_0000219,,
7153,2806,In vitro anticancer activity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623584,626.0,BAO_0000219,,
7154,15300,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623585,626.0,BAO_0000219,,
7155,16364,Percent selectivity was evaluated in renal ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623586,626.0,BAO_0000219,,
7156,13859,In vitro inhibitory activity against renal ACHN cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623587,626.0,BAO_0000219,,
7157,11970,Tested for cytotoxicity against ACHN cell lines in renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875279,626.0,BAO_0000219,,
7158,2450,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623588,626.0,BAO_0000219,,
7159,12696,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623589,626.0,BAO_0000219,,
7160,12400,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623590,626.0,BAO_0000219,,
7161,12888,Cytotoxic effect on renal cancer line ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL623591,626.0,BAO_0000219,,
7162,3156,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623592,626.0,BAO_0000219,,
7163,3381,In vitro inhibition of Renal Cancer ACHN cell lines,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623593,626.0,BAO_0000219,,
7164,16747,Antitumor activity against human renal adenocarcinoma ACHN cells,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL623594,626.0,BAO_0000219,,
7165,16748,Antitumor activity against human renal adenocarcinoma ACHN cells.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Expert,1,,CHEMBL621833,626.0,BAO_0000219,,
7166,12062,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621834,626.0,BAO_0000219,,
7167,14769,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621835,626.0,BAO_0000219,,
7168,15895,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621836,626.0,BAO_0000219,,
7169,17376,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621837,626.0,BAO_0000219,,
7170,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL875280,626.0,BAO_0000219,,
7171,14882,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621838,626.0,BAO_0000219,,
7172,15661,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,F,,,Homo sapiens,9606.0,,,ACHN,,80025,N,1,Intermediate,1,,CHEMBL621839,626.0,BAO_0000219,,
7173,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621840,,BAO_0000019,,
7174,14579,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,F,,,,,,,,,10647,H,8,Autocuration,1,,CHEMBL621841,,BAO_0000019,,
7175,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,F,,,Cytomegalovirus,10358.0,,,HEL,,50529,N,1,Expert,1,,CHEMBL622979,468.0,BAO_0000218,,
7176,17290,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,F,,,Cytomegalovirus,10358.0,,,,,50529,N,1,Intermediate,1,,CHEMBL876595,,BAO_0000218,,
7177,15891,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620221,,BAO_0000357,,
7178,15890,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),B,,,,,,,,,12159,H,8,Autocuration,1,,CHEMBL620222,,BAO_0000357,,
7179,3801,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,F,,,Bos taurus,9913.0,,,ADDP cell line,,80670,N,1,Intermediate,1,,CHEMBL620506,979.0,BAO_0000219,,
7180,9222,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620507,980.0,BAO_0000219,,
7181,9222,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620508,980.0,BAO_0000219,,
7182,7257,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620509,980.0,BAO_0000219,,
7183,7257,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620510,980.0,BAO_0000219,,
7184,7257,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,A,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620511,980.0,BAO_0000219,,
7185,8084,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,F,,,Mus musculus,10090.0,,,ADJ/PC6,,80671,N,1,Intermediate,1,,CHEMBL620512,980.0,BAO_0000219,,
7186,14943,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620513,,BAO_0000019,,
7187,14943,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620514,,BAO_0000019,,
7188,14943,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,F,,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620515,,BAO_0000019,,
7189,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620516,,BAO_0000218,,
7190,3546,AUC value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620517,,BAO_0000218,1969.0,
7191,3546,AUC value in dog after oral administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620518,,BAO_0000218,1969.0,
7192,3546,Cmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620519,,BAO_0000218,,
7193,3546,Bioavailability in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621386,,BAO_0000218,,
7194,3546,Tmax value in dog after oral administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621387,,BAO_0000218,,
7195,3184,Compound was evaluated for its clearance when administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621388,,BAO_0000218,,
7196,16456,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621389,,BAO_0000218,,
7197,4809,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621390,,BAO_0000218,,
7198,4219,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL621391,,BAO_0000100,,
7199,3748,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621392,,BAO_0000218,,
7200,3132,Time taken for EC90 was determined when tested in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621393,,BAO_0000218,,
7201,4219,Half life (iv) was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621394,,BAO_0000218,,
7202,16907,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL621395,,BAO_0000218,2107.0,
7203,6057,Area under the curve was calculated in dog after iv administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621396,,BAO_0000218,,
7204,6057,Area under the curve was calculated in dog after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621397,,BAO_0000218,,
7205,17853,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621398,,BAO_0000218,,
7206,3639,pKa was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618818,,BAO_0000218,,
7207,14541,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618819,,BAO_0000218,,
7208,16456,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618820,,BAO_0000218,,
7209,16456,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873810,,BAO_0000218,,
7210,2652,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876606,,BAO_0000218,,
7211,3624,Compound was evaluated for the half-life (t 1/2) in hours,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618821,,BAO_0000218,,
7212,1337,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618822,,BAO_0000218,178.0,
7213,1337,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL618823,,BAO_0000218,178.0,
7214,4709,Half life after intravenous administration of 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618824,,BAO_0000218,,
7215,15660,Half life was measured in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618825,,BAO_0000218,,
7216,5302,Half life period in dog after 5 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618826,,BAO_0000218,,
7217,17791,Half life period was evaluated in dog; 4-4.8,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618827,,BAO_0000218,,
7218,6348,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618828,,BAO_0000218,,
7219,4257,Half-life was determined in dog after a3 mg/kg of iv dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618829,,BAO_0000218,,
7220,3771,Half-life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618830,,BAO_0000218,,
7221,6305,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618831,,BAO_0000218,,
7222,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL619489,,BAO_0000218,1969.0,
7223,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619649,,BAO_0000218,,
7224,3045,Compound was evaluated for the half life period after iv administration in Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876607,,BAO_0000218,,
7225,3043,Compound was evaluated for the half life period after oral administration in conscious dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619650,,BAO_0000218,,
7226,4839,Compound was tested for half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619651,,BAO_0000218,,
7227,4839,Compound was tested for its half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619652,,BAO_0000218,,
7228,5802,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619653,,BAO_0000218,,
7229,17839,Half life of compound in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619654,,BAO_0000218,,
7230,4219,Half life (iv) was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619655,,BAO_0000218,,
7231,13966,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL619656,,BAO_0000218,178.0,
7232,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL873812,,BAO_0000218,1969.0,
7233,3994,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,F,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621365,,BAO_0000218,1969.0,
7234,4453,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621366,,BAO_0000218,,
7235,6535,Half life in dog plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621367,,BAO_0000218,1969.0,
7236,6535,Half life in dog plasma after administration of 0.25 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621368,,BAO_0000218,1969.0,
7237,6535,Half life in dog plasma after administration of 1 mg/kg iv,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621369,,BAO_0000218,1969.0,
7238,3132,Half life in dog plasma was determined at dose 10 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621370,,BAO_0000218,1969.0,
7239,5374,Half life in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621371,,BAO_0000218,,
7240,5007,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621372,,BAO_0000218,,
7241,16907,Half life upon exposure to human plasma,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621373,,BAO_0000218,1969.0,
7242,6057,Half life was calculated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621374,,BAO_0000218,,
7243,5006,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621375,,BAO_0000218,,
7244,5473,Half life was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621376,,BAO_0000218,,
7245,4368,Half life by intravenous administration of 1.2 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619624,,BAO_0000218,,
7246,6448,Half life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875840,,BAO_0000218,,
7247,4353,Half life in dog after intra venous administration of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619625,,BAO_0000218,,
7248,4353,Half life in dog after intra venous administration of the compound; ND means Not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619626,,BAO_0000218,,
7249,4353,Half life in dog after po administration of the compound,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619627,,BAO_0000218,,
7250,4353,Half life in dog after po administration of the compound; ND means Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873817,,BAO_0000218,,
7251,6265,Half life in dog at the single oral dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619628,,BAO_0000218,,
7252,5006,Half life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619629,,BAO_0000218,,
7253,5356,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619630,,BAO_0000218,,
7254,405,Half life in rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619631,,BAO_0000218,,
7255,6642,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL619632,,BAO_0000218,,
7256,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619633,,BAO_0000218,10000001.0,
7257,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL875841,,BAO_0000218,10000001.0,
7258,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619634,,BAO_0000218,10000001.0,
7259,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619635,,BAO_0000218,10000001.0,
7260,10107,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL619636,,BAO_0000218,10000001.0,
7261,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619637,,BAO_0000218,10000004.0,
7262,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619638,,BAO_0000218,10000004.0,
7263,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619639,,BAO_0000218,10000004.0,
7264,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619640,,BAO_0000218,10000004.0,
7265,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619641,,BAO_0000218,10000004.0,
7266,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619642,,BAO_0000218,10000004.0,
7267,10107,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Gut,,,50594,N,1,Intermediate,1,,CHEMBL619643,,BAO_0000218,10000004.0,
7268,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL619644,,BAO_0000218,948.0,
7269,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621112,,BAO_0000218,948.0,
7270,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621113,,BAO_0000218,948.0,
7271,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621114,,BAO_0000218,948.0,
7272,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621115,,BAO_0000218,948.0,
7273,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621116,,BAO_0000218,948.0,
7274,10107,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL621117,,BAO_0000218,948.0,
7275,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621118,,BAO_0000218,2113.0,
7276,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621119,,BAO_0000218,2113.0,
7277,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621120,,BAO_0000218,2113.0,
7278,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621757,,BAO_0000218,2113.0,
7279,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621758,,BAO_0000218,2113.0,
7280,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621759,,BAO_0000218,2113.0,
7281,10107,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621760,,BAO_0000218,2113.0,
7282,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621761,,BAO_0000218,2107.0,
7283,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621762,,BAO_0000218,2107.0,
7284,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621763,,BAO_0000218,2107.0,
7285,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624502,,BAO_0000218,2107.0,
7286,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624503,,BAO_0000218,2107.0,
7287,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624504,,BAO_0000218,2107.0,
7288,10107,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624505,,BAO_0000218,2107.0,
7289,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624506,,BAO_0000218,2048.0,
7290,5895,In vitro cytotoxicity against A2780 (human ovarian cancer),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624507,478.0,BAO_0000219,,
7291,6338,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624508,478.0,BAO_0000219,,
7292,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624509,478.0,BAO_0000219,,
7293,15163,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624510,478.0,BAO_0000219,,
7294,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL875956,478.0,BAO_0000219,,
7295,15000,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL839885,478.0,BAO_0000219,,
7296,14729,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL624511,478.0,BAO_0000219,,
7297,17270,In vitro cytotoxicity against A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624512,478.0,BAO_0000219,,
7298,5685,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624513,478.0,BAO_0000219,,
7299,3563,In vitro inhibitory activity against human ovarian cancer A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL624514,478.0,BAO_0000219,,
7300,17753,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618547,478.0,BAO_0000218,,
7301,16317,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618548,478.0,BAO_0000219,,
7302,16936,Inhibition of tubulin polymerization in analogy of ca.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618549,478.0,BAO_0000219,,
7303,3801,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618550,478.0,BAO_0000219,,
7304,6181,Cytotoxic effect in ovarian cancer cell line (A2780),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618551,478.0,BAO_0000219,,
7305,5318,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618552,478.0,BAO_0000219,,
7306,4840,Tested for the cytotoxicity in A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618553,478.0,BAO_0000219,,
7307,15748,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618554,478.0,BAO_0000219,,
7308,15748,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618555,478.0,BAO_0000219,,
7309,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618556,481.0,BAO_0000219,,
7310,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618557,481.0,BAO_0000219,,
7311,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618558,481.0,BAO_0000219,,
7312,15748,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),F,,,,,,,A2780cisR,,80017,N,1,Intermediate,1,,CHEMBL618559,481.0,BAO_0000219,,
7313,17753,In vivo log of cells killed after administration of compound in A2780 cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618560,478.0,BAO_0000218,,
7314,17753,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,F,In vivo,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618561,478.0,BAO_0000218,,
7315,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618562,478.0,BAO_0000219,,
7316,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618563,478.0,BAO_0000219,,
7317,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618564,478.0,BAO_0000219,,
7318,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618565,478.0,BAO_0000219,,
7319,17528,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618566,478.0,BAO_0000218,,
7320,6633,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL618567,478.0,BAO_0000219,,
7321,15000,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618568,478.0,BAO_0000219,,
7322,17528,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL618569,478.0,BAO_0000219,,
7323,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621857,478.0,BAO_0000219,,
7324,16936,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621858,478.0,BAO_0000219,,
7325,16936,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621859,478.0,BAO_0000219,,
7326,16936,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621860,478.0,BAO_0000219,,
7327,16936,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621861,478.0,BAO_0000219,,
7328,16936,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621862,478.0,BAO_0000219,,
7329,16936,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621863,478.0,BAO_0000219,,
7330,16936,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621864,478.0,BAO_0000219,,
7331,16936,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621865,478.0,BAO_0000219,,
7332,17737,In vitro antiproliferative activity against A2780 cell line,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621866,478.0,BAO_0000219,,
7333,17764,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,F,,,Mus musculus,10090.0,,,A2780,,81034,N,1,Expert,1,,CHEMBL621867,478.0,BAO_0000219,,
7334,3830,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL621868,478.0,BAO_0000219,,
7335,3829,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,F,,,Homo sapiens,9606.0,,,A2780,,81034,N,1,Intermediate,1,,CHEMBL875282,478.0,BAO_0000219,,
7336,3546,Vc value in dog after IV administration at a dose of 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621869,,BAO_0000218,,
7337,3546,Half life period in dog after IV administration at a dose of 5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621870,,BAO_0000218,,
7338,5668,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621871,,BAO_0000019,,
7339,3443,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621243,,BAO_0000218,1969.0,
7340,3443,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,,,Cercopithecidae,9527.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621244,,BAO_0000218,1969.0,
7341,4256,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621245,,BAO_0000218,,
7342,4256,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621246,,BAO_0000218,,
7343,4256,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621247,,BAO_0000218,,
7344,4256,Oral Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618386,,BAO_0000218,,
7345,1916,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618387,,BAO_0000218,,
7346,5302,Area under curve value in monkey at a dose of 5 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618388,,BAO_0000218,,
7347,4257,Area under curve was determined in monkey after a 3 mg/kg of oral dose,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618389,,BAO_0000218,,
7348,5355,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618574,,BAO_0000019,,
7349,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618575,,BAO_0000019,,
7350,5355,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618576,,BAO_0000019,,
7351,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618577,,BAO_0000218,,
7352,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876487,,BAO_0000218,,
7353,6062,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618578,,BAO_0000218,,
7354,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618579,,BAO_0000218,,
7355,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618580,,BAO_0000019,,
7356,5394,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618581,,BAO_0000218,,
7357,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618582,,BAO_0000218,,
7358,17509,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618583,,BAO_0000218,,
7359,17509,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618584,,BAO_0000218,,
7360,6641,Oral AUCN in monkey (dosed at 0.5 mpk iv ),A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618585,,BAO_0000218,,
7361,5355,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618586,,BAO_0000218,,
7362,3443,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618587,,BAO_0000218,,
7363,3443,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618588,,BAO_0000218,,
7364,17409,Binding towards monkey plasma protein at 10 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618589,,BAO_0000019,,
7365,17409,Binding towards monkey plasma protein at 100 uM,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618590,,BAO_0000019,,
7366,1052,Apparent bioavailability in squirrel monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872262,,BAO_0000218,,
7367,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618591,,BAO_0000218,,
7368,17509,Bioavailability in monkey (dose 2 mg/kg),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618592,,BAO_0000218,,
7369,5394,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL876488,,BAO_0000218,,
7370,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618593,,BAO_0000218,,
7371,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,monkey,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618594,,BAO_0000218,,
7372,3045,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL618595,,BAO_0000218,,
7373,17796,Clearance of the drug was measured in cynomolgus,A,,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621469,,BAO_0000019,,
7374,1399,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621470,,BAO_0000218,,
7375,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621471,,BAO_0000218,,
7376,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621472,,BAO_0000218,1969.0,
7377,17267,Plasma clearance in rhesus monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621473,,BAO_0000218,,
7378,6535,Plasma clearance in monkey after administration of 1 mg/kg iv,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621474,,BAO_0000218,,
7379,5922,Plasma clearance in cynomolgus monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621475,,BAO_0000218,,
7380,6221,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621476,,BAO_0000218,,
7381,5668,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624290,,BAO_0000218,,
7382,5355,The total clearance was determined after intravenous administration in cynomolgus monkeys,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624291,,BAO_0000218,,
7383,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624292,,BAO_0000218,,
7384,5355,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624293,,BAO_0000218,,
7385,4578,Tested for Clearance upon iv administration to african green monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624294,,BAO_0000218,,
7386,17592,Clearance in monkey,A,In vivo,,Cercopithecidae,9527.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624295,,BAO_0000218,,
7387,6641,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624296,,BAO_0000218,,
7388,6642,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624297,,BAO_0000218,,
7389,16367,Half life was evaluated after intravenous administration to dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624298,,BAO_0000218,,
7390,5472,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624299,,BAO_0000218,,
7391,5474,Half life was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624300,,BAO_0000218,,
7392,5654,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624301,,BAO_0000218,,
7393,6227,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624302,,BAO_0000218,,
7394,6227,Half life period after intravenous administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876026,,BAO_0000218,,
7395,6221,Half life period after oral administration (2.5 mg/kg) in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624303,,BAO_0000218,,
7396,4527,Half life period at a dose of 1 uM/kg in dog was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624304,,BAO_0000218,,
7397,5668,Half life period was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624305,,BAO_0000218,,
7398,5668,Half life period was determine after peroral administration at 5 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624306,,BAO_0000218,,
7399,3854,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624307,,BAO_0000218,,
7400,5505,Half life period was determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624308,,BAO_0000218,,
7401,6251,Half life period by iv administration in dog at a dose of 6 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624309,,BAO_0000218,,
7402,1918,Half life period was evaluated in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624310,,BAO_0000218,,
7403,5546,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625003,,BAO_0000218,,
7404,4809,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625004,,BAO_0000218,,
7405,6215,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625005,,BAO_0000218,,
7406,4527,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873813,,BAO_0000218,,
7407,17594,Half-life after oral dose of compound at 3 mg/kg in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625006,,BAO_0000218,,
7408,17839,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625007,,BAO_0000218,,
7409,17839,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876027,,BAO_0000218,,
7410,17839,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625008,,BAO_0000218,,
7411,17839,Half-life of compound in dog following p.o. administration of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625009,,BAO_0000218,,
7412,5210,Half-life of compound in plasma of dog was determined,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625010,,BAO_0000218,1969.0,
7413,5210,Half-life of compound was determined in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625011,,BAO_0000218,,
7414,2959,Half-life after administration of 4 mg/Kg oral dose in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621553,,BAO_0000218,,
7415,4137,Half-life after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621554,,BAO_0000218,,
7416,5064,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621555,,BAO_0000218,,
7417,5147,Half-life in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621556,,BAO_0000218,,
7418,5145,Half-life in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621557,,BAO_0000218,,
7419,6123,Half-life in dog after oral administration at 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621558,,BAO_0000218,,
7420,6123,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621559,,BAO_0000218,,
7421,4333,Half-life in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621560,,BAO_0000218,,
7422,4333,Half-life in dogs; ND indicates not determined,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL876028,,BAO_0000218,,
7423,12500,Half-life in plasma of dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621561,,BAO_0000218,1969.0,
7424,12500,Half-life in plasma of dog at dose of 3-10 mgkg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621562,,BAO_0000218,1969.0,
7425,6005,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621563,,BAO_0000218,,
7426,6062,Half-life was measured in dog after an iv dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621564,,BAO_0000218,,
7427,17650,Half-life was measured in dogs after an oral dose of 10 uM/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621565,,BAO_0000218,,
7428,5530,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621566,,BAO_0000218,,
7429,5530,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621567,,BAO_0000218,,
7430,5600,Half-life of the compound after 0.3 mg/kg po administration in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622978,,BAO_0000218,,
7431,6039,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL873814,,BAO_0000218,,
7432,6039,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623219,,BAO_0000218,,
7433,6039,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624477,,BAO_0000218,,
7434,6227,t1/2 in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624478,,BAO_0000218,,
7435,14541,Half-life period measured in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624479,,BAO_0000218,,
7436,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624480,,BAO_0000218,,
7437,4521,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623595,,BAO_0000218,,
7438,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623596,,BAO_0000218,,
7439,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",A,In vitro,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623597,,BAO_0000218,1969.0,
7440,5444,In vivo half life period was calculated at 1 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623598,,BAO_0000218,,
7441,5444,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623599,,BAO_0000218,,
7442,17853,Longer half-life in dog (i.v.) at 0.5 mpk,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623600,,BAO_0000218,,
7443,4353,Oral bioavailability in dog (dose 5 uM/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623601,,BAO_0000218,,
7444,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623602,,BAO_0000218,,
7445,16452,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623603,,BAO_0000218,,
7446,16452,Bioavailability in dog (dose 1 mg/kg i.v.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623604,,BAO_0000218,,
7447,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623605,,BAO_0000218,2048.0,
7448,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623606,,BAO_0000218,2048.0,
7449,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623607,,BAO_0000218,2048.0,
7450,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623608,,BAO_0000218,2048.0,
7451,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623609,,BAO_0000218,2048.0,
7452,10107,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL623610,,BAO_0000218,2048.0,
7453,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623611,,BAO_0000218,2385.0,
7454,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623612,,BAO_0000218,2385.0,
7455,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623613,,BAO_0000218,2385.0,
7456,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623614,,BAO_0000218,2385.0,
7457,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623615,,BAO_0000218,2385.0,
7458,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623616,,BAO_0000218,2385.0,
7459,10107,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL623617,,BAO_0000218,2385.0,
7460,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL875944,,BAO_0000218,14.0,
7461,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623618,,BAO_0000218,14.0,
7462,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623619,,BAO_0000218,14.0,
7463,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623620,,BAO_0000218,14.0,
7464,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623621,,BAO_0000218,14.0,
7465,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623622,,BAO_0000218,14.0,
7466,10107,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL623623,,BAO_0000218,14.0,
7467,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL623624,,BAO_0000218,2106.0,
7468,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618521,,BAO_0000218,2106.0,
7469,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618522,,BAO_0000218,2106.0,
7470,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618523,,BAO_0000218,2106.0,
7471,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618524,,BAO_0000218,2106.0,
7472,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL618525,,BAO_0000218,2106.0,
7473,10107,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL624586,,BAO_0000218,2106.0,
7474,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624587,,BAO_0000218,945.0,
7475,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624588,,BAO_0000218,945.0,
7476,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624589,,BAO_0000218,945.0,
7477,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624590,,BAO_0000218,945.0,
7478,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624591,,BAO_0000218,945.0,
7479,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624592,,BAO_0000218,945.0,
7480,10107,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL624593,,BAO_0000218,945.0,
7481,4689,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624594,,BAO_0000218,,
7482,4950,Tested for the bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624595,,BAO_0000218,,
7483,5328,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624596,,BAO_0000218,,
7484,406,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624597,,BAO_0000218,,
7485,12500,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624598,,BAO_0000218,,
7486,12500,Bioavailability in rat (dose 3-10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624599,,BAO_0000218,,
7487,5247,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875166,,BAO_0000218,,
7488,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624600,,BAO_0000218,1969.0,
7489,4186,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624601,,BAO_0000218,1969.0,
7490,6647,Half life after oral administration was determined in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624602,,BAO_0000218,,
7491,6484,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624603,,BAO_0000218,,
7492,3249,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624604,,BAO_0000218,,
7493,6281,Plasma half life in rat at oral dose 2.8 mg/mk body weight,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624605,,BAO_0000218,1969.0,
7494,3307,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624606,,BAO_0000218,,
7495,12058,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624607,,BAO_0000218,178.0,
7496,8833,Hill coefficient of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624608,,BAO_0000218,,
7497,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624609,,BAO_0000218,178.0,
7498,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624610,,BAO_0000218,178.0,
7499,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624611,,BAO_0000218,178.0,
7500,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624612,,BAO_0000218,178.0,
7501,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875167,,BAO_0000218,178.0,
7502,3193,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624613,,BAO_0000218,178.0,
7503,3193,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624614,,BAO_0000218,178.0,
7504,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624392,,BAO_0000218,,
7505,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624393,,BAO_0000218,955.0,
7506,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624394,,BAO_0000218,955.0,
7507,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624395,,BAO_0000218,955.0,
7508,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624396,,BAO_0000218,955.0,
7509,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624397,,BAO_0000218,955.0,
7510,13950,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624398,,BAO_0000218,2046.0,
7511,13950,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624399,,BAO_0000218,2046.0,
7512,13950,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624400,,BAO_0000218,2046.0,
7513,13950,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624401,,BAO_0000218,2046.0,
7514,13950,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624402,,BAO_0000218,2046.0,
7515,9866,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624403,,BAO_0000218,178.0,
7516,9866,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624404,,BAO_0000218,178.0,
7517,9866,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624405,,BAO_0000218,178.0,
7518,9866,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624406,,BAO_0000218,10000001.0,
7519,9866,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624407,,BAO_0000218,10000001.0,
7520,9866,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL624408,,BAO_0000218,10000001.0,
7521,9866,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618644,,BAO_0000218,948.0,
7522,9866,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618645,,BAO_0000218,948.0,
7523,9866,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL618646,,BAO_0000218,948.0,
7524,9866,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL618647,,BAO_0000218,2113.0,
7525,9866,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL618648,,BAO_0000218,2113.0,
7526,9866,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL618649,,BAO_0000218,2113.0,
7527,9866,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618650,,BAO_0000218,2107.0,
7528,9866,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618651,,BAO_0000218,2107.0,
7529,9866,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876497,,BAO_0000218,2107.0,
7530,9866,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618652,,BAO_0000218,2048.0,
7531,9866,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618653,,BAO_0000218,2048.0,
7532,9866,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618654,,BAO_0000218,2048.0,
7533,6351,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618655,,BAO_0000218,,
7534,1465,Compound was tested for solubility in water,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618656,,BAO_0000218,,
7535,5182,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),P,,,,,,,,,22229,U,0,Intermediate,1,,CHEMBL618657,,BAO_0000100,,
7536,17847,Solubility was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618658,,BAO_0000218,,
7537,15339,solubility in water (ug/mL) at 37 degree C.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618659,,BAO_0000218,,
7538,5202,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618660,,BAO_0000218,,
7539,1088,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618661,,BAO_0000218,,
7540,3169,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873807,,BAO_0000218,,
7541,5353,Half life in Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618662,,BAO_0000218,,
7542,2864,Half life period after 3 mg/kg iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618663,,BAO_0000218,,
7543,2864,Half life period after 3 mg/kg iv administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618664,,BAO_0000218,,
7544,2864,Half life period after 3 mg/kg iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618665,,BAO_0000218,,
7545,6362,Half life period in female Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876498,,BAO_0000218,,
7546,6249,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618666,,BAO_0000218,,
7547,3169,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620440,,BAO_0000218,,
7548,3169,Half-life in rats with metabolic oxidation,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620441,,BAO_0000218,,
7549,3169,Half-life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620442,,BAO_0000218,,
7550,17260,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620443,,BAO_0000218,,
7551,17260,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620444,,BAO_0000218,,
7552,17260,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620445,,BAO_0000218,,
7553,17260,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620446,,BAO_0000218,,
7554,2879,Biological half-life measured in plasma of rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620447,,BAO_0000218,1969.0,
7555,2879,Biological half-life measured in plasma of rat; 22-25,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621129,,BAO_0000218,1969.0,
7556,2879,Biological half-life measured in plasma of rat; 9-16,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621130,,BAO_0000218,1969.0,
7557,3184,Compound was evaluated for its half life when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873808,,BAO_0000218,,
7558,4891,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876598,,BAO_0000218,,
7559,429,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621131,,BAO_0000218,,
7560,5656,Half life (T1/2) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621132,,BAO_0000218,,
7561,4413,Half life of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621133,,BAO_0000218,,
7562,3598,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL621312,,BAO_0000218,,
7563,17267,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621313,,BAO_0000218,,
7564,4727,Half life of compound was determined in rat blood,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621314,,BAO_0000218,178.0,
7565,17651,Half life at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621315,,BAO_0000218,,
7566,17651,Half life at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621316,,BAO_0000218,,
7567,401,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621317,,BAO_0000218,,
7568,4942,Half life in rats in hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621318,,BAO_0000218,,
7569,17735,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621319,,BAO_0000218,,
7570,6056,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621377,,BAO_0000218,,
7571,5213,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621378,,BAO_0000218,,
7572,6616,Half life after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876599,,BAO_0000218,,
7573,5937,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621379,,BAO_0000218,,
7574,5819,Half life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621380,,BAO_0000218,1969.0,
7575,5819,Half life in rat plasma; Not detected,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621381,,BAO_0000218,1969.0,
7576,6803,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618515,,BAO_0000218,,
7577,17804,Half life period of compound was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618516,,BAO_0000218,,
7578,17804,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618517,,BAO_0000218,,
7579,5948,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618518,,BAO_0000218,,
7580,1916,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618519,,BAO_0000218,,
7581,1916,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618698,,BAO_0000218,,
7582,1916,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618862,,BAO_0000218,,
7583,4890,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618863,,BAO_0000218,,
7584,17764,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618864,,BAO_0000218,,
7585,4727,Half life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618865,,BAO_0000218,,
7586,17509,Half-life 24 hr after 10 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618866,,BAO_0000218,,
7587,17509,Half-life 24 hr after 2 mg/kg iv administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618867,,BAO_0000218,,
7588,6597,Half-life consistent with the observed metabolic steady state in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875828,,BAO_0000218,,
7589,17735,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618868,,BAO_0000218,,
7590,6597,Half-life for oxidative metabolic stability was determined using male human,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618869,,BAO_0000218,,
7591,17670,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618870,,BAO_0000218,,
7592,1696,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618871,,BAO_0000218,1969.0,
7593,1742,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618872,,BAO_0000218,1969.0,
7594,17800,Half-life in rats was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873816,,BAO_0000218,,
7595,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618873,,BAO_0000218,,
7596,11954,Area under curve after oral dose of 0.1 mg//kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621602,,BAO_0000019,,
7597,11954,Area under curve after oral dose of 0.3 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621603,,BAO_0000218,,
7598,11954,Area under curve after oral dose of 1 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621604,,BAO_0000218,,
7599,11954,Area under curve after oral dose of 10 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621605,,BAO_0000218,,
7600,11954,Area under curve after oral dose of 23.4 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621606,,BAO_0000218,,
7601,11954,Area under curve after oral dose of 3 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621607,,BAO_0000218,,
7602,11954,Area under curve after oral dose of 3.87 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621608,,BAO_0000218,,
7603,5237,Area under curve was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621609,,BAO_0000019,,
7604,4026,Area under curve at a dose of 10 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621610,,BAO_0000218,,
7605,5237,Area under curve was determined; ND=No data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621611,,BAO_0000218,,
7606,14793,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621612,,BAO_0000218,,
7607,14793,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622308,,BAO_0000218,,
7608,14793,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622309,,BAO_0000218,,
7609,14793,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622310,,BAO_0000218,,
7610,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622311,,BAO_0000218,,
7611,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622312,,BAO_0000218,,
7612,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622931,,BAO_0000218,,
7613,14793,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622932,,BAO_0000218,,
7614,14793,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622736,,BAO_0000218,1969.0,
7615,14793,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622737,,BAO_0000218,1969.0,
7616,14793,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622738,,BAO_0000218,1969.0,
7617,14793,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622739,,BAO_0000218,1969.0,
7618,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622740,,BAO_0000218,1969.0,
7619,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622741,,BAO_0000218,1969.0,
7620,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622742,,BAO_0000218,1969.0,
7621,14793,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622743,,BAO_0000218,1969.0,
7622,11637,AUC in mice,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL622744,,BAO_0000218,1969.0,
7623,11149,Area under curve was measured from the graph obtained from concentration Vs time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624134,,BAO_0000019,,
7624,10016,Area under curve value of compound per hour after oral administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624135,,BAO_0000019,,
7625,17796,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624136,,BAO_0000218,,
7626,17796,Area under curve was determined after oral administration in rats; No data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624137,,BAO_0000218,,
7627,17796,Area under curve was determined after oral administration in rats;No data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624320,,BAO_0000218,,
7628,12923,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624321,,BAO_0000218,,
7629,15372,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624322,,BAO_0000218,,
7630,15372,Area under curve was determined for the compound after iv dose of 5.06 in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624323,,BAO_0000218,,
7631,15372,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624324,,BAO_0000218,,
7632,15372,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624325,,BAO_0000218,,
7633,15372,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624326,,BAO_0000218,,
7634,15372,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624327,,BAO_0000218,,
7635,15372,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624328,,BAO_0000218,,
7636,14169,Area under curve was determined in Dogs after peroral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627848,,BAO_0000218,,
7637,14169,Area under curve was determined in Rats after peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627849,,BAO_0000218,,
7638,14258,Area under curve was determined in carotid blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627850,,BAO_0000218,,
7639,14258,Area under curve was determined in portal blood of rat when administered intradermally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627851,,BAO_0000218,,
7640,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627852,,BAO_0000218,,
7641,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627853,,BAO_0000218,,
7642,15011,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627854,,BAO_0000218,,
7643,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627855,,BAO_0000218,,
7644,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627856,,BAO_0000218,,
7645,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875339,,BAO_0000218,,
7646,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627857,,BAO_0000218,,
7647,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627858,,BAO_0000218,2106.0,
7648,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627859,,BAO_0000218,178.0,
7649,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627860,,BAO_0000218,955.0,
7650,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627019,,BAO_0000218,948.0,
7651,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627020,,BAO_0000218,2107.0,
7652,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627021,,BAO_0000218,2048.0,
7653,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627022,,BAO_0000218,2385.0,
7654,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627023,,BAO_0000218,,
7655,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627024,,BAO_0000218,2106.0,
7656,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627025,,BAO_0000218,2046.0,
7657,10130,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627026,,BAO_0000218,2113.0,
7658,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627027,,BAO_0000218,178.0,
7659,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627028,,BAO_0000218,955.0,
7660,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627029,,BAO_0000218,948.0,
7661,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627030,,BAO_0000218,2113.0,
7662,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627031,,BAO_0000218,2107.0,
7663,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627032,,BAO_0000218,2048.0,
7664,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627033,,BAO_0000218,2385.0,
7665,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627034,,BAO_0000218,,
7666,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627035,,BAO_0000218,2106.0,
7667,10130,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627036,,BAO_0000218,2046.0,
7668,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875340,,BAO_0000218,178.0,
7669,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627037,,BAO_0000218,948.0,
7670,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627038,,BAO_0000218,2113.0,
7671,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627039,,BAO_0000218,2107.0,
7672,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627040,,BAO_0000218,2385.0,
7673,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL624663,,BAO_0000218,2106.0,
7674,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL625963,,BAO_0000218,2046.0,
7675,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL876799,,BAO_0000218,955.0,
7676,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626133,,BAO_0000218,2048.0,
7677,10130,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626134,,BAO_0000218,,
7678,6295,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626135,,BAO_0000218,,
7679,6296,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626136,,BAO_0000218,,
7680,6296,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626137,,BAO_0000218,,
7681,6295,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626138,,BAO_0000218,,
7682,6296,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626139,,BAO_0000218,,
7683,17260,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626140,,BAO_0000218,,
7684,17260,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626141,,BAO_0000218,,
7685,17686,C24h in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626142,,BAO_0000218,,
7686,9866,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627930,,BAO_0000218,2385.0,
7687,9866,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627931,,BAO_0000218,2385.0,
7688,9866,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627932,,BAO_0000218,2385.0,
7689,9866,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627933,,BAO_0000218,2106.0,
7690,9866,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627934,,BAO_0000218,2106.0,
7691,9866,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627935,,BAO_0000218,2106.0,
7692,9866,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627936,,BAO_0000218,178.0,
7693,9866,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627937,,BAO_0000218,178.0,
7694,9866,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627938,,BAO_0000218,178.0,
7695,9866,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627939,,BAO_0000218,178.0,
7696,9866,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627940,,BAO_0000218,178.0,
7697,9866,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627941,,BAO_0000218,178.0,
7698,9866,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL876800,,BAO_0000218,178.0,
7699,9866,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627942,,BAO_0000218,178.0,
7700,9866,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627943,,BAO_0000218,178.0,
7701,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627944,,BAO_0000218,178.0,
7702,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627945,,BAO_0000218,178.0,
7703,9866,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628584,,BAO_0000218,178.0,
7704,9866,Biodistribution in rat blood in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628585,,BAO_0000218,178.0,
7705,9866,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628586,,BAO_0000218,178.0,
7706,9866,Biodistribution in rat blood in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628587,,BAO_0000218,178.0,
7707,9866,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628588,,BAO_0000218,178.0,
7708,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628589,,BAO_0000218,178.0,
7709,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625304,,BAO_0000218,178.0,
7710,9866,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625305,,BAO_0000218,178.0,
7711,9866,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625306,,BAO_0000218,178.0,
7712,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625307,,BAO_0000218,178.0,
7713,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625308,,BAO_0000218,178.0,
7714,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627740,,BAO_0000218,178.0,
7715,9866,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627741,,BAO_0000218,178.0,
7716,9866,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627742,,BAO_0000218,178.0,
7717,9866,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627743,,BAO_0000218,178.0,
7718,9866,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627744,,BAO_0000218,178.0,
7719,9866,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627745,,BAO_0000218,10000001.0,
7720,9866,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627746,,BAO_0000218,10000001.0,
7721,9866,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627747,,BAO_0000218,10000001.0,
7722,9866,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL876810,,BAO_0000218,10000001.0,
7723,9866,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627748,,BAO_0000218,10000001.0,
7724,9866,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627749,,BAO_0000218,10000001.0,
7725,9866,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627750,,BAO_0000218,10000001.0,
7726,9866,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618728,,BAO_0000218,10000001.0,
7727,9866,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618729,,BAO_0000218,10000001.0,
7728,9866,Biodistribution in rat bone in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618730,,BAO_0000218,10000001.0,
7729,9866,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618731,,BAO_0000218,10000001.0,
7730,9866,Biodistribution in rat bone in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618732,,BAO_0000218,10000001.0,
7731,9866,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618733,,BAO_0000218,10000001.0,
7732,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618734,,BAO_0000218,10000001.0,
7733,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618735,,BAO_0000218,10000001.0,
7734,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL876602,,BAO_0000218,10000001.0,
7735,9866,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618736,,BAO_0000218,10000001.0,
7736,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618737,,BAO_0000218,10000001.0,
7737,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618738,,BAO_0000218,10000001.0,
7738,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618739,,BAO_0000218,10000001.0,
7739,9866,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618740,,BAO_0000218,10000001.0,
7740,9866,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618741,,BAO_0000218,10000001.0,
7741,9866,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618742,,BAO_0000218,10000001.0,
7742,9866,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL618743,,BAO_0000218,10000001.0,
7743,17752,Half-life from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618744,,BAO_0000218,1969.0,
7744,5610,Half-life in male rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618745,,BAO_0000218,,
7745,5939,Half-life in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620479,,BAO_0000218,,
7746,5939,Half-life in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620480,,BAO_0000218,,
7747,17771,Half-life in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620481,,BAO_0000218,,
7748,1974,Half-life was evaluated in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620482,,BAO_0000218,,
7749,4239,Half-life was measured in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876603,,BAO_0000218,,
7750,6681,Half-life period for the compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620483,,BAO_0000218,,
7751,17752,Half-life period in rats after intravenous administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620484,,BAO_0000218,,
7752,6046,Half-life period in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620485,,BAO_0000218,,
7753,6685,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620486,,BAO_0000218,,
7754,6685,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620487,,BAO_0000218,,
7755,6685,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620488,,BAO_0000218,,
7756,4727,Half-life time in rat the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620489,,BAO_0000218,,
7757,1088,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620490,,BAO_0000218,,
7758,5610,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620491,,BAO_0000218,,
7759,3032,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876604,,BAO_0000218,1969.0,
7760,5199,Oral half life was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620492,,BAO_0000218,,
7761,14941,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620493,,BAO_0000218,,
7762,4408,Pharmacokinetic property (t1/2) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620494,,BAO_0000218,,
7763,2552,Plasma elimination half-life was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620495,,BAO_0000218,1969.0,
7764,5199,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620496,,BAO_0000218,1969.0,
7765,15662,Plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620497,,BAO_0000218,1969.0,
7766,1465,Plasma half-life was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620498,,BAO_0000218,1969.0,
7767,1446,Plasma half-life following oral administration in Fisher rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620499,,BAO_0000218,1969.0,
7768,6824,Plasma half-life in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620500,,BAO_0000218,1969.0,
7769,17533,Plasmatic Half-life after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873809,,BAO_0000218,1969.0,
7770,5979,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620501,,BAO_0000218,,
7771,4689,Terminal half life after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620502,,BAO_0000218,,
7772,4689,Terminal half life in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620503,,BAO_0000218,,
7773,2463,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620504,,BAO_0000218,,
7774,4883,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876605,,BAO_0000218,,
7775,4883,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620505,,BAO_0000218,,
7776,15662,plasma half life was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873811,,BAO_0000218,1969.0,
7777,3598,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL624016,,BAO_0000218,,
7778,4576,Half life of compound determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624017,,BAO_0000218,,
7779,4576,Mean residence time determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624018,,BAO_0000218,,
7780,4576,Plasma half life determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624019,,BAO_0000218,,
7781,4910,Compound was evaluated for Tmax in brain after intravenous administration in male rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624020,,BAO_0000218,955.0,
7782,4891,Compound was evaluated for pharmacokinetic parameter maximum time period,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624201,,BAO_0000218,,
7783,429,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL872528,,BAO_0000218,,
7784,5974,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624202,,BAO_0000218,,
7785,5974,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624203,,BAO_0000218,,
7786,5974,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624350,,BAO_0000218,,
7787,5974,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621320,,BAO_0000218,,
7788,17582,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621321,,BAO_0000218,,
7789,4026,Maximum time (Tmax) required to reach Cmax in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621322,,BAO_0000218,,
7790,4890,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621323,,BAO_0000218,,
7791,6571,Maximum time of clearance of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621324,,BAO_0000218,,
7792,4727,Maximum time at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621325,,BAO_0000218,,
7793,17651,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875837,,BAO_0000218,1969.0,
7794,17651,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621326,,BAO_0000218,1969.0,
7795,14465,Tmax in Guinea pig (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621327,,BAO_0000218,,
7796,14941,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621328,,BAO_0000218,,
7797,5960,Pharmacokinetic parameter (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621329,,BAO_0000218,,
7798,5022,Pharmacokinetic parameter (Tmax) was estimated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621330,,BAO_0000218,,
7799,4408,Pharmacokinetic property (Tmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621331,,BAO_0000218,,
7800,5983,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621332,,BAO_0000218,,
7801,4689,T max in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621333,,BAO_0000218,,
7802,2792,T max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621334,,BAO_0000218,,
7803,15011,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621335,,BAO_0000218,,
7804,14180,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621336,,BAO_0000218,,
7805,14180,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621337,,BAO_0000218,,
7806,14599,Area under curve was measured after i.v. administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621338,,BAO_0000218,,
7807,14599,Area under curve was measured after iv administration into Beagle dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875838,,BAO_0000218,,
7808,14599,Area under curve was measured after po administration into Beagle dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621339,,BAO_0000218,,
7809,14599,Area under curve was measured after po administration into Beagle dog.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621340,,BAO_0000218,,
7810,15675,Area under curve was measured at peroral dose of 3 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621341,,BAO_0000218,,
7811,12706,Area under curve was measured by using concentration Vs time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621342,,BAO_0000019,,
7812,12706,Area under curve was measured by using concentration Vs time; not tested,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621343,,BAO_0000019,,
7813,9750,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621344,,BAO_0000218,,
7814,9750,Area under curve(AUC) was measured in mice after oral administration.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621345,,BAO_0000218,,
7815,14691,Area under curve(AUC) value of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621346,,BAO_0000019,,
7816,14691,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL621347,,BAO_0000218,,
7817,14691,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621348,,BAO_0000218,,
7818,2939,Area under curve(carotid artery) was determined by the availability in blood,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL621349,,BAO_0000019,178.0,
7819,2939,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL621350,,BAO_0000019,178.0,
7820,2939,Area under curve(carotid artery) was determined by the availability in blood; No data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL875839,,BAO_0000019,178.0,
7821,2939,Area under curve(portal vein) was determined by the availability in blood,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620211,,BAO_0000019,178.0,
7822,2939,Area under curve(portal vein) was determined by the availability in blood; ND means no data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620212,,BAO_0000019,178.0,
7823,2939,Area under curve(portal vein) was determined by the availability in blood; No data,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL620213,,BAO_0000019,178.0,
7824,9552,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL620214,,BAO_0000218,1969.0,
7825,9552,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL620215,,BAO_0000218,1969.0,
7826,9552,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL620216,,BAO_0000218,1969.0,
7827,9552,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620888,,BAO_0000218,1969.0,
7828,9552,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL620889,,BAO_0000218,1969.0,
7829,9552,Area under plasma concentration vs time curve observed in rats for 0-3 h,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL620890,,BAO_0000019,1969.0,
7830,11911,Area under plasma time curve determined in male rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL620891,,BAO_0000218,1969.0,
7831,16618,Area under the MAP curve measured over 5 min.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL620892,,BAO_0000019,,
7832,14387,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621079,,BAO_0000218,,
7833,14387,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL621080,,BAO_0000218,,
7834,12836,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621081,,BAO_0000218,,
7835,12836,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,A,,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL621082,,BAO_0000218,,
7836,12836,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621083,,BAO_0000218,,
7837,14339,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621084,,BAO_0000218,,
7838,14339,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621085,,BAO_0000218,,
7839,14339,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621086,,BAO_0000218,,
7840,10524,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621087,,BAO_0000218,,
7841,9994,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622607,,BAO_0000218,,
7842,11325,Serum AUC in marmosets (IV dose),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622608,,BAO_0000218,,
7843,12536,Area under the curve after intravenous administration at a dose of 10 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624481,,BAO_0000019,,
7844,12536,Area under the curve after intravenous administration at a dose of 2 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624482,,BAO_0000019,,
7845,12536,Area under the curve after intravenous administration at a dose of 4 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624483,,BAO_0000019,,
7846,12536,Area under the curve after intravenous administration at a dose of 40 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624484,,BAO_0000019,,
7847,12536,Area under the curve after intravenous administration at a dose of 5 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624485,,BAO_0000019,,
7848,15556,Area under the curve for fumarate salt was evaluated in F344 Rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624486,,BAO_0000218,,
7849,2809,Area under the curve for the compound was calculated.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624487,,BAO_0000019,,
7850,9511,Area under the curve in concentration/ time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624488,,BAO_0000019,,
7851,12818,Area under the curve administered intraintestinal in rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624489,,BAO_0000218,,
7852,12818,Area under the curve administered intravenously in rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625184,,BAO_0000218,,
7853,15118,Area under the curve during intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625185,,BAO_0000019,,
7854,15118,Area under the curve during intravenous administration; Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875954,,BAO_0000019,,
7855,15118,Area under the curve during systemic administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625186,,BAO_0000019,,
7856,15118,Area under the curve during systemic administration; Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625187,,BAO_0000019,,
7857,2632,Area under the curve was calculated for the compound.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625188,,BAO_0000019,,
7858,14346,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625189,,BAO_0000218,,
7859,14346,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625190,,BAO_0000218,,
7860,14346,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621733,,BAO_0000218,,
7861,14346,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621734,,BAO_0000218,,
7862,11149,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621735,,BAO_0000218,,
7863,17796,Clearance of the drug was measured in the plasma of rat; No data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621736,,BAO_0000218,1969.0,
7864,5247,The pharmacokinetic parameter plasma clearance in vivo in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621737,,BAO_0000218,1969.0,
7865,4727,Plasma clearance at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621738,,BAO_0000218,,
7866,5654,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622806,,BAO_0000218,,
7867,5654,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623519,,BAO_0000218,,
7868,17260,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623520,,BAO_0000218,,
7869,17065,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623521,,BAO_0000218,,
7870,17671,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623522,,BAO_0000218,,
7871,6672,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623523,,BAO_0000218,,
7872,6673,Clearance rate in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623690,,BAO_0000218,,
7873,5978,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623691,,BAO_0000218,,
7874,5978,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623692,,BAO_0000218,,
7875,5978,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623693,,BAO_0000218,,
7876,5978,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623694,,BAO_0000218,,
7877,4413,Clearance of compound after iv administration of 20 mg/kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623695,,BAO_0000218,,
7878,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623696,,BAO_0000218,,
7879,2661,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623697,,BAO_0000218,,
7880,5005,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL623698,,BAO_0000218,1969.0,
7881,5005,Compound was tested for its plasma clearance rate in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL623699,,BAO_0000218,1969.0,
7882,15765,Mean (%CV) PK parameters for CL(mL/min/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623700,,BAO_0000218,,
7883,3747,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623701,,BAO_0000218,,
7884,16366,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623702,,BAO_0000218,1969.0,
7885,4199,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623703,,BAO_0000218,,
7886,17267,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623704,,BAO_0000218,,
7887,6535,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623705,,BAO_0000218,,
7888,6535,Plasma clearance in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623706,,BAO_0000218,,
7889,5041,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623707,,BAO_0000218,,
7890,5960,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623708,,BAO_0000218,,
7891,5937,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623709,,BAO_0000218,,
7892,5871,Plasma clearance in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623710,,BAO_0000218,,
7893,5874,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623711,,BAO_0000218,,
7894,6504,Plasma clearance in rat p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623712,,BAO_0000218,,
7895,6803,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623713,,BAO_0000218,,
7896,5041,Plasma clearance was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623714,,BAO_0000218,,
7897,5041,Plasma clearance was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623715,,BAO_0000218,,
7898,1916,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623716,,BAO_0000218,,
7899,5199,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622980,,BAO_0000218,,
7900,16367,Plasma administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622981,,BAO_0000218,,
7901,6362,Plasma clearance of the compound in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622982,,BAO_0000218,,
7902,15662,Plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622983,,BAO_0000218,,
7903,6215,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622984,,BAO_0000218,,
7904,1466,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622985,,BAO_0000218,,
7905,15662,plasma clearance was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623631,,BAO_0000218,1969.0,
7906,4723,In vivo CL/F determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623632,,BAO_0000218,,
7907,2792,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623633,,BAO_0000218,1969.0,
7908,2792,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623634,,BAO_0000218,1969.0,
7909,5213,Compound was tested for the lower blood clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623635,,BAO_0000218,,
7910,4687,Evaluated for the low clearance in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621195,,BAO_0000218,,
7911,3371,Pharmacokinetic property (CLb)of the compound was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621196,,BAO_0000218,,
7912,4690,Rapid clearance after intravenous administration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875287,,BAO_0000218,,
7913,5702,Clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621197,,BAO_0000218,,
7914,740,Compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621198,,BAO_0000218,1969.0,
7915,4853,Low plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621199,,BAO_0000218,1969.0,
7916,5789,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621200,,BAO_0000218,,
7917,4527,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621201,,BAO_0000218,,
7918,4527,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621202,,BAO_0000218,,
7919,6518,Plasma clearance after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621203,,BAO_0000218,,
7920,6518,Plasma clearance after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621204,,BAO_0000218,,
7921,9866,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621205,,BAO_0000218,948.0,
7922,9866,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621206,,BAO_0000218,948.0,
7923,9866,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621207,,BAO_0000218,948.0,
7924,9866,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621208,,BAO_0000218,948.0,
7925,9866,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621209,,BAO_0000218,948.0,
7926,9866,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL876484,,BAO_0000218,948.0,
7927,9866,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621210,,BAO_0000218,948.0,
7928,9866,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621211,,BAO_0000218,948.0,
7929,9866,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621212,,BAO_0000218,948.0,
7930,9866,Biodistribution in rat heart in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621213,,BAO_0000218,948.0,
7931,9866,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621214,,BAO_0000218,948.0,
7932,9866,Biodistribution in rat heart in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621215,,BAO_0000218,948.0,
7933,9866,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621216,,BAO_0000218,948.0,
7934,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621217,,BAO_0000218,948.0,
7935,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621218,,BAO_0000218,948.0,
7936,9866,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621219,,BAO_0000218,948.0,
7937,9866,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621220,,BAO_0000218,948.0,
7938,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621221,,BAO_0000218,948.0,
7939,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621222,,BAO_0000218,948.0,
7940,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621223,,BAO_0000218,948.0,
7941,9866,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL876485,,BAO_0000218,948.0,
7942,9866,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621224,,BAO_0000218,948.0,
7943,9866,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621225,,BAO_0000218,948.0,
7944,9866,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621226,,BAO_0000218,948.0,
7945,9866,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621227,,BAO_0000218,2113.0,
7946,9866,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621228,,BAO_0000218,2113.0,
7947,9866,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621229,,BAO_0000218,2113.0,
7948,9866,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621230,,BAO_0000218,2113.0,
7949,9866,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621231,,BAO_0000218,2113.0,
7950,9866,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621232,,BAO_0000218,2113.0,
7951,9866,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621233,,BAO_0000218,2113.0,
7952,9866,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621234,,BAO_0000218,2113.0,
7953,9866,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621235,,BAO_0000218,2113.0,
7954,9866,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621236,,BAO_0000218,2113.0,
7955,9866,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621237,,BAO_0000218,2113.0,
7956,9866,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL876486,,BAO_0000218,2113.0,
7957,9866,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622436,,BAO_0000218,160.0,
7958,9866,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622437,,BAO_0000218,160.0,
7959,9866,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622438,,BAO_0000218,160.0,
7960,9866,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622439,,BAO_0000218,2107.0,
7961,9866,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622440,,BAO_0000218,2107.0,
7962,9866,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622441,,BAO_0000218,2107.0,
7963,9866,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622442,,BAO_0000218,2107.0,
7964,9866,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622443,,BAO_0000218,2107.0,
7965,9866,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622444,,BAO_0000218,2107.0,
7966,9866,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622445,,BAO_0000218,2107.0,
7967,9866,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622446,,BAO_0000218,2107.0,
7968,9866,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622447,,BAO_0000218,2107.0,
7969,9866,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622448,,BAO_0000218,2107.0,
7970,9866,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622449,,BAO_0000218,2107.0,
7971,9866,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622450,,BAO_0000218,2107.0,
7972,9866,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622451,,BAO_0000218,2107.0,
7973,9866,Biodistribution in rat liver in the presence of GdDTPA at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622452,,BAO_0000218,2107.0,
7974,9866,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622453,,BAO_0000218,2107.0,
7975,9866,Biodistribution in rat liver in the presence of GdDTPA at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622454,,BAO_0000218,2107.0,
7976,9866,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622455,,BAO_0000218,2107.0,
7977,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876024,,BAO_0000218,2107.0,
7978,2792,T max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622456,,BAO_0000218,,
7979,15078,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622457,,BAO_0000218,,
7980,15078,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622458,,BAO_0000218,,
7981,15022,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622459,,BAO_0000218,,
7982,15022,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873343,,BAO_0000218,,
7983,15022,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622460,,BAO_0000218,,
7984,4576,Time for maximum plasma concentration determined in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622461,,BAO_0000218,1969.0,
7985,6681,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622462,,BAO_0000218,1969.0,
7986,16365,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622463,,BAO_0000218,,
7987,16365,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622464,,BAO_0000218,,
7988,16365,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622465,,BAO_0000218,,
7989,16365,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622466,,BAO_0000218,,
7990,16365,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622467,,BAO_0000218,,
7991,6824,Time of maximum plasma concentration in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622468,,BAO_0000218,1969.0,
7992,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876025,,BAO_0000218,1969.0,
7993,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622469,,BAO_0000218,1969.0,
7994,6685,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622470,,BAO_0000218,1969.0,
7995,15662,Time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622471,,BAO_0000218,,
7996,1742,Time required to reach maximum concentration in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622472,,BAO_0000218,1969.0,
7997,2774,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622473,,BAO_0000218,1969.0,
7998,5199,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624282,,BAO_0000218,1969.0,
7999,12873,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624283,,BAO_0000218,1969.0,
8000,12873,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624284,,BAO_0000218,1969.0,
8001,1916,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624285,,BAO_0000218,1969.0,
8002,16367,Time to reach Cmax after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624286,,BAO_0000218,,
8003,16366,Time to reach Cmax when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624287,,BAO_0000218,,
8004,216,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624288,,BAO_0000218,,
8005,6410,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624289,,BAO_0000218,1969.0,
8006,6410,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873344,,BAO_0000218,1969.0,
8007,6215,Tmax after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619623,,BAO_0000218,,
8008,3598,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL621399,,BAO_0000218,,
8009,4527,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621400,,BAO_0000218,,
8010,17670,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621401,,BAO_0000218,,
8011,1465,Tmax was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621402,,BAO_0000218,,
8012,2552,Tmax was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621403,,BAO_0000218,,
8013,5656,Tmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621121,,BAO_0000218,,
8014,17764,Tmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL872525,,BAO_0000218,,
8015,5610,Tmax in male rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621122,,BAO_0000218,,
8016,6046,Tmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621123,,BAO_0000218,,
8017,5874,Tmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621124,,BAO_0000218,,
8018,17596,Tmax in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621125,,BAO_0000218,,
8019,17804,Tmax was measured in rats after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621126,,BAO_0000218,,
8020,1908,Tmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621127,,BAO_0000218,,
8021,2959,Tmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621128,,BAO_0000218,,
8022,6757,Tmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618263,,BAO_0000218,,
8023,6757,Tmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618264,,BAO_0000218,,
8024,6757,Tmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618265,,BAO_0000218,,
8025,4186,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618266,,BAO_0000218,1969.0,
8026,15662,time required to reach maximum concentration (Cmax) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618267,,BAO_0000218,,
8027,429,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618450,,BAO_0000218,1088.0,
8028,429,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618451,,BAO_0000218,1088.0,
8029,5546,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618452,,BAO_0000218,,
8030,3173,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618453,,BAO_0000218,1088.0,
8031,3173,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618454,,BAO_0000218,1088.0,
8032,3173,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL618455,,BAO_0000218,1088.0,
8033,4257,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618456,,BAO_0000218,,
8034,6011,Compound distribution in rat tissues was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618457,,BAO_0000218,,
8035,5472,Volume of distribution was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618458,,BAO_0000218,,
8036,14346,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618459,,BAO_0000218,,
8037,14346,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876733,,BAO_0000218,,
8038,14346,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL618460,,BAO_0000218,,
8039,14346,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618461,,BAO_0000218,,
8040,15469,Area under the curve was determined after oral administration (300 uM/Kg),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618462,,BAO_0000019,,
8041,14346,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618463,,BAO_0000218,,
8042,14346,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618464,,BAO_0000218,,
8043,14346,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618465,,BAO_0000218,,
8044,14346,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618466,,BAO_0000218,,
8045,14346,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618467,,BAO_0000218,,
8046,15372,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618468,,BAO_0000218,,
8047,12935,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618469,,BAO_0000218,1969.0,
8048,12935,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL618470,,BAO_0000218,1969.0,
8049,14813,Plasma drug AUC in rat (PO dose),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618471,,BAO_0000218,,
8050,15792,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618472,,BAO_0000218,,
8051,3579,Area under was determined at a dose of 30 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL618473,,BAO_0000218,,
8052,12487,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL621699,,BAO_0000218,,
8053,12487,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621700,,BAO_0000218,,
8054,12487,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621701,,BAO_0000218,,
8055,12487,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL621702,,BAO_0000218,,
8056,12487,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621703,,BAO_0000218,,
8057,12487,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL621704,,BAO_0000218,,
8058,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624259,,BAO_0000218,,
8059,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624260,,BAO_0000218,,
8060,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624430,,BAO_0000218,,
8061,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624431,,BAO_0000218,,
8062,12902,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624432,,BAO_0000218,,
8063,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624433,,BAO_0000218,,
8064,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624434,,BAO_0000218,,
8065,12902,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624435,,BAO_0000218,,
8066,12745,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618570,,BAO_0000218,,
8067,12745,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618571,,BAO_0000218,,
8068,12745,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618572,,BAO_0000218,,
8069,12745,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618573,,BAO_0000218,,
8070,12745,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619267,,BAO_0000218,,
8071,12745,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619431,,BAO_0000218,,
8072,12745,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619432,,BAO_0000218,,
8073,12745,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619433,,BAO_0000218,,
8074,13298,AUC in mice after oral dose (50 mg/kg),A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619434,,BAO_0000218,1969.0,
8075,12226,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,A,,,Mus musculus,10090.0,,Serum,,,50594,N,1,Intermediate,1,,CHEMBL619435,,BAO_0000218,1977.0,
8076,12634,AUC (0-4 hr) ug/ml/h,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL619436,,BAO_0000019,1969.0,
8077,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619437,,BAO_0000218,,
8078,13889,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619438,,BAO_0000218,,
8079,10018,Compound was evaluated for Area under curve in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619439,,BAO_0000218,,
8080,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619440,,BAO_0000218,,
8081,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619441,,BAO_0000218,,
8082,8758,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619442,,BAO_0000218,,
8083,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875156,,BAO_0000019,,
8084,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619443,,BAO_0000019,,
8085,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL619444,,BAO_0000019,,
8086,2249,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623464,,BAO_0000019,,
8087,15115,Compound was evaluated for area under curve when administered through oral route in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623465,,BAO_0000218,,
8088,6518,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623466,,BAO_0000218,,
8089,6518,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623467,,BAO_0000218,,
8090,6249,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623468,,BAO_0000218,,
8091,2463,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622660,,BAO_0000218,,
8092,4969,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622661,,BAO_0000218,,
8093,17720,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622662,,BAO_0000218,,
8094,3457,Pharmacokinetic property (total body clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622663,,BAO_0000218,,
8095,5983,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622664,,BAO_0000218,,
8096,6295,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622665,,BAO_0000218,,
8097,6296,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622666,,BAO_0000218,,
8098,17686,Cl in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621615,,BAO_0000218,,
8099,17764,Clearance of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621616,,BAO_0000218,,
8100,5503,Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621617,,BAO_0000218,,
8101,4368,Clearance by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621618,,BAO_0000218,,
8102,6005,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621619,,BAO_0000218,,
8103,5031,Clearance rate after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621620,,BAO_0000218,,
8104,4890,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621786,,BAO_0000218,,
8105,5182,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621787,,BAO_0000218,,
8106,5979,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621788,,BAO_0000218,,
8107,5656,Clearance (Cl) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621789,,BAO_0000218,,
8108,17804,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621790,,BAO_0000218,,
8109,4839,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621791,,BAO_0000218,1969.0,
8110,5041,In vitro microsome metabolism clearance in rat was determined,A,In vitro,,Rattus norvegicus,10116.0,,,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL621792,,BAO_0000218,,
8111,5041,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,A,In vitro,,Rattus norvegicus,10116.0,,,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL621793,,BAO_0000218,,
8112,5974,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621794,,BAO_0000218,,
8113,5496,In vivo plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621795,,BAO_0000218,1969.0,
8114,5739,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621796,,BAO_0000218,,
8115,5676,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,Hepatocyte,,50597,N,1,Intermediate,1,,CHEMBL621797,401.0,BAO_0000218,2107.0,
8116,4239,Pharmacokinetic property (Plasma clearance) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621798,,BAO_0000218,,
8117,5676,Pharmacokinetic property (clearance) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621799,,BAO_0000218,,
8118,1918,"Plasma Clearance was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621800,,BAO_0000218,,
8119,17800,Plasma clearance (in vivo) in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621801,,BAO_0000218,,
8120,6056,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621802,,BAO_0000218,,
8121,5496,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618596,,BAO_0000218,,
8122,5939,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618597,,BAO_0000218,,
8123,5939,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618598,,BAO_0000218,,
8124,17752,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618599,,BAO_0000218,,
8125,4576,Plasma clearance rate determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618600,,BAO_0000218,,
8126,6011,Plasma clearance was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618601,,BAO_0000218,,
8127,5510,Plasma clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618602,,BAO_0000218,,
8128,5948,Plasma clearance value in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618603,,BAO_0000218,,
8129,6125,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618604,,BAO_0000218,2107.0,
8130,4839,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618605,,BAO_0000218,,
8131,17686,Total body clearance in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618606,,BAO_0000218,,
8132,6571,Clearance of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618607,,BAO_0000218,,
8133,3364,Clearance after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618608,,BAO_0000218,,
8134,13569,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618609,,BAO_0000218,,
8135,13569,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618610,,BAO_0000218,,
8136,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618611,,BAO_0000218,,
8137,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618612,,BAO_0000218,,
8138,13569,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618613,,BAO_0000218,,
8139,13569,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621076,,BAO_0000218,,
8140,13569,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621077,,BAO_0000218,,
8141,17670,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621078,,BAO_0000218,,
8142,5970,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621251,,BAO_0000218,,
8143,6495,Clearance in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621252,,BAO_0000218,,
8144,4590,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621253,,BAO_0000218,,
8145,6193,Clearance rate following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621254,,BAO_0000218,,
8146,2832,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621255,,BAO_0000218,,
8147,1052,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621256,,BAO_0000218,1969.0,
8148,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621257,,BAO_0000218,2107.0,
8149,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621258,,BAO_0000218,2107.0,
8150,9866,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621259,,BAO_0000218,2107.0,
8151,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621260,,BAO_0000218,2107.0,
8152,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876494,,BAO_0000218,2107.0,
8153,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621261,,BAO_0000218,2107.0,
8154,9866,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621262,,BAO_0000218,2107.0,
8155,9866,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621263,,BAO_0000218,2107.0,
8156,9866,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621264,,BAO_0000218,2107.0,
8157,9866,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621265,,BAO_0000218,2385.0,
8158,9866,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621266,,BAO_0000218,2385.0,
8159,9866,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621267,,BAO_0000218,2385.0,
8160,9866,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621268,,BAO_0000218,2385.0,
8161,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621269,,BAO_0000218,2385.0,
8162,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621270,,BAO_0000218,2385.0,
8163,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621271,,BAO_0000218,2385.0,
8164,9866,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621272,,BAO_0000218,2385.0,
8165,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621273,,BAO_0000218,2385.0,
8166,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621274,,BAO_0000218,2385.0,
8167,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL876495,,BAO_0000218,2385.0,
8168,9866,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621275,,BAO_0000218,2385.0,
8169,9866,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621276,,BAO_0000218,2385.0,
8170,9866,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621277,,BAO_0000218,2385.0,
8171,9866,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621278,,BAO_0000218,160.0,
8172,9866,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621279,,BAO_0000218,160.0,
8173,9866,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621280,,BAO_0000218,160.0,
8174,9866,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621281,,BAO_0000218,2106.0,
8175,9866,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621282,,BAO_0000218,2106.0,
8176,9866,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621283,,BAO_0000218,2106.0,
8177,9866,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621284,,BAO_0000218,2106.0,
8178,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621285,,BAO_0000218,2106.0,
8179,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621286,,BAO_0000218,2106.0,
8180,9866,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL623220,,BAO_0000218,2106.0,
8181,9866,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL623221,,BAO_0000218,2106.0,
8182,9866,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL876029,,BAO_0000218,2106.0,
8183,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623222,,BAO_0000218,945.0,
8184,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623223,,BAO_0000218,945.0,
8185,9866,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL621445,,BAO_0000218,945.0,
8186,13950,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621446,,BAO_0000218,178.0,
8187,13950,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621447,,BAO_0000218,178.0,
8188,13950,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL619681,,BAO_0000218,178.0,
8189,13950,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL619682,,BAO_0000218,178.0,
8190,13950,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL619683,,BAO_0000218,178.0,
8191,13950,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619684,,BAO_0000218,955.0,
8192,13950,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619685,,BAO_0000218,955.0,
8193,13950,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619686,,BAO_0000218,955.0,
8194,13950,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619687,,BAO_0000218,955.0,
8195,13950,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619688,,BAO_0000218,955.0,
8196,13950,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619689,,BAO_0000218,948.0,
8197,13950,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619690,,BAO_0000218,948.0,
8198,13950,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619691,,BAO_0000218,948.0,
8199,6062,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619692,,BAO_0000218,,
8200,3598,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL619693,,BAO_0000218,,
8201,1908,Vc value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619694,,BAO_0000218,,
8202,17596,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619695,,BAO_0000218,,
8203,4891,Compound was evaluated for pharmacokinetic parameter volume of distribution,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619696,,BAO_0000218,,
8204,740,Compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619697,,BAO_0000218,,
8205,16366,Steady state volume distribution was determined; steady state(ss),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619698,,BAO_0000218,,
8206,3364,Steady state volume of distribution after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619699,,BAO_0000218,,
8207,2552,Steady state volume of distribution dosing at 3 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619700,,BAO_0000218,,
8208,406,The compound was evaluated for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619701,,BAO_0000218,,
8209,12500,The compound was tested for volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL619702,,BAO_0000218,,
8210,12500,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620335,,BAO_0000218,,
8211,5656,Volume distribution (VD) after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620336,,BAO_0000218,,
8212,17671,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620337,,BAO_0000218,,
8213,1094,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620520,,BAO_0000218,,
8214,5833,Volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620521,,BAO_0000218,,
8215,5939,Volume distribution in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875825,,BAO_0000218,,
8216,5939,Volume distribution in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620522,,BAO_0000218,,
8217,6005,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620523,,BAO_0000218,,
8218,1696,Volume of distribution in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620524,,BAO_0000218,,
8219,6672,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620525,,BAO_0000218,,
8220,6673,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620526,,BAO_0000218,,
8221,5871,Volume of distribution in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620527,,BAO_0000218,,
8222,6803,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620528,,BAO_0000218,,
8223,5199,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620529,,BAO_0000218,,
8224,4727,Volume distribution at the dose of 2 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620530,,BAO_0000218,,
8225,16367,Steady state volume of distribution was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620531,,BAO_0000218,,
8226,5005,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Intermediate,1,,CHEMBL620532,,BAO_0000218,,
8227,5005,Compound was tested for its plasma volume distribution in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL620533,,BAO_0000218,,
8228,5005,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL620534,,BAO_0000218,,
8229,15765,Mean (%CV) PK parameters for Vdss(mL/kg).,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620535,,BAO_0000218,,
8230,2792,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875826,,BAO_0000218,,
8231,2792,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620536,,BAO_0000218,,
8232,5334,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620537,,BAO_0000218,,
8233,5334,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618526,,BAO_0000218,,
8234,5739,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618527,,BAO_0000218,,
8235,5789,Pharmacokinetic property (Vdss) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618528,,BAO_0000218,,
8236,4239,Pharmacokinetic property (vdss) was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618529,,BAO_0000218,,
8237,4709,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618530,,BAO_0000218,,
8238,6642,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618531,,BAO_0000218,,
8239,5247,The pharmacokinetic parameter volume of distribution in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618532,,BAO_0000218,,
8240,17720,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618533,,BAO_0000218,,
8241,17686,Vdss in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618534,,BAO_0000218,,
8242,4689,Volume distribution after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618535,,BAO_0000218,,
8243,5654,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618536,,BAO_0000218,,
8244,5654,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618537,,BAO_0000218,,
8245,4527,Volume distribution at a dose of 10 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618538,,BAO_0000218,,
8246,4521,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618539,,BAO_0000218,,
8247,6057,Volume distribution was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618540,,BAO_0000218,,
8248,5510,Volume distribution was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618541,,BAO_0000218,,
8249,2938,Volume of distribution after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618542,,BAO_0000218,,
8250,6679,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622544,,BAO_0000218,,
8251,6685,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622545,,BAO_0000218,,
8252,6685,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622546,,BAO_0000218,,
8253,6685,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622547,,BAO_0000218,,
8254,5145,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622548,,BAO_0000218,,
8255,6467,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622549,,BAO_0000218,,
8256,6467,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622550,,BAO_0000218,,
8257,15115,Compound was evaluated for area under curve when administered through oral route to mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622551,,BAO_0000218,,
8258,8758,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622552,,BAO_0000218,,
8259,8758,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622553,,BAO_0000218,,
8260,8267,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622554,,BAO_0000218,,
8261,8267,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622555,,BAO_0000218,,
8262,14239,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622556,,BAO_0000218,,
8263,14239,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622557,,BAO_0000218,,
8264,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622558,,BAO_0000218,178.0,
8265,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622559,,BAO_0000218,178.0,
8266,10754,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622560,,BAO_0000218,,
8267,14681,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622561,,BAO_0000218,,
8268,14681,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622562,,BAO_0000218,,
8269,14681,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622563,,BAO_0000218,,
8270,13118,Concentration of compound in Central nervous system,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622564,,BAO_0000019,,
8271,13118,Concentration of compound in Central nervous system; Not detectable,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622565,,BAO_0000019,,
8272,13318,"Concentration of diester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622566,,BAO_0000218,,
8273,13318,"Concentration of monoester in the blood, following oral administration in mice",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624515,,BAO_0000218,,
8274,13318,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624516,,BAO_0000218,,
8275,15692,Evaluated for Pharmacokinetic property: Area under the curve,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624517,,BAO_0000019,,
8276,14839,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624518,,BAO_0000218,,
8277,14839,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624519,,BAO_0000218,,
8278,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624520,,BAO_0000218,,
8279,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624521,,BAO_0000218,,
8280,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624522,,BAO_0000218,,
8281,14839,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624523,,BAO_0000218,,
8282,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624409,,BAO_0000218,,
8283,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624410,,BAO_0000218,,
8284,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL624411,,BAO_0000218,,
8285,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623531,,BAO_0000218,,
8286,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623532,,BAO_0000218,,
8287,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623533,,BAO_0000218,,
8288,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623534,,BAO_0000218,,
8289,14839,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623535,,BAO_0000218,,
8290,14839,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623536,,BAO_0000218,,
8291,14839,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623537,,BAO_0000218,,
8292,14839,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623538,,BAO_0000218,,
8293,14839,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623539,,BAO_0000218,,
8294,14839,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623540,,BAO_0000218,,
8295,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623541,,BAO_0000218,,
8296,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623542,,BAO_0000218,,
8297,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623543,,BAO_0000218,,
8298,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623544,,BAO_0000218,,
8299,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623545,,BAO_0000218,,
8300,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623546,,BAO_0000218,,
8301,5408,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623547,,BAO_0000218,1969.0,
8302,6827,High i.v. clearance in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623548,,BAO_0000218,,
8303,17538,In vitro clearance in rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL623549,,BAO_0000218,2107.0,
8304,6331,Intrinsic clearance in rat liver microsomes was determined,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL623550,,BAO_0000218,2107.0,
8305,5948,Intrinsic clearance in rat hepatocytes was determined,A,In vitro,,Rattus norvegicus,10116.0,,Liver,Hepatocyte,,50597,N,1,Intermediate,1,,CHEMBL875276,401.0,BAO_0000218,2107.0,
8306,4026,Plasma Clearance was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621872,,BAO_0000218,,
8307,6647,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621873,,BAO_0000218,,
8308,1696,Plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621874,,BAO_0000218,,
8309,6597,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621875,,BAO_0000218,,
8310,347,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621876,,BAO_0000218,,
8311,16423,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621877,,BAO_0000218,,
8312,2879,Plasma clearance was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621878,,BAO_0000218,,
8313,4883,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621879,,BAO_0000218,,
8314,5328,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621880,,BAO_0000218,1969.0,
8315,5160,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621881,,BAO_0000218,,
8316,17582,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621882,,BAO_0000218,,
8317,17651,Total clearance at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875283,,BAO_0000218,,
8318,17651,Total clearance at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621883,,BAO_0000218,,
8319,6596,Clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621884,,BAO_0000218,,
8320,4796,Plasma clearance rate determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621885,,BAO_0000218,,
8321,6850,Clearance of compound in rat was evaluated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621886,,BAO_0000218,,
8322,5932,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621887,,BAO_0000218,1969.0,
8323,3371,Pharmacokinetic property (blood clearance) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621888,,BAO_0000218,,
8324,2083,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621889,,BAO_0000218,,
8325,4942,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621890,,BAO_0000218,,
8326,6838,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL621891,,BAO_0000218,2107.0,
8327,5353,Clearance in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621892,,BAO_0000218,,
8328,6641,Clearance rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621893,,BAO_0000218,,
8329,6641,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621894,,BAO_0000218,,
8330,6641,Clearance rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621895,,BAO_0000218,,
8331,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875284,,BAO_0000218,,
8332,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618699,,BAO_0000218,,
8333,6444,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618700,,BAO_0000218,,
8334,6211,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618701,,BAO_0000218,,
8335,12873,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876600,,BAO_0000218,1969.0,
8336,6570,Clearance of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618702,,BAO_0000218,,
8337,3341,Compound was evaluated for Hepatic clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618703,,BAO_0000218,,
8338,4891,In vivo clearance after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618704,,BAO_0000218,,
8339,1094,Compound was tested for plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618705,,BAO_0000218,1969.0,
8340,2938,Hepatic clearance after intravenous administration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618706,,BAO_0000218,,
8341,17853,Lower clearance in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618707,,BAO_0000218,,
8342,6049,Pharmacokinetic parameter expressed as plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618708,,BAO_0000218,1969.0,
8343,5789,Pharmacokinetic property (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618709,,BAO_0000218,,
8344,4514,Plasma clearance in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618710,,BAO_0000218,,
8345,6448,Plasma clearance (Clp) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618711,,BAO_0000218,,
8346,6062,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618712,,BAO_0000218,,
8347,5710,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618713,,BAO_0000218,,
8348,4709,Plasma clearance after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618714,,BAO_0000218,,
8349,4521,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618715,,BAO_0000218,,
8350,1742,Plasma clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618716,,BAO_0000218,,
8351,6057,Plasma clearance measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876601,,BAO_0000218,,
8352,6057,Plasma clearance was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618717,,BAO_0000218,,
8353,5145,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618718,,BAO_0000218,,
8354,5833,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618719,,BAO_0000218,,
8355,6453,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618720,,BAO_0000218,,
8356,6640,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618721,,BAO_0000218,,
8357,6305,Plasma clearance in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621477,,BAO_0000218,,
8358,6642,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621478,,BAO_0000218,,
8359,5472,Plasma clearance was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621479,,BAO_0000218,,
8360,5472,Plasma clearance was evaluated in rat; Not tested,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621480,,BAO_0000218,,
8361,5144,Plasma clearance rate was determined for the compound in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621481,,BAO_0000218,,
8362,6685,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621482,,BAO_0000218,,
8363,6685,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621483,,BAO_0000218,,
8364,6685,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621484,,BAO_0000218,,
8365,13950,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621485,,BAO_0000218,948.0,
8366,13950,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL621486,,BAO_0000218,948.0,
8367,13950,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621487,,BAO_0000218,160.0,
8368,13950,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621488,,BAO_0000218,160.0,
8369,13950,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621489,,BAO_0000218,160.0,
8370,13950,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621490,,BAO_0000218,160.0,
8371,13950,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL621491,,BAO_0000218,160.0,
8372,13950,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621492,,BAO_0000218,2113.0,
8373,13950,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621493,,BAO_0000218,2113.0,
8374,13950,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621494,,BAO_0000218,2113.0,
8375,13950,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621495,,BAO_0000218,2113.0,
8376,13950,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621496,,BAO_0000218,2113.0,
8377,13950,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621497,,BAO_0000218,2107.0,
8378,13950,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621498,,BAO_0000218,2107.0,
8379,13950,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621499,,BAO_0000218,2107.0,
8380,13950,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618634,,BAO_0000218,2107.0,
8381,13950,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL618635,,BAO_0000218,2107.0,
8382,13950,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL618636,,BAO_0000218,2048.0,
8383,13950,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL619737,,BAO_0000218,2048.0,
8384,13950,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL619738,,BAO_0000218,2048.0,
8385,13950,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624329,,BAO_0000218,2048.0,
8386,13950,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624330,,BAO_0000218,2048.0,
8387,13950,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624331,,BAO_0000218,2385.0,
8388,13950,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624332,,BAO_0000218,2385.0,
8389,13950,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624333,,BAO_0000218,2385.0,
8390,13950,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624334,,BAO_0000218,2385.0,
8391,13950,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624335,,BAO_0000218,2385.0,
8392,13950,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620016,,BAO_0000218,2106.0,
8393,13950,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620169,,BAO_0000218,2106.0,
8394,13950,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620170,,BAO_0000218,2106.0,
8395,13950,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620171,,BAO_0000218,2106.0,
8396,13950,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL620172,,BAO_0000218,2106.0,
8397,13950,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620173,,BAO_0000218,945.0,
8398,13950,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620174,,BAO_0000218,945.0,
8399,13950,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620175,,BAO_0000218,945.0,
8400,13950,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620176,,BAO_0000218,945.0,
8401,13950,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL620177,,BAO_0000218,945.0,
8402,13950,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL620178,,BAO_0000218,2037.0,
8403,13950,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL620179,,BAO_0000218,2037.0,
8404,13950,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620180,,BAO_0000218,,
8405,6570,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620181,,BAO_0000218,,
8406,6571,Volume of distribution of compound in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620182,,BAO_0000218,,
8407,6453,Volume of distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620183,,BAO_0000218,,
8408,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620184,,BAO_0000218,,
8409,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620185,,BAO_0000218,,
8410,6444,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620186,,BAO_0000218,,
8411,5353,Volume of distribution was determined in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620187,,BAO_0000218,,
8412,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620188,,BAO_0000218,,
8413,5334,Volume of distribution was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620189,,BAO_0000218,,
8414,6641,Volumes of distribution in rat after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620190,,BAO_0000218,,
8415,6641,Volumes of distribution in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620191,,BAO_0000218,,
8416,6641,Volumes of distribution in rat after po administration; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620192,,BAO_0000218,,
8417,5676,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620193,,BAO_0000218,,
8418,6410,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620194,,BAO_0000218,,
8419,17670,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876730,,BAO_0000218,,
8420,6495,Volume distribution in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620195,,BAO_0000218,,
8421,5408,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620196,,BAO_0000218,,
8422,4883,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620197,,BAO_0000218,,
8423,6647,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620198,,BAO_0000218,,
8424,6495,Volume of distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620199,,BAO_0000218,,
8425,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620200,,BAO_0000218,,
8426,2661,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620201,,BAO_0000218,,
8427,5974,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620202,,BAO_0000218,,
8428,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620203,,BAO_0000218,,
8429,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620204,,BAO_0000218,,
8430,5974,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620205,,BAO_0000218,,
8431,5960,Pharmacokinetic parameter (Vss) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624664,,BAO_0000218,,
8432,5676,Pharmacokinetic property (Volume) in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624665,,BAO_0000218,,
8433,5948,Pharmacokinetic property (Vss) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624666,,BAO_0000218,,
8434,5979,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624667,,BAO_0000218,,
8435,5978,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624668,,BAO_0000218,,
8436,5978,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624669,,BAO_0000218,,
8437,5978,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624670,,BAO_0000218,,
8438,5978,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624671,,BAO_0000218,,
8439,6448,Steady state volume distribution in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624672,,BAO_0000218,,
8440,12873,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624673,,BAO_0000218,1969.0,
8441,4576,Steady state volume of distribution determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624674,,BAO_0000218,,
8442,17582,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624675,,BAO_0000218,,
8443,1466,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621728,,BAO_0000218,,
8444,5182,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621729,,BAO_0000218,,
8445,5182,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621730,,BAO_0000218,,
8446,6535,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621731,,BAO_0000218,,
8447,6535,Volume distribution in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621732,,BAO_0000218,,
8448,5041,Volume in steady state distribution value was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621908,,BAO_0000218,,
8449,5041,Volume in steady state distribution value was determined; ND denotes no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875347,,BAO_0000218,,
8450,5041,Volume in steady state distribution value was determined; ND denotes not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621909,,BAO_0000218,,
8451,17065,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621910,,BAO_0000218,,
8452,6597,Volume of distribution at steady state was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621911,,BAO_0000218,,
8453,15662,Volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621912,,BAO_0000218,,
8454,6485,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621913,,BAO_0000218,,
8455,17655,Volume of distribution in steady state was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621914,,BAO_0000218,,
8456,6616,Volume of distribution after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621915,,BAO_0000218,,
8457,1916,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621916,,BAO_0000218,,
8458,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621917,,BAO_0000218,2107.0,
8459,16438,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL621918,,BAO_0000218,2107.0,
8460,16438,Biodistribution of compound (oxidized form) in spleen tissue,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621919,,BAO_0000218,2106.0,
8461,16438,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621920,,BAO_0000218,2106.0,
8462,16438,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL621921,,BAO_0000218,2106.0,
8463,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622401,,BAO_0000218,2106.0,
8464,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL875348,,BAO_0000218,2106.0,
8465,16438,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL622402,,BAO_0000218,2106.0,
8466,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622403,,BAO_0000218,178.0,
8467,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL622404,,BAO_0000218,178.0,
8468,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622405,,BAO_0000218,955.0,
8469,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622406,,BAO_0000218,955.0,
8470,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622407,,BAO_0000218,955.0,
8471,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622408,,BAO_0000218,948.0,
8472,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622409,,BAO_0000218,948.0,
8473,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL622410,,BAO_0000218,948.0,
8474,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL622411,,BAO_0000218,2113.0,
8475,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627864,,BAO_0000218,2113.0,
8476,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627865,,BAO_0000218,2113.0,
8477,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627866,,BAO_0000218,2107.0,
8478,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627751,,BAO_0000218,2107.0,
8479,16438,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627752,,BAO_0000218,2106.0,
8480,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627753,,BAO_0000218,2106.0,
8481,16438,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627754,,BAO_0000218,2106.0,
8482,12467,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627755,,BAO_0000218,,
8483,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627756,,BAO_0000218,955.0,
8484,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627757,,BAO_0000218,955.0,
8485,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627758,,BAO_0000218,955.0,
8486,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627759,,BAO_0000218,955.0,
8487,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627760,,BAO_0000218,955.0,
8488,17208,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627761,,BAO_0000218,955.0,
8489,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL876811,,BAO_0000218,948.0,
8490,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627762,,BAO_0000218,948.0,
8491,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627763,,BAO_0000218,948.0,
8492,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627764,,BAO_0000218,948.0,
8493,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627765,,BAO_0000218,948.0,
8494,17208,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL627766,,BAO_0000218,948.0,
8495,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627767,,BAO_0000218,2113.0,
8496,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL627768,,BAO_0000218,2113.0,
8497,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL628422,,BAO_0000218,2113.0,
8498,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL628423,,BAO_0000218,2113.0,
8499,5089,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628424,,BAO_0000218,,
8500,5089,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628425,,BAO_0000218,,
8501,4257,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628426,,BAO_0000218,,
8502,6679,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628427,,BAO_0000218,,
8503,5546,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626938,,BAO_0000218,,
8504,6141,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626939,,BAO_0000218,,
8505,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626940,,BAO_0000218,,
8506,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626941,,BAO_0000218,,
8507,5334,Plasma clearance was reported in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626942,,BAO_0000218,,
8508,4689,Plasma clearance after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876812,,BAO_0000218,,
8509,6848,Plasma clearance of compound in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626943,,BAO_0000218,,
8510,6848,Plasma clearance of compound in rats was evaluated; ND indicates not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626944,,BAO_0000218,,
8511,6467,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626945,,BAO_0000218,,
8512,6467,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626946,,BAO_0000218,,
8513,4956,Plasma clearance rate in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626856,,BAO_0000218,,
8514,5529,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626857,,BAO_0000218,,
8515,406,The compound was evaluated for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626858,,BAO_0000218,1969.0,
8516,17655,Total plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627018,,BAO_0000218,1969.0,
8517,3293,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625331,,BAO_0000218,178.0,
8518,4075,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625332,,BAO_0000218,178.0,
8519,2792,C max was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877590,,BAO_0000218,,
8520,2792,C max was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625333,,BAO_0000218,,
8521,17594,Cmax after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625334,,BAO_0000218,,
8522,17594,Cmax after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625335,,BAO_0000218,,
8523,4762,Cmax of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625336,,BAO_0000218,,
8524,17509,Cmax 24 hr after 10 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625337,,BAO_0000218,,
8525,17509,Cmax 24 hr after 2 mg/kg oral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625338,,BAO_0000218,,
8526,1466,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625339,,BAO_0000218,1969.0,
8527,6535,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625340,,BAO_0000218,,
8528,6535,Cmax in rat after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625341,,BAO_0000218,,
8529,3169,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622687,,BAO_0000218,,
8530,6515,Cmax wa determined in rat plasma at 30 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622688,,BAO_0000218,1969.0,
8531,11149,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622689,,BAO_0000218,178.0,
8532,11149,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL620295,,BAO_0000218,178.0,
8533,17858,Cmax after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620296,,BAO_0000218,,
8534,6518,Cmax after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620297,,BAO_0000218,,
8535,6518,Cmax after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620298,,BAO_0000218,,
8536,4426,Cmax after oral administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620299,,BAO_0000218,,
8537,4426,Cmax after oral administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620300,,BAO_0000218,,
8538,4426,Cmax after oral administration at 20 mpk in rats d; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620301,,BAO_0000218,,
8539,5656,Cmax after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620302,,BAO_0000218,,
8540,6518,Cmax after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620303,,BAO_0000218,,
8541,6518,Cmax after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620304,,BAO_0000218,,
8542,6113,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620305,,BAO_0000218,,
8543,17764,Cmax after peroral administration in rats at 2.4 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620306,,BAO_0000218,,
8544,4756,Cmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620307,,BAO_0000218,,
8545,4756,Cmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620308,,BAO_0000218,,
8546,6402,Cmax by administering at 20 mg/kg p.o. in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620309,,BAO_0000218,,
8547,5610,Cmax in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620310,,BAO_0000218,,
8548,5207,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620311,,BAO_0000218,,
8549,6011,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620312,,BAO_0000218,,
8550,6504,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620313,,BAO_0000218,,
8551,6046,Cmax in rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620314,,BAO_0000218,,
8552,6504,Cmax in rat at the dose of 1 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620315,,BAO_0000218,,
8553,5874,Cmax in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620316,,BAO_0000218,,
8554,17686,Cmax in rat p.o. at 20 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620317,,BAO_0000218,,
8555,5836,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620318,,BAO_0000218,,
8556,17596,Cmax in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620319,,BAO_0000218,,
8557,16423,Cmax was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620320,,BAO_0000218,,
8558,17804,Cmax was measured in rats after peroral administration at 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620321,,BAO_0000218,,
8559,1908,Cmax value after oral dose at a dose of 10 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620322,,BAO_0000218,,
8560,13950,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620323,,BAO_0000218,,
8561,13950,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Frontal cortex,,,50597,N,1,Intermediate,1,,CHEMBL620324,,BAO_0000218,1870.0,
8562,13950,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Frontal cortex,,,50597,N,1,Intermediate,1,,CHEMBL620325,,BAO_0000218,1870.0,
8563,13950,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL620326,,BAO_0000218,10000000.0,
8564,13950,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL620327,,BAO_0000218,10000000.0,
8565,13950,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620328,,BAO_0000218,,
8566,13950,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620329,,BAO_0000218,,
8567,13950,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Midbrain,,,50597,N,1,Intermediate,1,,CHEMBL620330,,BAO_0000218,1891.0,
8568,13950,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Midbrain,,,50597,N,1,Intermediate,1,,CHEMBL875286,,BAO_0000218,1891.0,
8569,13950,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620331,,BAO_0000218,,
8570,13950,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620332,,BAO_0000218,,
8571,13950,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL620333,,BAO_0000218,2435.0,
8572,13950,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL620334,,BAO_0000218,2435.0,
8573,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621015,,BAO_0000218,178.0,
8574,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621016,,BAO_0000218,178.0,
8575,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621191,,BAO_0000218,178.0,
8576,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621192,,BAO_0000218,178.0,
8577,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621193,,BAO_0000218,178.0,
8578,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621194,,BAO_0000218,178.0,
8579,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624204,,BAO_0000218,178.0,
8580,16434,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624205,,BAO_0000218,178.0,
8581,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624206,,BAO_0000218,178.0,
8582,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624207,,BAO_0000218,178.0,
8583,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624208,,BAO_0000218,178.0,
8584,16435,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624209,,BAO_0000218,178.0,
8585,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624210,,BAO_0000218,178.0,
8586,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624211,,BAO_0000218,178.0,
8587,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624212,,BAO_0000218,178.0,
8588,16435,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624213,,BAO_0000218,178.0,
8589,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL876611,,BAO_0000218,178.0,
8590,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624214,,BAO_0000218,178.0,
8591,16434,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624215,,BAO_0000218,178.0,
8592,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624216,,BAO_0000218,178.0,
8593,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624217,,BAO_0000218,178.0,
8594,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624218,,BAO_0000218,178.0,
8595,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624219,,BAO_0000218,178.0,
8596,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624220,,BAO_0000218,178.0,
8597,16435,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624221,,BAO_0000218,178.0,
8598,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624222,,BAO_0000218,,
8599,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624223,,BAO_0000218,,
8600,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624224,,BAO_0000218,,
8601,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624225,,BAO_0000218,,
8602,17764,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622420,,BAO_0000218,,
8603,5031,Volume of steady state distribution after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622421,,BAO_0000218,,
8604,6215,Vss after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622422,,BAO_0000218,,
8605,17671,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622423,,BAO_0000218,,
8606,17752,Vss was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622424,,BAO_0000218,,
8607,6596,Vss in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622425,,BAO_0000218,,
8608,16423,Vss was evaluated after 10 uM/kg of intra arterial administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876612,,BAO_0000218,,
8609,15662,volume of distribution at steady state was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622426,,BAO_0000218,,
8610,6062,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622427,,BAO_0000218,,
8611,5874,Pharmacokinetic (PK) parameter Vz in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622428,,BAO_0000218,,
8612,4942,Volume distribution in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622429,,BAO_0000218,,
8613,17796,Volume of distribution in rat; No data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622430,,BAO_0000218,,
8614,4890,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622431,,BAO_0000218,,
8615,15765,% absorption predicted from in vitro rat ileum transport studies,A,,,Rattus norvegicus,10116.0,,Ileum,,,50597,N,1,Intermediate,1,,CHEMBL622432,,BAO_0000218,2116.0,
8616,13569,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622433,,BAO_0000218,,
8617,13569,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622434,,BAO_0000218,,
8618,13569,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622435,,BAO_0000218,,
8619,13569,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618748,,BAO_0000218,,
8620,13569,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618749,,BAO_0000218,,
8621,13569,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618750,,BAO_0000218,,
8622,13569,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618751,,BAO_0000218,,
8623,13569,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618752,,BAO_0000218,,
8624,4576,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618753,,BAO_0000218,,
8625,750,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL618754,,BAO_0000218,1969.0,
8626,750,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618755,,BAO_0000218,,
8627,4590,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618756,,BAO_0000218,,
8628,1716,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618757,,BAO_0000218,,
8629,1974,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618758,,BAO_0000218,,
8630,4502,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621088,,BAO_0000218,,
8631,3371,Pharmacokinetic property (cLogP) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621089,,BAO_0000218,,
8632,9099,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621090,,BAO_0000218,178.0,
8633,9099,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,F,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621091,,BAO_0000218,178.0,
8634,4590,Clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876731,,BAO_0000218,,
8635,3184,Compound was evaluated for its clearance when administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621092,,BAO_0000218,,
8636,16456,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621093,,BAO_0000218,,
8637,4199,Blood: Brain distribution ratio is determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621094,,BAO_0000218,,
8638,4199,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621095,,BAO_0000218,,
8639,4199,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621096,,BAO_0000218,,
8640,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621097,,BAO_0000218,2113.0,
8641,7449,Percent dose excreted in 0-48 hours administered ip to male rat,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621098,,BAO_0000218,,
8642,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621099,,BAO_0000218,2037.0,
8643,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621100,,BAO_0000218,2037.0,
8644,11977,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621101,,BAO_0000218,2037.0,
8645,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL621102,,BAO_0000218,2037.0,
8646,11977,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL876732,,BAO_0000218,2037.0,
8647,11977,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621103,,BAO_0000218,,
8648,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621104,,BAO_0000218,,
8649,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621105,,BAO_0000218,,
8650,11977,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621106,,BAO_0000218,,
8651,11977,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621107,,BAO_0000218,,
8652,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621108,,BAO_0000218,,
8653,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621109,,BAO_0000218,,
8654,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621110,,BAO_0000218,2113.0,
8655,17208,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL621111,,BAO_0000218,2113.0,
8656,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622541,,BAO_0000218,2107.0,
8657,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622542,,BAO_0000218,2107.0,
8658,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL622543,,BAO_0000218,2107.0,
8659,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624412,,BAO_0000218,2107.0,
8660,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624413,,BAO_0000218,2107.0,
8661,17208,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL624414,,BAO_0000218,2107.0,
8662,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624415,,BAO_0000218,2048.0,
8663,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624416,,BAO_0000218,2048.0,
8664,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624417,,BAO_0000218,2048.0,
8665,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624418,,BAO_0000218,2048.0,
8666,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624419,,BAO_0000218,2048.0,
8667,17208,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL624420,,BAO_0000218,2048.0,
8668,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL624421,,BAO_0000218,2385.0,
8669,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL624422,,BAO_0000218,2385.0,
8670,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL624423,,BAO_0000218,2385.0,
8671,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL625123,,BAO_0000218,2385.0,
8672,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL625124,,BAO_0000218,2385.0,
8673,17208,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL625125,,BAO_0000218,2385.0,
8674,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL625126,,BAO_0000218,14.0,
8675,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626947,,BAO_0000218,14.0,
8676,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626948,,BAO_0000218,14.0,
8677,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626949,,BAO_0000218,14.0,
8678,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626950,,BAO_0000218,14.0,
8679,17208,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL626951,,BAO_0000218,14.0,
8680,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626952,,BAO_0000218,2106.0,
8681,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626953,,BAO_0000218,2106.0,
8682,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626954,,BAO_0000218,2106.0,
8683,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626955,,BAO_0000218,2106.0,
8684,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626956,,BAO_0000218,2106.0,
8685,17208,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL626957,,BAO_0000218,2106.0,
8686,17208,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626958,,BAO_0000218,178.0,
8687,17208,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626959,,BAO_0000218,178.0,
8688,17208,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626960,,BAO_0000218,178.0,
8689,17208,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626961,,BAO_0000218,178.0,
8690,17208,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL627589,,BAO_0000218,178.0,
8691,17208,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL627590,,BAO_0000218,178.0,
8692,3132,Time taken for EC90 was determined when tested in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627591,,BAO_0000218,,
8693,3132,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627592,,BAO_0000218,,
8694,16597,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627593,,BAO_0000218,,
8695,5727,Half life in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627594,,BAO_0000218,,
8696,5302,Half life period in mouse after 10 mg/Kg dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876813,,BAO_0000218,,
8697,5302,Half life period in mouse after 10 mg/kg dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627595,,BAO_0000218,,
8698,6348,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627596,,BAO_0000218,,
8699,5964,Cmax value at 5 mg/kg po was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627597,,BAO_0000218,,
8700,6078,Cmax value evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627598,,BAO_0000218,,
8701,5206,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627599,,BAO_0000218,955.0,
8702,2959,Cmax value after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627600,,BAO_0000218,,
8703,5964,Cmax value at 1 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627601,,BAO_0000218,,
8704,5964,Cmax value at 5 mg/kg po in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627776,,BAO_0000218,,
8705,6757,Cmax value at a dose of 10 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627777,,BAO_0000218,,
8706,6757,Cmax value at a dose of 100 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627778,,BAO_0000218,,
8707,6757,Cmax value at a dose of 50 mg/kg in male SD rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627779,,BAO_0000218,,
8708,17617,Cmax value in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876814,,BAO_0000218,,
8709,1445,Cmax value was evaluated in rats at a dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627780,,BAO_0000218,,
8710,6082,Cmax value was determined after peroral administration of 20 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627781,,BAO_0000218,,
8711,1446,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627782,,BAO_0000218,,
8712,5407,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627783,,BAO_0000218,1969.0,
8713,2690,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627784,,BAO_0000218,1969.0,
8714,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627785,,BAO_0000218,,
8715,2661,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627786,,BAO_0000218,,
8716,4891,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627787,,BAO_0000218,1969.0,
8717,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627788,,BAO_0000218,1969.0,
8718,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626579,,BAO_0000218,1969.0,
8719,2807,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626580,,BAO_0000218,1969.0,
8720,3634,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876815,,BAO_0000218,,
8721,1881,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626581,,BAO_0000218,1969.0,
8722,1881,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626582,,BAO_0000218,1969.0,
8723,429,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626583,,BAO_0000218,,
8724,5974,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626205,,BAO_0000218,,
8725,5974,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626206,,BAO_0000218,,
8726,5974,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626207,,BAO_0000218,,
8727,5974,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623882,,BAO_0000218,,
8728,17582,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623883,,BAO_0000218,,
8729,17582,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623884,,BAO_0000218,,
8730,3032,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623885,,BAO_0000218,1969.0,
8731,6295,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623886,,BAO_0000218,1969.0,
8732,6619,Maximal concentration in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623887,,BAO_0000218,,
8733,6616,Maximal concentration after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623888,,BAO_0000218,,
8734,3249,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623889,,BAO_0000218,1969.0,
8735,17791,Maximal plasma concentration in rat after oral administration at 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623890,,BAO_0000218,1969.0,
8736,17791,Cmax in rat plasma after oral dose (50 mg/Kg),A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623891,,BAO_0000218,1969.0,
8737,1360,Maximal plasma concentration was determined.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623892,,BAO_0000218,1969.0,
8738,2552,Maximal plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623893,,BAO_0000218,1969.0,
8739,6571,Maximal concentration in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877616,,BAO_0000218,,
8740,6570,Maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623894,,BAO_0000218,,
8741,6567,Maximum concentration in rat plasma after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623895,,BAO_0000218,1969.0,
8742,3031,Maximum concentration of compound in rat was evaluated.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623896,,BAO_0000218,,
8743,3436,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623897,,BAO_0000218,,
8744,3436,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623898,,BAO_0000218,,
8745,2083,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623899,,BAO_0000218,,
8746,3436,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623900,,BAO_0000218,,
8747,4527,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623901,,BAO_0000218,,
8748,1974,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623902,,BAO_0000218,,
8749,3307,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Cerebrospinal fluid,,,50597,N,1,Intermediate,1,,CHEMBL623903,,BAO_0000218,1359.0,
8750,3307,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623904,,BAO_0000218,1969.0,
8751,1916,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL877617,,BAO_0000218,1969.0,
8752,1500,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623905,,BAO_0000218,,
8753,1500,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623906,,BAO_0000218,,
8754,4186,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623907,,BAO_0000218,1969.0,
8755,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623908,,BAO_0000218,,
8756,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623909,,BAO_0000218,,
8757,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623910,,BAO_0000218,,
8758,16434,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623911,,BAO_0000218,,
8759,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623912,,BAO_0000218,,
8760,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624616,,BAO_0000218,,
8761,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624617,,BAO_0000218,,
8762,16435,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624618,,BAO_0000218,,
8763,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624619,,BAO_0000218,,
8764,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624794,,BAO_0000218,,
8765,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624795,,BAO_0000218,,
8766,16435,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623921,,BAO_0000218,,
8767,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623922,,BAO_0000218,,
8768,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623923,,BAO_0000218,,
8769,16434,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623924,,BAO_0000218,,
8770,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623925,,BAO_0000218,,
8771,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623926,,BAO_0000218,,
8772,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623927,,BAO_0000218,,
8773,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623928,,BAO_0000218,,
8774,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623929,,BAO_0000218,,
8775,16435,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623930,,BAO_0000218,,
8776,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623931,,BAO_0000218,955.0,
8777,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622165,,BAO_0000218,955.0,
8778,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621249,,BAO_0000218,955.0,
8779,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621250,,BAO_0000218,955.0,
8780,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621448,,BAO_0000218,955.0,
8781,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621449,,BAO_0000218,955.0,
8782,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621450,,BAO_0000218,955.0,
8783,16434,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621451,,BAO_0000218,955.0,
8784,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621452,,BAO_0000218,955.0,
8785,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621453,,BAO_0000218,955.0,
8786,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621454,,BAO_0000218,955.0,
8787,16435,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621455,,BAO_0000218,955.0,
8788,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621456,,BAO_0000218,955.0,
8789,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625145,,BAO_0000218,955.0,
8790,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL875847,,BAO_0000218,955.0,
8791,16435,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625146,,BAO_0000218,955.0,
8792,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625147,,BAO_0000218,955.0,
8793,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625148,,BAO_0000218,955.0,
8794,16434,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625149,,BAO_0000218,955.0,
8795,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625150,,BAO_0000218,955.0,
8796,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625151,,BAO_0000218,955.0,
8797,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625152,,BAO_0000218,955.0,
8798,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625153,,BAO_0000218,955.0,
8799,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625154,,BAO_0000218,955.0,
8800,16435,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625155,,BAO_0000218,955.0,
8801,11977,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625156,,BAO_0000218,,
8802,11977,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624354,,BAO_0000218,,
8803,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624355,,BAO_0000218,10000000.0,
8804,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624356,,BAO_0000218,10000000.0,
8805,11977,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624357,,BAO_0000218,10000000.0,
8806,11977,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL624358,,BAO_0000218,10000000.0,
8807,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624359,,BAO_0000218,2435.0,
8808,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624360,,BAO_0000218,2435.0,
8809,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624361,,BAO_0000218,2435.0,
8810,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624362,,BAO_0000218,2435.0,
8811,11977,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL624363,,BAO_0000218,2435.0,
8812,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624364,,BAO_0000218,178.0,
8813,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624365,,BAO_0000218,178.0,
8814,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624366,,BAO_0000218,178.0,
8815,11977,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624367,,BAO_0000218,178.0,
8816,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624368,,BAO_0000218,955.0,
8817,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624369,,BAO_0000218,955.0,
8818,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624370,,BAO_0000218,955.0,
8819,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625069,,BAO_0000218,955.0,
8820,11977,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625070,,BAO_0000218,955.0,
8821,11977,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626051,,BAO_0000218,948.0,
8822,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626052,,BAO_0000218,948.0,
8823,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626053,,BAO_0000218,948.0,
8824,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626054,,BAO_0000218,948.0,
8825,11977,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626055,,BAO_0000218,948.0,
8826,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626056,,BAO_0000218,2113.0,
8827,11977,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626057,,BAO_0000218,2113.0,
8828,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625193,,BAO_0000218,2113.0,
8829,11977,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625194,,BAO_0000218,2113.0,
8830,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625195,,BAO_0000218,2107.0,
8831,11977,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625196,,BAO_0000218,2107.0,
8832,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625197,,BAO_0000218,2107.0,
8833,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625198,,BAO_0000218,2107.0,
8834,11977,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627929,,BAO_0000218,2107.0,
8835,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627074,,BAO_0000218,2048.0,
8836,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627075,,BAO_0000218,2048.0,
8837,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627076,,BAO_0000218,2048.0,
8838,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627077,,BAO_0000218,2048.0,
8839,11977,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627078,,BAO_0000218,2048.0,
8840,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627079,,BAO_0000218,2385.0,
8841,4573,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL873824,,BAO_0000218,,
8842,3132,Half life in mouse plasma was determined at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627080,,BAO_0000218,1969.0,
8843,17718,Half life was determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627081,,BAO_0000218,,
8844,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627082,,BAO_0000218,,
8845,5961,Half-life in male mice after 1 mg/kg intravenous dose,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627083,,BAO_0000218,,
8847,17731,Half life in mice plasma,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627085,,BAO_0000218,1969.0,
8848,17592,Half life in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627086,,BAO_0000218,,
8849,3132,Half life in mouse plasma at dose 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627087,,BAO_0000218,1969.0,
8850,17729,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627088,,BAO_0000218,,
8851,17729,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627089,,BAO_0000218,,
8852,17729,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627090,,BAO_0000218,,
8853,3277,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627091,,BAO_0000218,,
8854,3760,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627092,,BAO_0000218,,
8855,3760,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876785,,BAO_0000218,,
8856,2862,Half-life by iv administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627093,,BAO_0000218,,
8857,2862,Half-life by oral administration in mouse,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627094,,BAO_0000218,,
8858,5980,Half-life in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627095,,BAO_0000218,,
8859,6159,Half-life using mouse brain homogenate,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627096,,BAO_0000218,955.0,
8860,6254,Half-life was measured in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627097,,BAO_0000218,,
8861,6062,Half-life was measured in mouse after an iv dose of 1 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627098,,BAO_0000218,,
8862,1574,Half-life period was determined in mouse blood,A,,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL627099,,BAO_0000218,178.0,
8863,56,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL627100,,BAO_0000218,955.0,
8864,993,Plasma half life in mouse,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627101,,BAO_0000218,1969.0,
8865,6652,Stability of the peptide in the presence of mouse serum,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627102,,BAO_0000218,,
8866,17852,Terminal half life of compound was determined in mouse,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627103,,BAO_0000218,,
8867,2675,Terminal half life was evaluated in mice after intravenous administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627104,,BAO_0000218,,
8868,2675,Terminal half life was evaluated in mice after oral administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627105,,BAO_0000218,,
8869,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876786,,BAO_0000218,,
8870,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL873825,,BAO_0000218,,
8871,499,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627106,,BAO_0000218,,
8872,14239,half life period is evaluated by administering intravenously at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626336,,BAO_0000218,,
8873,5506,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877462,,BAO_0000218,,
8874,5506,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626337,,BAO_0000218,,
8875,17734,Half life after intraperitoneal administration of 100 mg/kg in mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626338,,BAO_0000218,,
8876,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626339,,BAO_0000218,,
8877,17728,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626340,,BAO_0000218,,
8878,17728,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625377,,BAO_0000218,,
8879,17728,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625378,,BAO_0000218,,
8880,17728,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625379,,BAO_0000218,,
8881,14294,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),A,,,Sus scrofa,9823.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL625380,,BAO_0000251,,
8882,14294,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),A,,,Sus scrofa,9823.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL625381,,BAO_0000251,,
8883,6056,Stability to porcine renal DHP-I,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625382,,BAO_0000019,,
8884,1317,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,A,In vivo,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL873828,,BAO_0000218,,
8885,1317,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,A,In vivo,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625383,,BAO_0000218,,
8886,5229,Half-life of the parent prodrug in porcine esterase solution,A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625384,,BAO_0000019,,
8887,4231,"First order rate constant, k was determined in in pig liver Esterase",A,,,Sus scrofa,9823.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625385,,BAO_0000019,,
8888,4231,Half life of the in pig liver Esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL625386,,BAO_0000221,2107.0,
8889,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623571,,BAO_0000221,2107.0,
8890,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623572,,BAO_0000221,2107.0,
8891,5318,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623573,,BAO_0000221,2107.0,
8892,3305,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623574,,BAO_0000221,2107.0,
8893,3305,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623575,,BAO_0000221,2107.0,
8894,2842,Half-life in the presence of pig liver esterase(PLE) was evaluated.,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623749,,BAO_0000221,2107.0,
8895,2842,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623750,,BAO_0000221,2107.0,
8896,889,Half-life in vitro in pig liver,A,In vitro,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623751,,BAO_0000221,2107.0,
8897,1904,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,A,,,Sus scrofa,9823.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL623752,,BAO_0000221,2107.0,
8898,4186,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623753,,BAO_0000218,1969.0,
8899,2774,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623754,,BAO_0000218,1969.0,
8900,1742,Maximum concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623755,,BAO_0000218,1969.0,
8901,3169,Maximum concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623756,,BAO_0000218,,
8902,3169,Maximum concentration in rats at 1-2 hours,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623757,,BAO_0000218,,
8903,2081,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623758,,BAO_0000218,,
8904,3307,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623759,,BAO_0000218,955.0,
8905,4727,Maximum concentration at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623760,,BAO_0000218,,
8906,6597,Maximum concentration was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623761,,BAO_0000218,,
8907,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623762,,BAO_0000218,1969.0,
8908,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL877594,,BAO_0000218,1969.0,
8909,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623763,,BAO_0000218,1969.0,
8910,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623764,,BAO_0000218,1969.0,
8911,16365,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623765,,BAO_0000218,1969.0,
8912,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623766,,BAO_0000218,178.0,
8913,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623767,,BAO_0000218,178.0,
8914,2591,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623768,,BAO_0000218,178.0,
8915,5978,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623769,,BAO_0000218,1969.0,
8916,5978,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623770,,BAO_0000218,1969.0,
8917,5978,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623771,,BAO_0000218,1969.0,
8918,5978,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623772,,BAO_0000218,1969.0,
8919,5978,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623773,,BAO_0000218,1969.0,
8920,5978,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623774,,BAO_0000218,1969.0,
8921,5978,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623775,,BAO_0000218,1969.0,
8922,14465,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623776,,BAO_0000218,,
8923,4723,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622191,,BAO_0000218,1969.0,
8924,4723,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622192,,BAO_0000218,1969.0,
8925,4576,Maximum plasma concentration determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622193,,BAO_0000218,1969.0,
8926,12873,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622194,,BAO_0000218,1969.0,
8927,12873,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622195,,BAO_0000218,1969.0,
8928,6824,Maximum plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622196,,BAO_0000218,1969.0,
8929,17065,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622197,,BAO_0000218,1969.0,
8930,2932,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622198,,BAO_0000218,1969.0,
8931,2932,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622199,,BAO_0000218,1969.0,
8932,2879,Maximum plasma concentration of compound was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622200,,BAO_0000218,1969.0,
8933,2864,Maximum plasma concentration after 20 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622201,,BAO_0000218,1969.0,
8934,16367,Maximum plasma concentration after oral administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623990,,BAO_0000218,1969.0,
8935,17717,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623991,,BAO_0000218,1969.0,
8936,17717,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623992,,BAO_0000218,1969.0,
8937,17717,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623993,,BAO_0000218,1969.0,
8938,17717,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623994,,BAO_0000218,1969.0,
8939,17720,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623995,,BAO_0000218,1969.0,
8940,17720,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623996,,BAO_0000218,1969.0,
8941,17720,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,F,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623997,,BAO_0000218,1969.0,
8942,4516,Maximum plasma concentration dosed orally in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623998,,BAO_0000218,1969.0,
8943,4516,Maximum plasma concentration dosed orally in rats after 6 hours,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623999,,BAO_0000218,1969.0,
8944,4516,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624000,,BAO_0000218,1969.0,
8945,5199,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624001,,BAO_0000218,1969.0,
8946,17538,Maximum plasma concentration in rat after po administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624002,,BAO_0000218,1969.0,
8947,6685,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624003,,BAO_0000218,1969.0,
8948,6685,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624004,,BAO_0000218,1969.0,
8949,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624005,,BAO_0000218,948.0,
8950,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624006,,BAO_0000218,948.0,
8951,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624007,,BAO_0000218,948.0,
8952,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624008,,BAO_0000218,948.0,
8953,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624009,,BAO_0000218,948.0,
8954,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL874387,,BAO_0000218,948.0,
8955,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624010,,BAO_0000218,948.0,
8956,16434,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624011,,BAO_0000218,948.0,
8957,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624012,,BAO_0000218,948.0,
8958,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624013,,BAO_0000218,948.0,
8959,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624736,,BAO_0000218,948.0,
8960,16435,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624737,,BAO_0000218,948.0,
8961,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624738,,BAO_0000218,948.0,
8962,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624739,,BAO_0000218,948.0,
8963,16434,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624740,,BAO_0000218,948.0,
8964,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624896,,BAO_0000218,948.0,
8965,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624897,,BAO_0000218,948.0,
8966,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624108,,BAO_0000218,948.0,
8967,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624109,,BAO_0000218,948.0,
8968,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624110,,BAO_0000218,948.0,
8969,16435,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624111,,BAO_0000218,948.0,
8970,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624112,,BAO_0000218,948.0,
8971,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624113,,BAO_0000218,948.0,
8972,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619709,,BAO_0000218,948.0,
8973,16435,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL619710,,BAO_0000218,948.0,
8974,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619711,,BAO_0000218,2113.0,
8975,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619712,,BAO_0000218,2113.0,
8976,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619713,,BAO_0000218,2113.0,
8977,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619714,,BAO_0000218,2113.0,
8978,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619715,,BAO_0000218,2113.0,
8979,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619716,,BAO_0000218,2113.0,
8980,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619717,,BAO_0000218,2113.0,
8981,16434,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619718,,BAO_0000218,2113.0,
8982,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619719,,BAO_0000218,2113.0,
8983,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL875329,,BAO_0000218,2113.0,
8984,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619720,,BAO_0000218,2113.0,
8985,16435,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619721,,BAO_0000218,2113.0,
8986,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619722,,BAO_0000218,2113.0,
8987,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619723,,BAO_0000218,2113.0,
8988,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619724,,BAO_0000218,2113.0,
8989,16435,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619725,,BAO_0000218,2113.0,
8990,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619726,,BAO_0000218,2113.0,
8991,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619727,,BAO_0000218,2113.0,
8992,16434,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619728,,BAO_0000218,2113.0,
8993,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL619729,,BAO_0000218,2113.0,
8994,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619730,,BAO_0000218,2385.0,
8995,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619731,,BAO_0000218,2385.0,
8996,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619732,,BAO_0000218,2385.0,
8997,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619733,,BAO_0000218,2385.0,
8998,11977,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL619734,,BAO_0000218,2385.0,
8999,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL619735,,BAO_0000218,14.0,
9000,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL875330,,BAO_0000218,14.0,
9001,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL628465,,BAO_0000218,14.0,
9002,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL628466,,BAO_0000218,14.0,
9003,11977,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL628467,,BAO_0000218,14.0,
9004,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628468,,BAO_0000218,2106.0,
9005,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628469,,BAO_0000218,2106.0,
9006,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628470,,BAO_0000218,2106.0,
9007,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628471,,BAO_0000218,2106.0,
9008,11977,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628472,,BAO_0000218,2106.0,
9009,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL625191,,BAO_0000218,2046.0,
9010,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL625192,,BAO_0000218,2046.0,
9011,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL875337,,BAO_0000218,2046.0,
9012,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626341,,BAO_0000218,2046.0,
9013,11977,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626342,,BAO_0000218,2046.0,
9014,11977,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621943,,BAO_0000218,2107.0,
9015,3748,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621944,,BAO_0000218,,
9016,15765,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621945,,BAO_0000218,,
9017,4871,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621946,,BAO_0000218,,
9018,4871,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621947,,BAO_0000218,,
9019,4872,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621948,,BAO_0000218,,
9020,4872,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621949,,BAO_0000218,,
9021,5413,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621950,,BAO_0000218,,
9022,5413,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621951,,BAO_0000218,,
9023,15272,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621952,,BAO_0000218,178.0,
9024,4689,Stability (%) in rat liver microsomes,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621953,,BAO_0000218,2107.0,
9025,6057,Area under curve was calculated after intravenous administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621954,,BAO_0000218,,
9026,6057,Area under the curve was calculated after iv administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621955,,BAO_0000218,,
9027,6057,Area under the curve was calculated in rat after peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621956,,BAO_0000218,,
9028,6211,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621957,,BAO_0000218,,
9029,5710,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621958,,BAO_0000218,,
9030,5710,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621959,,BAO_0000218,,
9031,17853,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621960,,BAO_0000218,,
9032,17853,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621961,,BAO_0000218,,
9033,15765,p value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621962,,BAO_0000218,,
9034,15765,p value of the compound,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876787,,BAO_0000218,,
9035,15765,p value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621963,,BAO_0000218,,
9036,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622637,,BAO_0000218,945.0,
9037,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622638,,BAO_0000218,945.0,
9038,6175,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL626561,,BAO_0000218,945.0,
9039,7991,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),F,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626562,,BAO_0000019,,
9040,429,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626563,,BAO_0000218,,
9041,429,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626564,,BAO_0000218,,
9042,6253,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626565,,BAO_0000218,,
9043,6253,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626566,,BAO_0000218,,
9044,3615,Clearance rate in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626567,,BAO_0000218,,
9045,4059,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626568,,BAO_0000218,,
9046,5124,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626569,,BAO_0000218,,
9047,5124,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626570,,BAO_0000218,,
9048,5124,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626571,,BAO_0000218,,
9049,429,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626572,,BAO_0000218,,
9050,4059,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626573,,BAO_0000218,1969.0,
9051,9659,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,A,,,Oryctolagus cuniculus,9986.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL626574,,BAO_0000251,2107.0,
9052,9659,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,A,,,Oryctolagus cuniculus,9986.0,,Liver,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL626575,,BAO_0000251,2107.0,
9053,3639,Dose at which bioavailability of intravenously administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626576,,BAO_0000218,,
9054,3639,Dose at which bioavailability of perorally administered compound was tested in rabbit,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626577,,BAO_0000218,,
9055,3639,The compound was tested for its bioavailability in rabbit (by oral dosage).,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626578,,BAO_0000218,,
9056,5124,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625263,,BAO_0000218,,
9057,5124,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625264,,BAO_0000218,,
9058,5124,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625265,,BAO_0000218,,
9059,14294,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),A,,,Oryctolagus cuniculus,9986.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL625266,,BAO_0000251,,
9060,14294,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),A,,,Oryctolagus cuniculus,9986.0,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL876796,,BAO_0000251,,
9061,429,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625267,,BAO_0000218,,
9062,5124,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL625268,,BAO_0000218,1969.0,
9063,5124,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL625269,,BAO_0000218,1969.0,
9064,5124,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624689,,BAO_0000218,1969.0,
9065,429,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624690,,BAO_0000218,,
9066,429,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),A,,,Oryctolagus cuniculus,9986.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL624691,,BAO_0000218,1088.0,
9067,429,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),A,,,Oryctolagus cuniculus,9986.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL624692,,BAO_0000218,1088.0,
9068,4059,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624693,,BAO_0000218,,
9069,4137,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624694,,BAO_0000218,,
9070,11672,In vitro Biological half-life in crude homogenate of rabbit renal cortex,A,In vitro,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL877596,,BAO_0000221,,
9071,12886,Time within which only 10% of the drug was degraded,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624695,,BAO_0000019,,
9072,3853,Half life period in rabbit liver homogenate,A,,,Oryctolagus cuniculus,9986.0,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL624696,,BAO_0000221,2107.0,
9073,3615,Half life value in rabbits,A,,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624697,,BAO_0000019,,
9074,6253,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624698,,BAO_0000218,178.0,
9075,6253,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,A,In vivo,,Oryctolagus cuniculus,9986.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624699,,BAO_0000218,178.0,
9076,6077,Half-life period in rabbits following intravenous administration at 2 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624700,,BAO_0000218,,
9077,17617,AUC 0-8 hr value in rats at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622903,,BAO_0000218,1969.0,
9078,17594,AUC after administration at 2000 mg/kg/day in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622904,,BAO_0000218,1969.0,
9079,6149,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622905,,BAO_0000218,1969.0,
9080,17260,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622906,,BAO_0000218,1969.0,
9081,17260,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622907,,BAO_0000218,1969.0,
9082,6644,AUC in rat after oral administration at 10.5 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622908,,BAO_0000218,1969.0,
9083,6644,AUC in rat after oral administration at 11.2 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622909,,BAO_0000218,1969.0,
9084,6644,AUC in rat after oral administration at 9.7 mg/kg dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622910,,BAO_0000218,1969.0,
9085,6495,AUC in rat brain after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622911,,BAO_0000218,955.0,
9086,6504,AUC in rat p.o.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622912,,BAO_0000218,1969.0,
9087,17686,AUC in rat p.o. at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622913,,BAO_0000218,1969.0,
9088,6495,AUC in rat plasma after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622914,,BAO_0000218,1969.0,
9089,216,AUC in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622915,,BAO_0000218,1969.0,
9090,1908,AUC value after IV dose at a dose of 5 mg/kg in rats.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622916,,BAO_0000218,1969.0,
9091,1908,AUC value after oral dose at a dose of 10 mg/kg in rats.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622917,,BAO_0000218,1969.0,
9092,6685,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622918,,BAO_0000218,1969.0,
9093,216,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622919,,BAO_0000218,1969.0,
9094,6049,Maximum plasma concentration was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622920,,BAO_0000218,1969.0,
9095,2463,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622921,,BAO_0000218,1969.0,
9096,6679,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622922,,BAO_0000218,1969.0,
9097,6681,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622923,,BAO_0000218,1969.0,
9098,4890,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL877604,,BAO_0000218,1969.0,
9099,6410,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622924,,BAO_0000218,1969.0,
9100,6410,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622925,,BAO_0000218,1969.0,
9101,16366,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622926,,BAO_0000218,1969.0,
9102,6227,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623625,,BAO_0000218,1969.0,
9103,3598,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Expert,1,,CHEMBL623626,,BAO_0000218,1969.0,
9104,1465,Maximum plasma drug concentration was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623627,,BAO_0000218,1969.0,
9105,4368,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623628,,BAO_0000218,,
9106,15662,Mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623629,,BAO_0000218,1969.0,
9107,15662,Mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623630,,BAO_0000218,1969.0,
9108,5355,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623804,,BAO_0000218,,
9109,5355,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623805,,BAO_0000218,,
9110,1567,Peak oral plasma concentration was determined in rats by oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623806,,BAO_0000218,1969.0,
9111,4026,Peak plasma concentration (Cmax) was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623807,,BAO_0000218,1969.0,
9112,6193,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623808,,BAO_0000218,1969.0,
9113,4026,Peak plasma concentration (Cmax) in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623809,,BAO_0000218,1969.0,
9114,6485,Peak plasma concentration at 1 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623810,,BAO_0000218,1969.0,
9115,17655,Peak plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623811,,BAO_0000218,1969.0,
9116,14941,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623812,,BAO_0000218,1969.0,
9117,5394,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877605,,BAO_0000218,,
9118,4408,Pharmacokinetic property (Cmax) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623813,,BAO_0000218,,
9119,5983,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623814,,BAO_0000218,,
9120,4878,Cmax in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623815,,BAO_0000218,,
9121,5862,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,Sprague-Dawley,,,,50597,N,1,Intermediate,1,,CHEMBL623816,,BAO_0000218,,
9122,4517,Cmax in rats after 20 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623145,,BAO_0000218,,
9123,5932,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623146,,BAO_0000218,1969.0,
9124,5436,Plasma concentration after oral administration of 100 mg/kg to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623147,,BAO_0000218,1969.0,
9125,4910,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623042,,BAO_0000218,955.0,
9126,4950,Tested for the Cmax in rat at 10 mg/kg per orally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623043,,BAO_0000218,,
9127,15078,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623044,,BAO_0000218,,
9128,15078,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623045,,BAO_0000218,,
9129,3360,Bioavailability as oral Cmax in rats at 30 mins,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623046,,BAO_0000218,,
9130,3360,Bioavailability as oral Cmax in rats at 6hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623226,,BAO_0000218,,
9131,15022,The maximum concentration of compound was measured at the dose of 100 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623227,,BAO_0000218,,
9132,15022,The maximum concentration of compound was measured at the dose of 300 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623228,,BAO_0000218,,
9133,15022,The maximum concentration of compound was measured at the dose of 30 umol/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623229,,BAO_0000218,,
9134,5160,The maximum plasma levels for the compounds were determined by LC-MS.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623230,,BAO_0000218,1969.0,
9135,15662,mean peak plasma concentration was observed after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623231,,BAO_0000218,1969.0,
9136,15662,mean peak plasma concentration was observed after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623232,,BAO_0000218,1969.0,
9137,4709,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623233,,BAO_0000218,,
9138,3535,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623234,,BAO_0000218,,
9139,3535,Concentration in plasma (portal) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623235,,BAO_0000218,,
9140,3535,Concentration in plasma (portal) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623236,,BAO_0000218,,
9141,3535,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623237,,BAO_0000218,,
9142,3535,Concentration in plasma (systemic) following oral dose in rats at 1 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623238,,BAO_0000218,,
9143,3535,Concentration in plasma (systemic) following oral dose in rats at 2 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623239,,BAO_0000218,,
9144,5005,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL623240,,BAO_0000218,1969.0,
9145,6326,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",A,,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL623241,,BAO_0000218,1898.0,
9146,6326,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",A,,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL623242,,BAO_0000218,1898.0,
9147,6326,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874394,,BAO_0000218,,
9148,6326,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623243,,BAO_0000218,,
9149,17411,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623244,,BAO_0000218,,
9150,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623245,,BAO_0000218,2113.0,
9151,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623246,,BAO_0000218,2113.0,
9152,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623247,,BAO_0000218,2113.0,
9153,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623248,,BAO_0000218,2113.0,
9154,16435,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623249,,BAO_0000218,2113.0,
9155,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625072,,BAO_0000218,2107.0,
9156,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625073,,BAO_0000218,2107.0,
9157,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625074,,BAO_0000218,2107.0,
9158,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625075,,BAO_0000218,2107.0,
9159,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625076,,BAO_0000218,2107.0,
9160,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625077,,BAO_0000218,2107.0,
9161,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625078,,BAO_0000218,2107.0,
9162,16434,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL874395,,BAO_0000218,2107.0,
9163,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625079,,BAO_0000218,2107.0,
9164,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625080,,BAO_0000218,2107.0,
9165,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625081,,BAO_0000218,2107.0,
9166,16435,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625082,,BAO_0000218,2107.0,
9167,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625083,,BAO_0000218,2107.0,
9168,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625084,,BAO_0000218,2107.0,
9169,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625085,,BAO_0000218,2107.0,
9170,16435,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625086,,BAO_0000218,2107.0,
9171,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625087,,BAO_0000218,2107.0,
9172,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625088,,BAO_0000218,2107.0,
9173,16434,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622205,,BAO_0000218,2107.0,
9174,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622206,,BAO_0000218,2107.0,
9175,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622207,,BAO_0000218,2107.0,
9176,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622366,,BAO_0000218,2107.0,
9177,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622367,,BAO_0000218,2107.0,
9178,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL875331,,BAO_0000218,2107.0,
9179,16435,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622368,,BAO_0000218,2107.0,
9180,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622369,,BAO_0000218,2048.0,
9181,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622370,,BAO_0000218,2048.0,
9182,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622371,,BAO_0000218,2048.0,
9183,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622372,,BAO_0000218,2048.0,
9184,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622373,,BAO_0000218,2048.0,
9185,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622374,,BAO_0000218,2048.0,
9186,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622375,,BAO_0000218,2048.0,
9187,16434,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622376,,BAO_0000218,2048.0,
9188,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622377,,BAO_0000218,2048.0,
9189,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622378,,BAO_0000218,2048.0,
9190,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622379,,BAO_0000218,2048.0,
9191,16435,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622380,,BAO_0000218,2048.0,
9192,16435,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622381,,BAO_0000218,2048.0,
9193,16435,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622382,,BAO_0000218,2048.0,
9194,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622383,,BAO_0000218,2048.0,
9195,6175,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL875332,,BAO_0000218,945.0,
9196,6175,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622384,,BAO_0000218,945.0,
9197,6175,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622385,,BAO_0000218,945.0,
9198,6175,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),A,,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622386,,BAO_0000218,945.0,
9199,10839,The compound was tested for the plasma binding in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622387,,BAO_0000218,,
9200,16459,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622388,,BAO_0000218,,
9201,16459,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622389,,BAO_0000218,,
9202,16459,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622390,,BAO_0000218,,
9203,16459,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622391,,BAO_0000218,,
9204,16459,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622392,,BAO_0000218,,
9205,16459,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622393,,BAO_0000218,,
9206,3278,Plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622394,,BAO_0000218,,
9207,3278,plasma level at 2 hr after administration of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622395,,BAO_0000218,,
9208,4684,Stability in rat serum measured as % recovery at 1 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL622396,,BAO_0000218,1977.0,
9209,4684,Stability in rat serum measured as % recovery at 10 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624894,,BAO_0000218,1977.0,
9210,4684,Stability in rat serum measured as % recovery at 10 mins,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624895,,BAO_0000218,1977.0,
9211,4684,Stability in rat serum measured as % recovery at 2 hr,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624058,,BAO_0000218,1977.0,
9212,4684,Stability in rat serum measured as % recovery at 3 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624059,,BAO_0000218,1977.0,
9213,4684,Stability in rat serum measured as % recovery at 3 mins,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624060,,BAO_0000218,1977.0,
9214,4684,Stability in rat serum measured as % recovery at 5 min,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624061,,BAO_0000218,1977.0,
9215,4684,Stability in rat serum measured as % recovery at 5 mins,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL624062,,BAO_0000218,1977.0,
9216,16456,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624063,,BAO_0000218,,
9217,16456,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624064,,BAO_0000218,,
9218,723,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624065,,BAO_0000218,1969.0,
9219,723,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624066,,BAO_0000218,1969.0,
9220,5160,Half life tested in mature male rat at a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877490,,BAO_0000218,,
9221,4709,Half life after intravenous administration of 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874442,,BAO_0000218,,
9222,5633,Half life period after administration (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626890,,BAO_0000218,,
9223,5302,Half life period in rat after 5 mg/Kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626891,,BAO_0000218,,
9224,5302,Half life period in rat after 5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626892,,BAO_0000218,,
9225,17791,Half life period was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626893,,BAO_0000218,,
9226,17791,Half life period was evaluated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626894,,BAO_0000218,,
9227,17791,Half life period was evaluated in rat; 0.5-1.0,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626895,,BAO_0000218,,
9228,17791,Half life period was evaluated in rat; 5.9-7.5,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626896,,BAO_0000218,,
9229,14512,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626897,,BAO_0000218,1969.0,
9230,6230,Half-life time in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626898,,BAO_0000218,,
9231,3364,Terminal half-life after iv administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626899,,BAO_0000218,,
9232,6874,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626900,,BAO_0000218,,
9233,857,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626901,,BAO_0000218,,
9234,858,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626902,,BAO_0000218,,
9235,858,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626903,,BAO_0000218,,
9236,5355,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874443,,BAO_0000218,,
9237,5355,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626904,,BAO_0000218,,
9238,6305,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626905,,BAO_0000218,,
9239,13501,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873830,,BAO_0000218,1969.0,
9240,17594,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626906,,BAO_0000218,,
9241,4186,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631076,,BAO_0000218,1969.0,
9242,2932,Biological half-life was measured in plasma of rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631077,,BAO_0000218,1969.0,
9243,17065,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631078,,BAO_0000218,,
9244,15765,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631079,,BAO_0000218,,
9245,2713,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631080,,BAO_0000218,,
9246,2661,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631081,,BAO_0000218,,
9247,2661,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631239,,BAO_0000218,,
9248,740,Compound was evaluated for plasma half life in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631240,,BAO_0000218,1969.0,
9249,6597,AUC value at a dose of 5 mg/kg (p.o.) in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631241,,BAO_0000218,1969.0,
9250,2959,AUC value after administration of 20 mg/Kg oral dose in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631242,,BAO_0000218,1969.0,
9251,17594,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631243,,BAO_0000218,1969.0,
9252,17596,AUC0-96 after administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874444,,BAO_0000218,1969.0,
9253,17594,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631244,,BAO_0000218,1969.0,
9254,3293,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631245,,BAO_0000218,,
9255,6757,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627162,,BAO_0000218,,
9256,6757,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627163,,BAO_0000218,,
9257,6757,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627164,,BAO_0000218,,
9258,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627165,,BAO_0000218,2113.0,
9259,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627166,,BAO_0000218,,
9260,5979,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627167,,BAO_0000218,,
9261,4026,Area under curve (AUC) at a dose of 30 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627822,,BAO_0000218,,
9262,5355,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627823,,BAO_0000218,,
9263,5355,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627824,,BAO_0000218,,
9264,5355,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627825,,BAO_0000218,,
9265,5633,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627826,,BAO_0000218,,
9266,1716,Area under curve (Pharmacokinetic property) was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627827,,BAO_0000218,,
9267,1716,Area under curve (Pharmacokinetic property) of the compound; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627828,,BAO_0000218,,
9268,4689,Area under curve after intravenous administration (1 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627829,,BAO_0000218,,
9269,4527,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627830,,BAO_0000218,,
9270,4527,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627831,,BAO_0000218,,
9271,15662,Area under curve in male SD rats was observed after oral administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627832,,BAO_0000218,,
9272,4413,Area under curve of compound after iv administration of 20 mg/kg dose in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627833,,BAO_0000218,,
9273,3598,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL627834,,BAO_0000218,,
9274,3598,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL628004,,BAO_0000218,,
9275,5964,Area under curve at 5 mg/kg po was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628005,,BAO_0000218,,
9276,4689,Area under curve in Rat at a oral dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628006,,BAO_0000218,,
9277,4186,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628007,,BAO_0000218,,
9278,5510,Area under curve was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625676,,BAO_0000218,,
9279,17858,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631309,,BAO_0000218,,
9280,17804,Area under curve after intravenous administration at 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631310,,BAO_0000218,,
9281,6106,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631311,,BAO_0000218,,
9282,5964,Area under curve at 4 hr in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631312,,BAO_0000218,,
9283,4026,Area under curve at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631313,,BAO_0000218,,
9284,4756,Area under curve at the dose of 2 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631314,,BAO_0000218,,
9285,4756,Area under curve at the dose of 5 mg/Kg administered perorally in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631315,,BAO_0000218,,
9286,5862,Area under curve for a 2-mpk po dose in SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631316,,BAO_0000218,,
9287,5862,Area under curve in SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631317,,BAO_0000218,,
9288,6644,Area under curve in rat after oral administration at 13 mg/kg dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874471,,BAO_0000218,,
9289,5871,Area under curve in rat by po administration at 0-24 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631318,,BAO_0000218,,
9290,5919,Area under curve in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631319,,BAO_0000218,1969.0,
9291,5939,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631320,,BAO_0000218,,
9292,5939,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631321,,BAO_0000218,,
9293,10,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631322,,BAO_0000218,,
9294,11149,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631323,,BAO_0000218,,
9295,5302,Area under curve value in rat at a dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631324,,BAO_0000218,,
9296,17796,Area under curve was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631325,,BAO_0000218,,
9297,4890,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631326,,BAO_0000218,,
9298,6011,Area under curve was determined after peroral administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631327,,BAO_0000218,,
9299,5375,Area under curve was determined at a dose 30 mpk administered orally.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631328,,BAO_0000218,,
9300,17764,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631329,,BAO_0000218,,
9301,4368,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627217,,BAO_0000218,,
9302,5610,Area under curve was determined in male rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626352,,BAO_0000218,,
9303,5833,Area under curve was determined in rat after PO administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626353,,BAO_0000218,,
9304,4257,Area under curve was determined in rat after a 3 mg/kg of oral dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626354,,BAO_0000218,,
9305,5937,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626355,,BAO_0000218,,
9306,5932,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626356,,BAO_0000218,,
9307,5932,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626357,,BAO_0000218,,
9308,17411,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626358,,BAO_0000218,,
9309,17411,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626359,,BAO_0000218,,
9310,17771,Peak plasma concentration in rat at a dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626360,,BAO_0000218,1969.0,
9311,1628,Plasma concentration at 2 hr in rats was evaluated.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626361,,BAO_0000218,,
9312,1628,Plasma concentration at 2 hr in rats was evaluated; Not available,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626362,,BAO_0000218,,
9313,17411,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626363,,BAO_0000218,,
9314,4910,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626970,,BAO_0000218,,
9315,4910,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626971,,BAO_0000218,,
9316,4910,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626972,,BAO_0000218,1969.0,
9317,4910,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626973,,BAO_0000218,1969.0,
9318,4910,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626974,,BAO_0000218,1969.0,
9319,4910,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874592,,BAO_0000218,1969.0,
9320,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626975,,BAO_0000218,,
9321,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626976,,BAO_0000218,,
9322,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626977,,BAO_0000218,,
9323,5510,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626978,,BAO_0000218,,
9324,16427,PK study was carried to determine the relative absorption ranking in rat.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626979,,BAO_0000218,,
9325,4689,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626980,,BAO_0000218,1969.0,
9326,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626981,,BAO_0000218,178.0,
9327,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626982,,BAO_0000218,178.0,
9328,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626983,,BAO_0000218,178.0,
9329,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622522,,BAO_0000218,178.0,
9330,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622523,,BAO_0000218,178.0,
9331,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622524,,BAO_0000218,178.0,
9332,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622525,,BAO_0000218,955.0,
9333,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622526,,BAO_0000218,955.0,
9334,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619849,,BAO_0000218,955.0,
9335,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL619850,,BAO_0000218,955.0,
9336,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623864,,BAO_0000218,955.0,
9337,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623865,,BAO_0000218,955.0,
9338,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623866,,BAO_0000218,948.0,
9339,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623867,,BAO_0000218,948.0,
9340,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL877615,,BAO_0000218,948.0,
9341,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623868,,BAO_0000218,948.0,
9342,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623869,,BAO_0000218,948.0,
9343,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623870,,BAO_0000218,948.0,
9344,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL623871,,BAO_0000218,2048.0,
9345,16434,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL623872,,BAO_0000218,2048.0,
9346,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622129,,BAO_0000218,2048.0,
9347,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622130,,BAO_0000218,2048.0,
9348,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622131,,BAO_0000218,2048.0,
9349,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622132,,BAO_0000218,2048.0,
9350,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622133,,BAO_0000218,2048.0,
9351,16435,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622134,,BAO_0000218,2048.0,
9352,16435,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622135,,BAO_0000218,2048.0,
9353,16435,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622136,,BAO_0000218,2048.0,
9354,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622137,,BAO_0000218,2385.0,
9355,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622138,,BAO_0000218,2385.0,
9356,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623017,,BAO_0000218,2385.0,
9357,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623018,,BAO_0000218,2385.0,
9358,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623019,,BAO_0000218,2385.0,
9359,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623020,,BAO_0000218,2385.0,
9360,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623021,,BAO_0000218,2385.0,
9361,16434,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623022,,BAO_0000218,2385.0,
9362,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623023,,BAO_0000218,2385.0,
9363,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623024,,BAO_0000218,2385.0,
9364,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623025,,BAO_0000218,2385.0,
9365,16435,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620545,,BAO_0000218,2385.0,
9366,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620546,,BAO_0000218,2385.0,
9367,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620547,,BAO_0000218,2385.0,
9368,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620548,,BAO_0000218,2385.0,
9369,16435,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620549,,BAO_0000218,2385.0,
9370,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620550,,BAO_0000218,2385.0,
9371,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620551,,BAO_0000218,2385.0,
9372,16434,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620552,,BAO_0000218,2385.0,
9373,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620553,,BAO_0000218,2385.0,
9374,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620554,,BAO_0000218,2385.0,
9375,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL875845,,BAO_0000218,2385.0,
9376,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620555,,BAO_0000218,2385.0,
9377,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620556,,BAO_0000218,2385.0,
9378,16435,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620557,,BAO_0000218,2385.0,
9379,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620558,,BAO_0000218,,
9380,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620559,,BAO_0000218,,
9381,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622939,,BAO_0000218,,
9382,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622940,,BAO_0000218,,
9383,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622941,,BAO_0000218,,
9384,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622942,,BAO_0000218,,
9385,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622943,,BAO_0000218,,
9386,16434,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622944,,BAO_0000218,,
9387,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622945,,BAO_0000218,,
9388,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622946,,BAO_0000218,,
9389,3341,Compound was evaluated for terminal half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622947,,BAO_0000218,,
9390,3634,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622948,,BAO_0000218,1969.0,
9391,3634,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622949,,BAO_0000218,1969.0,
9392,4839,Compound was tested for its half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622950,,BAO_0000218,,
9393,5005,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL622951,,BAO_0000218,1969.0,
9394,5005,Compound was tested for its plasma half life in Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL622952,,BAO_0000366,1969.0,
9395,5005,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Intermediate,1,,CHEMBL622953,,BAO_0000366,1969.0,
9396,1094,Compound was tested for plasma half-life period in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873818,,BAO_0000218,1969.0,
9397,5031,Elimination half life after i.v. administration of compound in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622954,,BAO_0000218,,
9398,6518,Elimination half-life after IV dosing at 0.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622955,,BAO_0000218,,
9399,6518,Elimination half-life after IV dosing at 1 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875229,,BAO_0000218,,
9400,6518,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622956,,BAO_0000218,,
9401,6518,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622957,,BAO_0000218,,
9402,5408,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622958,,BAO_0000218,955.0,
9403,5408,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622959,,BAO_0000218,1969.0,
9404,5408,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622960,,BAO_0000218,955.0,
9405,5408,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622961,,BAO_0000218,1969.0,
9406,4687,Evaluated for the half life in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622962,,BAO_0000218,,
9407,6640,Hafl life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622963,,BAO_0000218,,
9408,6640,Hafl life rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622964,,BAO_0000218,,
9409,6641,Hafl life rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622965,,BAO_0000218,,
9410,6640,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622966,,BAO_0000218,,
9411,6641,Hafl life rat; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622967,,BAO_0000218,,
9412,17411,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622968,,BAO_0000218,2113.0,
9413,17411,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622969,,BAO_0000218,2107.0,
9414,17411,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL875327,,BAO_0000218,2048.0,
9415,6570,Half life in rat after 1 mg/kg i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628638,,BAO_0000218,,
9416,6570,Half life in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628639,,BAO_0000218,,
9417,17411,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625840,,BAO_0000218,,
9418,4722,Half life of 10 mg/kg oral dose determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625841,,BAO_0000218,,
9419,5978,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625842,,BAO_0000218,,
9420,5978,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625843,,BAO_0000218,,
9421,5978,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625844,,BAO_0000218,,
9422,5978,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873822,,BAO_0000218,,
9423,5978,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625845,,BAO_0000218,,
9424,5978,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627059,,BAO_0000218,,
9425,5978,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627060,,BAO_0000218,,
9426,5978,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627061,,BAO_0000218,,
9427,4762,Half life of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627709,,BAO_0000218,,
9428,5327,Half life of compound determined after intravenous administration to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627710,,BAO_0000218,,
9429,4847,Half life of compound was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627711,,BAO_0000218,,
9430,17720,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627712,,BAO_0000218,1969.0,
9431,4723,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627713,,BAO_0000218,,
9432,4723,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627714,,BAO_0000218,,
9433,4256,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627889,,BAO_0000218,,
9434,4256,Half life determined in rat by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627890,,BAO_0000218,,
9435,4722,Half life determined in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627891,,BAO_0000218,,
9436,6535,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627892,,BAO_0000218,1969.0,
9437,6535,Half life in rat plasma after administration of 2 mg/kg iv,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627893,,BAO_0000218,1969.0,
9438,1435,Half life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627894,,BAO_0000218,1969.0,
9439,1435,Half life in rat plasma was determined; NA means not applicable,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627895,,BAO_0000218,1969.0,
9440,5206,Half life in rat was tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627896,,BAO_0000218,,
9441,6080,Half life measured in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627897,,BAO_0000218,1969.0,
9442,4449,Half life recorded in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627898,,BAO_0000218,,
9443,6057,Half life was calculated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627899,,BAO_0000218,,
9444,6057,Half life was calculated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873823,,BAO_0000218,,
9445,3747,Half life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627900,,BAO_0000218,,
9446,17858,Half life after 10 mg/kg oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627901,,BAO_0000218,,
9447,16365,Half life after administering orally a dose of 10 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627902,,BAO_0000218,,
9448,16365,Half life after administering orally a dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627903,,BAO_0000218,,
9449,5031,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627904,,BAO_0000218,,
9450,4722,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627905,,BAO_0000218,,
9451,6078,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627906,,BAO_0000218,,
9452,6078,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627907,,BAO_0000218,,
9453,6078,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876783,,BAO_0000218,,
9454,6078,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627908,,BAO_0000218,,
9455,17065,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627909,,BAO_0000218,,
9456,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627910,,BAO_0000218,,
9457,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627911,,BAO_0000218,,
9458,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627912,,BAO_0000218,,
9459,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627913,,BAO_0000218,,
9460,1353,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627914,,BAO_0000218,,
9461,16423,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627915,,BAO_0000218,,
9462,16423,Area under the curve was evaluated after 20 uM/kg of peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627916,,BAO_0000218,,
9463,6062,Area under the curve was measured in rat after an iv dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627917,,BAO_0000218,,
9464,6056,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627918,,BAO_0000218,,
9465,5182,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627919,,BAO_0000218,,
9466,6410,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627920,,BAO_0000218,,
9467,6410,Area under the curve was evaluated at an oral dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627921,,BAO_0000218,,
9468,4723,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627922,,BAO_0000218,,
9469,4723,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876784,,BAO_0000218,,
9470,4723,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627923,,BAO_0000218,,
9471,4723,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626208,,BAO_0000218,,
9472,4723,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626209,,BAO_0000218,,
9473,4723,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626210,,BAO_0000218,,
9474,2463,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627994,,BAO_0000218,1969.0,
9475,4709,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627995,,BAO_0000218,,
9476,4075,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627996,,BAO_0000218,,
9477,5394,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627997,,BAO_0000218,,
9478,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627998,,BAO_0000218,,
9479,2661,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628640,,BAO_0000218,,
9480,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628641,,BAO_0000218,,
9481,2661,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628642,,BAO_0000218,,
9482,17791,Compound was evaluated for area under the curve expressed as (h*ug/ml),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628643,,BAO_0000218,,
9483,2591,Compound was tested for area under curve in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628644,,BAO_0000218,,
9484,6567,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628645,,BAO_0000218,,
9485,6211,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628646,,BAO_0000218,,
9486,5529,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628647,,BAO_0000218,,
9487,5408,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628648,,BAO_0000218,,
9488,5408,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625358,,BAO_0000218,,
9489,5408,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625359,,BAO_0000218,,
9490,5408,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625360,,BAO_0000218,,
9491,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625361,,BAO_0000218,,
9492,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625362,,BAO_0000218,,
9493,429,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625363,,BAO_0000218,,
9494,4796,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625364,,BAO_0000218,,
9495,5974,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625365,,BAO_0000218,,
9496,5974,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625366,,BAO_0000218,,
9497,5974,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625367,,BAO_0000218,,
9498,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625368,,BAO_0000218,2113.0,
9499,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625369,,BAO_0000218,2113.0,
9500,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625370,,BAO_0000218,2113.0,
9501,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625371,,BAO_0000218,2113.0,
9502,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625372,,BAO_0000218,2113.0,
9503,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625373,,BAO_0000218,2113.0,
9504,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625374,,BAO_0000218,2107.0,
9505,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL877593,,BAO_0000218,2107.0,
9506,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625375,,BAO_0000218,2107.0,
9507,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625376,,BAO_0000218,2107.0,
9508,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621973,,BAO_0000218,2107.0,
9509,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621974,,BAO_0000218,2107.0,
9510,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL621975,,BAO_0000218,2048.0,
9511,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622166,,BAO_0000218,2048.0,
9512,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622167,,BAO_0000218,2048.0,
9513,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622168,,BAO_0000218,2048.0,
9514,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622169,,BAO_0000218,2048.0,
9515,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622170,,BAO_0000218,2048.0,
9516,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622171,,BAO_0000218,2046.0,
9517,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622172,,BAO_0000218,2046.0,
9518,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622173,,BAO_0000218,2046.0,
9519,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622174,,BAO_0000218,2046.0,
9520,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622175,,BAO_0000218,2046.0,
9521,11450,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622176,,BAO_0000218,2046.0,
9522,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622177,,BAO_0000218,2046.0,
9523,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622178,,BAO_0000218,2046.0,
9524,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622179,,BAO_0000218,2046.0,
9525,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622180,,BAO_0000218,2046.0,
9526,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622181,,BAO_0000218,,
9527,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622182,,BAO_0000218,,
9528,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622183,,BAO_0000218,,
9529,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622184,,BAO_0000218,,
9530,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622185,,BAO_0000218,,
9531,16435,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622186,,BAO_0000218,,
9532,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622187,,BAO_0000218,,
9533,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625002,,BAO_0000218,,
9534,16434,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622090,,BAO_0000218,,
9535,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622091,,BAO_0000218,,
9536,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622092,,BAO_0000218,,
9537,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622093,,BAO_0000218,,
9538,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622094,,BAO_0000218,,
9539,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622095,,BAO_0000218,,
9540,16435,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622264,,BAO_0000218,,
9541,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622265,,BAO_0000218,2106.0,
9542,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622266,,BAO_0000218,2106.0,
9543,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622267,,BAO_0000218,2106.0,
9544,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622268,,BAO_0000218,2106.0,
9545,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622269,,BAO_0000218,2106.0,
9546,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625071,,BAO_0000218,2106.0,
9547,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621621,,BAO_0000218,2106.0,
9548,16434,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621622,,BAO_0000218,2106.0,
9549,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621623,,BAO_0000218,2106.0,
9550,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621624,,BAO_0000218,2106.0,
9551,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621625,,BAO_0000218,2106.0,
9552,16435,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621626,,BAO_0000218,2106.0,
9553,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621627,,BAO_0000218,2106.0,
9554,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621628,,BAO_0000218,2106.0,
9555,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL875328,,BAO_0000218,2106.0,
9556,16435,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621629,,BAO_0000218,2106.0,
9557,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621630,,BAO_0000218,2106.0,
9558,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621631,,BAO_0000218,2106.0,
9559,16434,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621632,,BAO_0000218,2106.0,
9560,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621633,,BAO_0000218,2106.0,
9561,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621634,,BAO_0000218,2106.0,
9562,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621635,,BAO_0000218,2106.0,
9563,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621636,,BAO_0000218,2106.0,
9564,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621637,,BAO_0000218,2106.0,
9565,16435,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL621638,,BAO_0000218,2106.0,
9566,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618883,,BAO_0000218,,
9567,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618884,,BAO_0000218,,
9568,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628627,,BAO_0000218,,
9569,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628628,,BAO_0000218,,
9570,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628629,,BAO_0000218,,
9571,16365,Half life after administering orally a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628630,,BAO_0000218,,
9572,16365,Half life after administering orally a dose of 3 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628631,,BAO_0000218,,
9573,16365,Half life after administering intravenously a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628632,,BAO_0000218,,
9574,526,Half life after oral dosing in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628633,,BAO_0000218,,
9575,16365,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628634,,BAO_0000218,,
9576,4368,Half life by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627789,,BAO_0000218,,
9577,3371,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627790,,BAO_0000218,,
9578,6448,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627791,,BAO_0000218,,
9579,6453,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627792,,BAO_0000218,,
9580,4353,Half life in rat after intravenous administration of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627793,,BAO_0000218,,
9581,4353,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627794,,BAO_0000218,1969.0,
9582,4353,Half life in rat after po administration of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627795,,BAO_0000218,,
9583,4353,Half life in rat after po administration of the compound; ND means Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627796,,BAO_0000218,,
9584,4353,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875335,,BAO_0000218,1969.0,
9585,4353,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627797,,BAO_0000218,1969.0,
9586,5789,Half life in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627798,,BAO_0000218,,
9587,17686,Half life in rat i.v. at 2 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627799,,BAO_0000218,,
9588,6495,Half life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627800,,BAO_0000218,,
9589,484,Half life in rats after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627801,,BAO_0000218,,
9590,6467,Half life in rats at the dose of 1.0 mpk by i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627802,,BAO_0000218,,
9591,6642,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL627803,,BAO_0000218,,
9592,16367,Half life was evaluated after intravenous administration to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873820,,BAO_0000218,,
9593,1369,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627804,,BAO_0000218,,
9594,5472,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627805,,BAO_0000218,,
9595,6049,Half life was evaluated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627806,,BAO_0000218,,
9596,5472,Half life was evaluated in rat; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627107,,BAO_0000218,,
9597,16366,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627108,,BAO_0000218,,
9598,11149,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627109,,BAO_0000218,,
9599,11149,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627110,,BAO_0000218,178.0,
9600,2891,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627111,,BAO_0000218,,
9601,2891,Half life was measured in monkey at dose of 10 mg/kg by po administration,A,In vivo,,Primates,9443.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627112,,BAO_0000218,,
9602,2891,Half life was measured in rat at dose of 30 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627113,,BAO_0000218,,
9603,2891,Half life was measured in rat at dose of 30 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL627114,,BAO_0000218,,
9604,4026,Half life (t1/2) was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627115,,BAO_0000218,,
9605,4527,Half life period at a dose of 10 uM/kg in rat was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627116,,BAO_0000218,,
9606,4527,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627117,,BAO_0000218,,
9607,5503,Half life period was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627118,,BAO_0000218,,
9608,4426,Half life period after intravenous administration at 20 mpk in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627119,,BAO_0000218,,
9609,4426,Half life period after intravenous administration at 20 mpk in rats; Not performed.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627120,,BAO_0000218,,
9610,6109,Half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626922,,BAO_0000218,,
9611,5654,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626923,,BAO_0000218,,
9612,5654,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626924,,BAO_0000218,,
9613,4755,Half life period in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626925,,BAO_0000218,1969.0,
9614,5862,Half life period in SD rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626926,,BAO_0000218,,
9615,1515,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626927,,BAO_0000218,1969.0,
9616,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626928,,BAO_0000218,1969.0,
9617,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626929,,BAO_0000218,1969.0,
9618,1515,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626930,,BAO_0000218,1969.0,
9619,5960,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626931,,BAO_0000218,,
9620,6103,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626932,,BAO_0000218,,
9621,6317,Half life period in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626933,,BAO_0000218,,
9622,6644,Half life period in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873826,,BAO_0000218,,
9623,6644,Half life period in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626934,,BAO_0000218,,
9624,6644,Half life period in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626935,,BAO_0000218,,
9625,6644,Half life period in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626936,,BAO_0000218,,
9626,5974,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626937,,BAO_0000218,,
9627,6295,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625906,,BAO_0000218,,
9628,6296,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625907,,BAO_0000218,,
9629,16427,PK study was carried to determine AUC (area under curve) value in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625908,,BAO_0000218,,
9630,16367,Pharmacokinetic parameter AUC after intravenous administration to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625909,,BAO_0000218,,
9631,16367,Pharmacokinetic parameter AUC after oral administration to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625910,,BAO_0000218,,
9632,16365,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625911,,BAO_0000218,,
9633,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625912,,BAO_0000218,,
9634,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626538,,BAO_0000218,,
9635,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876794,,BAO_0000218,,
9636,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626539,,BAO_0000218,,
9637,16365,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626540,,BAO_0000218,,
9638,5394,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626541,,BAO_0000218,,
9639,5394,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626542,,BAO_0000218,,
9640,2792,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626543,,BAO_0000218,,
9641,2792,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626544,,BAO_0000218,,
9642,2792,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626545,,BAO_0000218,,
9643,2792,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626546,,BAO_0000218,,
9644,5334,Pharmacokinetic parameter area under curve was reported,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626547,,BAO_0000218,,
9645,4408,Pharmacokinetic property (AUC) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626548,,BAO_0000218,,
9646,5983,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626549,,BAO_0000218,,
9647,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626550,,BAO_0000218,,
9648,4397,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626551,,BAO_0000218,,
9649,5491,Pharmacokinetic property was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623777,,BAO_0000218,,
9650,5491,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623778,,BAO_0000218,,
9651,5491,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623779,,BAO_0000218,,
9652,4199,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623780,,BAO_0000218,1969.0,
9653,4199,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622015,,BAO_0000218,1969.0,
9654,4199,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622016,,BAO_0000218,1969.0,
9655,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622017,,BAO_0000218,,
9656,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622018,,BAO_0000218,,
9657,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622019,,BAO_0000218,,
9658,5173,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622020,,BAO_0000218,,
9659,16366,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622021,,BAO_0000218,,
9660,16366,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622022,,BAO_0000218,,
9661,5327,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622023,,BAO_0000218,,
9662,6681,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622024,,BAO_0000218,,
9663,12873,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622693,,BAO_0000218,,
9664,12873,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622694,,BAO_0000218,,
9665,6685,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622695,,BAO_0000218,,
9666,6685,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622696,,BAO_0000218,,
9667,6685,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622697,,BAO_0000218,,
9668,6619,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622874,,BAO_0000218,,
9669,6619,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622875,,BAO_0000218,,
9670,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622876,,BAO_0000218,,
9671,4796,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622877,,BAO_0000218,,
9672,4910,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622878,,BAO_0000218,,
9673,4910,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622879,,BAO_0000218,1969.0,
9674,4839,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877602,,BAO_0000218,,
9675,15078,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622880,,BAO_0000218,,
9676,15078,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622881,,BAO_0000218,,
9677,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622882,,BAO_0000218,,
9678,15078,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622883,,BAO_0000218,,
9679,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622884,,BAO_0000218,2046.0,
9680,11450,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622885,,BAO_0000218,2046.0,
9681,8151,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622886,,BAO_0000218,,
9682,8151,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622887,,BAO_0000218,,
9683,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622888,,BAO_0000218,1088.0,
9684,8677,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622889,,BAO_0000218,178.0,
9685,8677,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622890,,BAO_0000218,178.0,
9686,8677,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622891,,BAO_0000218,178.0,
9687,8677,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL877603,,BAO_0000218,178.0,
9688,8677,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622892,,BAO_0000218,955.0,
9689,8677,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622893,,BAO_0000218,955.0,
9690,8677,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622894,,BAO_0000218,955.0,
9691,8677,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622895,,BAO_0000218,955.0,
9692,8677,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622896,,BAO_0000218,955.0,
9693,8677,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622897,,BAO_0000218,948.0,
9694,8677,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622898,,BAO_0000218,948.0,
9695,8677,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622899,,BAO_0000218,948.0,
9696,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622900,,BAO_0000218,2113.0,
9697,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624114,,BAO_0000218,2113.0,
9698,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624115,,BAO_0000218,2113.0,
9699,8677,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624116,,BAO_0000218,2113.0,
9700,8677,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624117,,BAO_0000218,2107.0,
9701,8677,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624118,,BAO_0000218,2107.0,
9702,8677,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624119,,BAO_0000218,2107.0,
9703,8677,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624120,,BAO_0000218,2107.0,
9704,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624121,,BAO_0000218,2048.0,
9705,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624122,,BAO_0000218,2048.0,
9706,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624123,,BAO_0000218,2048.0,
9707,8677,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624124,,BAO_0000218,2048.0,
9708,8677,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624125,,BAO_0000218,2385.0,
9709,8677,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624126,,BAO_0000218,2385.0,
9710,8677,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624127,,BAO_0000218,2385.0,
9711,8677,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624128,,BAO_0000218,2385.0,
9712,8677,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL624129,,BAO_0000218,14.0,
9713,8677,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL624130,,BAO_0000218,14.0,
9714,8677,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622340,,BAO_0000218,14.0,
9715,8677,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622341,,BAO_0000218,14.0,
9716,8677,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622342,,BAO_0000218,160.0,
9717,8677,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622343,,BAO_0000218,160.0,
9718,8677,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622344,,BAO_0000218,160.0,
9719,8677,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622345,,BAO_0000218,160.0,
9720,8677,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622346,,BAO_0000218,2106.0,
9721,8677,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622347,,BAO_0000218,2106.0,
9722,8677,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622348,,BAO_0000218,2106.0,
9723,8677,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622349,,BAO_0000218,2106.0,
9724,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622350,,BAO_0000218,,
9725,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622351,,BAO_0000218,,
9726,16434,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622352,,BAO_0000218,,
9727,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622353,,BAO_0000218,,
9728,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622354,,BAO_0000218,,
9729,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622355,,BAO_0000218,,
9730,16435,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622356,,BAO_0000218,,
9731,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622357,,BAO_0000218,,
9732,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622358,,BAO_0000218,,
9733,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622359,,BAO_0000218,,
9734,16435,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874393,,BAO_0000218,,
9735,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622872,,BAO_0000218,,
9736,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622873,,BAO_0000218,,
9737,16434,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623047,,BAO_0000218,,
9738,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623048,,BAO_0000218,,
9739,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623049,,BAO_0000218,,
9740,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623050,,BAO_0000218,,
9741,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623051,,BAO_0000218,,
9742,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623052,,BAO_0000218,,
9743,16435,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626343,,BAO_0000218,,
9744,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626344,,BAO_0000218,,
9745,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626345,,BAO_0000218,,
9746,16434,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626346,,BAO_0000218,,
9747,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626347,,BAO_0000218,,
9748,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626348,,BAO_0000218,,
9749,16434,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626349,,BAO_0000218,,
9750,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626350,,BAO_0000218,,
9751,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626351,,BAO_0000218,,
9752,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627650,,BAO_0000218,,
9753,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627651,,BAO_0000218,,
9754,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627652,,BAO_0000218,,
9755,16435,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627653,,BAO_0000218,,
9756,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627654,,BAO_0000218,,
9757,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627835,,BAO_0000218,,
9758,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627836,,BAO_0000218,,
9759,13091,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627837,,BAO_0000218,,
9760,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627838,,BAO_0000218,,
9761,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875338,,BAO_0000218,,
9762,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627839,,BAO_0000218,,
9763,13091,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627840,,BAO_0000218,,
9764,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627841,,BAO_0000218,,
9765,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627842,,BAO_0000218,,
9766,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627843,,BAO_0000218,,
9767,13091,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627844,,BAO_0000218,,
9768,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627845,,BAO_0000218,,
9769,5874,Half life period in rat by iv administration at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627846,,BAO_0000218,,
9770,1515,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627847,,BAO_0000218,1969.0,
9771,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873821,,BAO_0000218,1969.0,
9772,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626079,,BAO_0000218,1969.0,
9773,1515,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626080,,BAO_0000218,1969.0,
9774,5491,Half life period was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626081,,BAO_0000218,1969.0,
9775,5491,Half life period was evaluated in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875344,,BAO_0000218,1969.0,
9776,1918,Half life period was evaluated in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626082,,BAO_0000218,,
9777,1918,"Half life period was evaluated in rats, iv",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626250,,BAO_0000218,,
9778,6113,Half life period after intravenous administration at 5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626251,,BAO_0000218,,
9779,5546,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626252,,BAO_0000218,,
9780,5553,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626253,,BAO_0000218,,
9781,4188,Half life stability of compound was evaluated in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626254,,BAO_0000218,1969.0,
9782,6215,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626255,,BAO_0000218,,
9783,6141,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626256,,BAO_0000218,,
9784,5182,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626257,,BAO_0000218,,
9785,5182,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626258,,BAO_0000218,,
9786,5710,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626259,,BAO_0000218,,
9787,5789,Half in rat i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626260,,BAO_0000218,,
9788,6011,Half period in rat after intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875345,,BAO_0000218,,
9789,17594,Half-life after repeated oral dose of compound at 1 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626261,,BAO_0000218,,
9790,12357,Half-life measured in in vitro Cathepsin B assay in rat liver,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626262,,BAO_0000218,2107.0,
9791,5210,Half-life of compound was determined in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626263,,BAO_0000218,,
9792,17596,Half-life at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625270,,BAO_0000218,,
9793,6672,Half-life determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625271,,BAO_0000218,,
9794,6673,Half-life determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625272,,BAO_0000218,,
9795,4910,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625273,,BAO_0000218,955.0,
9796,3741,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625274,,BAO_0000218,1969.0,
9797,17671,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625275,,BAO_0000218,,
9798,4910,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625276,,BAO_0000218,1969.0,
9799,17537,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625277,,BAO_0000218,1969.0,
9800,4965,Half-life in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625278,,BAO_0000218,1969.0,
9801,17537,Half-life in rat plasma; Not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625279,,BAO_0000218,1969.0,
9802,6124,Half-life in rat serum,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL625280,,BAO_0000218,1977.0,
9803,6124,Half-life in rat serum; na is not available,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL876797,,BAO_0000218,1977.0,
9804,6078,Half-life was calculated in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625281,,BAO_0000218,,
9805,17668,Half-life was calculated in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL873827,,BAO_0000218,1969.0,
9806,3185,Half-life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625282,,BAO_0000218,,
9807,4883,Half-life was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625283,,BAO_0000218,,
9808,2959,Half-life after administration of 20 mg/Kg oral dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625284,,BAO_0000218,,
9809,4029,Half-life after administration of 3.2 mg/kg intravenously in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625285,,BAO_0000218,,
9810,4029,Half-life after intravenous administration in female rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625286,,BAO_0000218,,
9811,4029,Half-life after intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625287,,BAO_0000218,,
9812,6180,Half-life after intravenous dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625288,,BAO_0000218,,
9813,1557,Half-life in a rat liver homogenate preparation,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625289,,BAO_0000218,2107.0,
9814,12500,Half-life in plasma of rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625290,,BAO_0000218,1969.0,
9815,12500,Half-life in plasma of rat at dose of 3-10 mgkg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876798,,BAO_0000218,1969.0,
9816,5064,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625291,,BAO_0000218,,
9817,5145,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625292,,BAO_0000218,,
9818,5147,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625293,,BAO_0000218,,
9819,5833,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622832,,BAO_0000218,,
9820,6596,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622833,,BAO_0000218,,
9821,17655,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622834,,BAO_0000218,,
9822,6495,Half-life in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622835,,BAO_0000218,,
9823,17538,Half-life in rat after po administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622836,,BAO_0000218,,
9824,17538,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622837,,BAO_0000218,,
9825,10,Half-life in rat at 3 mg/kg dose administered intravenously,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622838,,BAO_0000218,,
9826,17669,Half-life in rat brain homogenate,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622839,,BAO_0000218,955.0,
9827,17065,Half-life in rat plasma,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622840,,BAO_0000218,1969.0,
9828,4333,Half-life in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622841,,BAO_0000218,,
9829,6827,Half-life in Dawley rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622842,,BAO_0000218,,
9830,889,Half-life in vitro in rat plasma,A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622843,,BAO_0000218,1969.0,
9831,889,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622844,,BAO_0000218,1969.0,
9832,3747,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622845,,BAO_0000218,,
9833,15022,The area under the curve of compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622846,,BAO_0000218,,
9834,15022,The area under the curve of compound was measured at the dose of 300 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622847,,BAO_0000218,,
9835,15022,The area under the curve of compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622848,,BAO_0000218,,
9836,3360,Bioavailability as oral AUC in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622849,,BAO_0000218,,
9837,5334,The plasma concentration versus time curve (AUC) was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622850,,BAO_0000218,1969.0,
9838,17411,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876807,,BAO_0000218,,
9839,17411,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622851,,BAO_0000218,,
9840,17411,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622852,,BAO_0000218,,
9841,6570,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622853,,BAO_0000218,,
9842,6570,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622854,,BAO_0000218,,
9843,17411,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622855,,BAO_0000218,,
9844,14941,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622856,,BAO_0000218,1969.0,
9845,14941,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622857,,BAO_0000218,1969.0,
9846,17538,AUC in rat after po administration at a dose of 10 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622858,,BAO_0000218,1969.0,
9847,17752,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622859,,BAO_0000218,1969.0,
9848,17509,Area under curve value 24 hr after 10 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622860,,BAO_0000218,,
9849,17509,Area under curve value 24 hr after 10 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622861,,BAO_0000218,,
9850,17509,Area under curve value 24 hr after 2 mg/kg iv administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622862,,BAO_0000218,,
9851,17509,Area under curve value 24 hr after 2 mg/kg oral administration in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622863,,BAO_0000218,,
9852,17509,Area under curve value 6 hr after po administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623817,,BAO_0000218,,
9853,17717,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623818,,BAO_0000218,,
9854,17717,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623819,,BAO_0000218,,
9855,17717,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623820,,BAO_0000218,,
9856,17717,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623821,,BAO_0000218,,
9857,6642,AUC normalized for dose (AUCN) in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623822,,BAO_0000218,1969.0,
9858,6640,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623823,,BAO_0000218,,
9859,6641,Area under curve in rat after p.o. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623824,,BAO_0000218,,
9860,6641,Area under curve in rat after p.o. administration; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623825,,BAO_0000218,,
9861,6641,Area under curve in rat after peroral administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622070,,BAO_0000218,,
9862,3603,Area under curve (carotid artery) value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622071,,BAO_0000218,,
9863,3550,Bioavailability expressed as the area under curve of rat carotid artery,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622072,,BAO_0000218,,
9864,15662,Area under curve in male SD rats was observed after intravenous administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622073,,BAO_0000218,,
9865,17720,Area under curve of the compound was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622074,,BAO_0000218,,
9866,5407,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622075,,BAO_0000218,,
9867,17752,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622076,,BAO_0000218,1969.0,
9868,17752,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622077,,BAO_0000218,1969.0,
9869,3603,Area under curve (portal vein) value of the compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622078,,BAO_0000218,,
9870,3550,Bioavailability expressed as the area under curve of rat portal vein,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622079,,BAO_0000218,,
9871,17655,Area Under plasma concentration time curve in rat upon peroral administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622080,,BAO_0000218,1969.0,
9872,17582,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877612,,BAO_0000218,,
9873,17582,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622081,,BAO_0000218,,
9874,17791,Compound was evaluated for oral bioavailability in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622082,,BAO_0000218,,
9875,17791,Compound was evaluated for oral bioavailability in rats after iv administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622083,,BAO_0000218,,
9876,17791,Compound was evaluated for oral bioavailability in rats; 30-80,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622084,,BAO_0000218,,
9877,17791,Compound was evaluated for oral bioavailability in rats; 50-60,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622085,,BAO_0000218,,
9878,17791,Compound was evaluated for oral bioavailability in rats; no data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622086,,BAO_0000218,,
9879,17791,Compound was evaluated for oral bioavailability in rats; peptide,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622087,,BAO_0000218,,
9880,7768,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622088,,BAO_0000218,178.0,
9881,7768,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622089,,BAO_0000218,178.0,
9882,7768,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623685,,BAO_0000218,178.0,
9883,7768,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623686,,BAO_0000218,178.0,
9884,8677,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623687,,BAO_0000218,945.0,
9885,8677,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623688,,BAO_0000218,945.0,
9886,8677,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL623689,,BAO_0000218,945.0,
9887,8677,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Stomach,,,50597,N,1,Intermediate,1,,CHEMBL622485,,BAO_0000218,945.0,
9888,8677,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622486,,BAO_0000218,2046.0,
9889,8677,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL877613,,BAO_0000218,2046.0,
9890,8677,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622487,,BAO_0000218,2046.0,
9891,8677,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622488,,BAO_0000218,2046.0,
9892,8677,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622489,,BAO_0000218,948.0,
9893,6899,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622490,,BAO_0000218,1088.0,
9894,6899,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622491,,BAO_0000218,1088.0,
9895,6899,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622492,,BAO_0000218,2107.0,
9896,6899,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622493,,BAO_0000218,1088.0,
9897,6899,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622494,,BAO_0000218,1088.0,
9898,8677,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622495,,BAO_0000218,2385.0,
9899,6899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622496,,BAO_0000218,,
9900,6899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622497,,BAO_0000218,1088.0,
9901,2189,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622498,,BAO_0000218,,
9902,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624918,,BAO_0000218,1088.0,
9903,2189,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624919,,BAO_0000218,1088.0,
9904,10839,Biodistribution of compound in rat blood after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624920,,BAO_0000218,178.0,
9905,10839,Biodistribution of compound in rat blood after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624921,,BAO_0000218,178.0,
9906,10839,Biodistribution of compound in rat brain after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624922,,BAO_0000218,955.0,
9907,10839,Biodistribution of compound in rat heart after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624923,,BAO_0000218,948.0,
9908,10839,Biodistribution of compound in rat heart after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624924,,BAO_0000218,948.0,
9909,10839,Biodistribution of compound in rat kidney after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624925,,BAO_0000218,2113.0,
9910,10839,Biodistribution of compound in rat kidney after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624926,,BAO_0000218,2113.0,
9911,10839,Biodistribution of compound in rat liver after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624927,,BAO_0000218,2107.0,
9912,10839,Biodistribution of compound in rat liver after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL874402,,BAO_0000218,2107.0,
9913,10839,Biodistribution of compound in rat lung after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624928,,BAO_0000218,2048.0,
9914,10839,Biodistribution of compound in rat lung after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624929,,BAO_0000218,2048.0,
9915,10839,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624930,,BAO_0000218,2385.0,
9916,10839,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624931,,BAO_0000218,2385.0,
9917,4043,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624932,,BAO_0000218,948.0,
9918,4043,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624933,,BAO_0000218,948.0,
9919,4043,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624934,,BAO_0000218,2107.0,
9920,4043,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624935,,BAO_0000218,2107.0,
9921,4043,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624936,,BAO_0000218,,
9922,4043,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624937,,BAO_0000218,,
9923,4043,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL624938,,BAO_0000218,2106.0,
9924,4043,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL624939,,BAO_0000218,2106.0,
9925,4043,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624940,,BAO_0000218,,
9926,4043,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874403,,BAO_0000218,,
9927,1446,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624941,,BAO_0000218,,
9928,9971,Dose required to lower urine osmolality to 300 mOsm/kg in rat,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624942,,BAO_0000218,1088.0,
9929,9971,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624943,,BAO_0000218,1088.0,
9930,5765,% Bioavailability after 1 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624944,,BAO_0000218,,
9931,5765,% Bioavailability after 4 day of the drug administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624945,,BAO_0000218,,
9932,4257,Absolute bioavailability was evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624946,,BAO_0000218,,
9933,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624947,,BAO_0000218,,
9934,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624948,,BAO_0000218,,
9935,13091,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624949,,BAO_0000218,,
9936,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622025,,BAO_0000218,2113.0,
9937,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622026,,BAO_0000218,2113.0,
9938,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622027,,BAO_0000218,2113.0,
9939,13091,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622028,,BAO_0000218,2113.0,
9940,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622029,,BAO_0000218,2107.0,
9941,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622208,,BAO_0000218,2107.0,
9942,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622209,,BAO_0000218,2107.0,
9943,13091,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622210,,BAO_0000218,2107.0,
9944,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622211,,BAO_0000218,,
9945,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622212,,BAO_0000218,,
9946,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622213,,BAO_0000218,,
9947,13091,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874404,,BAO_0000218,,
9948,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620452,,BAO_0000218,2385.0,
9949,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620453,,BAO_0000218,2385.0,
9950,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL620454,,BAO_0000218,2385.0,
9951,13091,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624067,,BAO_0000218,2385.0,
9952,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624068,,BAO_0000218,,
9953,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL624069,,BAO_0000218,992.0,
9954,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL624070,,BAO_0000218,992.0,
9955,13091,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL624071,,BAO_0000218,992.0,
9956,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624072,,BAO_0000218,995.0,
9957,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624073,,BAO_0000218,995.0,
9958,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624788,,BAO_0000218,995.0,
9959,13091,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624789,,BAO_0000218,995.0,
9960,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624790,,BAO_0000218,,
9961,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624791,,BAO_0000218,,
9962,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624792,,BAO_0000218,,
9963,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624793,,BAO_0000218,,
9964,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL877491,,BAO_0000218,2385.0,
9965,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624957,,BAO_0000218,2385.0,
9966,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624958,,BAO_0000218,2385.0,
9967,13091,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624959,,BAO_0000218,2385.0,
9968,11977,Dissociation constant was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624960,,BAO_0000218,,
9969,14941,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624961,,BAO_0000218,,
9970,15078,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624962,,BAO_0000218,,
9971,15078,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624963,,BAO_0000218,,
9972,4755,Observed rate constant in 80% rat plasma at 37 degree Centigrade,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624964,,BAO_0000218,,
9973,589,LogP value was evaluated in the in situ rat gut perfusion assay,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624965,,BAO_0000218,,
9974,17582,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624966,,BAO_0000218,,
9975,5031,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624967,,BAO_0000218,,
9976,17764,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624968,,BAO_0000218,,
9977,17720,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624969,,BAO_0000218,,
9978,2862,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL624970,,BAO_0000218,,
9979,16423,Half-life was evaluated after 10 uM/kg of intra arterial administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624971,,BAO_0000218,,
9980,16423,Half-life was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624972,,BAO_0000218,,
9981,6005,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624973,,BAO_0000218,,
9982,2938,Half-life was evaluated in plasma of rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL624974,,BAO_0000218,1969.0,
9983,6410,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624975,,BAO_0000218,,
9984,6410,Half-life was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877492,,BAO_0000218,,
9985,6062,Half-life was measured in rat after an iv dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624976,,BAO_0000218,,
9986,6571,Half-life period of compound in rats after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624977,,BAO_0000218,,
9987,3136,Half-life period of compound was measured in rat plasma.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626848,,BAO_0000218,1969.0,
9988,3136,Half-life period of compound was measured in rat plasma; ND is not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626849,,BAO_0000218,1969.0,
9989,3136,Half-life period of compound was measured in rat plasma; not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626850,,BAO_0000218,1969.0,
9990,4521,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626851,,BAO_0000218,,
9991,5871,Half-life period in rat by iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626852,,BAO_0000218,,
9992,6077,Half-life period in rats following intravenous administration at 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626853,,BAO_0000218,,
9993,6679,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626854,,BAO_0000218,,
9994,5144,Half-life period was determined for the compound in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627486,,BAO_0000218,,
9995,4498,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627487,,BAO_0000218,,
9996,4498,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627488,,BAO_0000218,,
9997,1908,Half-life value after IV dose at a dose of 5 mg/kg in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627489,,BAO_0000218,,
9998,6211,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627490,,BAO_0000218,,
9999,5529,Half-life was determined in rat after intravenous administration (0.5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873829,,BAO_0000218,,
10000,6444,Half-life was determined in rat at a dose of 1 mpk i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627655,,BAO_0000218,,
10001,6444,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625994,,BAO_0000218,,
10002,6444,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625995,,BAO_0000218,,
10003,5207,Half-life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625996,,BAO_0000218,,
10004,530,In vitro half life in rat plasma,A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625850,,BAO_0000218,1969.0,
10005,1116,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",A,In vitro,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625851,,BAO_0000218,1969.0,
10006,3219,In vitro half life in rat,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625852,,BAO_0000218,,
10007,6109,In vivo half life period after intravenous administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625853,,BAO_0000218,,
10008,17582,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625854,,BAO_0000218,,
10009,17582,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874450,,BAO_0000218,,
10010,5974,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625855,,BAO_0000218,,
10011,5974,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625856,,BAO_0000218,,
10012,5974,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625857,,BAO_0000218,,
10013,5974,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873831,,BAO_0000218,,
10014,17853,Longer half-life in rat (i.v.) at 0.5 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625858,,BAO_0000218,,
10015,17853,Longer half-life in rat (p.o.) at 2.0 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625859,,BAO_0000218,,
10016,3457,Pharmacokinetic property (half life) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625860,,BAO_0000218,,
10017,2792,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625861,,BAO_0000218,,
10018,2792,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625862,,BAO_0000218,,
10019,2792,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625863,,BAO_0000218,,
10020,2792,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625864,,BAO_0000218,,
10021,5739,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625865,,BAO_0000218,,
10022,15765,Pharmacokinetic half time was determined intravenously in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625866,,BAO_0000218,,
10023,6567,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625867,,BAO_0000218,1969.0,
10024,2448,Plasma half life of hydrolysis of the compound,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625868,,BAO_0000218,1969.0,
10025,5423,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625869,,BAO_0000218,1969.0,
10026,4853,Plasma half life period was calculated in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874451,,BAO_0000218,1969.0,
10027,4514,Plasma half-life in Sprague-Dawley rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625870,,BAO_0000218,1969.0,
10028,4514,Plasma half-life in Sprague-Dawley rats; Not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625871,,BAO_0000218,1969.0,
10029,1500,Plasma half-life in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625872,,BAO_0000218,1969.0,
10030,1500,Plasma half-life in rats; <MQL,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625873,,BAO_0000218,1969.0,
10031,5334,Plasma half-life period (0-8 h) was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625874,,BAO_0000218,1969.0,
10032,5334,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625875,,BAO_0000218,1969.0,
10033,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625876,,BAO_0000218,1969.0,
10034,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631258,,BAO_0000218,1969.0,
10035,4956,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631259,,BAO_0000218,1969.0,
10036,4956,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631260,,BAO_0000218,1969.0,
10037,7768,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631261,,BAO_0000218,178.0,
10038,7768,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631262,,BAO_0000218,178.0,
10039,7768,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631263,,BAO_0000218,178.0,
10040,7768,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631264,,BAO_0000218,,
10041,7768,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631265,,BAO_0000218,,
10042,7768,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631266,,BAO_0000218,,
10043,7768,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631267,,BAO_0000218,,
10044,7768,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631268,,BAO_0000218,,
10045,7768,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631269,,BAO_0000218,,
10046,7768,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631270,,BAO_0000218,,
10047,7768,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631271,,BAO_0000218,948.0,
10048,7768,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631272,,BAO_0000218,948.0,
10049,7768,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631273,,BAO_0000218,948.0,
10050,7768,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631274,,BAO_0000218,948.0,
10051,7768,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631275,,BAO_0000218,948.0,
10052,7768,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626984,,BAO_0000218,948.0,
10053,7768,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626985,,BAO_0000218,948.0,
10054,7768,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626986,,BAO_0000218,2107.0,
10055,7768,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626987,,BAO_0000218,2107.0,
10056,7768,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626988,,BAO_0000218,2107.0,
10057,7768,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626989,,BAO_0000218,2107.0,
10058,7768,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626990,,BAO_0000218,2107.0,
10059,7768,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626991,,BAO_0000218,2107.0,
10060,7768,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626992,,BAO_0000218,2107.0,
10061,7768,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626993,,BAO_0000218,2048.0,
10062,7768,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL874593,,BAO_0000218,2048.0,
10063,7768,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626994,,BAO_0000218,2048.0,
10064,7768,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626995,,BAO_0000218,2048.0,
10065,7768,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626190,,BAO_0000218,2048.0,
10066,7768,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626191,,BAO_0000218,2048.0,
10067,7768,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626364,,BAO_0000218,2048.0,
10068,7768,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626365,,BAO_0000218,2046.0,
10069,7768,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626366,,BAO_0000218,2046.0,
10070,7768,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626367,,BAO_0000218,2046.0,
10071,7768,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626368,,BAO_0000218,2046.0,
10072,7768,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626369,,BAO_0000218,2046.0,
10073,7768,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626370,,BAO_0000218,2046.0,
10074,4498,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626371,,BAO_0000218,,
10075,4498,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626372,,BAO_0000218,,
10076,3603,Bioavailability after a dose of 10 mg/kg p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626373,,BAO_0000218,,
10077,6215,Bioavailability after peroral administration (10 mg/kg) was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626374,,BAO_0000218,,
10078,5710,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626375,,BAO_0000218,,
10079,5710,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626376,,BAO_0000218,,
10080,5676,Bioavailability in rat po was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626377,,BAO_0000218,,
10081,17667,Bioavailability of compound at 10 mg/kg in rat after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626378,,BAO_0000218,,
10082,17667,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626379,,BAO_0000218,,
10083,6848,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626380,,BAO_0000218,,
10084,6848,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626381,,BAO_0000218,,
10085,17267,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626382,,BAO_0000218,,
10086,6362,Bioavailability in rat (Sprague-Dawley) (female),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626383,,BAO_0000218,,
10087,17671,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874652,,BAO_0000218,,
10088,17671,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626384,,BAO_0000218,,
10089,4333,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626385,,BAO_0000218,,
10090,6077,Bioavailability in rat at an oral dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626386,,BAO_0000218,,
10091,3278,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626387,,BAO_0000218,,
10092,5964,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626388,,BAO_0000218,,
10093,4884,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626389,,BAO_0000218,,
10094,4905,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626390,,BAO_0000218,,
10095,4884,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626391,,BAO_0000218,,
10096,6850,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626392,,BAO_0000218,,
10097,2864,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626393,,BAO_0000218,,
10098,5780,Bioavailability was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623026,,BAO_0000218,,
10099,1465,Bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623027,,BAO_0000218,,
10100,5199,Bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623028,,BAO_0000218,,
10101,5765,Bioavailability in rat after 1 day dosing,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623029,,BAO_0000218,,
10102,5765,Bioavailability in rat after 4 day dosing,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623030,,BAO_0000218,,
10103,6518,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623031,,BAO_0000218,,
10104,6518,Bioavailability after IV dosing at 1 mg/kg in rat; no data,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623032,,BAO_0000218,,
10105,6518,Bioavailability after oral administration at a dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623033,,BAO_0000218,,
10106,6518,Bioavailability after oral administration at a dose of 4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623034,,BAO_0000218,,
10107,2083,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623035,,BAO_0000218,,
10108,17260,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623036,,BAO_0000218,,
10109,4956,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623037,,BAO_0000218,,
10110,4368,Bioavailability by intravenous administration of 3.4 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623038,,BAO_0000218,,
10111,17752,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874385,,BAO_0000218,1969.0,
10112,1446,Bioavailability in rat (Fisher) (fasted),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623039,,BAO_0000218,,
10113,2891,Bioavailability in monkey after po administration of 10 mg/kg dose,A,In vivo,,Primates,9443.0,,,,,22224,U,0,Intermediate,1,,CHEMBL623040,,BAO_0000218,,
10114,2891,Oral bioavailability in monkey (dose 10 mg/kg),A,In vivo,,Primates,9443.0,,,,,22224,U,0,Intermediate,1,,CHEMBL623041,,BAO_0000218,,
10115,6672,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623741,,BAO_0000218,,
10116,6673,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623742,,BAO_0000218,,
10117,17655,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623743,,BAO_0000218,,
10118,17796,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623744,,BAO_0000218,,
10119,17853,Bioavailability in rat (dose 2.0 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623745,,BAO_0000218,,
10120,4521,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623746,,BAO_0000218,,
10121,4940,Oral bioavailability in rat (dose 5 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623747,,BAO_0000218,,
10122,2891,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL623748,,BAO_0000218,,
10123,2891,Bioavailability in rat after po administration of 30 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL623916,,BAO_0000218,,
10124,4521,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623917,,BAO_0000218,,
10125,17686,Bioavailability in rat (dose 2 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623918,,BAO_0000218,,
10126,17796,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874386,,BAO_0000218,,
10127,17796,Bioavailability in rat; Only traces detected in rat plasma,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623919,,BAO_0000218,1969.0,
10128,5064,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623920,,BAO_0000218,,
10129,5147,Bioavailability upon oral administration of compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623148,,BAO_0000218,,
10130,1916,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623149,,BAO_0000218,,
10131,6049,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623150,,BAO_0000218,,
10132,1445,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623151,,BAO_0000218,,
10133,1445,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623152,,BAO_0000218,,
10134,2862,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL623153,,BAO_0000218,,
10135,2862,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL623154,,BAO_0000218,,
10136,4194,In vitro and metabolic stability was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623155,,BAO_0000218,,
10137,4194,In vitro metabolic stability in rat hepatocytes,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623156,,BAO_0000218,,
10138,5486,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623157,,BAO_0000218,,
10139,17582,Metabolic rate for compound was observed in rat hepatocytes,A,In vitro,,Rattus norvegicus,10116.0,,Liver,Hepatocyte,,50597,N,1,Intermediate,1,,CHEMBL623158,401.0,BAO_0000218,2107.0,
10140,5600,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623159,,BAO_0000218,,
10141,14294,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874390,,BAO_0000218,,
10142,14294,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623160,,BAO_0000218,,
10143,14294,Metabolism of compound in rat S9 microsomes; Trace,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623161,,BAO_0000218,,
10144,17847,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623162,,BAO_0000218,,
10145,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623163,,BAO_0000218,,
10146,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623164,,BAO_0000218,,
10147,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623165,,BAO_0000218,,
10148,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623166,,BAO_0000218,,
10149,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624983,,BAO_0000218,,
10150,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624984,,BAO_0000218,,
10151,11020,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624985,,BAO_0000218,,
10152,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622970,,BAO_0000218,,
10153,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622971,,BAO_0000218,,
10154,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622972,,BAO_0000218,,
10155,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622973,,BAO_0000218,,
10156,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622974,,BAO_0000218,,
10157,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622975,,BAO_0000218,,
10158,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622976,,BAO_0000218,,
10159,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622977,,BAO_0000218,,
10160,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624351,,BAO_0000218,,
10161,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624352,,BAO_0000218,,
10162,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624353,,BAO_0000218,,
10163,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622397,,BAO_0000218,,
10164,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622398,,BAO_0000218,,
10165,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622399,,BAO_0000218,,
10166,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622400,,BAO_0000218,,
10167,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628428,,BAO_0000218,,
10168,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628590,,BAO_0000218,,
10169,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628591,,BAO_0000218,,
10170,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628592,,BAO_0000218,,
10171,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628593,,BAO_0000218,,
10172,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875333,,BAO_0000218,,
10173,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628594,,BAO_0000218,,
10174,4969,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628595,,BAO_0000218,1969.0,
10175,6737,Stability in rat plasma was determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628596,,BAO_0000218,1969.0,
10176,6737,Stability in rat plasma was determined; ND= no data,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628597,,BAO_0000218,1969.0,
10177,5089,Tested for plasma half life period in rat (0-8 hr),A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628598,,BAO_0000218,1969.0,
10178,5089,Tested for plasma half life period in rat (0-8 hr); Not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628599,,BAO_0000218,1969.0,
10179,1466,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628600,,BAO_0000218,,
10180,1466,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628601,,BAO_0000218,,
10181,4950,Tested for the half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628602,,BAO_0000218,,
10182,2412,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628603,,BAO_0000218,,
10183,2412,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628604,,BAO_0000218,,
10184,2412,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628605,,BAO_0000218,,
10185,2412,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628606,,BAO_0000218,,
10186,2412,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,A,In vitro,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628607,,BAO_0000218,,
10187,15022,The biological half life the compound was measured at the dose of 100 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628608,,BAO_0000218,,
10188,15022,The biological half life the compound was measured at the dose of 30 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628609,,BAO_0000218,,
10189,406,The compound was evaluated for plasma half life period in rat,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628610,,BAO_0000218,1969.0,
10190,15078,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL873819,,BAO_0000218,,
10191,15078,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628611,,BAO_0000218,,
10192,5247,The pharmacokinetic parameter half-life period in vivo in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628612,,BAO_0000218,,
10193,5041,"The pharmacokinetic property, Half-life was determined",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628613,,BAO_0000218,,
10194,5041,"The pharmacokinetic property, Half-life in rat in vivo",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628614,,BAO_0000218,,
10195,5041,"The pharmacokinetic property, Half-life was determined; ND denotes no data",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628615,,BAO_0000218,,
10196,5041,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628616,,BAO_0000218,,
10197,3918,The plasma half life period in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627924,,BAO_0000218,1969.0,
10198,2906,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627925,,BAO_0000218,2107.0,
10199,6467,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627926,,BAO_0000218,,
10200,5510,t1/2 (apparent elimination)of the compound was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627927,,BAO_0000218,,
10201,3788,t1/2 value in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627928,,BAO_0000218,,
10202,17796,Half life in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627539,,BAO_0000218,,
10203,12873,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876790,,BAO_0000218,1969.0,
10204,5983,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL858186,,BAO_0000218,,
10205,15765,Half-life period in fasted rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627540,,BAO_0000218,,
10206,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627541,,BAO_0000218,,
10207,2661,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627715,,BAO_0000218,,
10208,429,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627716,,BAO_0000218,,
10209,17655,Maximum time required to achieve Cmax was determined in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627717,,BAO_0000218,,
10210,17717,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627718,,BAO_0000218,,
10211,17717,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627719,,BAO_0000218,,
10212,17717,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627720,,BAO_0000218,,
10213,6570,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627721,,BAO_0000218,,
10214,6570,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627722,,BAO_0000218,,
10215,5978,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627723,,BAO_0000218,,
10216,5978,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626058,,BAO_0000218,,
10217,5978,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626059,,BAO_0000218,,
10218,5978,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626060,,BAO_0000218,,
10219,17720,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626061,,BAO_0000218,1969.0,
10220,4723,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876791,,BAO_0000218,,
10221,4723,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626062,,BAO_0000218,,
10222,4756,Tmax at the dose of 2 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626063,,BAO_0000218,,
10223,4756,Tmax at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626064,,BAO_0000218,,
10224,17720,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626065,,BAO_0000218,1969.0,
10225,17720,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626066,,BAO_0000218,1969.0,
10226,1466,tmax upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626067,,BAO_0000218,,
10227,7449,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626068,,BAO_0000218,,
10228,7449,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626069,,BAO_0000218,,
10229,7449,Percent total excretion of 3-methoxyacetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626070,,BAO_0000218,,
10230,7449,Percent total excretion of N-methoxyacetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626071,,BAO_0000218,,
10231,7449,Percent total excretion of N-methoxyacetaminophen sulfate,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626072,,BAO_0000218,,
10232,7449,Percent total excretion of acetaminophen,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626073,,BAO_0000218,,
10233,7768,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626741,,BAO_0000218,2046.0,
10234,17655,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626742,,BAO_0000218,,
10235,17735,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626743,,BAO_0000218,,
10236,5960,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876792,,BAO_0000218,,
10237,17735,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626744,,BAO_0000218,,
10238,7116,Compound was tested for antidiuretic activity in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626745,,BAO_0000218,,
10239,4878,AUC in rat after 3mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626746,,BAO_0000218,1969.0,
10240,5939,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626747,,BAO_0000218,,
10241,5939,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626748,,BAO_0000218,,
10242,16367,Bioavailability administered orally at a dose of 10 mg/kg to rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626749,,BAO_0000218,,
10243,16366,Oral Bioavailability was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626750,,BAO_0000218,,
10244,4426,Oral bioavailability in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626751,,BAO_0000218,,
10245,4426,Oral bioavailability in rat; Not performed.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626913,,BAO_0000218,,
10246,5041,Bioavailability,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626914,,BAO_0000218,,
10247,5041,Bioavailability was determined; ND denotes no data,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626915,,BAO_0000218,,
10248,1500,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626916,,BAO_0000218,,
10249,1500,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626917,,BAO_0000218,,
10250,17409,Binding towards rat plasma protein at 10 uM,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626918,,BAO_0000218,,
10251,17409,Binding towards rat plasma protein at 100 uM,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626919,,BAO_0000218,,
10252,2959,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626920,,BAO_0000218,,
10253,13501,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621976,,BAO_0000218,,
10254,6567,Bioavailability in rat after 5 mg/kg oral gavage,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877599,,BAO_0000218,,
10255,6571,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621977,,BAO_0000218,,
10256,6715,Bioavailability in rat (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621978,,BAO_0000218,,
10257,6715,Bioavailability in rat (dose 3 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621979,,BAO_0000218,,
10258,2932,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621980,,BAO_0000218,,
10259,4171,Bioavailability of the compound in rats after administration of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621981,,BAO_0000218,,
10260,17509,Bioavailability after administration of 10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621982,,BAO_0000218,,
10261,17509,Bioavailability after administration of 2 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL882953,,BAO_0000218,,
10262,4527,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621983,,BAO_0000218,,
10263,4026,Bioavailability in dogs was determined; high,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621984,,BAO_0000218,,
10264,6659,Bioavailability in monkey after intravenous administration at 1 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621985,,BAO_0000218,,
10265,6659,Bioavailability in monkey after peroral administration at 10 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621986,,BAO_0000218,,
10266,6659,Bioavailability in rat after intravenous administration at 1 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621987,,BAO_0000218,,
10267,6659,Bioavailability in rat after intravenous administration at 2 mpk,F,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877600,,BAO_0000218,,
10268,6659,Bioavailability in rat after peroral administration at 30 mpk,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621988,,BAO_0000218,,
10269,6659,Bioavailability in rat after peroral administration at at 100 mpk,F,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621989,,BAO_0000218,,
10270,6597,Bioavailability in rats was evaluated,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621990,,BAO_0000218,,
10271,1202,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621991,,BAO_0000218,,
10272,1202,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621992,,BAO_0000218,,
10273,1202,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621993,,BAO_0000218,,
10274,1202,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621994,,BAO_0000218,,
10275,5207,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621995,,BAO_0000218,,
10276,5970,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621996,,BAO_0000218,,
10277,17538,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621997,,BAO_0000218,,
10278,17538,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621998,,BAO_0000218,,
10279,1466,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621999,,BAO_0000218,,
10280,2879,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622000,,BAO_0000218,,
10281,2879,Bioavailability was measured in rat after oral administration; 2-4,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622001,,BAO_0000218,,
10282,2879,Bioavailability was measured in rat after oral administration; 3-7,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622002,,BAO_0000218,,
10283,3777,Bioavailability in rat (intraduodenal administration),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622003,,BAO_0000218,,
10284,3777,Bioavailability in rat (intraduodenal administration),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877601,,BAO_0000218,,
10285,3777,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624871,,BAO_0000218,,
10286,3777,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622004,,BAO_0000218,,
10287,5423,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL882954,,BAO_0000218,,
10288,16365,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622005,,BAO_0000218,,
10289,16365,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622006,,BAO_0000218,,
10290,4239,Bioavailability was measured in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622007,,BAO_0000218,,
10291,5438,Bioavailability was reported,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622008,,BAO_0000218,,
10292,5334,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622009,,BAO_0000218,,
10293,5334,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622010,,BAO_0000218,,
10294,4199,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622011,,BAO_0000218,,
10295,4199,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622012,,BAO_0000218,,
10296,4199,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622013,,BAO_0000218,,
10297,4890,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622014,,BAO_0000218,,
10298,2792,Bioavailability was determined at 3 mg/kg po dose in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624749,,BAO_0000218,,
10299,5529,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624750,,BAO_0000218,,
10300,6685,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624751,,BAO_0000218,,
10301,6685,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624752,,BAO_0000218,,
10302,6685,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624753,,BAO_0000218,,
10303,6005,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624754,,BAO_0000218,,
10304,6410,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624755,,BAO_0000218,,
10305,6410,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624756,,BAO_0000218,,
10306,6103,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624757,,BAO_0000218,,
10307,6410,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624758,,BAO_0000218,,
10308,6410,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622270,,BAO_0000218,,
10309,5353,Bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622271,,BAO_0000218,,
10310,4727,Bioavailability in rat at the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622272,,BAO_0000218,,
10311,17804,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622273,,BAO_0000218,,
10312,5809,Bioavailability in rat (cannulated) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622274,,BAO_0000218,,
10313,17804,Bioavailability value of compound in rats was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622275,,BAO_0000218,,
10314,3634,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622276,,BAO_0000218,,
10315,3341,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622277,,BAO_0000218,,
10316,2690,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622278,,BAO_0000218,,
10317,3184,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622279,,BAO_0000218,,
10318,740,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622280,,BAO_0000218,,
10319,1806,Compound was evaluated for oral bioavailability in rats; 15-27 %,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624083,,BAO_0000218,,
10320,4891,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624084,,BAO_0000218,,
10321,3634,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624085,,BAO_0000218,,
10322,64,Compound was tested for bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624086,,BAO_0000218,,
10323,4839,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624087,,BAO_0000218,,
10324,1094,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624088,,BAO_0000218,,
10325,5005,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Intermediate,1,,CHEMBL624089,,BAO_0000218,,
10326,5005,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Intermediate,1,,CHEMBL624090,,BAO_0000218,,
10327,4687,Evaluated for the bioavailability in rat (in vivo),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624091,,BAO_0000218,,
10328,17804,F value of compound in rats was determined after peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624092,,BAO_0000218,,
10329,5974,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624093,,BAO_0000218,,
10330,5974,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624094,,BAO_0000218,,
10331,5974,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624095,,BAO_0000218,,
10332,5974,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624096,,BAO_0000218,,
10333,1088,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624097,,BAO_0000218,,
10334,1742,Maximum fall in carotid flow in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624098,,BAO_0000218,,
10335,4689,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874392,,BAO_0000218,,
10336,2463,Oral bioavailability in rat (dose 5 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624099,,BAO_0000218,,
10337,5654,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624100,,BAO_0000218,,
10338,5654,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624101,,BAO_0000218,,
10339,6874,Oral bioavailability in rat (male Wistar),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624102,,BAO_0000218,,
10340,5633,Oral bioavailability after administration (30 mg/kg) in rat; good,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624103,,BAO_0000218,,
10341,5496,Oral bioavailability at the dose of 2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624104,,BAO_0000218,,
10342,2358,Oral bioavailability determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624105,,BAO_0000218,,
10343,16456,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624106,,BAO_0000218,,
10344,5302,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624107,,BAO_0000218,,
10345,5302,Oral bioavailability in rat (dose single 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623943,,BAO_0000218,,
10346,5302,Oral bioavailability in rat (dose 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623944,,BAO_0000218,,
10347,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623945,,BAO_0000218,,
10348,11020,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623946,,BAO_0000218,,
10349,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623947,,BAO_0000218,,
10350,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623948,,BAO_0000218,,
10351,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623949,,BAO_0000218,,
10352,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623950,,BAO_0000218,,
10353,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874398,,BAO_0000218,,
10354,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623951,,BAO_0000218,,
10355,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623952,,BAO_0000218,,
10356,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623953,,BAO_0000218,,
10357,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623954,,BAO_0000218,,
10358,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623955,,BAO_0000218,,
10359,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623956,,BAO_0000218,,
10360,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627807,,BAO_0000218,,
10361,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627808,,BAO_0000218,,
10362,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627809,,BAO_0000218,,
10363,11020,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627810,,BAO_0000218,,
10364,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627811,,BAO_0000218,,
10365,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627812,,BAO_0000218,,
10366,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627813,,BAO_0000218,,
10367,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627814,,BAO_0000218,,
10368,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875336,,BAO_0000218,,
10369,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627815,,BAO_0000218,,
10370,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627816,,BAO_0000218,,
10371,11020,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627817,,BAO_0000218,,
10372,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627818,,BAO_0000218,,
10373,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627819,,BAO_0000218,,
10374,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627820,,BAO_0000218,,
10375,11020,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627821,,BAO_0000218,,
10376,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628464,,BAO_0000218,,
10377,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626239,,BAO_0000218,,
10378,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626240,,BAO_0000218,,
10379,11020,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626241,,BAO_0000218,,
10380,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626242,,BAO_0000218,,
10381,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626243,,BAO_0000218,,
10382,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626244,,BAO_0000218,,
10383,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626907,,BAO_0000218,,
10384,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626908,,BAO_0000218,,
10385,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626909,,BAO_0000218,,
10386,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626910,,BAO_0000218,,
10387,7449,Percent total excretion of acetaminophen cysteine conjugate,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875342,,BAO_0000218,,
10388,7449,Percent total excretion of acetaminophen glucuronide,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626911,,BAO_0000218,,
10389,7449,Percent total excretion of acetaminophen sulfate,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626912,,BAO_0000218,,
10390,7449,Percent total excretion of acetaminophen-mercapturic acid,F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627065,,BAO_0000218,,
10391,3172,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627066,,BAO_0000218,1088.0,
10392,16456,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627067,,BAO_0000218,,
10393,10839,Biodistribution of compound in rat muscle after 5 min of administration,A,In vivo,,ratrat,8656.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627068,,BAO_0000218,2385.0,
10394,10839,Biodistribution of compound in rat muscle after 5 min of administration.,A,In vivo,,ratrat,8656.0,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627069,,BAO_0000218,2385.0,
10395,5334,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627070,,BAO_0000218,,
10396,5334,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627071,,BAO_0000218,,
10397,5334,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627072,,BAO_0000218,,
10398,5334,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627073,,BAO_0000218,,
10399,5334,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625387,,BAO_0000218,,
10400,5334,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625388,,BAO_0000218,,
10401,5334,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL625389,,BAO_0000218,1969.0,
10402,5334,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),A,In vivo,,Ovis aries,9940.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL875343,,BAO_0000218,1969.0,
10403,1735,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),A,,,Serpentes,8570.0,,,,,50497,N,1,Intermediate,1,,CHEMBL876795,,BAO_0000218,,
10404,1469,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,A,,,Serpentes,8570.0,,,,,50497,N,1,Intermediate,1,,CHEMBL626552,,BAO_0000218,,
10405,1336,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,A,,,Serpentes,8570.0,,,,,50497,N,1,Intermediate,1,,CHEMBL626553,,BAO_0000218,,
10406,12403,The human biological plasma half life of the compound,A,,,Homo sapiens,9606.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626554,,BAO_0000366,1969.0,
10407,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626555,,BAO_0000218,1088.0,
10408,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626556,,BAO_0000218,,
10409,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626557,,BAO_0000218,,
10410,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626558,,BAO_0000218,,
10411,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626559,,BAO_0000218,,
10412,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626560,,BAO_0000218,,
10413,8004,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876803,,BAO_0000218,,
10414,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627964,,BAO_0000218,,
10415,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627965,,BAO_0000218,,
10416,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627966,,BAO_0000218,,
10417,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627967,,BAO_0000218,,
10418,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627968,,BAO_0000218,,
10419,8004,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627969,,BAO_0000218,,
10420,8004,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627970,,BAO_0000218,,
10421,8004,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627971,,BAO_0000218,178.0,
10422,8004,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627972,,BAO_0000218,178.0,
10423,15917,Dissociation constant against binding to human cyclophilin A,B,,,Homo sapiens,9606.0,,,,,180,D,9,Expert,1,,CHEMBL856029,,BAO_0000357,,
10424,12396,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,B,,,Bos taurus,9913.0,,,,,11591,H,8,Expert,1,,CHEMBL627973,,BAO_0000019,,
10425,7065,-Log C was determined by performing the electroshock minimum test,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627974,,BAO_0000019,,
10426,7065,-Log C was determined by performing the foot shock test,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627975,,BAO_0000019,,
10427,7065,-Log C was determined by performing the incl screen test,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627976,,BAO_0000019,,
10428,7065,-Log C was determined by performing the maximum electroshock test,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627977,,BAO_0000019,,
10429,7065,-Log C was determined by performing the pentylenetetrazole test,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627978,,BAO_0000019,,
10430,12415,Tested for experimental arotinoid inhibitory dose,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627979,,BAO_0000019,,
10431,10256,Negative log transformed activity,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL876804,,BAO_0000019,,
10432,7991,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627980,,BAO_0000019,,
10433,14342,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,A,,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL627981,,BAO_0000218,,
10434,14342,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,A,,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL627982,,BAO_0000218,,
10435,14342,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,A,,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL627983,,BAO_0000218,,
10436,14342,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,A,,,Cavia porcellus,10141.0,,Ileum,,,50512,N,1,Intermediate,1,,CHEMBL627984,,BAO_0000218,2116.0,
10437,6047,Solubility in water was determined; values expressed as -log,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL627985,,BAO_0000100,,
10438,17269,Ratio of Kcat to that of Km was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627986,,BAO_0000019,,
10439,10026,Observed first order rate constant,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627987,,BAO_0000019,,
10440,14583,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627988,,BAO_0000019,,
10441,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627989,,BAO_0000218,,
10442,2661,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627990,,BAO_0000218,,
10443,4029,Oral Bioavailability after administration of 10 mg/kg in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876805,,BAO_0000218,,
10444,17735,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627991,,BAO_0000218,,
10445,4576,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627992,,BAO_0000218,,
10446,17582,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627993,,BAO_0000218,,
10447,17651,Oral bioavailability at 1 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622817,,BAO_0000218,,
10448,17651,Oral bioavailability at 10 mg/kg was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622818,,BAO_0000218,,
10449,17670,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622819,,BAO_0000218,,
10450,5045,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL872267,,BAO_0000218,,
10451,1696,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622820,,BAO_0000218,,
10452,17764,Oral bioavailability after intravenous administration in rats at 24 uM/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622821,,BAO_0000218,,
10453,6448,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622822,,BAO_0000218,,
10454,6596,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622823,,BAO_0000218,,
10455,17547,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622824,,BAO_0000218,,
10456,17771,Oral bioavailability in rat at a dose of 3 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622825,,BAO_0000218,,
10457,6495,Oral bioavailability in rat after oral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622901,,BAO_0000218,,
10458,4558,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622902,,BAO_0000218,,
10459,17596,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621844,,BAO_0000218,,
10460,6827,Oral bioavailability in Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621845,,BAO_0000218,,
10461,4026,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621846,,BAO_0000218,,
10462,10,Oral bioavailability in rat (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621847,,BAO_0000218,,
10463,17717,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877609,,BAO_0000218,,
10464,17717,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621848,,BAO_0000218,,
10465,17717,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621849,,BAO_0000218,,
10466,17717,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622030,,BAO_0000218,,
10467,4796,Percent oral bioavailability determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622031,,BAO_0000218,,
10468,4883,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622032,,BAO_0000218,,
10469,2137,The compound was evaluated for bioavailability in rats; 32-51,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622033,,BAO_0000218,,
10470,2959,Bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622034,,BAO_0000218,,
10471,1361,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622035,,BAO_0000218,,
10472,4727,Bioavailability percent in rat at the dose of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL882966,,BAO_0000218,,
10473,16423,Bioavailability was evaluated after 20 uM/kg of peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622036,,BAO_0000218,,
10474,5206,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622037,,BAO_0000218,,
10475,6448,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622038,,BAO_0000218,,
10476,17723,Bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622039,,BAO_0000218,,
10477,17738,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622040,,BAO_0000218,178.0,
10478,17738,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622041,,BAO_0000218,178.0,
10479,17738,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622042,,BAO_0000218,178.0,
10480,17738,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622043,,BAO_0000218,178.0,
10481,17738,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622044,,BAO_0000218,178.0,
10482,17738,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL622045,,BAO_0000218,10000001.0,
10483,17738,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL622046,,BAO_0000218,10000001.0,
10484,17738,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL622047,,BAO_0000218,10000001.0,
10485,17738,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL877610,,BAO_0000218,10000001.0,
10486,17738,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622048,,BAO_0000218,955.0,
10487,17738,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622049,,BAO_0000218,955.0,
10488,17738,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622050,,BAO_0000218,955.0,
10489,17738,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622051,,BAO_0000218,955.0,
10490,17738,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622052,,BAO_0000218,,
10491,17738,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622053,,BAO_0000218,,
10492,17738,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622054,,BAO_0000218,,
10493,17738,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622055,,BAO_0000218,,
10494,5237,Oral bioavailability in rats was determined; High,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622056,,BAO_0000218,,
10495,5503,Oral bioavailability in the rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622057,,BAO_0000218,,
10496,15765,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628008,,BAO_0000218,,
10497,15660,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622058,,BAO_0000218,,
10498,5978,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622059,,BAO_0000218,,
10499,5978,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622060,,BAO_0000218,,
10500,5978,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622061,,BAO_0000218,,
10501,5978,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622062,,BAO_0000218,,
10502,5656,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622063,,BAO_0000218,,
10503,3598,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL877611,,BAO_0000218,,
10504,4216,Oral bioavailability of compound in Sprague Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622064,,BAO_0000218,,
10505,17839,Oral bioavailability of compound in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622065,,BAO_0000218,,
10506,6570,Oral bioavailability in rat (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622066,,BAO_0000218,,
10507,5334,Oral bioavailability of compound in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622067,,BAO_0000218,,
10508,6886,Oral bioavailability of compound in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622068,,BAO_0000218,,
10509,5210,Oral bioavailability of compound was determined in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622069,,BAO_0000218,,
10510,4170,Oral bioavailability at a dose of 30 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624796,,BAO_0000218,,
10511,6028,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624797,,BAO_0000218,,
10512,6028,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623053,,BAO_0000218,,
10513,6078,Oral bioavailability evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623054,,BAO_0000218,,
10514,6168,Oral bioavailability in fasted rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623055,,BAO_0000218,,
10515,6168,Oral bioavailability in fed rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623056,,BAO_0000218,,
10516,5160,Oral bioavailability in rat (mature male) (dose 30 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623057,,BAO_0000218,,
10517,6057,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623058,,BAO_0000218,,
10518,6535,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623059,,BAO_0000218,,
10519,6535,Oral bioavailability in rat after administration of 10 mg/kg po,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623060,,BAO_0000218,,
10520,4194,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623061,,BAO_0000218,,
10521,6230,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623062,,BAO_0000218,,
10522,6619,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623063,,BAO_0000218,,
10523,17607,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623064,,BAO_0000218,,
10524,4942,Oral bioavailability in ratrs,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623065,,BAO_0000218,,
10525,4942,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623066,,BAO_0000218,,
10526,6646,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623067,,BAO_0000218,,
10527,5237,Oral bioavailability in rats was determined; High,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623068,,BAO_0000218,,
10528,6646,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623069,,BAO_0000218,,
10529,4449,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623070,,BAO_0000218,,
10530,6057,Oral bioavailability was calculated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623071,,BAO_0000218,,
10531,2552,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623072,,BAO_0000218,,
10532,5496,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623073,,BAO_0000218,,
10533,6484,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623074,,BAO_0000218,,
10534,6485,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623075,,BAO_0000218,,
10535,6616,Oral bioavailability after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623076,,BAO_0000218,,
10536,4969,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623077,,BAO_0000218,,
10537,5862,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623078,,BAO_0000218,,
10538,4514,Oral bioavailability in Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623079,,BAO_0000218,,
10539,4514,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623080,,BAO_0000218,,
10540,4514,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623081,,BAO_0000218,,
10541,5546,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623082,,BAO_0000218,,
10542,6168,Oral bioavailability in fasted rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874400,,BAO_0000218,,
10543,6168,Oral bioavailability in fed rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623083,,BAO_0000218,,
10544,3624,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623084,,BAO_0000218,,
10545,5213,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623085,,BAO_0000218,,
10546,5496,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623086,,BAO_0000218,,
10547,5553,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623087,,BAO_0000218,,
10548,5833,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623088,,BAO_0000218,,
10549,5836,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623089,,BAO_0000218,,
10550,5865,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623090,,BAO_0000218,,
10551,5960,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623091,,BAO_0000218,,
10552,6249,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623092,,BAO_0000218,,
10553,6448,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623093,,BAO_0000218,,
10554,6453,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874401,,BAO_0000218,,
10555,6640,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623094,,BAO_0000218,,
10556,17607,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623095,,BAO_0000218,,
10557,5939,Oral bioavailability in rat after peroral administration at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623096,,BAO_0000218,,
10558,5939,Oral bioavailability in rat after peroral administration at 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624913,,BAO_0000218,,
10559,6281,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624914,,BAO_0000218,,
10560,5874,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624915,,BAO_0000218,,
10561,5213,Oral bioavailability in rat; Not measured,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624916,,BAO_0000218,,
10562,4964,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624917,,BAO_0000218,,
10563,11020,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625157,,BAO_0000218,,
10564,6251,In vitro metabolic potential in rat liver microsomes,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625158,,BAO_0000218,2107.0,
10565,1568,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625159,,BAO_0000218,,
10566,3032,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625160,,BAO_0000218,,
10567,3748,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625161,,BAO_0000218,,
10568,401,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625162,,BAO_0000218,,
10569,6512,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625163,,BAO_0000218,,
10570,17617,Oral bioavailability in rats at 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625164,,BAO_0000218,,
10571,6679,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625165,,BAO_0000218,,
10572,6742,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625166,,BAO_0000218,,
10573,589,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625167,,BAO_0000218,,
10574,589,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625168,,BAO_0000218,,
10575,3185,Plasma clearance of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625169,,BAO_0000218,,
10576,17596,Plasma clearance at 10 mg/kg in rat upon intravenous administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626264,,BAO_0000218,,
10577,2713,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626265,,BAO_0000218,,
10578,12500,The compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626266,,BAO_0000218,1969.0,
10579,12500,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626267,,BAO_0000218,1969.0,
10580,2713,Plasma concentration upon oral administration of 1 mg/Kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626268,,BAO_0000218,,
10581,1446,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626269,,BAO_0000218,,
10582,6227,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626270,,BAO_0000218,,
10583,4709,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626271,,BAO_0000218,,
10584,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626272,,BAO_0000218,,
10585,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626273,,BAO_0000218,,
10586,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875346,,BAO_0000218,,
10587,5510,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626274,,BAO_0000218,,
10588,4514,Compound was tested for protein binding in rat plasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626275,,BAO_0000218,,
10589,2713,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624646,,BAO_0000218,,
10590,2713,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624647,,BAO_0000218,,
10591,5340,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624648,,BAO_0000218,2107.0,
10592,12058,Area under curve ratio was determined (po/iv) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624649,,BAO_0000218,,
10593,11195,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624650,,BAO_0000218,,
10594,11195,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624651,,BAO_0000218,,
10595,11195,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624652,,BAO_0000218,,
10596,6495,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624653,,BAO_0000218,,
10597,6078,Ratio of AUCbrain to AUCplasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624654,,BAO_0000218,,
10598,5656,Ratio of brain to plasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624655,,BAO_0000218,,
10599,4910,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624656,,BAO_0000218,,
10600,4910,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624657,,BAO_0000218,,
10601,4910,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624658,,BAO_0000218,,
10602,10130,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624659,,BAO_0000218,,
10603,10130,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624660,,BAO_0000218,,
10604,10130,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624661,,BAO_0000218,,
10605,5213,Steady state brain :blood ratio was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624662,,BAO_0000218,,
10606,4910,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625199,,BAO_0000218,,
10607,4910,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625200,,BAO_0000218,,
10608,4910,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625201,,BAO_0000218,,
10609,4910,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625202,,BAO_0000218,,
10610,2083,Percentage recovery after 3h incubation with rat hapatocytes was determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625203,,BAO_0000218,,
10611,2082,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625204,,BAO_0000218,,
10612,2082,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625205,,BAO_0000218,,
10613,6351,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625206,,BAO_0000218,,
10614,14583,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625207,,BAO_0000019,,
10615,14583,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625208,,BAO_0000019,,
10616,4608,In vivo absorption in Caco-2 cell line monolayers was determined,A,,,Homo sapiens,9606.0,,,Caco-2,,50587,N,1,Intermediate,1,,CHEMBL625209,495.0,BAO_0000218,,
10617,13668,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625210,,BAO_0000100,,
10618,5669,Area under curve was determine after peroral administration at 10 mpk in Rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625211,,BAO_0000218,,
10619,5669,Area under curve was determine after peroral administration at 10 mpk in Rhesus,A,,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL625212,,BAO_0000218,,
10620,5669,Area under curve was determine after peroral administration at 160 mpk in Rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625213,,BAO_0000218,,
10621,5669,Area under curve was determine after peroral administration at 20 mpk in Rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625214,,BAO_0000218,,
10622,5669,Area under curve was determine after peroral administration at 50 mpk in Rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874542,,BAO_0000218,,
10623,6472,Calculated partition coefficient (clogP) (AlogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625215,,BAO_0000100,,
10624,15106,Activated partial thromboplastin time measured,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625216,,BAO_0000019,,
10625,15207,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625217,,BAO_0000100,,
10626,15207,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625218,,BAO_0000100,,
10627,13941,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622864,,BAO_0000218,1969.0,
10628,13941,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622865,,BAO_0000218,1969.0,
10629,13941,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622866,,BAO_0000218,1969.0,
10630,13941,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622867,,BAO_0000218,1969.0,
10631,15240,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,A,,,Cavia porcellus,10141.0,,Plasma,,,50512,N,1,Intermediate,1,,CHEMBL876808,,BAO_0000218,1969.0,
10632,10655,AUC in brain,A,,,,,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL627725,,BAO_0000019,955.0,
10633,10655,AUC in serum,A,,,,,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL627726,,BAO_0000019,1977.0,
10634,6504,AUC was determined,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627727,,BAO_0000019,1969.0,
10635,10615,AUC of the compound.,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627728,,BAO_0000019,1969.0,
10636,10353,AUC value (0-4 hr),A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627729,,BAO_0000019,1969.0,
10637,14907,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627730,,BAO_0000019,1969.0,
10638,14907,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627731,,BAO_0000019,1969.0,
10639,14907,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627732,,BAO_0000019,1969.0,
10640,14907,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627733,,BAO_0000019,1969.0,
10641,16359,AUC(area under curve) was determined after intravenous administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627734,,BAO_0000218,1969.0,
10642,16359,AUC(area under curve) was determined after oral administration in rats,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627735,,BAO_0000218,1969.0,
10643,15240,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,A,,,Cavia porcellus,10141.0,,Plasma,,,50512,N,1,Intermediate,1,,CHEMBL627736,,BAO_0000218,1969.0,
10644,15240,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876809,,BAO_0000218,1969.0,
10645,15469,Area Under Curve after oral dosing of 100 uM/Kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627737,,BAO_0000019,,
10646,15469,Area Under Curve after oral dosing of 30 uM/Kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627738,,BAO_0000019,,
10647,13520,Area Under Curve was measured by ploting the graph between concentration verses time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627739,,BAO_0000019,,
10648,17025,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626143,,BAO_0000218,,
10649,17025,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626144,,BAO_0000218,,
10650,17025,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL626145,,BAO_0000218,,
10651,17025,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626146,,BAO_0000218,,
10652,12032,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626147,,BAO_0000218,178.0,
10653,10291,Area under curve (AUC) was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626148,,BAO_0000019,,
10654,5767,Area under curve (AUC) following ip administration at 1 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626149,,BAO_0000218,,
10655,1434,Area under curve (AUC) was determined; ND is Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626150,,BAO_0000019,,
10656,14925,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626151,,BAO_0000218,,
10657,14925,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626152,,BAO_0000218,,
10658,14925,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626153,,BAO_0000218,,
10659,1434,Area under curve (AUR) was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626154,,BAO_0000019,,
10660,11883,Area under curve at 1 uM/dg administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626155,,BAO_0000019,,
10661,11883,Area under curve at 10 uM/dg administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626156,,BAO_0000019,,
10662,11883,Area under curve at 2 uM/dg administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626157,,BAO_0000019,,
10663,11883,Area under curve at 20 uM/dg administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626158,,BAO_0000019,,
10664,15233,Area under curve at a peroral dose of 3 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626159,,BAO_0000218,,
10665,15233,Area under curve at a peroral dose of 3 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626160,,BAO_0000218,,
10666,15233,Area under curve at an iv dose of 1 mg/kg in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626161,,BAO_0000218,,
10667,15233,Area under curve at an iv dose of 1 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626162,,BAO_0000218,,
10668,12978,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626163,,BAO_0000019,,
10669,12978,Area under curve gives the effective duration for the angiotensin II antagonist effect.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626164,,BAO_0000019,,
10670,11355,Area under curve measured as conc vs time after intravenous administration to mice.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626165,,BAO_0000218,,
10671,11355,Area under curve measured as conc vs time after peroral administration to mice.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626166,,BAO_0000218,,
10672,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626167,,BAO_0000218,,
10673,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626168,,BAO_0000218,,
10674,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL877463,,BAO_0000218,,
10675,12923,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626169,,BAO_0000218,,
10676,17738,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626170,,BAO_0000218,948.0,
10677,17738,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626171,,BAO_0000218,948.0,
10678,17738,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626172,,BAO_0000218,948.0,
10679,17738,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626173,,BAO_0000218,948.0,
10680,17738,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626174,,BAO_0000218,2113.0,
10681,17738,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626175,,BAO_0000218,2113.0,
10682,17738,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626176,,BAO_0000218,2113.0,
10683,17738,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626177,,BAO_0000218,2113.0,
10684,17738,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622499,,BAO_0000218,2113.0,
10685,17738,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622500,,BAO_0000218,2107.0,
10686,17738,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622501,,BAO_0000218,2107.0,
10687,17738,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622502,,BAO_0000218,2107.0,
10688,17738,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622503,,BAO_0000218,2107.0,
10689,17738,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL877614,,BAO_0000218,2107.0,
10690,17738,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624839,,BAO_0000218,2048.0,
10691,17738,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624840,,BAO_0000218,2048.0,
10692,17738,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624841,,BAO_0000218,2048.0,
10693,17738,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624842,,BAO_0000218,2048.0,
10694,17738,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624843,,BAO_0000218,2385.0,
10695,17738,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624844,,BAO_0000218,2385.0,
10696,17738,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624845,,BAO_0000218,2385.0,
10697,17738,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL621904,,BAO_0000218,2385.0,
10698,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621905,,BAO_0000218,178.0,
10699,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL874382,,BAO_0000218,178.0,
10700,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL621906,,BAO_0000218,178.0,
10701,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL621907,,BAO_0000218,955.0,
10702,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622096,,BAO_0000218,955.0,
10703,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622097,,BAO_0000218,955.0,
10704,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622098,,BAO_0000218,948.0,
10705,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622099,,BAO_0000218,948.0,
10706,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622100,,BAO_0000218,948.0,
10707,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622101,,BAO_0000218,2113.0,
10708,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622102,,BAO_0000218,2113.0,
10709,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622103,,BAO_0000218,2113.0,
10710,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622104,,BAO_0000218,2107.0,
10711,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622105,,BAO_0000218,2107.0,
10712,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622106,,BAO_0000218,2107.0,
10713,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622107,,BAO_0000218,2048.0,
10714,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622108,,BAO_0000218,2048.0,
10715,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622109,,BAO_0000218,2048.0,
10716,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622110,,BAO_0000218,2385.0,
10717,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622111,,BAO_0000218,2385.0,
10718,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL874383,,BAO_0000218,2385.0,
10719,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622112,,BAO_0000218,14.0,
10720,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622113,,BAO_0000218,14.0,
10721,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL622114,,BAO_0000218,14.0,
10722,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622115,,BAO_0000218,2106.0,
10723,11195,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622116,,BAO_0000218,2106.0,
10724,6193,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622117,,BAO_0000218,,
10725,6803,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622118,,BAO_0000218,,
10726,6647,Oral bioavailability in rats at 6 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622119,,BAO_0000218,,
10727,6647,Oral bioavailability in rat (dose 6 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622120,,BAO_0000218,,
10728,6647,Oral bioavailability in rats at 6 mg/kg dose; Not tested,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622121,,BAO_0000218,,
10729,6640,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622122,,BAO_0000218,,
10730,6641,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622123,,BAO_0000218,,
10731,6641,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622124,,BAO_0000218,,
10732,6642,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622125,,BAO_0000218,,
10733,5472,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622126,,BAO_0000218,,
10734,6141,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620455,,BAO_0000218,,
10735,4390,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620456,,BAO_0000218,,
10736,5472,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620457,,BAO_0000218,,
10737,5472,Oral bioavailability was evaluated; Not tested,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620458,,BAO_0000218,,
10738,5438,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620459,,BAO_0000218,,
10739,4883,Oral bioavailability in rat by oral dosing,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620460,,BAO_0000218,,
10740,1908,Oral bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620461,,BAO_0000218,,
10741,4853,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620462,,BAO_0000218,,
10742,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620463,,BAO_0000218,,
10743,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620464,,BAO_0000218,,
10744,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620465,,BAO_0000218,,
10745,4853,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620466,,BAO_0000218,,
10746,4853,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620467,,BAO_0000218,,
10747,4853,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620468,,BAO_0000218,,
10748,12873,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620469,,BAO_0000218,,
10749,12873,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620470,,BAO_0000218,,
10750,3169,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620471,,BAO_0000218,,
10751,6305,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620472,,BAO_0000218,,
10752,4762,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620473,,BAO_0000218,,
10753,17847,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620474,,BAO_0000218,,
10754,6211,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620475,,BAO_0000218,,
10755,6011,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620476,,BAO_0000218,,
10756,6317,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620477,,BAO_0000218,,
10757,6644,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620478,,BAO_0000218,,
10758,6644,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618768,,BAO_0000218,,
10759,6644,Oral bioavailability in rat after oral administration at 13 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618769,,BAO_0000218,,
10760,6644,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618770,,BAO_0000218,,
10761,6113,Oral bioavailability (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618771,,BAO_0000218,,
10762,5937,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618772,,BAO_0000218,,
10763,5711,Oral bioavailability in rat at 10 mg/kg of the compound,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618773,,BAO_0000218,,
10764,17717,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875842,,BAO_0000218,,
10765,17717,Bioavailability in rat (dose 3 mg/kg i.v.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618774,,BAO_0000218,,
10766,17717,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618775,,BAO_0000218,,
10767,17717,Oral bioavailability in rat (dose 60 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618776,,BAO_0000218,,
10768,4722,Percent bioavailability (F) in rats after iv administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618777,,BAO_0000218,,
10769,4722,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618778,,BAO_0000218,,
10770,4353,Bioavailability in rat (dose 5 uM/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618779,,BAO_0000218,,
10771,15662,Oral bioavailability,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618780,,BAO_0000218,,
10772,4756,Bioavailability in rat (dose 2 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618781,,BAO_0000218,,
10773,4756,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618782,,BAO_0000218,,
10774,3436,Oral bioavailability in rat (dose 20 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618783,,BAO_0000218,,
10775,17800,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618784,,BAO_0000218,,
10776,15762,Percent oral bioavailability evaluated in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618785,,BAO_0000218,,
10777,5089,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618786,,BAO_0000218,,
10778,5089,Percent oral bioavailability in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618787,,BAO_0000218,,
10779,3185,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618788,,BAO_0000218,,
10780,5145,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618789,,BAO_0000218,,
10781,3457,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618790,,BAO_0000218,,
10782,3457,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618791,,BAO_0000218,,
10783,5983,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875843,,BAO_0000218,,
10784,5739,Oral bioavailability in rat (dose 20 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL618792,,BAO_0000218,,
10785,3579,Cmax at a dose of 30 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623395,,BAO_0000218,,
10786,17788,Cmax in monkeys at a dose of 1 mg/kg,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623396,,BAO_0000218,,
10787,14956,Cmax in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623397,,BAO_0000218,,
10788,17788,Cmax in rats at a dose of 1 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623398,,BAO_0000218,,
10789,9750,Cmax was measured in mice after an oral dose of 50 mg/kg.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623399,,BAO_0000218,,
10790,12767,"Cmax value at a dose of 12.7 uM/kg, po",A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623400,,BAO_0000218,,
10791,12767,"Cmax value at a dose of 6.3 uM/kg, iv",A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623401,,BAO_0000218,,
10792,12767,"Cmax value at a dose of 7.1 uM/kg, iv",A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623402,,BAO_0000218,,
10793,12703,Cmax value of compound was determined after 1 hr,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623403,,BAO_0000218,,
10794,15778,Cmax value of the compound,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623404,,BAO_0000218,,
10795,12818,Cmax value administered intraintestinal in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625997,,BAO_0000218,,
10796,14964,Cmax value administered perorally was determined in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625998,,BAO_0000218,,
10797,15808,Cmax value at the dose of 2.3 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625999,,BAO_0000218,,
10798,15808,Cmax value at the dose of 5 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626000,,BAO_0000218,,
10799,15778,Cmax value in the period of 8 hr after dosing. ,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626001,,BAO_0000218,,
10800,3715,Cmax value at a oral dose of 20 mg/kg; Not tested,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626002,,BAO_0000218,,
10801,3715,Cmax value at a oral dose of 20 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626003,,BAO_0000218,,
10802,1446,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626004,,BAO_0000218,,
10803,15240,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL626005,,BAO_0000218,,
10804,15240,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626006,,BAO_0000218,,
10805,14810,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626007,,BAO_0000218,1969.0,
10806,14239,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL626008,,BAO_0000218,1969.0,
10807,12555,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL626009,,BAO_0000218,2107.0,
10808,10754,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626010,,BAO_0000218,,
10809,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626011,,BAO_0000218,178.0,
10810,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626012,,BAO_0000218,178.0,
10811,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626013,,BAO_0000218,178.0,
10812,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL626014,,BAO_0000218,178.0,
10813,10754,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL877496,,BAO_0000218,178.0,
10814,14600,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626015,,BAO_0000218,,
10815,14600,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626016,,BAO_0000218,,
10816,14600,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,F,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626017,,BAO_0000218,,
10817,13543,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626018,,BAO_0000218,1969.0,
10818,13543,Bioavailability as maximal plasma concentration in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626692,,BAO_0000218,1969.0,
10819,13543,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626693,,BAO_0000218,1969.0,
10820,13543,Bioavailability as maximal plasma concentration in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626694,,BAO_0000218,1969.0,
10821,14600,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL626695,,BAO_0000218,178.0,
10822,14600,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL626696,,BAO_0000218,178.0,
10823,14600,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL626697,,BAO_0000218,178.0,
10824,14600,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL626859,,BAO_0000218,178.0,
10825,14600,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL626860,,BAO_0000218,178.0,
10826,14600,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,A,In vivo,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL626861,,BAO_0000218,178.0,
10827,14681,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626296,,BAO_0000218,,
10828,15905,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626297,,BAO_0000218,,
10829,15905,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626298,,BAO_0000218,1969.0,
10830,13304,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626299,,BAO_0000218,1969.0,
10831,15137,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626300,,BAO_0000218,1969.0,
10832,15137,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626301,,BAO_0000218,1969.0,
10833,15137,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626962,,BAO_0000218,1969.0,
10834,15137,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626963,,BAO_0000218,1969.0,
10835,15137,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626964,,BAO_0000218,1969.0,
10836,14839,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL626965,,BAO_0000218,1969.0,
10837,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL626966,,BAO_0000218,1969.0,
10838,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL626967,,BAO_0000218,1969.0,
10839,14839,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL626968,,BAO_0000218,1969.0,
10840,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626969,,BAO_0000218,948.0,
10841,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627126,,BAO_0000218,948.0,
10842,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631276,,BAO_0000218,948.0,
10843,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631277,,BAO_0000218,948.0,
10844,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631278,,BAO_0000218,948.0,
10845,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL874457,,BAO_0000218,948.0,
10846,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631279,,BAO_0000218,948.0,
10847,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631280,,BAO_0000218,948.0,
10848,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631281,,BAO_0000218,948.0,
10849,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631968,,BAO_0000218,948.0,
10850,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631969,,BAO_0000218,948.0,
10851,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631970,,BAO_0000218,948.0,
10852,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631971,,BAO_0000218,948.0,
10853,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL631972,,BAO_0000218,948.0,
10854,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630435,,BAO_0000218,948.0,
10855,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630436,,BAO_0000218,948.0,
10856,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630437,,BAO_0000218,948.0,
10857,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630438,,BAO_0000218,948.0,
10858,8418,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630439,,BAO_0000218,948.0,
10859,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630440,,BAO_0000218,2113.0,
10860,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630441,,BAO_0000218,2113.0,
10861,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630442,,BAO_0000218,2113.0,
10862,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625234,,BAO_0000218,2113.0,
10863,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625235,,BAO_0000218,2113.0,
10864,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625236,,BAO_0000218,2113.0,
10865,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625237,,BAO_0000218,2113.0,
10866,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626125,,BAO_0000218,2113.0,
10867,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626126,,BAO_0000218,2113.0,
10868,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626127,,BAO_0000218,2113.0,
10869,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626128,,BAO_0000218,2113.0,
10870,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626129,,BAO_0000218,2113.0,
10871,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626130,,BAO_0000218,2113.0,
10872,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626131,,BAO_0000218,2113.0,
10873,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626132,,BAO_0000218,2113.0,
10874,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626752,,BAO_0000218,2113.0,
10875,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626753,,BAO_0000218,2113.0,
10876,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626754,,BAO_0000218,2113.0,
10877,8418,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626755,,BAO_0000218,2113.0,
10878,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626756,,BAO_0000218,2107.0,
10879,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626757,,BAO_0000218,2107.0,
10880,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626758,,BAO_0000218,2107.0,
10881,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626759,,BAO_0000218,2107.0,
10882,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626760,,BAO_0000218,2107.0,
10883,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626394,,BAO_0000218,,
10884,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626395,,BAO_0000218,,
10885,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626396,,BAO_0000218,,
10886,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626397,,BAO_0000218,,
10887,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626398,,BAO_0000218,,
10888,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626399,,BAO_0000218,,
10889,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874653,,BAO_0000218,,
10890,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626400,,BAO_0000218,,
10891,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626401,,BAO_0000218,,
10892,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626402,,BAO_0000218,,
10893,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626403,,BAO_0000218,,
10894,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626404,,BAO_0000218,,
10895,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626405,,BAO_0000218,,
10896,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625529,,BAO_0000218,,
10897,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625530,,BAO_0000218,,
10898,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625531,,BAO_0000218,,
10899,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625532,,BAO_0000218,,
10900,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625533,,BAO_0000218,,
10901,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875474,,BAO_0000218,,
10902,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625534,,BAO_0000218,,
10903,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625535,,BAO_0000218,,
10904,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625536,,BAO_0000218,,
10905,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625537,,BAO_0000218,,
10906,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625538,,BAO_0000218,,
10907,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625539,,BAO_0000218,,
10908,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625540,,BAO_0000218,,
10909,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625541,,BAO_0000218,,
10910,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625542,,BAO_0000218,,
10911,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625543,,BAO_0000218,,
10912,6996,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625544,,BAO_0000218,,
10913,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625545,,BAO_0000218,,
10914,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625546,,BAO_0000218,,
10915,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625547,,BAO_0000218,,
10916,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625548,,BAO_0000218,,
10917,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625549,,BAO_0000218,,
10918,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625550,,BAO_0000218,,
10919,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625551,,BAO_0000218,,
10920,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875475,,BAO_0000218,,
10921,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625552,,BAO_0000218,,
10922,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625553,,BAO_0000218,,
10923,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625554,,BAO_0000218,,
10924,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625555,,BAO_0000218,,
10925,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625556,,BAO_0000218,,
10926,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624986,,BAO_0000218,,
10927,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624987,,BAO_0000218,,
10928,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624988,,BAO_0000218,,
10929,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624989,,BAO_0000218,1637.0,
10930,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624990,,BAO_0000218,1637.0,
10931,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL874391,,BAO_0000218,1637.0,
10932,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624991,,BAO_0000218,1637.0,
10933,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624992,,BAO_0000218,1637.0,
10934,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624993,,BAO_0000218,1637.0,
10935,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624994,,BAO_0000218,1637.0,
10936,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624995,,BAO_0000218,1637.0,
10937,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624996,,BAO_0000218,1637.0,
10938,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624997,,BAO_0000218,1637.0,
10939,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624998,,BAO_0000218,1637.0,
10940,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624999,,BAO_0000218,1637.0,
10941,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL882955,,BAO_0000218,1637.0,
10942,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625000,,BAO_0000218,1637.0,
10943,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625001,,BAO_0000218,1637.0,
10944,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625089,,BAO_0000218,1637.0,
10945,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625090,,BAO_0000218,1637.0,
10946,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625091,,BAO_0000218,1637.0,
10947,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625092,,BAO_0000218,1637.0,
10948,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625093,,BAO_0000218,1637.0,
10949,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625094,,BAO_0000218,1637.0,
10950,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL625095,,BAO_0000218,1637.0,
10951,2249,Compound was evaluated for its bioavailability in the dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625096,,BAO_0000218,,
10952,2249,Compound was evaluated for its bioavailability in the rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625097,,BAO_0000218,,
10953,17515,Compound was evaluated for oral bioavailability,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL882956,,BAO_0000218,,
10954,14541,Compound was evaluated for percentage of Oral bioavailability in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625098,,BAO_0000218,,
10955,12797,Bioavailability in guinea pig,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625099,,BAO_0000218,,
10956,12797,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625100,,BAO_0000218,,
10957,12797,Compound was evaluated for the oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625101,,BAO_0000218,,
10958,12797,Compound was evaluated for the oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874396,,BAO_0000218,,
10959,11727,Bioavailability in dog (dosed i.v.),F,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625102,,BAO_0000218,,
10960,13249,Compound was tested for in vivo bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625103,,BAO_0000218,,
10961,13249,Compound was tested for in vivo bioavailability in hamsters,A,In vivo,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL625104,,BAO_0000218,,
10962,13249,Compound was tested for in vivo bioavailability in monkey,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625105,,BAO_0000218,,
10963,13249,Compound was tested for in vivo bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625106,,BAO_0000218,,
10964,9552,Oral bioavailability in mouse,A,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625107,,BAO_0000218,,
10965,9552,Compound was tested for percent of oral bioavailability in mice; 56-74,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625108,,BAO_0000218,,
10966,14839,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625109,,BAO_0000218,,
10967,14839,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625110,,BAO_0000218,,
10968,14839,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625111,,BAO_0000218,,
10969,14839,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625112,,BAO_0000218,,
10970,14839,Oral bioavailability in nude mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875334,,BAO_0000218,,
10971,11219,Bioavailability in monkey (i.d. dosing),A,In vivo,,Primates,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628617,,BAO_0000218,,
10972,9552,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628618,,BAO_0000218,,
10973,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628619,,BAO_0000218,,
10974,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628620,,BAO_0000218,,
10975,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL628621,,BAO_0000218,,
10976,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL628622,,BAO_0000218,,
10977,14839,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL628623,,BAO_0000218,,
10978,14839,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,A,In vivo,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL628624,,BAO_0000218,1969.0,
10979,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL628625,,BAO_0000218,1969.0,
10980,14839,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,A,In vivo,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL628626,,BAO_0000218,1969.0,
10981,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627041,,BAO_0000218,1969.0,
10982,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627042,,BAO_0000218,1969.0,
10983,14839,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627043,,BAO_0000218,1969.0,
10984,13932,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627044,,BAO_0000218,1969.0,
10985,11637,Cmax in mouse plasma,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL627045,,BAO_0000218,1969.0,
10986,11637,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL627046,,BAO_0000218,1969.0,
10987,13960,Maximal plasma concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627047,,BAO_0000218,1969.0,
10988,15905,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627048,,BAO_0000218,1969.0,
10989,14062,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627049,,BAO_0000218,,
10990,14062,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627050,,BAO_0000218,,
10991,14062,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627051,,BAO_0000218,,
10992,14062,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627052,,BAO_0000218,,
10993,14062,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627053,,BAO_0000218,,
10994,14062,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627054,,BAO_0000218,,
10995,15011,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627055,,BAO_0000218,,
10996,15011,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627056,,BAO_0000218,,
10997,15011,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627057,,BAO_0000218,,
10998,15011,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627058,,BAO_0000218,,
10999,15011,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626211,,BAO_0000218,,
11000,10291,Maximum Concentration of the compound.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626212,,BAO_0000218,,
11001,14599,Maximum Concentration was measured after iv administration into Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626213,,BAO_0000218,,
11002,14599,Maximum Concentration was measured after iv administration into Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626214,,BAO_0000218,,
11003,14599,Maximum Concentration was measured after po administration into Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626215,,BAO_0000218,,
11004,14599,Maximum Concentration was measured after po administration into Beagle dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626216,,BAO_0000218,,
11005,12767,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626217,,BAO_0000218,178.0,
11006,12767,Maximum blood level reached after an iv dose of 12.2 uM/kg,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626218,,BAO_0000218,178.0,
11007,12767,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626219,,BAO_0000218,178.0,
11008,12767,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626220,,BAO_0000218,178.0,
11009,12767,Maximum blood level reached after an oral dose of 5.0 mg/kg,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626221,,BAO_0000218,178.0,
11010,12767,Maximum blood level reached at dose of 10.6 uM/kg orally,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626222,,BAO_0000218,178.0,
11011,14706,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL626223,,BAO_0000218,,
11012,14706,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL626224,,BAO_0000218,,
11013,14793,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL626225,,BAO_0000218,955.0,
11014,14793,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL626226,,BAO_0000218,955.0,
11015,14793,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL626227,,BAO_0000218,955.0,
11016,14793,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL626228,,BAO_0000218,955.0,
11017,14793,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626229,,BAO_0000218,,
11018,14793,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626921,,BAO_0000218,,
11019,14793,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876793,,BAO_0000218,,
11020,14793,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625309,,BAO_0000218,,
11021,10524,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),A,In vivo,,Bacillus subtilis,1423.0,,,,,50278,N,1,Intermediate,1,,CHEMBL625310,,BAO_0000218,,
11022,11871,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625311,,BAO_0000218,,
11023,11871,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625312,,BAO_0000218,,
11024,3437,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625313,,BAO_0000218,,
11025,12038,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625314,,BAO_0000218,,
11026,12038,Maximum concentration in male rats after iv administration of 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625315,,BAO_0000218,,
11027,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625316,,BAO_0000218,2107.0,
11028,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625317,,BAO_0000218,2107.0,
11029,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625318,,BAO_0000218,2107.0,
11030,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625319,,BAO_0000218,2107.0,
11031,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625320,,BAO_0000218,2107.0,
11032,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625321,,BAO_0000218,2107.0,
11033,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625322,,BAO_0000218,2107.0,
11034,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL876801,,BAO_0000218,2107.0,
11035,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625323,,BAO_0000218,2107.0,
11036,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625324,,BAO_0000218,2107.0,
11037,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625325,,BAO_0000218,2107.0,
11038,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625326,,BAO_0000218,2107.0,
11039,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625327,,BAO_0000218,2107.0,
11040,8418,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625328,,BAO_0000218,2107.0,
11041,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625329,,BAO_0000218,2048.0,
11042,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625330,,BAO_0000218,2048.0,
11043,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627774,,BAO_0000218,2048.0,
11044,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627775,,BAO_0000218,2048.0,
11045,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627949,,BAO_0000218,2048.0,
11046,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627950,,BAO_0000218,2048.0,
11047,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627951,,BAO_0000218,2048.0,
11048,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627952,,BAO_0000218,2048.0,
11049,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627953,,BAO_0000218,2048.0,
11050,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627954,,BAO_0000218,2048.0,
11051,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627955,,BAO_0000218,2048.0,
11052,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627956,,BAO_0000218,2048.0,
11053,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL876802,,BAO_0000218,2048.0,
11054,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627957,,BAO_0000218,2048.0,
11055,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627958,,BAO_0000218,2048.0,
11056,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627959,,BAO_0000218,2048.0,
11057,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627960,,BAO_0000218,2048.0,
11058,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627961,,BAO_0000218,2048.0,
11059,8418,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627962,,BAO_0000218,2048.0,
11060,9796,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627963,,BAO_0000218,,
11061,9796,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624759,,BAO_0000218,,
11062,9796,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624760,,BAO_0000218,,
11063,9796,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624761,,BAO_0000218,,
11064,9796,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877607,,BAO_0000218,,
11065,9796,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624762,,BAO_0000218,2107.0,
11066,9796,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624763,,BAO_0000218,2107.0,
11067,9796,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624764,,BAO_0000218,2107.0,
11068,9796,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624765,,BAO_0000218,2107.0,
11069,9796,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624766,,BAO_0000218,2107.0,
11070,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624767,,BAO_0000218,,
11071,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624768,,BAO_0000218,,
11072,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624769,,BAO_0000218,,
11073,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624770,,BAO_0000218,,
11074,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624771,,BAO_0000218,,
11075,6996,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624772,,BAO_0000218,,
11076,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624773,,BAO_0000218,,
11077,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624774,,BAO_0000218,,
11078,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624775,,BAO_0000218,,
11079,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624776,,BAO_0000218,,
11080,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624777,,BAO_0000218,,
11081,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624778,,BAO_0000218,,
11082,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624779,,BAO_0000218,,
11083,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624780,,BAO_0000218,,
11084,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624781,,BAO_0000218,,
11085,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877608,,BAO_0000218,,
11086,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624782,,BAO_0000218,,
11087,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624783,,BAO_0000218,,
11088,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624784,,BAO_0000218,,
11089,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624785,,BAO_0000218,,
11090,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624786,,BAO_0000218,,
11091,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624787,,BAO_0000218,,
11092,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628676,,BAO_0000218,,
11093,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621842,,BAO_0000218,,
11094,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL621843,,BAO_0000218,,
11095,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623873,,BAO_0000218,,
11096,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623874,,BAO_0000218,,
11097,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623875,,BAO_0000218,,
11098,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623876,,BAO_0000218,,
11099,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623877,,BAO_0000218,,
11100,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623878,,BAO_0000218,,
11101,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623879,,BAO_0000218,,
11102,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623880,,BAO_0000218,,
11103,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623881,,BAO_0000218,,
11104,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623957,,BAO_0000218,,
11105,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623958,,BAO_0000218,,
11106,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623959,,BAO_0000218,,
11107,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623960,,BAO_0000218,,
11108,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623961,,BAO_0000218,,
11109,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623962,,BAO_0000218,,
11110,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624676,,BAO_0000218,,
11111,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624677,,BAO_0000218,,
11112,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624678,,BAO_0000218,,
11113,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624679,,BAO_0000218,,
11114,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624680,,BAO_0000218,,
11115,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624849,,BAO_0000218,,
11116,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624850,,BAO_0000218,,
11117,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874399,,BAO_0000218,,
11118,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624851,,BAO_0000218,,
11119,11732,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624852,,BAO_0000218,,
11120,13359,Oral bioavailability in rat (dose 10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624853,,BAO_0000218,,
11121,16618,Oral bioavailability in rat (Sprague-Dawley),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624854,,BAO_0000218,,
11122,13960,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624855,,BAO_0000218,,
11123,13917,Oral bioavailability in rats was determined in vivo,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624856,,BAO_0000218,,
11124,14266,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL882957,,BAO_0000218,,
11125,12359,Oral bioavailability of compound in monkey,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624857,,BAO_0000218,,
11126,12359,Oral bioavailability of compound in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622202,,BAO_0000218,,
11127,12359,Bioavailability in rat of PMEA prodrug,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622203,,BAO_0000218,,
11128,12359,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625522,,BAO_0000218,,
11129,10791,Serum conc at 3 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622868,,BAO_0000218,,
11130,10791,Urine conc 0-5 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL622869,,BAO_0000218,1088.0,
11131,10791,Urine conc 0-24 hours following 25 mg/kg dose,A,In vivo,,Macaca mulatta,9544.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL622870,,BAO_0000218,1088.0,
11132,138,Oral bioavailability in African green monkeys; 20-25,A,In vivo,,Chlorocebus aethiops,9534.0,,,,,22224,U,0,Autocuration,1,,CHEMBL622871,,BAO_0000218,,
11133,14521,Oral bioavailability in cynomolgus monkey.,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL620560,,BAO_0000218,,
11134,13953,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620561,,BAO_0000218,,
11135,12836,Oral bioavailability in dog at 10 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620562,,BAO_0000218,,
11136,12836,Oral bioavailability in hamster at 10 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL620563,,BAO_0000218,,
11137,12836,Oral bioavailability in rat at 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL620564,,BAO_0000218,,
11138,14521,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872265,,BAO_0000218,,
11139,13953,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620565,,BAO_0000218,,
11140,6799,Oral bioavailability,A,In vivo,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620566,,BAO_0000218,,
11141,11311,Oral bioavailability was determined; range 49-102%,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL620567,,BAO_0000218,,
11142,4013,Oral bioavailability was determined in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL620568,,BAO_0000218,,
11143,4013,Oral bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620569,,BAO_0000218,,
11144,17591,Oral bioavailability,A,In vivo,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620570,,BAO_0000218,,
11145,17591,Oral bioavailability was determined; Not orally available,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL620571,,BAO_0000218,,
11146,15011,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620572,,BAO_0000218,,
11147,15011,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620573,,BAO_0000218,,
11148,15011,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,A,In vivo,,Mus musculus,10090.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620574,,BAO_0000218,,
11149,9552,Oral bioavailability in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620575,,BAO_0000218,,
11150,9552,Oral bioavailability in dog (female mongrel),A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620576,,BAO_0000218,,
11151,3639,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875846,,BAO_0000218,,
11152,13397,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620577,,BAO_0000218,,
11153,3031,Percentage Bioavailability was evaluated.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL620578,,BAO_0000218,,
11154,12818,Bioavailability in rat administered i.d.,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL620579,,BAO_0000218,,
11155,4847,Bioavailability,A,In vivo,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL621248,,BAO_0000218,,
11156,12421,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625390,,BAO_0000218,,
11157,11966,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625391,,BAO_0000218,,
11158,11218,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),A,In vivo,,Primates,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL872266,,BAO_0000218,,
11159,13129,Oral bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625392,,BAO_0000218,,
11160,12350,The oral bioavailability was measured on rats after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625393,,BAO_0000218,,
11161,2231,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625394,,BAO_0000218,,
11162,2231,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL625395,,BAO_0000218,,
11163,12187,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625396,,BAO_0000218,,
11164,12421,Bioavailability in dog (male Beagle) i.v. administration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625397,,BAO_0000218,,
11165,13256,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625398,,BAO_0000218,,
11166,13256,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625399,,BAO_0000218,178.0,
11167,13256,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Cerebellum,,,50594,N,1,Intermediate,1,,CHEMBL626074,,BAO_0000218,2037.0,
11168,13256,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626075,,BAO_0000218,,
11169,2231,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626076,,BAO_0000218,1969.0,
11170,2231,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL626077,,BAO_0000218,1969.0,
11171,12178,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626078,,BAO_0000218,178.0,
11172,12178,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL625846,,BAO_0000218,178.0,
11173,12178,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL625847,,BAO_0000218,178.0,
11174,15633,Maximum concentration observed in rats at an oral dose of 50 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL625848,,BAO_0000218,,
11175,14258,Maximum concentration of compound in plasma administered orally to rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625849,,BAO_0000218,1969.0,
11176,14224,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626023,,BAO_0000218,1969.0,
11177,14224,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626024,,BAO_0000218,1969.0,
11178,14224,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626025,,BAO_0000218,1969.0,
11179,5566,Maximum concentration after 10 mg/kg by oral administration,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626026,,BAO_0000218,,
11180,16935,Maximum concentration at a dose of 1.5 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626027,,BAO_0000218,,
11181,16935,Maximum concentration at a dose of 2.0 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626028,,BAO_0000218,,
11182,14224,Maximum concentration in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626029,,BAO_0000218,1969.0,
11183,12536,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626030,,BAO_0000218,1969.0,
11184,12536,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626031,,BAO_0000218,1969.0,
11185,12536,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626032,,BAO_0000218,1969.0,
11186,12536,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626033,,BAO_0000218,1969.0,
11187,12536,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626034,,BAO_0000218,1969.0,
11188,9994,Maximum concentration in plasma after oral administration in dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626035,,BAO_0000218,1969.0,
11189,1434,Maximum concentration in plasma at Tmax,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626036,,BAO_0000218,1969.0,
11190,12836,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Expert,1,,CHEMBL626037,,BAO_0000218,1969.0,
11191,12836,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,,Plasma,,,100712,N,1,Intermediate,1,,CHEMBL626038,,BAO_0000218,1969.0,
11192,12836,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626039,,BAO_0000218,1969.0,
11193,12545,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626040,,BAO_0000218,1969.0,
11194,13856,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,50592,N,1,Intermediate,1,,CHEMBL626041,,BAO_0000218,1969.0,
11195,3550,Maximum concentration was calculated,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626042,,BAO_0000218,,
11196,2632,Maximum concentration was calculated.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626043,,BAO_0000218,,
11197,5566,Maximum concentration at a peroral dose of 10 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626044,,BAO_0000218,,
11198,11883,Maximum concentration of the drug at 10 uM/dg administered perorally,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626045,,BAO_0000218,,
11199,11883,Maximum concentration of the drug at 2 uM/dg administered intravenously,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626046,,BAO_0000218,,
11200,14122,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626047,,BAO_0000218,1969.0,
11201,14122,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Cricetinae,10026.0,,Plasma,,,100712,N,1,Intermediate,1,,CHEMBL626048,,BAO_0000218,1969.0,
11202,14122,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626049,,BAO_0000218,1969.0,
11203,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626050,,BAO_0000218,1969.0,
11204,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL874541,,BAO_0000218,1969.0,
11205,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,,Plasma,,,100712,N,1,Intermediate,1,,CHEMBL622826,,BAO_0000218,1969.0,
11206,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,A,In vivo,,Cricetinae,10026.0,,Plasma,,,100712,N,1,Intermediate,1,,CHEMBL622827,,BAO_0000218,1969.0,
11207,12542,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622828,,BAO_0000218,1969.0,
11208,14080,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622829,,BAO_0000218,1969.0,
11209,11911,Maximum concentration reached following intravenous administration in male rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876806,,BAO_0000218,,
11210,13204,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622830,,BAO_0000218,,
11211,13204,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622831,,BAO_0000218,,
11212,14346,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626794,,BAO_0000218,,
11213,14346,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626795,,BAO_0000218,,
11214,14346,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626796,,BAO_0000218,,
11215,14346,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626797,,BAO_0000218,,
11216,14127,Maximum drug concentration is determined after oral dosing in rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626798,,BAO_0000218,,
11217,14339,Maximum observed concentration in oral (5 mg/kg) fasted dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626799,,BAO_0000218,,
11218,14339,Maximum observed concentration in oral (5 mg/kg) fed dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626800,,BAO_0000218,,
11219,13494,Maximum plasma concentration,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626801,,BAO_0000218,1969.0,
11220,14925,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876816,,BAO_0000218,1969.0,
11221,14474,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626802,,BAO_0000218,1969.0,
11222,14474,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626803,,BAO_0000218,1969.0,
11223,13917,Maximum plasma concentration following oral administration of 30 umol/kg,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626804,,BAO_0000218,1969.0,
11224,9796,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626805,,BAO_0000218,1969.0,
11225,9796,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626309,,BAO_0000218,1969.0,
11226,9796,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626310,,BAO_0000218,1969.0,
11227,9796,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626311,,BAO_0000218,1969.0,
11228,9796,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626312,,BAO_0000218,1969.0,
11229,9796,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626313,,BAO_0000218,995.0,
11230,9796,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626314,,BAO_0000218,995.0,
11231,9796,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626315,,BAO_0000218,995.0,
11232,9796,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626316,,BAO_0000218,995.0,
11233,9796,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626317,,BAO_0000218,995.0,
11234,8363,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626318,,BAO_0000218,,
11235,8363,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626319,,BAO_0000218,,
11236,8363,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626320,,BAO_0000218,,
11237,8363,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875053,,BAO_0000218,,
11238,8363,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626321,,BAO_0000218,,
11239,8363,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626322,,BAO_0000218,,
11240,8363,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626323,,BAO_0000218,,
11241,8363,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626324,,BAO_0000218,,
11242,8363,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626325,,BAO_0000218,,
11243,8363,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626326,,BAO_0000218,,
11244,8363,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626327,,BAO_0000218,,
11245,8363,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626328,,BAO_0000218,,
11246,8684,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626329,,BAO_0000218,178.0,
11247,8684,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626330,,BAO_0000218,178.0,
11248,8684,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626331,,BAO_0000218,178.0,
11249,8684,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626332,,BAO_0000218,178.0,
11250,8684,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626333,,BAO_0000218,178.0,
11251,8684,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626334,,BAO_0000218,178.0,
11252,8684,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626335,,BAO_0000218,178.0,
11253,8684,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624798,,BAO_0000218,178.0,
11254,8684,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624799,,BAO_0000218,955.0,
11255,8684,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624800,,BAO_0000218,955.0,
11256,8684,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624801,,BAO_0000218,955.0,
11257,8684,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624802,,BAO_0000218,955.0,
11258,8684,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624803,,BAO_0000218,955.0,
11259,8684,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624804,,BAO_0000218,955.0,
11260,8684,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624805,,BAO_0000218,955.0,
11261,8684,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL624806,,BAO_0000218,955.0,
11262,8684,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624807,,BAO_0000218,,
11263,8684,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624808,,BAO_0000218,,
11264,8684,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624809,,BAO_0000218,,
11265,8684,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624810,,BAO_0000218,,
11266,8684,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877618,,BAO_0000218,,
11267,8684,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624811,,BAO_0000218,,
11268,8684,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624812,,BAO_0000218,,
11269,8684,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624813,,BAO_0000218,,
11270,8684,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624814,,BAO_0000218,,
11271,8684,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624815,,BAO_0000218,,
11272,8684,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624816,,BAO_0000218,,
11273,8684,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624817,,BAO_0000218,,
11274,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624818,,BAO_0000218,,
11275,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624819,,BAO_0000218,,
11276,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624820,,BAO_0000218,,
11277,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624821,,BAO_0000218,,
11278,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624822,,BAO_0000218,,
11279,6996,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624823,,BAO_0000218,,
11280,15599,Observed diffusion coefficient in organic solvent for Escherichia coli,A,,,Escherichia coli,562.0,,,,,50212,N,1,Intermediate,1,,CHEMBL624824,,BAO_0000218,,
11281,9614,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624825,,BAO_0000218,178.0,
11282,9614,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624826,,BAO_0000218,178.0,
11283,9614,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,Cardiac atrium,,,50597,N,1,Intermediate,1,,CHEMBL876817,,BAO_0000218,2081.0,
11284,9614,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,Cardiac atrium,,,50597,N,1,Intermediate,1,,CHEMBL624827,,BAO_0000218,2081.0,
11285,9614,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624828,,BAO_0000218,,
11286,9614,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624829,,BAO_0000218,,
11287,9614,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624830,,BAO_0000218,2107.0,
11288,9614,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624831,,BAO_0000218,2107.0,
11289,9614,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,Cardiac atrium,,,50597,N,1,Intermediate,1,,CHEMBL624832,,BAO_0000218,2081.0,
11290,9614,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,Cardiac atrium,,,50597,N,1,Intermediate,1,,CHEMBL624833,,BAO_0000218,2081.0,
11291,9614,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624834,,BAO_0000218,,
11292,9614,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624835,,BAO_0000218,,
11293,9614,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL624836,,BAO_0000218,2106.0,
11294,9614,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL624837,,BAO_0000218,2106.0,
11295,9071,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624838,,BAO_0000218,178.0,
11296,9071,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622188,,BAO_0000218,178.0,
11297,9071,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622189,,BAO_0000218,948.0,
11298,9071,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622190,,BAO_0000218,948.0,
11299,9071,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625170,,BAO_0000218,948.0,
11300,9071,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625171,,BAO_0000218,2113.0,
11301,9071,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625172,,BAO_0000218,2113.0,
11302,9071,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625173,,BAO_0000218,2113.0,
11303,9071,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625174,,BAO_0000218,2107.0,
11304,9071,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625175,,BAO_0000218,2107.0,
11305,9071,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625176,,BAO_0000218,2107.0,
11306,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625177,,BAO_0000218,2048.0,
11307,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625178,,BAO_0000218,2048.0,
11308,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625179,,BAO_0000218,2048.0,
11309,9071,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625180,,BAO_0000218,2048.0,
11310,10677,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625181,,BAO_0000218,,
11311,9750,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL625182,,BAO_0000218,1088.0,
11312,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625183,,BAO_0000218,,
11313,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875848,,BAO_0000218,,
11314,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622260,,BAO_0000218,,
11315,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622261,,BAO_0000218,,
11316,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622262,,BAO_0000218,,
11317,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622263,,BAO_0000218,2113.0,
11318,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622418,,BAO_0000218,2113.0,
11319,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622419,,BAO_0000218,2107.0,
11320,13256,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623388,,BAO_0000218,,
11321,13256,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL623389,,BAO_0000218,2107.0,
11322,13256,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623390,,BAO_0000218,,
11323,13256,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623391,,BAO_0000218,,
11324,13256,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623392,,BAO_0000218,178.0,
11325,13256,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Cerebellum,,,50594,N,1,Intermediate,1,,CHEMBL623393,,BAO_0000218,2037.0,
11326,13256,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623394,,BAO_0000218,,
11327,13256,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618885,,BAO_0000218,,
11328,13256,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618886,,BAO_0000218,2107.0,
11329,13256,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618887,,BAO_0000218,,
11330,13256,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619535,,BAO_0000218,,
11331,13256,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL619536,,BAO_0000218,178.0,
11332,13256,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Cerebellum,,,50594,N,1,Intermediate,1,,CHEMBL619537,,BAO_0000218,2037.0,
11333,13256,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619705,,BAO_0000218,,
11334,13256,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619706,,BAO_0000218,,
11335,13256,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL619707,,BAO_0000218,2107.0,
11336,13256,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL619708,,BAO_0000218,,
11337,13256,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625219,,BAO_0000218,,
11338,13256,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL625220,,BAO_0000218,178.0,
11339,13256,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Cerebellum,,,50594,N,1,Intermediate,1,,CHEMBL625221,,BAO_0000218,2037.0,
11340,13256,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625222,,BAO_0000218,,
11341,13256,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625223,,BAO_0000218,,
11342,13256,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL625224,,BAO_0000218,2107.0,
11343,13256,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625225,,BAO_0000218,,
11344,8829,Biodistribution in Rat blood after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625226,,BAO_0000218,178.0,
11345,8829,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625227,,BAO_0000218,178.0,
11346,8829,Biodistribution in Rat blood after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625228,,BAO_0000218,178.0,
11347,8829,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875354,,BAO_0000218,178.0,
11348,8829,Biodistribution in Rat blood after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625229,,BAO_0000218,178.0,
11349,8829,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625230,,BAO_0000218,178.0,
11350,8829,Biodistribution in Rat heart after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625231,,BAO_0000218,948.0,
11351,8829,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625900,,BAO_0000218,948.0,
11352,8829,Biodistribution in Rat heart after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625901,,BAO_0000218,948.0,
11353,8829,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625902,,BAO_0000218,948.0,
11354,8829,Biodistribution in Rat heart after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625903,,BAO_0000218,948.0,
11355,8829,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625904,,BAO_0000218,948.0,
11356,8829,Biodistribution in Rat liver after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625905,,BAO_0000218,2107.0,
11357,8829,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627861,,BAO_0000218,2107.0,
11358,8829,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627862,,BAO_0000218,2107.0,
11359,8829,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627863,,BAO_0000218,2107.0,
11360,8829,Biodistribution in Rat liver after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627769,,BAO_0000218,2107.0,
11361,13249,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL627770,,BAO_0000218,1969.0,
11362,13622,Cmax in cynomolgus monkey (PO dose),A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL627771,,BAO_0000218,,
11363,13622,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627772,,BAO_0000218,,
11364,13622,Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627773,,BAO_0000218,,
11365,13494,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621922,,BAO_0000218,1969.0,
11366,12170,Cmax in rat plasma after oral dose (10 mg/kg),A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621923,,BAO_0000218,1969.0,
11367,12170,Cmax in plasma after oral dose (10 mg/kg),A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621924,,BAO_0000218,1969.0,
11368,17025,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621925,,BAO_0000218,1969.0,
11369,17025,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621926,,BAO_0000218,1969.0,
11370,17025,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,A,In vivo,,Oryctolagus cuniculus,9986.0,,Plasma,,,50592,N,1,Intermediate,1,,CHEMBL621927,,BAO_0000218,1969.0,
11371,17025,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621928,,BAO_0000218,1969.0,
11372,14187,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621929,,BAO_0000218,1969.0,
11373,14816,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL621930,,BAO_0000218,1969.0,
11374,17820,Maximum plasma concentration after oral dosing in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621931,,BAO_0000218,1969.0,
11375,14380,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621932,,BAO_0000218,1969.0,
11376,14380,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621933,,BAO_0000218,1969.0,
11377,14691,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621934,,BAO_0000218,1969.0,
11378,14691,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL621935,,BAO_0000218,1969.0,
11379,13375,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL621936,,BAO_0000218,1969.0,
11380,6236,Maximum plasma concentration was determined,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621937,,BAO_0000218,1969.0,
11381,14380,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621938,,BAO_0000218,1969.0,
11382,14380,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621939,,BAO_0000218,1969.0,
11383,14380,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621940,,BAO_0000218,1969.0,
11384,14380,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621941,,BAO_0000218,1969.0,
11385,14380,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL621942,,BAO_0000218,1969.0,
11386,14380,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626178,,BAO_0000218,1969.0,
11387,14380,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626179,,BAO_0000218,1969.0,
11388,14380,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626180,,BAO_0000218,1969.0,
11389,13622,Plasma Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626181,,BAO_0000218,1969.0,
11390,15372,Maximum serum concentration after po dose of 5.22 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626182,,BAO_0000218,,
11391,15372,Maximum serum concentration after po dose of 5.46 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626183,,BAO_0000218,,
11392,15372,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626184,,BAO_0000218,,
11393,15372,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626185,,BAO_0000218,,
11394,14925,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626186,,BAO_0000218,1969.0,
11395,14925,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL877589,,BAO_0000218,1969.0,
11396,11883,Maximum concentration of the drug at 1 uM/dg administered intravenously,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626187,,BAO_0000218,,
11397,11883,Maximum concentration of the drug at 20 uM/dg administered perorally,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626188,,BAO_0000218,,
11398,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626189,,BAO_0000218,,
11399,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL626855,,BAO_0000218,178.0,
11400,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL623781,,BAO_0000218,178.0,
11401,13391,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL623782,,BAO_0000218,178.0,
11402,16360,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623783,,BAO_0000218,1969.0,
11403,3673,Cmax in dog plasma after 1mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623784,,BAO_0000218,1969.0,
11404,14431,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623785,,BAO_0000218,1969.0,
11405,14431,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623786,,BAO_0000218,1969.0,
11406,14964,Oral maximum concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623787,,BAO_0000218,,
11407,14964,Oral maximum concentration in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623788,,BAO_0000218,,
11408,14209,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623789,,BAO_0000218,1969.0,
11409,11355,Peak concentration in blood after intravenous administration to mice,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623790,,BAO_0000218,178.0,
11410,11355,Peak concentration in blood after peroral administration to mice,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL623791,,BAO_0000218,178.0,
11411,11966,Peak concentration in rat plasma was determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623792,,BAO_0000218,1969.0,
11412,8918,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623793,,BAO_0000218,1969.0,
11413,8918,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623794,,BAO_0000218,1969.0,
11414,8918,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623795,,BAO_0000218,1969.0,
11415,8684,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623796,,BAO_0000218,,
11416,8684,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623797,,BAO_0000218,,
11417,8684,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623798,,BAO_0000218,,
11418,8684,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623799,,BAO_0000218,,
11419,8684,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624490,,BAO_0000218,160.0,
11420,8684,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624491,,BAO_0000218,160.0,
11421,8684,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624492,,BAO_0000218,160.0,
11422,8684,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624493,,BAO_0000218,160.0,
11423,8684,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL877595,,BAO_0000218,160.0,
11424,8684,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624494,,BAO_0000218,160.0,
11425,8684,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624495,,BAO_0000218,160.0,
11426,8684,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL624681,,BAO_0000218,160.0,
11427,8684,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624682,,BAO_0000218,,
11428,8684,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624683,,BAO_0000218,,
11429,8684,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624684,,BAO_0000218,,
11430,8684,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624685,,BAO_0000218,,
11431,8684,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624686,,BAO_0000218,,
11432,8684,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624687,,BAO_0000218,,
11433,8684,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624688,,BAO_0000218,,
11434,8684,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627161,,BAO_0000218,,
11435,8684,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622127,,BAO_0000218,,
11436,8684,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622128,,BAO_0000218,,
11437,8684,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874384,,BAO_0000218,,
11438,8684,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624898,,BAO_0000218,,
11439,8684,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624899,,BAO_0000218,,
11440,8684,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624900,,BAO_0000218,,
11441,8684,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624901,,BAO_0000218,,
11442,8684,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624902,,BAO_0000218,,
11443,8684,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624903,,BAO_0000218,,
11444,8684,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624904,,BAO_0000218,,
11445,8684,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624905,,BAO_0000218,,
11446,8684,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624906,,BAO_0000218,,
11447,8684,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624907,,BAO_0000218,,
11448,8684,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624908,,BAO_0000218,,
11449,8684,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624909,,BAO_0000218,,
11450,8684,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624910,,BAO_0000218,,
11451,8684,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624911,,BAO_0000218,2385.0,
11452,8684,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL874388,,BAO_0000218,2385.0,
11453,8684,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL624912,,BAO_0000218,2385.0,
11454,8684,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622930,,BAO_0000218,2385.0,
11455,8684,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623121,,BAO_0000218,2385.0,
11456,8684,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623122,,BAO_0000218,2385.0,
11457,8684,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623123,,BAO_0000218,2385.0,
11458,8684,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623124,,BAO_0000218,2385.0,
11459,8684,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623125,,BAO_0000218,,
11460,8684,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623126,,BAO_0000218,,
11461,8684,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623127,,BAO_0000218,,
11462,8684,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623128,,BAO_0000218,,
11463,8684,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623129,,BAO_0000218,,
11464,8684,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623130,,BAO_0000218,,
11465,8684,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623131,,BAO_0000218,,
11466,8684,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623132,,BAO_0000218,,
11467,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623133,,BAO_0000218,2107.0,
11468,8319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623134,,BAO_0000218,,
11469,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874389,,BAO_0000218,,
11470,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623135,,BAO_0000218,,
11471,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623136,,BAO_0000218,,
11472,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623137,,BAO_0000218,,
11473,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623138,,BAO_0000218,,
11474,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623139,,BAO_0000218,2113.0,
11475,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623140,,BAO_0000218,2113.0,
11476,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623141,,BAO_0000218,2107.0,
11477,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623142,,BAO_0000218,2107.0,
11478,8319,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623143,,BAO_0000218,,
11479,14571,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL623144,,BAO_0000218,1088.0,
11480,14571,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623405,,BAO_0000218,1088.0,
11481,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624074,,BAO_0000218,,
11482,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624075,,BAO_0000218,,
11483,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624076,,BAO_0000218,,
11484,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624077,,BAO_0000218,,
11485,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624078,,BAO_0000218,,
11486,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624079,,BAO_0000218,2113.0,
11487,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624261,,BAO_0000218,2113.0,
11488,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624262,,BAO_0000218,,
11489,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624263,,BAO_0000218,,
11490,8319,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624264,,BAO_0000218,,
11491,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624265,,BAO_0000218,,
11492,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624266,,BAO_0000218,,
11493,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624267,,BAO_0000218,,
11494,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624268,,BAO_0000218,,
11495,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875227,,BAO_0000218,,
11496,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624269,,BAO_0000218,2113.0,
11497,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624270,,BAO_0000218,2113.0,
11498,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624271,,BAO_0000218,,
11499,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624272,,BAO_0000218,,
11500,8319,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624273,,BAO_0000218,,
11501,12064,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624274,,BAO_0000218,1088.0,
11502,12064,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624275,,BAO_0000218,1088.0,
11503,12064,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624276,,BAO_0000218,1088.0,
11504,12038,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624277,,BAO_0000218,1088.0,
11505,14314,% dose converted to 2-amino-5-chlorophenyl sulfate,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624278,,BAO_0000019,,
11506,14314,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624279,,BAO_0000019,,
11507,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL624280,,BAO_0000218,1988.0,
11508,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL624281,,BAO_0000218,1988.0,
11509,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL622933,,BAO_0000218,1988.0,
11510,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL622934,,BAO_0000218,1988.0,
11511,8829,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622935,,BAO_0000218,2107.0,
11512,8829,Biodistribution in Rat liver after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622936,,BAO_0000218,2107.0,
11513,8829,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL875228,,BAO_0000218,2107.0,
11514,8829,Biodistribution in Rat lung after 24 hours of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622937,,BAO_0000218,2048.0,
11515,8829,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622938,,BAO_0000218,2048.0,
11516,8829,Biodistribution in Rat lung after 30 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL619736,,BAO_0000218,2048.0,
11517,8829,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625117,,BAO_0000218,2048.0,
11518,8829,Biodistribution in Rat lung after 5 minutes of iv administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625118,,BAO_0000218,2048.0,
11519,8829,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625119,,BAO_0000218,2048.0,
11520,14972,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL625120,,BAO_0000218,2037.0,
11521,14972,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625121,,BAO_0000218,,
11522,14972,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",A,In vivo,,Rattus norvegicus,10116.0,,Thalamus,,,50597,N,1,Intermediate,1,,CHEMBL625122,,BAO_0000218,10000006.0,
11523,14608,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL622204,,BAO_0000218,178.0,
11524,14608,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL877503,,BAO_0000218,178.0,
11525,14608,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627127,,BAO_0000218,178.0,
11526,14608,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,,,,Hippocampus,,,22224,U,0,Autocuration,1,,CHEMBL627128,,BAO_0000218,10000000.0,
11527,14608,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,,,,Hippocampus,,,22224,U,0,Autocuration,1,,CHEMBL627129,,BAO_0000218,10000000.0,
11528,14608,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,,,,Hippocampus,,,22224,U,0,Autocuration,1,,CHEMBL627130,,BAO_0000218,10000000.0,
11529,14608,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627131,,BAO_0000218,955.0,
11530,14608,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627132,,BAO_0000218,955.0,
11531,14608,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL627133,,BAO_0000218,955.0,
11532,14608,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL627134,,BAO_0000218,2037.0,
11533,14608,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL627135,,BAO_0000218,2037.0,
11534,14608,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL627136,,BAO_0000218,2037.0,
11535,14608,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628435,,BAO_0000218,,
11536,14608,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628436,,BAO_0000218,,
11537,14608,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628437,,BAO_0000218,,
11538,14608,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL628438,,BAO_0000218,948.0,
11539,14608,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL628439,,BAO_0000218,948.0,
11540,14608,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL628440,,BAO_0000218,948.0,
11541,14608,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL628441,,BAO_0000218,10000000.0,
11542,14608,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL628442,,BAO_0000218,10000000.0,
11543,14608,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL628443,,BAO_0000218,10000000.0,
11544,14608,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628444,,BAO_0000218,2113.0,
11545,14608,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628445,,BAO_0000218,2113.0,
11546,14608,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL877504,,BAO_0000218,2113.0,
11547,14608,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628446,,BAO_0000218,2107.0,
11548,14608,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626874,,BAO_0000218,2107.0,
11549,14608,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626875,,BAO_0000218,2107.0,
11550,14608,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626876,,BAO_0000218,2048.0,
11551,14608,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626877,,BAO_0000218,2048.0,
11552,14608,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626878,,BAO_0000218,2048.0,
11553,14608,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL626879,,BAO_0000218,2385.0,
11554,8918,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626880,,BAO_0000218,1969.0,
11555,8918,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL626881,,BAO_0000218,1969.0,
11556,8918,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626882,,BAO_0000218,1969.0,
11557,14470,Peak plasma concentration was measured in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626883,,BAO_0000218,1969.0,
11558,14393,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626884,,BAO_0000218,,
11559,14886,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626885,,BAO_0000218,,
11560,14886,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626886,,BAO_0000218,,
11561,14886,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626887,,BAO_0000218,,
11562,14393,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626888,,BAO_0000218,,
11563,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626889,,BAO_0000218,,
11564,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626761,,BAO_0000218,,
11565,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626762,,BAO_0000218,,
11566,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626763,,BAO_0000218,,
11567,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626764,,BAO_0000218,,
11568,13465,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626765,,BAO_0000218,,
11569,13465,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626766,,BAO_0000218,,
11570,13465,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626767,,BAO_0000218,,
11571,13465,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626768,,BAO_0000218,,
11572,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626769,,BAO_0000218,,
11573,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL874463,,BAO_0000218,,
11574,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626770,,BAO_0000218,,
11575,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626771,,BAO_0000218,,
11576,13465,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626772,,BAO_0000218,,
11577,14731,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL626773,,BAO_0000218,,
11578,14731,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626774,,BAO_0000218,,
11579,13376,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626775,,BAO_0000218,,
11580,13376,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626776,,BAO_0000218,,
11581,14443,Maximum concentration (Cmax) in rat when administered orally,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626777,,BAO_0000218,,
11582,13465,Maximal concentration in monkey plasma after 25 mg/kg oral dose,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626778,,BAO_0000218,1969.0,
11583,16359,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626779,,BAO_0000218,,
11584,16359,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626780,,BAO_0000218,,
11585,15618,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626781,,BAO_0000218,1969.0,
11586,14554,Pharmacokinetic profile Cmax was evaluated in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632164,,BAO_0000218,,
11587,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL632165,,BAO_0000218,,
11588,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL632166,,BAO_0000218,,
11589,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL632167,,BAO_0000218,,
11590,11537,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL632168,,BAO_0000218,,
11591,2021,Cmax in rat plasma,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL632169,,BAO_0000218,1969.0,
11592,5932,Cmax in dog plasma after 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL632170,,BAO_0000218,1969.0,
11593,5932,Cmax in rat plasma after 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL632171,,BAO_0000218,1969.0,
11594,17320,Plasma level in rats at 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL632172,,BAO_0000218,1969.0,
11595,15831,Tested for maximum plasma concentration in mice,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL632173,,BAO_0000218,1969.0,
11596,15078,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632174,,BAO_0000218,,
11597,14941,The Cmax values in female wistar rats.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632175,,BAO_0000218,,
11598,15343,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL632176,,BAO_0000218,1969.0,
11599,15343,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL632177,,BAO_0000218,1969.0,
11600,14856,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL632178,,BAO_0000218,1969.0,
11601,13129,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632179,,BAO_0000218,,
11602,13098,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632180,,BAO_0000218,178.0,
11603,13098,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632181,,BAO_0000218,178.0,
11604,13098,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632182,,BAO_0000218,178.0,
11605,15478,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,A,In vivo,,Mus musculus,10090.0,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL632183,,BAO_0000218,178.0,
11606,15341,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL632184,,BAO_0000218,,
11607,15341,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874470,,BAO_0000218,,
11608,8684,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631302,,BAO_0000218,,
11609,8684,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631303,,BAO_0000218,,
11610,8684,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631304,,BAO_0000218,,
11611,8684,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631305,,BAO_0000218,,
11612,8684,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631306,,BAO_0000218,,
11613,8684,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631307,,BAO_0000218,,
11614,8684,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631308,,BAO_0000218,,
11615,8684,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625557,,BAO_0000218,,
11616,8684,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625558,,BAO_0000218,2106.0,
11617,8684,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625559,,BAO_0000218,2106.0,
11618,8684,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625560,,BAO_0000218,2106.0,
11619,8684,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625561,,BAO_0000218,2106.0,
11620,8684,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625562,,BAO_0000218,2106.0,
11621,8684,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL875320,,BAO_0000218,2106.0,
11622,8684,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625563,,BAO_0000218,2106.0,
11623,8684,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625564,,BAO_0000218,2106.0,
11624,8684,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL625565,,BAO_0000218,995.0,
11625,8684,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL625566,,BAO_0000218,995.0,
11626,8684,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL625567,,BAO_0000218,995.0,
11627,8684,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL625568,,BAO_0000218,995.0,
11628,8684,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL628217,,BAO_0000218,995.0,
11629,8684,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL628218,,BAO_0000218,995.0,
11630,8684,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL628219,,BAO_0000218,995.0,
11631,8684,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL628220,,BAO_0000218,995.0,
11632,8926,Distribution in the blood after 120 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628221,,BAO_0000019,,
11633,8926,Distribution in the blood after 15 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628222,,BAO_0000019,,
11634,8926,Distribution in the blood after 30 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628223,,BAO_0000019,,
11635,8926,Distribution in the blood after 5 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628224,,BAO_0000019,,
11636,8926,Distribution in the blood after 60 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628225,,BAO_0000019,,
11637,8926,Distribution in the blood after 90 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628226,,BAO_0000019,,
11638,8926,Distribution in the bone after 120 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628227,,BAO_0000019,,
11639,8926,Distribution in the bone after 15 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875481,,BAO_0000019,,
11640,8926,Distribution in the bone after 30 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628228,,BAO_0000019,,
11641,8926,Distribution in the bone after 5 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628229,,BAO_0000019,,
11642,8926,Distribution in the bone after 60 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628230,,BAO_0000019,,
11643,8926,Distribution in the bone after 90 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628231,,BAO_0000019,,
11644,8926,Distribution in the heart after 120 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628232,,BAO_0000019,,
11645,8926,Distribution in the heart after 15 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628233,,BAO_0000019,,
11646,8926,Distribution in the heart after 30 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628234,,BAO_0000019,,
11647,8926,Distribution in the heart after 5 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628235,,BAO_0000019,,
11648,8926,Distribution in the heart after 60 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628236,,BAO_0000019,,
11649,8926,Distribution in the heart after 90 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628237,,BAO_0000019,,
11650,8926,Distribution in the kidneys after 120 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628238,,BAO_0000019,,
11651,8926,Distribution in the kidneys after 15 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628239,,BAO_0000019,,
11652,8926,Distribution in the kidneys after 30 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628240,,BAO_0000019,,
11653,8926,Distribution in the kidneys after 5 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628241,,BAO_0000019,,
11654,8926,Distribution in the kidneys after 60 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628242,,BAO_0000019,,
11655,8926,Distribution in the kidneys after 90 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875482,,BAO_0000019,,
11656,8926,Distribution in the liver after 120 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628243,,BAO_0000019,,
11657,8926,Distribution in the liver after 15 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628244,,BAO_0000019,,
11658,8926,Distribution in the liver after 30 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628245,,BAO_0000019,,
11659,8926,Distribution in the liver after 5 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628246,,BAO_0000019,,
11660,8926,Distribution in the liver after 60 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628247,,BAO_0000019,,
11661,8926,Distribution in the liver after 90 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628248,,BAO_0000019,,
11662,8926,Distribution in the lung after 120 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628249,,BAO_0000019,,
11663,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625452,,BAO_0000218,,
11664,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625453,,BAO_0000218,,
11665,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625454,,BAO_0000218,,
11666,14839,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623844,,BAO_0000218,,
11667,12178,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623845,,BAO_0000218,,
11668,12178,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623846,,BAO_0000218,,
11669,12178,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623847,,BAO_0000218,,
11670,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623848,,BAO_0000218,,
11671,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623849,,BAO_0000218,,
11672,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623850,,BAO_0000218,,
11673,12186,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623851,,BAO_0000218,,
11674,12187,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623852,,BAO_0000218,,
11675,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL624551,,BAO_0000218,,
11676,12187,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL624552,,BAO_0000218,,
11677,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624553,,BAO_0000218,,
11678,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624554,,BAO_0000218,,
11679,12187,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624555,,BAO_0000218,,
11680,12187,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624741,,BAO_0000218,,
11681,14122,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624742,,BAO_0000218,,
11682,14122,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL624743,,BAO_0000218,,
11683,14122,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877606,,BAO_0000218,,
11684,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624744,,BAO_0000218,,
11685,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624745,,BAO_0000218,178.0,
11686,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624746,,BAO_0000218,178.0,
11687,13391,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL624747,,BAO_0000218,178.0,
11688,16360,Oral absorption expressed as Area under curve was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624748,,BAO_0000019,,
11689,3673,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622504,,BAO_0000218,,
11690,14122,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622505,,BAO_0000218,,
11691,14122,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL622506,,BAO_0000218,,
11692,14122,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",A,,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL622507,,BAO_0000218,,
11693,14122,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622508,,BAO_0000218,,
11694,13889,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622509,,BAO_0000019,,
11695,14393,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622510,,BAO_0000218,,
11696,17279,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622511,,BAO_0000218,,
11697,14548,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL622512,,BAO_0000218,,
11698,14548,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL622513,,BAO_0000218,,
11699,14548,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL622514,,BAO_0000218,,
11700,14548,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622515,,BAO_0000218,,
11701,14548,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622516,,BAO_0000218,,
11702,14548,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622517,,BAO_0000218,,
11703,14548,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622518,,BAO_0000218,,
11704,14548,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622519,,BAO_0000218,,
11705,14608,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622520,,BAO_0000218,2385.0,
11706,14608,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622521,,BAO_0000218,2385.0,
11707,14608,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL625113,,BAO_0000218,14.0,
11708,14608,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL625114,,BAO_0000218,14.0,
11709,14608,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL874397,,BAO_0000218,14.0,
11710,14608,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625115,,BAO_0000218,2106.0,
11711,14608,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625116,,BAO_0000218,2106.0,
11712,14608,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL623932,,BAO_0000218,2106.0,
11713,14608,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL623933,,BAO_0000218,2435.0,
11714,14608,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL623934,,BAO_0000218,2435.0,
11715,14608,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL623935,,BAO_0000218,2435.0,
11716,14608,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL623936,,BAO_0000218,2046.0,
11717,14608,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL623937,,BAO_0000218,2046.0,
11718,14608,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL623938,,BAO_0000218,2046.0,
11719,15383,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623939,,BAO_0000218,,
11720,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623940,,BAO_0000218,,
11721,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623941,,BAO_0000218,,
11722,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627216,,BAO_0000218,,
11723,15383,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623942,,BAO_0000218,,
11724,15383,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618793,,BAO_0000218,955.0,
11725,15383,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618794,,BAO_0000218,955.0,
11726,15383,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL618795,,BAO_0000218,955.0,
11727,15383,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618796,,BAO_0000218,,
11728,15383,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618797,,BAO_0000218,,
11729,15383,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618798,,BAO_0000218,2113.0,
11730,15383,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618799,,BAO_0000218,2113.0,
11731,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618800,,BAO_0000218,2113.0,
11732,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618801,,BAO_0000218,2113.0,
11733,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618802,,BAO_0000218,2113.0,
11734,15383,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL618803,,BAO_0000218,2113.0,
11735,15383,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618804,,BAO_0000218,2107.0,
11736,15383,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618805,,BAO_0000218,2107.0,
11737,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618806,,BAO_0000218,2107.0,
11738,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618807,,BAO_0000218,2107.0,
11739,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618808,,BAO_0000218,2107.0,
11740,15383,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL618809,,BAO_0000218,2107.0,
11741,15383,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618810,,BAO_0000218,2385.0,
11742,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,A,,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618811,,BAO_0000218,2385.0,
11743,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL875844,,BAO_0000218,2385.0,
11744,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618812,,BAO_0000218,2385.0,
11745,15383,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL618813,,BAO_0000218,2385.0,
11746,15383,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618814,,BAO_0000218,,
11747,15383,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618815,,BAO_0000218,,
11748,15383,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618816,,BAO_0000218,,
11749,15383,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL618817,,BAO_0000218,,
11750,15383,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL620544,,BAO_0000218,,
11751,15341,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626230,,BAO_0000218,,
11752,15341,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626231,,BAO_0000218,,
11753,15341,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626232,,BAO_0000218,,
11754,14906,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626233,,BAO_0000218,1969.0,
11755,14906,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626234,,BAO_0000218,1969.0,
11756,14906,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL875341,,BAO_0000218,1969.0,
11757,14215,The maximum plasma concentration (100 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL626235,,BAO_0000218,1969.0,
11758,14215,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,A,In vivo,,Callithrix,9481.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626236,,BAO_0000218,1969.0,
11759,14215,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626237,,BAO_0000218,1969.0,
11760,14215,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626238,,BAO_0000218,1969.0,
11761,14215,The maximum plasma concentration (200 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL622412,,BAO_0000218,1969.0,
11762,14215,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623114,,BAO_0000218,1969.0,
11763,14215,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,A,In vivo,,Callithrix,9481.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623115,,BAO_0000218,1969.0,
11764,14215,The maximum plasma concentration (25 mg/kg) administered orally in monkey,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623116,,BAO_0000218,1969.0,
11765,14215,The maximum plasma concentration (30 mg/kg) administered orally in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623117,,BAO_0000218,1969.0,
11766,14215,The maximum plasma concentration (400 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL623118,,BAO_0000218,1969.0,
11767,14215,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623119,,BAO_0000218,1969.0,
11768,14215,The maximum plasma concentration (50 mg/kg) administered orally in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623120,,BAO_0000218,1969.0,
11769,14215,The maximum plasma concentration (800 mg/kg) administered orally in human,A,In vivo,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL623286,,BAO_0000218,1969.0,
11770,14067,The maximum plasma concentration was measured on rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623287,,BAO_0000218,1969.0,
11771,12350,The maximum plasma concentration was measured on rats after oral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623288,,BAO_0000218,1969.0,
11772,14813,Plasma drug Cmax in rat (PO dose),A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623289,,BAO_0000218,1969.0,
11773,12536,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623290,,BAO_0000218,,
11774,14169,maximum Plasma concentration in Dog was determined after Peroral administration,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623291,,BAO_0000218,1969.0,
11775,14169,maximum Plasma concentration in Rats was determined after Peroral administration,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623292,,BAO_0000218,1969.0,
11776,15604,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL623293,,BAO_0000218,1969.0,
11777,15604,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623294,,BAO_0000218,1969.0,
11778,15604,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623295,,BAO_0000218,1969.0,
11779,14387,maximum concentration was measured when administered through oral route in mice,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623296,,BAO_0000218,,
11780,15115,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875349,,BAO_0000218,,
11781,15115,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623297,,BAO_0000019,,
11782,15115,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623298,,BAO_0000019,,
11783,15115,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL623299,,BAO_0000019,,
11784,16359,Pharmacokinetic parameter was evaluated in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623300,,BAO_0000218,,
11785,12829,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623301,,BAO_0000218,,
11786,12829,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623302,,BAO_0000218,,
11787,12829,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623303,,BAO_0000218,,
11788,12829,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623304,,BAO_0000218,,
11789,12829,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623305,,BAO_0000218,,
11790,15137,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623306,,BAO_0000218,1969.0,
11791,15137,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623307,,BAO_0000218,1969.0,
11792,15137,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL623308,,BAO_0000218,1969.0,
11793,15137,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,A,,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL623309,,BAO_0000218,1969.0,
11794,13509,Plasma Concentration after 120 min of oral administration to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623310,,BAO_0000218,,
11795,13509,Plasma Concentration after 30 min of oral administration to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623311,,BAO_0000218,,
11796,13509,Plasma Concentration after 60 min of oral administration to mice,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL623312,,BAO_0000218,,
11797,13509,Plasma Concentration after 60 min of oral administration to mice; Not determined,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL875350,,BAO_0000218,,
11798,13509,Plasma Concentration after 90 min of oral administration to mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628635,,BAO_0000218,,
11799,12064,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628636,,BAO_0000218,,
11800,12064,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628637,,BAO_0000218,,
11801,12064,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628058,,BAO_0000218,,
11802,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628059,,BAO_0000218,,
11803,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628060,,BAO_0000218,,
11804,8926,Distribution in the lung after 15 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628061,,BAO_0000019,,
11805,8926,Distribution in the lung after 30 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628062,,BAO_0000019,,
11806,8926,Distribution in the lung after 5 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628063,,BAO_0000019,,
11807,8926,Distribution in the lung after 60 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628064,,BAO_0000019,,
11808,8926,Distribution in the lung after 90 min of intravenous administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628065,,BAO_0000019,,
11809,8926,Distribution in the muscle after 120 min of intravenous administration,A,,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL628066,,BAO_0000019,2385.0,
11810,8926,Distribution in the muscle after 15 min of intravenous administration,A,,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL628067,,BAO_0000019,2385.0,
11811,8926,Distribution in the muscle after 30 min of intravenous administration,A,,,Mus musculus,10090.0,,Muscle tissue,,,50594,N,1,Intermediate,1,,CHEMBL874646,,BAO_0000218,2385.0,
11812,8926,Distribution in the muscle after 5 min of intravenous administration,A,,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL628068,,BAO_0000019,2385.0,
11813,8926,Distribution in the muscle after 60 min of intravenous administration,A,,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL628069,,BAO_0000019,2385.0,
11814,8926,Distribution in the muscle after 90 min of intravenous administration,A,,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL628070,,BAO_0000019,2385.0,
11815,8926,Distribution in the spleen after 120 min of intravenous administration,A,,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL628071,,BAO_0000019,2106.0,
11816,8926,Distribution in the spleen after 15 min of intravenous administration,A,,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL628072,,BAO_0000019,2106.0,
11817,8926,Distribution in the spleen after 30 min of intravenous administration,A,,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL628073,,BAO_0000019,2106.0,
11818,8926,Distribution in the spleen after 5 min of intravenous administration,A,,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL628074,,BAO_0000019,2106.0,
11819,8926,Distribution in the spleen after 60 min of intravenous administration,A,,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL628075,,BAO_0000019,2106.0,
11820,8926,Distribution in the spleen after 90 min of intravenous administration,A,,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL628076,,BAO_0000019,2106.0,
11821,7570,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Adrenal cortex,,,50597,N,1,Intermediate,1,,CHEMBL628077,,BAO_0000218,1235.0,
11822,7570,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628078,,BAO_0000218,178.0,
11823,7570,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628079,,BAO_0000218,2107.0,
11824,7570,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL628080,,BAO_0000218,992.0,
11825,7570,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL628081,,BAO_0000218,2046.0,
11826,7570,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Adrenal cortex,,,50597,N,1,Intermediate,1,,CHEMBL628082,,BAO_0000218,1235.0,
11827,7570,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL874647,,BAO_0000218,178.0,
11828,7570,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626406,,BAO_0000218,2107.0,
11829,7570,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL626407,,BAO_0000218,992.0,
11830,7570,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626408,,BAO_0000218,2046.0,
11831,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626409,,BAO_0000218,178.0,
11832,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626410,,BAO_0000218,178.0,
11833,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626411,,BAO_0000218,178.0,
11834,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626412,,BAO_0000218,178.0,
11835,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626413,,BAO_0000218,178.0,
11836,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626414,,BAO_0000218,178.0,
11837,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626415,,BAO_0000218,178.0,
11838,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626416,,BAO_0000218,178.0,
11839,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627062,,BAO_0000218,178.0,
11840,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627063,,BAO_0000218,178.0,
11841,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627064,,BAO_0000218,178.0,
11842,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627227,,BAO_0000218,178.0,
11843,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627228,,BAO_0000218,178.0,
11844,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627229,,BAO_0000218,178.0,
11845,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625792,,BAO_0000218,178.0,
11846,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625793,,BAO_0000218,178.0,
11847,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625794,,BAO_0000218,178.0,
11848,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625795,,BAO_0000218,178.0,
11849,13792,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625796,,BAO_0000218,,
11850,13376,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625797,,BAO_0000218,,
11851,13376,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625798,,BAO_0000218,,
11852,14380,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875613,,BAO_0000218,,
11853,14380,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625799,,BAO_0000218,,
11854,14380,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625800,,BAO_0000218,,
11855,14380,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625801,,BAO_0000218,,
11856,14380,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625802,,BAO_0000218,,
11857,14380,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625803,,BAO_0000218,,
11858,14380,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625804,,BAO_0000019,,
11859,14380,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622530,,BAO_0000218,,
11860,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622531,,BAO_0000218,,
11861,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622532,,BAO_0000218,,
11862,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623176,,BAO_0000218,,
11863,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623177,,BAO_0000218,,
11864,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623178,,BAO_0000218,,
11865,13701,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623179,,BAO_0000218,,
11866,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623180,,BAO_0000218,,
11867,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623181,,BAO_0000218,,
11868,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624131,,BAO_0000218,,
11869,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624132,,BAO_0000218,,
11870,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624133,,BAO_0000218,,
11871,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624846,,BAO_0000218,,
11872,13701,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624847,,BAO_0000218,,
11873,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL624848,,BAO_0000218,,
11874,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625012,,BAO_0000218,,
11875,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625013,,BAO_0000218,,
11876,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625014,,BAO_0000218,,
11877,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625015,,BAO_0000218,,
11878,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625016,,BAO_0000218,,
11879,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625017,,BAO_0000218,,
11880,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625018,,BAO_0000218,,
11881,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625019,,BAO_0000218,,
11882,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625020,,BAO_0000218,,
11883,13701,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625021,,BAO_0000218,,
11884,14393,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625022,,BAO_0000218,,
11885,14731,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625023,,BAO_0000218,,
11886,14731,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL625024,,BAO_0000218,,
11887,14731,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL627626,,BAO_0000218,,
11888,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,,,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL627627,,BAO_0000218,955.0,
11889,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,A,,,,,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL627628,,BAO_0000218,1977.0,
11890,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,,,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL627629,,BAO_0000218,955.0,
11891,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,A,,,,,,Serum,,,22224,U,0,Autocuration,1,,CHEMBL627630,,BAO_0000218,1977.0,
11892,16359,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627631,,BAO_0000019,,
11893,16359,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629515,,BAO_0000218,,
11894,15383,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL629516,,BAO_0000218,2106.0,
11895,15383,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL629517,,BAO_0000218,2106.0,
11896,15383,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL629518,,BAO_0000218,2106.0,
11897,15383,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL877499,,BAO_0000218,,
11898,15383,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629519,,BAO_0000218,,
11899,15383,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629520,,BAO_0000218,,
11900,15383,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629521,,BAO_0000218,,
11901,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629522,,BAO_0000218,,
11902,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629523,,BAO_0000218,,
11903,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629524,,BAO_0000218,,
11904,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629525,,BAO_0000218,,
11905,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629526,,BAO_0000218,,
11906,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629527,,BAO_0000218,,
11907,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629528,,BAO_0000218,,
11908,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629529,,BAO_0000218,,
11909,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629530,,BAO_0000218,,
11910,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629531,,BAO_0000218,,
11911,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628656,,BAO_0000218,,
11912,14439,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628657,,BAO_0000218,,
11913,13751,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628658,,BAO_0000218,,
11914,13751,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628659,,BAO_0000218,,
11915,13751,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877500,,BAO_0000218,,
11916,13751,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628660,,BAO_0000218,,
11917,13751,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628661,,BAO_0000218,,
11918,13751,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628662,,BAO_0000218,,
11919,13751,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628663,,BAO_0000218,,
11920,13751,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628664,,BAO_0000218,,
11921,13751,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628665,,BAO_0000218,178.0,
11922,13751,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628666,,BAO_0000218,178.0,
11923,13751,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628667,,BAO_0000218,178.0,
11924,13751,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628668,,BAO_0000218,178.0,
11925,13751,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628669,,BAO_0000218,178.0,
11926,13751,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628670,,BAO_0000218,178.0,
11927,13751,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628671,,BAO_0000218,178.0,
11928,13751,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL628672,,BAO_0000218,10000001.0,
11929,13751,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL630300,,BAO_0000218,10000001.0,
11930,13751,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL629787,,BAO_0000218,10000001.0,
11931,13751,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL629788,,BAO_0000218,10000001.0,
11932,13751,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629789,,BAO_0000218,955.0,
11933,13751,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629790,,BAO_0000218,955.0,
11934,13751,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629791,,BAO_0000218,955.0,
11935,13751,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629792,,BAO_0000218,955.0,
11936,13751,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629793,,BAO_0000218,955.0,
11937,13751,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629794,,BAO_0000218,955.0,
11938,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874459,,BAO_0000218,,
11939,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629795,,BAO_0000218,,
11940,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629796,,BAO_0000218,,
11941,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629797,,BAO_0000218,,
11942,10677,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629798,,BAO_0000218,,
11943,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Adrenal gland,,,50597,N,1,Intermediate,1,,CHEMBL629799,,BAO_0000218,2369.0,
11944,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Adrenal gland,,,50597,N,1,Intermediate,1,,CHEMBL629800,,BAO_0000218,2369.0,
11945,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Adrenal gland,,,50597,N,1,Intermediate,1,,CHEMBL629801,,BAO_0000218,2369.0,
11946,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,A,In vivo,,Rattus norvegicus,10116.0,,Adrenal gland,,,50597,N,1,Intermediate,1,,CHEMBL629802,,BAO_0000218,2369.0,
11947,10911,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Adrenal gland,,,50597,N,1,Intermediate,1,,CHEMBL629803,,BAO_0000218,2369.0,
11948,10911,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629804,,BAO_0000218,178.0,
11949,10911,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629805,,BAO_0000218,178.0,
11950,10911,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629806,,BAO_0000218,178.0,
11951,10911,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629807,,BAO_0000218,178.0,
11952,10911,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629808,,BAO_0000218,178.0,
11953,10911,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629809,,BAO_0000218,955.0,
11954,10911,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629810,,BAO_0000218,955.0,
11955,10911,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629811,,BAO_0000218,955.0,
11956,10911,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629812,,BAO_0000218,955.0,
11957,10911,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629813,,BAO_0000218,955.0,
11958,10911,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL874460,,BAO_0000218,955.0,
11959,10911,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629814,,BAO_0000218,,
11960,10911,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629815,,BAO_0000218,,
11961,10911,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629816,,BAO_0000218,,
11962,10911,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629817,,BAO_0000218,,
11963,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626643,,BAO_0000218,2113.0,
11964,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626644,,BAO_0000218,2113.0,
11965,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626806,,BAO_0000218,2113.0,
11966,10911,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626807,,BAO_0000218,2113.0,
11967,10911,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627261,,BAO_0000218,2107.0,
11968,10911,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627262,,BAO_0000218,2107.0,
11969,10911,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627263,,BAO_0000218,2107.0,
11970,10911,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627264,,BAO_0000218,2107.0,
11971,10911,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627265,,BAO_0000218,2048.0,
11972,10911,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627266,,BAO_0000218,2048.0,
11973,10911,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627267,,BAO_0000218,2048.0,
11974,10911,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627268,,BAO_0000218,2048.0,
11975,10911,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627269,,BAO_0000218,2385.0,
11976,10911,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627270,,BAO_0000218,2385.0,
11977,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627271,,BAO_0000218,,
11978,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627946,,BAO_0000218,,
11979,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875472,,BAO_0000218,,
11980,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627947,,BAO_0000218,,
11981,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627948,,BAO_0000218,,
11982,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628113,,BAO_0000218,,
11983,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628114,,BAO_0000218,,
11984,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628115,,BAO_0000218,,
11985,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628116,,BAO_0000218,,
11986,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628117,,BAO_0000218,,
11987,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628118,,BAO_0000218,,
11988,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628119,,BAO_0000218,,
11989,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628120,,BAO_0000218,,
11990,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628121,,BAO_0000218,,
11991,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628122,,BAO_0000218,,
11992,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627297,,BAO_0000218,,
11993,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627298,,BAO_0000218,,
11994,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627299,,BAO_0000218,,
11995,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627300,,BAO_0000218,,
11996,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627301,,BAO_0000218,,
11997,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627302,,BAO_0000218,,
11998,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627303,,BAO_0000218,,
11999,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627304,,BAO_0000218,,
12000,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627305,,BAO_0000218,,
12001,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627306,,BAO_0000218,,
12002,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623982,,BAO_0000218,,
12003,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623983,,BAO_0000218,,
12004,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623984,,BAO_0000218,,
12005,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623985,,BAO_0000218,,
12006,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623986,,BAO_0000218,,
12007,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623987,,BAO_0000218,,
12008,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623988,,BAO_0000218,,
12009,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623989,,BAO_0000218,,
12010,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622215,,BAO_0000218,,
12011,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622216,,BAO_0000218,,
12012,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877481,,BAO_0000218,,
12013,16359,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622217,,BAO_0000218,,
12014,13701,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622218,,BAO_0000218,,
12015,14554,Pharmacokinetic profile AUC was evaluated in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622219,,BAO_0000218,,
12016,6241,Pharmacokinetic property (Area under curve),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622220,,BAO_0000019,,
12017,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622221,,BAO_0000218,,
12018,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622222,,BAO_0000218,,
12019,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL622223,,BAO_0000218,,
12020,11537,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622224,,BAO_0000218,,
12021,13118,Plasma concentration (AUC) was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622225,,BAO_0000019,,
12022,13118,Plasma concentration (AUC) was determined; Not detectable,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622226,,BAO_0000019,,
12023,9562,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),A,,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL624154,,BAO_0000218,,
12024,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624155,,BAO_0000218,,
12025,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624156,,BAO_0000218,,
12026,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624157,,BAO_0000218,,
12027,10363,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624158,,BAO_0000218,,
12028,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624159,,BAO_0000218,,
12029,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624160,,BAO_0000218,,
12030,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624161,,BAO_0000218,,
12031,12504,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624162,,BAO_0000218,,
12032,13317,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624163,,BAO_0000218,,
12033,15078,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624164,,BAO_0000218,,
12034,14941,The AUC(0-infinity) values in female wistar rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624165,,BAO_0000218,,
12035,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624166,,BAO_0000218,,
12036,15078,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624167,,BAO_0000218,,
12037,14941,The AUC(0-t)values in female wistar rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624168,,BAO_0000218,,
12038,14067,The Area under the concentration time curve of compound was measured on rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624169,,BAO_0000218,,
12039,14215,The area under curve (100 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL624170,,BAO_0000218,,
12040,14215,The area under curve (12.5 mg/kg) administered intravenously in marmoset,A,,,Callithrix,9481.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624171,,BAO_0000218,,
12041,14215,The area under curve (12.5 mg/kg) administered intravenously in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624172,,BAO_0000218,,
12042,14215,The area under curve (15 mg/kg) administered intravenously in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624173,,BAO_0000218,,
12043,14215,The area under curve (200 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL877488,,BAO_0000218,,
12044,14215,The area under curve (25 mg/kg) administered intravenously in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624174,,BAO_0000218,,
12045,14215,The area under curve (25 mg/kg) administered orally in marmoset,A,,,Callithrix,9481.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624175,,BAO_0000218,,
12046,14215,The area under curve (25 mg/kg) administered orally in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL624176,,BAO_0000218,,
12047,14215,The area under curve (30 mg/kg) administered orally in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624177,,BAO_0000218,,
12048,14215,The area under curve (400 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL624178,,BAO_0000218,,
12049,14215,The area under curve (50 mg/kg) administered orally in fasted rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624179,,BAO_0000218,,
12050,14215,The area under curve (50 mg/kg) administered orally in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627689,,BAO_0000218,,
12051,14215,The area under curve (800 mg/kg) administered orally in humans,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL627690,,BAO_0000218,,
12052,11324,The compound was evaluated for area under the curve,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627691,,BAO_0000019,,
12053,11324,The compound was evaluated for area under the curve in marmosets,A,,,Callithrix,9481.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627692,,BAO_0000019,,
12054,11324,The compound was evaluated for area under the curve in marmosets,A,,,Callithrix,9481.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627693,,BAO_0000019,,
12055,13875,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627694,,BAO_0000218,,
12056,13875,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627695,,BAO_0000218,,
12057,13875,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627696,,BAO_0000218,,
12058,13875,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627697,,BAO_0000218,,
12059,13875,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627698,,BAO_0000218,,
12060,13875,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627699,,BAO_0000218,,
12061,13807,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627700,,BAO_0000218,,
12062,14127,Total drug exposure is determined after oral dosing in rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627701,,BAO_0000218,,
12063,15116,Total drug exposure (5 mg/kg) when administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627702,,BAO_0000218,,
12064,15116,Total drug exposure (5 mg/kg) when administered orally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627703,,BAO_0000218,,
12065,15604,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626873,,BAO_0000218,,
12066,15604,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629583,,BAO_0000218,,
12067,15604,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629584,,BAO_0000218,,
12068,15604,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629585,,BAO_0000218,,
12069,13751,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629586,,BAO_0000218,955.0,
12070,13751,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL629587,,BAO_0000218,955.0,
12071,13751,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629588,,BAO_0000218,,
12072,13751,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629589,,BAO_0000218,,
12073,13751,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629590,,BAO_0000218,,
12074,13751,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629591,,BAO_0000218,,
12075,13751,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629592,,BAO_0000218,,
12076,13751,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629593,,BAO_0000218,,
12077,13751,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629594,,BAO_0000218,,
12078,13751,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL629595,,BAO_0000218,948.0,
12079,13751,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630290,,BAO_0000218,948.0,
12080,13751,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627137,,BAO_0000218,948.0,
12081,13751,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627138,,BAO_0000218,948.0,
12082,13751,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627139,,BAO_0000218,948.0,
12083,13751,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627140,,BAO_0000218,948.0,
12084,13751,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627141,,BAO_0000218,948.0,
12085,13751,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627142,,BAO_0000218,2113.0,
12086,13751,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627143,,BAO_0000218,2113.0,
12087,13751,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL874449,,BAO_0000218,2113.0,
12088,13751,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627144,,BAO_0000218,2113.0,
12089,13751,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627145,,BAO_0000218,2113.0,
12090,13751,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627146,,BAO_0000218,2113.0,
12091,13751,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627147,,BAO_0000218,2113.0,
12092,13751,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627148,,BAO_0000218,2107.0,
12093,13751,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627149,,BAO_0000218,2048.0,
12094,13751,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL632160,,BAO_0000218,2048.0,
12095,13751,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL632161,,BAO_0000218,2048.0,
12096,13751,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL632162,,BAO_0000218,2048.0,
12097,13751,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL632163,,BAO_0000218,2048.0,
12098,13751,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL874469,,BAO_0000218,2048.0,
12099,13751,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627182,,BAO_0000218,2048.0,
12100,13751,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627183,,BAO_0000218,2385.0,
12101,13751,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627184,,BAO_0000218,2385.0,
12102,13751,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627185,,BAO_0000218,2385.0,
12103,13751,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627186,,BAO_0000218,2385.0,
12104,13751,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627187,,BAO_0000218,2385.0,
12105,13751,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627188,,BAO_0000218,2385.0,
12106,13751,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627189,,BAO_0000218,2385.0,
12107,13751,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627190,,BAO_0000218,,
12108,13751,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627191,,BAO_0000218,2107.0,
12109,13751,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627192,,BAO_0000218,2107.0,
12110,13751,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627193,,BAO_0000218,2107.0,
12111,10911,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL874590,,BAO_0000218,2385.0,
12112,10911,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627194,,BAO_0000218,2385.0,
12113,10911,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627195,,BAO_0000218,2385.0,
12114,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL627196,,BAO_0000218,992.0,
12115,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL627197,,BAO_0000218,992.0,
12116,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL627198,,BAO_0000218,992.0,
12117,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,A,In vivo,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL627199,,BAO_0000218,992.0,
12118,10911,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Female gonad,,,50597,N,1,Intermediate,1,,CHEMBL627200,,BAO_0000218,992.0,
12119,10911,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627201,,BAO_0000218,1969.0,
12120,10911,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627202,,BAO_0000218,1969.0,
12121,10911,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627203,,BAO_0000218,1969.0,
12122,10911,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627204,,BAO_0000218,1969.0,
12123,10911,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627205,,BAO_0000218,2106.0,
12124,10911,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627206,,BAO_0000218,2106.0,
12125,10911,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627207,,BAO_0000218,2106.0,
12126,10911,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627208,,BAO_0000218,2106.0,
12127,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627209,,BAO_0000218,2046.0,
12128,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627210,,BAO_0000218,2046.0,
12129,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627211,,BAO_0000218,2046.0,
12130,10911,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627212,,BAO_0000218,2046.0,
12131,10911,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL627213,,BAO_0000218,995.0,
12132,10911,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626599,,BAO_0000218,995.0,
12133,10911,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626600,,BAO_0000218,995.0,
12134,10911,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL626601,,BAO_0000218,995.0,
12135,8081,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627484,,BAO_0000019,,
12136,17248,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),A,,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL627485,,BAO_0000218,1969.0,
12137,17248,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,A,,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL628147,,BAO_0000218,1969.0,
12138,17248,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,A,,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL628148,,BAO_0000218,1969.0,
12139,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628149,,BAO_0000218,1969.0,
12140,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628150,,BAO_0000218,1969.0,
12141,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628318,,BAO_0000218,1969.0,
12142,17248,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628319,,BAO_0000218,1969.0,
12143,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875609,,BAO_0000218,,
12144,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628320,,BAO_0000019,,
12145,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628321,,BAO_0000019,,
12146,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628322,,BAO_0000019,,
12147,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628323,,BAO_0000019,,
12148,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628324,,BAO_0000019,,
12149,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628325,,BAO_0000019,,
12150,7040,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628326,,BAO_0000019,,
12151,9614,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Adrenal medulla,,,50588,N,1,Intermediate,1,,CHEMBL628327,,BAO_0000218,1236.0,
12152,9614,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Adrenal medulla,,,50588,N,1,Intermediate,1,,CHEMBL628328,,BAO_0000218,1236.0,
12153,9614,"Concentration of compound in blood of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL628329,,BAO_0000218,178.0,
12154,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628330,,BAO_0000218,2107.0,
12155,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628331,,BAO_0000218,2107.0,
12156,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628332,,BAO_0000218,2107.0,
12157,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628333,,BAO_0000218,2107.0,
12158,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628334,,BAO_0000218,2107.0,
12159,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628335,,BAO_0000218,2107.0,
12160,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628336,,BAO_0000218,2107.0,
12161,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628337,,BAO_0000218,2107.0,
12162,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628338,,BAO_0000218,2107.0,
12163,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL875610,,BAO_0000218,2107.0,
12164,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628339,,BAO_0000218,2107.0,
12165,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628340,,BAO_0000218,2107.0,
12166,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628341,,BAO_0000218,2107.0,
12167,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622214,,BAO_0000218,2107.0,
12168,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623167,,BAO_0000218,2107.0,
12169,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623168,,BAO_0000218,2107.0,
12170,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623169,,BAO_0000218,2107.0,
12171,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623170,,BAO_0000218,2107.0,
12172,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627224,,BAO_0000218,2048.0,
12173,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL875634,,BAO_0000218,2048.0,
12174,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627225,,BAO_0000218,2048.0,
12175,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627226,,BAO_0000218,2048.0,
12176,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626083,,BAO_0000218,2048.0,
12177,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626084,,BAO_0000218,2048.0,
12178,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626085,,BAO_0000218,2048.0,
12179,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626086,,BAO_0000218,2048.0,
12180,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626087,,BAO_0000218,2048.0,
12181,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626088,,BAO_0000218,2048.0,
12182,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626089,,BAO_0000218,2048.0,
12183,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626090,,BAO_0000218,2048.0,
12184,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626091,,BAO_0000218,2048.0,
12185,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626092,,BAO_0000218,2048.0,
12186,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626093,,BAO_0000218,2048.0,
12187,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626094,,BAO_0000218,2048.0,
12188,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626095,,BAO_0000218,2048.0,
12189,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL626096,,BAO_0000218,2048.0,
12190,15604,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626097,,BAO_0000218,,
12191,15604,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626098,,BAO_0000218,,
12192,1806,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626099,,BAO_0000218,1969.0,
12193,1806,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL626100,,BAO_0000218,1969.0,
12194,17237,AUC 0-inf in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626101,,BAO_0000218,1969.0,
12195,17237,AUC 0-inf in guinea pig,A,,,Cavia porcellus,10141.0,,Plasma,,,50512,N,1,Intermediate,1,,CHEMBL626102,,BAO_0000218,1969.0,
12196,17237,AUC 0-t in dog,A,,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626103,,BAO_0000218,1969.0,
12197,17237,AUC 0-t in guinea pig,A,,,Cavia porcellus,10141.0,,Plasma,,,50512,N,1,Intermediate,1,,CHEMBL628391,,BAO_0000218,1969.0,
12198,15194,The compound was tested for brain to plasma partition in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628392,,BAO_0000218,,
12199,15194,The compound was tested for brain to plasma partition in rat.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628393,,BAO_0000218,,
12200,8787,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,A,,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL628394,,BAO_0000019,178.0,
12201,17025,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628395,,BAO_0000218,,
12202,17025,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628396,,BAO_0000218,,
12203,17025,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL628397,,BAO_0000218,,
12204,17025,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628398,,BAO_0000218,,
12205,4236,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL628399,,BAO_0000218,,
12206,15343,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628400,,BAO_0000218,,
12207,15343,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874907,,BAO_0000218,,
12208,17720,Area under curve of the compound was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628401,,BAO_0000019,,
12209,17788,AUC in monkeys at a dose of 1 mg/kg,A,,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL628402,,BAO_0000218,1969.0,
12210,17788,AUC in rats at a dose of 1 mg/kg,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628403,,BAO_0000218,1969.0,
12211,8778,Compound was evaluated for the overall absorbance loss at pH of 2,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628404,,BAO_0000019,,
12212,8778,Compound was evaluated for the overall absorbance loss at pH of 4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628405,,BAO_0000019,,
12213,8778,Compound was evaluated for the overall absorbance loss at pH of 7,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628406,,BAO_0000019,,
12214,2249,Compound was evaluated for its absorption in the rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628407,,BAO_0000218,,
12215,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628408,,BAO_0000218,1088.0,
12216,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629171,,BAO_0000218,1088.0,
12217,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629172,,BAO_0000218,1088.0,
12218,8881,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629173,,BAO_0000218,1088.0,
12219,15286,In vitro percent permeability into rat ileum,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629174,,BAO_0000218,,
12220,15286,In vitro percent permeability into rat ileum; Range is 10-17,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629175,,BAO_0000218,,
12221,15286,In vitro percent permeability into rat ileum; Range is 10-18,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629176,,BAO_0000218,,
12222,15286,In vitro percent permeability into rat ileum; Range is 10-19,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629177,,BAO_0000218,,
12223,15286,In vitro percent permeability into rat ileum; Range is 12-15,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629178,,BAO_0000218,,
12224,15286,In vitro percent permeability into rat ileum; Range is 13-19,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631869,,BAO_0000218,,
12225,15286,In vitro percent permeability into rat ileum; Range is 14-17,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631870,,BAO_0000218,,
12226,15286,In vitro percent permeability into rat ileum; Range is 15-18,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631871,,BAO_0000218,,
12227,15286,In vitro percent permeability into rat ileum; Range is 2-5,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631872,,BAO_0000218,,
12228,15286,In vitro percent permeability into rat ileum; Range is 23-42,A,,,,,,Ileum,,,22224,U,0,Autocuration,1,,CHEMBL875775,,BAO_0000221,2116.0,
12229,15286,In vitro percent permeability into rat ileum; Range is 28-36,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631873,,BAO_0000218,,
12230,15286,In vitro percent permeability into rat ileum; Range is 29-35,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631874,,BAO_0000218,,
12231,15286,In vitro percent permeability into rat ileum; Range is 46-66,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631875,,BAO_0000218,,
12232,15286,In vitro percent permeability into rat ileum; Range is 50-68,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631876,,BAO_0000218,,
12233,15286,In vitro percent permeability into rat ileum; Range is 78-81,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631877,,BAO_0000218,,
12234,15286,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631878,,BAO_0000218,,
12235,15286,In vitro percent permeability into rat ileum; nd indicates not detected,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631879,,BAO_0000218,,
12236,15286,In vitro percent permeability into rat ileum; nt indicates not detected,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631880,,BAO_0000218,,
12237,15286,In vitro percent permeability into rat ileum; nt indicates not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631881,,BAO_0000218,,
12238,13770,Compound was tested for oral absorption in bile-duct cannulated rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631882,,BAO_0000218,,
12239,13770,Compound was tested for oral absorption in bile-duct cannulated rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630749,,BAO_0000218,,
12240,5202,Oral absorption using Caco-2 cell monolayers.,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL630750,,BAO_0000218,,
12241,14920,Percent of the drug absorbed after administration to humans was determined,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL630253,,BAO_0000218,,
12242,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL630254,,BAO_0000218,1969.0,
12243,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL630255,,BAO_0000218,1969.0,
12244,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL630256,,BAO_0000218,1969.0,
12245,13751,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL875781,,BAO_0000218,2107.0,
12246,13751,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL630257,,BAO_0000218,2107.0,
12247,13751,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL630258,,BAO_0000218,2107.0,
12248,15807,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630259,,BAO_0000218,,
12249,15807,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL630260,,BAO_0000218,2435.0,
12250,15807,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",A,,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL630261,,BAO_0000218,2435.0,
12251,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630262,,BAO_0000218,,
12252,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630263,,BAO_0000218,,
12253,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630264,,BAO_0000218,,
12254,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630265,,BAO_0000218,,
12255,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630266,,BAO_0000218,,
12256,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630267,,BAO_0000218,2113.0,
12257,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630268,,BAO_0000218,2113.0,
12258,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630269,,BAO_0000218,,
12259,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630270,,BAO_0000218,,
12260,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630141,,BAO_0000218,2048.0,
12261,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630142,,BAO_0000218,2048.0,
12262,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630143,,BAO_0000218,2385.0,
12263,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630144,,BAO_0000218,2385.0,
12264,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,A,,,Rattus norvegicus,10116.0,,Prostate gland,,,50597,N,1,Intermediate,1,,CHEMBL630145,,BAO_0000218,2367.0,
12265,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,A,,,Rattus norvegicus,10116.0,,Prostate gland,,,50597,N,1,Intermediate,1,,CHEMBL630146,,BAO_0000218,2367.0,
12266,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630147,,BAO_0000218,,
12267,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630148,,BAO_0000218,,
12268,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630149,,BAO_0000218,,
12269,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630150,,BAO_0000218,2106.0,
12270,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630151,,BAO_0000218,2106.0,
12271,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL632031,,BAO_0000218,2046.0,
12272,14950,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL632032,,BAO_0000218,2046.0,
12273,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632033,,BAO_0000218,,
12274,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632034,,BAO_0000218,,
12275,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL632035,,BAO_0000218,2385.0,
12276,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632036,,BAO_0000218,,
12277,14950,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL632037,,BAO_0000218,2046.0,
12278,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632038,,BAO_0000218,178.0,
12279,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632039,,BAO_0000218,178.0,
12280,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632040,,BAO_0000218,178.0,
12281,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL632041,,BAO_0000218,178.0,
12282,9614,"Concentration of compound in blood of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Blood,,,50588,N,1,Intermediate,1,,CHEMBL632042,,BAO_0000218,178.0,
12283,9614,"Concentration of compound in left ventricle of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL632043,,BAO_0000218,,
12284,9614,"Concentration of compound in left ventricle of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL632044,,BAO_0000218,,
12285,9614,"Concentration of compound in liver of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL632045,,BAO_0000218,2107.0,
12286,9614,"Concentration of compound in liver of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Liver,,,50588,N,1,Intermediate,1,,CHEMBL632046,,BAO_0000218,2107.0,
12287,9614,"Concentration of compound in lung of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL632047,,BAO_0000218,2048.0,
12288,9614,"Concentration of compound in lung of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Lung,,,50588,N,1,Intermediate,1,,CHEMBL632048,,BAO_0000218,2048.0,
12289,9614,"Concentration of compound in muscle of dog 1, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Muscle tissue,,,50588,N,1,Intermediate,1,,CHEMBL632049,,BAO_0000218,2385.0,
12290,9614,"Concentration of compound in muscle of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Muscle tissue,,,50588,N,1,Intermediate,1,,CHEMBL876418,,BAO_0000218,2385.0,
12291,9614,"Concentration of compound in spleen of dog 1,after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL632050,,BAO_0000218,2106.0,
12292,9614,"Concentration of compound in spleen of dog 2, after administering intravenously",A,,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL632051,,BAO_0000218,2106.0,
12293,10353,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632052,,BAO_0000218,,
12294,10353,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632053,,BAO_0000218,,
12295,10353,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632054,,BAO_0000218,,
12296,10353,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632055,,BAO_0000218,,
12297,10353,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631181,,BAO_0000218,,
12298,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631182,,BAO_0000218,,
12299,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631183,,BAO_0000218,,
12300,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631184,,BAO_0000218,,
12301,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629774,,BAO_0000218,,
12302,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629775,,BAO_0000218,,
12303,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL876549,,BAO_0000218,,
12304,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628172,,BAO_0000218,,
12305,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628173,,BAO_0000218,,
12306,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628174,,BAO_0000218,,
12307,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628175,,BAO_0000218,,
12308,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628176,,BAO_0000218,,
12309,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628177,,BAO_0000218,,
12310,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628178,,BAO_0000218,,
12311,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628179,,BAO_0000218,,
12312,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628180,,BAO_0000218,,
12313,9196,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628181,,BAO_0000218,,
12314,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628182,,BAO_0000218,,
12315,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628183,,BAO_0000218,,
12316,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628184,,BAO_0000218,,
12317,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628185,,BAO_0000218,,
12318,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875617,,BAO_0000218,,
12319,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628186,,BAO_0000218,,
12320,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628187,,BAO_0000218,,
12321,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628188,,BAO_0000218,,
12322,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628189,,BAO_0000218,,
12323,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628190,,BAO_0000218,,
12324,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628191,,BAO_0000218,,
12325,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626513,,BAO_0000218,,
12326,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626514,,BAO_0000218,2046.0,
12327,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626515,,BAO_0000218,2046.0,
12328,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626516,,BAO_0000218,2046.0,
12329,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626517,,BAO_0000218,2046.0,
12330,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626518,,BAO_0000218,2046.0,
12331,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626519,,BAO_0000218,2046.0,
12332,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626520,,BAO_0000218,2046.0,
12333,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626521,,BAO_0000218,2046.0,
12334,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626522,,BAO_0000218,2046.0,
12335,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626523,,BAO_0000218,2046.0,
12336,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626524,,BAO_0000218,2046.0,
12337,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626688,,BAO_0000218,2046.0,
12338,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626689,,BAO_0000218,2046.0,
12339,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626690,,BAO_0000218,2046.0,
12340,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626691,,BAO_0000218,2046.0,
12341,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL627319,,BAO_0000218,2046.0,
12342,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624052,,BAO_0000218,2046.0,
12343,8608,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL624053,,BAO_0000218,2046.0,
12344,8085,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624054,,BAO_0000218,,
12345,8085,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624055,,BAO_0000218,,
12346,8085,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624056,,BAO_0000218,,
12347,8085,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL624057,,BAO_0000218,995.0,
12348,8085,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL622281,,BAO_0000218,995.0,
12349,8085,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL622282,,BAO_0000218,995.0,
12350,8085,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL622283,,BAO_0000218,995.0,
12351,8085,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL622284,,BAO_0000218,995.0,
12352,8085,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL622285,,BAO_0000218,995.0,
12353,8085,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL622286,,BAO_0000218,995.0,
12354,7657,Distribution coefficient (D %) between octanol and buffer of pH 7.4,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622287,,BAO_0000100,,
12355,8935,Partition coefficient (logD7.4),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622288,,BAO_0000218,,
12356,13792,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622289,,BAO_0000218,,
12357,13792,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622290,,BAO_0000218,955.0,
12358,13792,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622291,,BAO_0000218,,
12359,13792,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622292,,BAO_0000218,955.0,
12360,13792,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622293,,BAO_0000218,,
12361,13792,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL622294,,BAO_0000218,955.0,
12362,13792,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL622295,,BAO_0000218,,
12363,13792,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,A,,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL622296,,BAO_0000218,955.0,
12364,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL874409,,BAO_0000218,1969.0,
12365,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622297,,BAO_0000218,1969.0,
12366,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622298,,BAO_0000218,1969.0,
12367,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622299,,BAO_0000218,1969.0,
12368,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622300,,BAO_0000218,1969.0,
12369,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622301,,BAO_0000218,1969.0,
12370,14103,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622302,,BAO_0000218,1969.0,
12371,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622303,,BAO_0000218,1969.0,
12372,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622304,,BAO_0000218,1969.0,
12373,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622305,,BAO_0000218,1969.0,
12374,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622306,,BAO_0000218,1969.0,
12375,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626864,,BAO_0000218,1969.0,
12376,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626865,,BAO_0000218,1969.0,
12377,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626866,,BAO_0000218,1969.0,
12378,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626867,,BAO_0000218,1969.0,
12379,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626868,,BAO_0000218,1969.0,
12380,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626869,,BAO_0000218,1969.0,
12381,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626870,,BAO_0000218,1969.0,
12382,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626871,,BAO_0000218,1969.0,
12383,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626872,,BAO_0000218,1969.0,
12384,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL632185,,BAO_0000218,1969.0,
12385,14103,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL632186,,BAO_0000218,1969.0,
12386,12904,Amount of acetic acid produced by the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629310,,BAO_0000019,,
12387,12904,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629311,,BAO_0000019,,
12388,9663,Log of (Cbrain/Cblood) in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629312,,BAO_0000218,,
12389,7652,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629313,,BAO_0000221,,
12390,7652,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629314,,BAO_0000221,,
12391,7652,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629315,,BAO_0000221,,
12392,7652,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629316,,BAO_0000219,,
12393,7652,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629317,,BAO_0000221,,
12394,7652,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629318,,BAO_0000019,,
12395,7652,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877497,,BAO_0000019,,
12396,7652,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629319,,BAO_0000019,,
12397,7652,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629320,,BAO_0000019,,
12398,7652,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629496,,BAO_0000019,,
12399,7652,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629497,,BAO_0000019,,
12400,7652,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629498,,BAO_0000019,,
12401,7652,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629499,,BAO_0000019,,
12402,7652,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629500,,BAO_0000019,,
12403,7652,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629501,,BAO_0000019,,
12404,7652,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629502,,BAO_0000019,,
12405,8267,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629503,,BAO_0000218,,
12406,8267,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629504,,BAO_0000218,,
12407,14479,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629505,,BAO_0000019,,
12408,17515,Compound was evaluated for total body clearance,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629506,,BAO_0000019,,
12409,17515,Compound was evaluated for volume of distribution at steady state,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629507,,BAO_0000019,,
12410,8142,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877498,,BAO_0000019,,
12411,14849,Percentage of the diamine which is monoprotonated at pH 7.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629508,,BAO_0000019,,
12412,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629509,,BAO_0000019,,
12413,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629510,,BAO_0000218,178.0,
12414,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629511,,BAO_0000218,178.0,
12415,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629512,,BAO_0000218,178.0,
12416,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629513,,BAO_0000218,178.0,
12417,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629514,,BAO_0000218,178.0,
12418,8631,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628447,,BAO_0000218,178.0,
12419,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628448,,BAO_0000218,178.0,
12420,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628449,,BAO_0000218,178.0,
12421,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631119,,BAO_0000218,178.0,
12422,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631120,,BAO_0000218,178.0,
12423,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631121,,BAO_0000218,178.0,
12424,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL874458,,BAO_0000218,178.0,
12425,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631122,,BAO_0000218,178.0,
12426,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631123,,BAO_0000218,178.0,
12427,8631,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631124,,BAO_0000218,178.0,
12428,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631125,,BAO_0000218,178.0,
12429,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631290,,BAO_0000218,178.0,
12430,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631291,,BAO_0000218,178.0,
12431,8631,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631292,,BAO_0000218,178.0,
12432,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631293,,BAO_0000218,178.0,
12433,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631294,,BAO_0000218,178.0,
12434,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631295,,BAO_0000218,178.0,
12435,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631296,,BAO_0000218,178.0,
12436,8631,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631297,,BAO_0000218,178.0,
12437,10263,Maximum biodistribution (Bmax) was determined.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631298,,BAO_0000218,,
12438,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631299,,BAO_0000218,,
12439,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631300,,BAO_0000218,,
12440,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631301,,BAO_0000218,,
12441,12364,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630291,,BAO_0000218,,
12442,14793,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630292,,BAO_0000218,,
12443,14793,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630293,,BAO_0000218,,
12444,14793,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630294,,BAO_0000218,,
12445,14793,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630295,,BAO_0000218,,
12446,14793,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630296,,BAO_0000218,,
12447,14793,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626782,,BAO_0000218,,
12448,14793,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626783,,BAO_0000218,,
12449,14793,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626784,,BAO_0000218,,
12450,14793,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626785,,BAO_0000218,,
12451,14793,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626786,,BAO_0000218,,
12452,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626787,,BAO_0000218,,
12453,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626788,,BAO_0000218,,
12454,9196,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625927,,BAO_0000218,,
12455,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625928,,BAO_0000218,178.0,
12456,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625929,,BAO_0000218,178.0,
12457,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625930,,BAO_0000218,178.0,
12458,8374,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625931,,BAO_0000218,178.0,
12459,8374,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627230,,BAO_0000218,178.0,
12460,8374,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627231,,BAO_0000218,178.0,
12461,8374,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627232,,BAO_0000218,178.0,
12462,8374,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627233,,BAO_0000218,178.0,
12463,8374,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875470,,BAO_0000218,178.0,
12464,8374,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627234,,BAO_0000218,178.0,
12465,8374,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627235,,BAO_0000218,178.0,
12466,8374,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627236,,BAO_0000218,178.0,
12467,8374,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627237,,BAO_0000218,178.0,
12468,8374,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627238,,BAO_0000218,178.0,
12469,8374,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627239,,BAO_0000218,178.0,
12470,8374,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627240,,BAO_0000218,178.0,
12471,8374,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627241,,BAO_0000218,178.0,
12472,8374,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627242,,BAO_0000218,178.0,
12473,8374,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627243,,BAO_0000218,178.0,
12474,8374,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627244,,BAO_0000218,178.0,
12475,8374,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627245,,BAO_0000218,178.0,
12476,8374,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627246,,BAO_0000218,178.0,
12477,8374,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627247,,BAO_0000218,178.0,
12478,8374,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627248,,BAO_0000218,178.0,
12479,8374,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627249,,BAO_0000218,178.0,
12480,8374,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625569,,BAO_0000218,178.0,
12481,8374,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625570,,BAO_0000218,178.0,
12482,8374,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625571,,BAO_0000218,178.0,
12483,8374,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625572,,BAO_0000218,178.0,
12484,8374,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625573,,BAO_0000218,178.0,
12485,8374,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625574,,BAO_0000218,178.0,
12486,8374,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626245,,BAO_0000218,178.0,
12487,8374,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626246,,BAO_0000218,178.0,
12488,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626247,,BAO_0000218,,
12489,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626248,,BAO_0000218,,
12490,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626249,,BAO_0000218,,
12491,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626420,,BAO_0000218,,
12492,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626421,,BAO_0000218,,
12493,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626422,,BAO_0000218,,
12494,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626423,,BAO_0000218,,
12495,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626424,,BAO_0000218,,
12496,12023,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626425,,BAO_0000218,,
12497,12023,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875476,,BAO_0000218,,
12498,12023,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL626426,,BAO_0000218,,
12499,10580,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626427,,BAO_0000100,,
12500,10580,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626428,,BAO_0000100,,
12501,16032,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626429,,BAO_0000019,,
12502,16032,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL625025,,BAO_0000019,1088.0,
12503,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625026,,BAO_0000218,178.0,
12504,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625027,,BAO_0000218,178.0,
12505,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL874410,,BAO_0000218,178.0,
12506,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625028,,BAO_0000218,178.0,
12507,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625029,,BAO_0000218,178.0,
12508,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625030,,BAO_0000218,178.0,
12509,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625031,,BAO_0000218,178.0,
12510,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625032,,BAO_0000218,178.0,
12511,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625033,,BAO_0000218,178.0,
12512,8594,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625034,,BAO_0000218,178.0,
12513,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624872,,BAO_0000218,948.0,
12514,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624873,,BAO_0000218,948.0,
12515,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624874,,BAO_0000218,948.0,
12516,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624875,,BAO_0000218,948.0,
12517,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624876,,BAO_0000218,948.0,
12518,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624877,,BAO_0000218,948.0,
12519,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624878,,BAO_0000218,948.0,
12520,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624879,,BAO_0000218,948.0,
12521,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624880,,BAO_0000218,948.0,
12522,8594,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624881,,BAO_0000218,948.0,
12523,8594,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL624882,,BAO_0000218,948.0,
12524,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624883,,BAO_0000218,2113.0,
12525,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624884,,BAO_0000218,2113.0,
12526,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624885,,BAO_0000218,2113.0,
12527,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624886,,BAO_0000218,2113.0,
12528,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624887,,BAO_0000218,2113.0,
12529,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624888,,BAO_0000218,2113.0,
12530,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624889,,BAO_0000218,2113.0,
12531,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL624890,,BAO_0000218,2113.0,
12532,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621964,,BAO_0000218,2113.0,
12533,8594,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL621965,,BAO_0000218,2113.0,
12534,8594,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621966,,BAO_0000218,2107.0,
12535,8594,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL621967,,BAO_0000218,2107.0,
12536,8594,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL622164,,BAO_0000218,2107.0,
12537,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623097,,BAO_0000019,,
12538,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623098,,BAO_0000019,,
12539,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623099,,BAO_0000019,,
12540,7653,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623100,,BAO_0000019,,
12541,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628673,,BAO_0000218,,
12542,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628674,,BAO_0000218,,
12543,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628675,,BAO_0000218,,
12544,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627644,,BAO_0000218,,
12545,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627645,,BAO_0000218,,
12546,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627646,,BAO_0000218,,
12547,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627647,,BAO_0000218,,
12548,9104,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627648,,BAO_0000218,,
12549,12902,Free level in rat plasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627649,,BAO_0000218,,
12550,6614,Level reaching in blood plasma of rat or human was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628313,,BAO_0000019,,
12551,9663,Log (Cbrain/Cblood) in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628314,,BAO_0000218,,
12552,17658,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628315,,BAO_0000019,,
12553,17658,Mean percentage of compound transport through membrane; expressed as membrane transport,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628316,,BAO_0000019,,
12554,14314,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628317,,BAO_0000218,,
12555,7385,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628473,,BAO_0000019,,
12556,7385,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628474,,BAO_0000019,,
12557,7385,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628475,,BAO_0000019,,
12558,1329,Net water uptake by a carrier mediated transport (%cm) mechanism,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628476,,BAO_0000019,,
12559,12187,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628477,,BAO_0000218,,
12560,12187,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL628478,,BAO_0000218,,
12561,12187,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL628479,,BAO_0000218,,
12562,12187,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628480,,BAO_0000218,,
12563,12187,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628481,,BAO_0000218,,
12564,12187,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628482,,BAO_0000218,,
12565,12187,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628483,,BAO_0000218,,
12566,9278,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628484,,BAO_0000218,1969.0,
12567,9278,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628485,,BAO_0000218,1969.0,
12568,9278,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",A,,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL628486,,BAO_0000218,1969.0,
12569,9278,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",A,,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL628487,,BAO_0000218,1969.0,
12570,9278,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628488,,BAO_0000218,1969.0,
12571,9278,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628489,,BAO_0000218,1969.0,
12572,9278,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628490,,BAO_0000218,1969.0,
12573,12186,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL628491,,BAO_0000218,,
12574,12186,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,A,,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL877507,,BAO_0000218,,
12575,12186,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628492,,BAO_0000218,,
12576,12041,% metabolized in monkey S-9 after 2 hours (10 ug/mL),A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628493,,BAO_0000019,,
12577,12041,% metabolized in monkey S-9 after 2 hours (1 ug/ml),A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628494,,BAO_0000019,,
12578,12041,% metabolized in monkey S-9 after 2 hours (10 ug/ml),A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL628495,,BAO_0000019,,
12579,6737,Permeability in Caco-2 assay at 10E-6,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL628496,,BAO_0000218,,
12580,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,A,,,,,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL628497,,BAO_0000218,955.0,
12581,13758,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,A,,,,,,Brain,,,22224,U,0,Autocuration,1,,CHEMBL628498,,BAO_0000218,955.0,
12582,5676,Plasma protein binding was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628499,,BAO_0000019,,
12583,14793,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627656,,BAO_0000218,,
12584,14793,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627657,,BAO_0000218,,
12585,14793,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626808,,BAO_0000218,,
12586,14793,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626809,,BAO_0000218,,
12587,14793,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626810,,BAO_0000218,,
12588,14793,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626811,,BAO_0000218,,
12589,14793,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874465,,BAO_0000218,,
12590,14793,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626812,,BAO_0000218,,
12591,14793,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626813,,BAO_0000218,,
12592,14793,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626814,,BAO_0000218,,
12593,14000,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626815,,BAO_0000019,,
12594,5948,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628566,,BAO_0000019,,
12595,13824,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL628567,,BAO_0000100,,
12596,10778,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL628568,,BAO_0000100,,
12597,17237,C max in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628569,,BAO_0000218,,
12598,17237,C max in guinea pig,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL628570,,BAO_0000218,,
12599,2809,C max value was evaluated,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628571,,BAO_0000218,,
12600,11954,Cmax value after oral dose of 0.1 mg//kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628572,,BAO_0000218,,
12601,11954,Cmax value after oral dose of 0.3 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628573,,BAO_0000218,,
12602,11954,Cmax value after oral dose of 1 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628574,,BAO_0000218,,
12603,11954,Cmax value after oral dose of 10 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628575,,BAO_0000218,,
12604,11954,Cmax value after oral dose of 23.4 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628576,,BAO_0000218,,
12605,11954,Cmax value after oral dose of 3 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628577,,BAO_0000218,,
12606,11954,Cmax value after oral dose of 3.87 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628578,,BAO_0000218,,
12607,12768,Cmax value in female Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL874466,,BAO_0000218,,
12608,12768,Cmax value in male rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628579,,BAO_0000218,,
12609,12780,Cmax value in rat plasma when administered 20 mg/kg perorally,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628580,,BAO_0000218,1969.0,
12610,15592,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628581,,BAO_0000218,1969.0,
12611,15592,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL628582,,BAO_0000218,1969.0,
12612,17025,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628583,,BAO_0000218,,
12613,17025,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625782,,BAO_0000218,,
12614,17025,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL625783,,BAO_0000218,,
12615,17025,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625784,,BAO_0000218,,
12616,4236,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,A,,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL625785,,BAO_0000218,1969.0,
12617,15791,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625786,,BAO_0000218,,
12618,11149,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874467,,BAO_0000019,,
12619,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625787,,BAO_0000218,,
12620,15778,cytotoxicity against HIV protease enzyme.,A,,,Human immunodeficiency virus,12721.0,,,,,50677,N,1,Intermediate,1,,CHEMBL625964,,BAO_0000218,,
12621,12745,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625965,,BAO_0000218,,
12622,12745,Apparent clearance in mice after oral administration of 100 mg/kg of dose,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625966,,BAO_0000218,,
12623,13941,The plasma clearance in dog.,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625967,,BAO_0000218,1969.0,
12624,13941,The plasma clearance in rat.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625968,,BAO_0000218,1969.0,
12625,16449,Clearance from plasma in male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625969,,BAO_0000218,1969.0,
12626,16449,Clearance from plasma in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,,Plasma,,,100710,N,1,Intermediate,1,,CHEMBL625970,,BAO_0000218,1969.0,
12627,14224,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625971,,BAO_0000218,1969.0,
12628,14224,Clearance of compound in dog plasma,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625972,,BAO_0000218,1969.0,
12629,14224,Clearance of compound in human plasma,A,In vivo,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL625973,,BAO_0000218,1969.0,
12630,14317,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625974,,BAO_0000218,,
12631,14317,Clearance of compound when administered intravenously as an individual dose to a single dog.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625975,,BAO_0000218,,
12632,14224,"Clearance (10 mg/kg, intravenously) in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625976,,BAO_0000218,1969.0,
12633,17237,Clearance value in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625977,,BAO_0000218,,
12634,17237,Clearance value in guinea pig,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL625978,,BAO_0000218,,
12635,14187,Clearance values in rats after iv administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874468,,BAO_0000218,,
12636,4806,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL625421,,BAO_0000218,1969.0,
12637,15025,In vivo clearance (5 mg/kg) was determined in rabbits,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL625422,,BAO_0000218,,
12638,13197,Plasma Clearance rate was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625423,,BAO_0000218,,
12639,13197,Plasma Clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Saimiri,9520.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625424,,BAO_0000218,,
12640,13960,Plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625425,,BAO_0000218,,
12641,17820,Plasma clearance of the compound,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625426,,BAO_0000218,,
12642,14706,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL625427,,BAO_0000218,,
12643,14706,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL625428,,BAO_0000218,,
12644,6504,Plasma clearance was determined,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625429,,BAO_0000218,,
12645,14925,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625430,,BAO_0000218,,
12646,13197,Plasma clearance rate was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625431,,BAO_0000218,,
12647,13197,Plasma clearance rate was determined for the compound in squirrel monkeys,A,In vivo,,Saimiri,9520.0,,,,,22224,U,0,Autocuration,1,,CHEMBL627307,,BAO_0000218,,
12648,3437,Slow clearance (CL) was determined,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627308,,BAO_0000218,,
12649,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627309,,BAO_0000218,,
12650,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627310,,BAO_0000218,,
12651,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627311,,BAO_0000218,,
12652,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627312,,BAO_0000218,,
12653,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627313,,BAO_0000218,,
12654,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627314,,BAO_0000218,,
12655,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627315,,BAO_0000218,,
12656,9196,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627316,,BAO_0000218,,
12657,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627317,,BAO_0000218,,
12658,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627318,,BAO_0000218,,
12659,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627999,,BAO_0000218,,
12660,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628000,,BAO_0000218,,
12661,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628001,,BAO_0000218,,
12662,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628002,,BAO_0000218,,
12663,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625610,,BAO_0000218,,
12664,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625611,,BAO_0000218,,
12665,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625612,,BAO_0000218,,
12666,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625613,,BAO_0000218,,
12667,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875479,,BAO_0000218,,
12668,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625614,,BAO_0000218,,
12669,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625615,,BAO_0000218,,
12670,9196,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626302,,BAO_0000218,,
12671,8374,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626303,,BAO_0000218,178.0,
12672,8374,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627420,,BAO_0000218,178.0,
12673,13477,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627421,,BAO_0000218,,
12674,13477,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625695,,BAO_0000218,,
12675,13477,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625696,,BAO_0000218,,
12676,10009,Distribution of compound in mice brain was measured after 1 hr,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL875606,,BAO_0000218,955.0,
12677,10009,Distribution of compound in mice brain was measured after 24 hr r,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625697,,BAO_0000218,955.0,
12678,10009,Distribution of compound in mice brain was measured after 2 hr,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625698,,BAO_0000218,955.0,
12679,10009,Distribution of compound in mice brain was measured after 3 hr,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625699,,BAO_0000218,955.0,
12680,10009,Distribution of compound in mice brain was measured after 6 hr,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL625700,,BAO_0000218,955.0,
12681,10009,Distribution of compound in mice liver was measured after 1 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625701,,BAO_0000218,,
12682,10009,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625702,,BAO_0000218,,
12683,10009,Distribution of compound in mice liver was measured after 2 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625703,,BAO_0000218,,
12684,10009,Distribution of compound in mice liver was measured after 3 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625704,,BAO_0000218,,
12685,10009,Distribution of compound in mice liver was measured after 6 hr,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625705,,BAO_0000218,,
12686,8170,Distribution in dog adrenal medulla 30 min after administration.,A,,,Canis lupus familiaris,9615.0,,Adrenal medulla,,,50588,N,1,Intermediate,1,,CHEMBL625706,,BAO_0000218,1236.0,
12687,8170,Distribution in dog adrenal medulla 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Adrenal medulla,,,50588,N,1,Intermediate,1,,CHEMBL625707,,BAO_0000218,1236.0,
12688,8170,Distribution in female dog Ovary 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625708,,BAO_0000218,,
12689,8170,Distribution in female dog Ovary 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625709,,BAO_0000218,,
12690,8170,Distribution in female dog adipose 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624180,,BAO_0000218,,
12691,8170,Distribution in female dog adipose 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624181,,BAO_0000218,,
12692,8170,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Adrenal cortex,,,50588,N,1,Intermediate,1,,CHEMBL624182,,BAO_0000218,1235.0,
12693,8170,Distribution in female dog adrenal cortex 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Adrenal cortex,,,50588,N,1,Intermediate,1,,CHEMBL624183,,BAO_0000218,1235.0,
12694,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624184,,BAO_0000218,2107.0,
12695,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL877489,,BAO_0000218,2107.0,
12696,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624185,,BAO_0000218,2107.0,
12697,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624186,,BAO_0000218,2107.0,
12698,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624187,,BAO_0000218,2107.0,
12699,8594,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL624188,,BAO_0000218,2107.0,
12700,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624189,,BAO_0000218,2048.0,
12701,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624190,,BAO_0000218,2048.0,
12702,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624191,,BAO_0000218,2048.0,
12703,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624192,,BAO_0000218,2048.0,
12704,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624193,,BAO_0000218,2048.0,
12705,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624194,,BAO_0000218,2048.0,
12706,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624891,,BAO_0000218,2048.0,
12707,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624892,,BAO_0000218,2048.0,
12708,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL624893,,BAO_0000218,2048.0,
12709,8594,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627632,,BAO_0000218,2048.0,
12710,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627633,,BAO_0000218,,
12711,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627634,,BAO_0000218,,
12712,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627635,,BAO_0000218,,
12713,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627636,,BAO_0000218,,
12714,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626816,,BAO_0000218,,
12715,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626817,,BAO_0000218,,
12716,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626818,,BAO_0000218,,
12717,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626819,,BAO_0000218,,
12718,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626820,,BAO_0000218,,
12719,8594,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626821,,BAO_0000218,,
12720,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626822,,BAO_0000218,2046.0,
12721,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626823,,BAO_0000218,2046.0,
12722,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626824,,BAO_0000218,2046.0,
12723,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626825,,BAO_0000218,2046.0,
12724,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626826,,BAO_0000218,2046.0,
12725,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626827,,BAO_0000218,2046.0,
12726,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626828,,BAO_0000218,2046.0,
12727,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626829,,BAO_0000218,2046.0,
12728,8594,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL626830,,BAO_0000218,2046.0,
12729,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627150,,BAO_0000218,,
12730,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627151,,BAO_0000218,,
12731,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627152,,BAO_0000218,,
12732,8594,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627153,,BAO_0000218,,
12733,12904,Rate of acetate production by the compound was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627154,,BAO_0000019,,
12734,12904,Rate of acetate production by the compound was determined; Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627155,,BAO_0000019,,
12735,3730,Rate of hydrolysis of nitrocefin by compound was evaluated in water,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627156,,BAO_0000019,,
12736,3627,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627157,,BAO_0000019,,
12737,13799,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL627158,,BAO_0000218,,
12738,13799,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,A,,,Oryctolagus cuniculus,9986.0,,Plasma,,,50592,N,1,Intermediate,1,,CHEMBL627159,,BAO_0000218,1969.0,
12739,13799,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627160,,BAO_0000218,,
12740,13799,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628540,,BAO_0000218,,
12741,13799,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628541,,BAO_0000218,1969.0,
12742,13799,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628542,,BAO_0000218,1969.0,
12743,6629,Solubility after at a pH 1.2,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL628543,,BAO_0000100,,
12744,6629,Solubility after at pH 1.2,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL628544,,BAO_0000100,,
12745,6629,Solubility after injection of water,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL628545,,BAO_0000100,,
12746,14000,Statistical significance of IC 50 values; Expressed as R value,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628546,,BAO_0000019,,
12747,8267,Systemic availability with respect to methyldopa was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874455,,BAO_0000019,,
12748,13799,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628547,,BAO_0000218,,
12749,13799,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL628548,,BAO_0000218,1969.0,
12750,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628549,,BAO_0000218,1988.0,
12751,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628550,,BAO_0000218,1988.0,
12752,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628551,,BAO_0000218,1988.0,
12753,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628552,,BAO_0000218,1088.0,
12754,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628553,,BAO_0000218,1088.0,
12755,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628554,,BAO_0000218,1088.0,
12756,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628555,,BAO_0000218,1088.0,
12757,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628556,,BAO_0000218,1088.0,
12758,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Kidney,,,50592,N,1,Intermediate,1,,CHEMBL628557,,BAO_0000218,2113.0,
12759,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628558,,BAO_0000218,1988.0,
12760,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628559,,BAO_0000218,1988.0,
12761,7132,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628560,,BAO_0000218,1988.0,
12762,7132,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL874456,,BAO_0000218,1088.0,
12763,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628561,,BAO_0000218,1988.0,
12764,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL628562,,BAO_0000218,1988.0,
12765,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628563,,BAO_0000218,1088.0,
12766,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628564,,BAO_0000218,1088.0,
12767,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL628565,,BAO_0000218,1088.0,
12768,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL631248,,BAO_0000218,1088.0,
12769,7132,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL631249,,BAO_0000218,1088.0,
12770,7132,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Kidney,,,50592,N,1,Intermediate,1,,CHEMBL627214,,BAO_0000218,2113.0,
12771,7132,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL874591,,BAO_0000218,1988.0,
12772,7132,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL627215,,BAO_0000218,1988.0,
12773,7132,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL625471,,BAO_0000218,1988.0,
12774,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL625472,,BAO_0000218,,
12775,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL625473,,BAO_0000218,,
12776,13317,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625474,,BAO_0000218,,
12777,15341,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625475,,BAO_0000218,,
12778,15341,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625476,,BAO_0000218,,
12779,15341,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625477,,BAO_0000218,,
12780,15341,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625478,,BAO_0000218,,
12781,12801,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Rattus norvegicus,10116.0,,esophageal tunica muscularis mucosae,,,50597,N,1,Intermediate,1,,CHEMBL625479,,BAO_0000218,,
12782,12801,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,A,In vitro,,Rattus norvegicus,10116.0,,esophageal tunica muscularis mucosae,,,50597,N,1,Intermediate,1,,CHEMBL625480,,BAO_0000218,,
12783,14856,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625481,,BAO_0000218,1969.0,
12784,14062,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625482,,BAO_0000218,,
12785,14062,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625483,,BAO_0000218,,
12786,14062,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625484,,BAO_0000218,,
12787,14062,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625485,,BAO_0000218,,
12788,14346,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625486,,BAO_0000218,1969.0,
12789,14346,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625487,,BAO_0000218,1969.0,
12790,14346,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625488,,BAO_0000218,1969.0,
12791,14346,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625489,,BAO_0000218,1969.0,
12792,14346,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625490,,BAO_0000218,1969.0,
12793,14346,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL625491,,BAO_0000218,1969.0,
12794,14346,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625492,,BAO_0000218,1969.0,
12795,15711,plasma clearance in human,A,In vivo,,Homo sapiens,9606.0,,Plasma,,,50587,N,1,Intermediate,1,,CHEMBL625493,,BAO_0000218,1969.0,
12796,14886,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625494,,BAO_0000218,,
12797,14886,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625495,,BAO_0000218,,
12798,14886,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625496,,BAO_0000218,,
12799,4115,1-Octanol/water partition coefficient measured at 7.4,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625497,,BAO_0000100,,
12800,13733,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625498,,BAO_0000100,,
12801,12102,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625499,,BAO_0000019,,
12802,12676,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625500,,BAO_0000100,,
12803,13733,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625501,,BAO_0000100,,
12804,13740,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625502,,BAO_0000100,,
12805,12766,Calculated partition coefficient (clogP) (relative to BAY K 8644),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625503,,BAO_0000100,,
12806,2764,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625504,,BAO_0000100,,
12807,12355,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625505,,BAO_0000100,,
12808,11314,Calculated partition coefficient of the compound,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625506,,BAO_0000100,,
12809,12706,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625507,,BAO_0000019,,
12810,12645,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625508,,BAO_0000100,,
12811,13668,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625509,,BAO_0000100,,
12812,12819,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625510,,BAO_0000100,,
12813,13668,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL883125,,BAO_0000100,,
12814,13017,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625511,,BAO_0000100,,
12815,2448,Partition coefficient of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874650,,BAO_0000019,,
12816,11526,Partition coefficient of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625512,,BAO_0000019,,
12817,12426,Partition coefficient of compound was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625513,,BAO_0000019,,
12818,2448,Partition coefficient was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625514,,BAO_0000019,,
12819,12001,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625515,,BAO_0000100,,
12820,12426,partition coefficient of compound was determined,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625516,,BAO_0000100,,
12821,13204,The total body administered intravenously in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625517,,BAO_0000218,,
12822,13204,The total body administered intravenously in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625518,,BAO_0000218,,
12823,13889,Time taken for the administration to female NIH mice weighing 25-30 g.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625519,,BAO_0000218,,
12824,13889,Time taken for the administration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625520,,BAO_0000019,,
12825,17025,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL874651,,BAO_0000218,,
12826,17025,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625521,,BAO_0000218,,
12827,17025,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL623171,,BAO_0000218,,
12828,17025,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623853,,BAO_0000218,,
12829,15067,Plasma clearance for the compound was determined.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623854,,BAO_0000019,,
12830,3091,CLog P value of the compound,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874405,,BAO_0000100,,
12831,15592,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL623855,,BAO_0000100,,
12832,14738,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL623856,,BAO_0000100,,
12833,14738,ClogP value of the compound; nd ='no data',P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623857,,BAO_0000100,,
12834,14738,ClogP value of the compound; nd ='not determined',P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623858,,BAO_0000100,,
12835,6076,CLog P was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623859,,BAO_0000100,,
12836,17840,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL839829,,BAO_0000100,,
12837,13589,CLogP was calculated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623860,,BAO_0000019,,
12838,17655,CLogP value was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623861,,BAO_0000019,,
12839,5867,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623862,,BAO_0000019,,
12840,5867,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL874406,,BAO_0000100,,
12841,10783,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL623863,,BAO_0000100,,
12842,14849,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624021,,BAO_0000100,,
12843,8170,Distribution in female dog adrenal medulla 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Adrenal medulla,,,50588,N,1,Intermediate,1,,CHEMBL624022,,BAO_0000218,1236.0,
12844,8170,Distribution in female dog adrenal medulla 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Adrenal medulla,,,50588,N,1,Intermediate,1,,CHEMBL624023,,BAO_0000218,1236.0,
12845,8170,Distribution in female dog bile 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624024,,BAO_0000218,,
12846,8170,Distribution in female dog bile 72 hr after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624025,,BAO_0000218,,
12847,8170,Distribution in female dog blood 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624026,,BAO_0000218,,
12848,8170,Distribution in female dog blood 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624027,,BAO_0000218,,
12849,8170,Distribution in female dog heart 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624028,,BAO_0000218,,
12850,8170,Distribution in female dog heart 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624029,,BAO_0000218,,
12851,8170,Distribution in female dog kidney 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624030,,BAO_0000218,,
12852,8170,Distribution in female dog kidney 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624031,,BAO_0000218,,
12853,8170,Distribution in female dog large intestine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Intestine,,,50588,N,1,Intermediate,1,,CHEMBL624032,,BAO_0000218,160.0,
12854,8170,Distribution in female dog large intestine 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Intestine,,,50588,N,1,Intermediate,1,,CHEMBL874407,,BAO_0000218,160.0,
12855,8170,Distribution in female dog liver 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624033,,BAO_0000218,,
12856,8170,Distribution in female dog liver 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624034,,BAO_0000218,,
12857,8170,Distribution in female dog lung 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624035,,BAO_0000218,,
12858,8170,Distribution in female dog lung 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624036,,BAO_0000218,,
12859,8170,Distribution in female dog muscle 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Muscle tissue,,,50588,N,1,Intermediate,1,,CHEMBL624037,,BAO_0000218,2385.0,
12860,8170,Distribution in female dog muscle 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Muscle tissue,,,50588,N,1,Intermediate,1,,CHEMBL624038,,BAO_0000218,2385.0,
12861,8170,Distribution in female dog pancreas 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624039,,BAO_0000218,,
12862,8170,Distribution in female dog pancreas 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624040,,BAO_0000218,,
12863,8170,Distribution in female dog small intestine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Intestine,,,50588,N,1,Intermediate,1,,CHEMBL624041,,BAO_0000218,160.0,
12864,8170,Distribution in female dog small intestine 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Intestine,,,50588,N,1,Intermediate,1,,CHEMBL624042,,BAO_0000218,160.0,
12865,8170,Distribution in female dog spleen 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL624043,,BAO_0000218,2106.0,
12866,8170,Distribution in female dog spleen 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Spleen,,,50588,N,1,Intermediate,1,,CHEMBL624044,,BAO_0000218,2106.0,
12867,8170,Distribution in female dog stomach 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Stomach,,,50588,N,1,Intermediate,1,,CHEMBL624045,,BAO_0000218,945.0,
12868,8170,Distribution in female dog stomach 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Stomach,,,50588,N,1,Intermediate,1,,CHEMBL624046,,BAO_0000218,945.0,
12869,8170,Distribution in female dog thyroid 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Thyroid gland,,,50588,N,1,Intermediate,1,,CHEMBL624047,,BAO_0000218,2046.0,
12870,8170,Distribution in female dog thyroid 72 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Thyroid gland,,,50588,N,1,Intermediate,1,,CHEMBL624048,,BAO_0000218,2046.0,
12871,8170,Distribution in female dog urine 24 hours after administration.,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL874408,,BAO_0000218,1088.0,
12872,8170,Distribution in female dog urine 72 hr after administration.,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL624049,,BAO_0000218,1088.0,
12873,14283,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL624050,,BAO_0000218,1969.0,
12874,5623,Plasma concentration at 7 hr after intravenous dosing,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624051,,BAO_0000019,,
12875,13477,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623278,,BAO_0000218,,
12876,13477,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623279,,BAO_0000218,,
12877,13477,Plasma concentration of 3 mg/kg iv after 1 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623280,,BAO_0000218,,
12878,13477,Plasma concentration of 3 mg/kg iv after 2 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623963,,BAO_0000218,,
12879,13477,Plasma concentration of 3 mg/kg iv after 4 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623964,,BAO_0000218,,
12880,13477,Plasma concentration of 3 mg/kg iv after 6 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623965,,BAO_0000218,,
12881,13477,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623966,,BAO_0000218,,
12882,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874415,,BAO_0000218,,
12883,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623967,,BAO_0000218,,
12884,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623968,,BAO_0000218,,
12885,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623969,,BAO_0000218,,
12886,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628409,,BAO_0000218,,
12887,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628410,,BAO_0000218,,
12888,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628411,,BAO_0000218,,
12889,13477,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628412,,BAO_0000218,,
12890,12553,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628413,,BAO_0000019,,
12891,14548,The concentration in plasmat; Not determined,A,,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL628414,,BAO_0000019,1969.0,
12892,14393,Tissue level at 10 mg/kg/po in wistar rats in blood,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628415,,BAO_0000218,,
12893,14393,Tissue level at 10 mg/kg/po in wistar rats in brown fat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628416,,BAO_0000218,,
12894,14393,Tissue level at 10 mg/kg/po in wistar rats in heart,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628417,,BAO_0000218,,
12895,14393,Tissue level at 10 mg/kg/po in wistar rats in liver,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL874908,,BAO_0000218,2107.0,
12896,14393,Tissue level at 10 mg/kg/po in wistar rats in plasma,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628418,,BAO_0000218,,
12897,14393,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL628419,,BAO_0000218,2385.0,
12898,14393,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628420,,BAO_0000218,,
12899,1629,Water solubility at 37 degree C.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628421,,BAO_0000019,,
12900,8194,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626726,,BAO_0000100,,
12901,8194,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626727,,BAO_0000100,,
12902,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626728,,BAO_0000218,178.0,
12903,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626729,,BAO_0000218,178.0,
12904,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626730,,BAO_0000218,178.0,
12905,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626731,,BAO_0000218,178.0,
12906,8594,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL626732,,BAO_0000218,178.0,
12907,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626733,,BAO_0000218,948.0,
12908,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626734,,BAO_0000218,948.0,
12909,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626735,,BAO_0000218,948.0,
12910,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL874909,,BAO_0000218,948.0,
12911,8594,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL626736,,BAO_0000218,948.0,
12912,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL626737,,BAO_0000218,2113.0,
12913,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630999,,BAO_0000218,2113.0,
12914,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL631000,,BAO_0000218,2113.0,
12915,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL631001,,BAO_0000218,2113.0,
12916,8594,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL631002,,BAO_0000218,2113.0,
12917,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631003,,BAO_0000218,2107.0,
12918,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631004,,BAO_0000218,2107.0,
12919,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631005,,BAO_0000218,2107.0,
12920,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631006,,BAO_0000218,2107.0,
12921,8594,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631007,,BAO_0000218,2107.0,
12922,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL631008,,BAO_0000218,2048.0,
12923,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL631009,,BAO_0000218,2048.0,
12924,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL631010,,BAO_0000218,2048.0,
12925,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL631011,,BAO_0000218,2048.0,
12926,8594,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL631012,,BAO_0000218,2048.0,
12927,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630271,,BAO_0000218,2046.0,
12928,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630272,,BAO_0000218,2046.0,
12929,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630273,,BAO_0000218,2046.0,
12930,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630274,,BAO_0000218,2046.0,
12931,8594,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630275,,BAO_0000218,2046.0,
12932,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875782,,BAO_0000218,,
12933,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630276,,BAO_0000218,,
12934,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630277,,BAO_0000218,,
12935,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630278,,BAO_0000218,,
12936,8594,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630279,,BAO_0000218,,
12937,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630280,,BAO_0000019,,
12938,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630281,,BAO_0000019,,
12939,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL630282,,BAO_0000218,,
12940,7132,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL630283,,BAO_0000218,,
12941,5797,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630284,,BAO_0000019,,
12942,7849,Alkylating activity was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630285,,BAO_0000019,,
12943,14220,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),A,,,,,,,,Microsomes,22224,U,0,Autocuration,1,,CHEMBL630286,,BAO_0000251,,
12944,8650,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL630069,,BAO_0000218,,
12945,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL630070,,BAO_0000218,,
12946,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL630071,,BAO_0000218,,
12947,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL630072,,BAO_0000218,,
12948,8650,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL875110,,BAO_0000218,,
12949,7116,Compound was tested for antidiuretic activity in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630073,,BAO_0000218,,
12950,14131,Compound was tested for inactivation kinetic values,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630074,,BAO_0000019,,
12951,7415,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630075,,BAO_0000218,,
12952,13178,Dissociation rate calculated from the first-order equation using the t1/2 value,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630076,,BAO_0000019,,
12953,8815,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL630077,,BAO_0000100,,
12954,1450,Aqueous solubility was measured,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL630078,,BAO_0000100,,
12955,1450,Aqueous solubility was measured at a pH 4,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL630079,,BAO_0000100,,
12956,1450,Aqueous solubility (pH 7),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL630080,,BAO_0000100,,
12957,1450,Aqueous solubility was measured at a pH 9,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL630081,,BAO_0000100,,
12958,12711,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630082,,BAO_0000019,,
12959,12711,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630083,,BAO_0000019,,
12960,12711,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630084,,BAO_0000019,,
12961,15032,Aqueous solubility of the compound,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL629198,,BAO_0000100,,
12962,9964,Aqueous solubility at 37 degree Celsius at pH 7.38,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL629199,,BAO_0000100,,
12963,14962,Aqueous solubility in pH 7.4 phosphate buffer,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL629200,,BAO_0000100,,
12964,12487,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629201,,BAO_0000218,,
12965,12487,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629202,,BAO_0000218,,
12966,10026,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL875111,,BAO_0000218,,
12967,10026,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL629203,,BAO_0000218,,
12968,10026,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL629204,,BAO_0000218,,
12969,10026,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL629205,,BAO_0000218,,
12970,10026,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL629206,,BAO_0000218,,
12971,10026,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631185,,BAO_0000019,,
12972,7415,Compound was evaluated for the average bile flow rat in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631186,,BAO_0000218,,
12973,17025,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL631187,,BAO_0000218,,
12974,17025,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",A,,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL631188,,BAO_0000218,,
12975,10184,Average half life period was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL876419,,BAO_0000019,,
12976,10184,Average half life period was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631189,,BAO_0000019,,
12977,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL631190,,BAO_0000218,,
12978,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL631191,,BAO_0000218,,
12979,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL631192,,BAO_0000218,,
12980,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL632400,,BAO_0000218,,
12981,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL630564,,BAO_0000218,,
12982,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL630565,,BAO_0000218,,
12983,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL630566,,BAO_0000218,,
12984,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL631229,,BAO_0000218,,
12985,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL631230,,BAO_0000218,,
12986,6030,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL876428,,BAO_0000100,,
12987,6147,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631231,,BAO_0000100,,
12988,14556,Calculated partition coefficient (clogP) (MacLogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631232,,BAO_0000100,,
12989,768,Hydrophilicity was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631233,,BAO_0000019,,
12990,14452,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631234,,BAO_0000100,,
12991,5237,Increased absorption was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL883126,,BAO_0000019,,
12992,14378,Lipophilicity value was evaluated,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631235,,BAO_0000100,,
12993,14418,Log P value of the compound.,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631236,,BAO_0000100,,
12994,5249,Partition coefficient of compound was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631237,,BAO_0000019,,
12995,14621,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631238,,BAO_0000100,,
12996,12542,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL876429,,BAO_0000100,,
12997,12542,Partition coefficient was measured by medchem software; Not calculated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631414,,BAO_0000019,,
12998,12542,Partition coefficient was measured by octanol-water using standard shake-flask method,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631415,,BAO_0000100,,
12999,15462,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631416,,BAO_0000100,,
13000,14884,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631417,,BAO_0000019,,
13001,16526,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631418,,BAO_0000100,,
13002,13693,The Octanol/Water partition coefficient CLogP,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631419,,BAO_0000100,,
13003,13693,The pharmacokinetic parameter C Log p was reported,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631420,,BAO_0000019,,
13004,13779,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631421,,BAO_0000100,,
13005,14772,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631422,,BAO_0000100,,
13006,14393,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL631423,,BAO_0000100,,
13007,14793,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL876430,,BAO_0000218,1969.0,
13008,14793,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL631424,,BAO_0000218,1969.0,
13009,13744,Compound was administered intravenously in dog to evaluate plasma clearance values,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL631425,,BAO_0000218,1969.0,
13010,13744,Compound was administered intravenously in monkey to evaluate plasma clearance values,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL631426,,BAO_0000218,1969.0,
13011,13744,Compound was administered intravenously in mouse to evaluate plasma clearance values,A,In vivo,,Mus musculus,10090.0,,Plasma,,,50594,N,1,Intermediate,1,,CHEMBL631427,,BAO_0000218,1969.0,
13012,13207,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL631428,,BAO_0000218,1969.0,
13013,5669,Intrinsic clearance in Rhesus liver microsome,A,In vitro,,Macaca mulatta,9544.0,,Liver,,Microsomes,50797,N,1,Intermediate,1,,CHEMBL631429,,BAO_0000218,2107.0,
13014,5669,Intrinsic clearance in dog liver microsome,A,In vitro,,Canis lupus familiaris,9615.0,,Liver,,Microsomes,50588,N,1,Intermediate,1,,CHEMBL631430,,BAO_0000218,2107.0,
13015,5669,Intrinsic clearance in rat liver microsome,A,In vitro,,Rattus norvegicus,10116.0,,Liver,,Microsomes,50597,N,1,Intermediate,1,,CHEMBL631431,,BAO_0000218,2107.0,
13016,4853,Low plasma clearance was calculated in rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,Plasma,,,50797,N,1,Intermediate,1,,CHEMBL631432,,BAO_0000218,1969.0,
13017,16452,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631433,,BAO_0000218,,
13018,11954,Plasma clearance after intravenous dose of 0.3 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631434,,BAO_0000218,,
13019,11954,Plasma clearance after intravenous dose of 1 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631435,,BAO_0000218,,
13020,11954,Plasma clearance after intravenous dose of 3 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631436,,BAO_0000218,,
13021,11954,Plasma clearance after intravenous dose of 3.87 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631437,,BAO_0000218,,
13022,5669,Plasma clearance after peroral administration at 10 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631438,,BAO_0000218,,
13023,5669,Plasma clearance after peroral administration at 10 mpk in Rhesus,A,In vivo,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL876431,,BAO_0000218,,
13024,5669,Plasma clearance after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631439,,BAO_0000218,,
13025,13662,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631440,,BAO_0000218,,
13026,8272,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631441,,BAO_0000019,,
13027,13410,Critical Micellar concentration was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631442,,BAO_0000019,,
13028,13410,Critical Micellar concentration of the compound. was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626525,,BAO_0000019,,
13029,12628,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627168,,BAO_0000019,,
13030,9675,Critical micellar concentration was measured in water by the dye solubilization method,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875618,,BAO_0000019,,
13031,12628,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626612,,BAO_0000019,,
13032,12766,CMR value (relative to BAY K 8644),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626613,,BAO_0000019,,
13033,7849,Carbamoylating activity was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626614,,BAO_0000019,,
13034,12187,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,A,,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626615,,BAO_0000218,,
13035,2040,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626616,,BAO_0000019,,
13036,2040,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626617,,BAO_0000019,,
13037,14180,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626618,,BAO_0000218,1969.0,
13038,14180,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626619,,BAO_0000218,1969.0,
13039,14474,"Clearance rate at 0.46 mg/kg, iv, in dogs",A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626620,,BAO_0000218,,
13040,14474,"Clearance rate at 5.5 mg/kg, iv, in rat",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626621,,BAO_0000218,,
13041,14548,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL626622,,BAO_0000218,,
13042,14548,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL626623,,BAO_0000218,,
13043,14548,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626624,,BAO_0000218,,
13044,14548,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626625,,BAO_0000218,,
13045,6125,Clearance rate constant using isolated perfused rat liver (IPRL) assay,A,Ex vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL626626,,BAO_0000218,2107.0,
13046,6874,Tested for the total clearance of the compound,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626627,,BAO_0000218,,
13047,15343,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626628,,BAO_0000218,,
13048,6236,Total body clearance was determined,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626629,,BAO_0000218,,
13049,11510,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626630,,BAO_0000218,,
13050,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626631,,BAO_0000218,,
13051,8194,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626632,,BAO_0000100,,
13052,8194,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626633,,BAO_0000100,,
13053,8194,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626634,,BAO_0000100,,
13054,8194,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626635,,BAO_0000100,,
13055,8194,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626636,,BAO_0000100,,
13056,8194,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626637,,BAO_0000100,,
13057,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL626638,,BAO_0000218,,
13058,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL626639,,BAO_0000218,,
13059,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL626640,,BAO_0000218,,
13060,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL626641,,BAO_0000218,,
13061,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL627272,,BAO_0000218,,
13062,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL627273,,BAO_0000218,,
13063,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL627441,,BAO_0000218,,
13064,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL628355,,BAO_0000218,,
13065,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL628356,,BAO_0000218,,
13066,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL628357,,BAO_0000218,,
13067,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL628358,,BAO_0000218,,
13068,13273,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),A,,,Pneumocystis carinii,4754.0,,,,,50339,N,1,Intermediate,1,,CHEMBL622307,,BAO_0000218,,
13069,13118,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622527,,BAO_0000019,,
13070,13118,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622528,,BAO_0000019,,
13071,13118,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622529,,BAO_0000019,,
13072,13118,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622992,,BAO_0000019,,
13073,13118,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622993,,BAO_0000019,,
13074,13118,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622994,,BAO_0000019,,
13075,10633,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622995,,BAO_0000218,,
13076,10633,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622996,,BAO_0000218,,
13077,10633,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622997,,BAO_0000218,,
13078,10633,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622998,,BAO_0000218,,
13079,5767,Cp max following ip administration at 1 mg/kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622999,,BAO_0000218,,
13080,3302,Maximum concentration in plasma was reported at 0.5 hour,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623000,,BAO_0000218,1969.0,
13081,3302,Maximum concentration in plasma was reported at 2 hour,A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL623001,,BAO_0000218,1969.0,
13082,12467,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL623002,,BAO_0000218,,
13083,11778,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL623003,,BAO_0000100,,
13084,4321,Steady state concentration was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623004,,BAO_0000019,,
13085,14884,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623005,,BAO_0000019,,
13086,15234,Partition coefficient (logD7.4),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623006,,BAO_0000019,,
13087,14198,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623007,,BAO_0000218,2107.0,
13088,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL623008,,BAO_0000218,10000001.0,
13089,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL876654,,BAO_0000218,2037.0,
13090,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623009,,BAO_0000218,,
13091,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623010,,BAO_0000218,,
13092,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623011,,BAO_0000218,948.0,
13093,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL623012,,BAO_0000218,160.0,
13094,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623013,,BAO_0000019,,
13095,8151,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623014,,BAO_0000019,,
13096,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623015,,BAO_0000019,1088.0,
13097,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL623016,,BAO_0000019,1088.0,
13098,8151,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL624858,,BAO_0000019,1088.0,
13099,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624859,,BAO_0000218,,
13100,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624860,,BAO_0000218,,
13101,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624861,,BAO_0000218,,
13102,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624862,,BAO_0000218,,
13103,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624863,,BAO_0000218,,
13104,8151,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876655,,BAO_0000218,,
13105,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624864,,BAO_0000218,,
13106,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624865,,BAO_0000218,,
13107,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624866,,BAO_0000218,,
13108,6996,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,F,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Expert,1,,CHEMBL624867,,BAO_0000218,,
13109,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL624868,,BAO_0000218,,
13110,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628450,,BAO_0000218,,
13111,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628451,,BAO_0000218,,
13112,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628452,,BAO_0000218,,
13113,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628453,,BAO_0000218,,
13114,6996,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628454,,BAO_0000218,,
13115,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628455,,BAO_0000218,,
13116,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628456,,BAO_0000218,,
13117,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628457,,BAO_0000218,,
13118,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL877505,,BAO_0000218,,
13119,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628458,,BAO_0000218,,
13120,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628459,,BAO_0000218,,
13121,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628460,,BAO_0000218,,
13122,6996,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628461,,BAO_0000218,,
13123,6996,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628462,,BAO_0000218,,
13124,6996,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628463,,BAO_0000218,,
13125,6996,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",F,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL625666,,BAO_0000218,,
13126,6996,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625667,,BAO_0000218,,
13127,6996,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Expert,1,,CHEMBL625668,,BAO_0000218,,
13128,6996,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625669,,BAO_0000218,,
13129,7114,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625670,,BAO_0000019,,
13130,7114,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625671,,BAO_0000218,,
13131,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL625672,,BAO_0000218,,
13132,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL625673,,BAO_0000218,,
13133,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL625674,,BAO_0000218,,
13134,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL625675,,BAO_0000218,,
13135,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL627637,,BAO_0000218,,
13136,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL627638,,BAO_0000218,,
13137,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL627639,,BAO_0000218,,
13138,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL627640,,BAO_0000218,,
13139,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL627641,,BAO_0000218,,
13140,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL627642,,BAO_0000218,,
13141,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL877506,,BAO_0000218,,
13142,8613,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627275,,BAO_0000218,,
13143,11219,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL627643,,BAO_0000218,,
13144,11219,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL631246,,BAO_0000218,,
13145,11219,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL631247,,BAO_0000218,,
13146,11219,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL629532,,BAO_0000218,,
13147,11219,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL629533,,BAO_0000218,,
13148,11219,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL629534,,BAO_0000218,,
13149,11219,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,A,,,Mustela putorius furo,9669.0,,,,,50506,N,1,Intermediate,1,,CHEMBL629535,,BAO_0000218,,
13150,14837,Pharmacokinetic parameter :drug bound to plasma was reported,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625932,,BAO_0000019,,
13151,14837,compound was evaluated for drug bound in plasma,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625933,,BAO_0000019,,
13152,15343,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625934,,BAO_0000218,,
13153,13761,Bioavailability,A,,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625935,,BAO_0000218,,
13154,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625936,,BAO_0000218,,
13155,14810,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625937,,BAO_0000218,,
13156,13249,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625938,,BAO_0000218,,
13157,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL625939,,BAO_0000218,1970.0,
13158,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL625940,,BAO_0000218,1970.0,
13159,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL874464,,BAO_0000218,1970.0,
13160,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL625941,,BAO_0000218,1970.0,
13161,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL625942,,BAO_0000218,1970.0,
13162,9267,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,A,,,Rattus norvegicus,10116.0,,Bile,,,50597,N,1,Intermediate,1,,CHEMBL625943,,BAO_0000218,1970.0,
13163,15549,In vitro protein binding in human serum at 5 ug/ml,A,,,Homo sapiens,9606.0,,Serum,,,50587,N,1,Intermediate,1,,CHEMBL625944,,BAO_0000218,1977.0,
13164,10929,Serum protein binding ability was measured,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625945,,BAO_0000019,,
13165,15444,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625946,,BAO_0000019,,
13166,12860,Oral bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625947,,BAO_0000218,,
13167,12170,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625948,,BAO_0000218,,
13168,15173,Absolute oral bioavailability at an iv dose of 14 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625949,,BAO_0000218,,
13169,15173,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625950,,BAO_0000218,,
13170,15173,Oral bioavailability (dose 15 mg/kg i.v.),A,In vivo,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625951,,BAO_0000218,,
13171,15173,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625952,,BAO_0000218,,
13172,15173,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625953,,BAO_0000218,,
13173,15173,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625954,,BAO_0000218,,
13174,15173,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL882959,,BAO_0000218,,
13175,11767,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625955,,BAO_0000218,,
13176,11219,Bioavailability in ferret,A,In vivo,,Mustela putorius furo,9669.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625956,,BAO_0000218,,
13177,12186,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL625957,,BAO_0000218,,
13178,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625958,,BAO_0000218,,
13179,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625959,,BAO_0000218,,
13180,11510,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626642,,BAO_0000218,,
13181,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631330,,BAO_0000218,,
13182,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631331,,BAO_0000218,,
13183,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631332,,BAO_0000218,,
13184,11510,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631333,,BAO_0000218,,
13185,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632018,,BAO_0000218,,
13186,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632019,,BAO_0000218,,
13187,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632020,,BAO_0000218,,
13188,11510,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632021,,BAO_0000218,,
13189,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632022,,BAO_0000218,,
13190,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632023,,BAO_0000218,,
13191,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632024,,BAO_0000218,,
13192,11510,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874472,,BAO_0000218,,
13193,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632025,,BAO_0000218,,
13194,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632026,,BAO_0000218,,
13195,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632027,,BAO_0000218,,
13196,11510,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632028,,BAO_0000218,,
13197,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626430,,BAO_0000218,,
13198,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626431,,BAO_0000218,,
13199,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626432,,BAO_0000218,,
13200,11510,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626433,,BAO_0000218,,
13201,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626434,,BAO_0000218,,
13202,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627280,,BAO_0000218,,
13203,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627281,,BAO_0000218,,
13204,11510,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627282,,BAO_0000218,,
13205,7199,Total body clearance was measured at given dose,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627283,,BAO_0000019,,
13206,7199,Total body clearance was measured at given dose.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627284,,BAO_0000218,,
13207,7095,Metabolic clearance from the body in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627285,,BAO_0000218,,
13208,7095,Renal clearance from the body,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627286,,BAO_0000218,,
13209,7095,Renal clearance from the body in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875477,,BAO_0000218,,
13210,12528,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627287,,BAO_0000218,,
13211,12528,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627288,,BAO_0000218,,
13212,7095,Total clearance from the body in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627289,,BAO_0000218,,
13213,14223,Clearance into cortex from rat plasma or PBS,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627290,,BAO_0000218,1969.0,
13214,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627291,,BAO_0000218,,
13215,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627292,,BAO_0000218,,
13216,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627293,,BAO_0000218,,
13217,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627294,,BAO_0000218,,
13218,13569,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875478,,BAO_0000218,,
13219,13979,Clearance was determined,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627295,,BAO_0000218,,
13220,14315,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627296,,BAO_0000218,,
13221,14315,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,A,In vivo,,Oryctolagus cuniculus,9986.0,,,,,50592,N,1,Intermediate,1,,CHEMBL626119,,BAO_0000218,,
13222,14315,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626120,,BAO_0000218,,
13223,12174,Clearance in rat after iv dose (100 ug/kg),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626121,,BAO_0000218,,
13224,12797,Clearance in guinea pig,A,In vivo,,Cavia porcellus,10141.0,,,,,22224,U,0,Autocuration,1,,CHEMBL626122,,BAO_0000218,,
13225,12797,Compound was evaluated for clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626123,,BAO_0000218,,
13226,12797,Compound was evaluated for the clearance in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL623456,,BAO_0000218,,
13227,12797,Compound was evaluated for the clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623457,,BAO_0000218,,
13228,11500,Compound was tested in vivo for clearance after iv administration in the rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623458,,BAO_0000218,,
13229,15173,IV clearance determined at an iv dose of 14 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623459,,BAO_0000218,,
13230,15173,IV clearance determined at an iv dose of 15.2 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875484,,BAO_0000218,,
13231,15173,IV clearance determined at an iv dose of 15 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623460,,BAO_0000218,,
13232,15173,IV clearance determined at an peroral dose of 30 mg/kg.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623461,,BAO_0000218,,
13233,15173,IV clearance determined at an peroral dose of 30.2 mg/kg.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623462,,BAO_0000218,,
13234,15173,IV clearance determined at an peroral dose of 30.3 mg/kg.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627386,,BAO_0000218,,
13235,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627387,,BAO_0000218,2113.0,
13236,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627388,,BAO_0000218,2107.0,
13237,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627389,,BAO_0000218,2048.0,
13238,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627390,,BAO_0000218,2385.0,
13239,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627391,,BAO_0000218,1969.0,
13240,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627392,,BAO_0000218,,
13241,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL627393,,BAO_0000218,2106.0,
13242,14198,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Trachea,,,50597,N,1,Intermediate,1,,CHEMBL627394,,BAO_0000218,3126.0,
13243,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627395,,BAO_0000218,10000001.0,
13244,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL875485,,BAO_0000218,2037.0,
13245,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627396,,BAO_0000218,,
13246,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627397,,BAO_0000218,,
13247,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL627398,,BAO_0000218,948.0,
13248,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL627399,,BAO_0000218,10000001.0,
13249,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627400,,BAO_0000218,2113.0,
13250,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627401,,BAO_0000218,2107.0,
13251,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627402,,BAO_0000218,2048.0,
13252,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL627403,,BAO_0000218,2385.0,
13253,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL627404,,BAO_0000218,1969.0,
13254,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623101,,BAO_0000218,,
13255,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL877480,,BAO_0000218,2106.0,
13256,14198,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Trachea,,,50597,N,1,Intermediate,1,,CHEMBL623102,,BAO_0000218,3126.0,
13257,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL623103,,BAO_0000218,10000001.0,
13258,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL623104,,BAO_0000218,2037.0,
13259,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623105,,BAO_0000218,,
13260,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623106,,BAO_0000218,,
13261,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL623107,,BAO_0000218,948.0,
13262,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL623108,,BAO_0000218,160.0,
13263,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL623109,,BAO_0000218,2113.0,
13264,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL623110,,BAO_0000218,2107.0,
13265,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL623111,,BAO_0000218,2048.0,
13266,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625060,,BAO_0000218,2385.0,
13267,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625061,,BAO_0000218,1969.0,
13268,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625062,,BAO_0000218,,
13269,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625063,,BAO_0000218,2106.0,
13270,14198,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Trachea,,,50597,N,1,Intermediate,1,,CHEMBL625064,,BAO_0000218,3126.0,
13271,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Bone,,,50597,N,1,Intermediate,1,,CHEMBL625065,,BAO_0000218,10000001.0,
13272,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL625066,,BAO_0000218,2037.0,
13273,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625067,,BAO_0000218,,
13274,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625068,,BAO_0000218,,
13275,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL622159,,BAO_0000218,948.0,
13276,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Intestine,,,50597,N,1,Intermediate,1,,CHEMBL622160,,BAO_0000218,160.0,
13277,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL622161,,BAO_0000218,2113.0,
13278,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL622162,,BAO_0000218,2048.0,
13279,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL622163,,BAO_0000218,2385.0,
13280,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622313,,BAO_0000218,1969.0,
13281,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622314,,BAO_0000218,,
13282,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622315,,BAO_0000218,2106.0,
13283,14198,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,A,In vivo,,Rattus norvegicus,10116.0,,Trachea,,,50597,N,1,Intermediate,1,,CHEMBL622316,,BAO_0000218,3126.0,
13284,15599,Normal diffusion coefficient in water for Escherichia coli,A,,,Escherichia coli,562.0,,,,,50212,N,1,Intermediate,1,,CHEMBL877486,,BAO_0000218,,
13285,8204,Average max percent decrease in RVR (renal vascular resistance) was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622317,,BAO_0000019,,
13286,8204,Average max percent decrease in RVR (renal vascular resistance) was determined.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622318,,BAO_0000019,,
13287,6154,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622319,,BAO_0000019,,
13288,6154,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622320,,BAO_0000019,,
13289,6154,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622321,,BAO_0000019,,
13290,6154,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622322,,BAO_0000019,,
13291,7114,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622323,,BAO_0000019,,
13292,7114,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622324,,BAO_0000218,,
13293,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622325,,BAO_0000218,1088.0,
13294,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622326,,BAO_0000218,1088.0,
13295,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL877487,,BAO_0000218,1088.0,
13296,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622327,,BAO_0000218,1088.0,
13297,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622328,,BAO_0000218,1088.0,
13298,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622329,,BAO_0000218,1088.0,
13299,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622330,,BAO_0000218,1088.0,
13300,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622331,,BAO_0000218,1088.0,
13301,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622332,,BAO_0000218,1088.0,
13302,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622333,,BAO_0000218,1088.0,
13303,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL627658,,BAO_0000218,1088.0,
13304,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630428,,BAO_0000218,1088.0,
13305,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630429,,BAO_0000218,1088.0,
13306,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630430,,BAO_0000218,1088.0,
13307,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630431,,BAO_0000218,1088.0,
13308,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL630432,,BAO_0000218,1088.0,
13309,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL630433,,BAO_0000218,1088.0,
13310,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL630434,,BAO_0000218,1088.0,
13311,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629372,,BAO_0000218,1088.0,
13312,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629553,,BAO_0000218,1088.0,
13313,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629554,,BAO_0000218,1088.0,
13314,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL874447,,BAO_0000218,1088.0,
13315,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629555,,BAO_0000218,1088.0,
13316,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629556,,BAO_0000218,1088.0,
13317,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629557,,BAO_0000218,1088.0,
13318,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629558,,BAO_0000218,1088.0,
13319,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629559,,BAO_0000218,1088.0,
13320,8133,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629560,,BAO_0000218,1088.0,
13321,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629561,,BAO_0000218,1088.0,
13322,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629562,,BAO_0000218,1088.0,
13323,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629563,,BAO_0000218,1088.0,
13324,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629564,,BAO_0000218,1088.0,
13325,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629565,,BAO_0000218,1088.0,
13326,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629566,,BAO_0000218,1088.0,
13327,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629567,,BAO_0000218,1088.0,
13328,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629568,,BAO_0000218,1088.0,
13329,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629569,,BAO_0000218,1088.0,
13330,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL629570,,BAO_0000218,1088.0,
13331,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL629571,,BAO_0000218,1088.0,
13332,12170,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629572,,BAO_0000218,,
13333,12170,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629573,,BAO_0000218,,
13334,4985,Bioavailability (dose 20 mg/kg),A,In vivo,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629574,,BAO_0000218,,
13335,15145,Bioavailability in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629575,,BAO_0000218,,
13336,14080,Bioavailability in rat (Sprague-Dawley) (male),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL874448,,BAO_0000218,,
13337,11219,Bioavailability in monkey (dose 10 mg/kg i.d.),A,In vivo,,Primates,9443.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629576,,BAO_0000218,,
13338,15145,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629577,,BAO_0000218,,
13339,15145,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629578,,BAO_0000218,,
13340,1202,Bioavailability in dog (dose 3.0 mg/kg p.o.),A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629579,,BAO_0000218,,
13341,1202,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL882958,,BAO_0000218,,
13342,1202,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,A,In vivo,,Pan troglodytes,9598.0,,,,,50505,N,1,Intermediate,1,,CHEMBL629580,,BAO_0000218,,
13343,4026,Bioavailability,A,In vivo,,Eutheria,9347.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629581,,BAO_0000218,,
13344,1492,Bioavailability in squirrel monkey,A,In vivo,,Saimiri,9520.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629582,,BAO_0000218,,
13345,12793,Bioavailability was evaluated in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628522,,BAO_0000218,,
13346,12793,Bioavailability was evaluated in hamster,A,In vivo,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL625432,,BAO_0000218,,
13347,12793,Bioavailability in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625433,,BAO_0000218,,
13348,14793,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625434,,BAO_0000218,1969.0,
13349,14793,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL625435,,BAO_0000218,1969.0,
13350,14793,Bioavailability in rat (dose 10 mg/kg p.o.),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625436,,BAO_0000218,,
13351,14731,Bioavailability was measured in cynomolgus monkeys.,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL874588,,BAO_0000218,,
13352,14731,Bioavailability was measured in nude mice.,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625437,,BAO_0000218,,
13353,12187,Bioavailability in ferret (dose 10 mg/kg i.d.),A,In vivo,,Mustela putorius furo,9669.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625438,,BAO_0000218,,
13354,12187,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625439,,BAO_0000218,,
13355,12187,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625440,,BAO_0000218,,
13356,12187,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),A,In vivo,,Simiiformes,314293.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625441,,BAO_0000218,,
13357,12187,Bioavailability in rat (dose 10 mg/kg i.d.),A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625442,,BAO_0000218,,
13358,12187,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625443,,BAO_0000218,,
13359,17431,Bioavailability was determined; extremely poor,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625444,,BAO_0000218,,
13360,13318,% bioavailability in mice after oral administration of prodrug,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625445,,BAO_0000218,,
13361,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625446,,BAO_0000218,,
13362,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL882960,,BAO_0000218,,
13363,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625447,,BAO_0000218,,
13364,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625448,,BAO_0000218,,
13365,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625449,,BAO_0000218,,
13366,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL874589,,BAO_0000218,,
13367,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625450,,BAO_0000218,,
13368,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625451,,BAO_0000218,,
13369,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626584,,BAO_0000218,,
13370,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626585,,BAO_0000218,,
13371,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626586,,BAO_0000218,,
13372,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626587,,BAO_0000218,,
13373,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626588,,BAO_0000218,,
13374,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626589,,BAO_0000218,,
13375,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626590,,BAO_0000218,,
13376,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626591,,BAO_0000218,,
13377,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL627181,,BAO_0000218,,
13378,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628083,,BAO_0000218,,
13379,15173,IV clearance determined at an peroral dose of 15 mg/kg.,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628084,,BAO_0000218,,
13380,7732,Mouse oral clearance was measured against Hymenolepiasis nana.,F,In vivo,,Hymenolepis nana,102285.0,,,,,50064,N,1,Expert,1,,CHEMBL628085,,BAO_0000218,,
13381,7732,Mouse oral clearance was measured against Nematospiroides dubius,F,In vivo,,Heligmosomoides polygyrus,6339.0,,,,,50545,N,1,Expert,1,,CHEMBL628086,,BAO_0000218,,
13382,7732,Mouse oral clearance was measured against N. dubius; NT is Not Tested,F,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628087,,BAO_0000218,,
13383,7732,Mouse oral clearance was measured against N. nana; NT is Not Tested,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628088,,BAO_0000218,,
13384,7732,Mouse oral clearance was measured against N. nana; NT is Not Tested,B,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628089,,BAO_0000218,,
13385,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628090,,BAO_0000218,,
13386,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628091,,BAO_0000218,,
13387,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628092,,BAO_0000218,,
13388,8328,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628093,,BAO_0000218,,
13389,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875607,,BAO_0000218,,
13390,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625710,,BAO_0000218,,
13391,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625711,,BAO_0000218,,
13392,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625712,,BAO_0000218,,
13393,8328,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625713,,BAO_0000218,,
13394,13376,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625714,,BAO_0000218,,
13395,13477,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,A,In vivo,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL625715,,BAO_0000218,,
13396,13477,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625716,,BAO_0000218,,
13397,13477,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625717,,BAO_0000218,,
13398,13313,Plasma clearance was determined for the compound in rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625718,,BAO_0000218,,
13399,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625719,,BAO_0000218,,
13400,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625720,,BAO_0000218,,
13401,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625721,,BAO_0000218,,
13402,12504,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625722,,BAO_0000218,,
13403,13129,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625723,,BAO_0000218,,
13404,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,,,,,50545,N,1,Intermediate,1,,CHEMBL625724,,BAO_0000218,,
13405,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,,,,,50545,N,1,Intermediate,1,,CHEMBL625725,,BAO_0000218,,
13406,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,,,,,50545,N,1,Intermediate,1,,CHEMBL625726,,BAO_0000218,,
13407,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,,,,,50545,N,1,Intermediate,1,,CHEMBL875608,,BAO_0000218,,
13408,7732,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,A,In vivo,,Heligmosomoides polygyrus,6339.0,,,,,50545,N,1,Intermediate,1,,CHEMBL625727,,BAO_0000218,,
13409,9278,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Rattus norvegicus,10116.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL625728,,BAO_0000218,1088.0,
13410,9278,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625729,,BAO_0000218,,
13411,9278,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL625730,,BAO_0000218,,
13412,9278,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,A,In vivo,,Rattus norvegicus,10116.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL625731,,BAO_0000218,1088.0,
13413,9278,Urinary clearance was determined in rat at 25 mg/kg os dosage,A,In vivo,,Rattus norvegicus,10116.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL626417,,BAO_0000218,1088.0,
13414,9278,Urinary clearance was determined at 100 mg/kg oral dosage in human,A,In vivo,,Homo sapiens,9606.0,,Urine,,,50587,N,1,Intermediate,1,,CHEMBL626418,,BAO_0000218,1088.0,
13415,9278,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,A,In vivo,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL626419,,BAO_0000218,1088.0,
13416,5932,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626592,,BAO_0000218,1969.0,
13417,5932,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626593,,BAO_0000218,1969.0,
13418,5182,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626594,,BAO_0000218,,
13419,10499,Clearance rate in dogs,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625035,,BAO_0000218,,
13420,6051,Compound was measured for intrinsic clearance,A,In vitro,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625036,,BAO_0000019,,
13421,17508,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625037,,BAO_0000100,,
13422,6228,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625038,,BAO_0000100,,
13423,6231,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625039,,BAO_0000100,,
13424,17740,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625040,,BAO_0000100,,
13425,6495,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625041,,BAO_0000100,,
13426,2171,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625042,,BAO_0000100,,
13427,3255,Partition coefficient of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874411,,BAO_0000019,,
13428,6821,Permeability,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625043,,BAO_0000019,,
13429,2685,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625044,,BAO_0000100,,
13430,17584,Partition coefficient (logD),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625045,,BAO_0000019,,
13431,13824,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625046,,BAO_0000100,,
13432,13824,Calculated partition coefficient (clogP) (CLOGP3 V3.4),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625047,,BAO_0000100,,
13433,16479,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625048,,BAO_0000100,,
13434,11997,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625049,,BAO_0000100,,
13435,2988,Calculated logarithm of partition coefficient (P) was determined,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625050,,BAO_0000100,,
13436,931,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625051,,BAO_0000100,,
13437,4381,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL874412,,BAO_0000100,,
13438,4397,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625052,,BAO_0000100,,
13439,5889,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL625053,,BAO_0000100,,
13440,6154,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623250,,BAO_0000019,,
13441,6154,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623251,,BAO_0000019,,
13442,6154,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623252,,BAO_0000019,,
13443,6154,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623253,,BAO_0000019,,
13444,6154,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623254,,BAO_0000019,,
13445,6154,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623255,,BAO_0000019,,
13446,6887,Percent degradation of compound at a pH of 1 over a 18 hr period,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626831,,BAO_0000019,,
13447,6887,Percent degradation of compound at pH of 1 over an 18 hr period,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877494,,BAO_0000019,,
13448,14116,Delta Logarithm of Partition Coefficient value was determined.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626832,,BAO_0000019,,
13449,11137,Delta logPoct-cyc,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626833,,BAO_0000019,,
13450,7230,Lipophilicity estimated on reversed phase TLC,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626834,,BAO_0000100,,
13451,15741,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626835,,BAO_0000019,,
13452,9663,Delta logPoct-cyc,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626836,,BAO_0000019,,
13453,9663,Change in logarithm of partition coefficient of the compound,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626837,,BAO_0000100,,
13454,13807,Delta logD (pH 6.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626838,,BAO_0000019,,
13455,13807,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626839,,BAO_0000100,,
13456,17425,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626840,,BAO_0000019,,
13457,12143,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626841,,BAO_0000019,,
13458,12608,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626842,,BAO_0000219,,
13459,12608,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626843,,BAO_0000219,,
13460,8649,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626844,,BAO_0000218,,
13461,8649,Amount of deuterium retained was reported after normal workup in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL877495,,BAO_0000218,,
13462,8649,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626845,,BAO_0000218,,
13463,8649,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626846,,BAO_0000218,,
13464,8649,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626847,,BAO_0000218,,
13465,8649,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628677,,BAO_0000218,,
13466,8649,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628678,,BAO_0000218,,
13467,9659,Compound was subjected to electrochemical oxidation,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628679,,BAO_0000019,,
13468,9659,Compound was subjected to photochemical oxidation,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628680,,BAO_0000019,,
13469,9659,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628681,,BAO_0000019,,
13470,9659,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628682,,BAO_0000019,,
13471,9659,Oxidation of compound by methemoglobin in presence of hydroperoxide,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628683,,BAO_0000019,,
13472,9607,Percent diffusion through fuzzy rat skin after 48 h of incubation,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628684,,BAO_0000218,,
13473,7057,Dissociation constant (pKa),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL877501,,BAO_0000100,,
13474,7057,Dissociation constant value of the compound; ND means not determined.,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628685,,BAO_0000100,,
13475,7911,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628686,,BAO_0000218,178.0,
13476,7911,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL628687,,BAO_0000218,178.0,
13477,7911,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628688,,BAO_0000218,,
13478,7911,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628689,,BAO_0000218,,
13479,7911,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628690,,BAO_0000218,2107.0,
13480,7911,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL629363,,BAO_0000218,2107.0,
13481,7911,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL629364,,BAO_0000218,2106.0,
13482,7911,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL629365,,BAO_0000218,2106.0,
13483,7911,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629366,,BAO_0000218,,
13484,7911,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629367,,BAO_0000218,1088.0,
13485,7911,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL629368,,BAO_0000218,1988.0,
13486,7911,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL877502,,BAO_0000218,1088.0,
13487,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,A,,,Mus musculus,10090.0,,Cerebellum,,,50594,N,1,Intermediate,1,,CHEMBL629369,,BAO_0000218,2037.0,
13488,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL629370,,BAO_0000218,955.0,
13489,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL629371,,BAO_0000218,1088.0,
13490,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL626276,,BAO_0000218,1088.0,
13491,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL626277,,BAO_0000218,1088.0,
13492,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL631250,,BAO_0000218,1088.0,
13493,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631251,,BAO_0000218,1088.0,
13494,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631252,,BAO_0000218,1088.0,
13495,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631253,,BAO_0000218,1088.0,
13496,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631254,,BAO_0000218,1088.0,
13497,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631255,,BAO_0000218,1088.0,
13498,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631256,,BAO_0000218,1088.0,
13499,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631257,,BAO_0000218,1088.0,
13500,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628009,,BAO_0000218,1088.0,
13501,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628010,,BAO_0000218,1088.0,
13502,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628011,,BAO_0000218,1088.0,
13503,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628012,,BAO_0000218,1088.0,
13504,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628013,,BAO_0000218,1088.0,
13505,8133,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628014,,BAO_0000218,1088.0,
13506,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628015,,BAO_0000218,1088.0,
13507,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628016,,BAO_0000218,1088.0,
13508,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL874461,,BAO_0000218,1088.0,
13509,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628017,,BAO_0000218,1088.0,
13510,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628018,,BAO_0000218,1088.0,
13511,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628019,,BAO_0000218,1088.0,
13512,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628020,,BAO_0000218,1088.0,
13513,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628021,,BAO_0000218,1088.0,
13514,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628022,,BAO_0000218,1088.0,
13515,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL628023,,BAO_0000218,1088.0,
13516,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL628024,,BAO_0000218,1088.0,
13517,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL628025,,BAO_0000218,1088.0,
13518,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL628026,,BAO_0000218,1088.0,
13519,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL628027,,BAO_0000218,1088.0,
13520,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",A,,,Simiiformes,314293.0,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL628028,,BAO_0000218,1088.0,
13521,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628029,,BAO_0000218,1088.0,
13522,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628030,,BAO_0000218,1088.0,
13523,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628031,,BAO_0000218,1088.0,
13524,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628032,,BAO_0000218,1088.0,
13525,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628033,,BAO_0000218,1088.0,
13526,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628034,,BAO_0000218,1088.0,
13527,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628035,,BAO_0000218,1088.0,
13528,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628036,,BAO_0000218,1088.0,
13529,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL874462,,BAO_0000218,1088.0,
13530,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628037,,BAO_0000218,,
13531,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628123,,BAO_0000218,,
13532,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628124,,BAO_0000218,,
13533,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628125,,BAO_0000218,,
13534,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628126,,BAO_0000218,,
13535,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628127,,BAO_0000218,,
13536,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628128,,BAO_0000218,,
13537,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628129,,BAO_0000218,,
13538,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628130,,BAO_0000218,,
13539,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628131,,BAO_0000218,,
13540,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628132,,BAO_0000218,,
13541,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628133,,BAO_0000218,,
13542,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628134,,BAO_0000218,,
13543,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628135,,BAO_0000218,,
13544,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628136,,BAO_0000218,,
13545,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628137,,BAO_0000218,,
13546,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628138,,BAO_0000218,,
13547,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628139,,BAO_0000218,,
13548,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628140,,BAO_0000218,,
13549,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628141,,BAO_0000218,,
13550,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628142,,BAO_0000218,,
13551,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628143,,BAO_0000218,,
13552,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628144,,BAO_0000218,,
13553,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628145,,BAO_0000218,,
13554,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL628146,,BAO_0000218,,
13555,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625355,,BAO_0000218,,
13556,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625356,,BAO_0000218,,
13557,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625357,,BAO_0000218,,
13558,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625527,,BAO_0000218,,
13559,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL875473,,BAO_0000218,,
13560,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL625528,,BAO_0000218,,
13561,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626304,,BAO_0000218,,
13562,9025,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,A,In vivo,,Canis lupus familiaris,9615.0,,Artery,,,50588,N,1,Intermediate,1,,CHEMBL624138,,BAO_0000218,1637.0,
13563,6448,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624139,,BAO_0000100,,
13564,17221,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624140,,BAO_0000100,,
13565,6545,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624141,,BAO_0000100,,
13566,577,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624142,,BAO_0000100,,
13567,6285,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624143,,BAO_0000100,,
13568,6500,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624144,,BAO_0000100,,
13569,6716,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624145,,BAO_0000100,,
13570,13658,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624146,,BAO_0000100,,
13571,6549,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624147,,BAO_0000100,,
13572,14685,Calculated partition coefficient (clogP) (MacLogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL883123,,BAO_0000100,,
13573,6893,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624148,,BAO_0000019,,
13574,3687,Kinetic parameter was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874416,,BAO_0000019,,
13575,4207,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624149,,BAO_0000100,,
13576,4626,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624150,,BAO_0000100,,
13577,1021,Lipophilicity was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624151,,BAO_0000100,,
13578,3777,Lipophilicity was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624152,,BAO_0000100,,
13579,17533,Lipophilicity was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622139,,BAO_0000100,,
13580,6524,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622140,,BAO_0000100,,
13581,17533,Lipophilicity was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622141,,BAO_0000100,,
13582,6480,Lipophilicity in octanol-water,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622142,,BAO_0000100,,
13583,17606,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622143,,BAO_0000100,,
13584,6863,Octanol-water partition coefficient was determined,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622144,,BAO_0000100,,
13585,1356,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877473,,BAO_0000019,,
13586,3326,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622145,,BAO_0000100,,
13587,1356,Partition coefficient was determined; ND means not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622146,,BAO_0000019,,
13588,12984,Calculated partition coefficient (clogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622147,,BAO_0000100,,
13589,17363,Partition coefficient of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622148,,BAO_0000019,,
13590,6827,Permeability was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL883124,,BAO_0000019,,
13591,261,The compound was evaluated for the partition coefficient,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622149,,BAO_0000100,,
13592,2685,Partition coefficient (logP),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622150,,BAO_0000019,,
13593,414,The lipophilicity was reported,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622151,,BAO_0000100,,
13594,15769,logarithm of the octanol-water partition coefficient for the compound,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL622152,,BAO_0000100,,
13595,17248,Clogp value was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622153,,BAO_0000019,,
13596,16935,Clp at a dose of 1.5 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877474,,BAO_0000218,,
13597,16935,Clp at a dose of 2.0 mg/kg,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622154,,BAO_0000218,,
13598,14832,"Clp, plasma clearance at a dose of 10 mg/kg",A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622155,,BAO_0000218,1969.0,
13599,14832,"Clp, plasma clearance at a dose of 50 mg/kg",A,In vivo,,,,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622156,,BAO_0000218,1969.0,
13600,2399,Compound was tested for plasma clearance in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622157,,BAO_0000218,1969.0,
13601,2399,Compound was tested for plasma clearance in rat; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622158,,BAO_0000218,1969.0,
13602,6227,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622807,,BAO_0000218,,
13603,6227,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,A,In vivo,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL622808,,BAO_0000218,,
13604,5623,Plasma clearance by iv administration at a dose 0.003 ug/mL,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622809,,BAO_0000218,,
13605,4854,Plasma clearance determined,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622810,,BAO_0000218,,
13606,4493,Plasma clearance after iv administration at 3 mg/kg in hamster,A,In vivo,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL876653,,BAO_0000218,,
13607,4493,Plasma clearance after iv administration at 4 mg/kg in hamster,A,In vivo,,Cricetinae,10026.0,,,,,100712,N,1,Intermediate,1,,CHEMBL622811,,BAO_0000218,,
13608,14956,Rate of clearance in rat was determined,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622986,,BAO_0000218,,
13609,15372,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622987,,BAO_0000218,1969.0,
13610,15372,Total plasma clearance after iv dose of 5.10 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622988,,BAO_0000218,1969.0,
13611,15372,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622989,,BAO_0000218,1969.0,
13612,15372,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622990,,BAO_0000218,1969.0,
13613,15604,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,A,In vivo,,Simiiformes,314293.0,,Plasma,,,22224,U,0,Autocuration,1,,CHEMBL622991,,BAO_0000218,1969.0,
13614,15604,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,A,In vivo,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL622227,,BAO_0000218,1969.0,
13615,15604,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL622228,,BAO_0000218,1969.0,
13616,14964,Clpl value in rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622229,,BAO_0000218,,
13617,15240,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,A,In vivo,,Cavia porcellus,10141.0,,,,,50512,N,1,Intermediate,1,,CHEMBL622230,,BAO_0000218,,
13618,16449,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL622231,,BAO_0000218,,
13619,16449,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,,,,,100710,N,1,Intermediate,1,,CHEMBL622232,,BAO_0000218,,
13620,12902,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622233,,BAO_0000218,,
13621,12902,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622234,,BAO_0000218,,
13622,12902,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622235,,BAO_0000218,,
13623,12902,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622236,,BAO_0000218,,
13624,12902,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622237,,BAO_0000218,,
13625,12902,Cmax in minutes at a po dose of 10.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877482,,BAO_0000218,,
13626,12902,Cmax in minutes at a po dose of 20.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622238,,BAO_0000218,,
13627,12902,Cmax in minutes at a po dose of 40.0(pmol/g/h).,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL622239,,BAO_0000218,,
13628,11149,Cmax was calculated as maximum concentration reached in the blood,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL622240,,BAO_0000218,178.0,
13629,11149,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL622241,,BAO_0000218,178.0,
13630,5669,Cmax was determine after peroral administration at 10 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631013,,BAO_0000218,,
13631,5669,Cmax was determine after peroral administration at 10 mpk in Rhesus,A,In vivo,,Macaca mulatta,9544.0,,,,,50797,N,1,Intermediate,1,,CHEMBL631014,,BAO_0000218,,
13632,5669,Cmax was determine after peroral administration at 10 mpk in dog,A,In vivo,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631015,,BAO_0000218,,
13633,5669,Cmax was determine after peroral administration at 160 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631016,,BAO_0000218,,
13634,5669,Cmax was determine after peroral administration at 20 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631017,,BAO_0000218,,
13635,5669,Cmax was determine after peroral administration at 50 mpk in Rat,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631018,,BAO_0000218,,
13636,4236,Cmax was determined,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631019,,BAO_0000218,,
13637,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL875761,,BAO_0000218,955.0,
13638,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL631020,,BAO_0000218,955.0,
13639,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL631669,,BAO_0000218,955.0,
13640,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL631670,,BAO_0000218,955.0,
13641,13792,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,A,,,Mus musculus,10090.0,,Striatum,,,50594,N,1,Intermediate,1,,CHEMBL631671,,BAO_0000218,2435.0,
13642,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631672,,BAO_0000218,178.0,
13643,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631673,,BAO_0000218,178.0,
13644,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631856,,BAO_0000218,178.0,
13645,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631857,,BAO_0000218,178.0,
13646,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631858,,BAO_0000218,178.0,
13647,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631859,,BAO_0000218,178.0,
13648,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631860,,BAO_0000218,178.0,
13649,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631861,,BAO_0000218,178.0,
13650,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631862,,BAO_0000218,178.0,
13651,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631863,,BAO_0000218,178.0,
13652,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631864,,BAO_0000218,178.0,
13653,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631865,,BAO_0000218,178.0,
13654,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631866,,BAO_0000218,178.0,
13655,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629360,,BAO_0000218,178.0,
13656,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629361,,BAO_0000218,178.0,
13657,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL629362,,BAO_0000218,178.0,
13658,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630740,,BAO_0000218,178.0,
13659,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630741,,BAO_0000218,178.0,
13660,8418,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,A,,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630742,,BAO_0000218,178.0,
13661,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630743,,BAO_0000218,,
13662,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630744,,BAO_0000218,,
13663,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630745,,BAO_0000218,,
13664,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630746,,BAO_0000218,,
13665,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630747,,BAO_0000218,,
13666,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630748,,BAO_0000218,,
13667,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632056,,BAO_0000218,,
13668,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632057,,BAO_0000218,,
13669,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632058,,BAO_0000218,,
13670,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632059,,BAO_0000218,,
13671,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632060,,BAO_0000218,,
13672,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632061,,BAO_0000218,,
13673,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629207,,BAO_0000218,,
13674,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629208,,BAO_0000218,,
13675,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629209,,BAO_0000218,,
13676,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629210,,BAO_0000218,,
13677,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629211,,BAO_0000218,,
13678,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629212,,BAO_0000218,,
13679,8418,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629213,,BAO_0000218,,
13680,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629214,,BAO_0000218,1088.0,
13681,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629215,,BAO_0000218,1088.0,
13682,8133,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL635154,,BAO_0000218,1088.0,
13683,6996,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629216,,BAO_0000218,,
13684,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629217,,BAO_0000218,,
13685,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629218,,BAO_0000218,,
13686,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629219,,BAO_0000218,,
13687,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629220,,BAO_0000218,,
13688,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629221,,BAO_0000218,,
13689,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631127,,BAO_0000218,,
13690,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631128,,BAO_0000218,,
13691,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631129,,BAO_0000218,,
13692,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631130,,BAO_0000218,,
13693,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631131,,BAO_0000218,,
13694,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631132,,BAO_0000218,,
13695,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631133,,BAO_0000218,,
13696,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631134,,BAO_0000218,,
13697,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875120,,BAO_0000218,,
13698,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631135,,BAO_0000218,,
13699,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631136,,BAO_0000218,,
13700,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631137,,BAO_0000218,,
13701,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631138,,BAO_0000218,,
13702,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631139,,BAO_0000218,,
13703,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631140,,BAO_0000218,,
13704,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631141,,BAO_0000218,,
13705,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631142,,BAO_0000218,,
13706,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631143,,BAO_0000218,,
13707,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631144,,BAO_0000218,,
13708,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631145,,BAO_0000218,,
13709,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631146,,BAO_0000218,,
13710,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631147,,BAO_0000218,,
13711,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631148,,BAO_0000218,,
13712,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631149,,BAO_0000218,,
13713,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631150,,BAO_0000218,,
13714,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631151,,BAO_0000218,,
13715,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631152,,BAO_0000218,,
13716,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631443,,BAO_0000218,,
13717,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631444,,BAO_0000218,,
13718,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631445,,BAO_0000218,,
13719,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631446,,BAO_0000218,,
13720,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631447,,BAO_0000218,,
13721,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631448,,BAO_0000218,,
13722,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631449,,BAO_0000218,,
13723,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL631450,,BAO_0000218,,
13724,6996,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629724,,BAO_0000218,,
13725,9716,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL629725,,BAO_0000218,14.0,
13726,9716,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Zone of skin,,,50594,N,1,Intermediate,1,,CHEMBL629726,,BAO_0000218,14.0,
13727,9716,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL629727,,BAO_0000218,2106.0,
13728,9716,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL630404,,BAO_0000218,2106.0,
13729,9716,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL630405,,BAO_0000218,2106.0,
13730,9716,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL630406,,BAO_0000218,2106.0,
13731,9716,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL630407,,BAO_0000218,945.0,
13732,9716,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL630573,,BAO_0000218,945.0,
13733,9716,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL630574,,BAO_0000218,945.0,
13734,9716,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL630575,,BAO_0000218,945.0,
13735,9716,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630576,,BAO_0000218,,
13736,9716,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630577,,BAO_0000218,,
13737,9716,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630578,,BAO_0000218,,
13738,9716,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630579,,BAO_0000218,,
13739,12192,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL630580,,BAO_0000218,2113.0,
13740,12192,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL630581,,BAO_0000218,2113.0,
13741,12192,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),A,,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL630582,,BAO_0000218,2113.0,
13742,12192,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630583,,BAO_0000218,,
13743,12192,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630584,,BAO_0000218,,
13744,12192,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630585,,BAO_0000218,,
13745,12192,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630586,,BAO_0000218,,
13746,12192,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630587,,BAO_0000218,,
13747,12192,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630588,,BAO_0000218,,
13748,12192,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630589,,BAO_0000218,,
13749,12192,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL630590,,BAO_0000218,,
13750,12192,Removal of 238-Plutonium(IV) in feces at 24 h,A,,,,,,Feces,,,22224,U,0,Autocuration,1,,CHEMBL630591,,BAO_0000019,1988.0,
13751,12192,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),A,,,,,,Feces,,,22224,U,0,Autocuration,1,,CHEMBL630592,,BAO_0000019,1988.0,
13752,12192,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630593,,BAO_0000019,,
13753,12192,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630594,,BAO_0000019,,
13754,12192,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630595,,BAO_0000019,1088.0,
13755,12192,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630596,,BAO_0000019,1088.0,
13756,12192,Removal of 238-Plutonium(IV) in urine after 0-24 h,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630597,,BAO_0000019,1088.0,
13757,12192,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630598,,BAO_0000019,1088.0,
13758,12192,Removal of 238-Plutonium(IV) in urine after 0-4 h,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630599,,BAO_0000019,1088.0,
13759,12192,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630600,,BAO_0000019,1088.0,
13760,12192,Removal of 238-Plutonium(IV) in urine after 4-24 h,A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630601,,BAO_0000019,1088.0,
13761,12192,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630602,,BAO_0000019,1088.0,
13762,12192,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630603,,BAO_0000019,1088.0,
13763,12192,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),A,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL630604,,BAO_0000019,1088.0,
13764,12017,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624869,,BAO_0000218,178.0,
13765,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL624870,,BAO_0000218,178.0,
13766,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623189,,BAO_0000218,178.0,
13767,12017,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623190,,BAO_0000218,178.0,
13768,12017,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623191,,BAO_0000218,178.0,
13769,12017,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623192,,BAO_0000218,,
13770,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623193,,BAO_0000218,,
13771,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623194,,BAO_0000218,,
13772,12017,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623195,,BAO_0000218,,
13773,12017,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623196,,BAO_0000218,,
13774,11836,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623197,,BAO_0000218,,
13775,11836,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623198,,BAO_0000218,,
13776,11836,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623199,,BAO_0000218,,
13777,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623200,,BAO_0000218,2385.0,
13778,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623201,,BAO_0000218,2385.0,
13779,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623202,,BAO_0000218,2385.0,
13780,11836,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623203,,BAO_0000218,2385.0,
13781,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623204,,BAO_0000218,2385.0,
13782,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623205,,BAO_0000218,2385.0,
13783,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623206,,BAO_0000218,2385.0,
13784,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623207,,BAO_0000218,2385.0,
13785,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623208,,BAO_0000218,2385.0,
13786,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623209,,BAO_0000218,2385.0,
13787,11836,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL623210,,BAO_0000218,2385.0,
13788,11836,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623211,,BAO_0000218,,
13789,11836,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,A,,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL623212,,BAO_0000218,995.0,
13790,12640,Tested in vitro for intrinsic activity relative to quinpirole,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623213,,BAO_0000019,,
13791,14218,"Relative ion enhancement, determined in pulsed ultrafiltration",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623214,,BAO_0000019,,
13792,11296,% ionization at the pH 7.4 at 37 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623215,,BAO_0000019,,
13793,10929,Percentage ionization was measured,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623216,,BAO_0000019,,
13794,13841,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,A,,,Bos taurus,9913.0,,,,,50591,N,1,Intermediate,1,,CHEMBL623217,,BAO_0000218,,
13795,10431,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623218,,BAO_0000019,,
13796,10431,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623913,,BAO_0000019,,
13797,10431,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL623914,,BAO_0000019,,
13798,8826,Compound was evaluated for the partition coefficient in octanol/water,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL623915,,BAO_0000100,,
13799,8826,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL624080,,BAO_0000100,,
13800,9884,Equilibrium constant measured by the pulse radiolysis at pH 7,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL624081,,BAO_0000019,,
13801,9827,In vitro hydrolytic rate constant determined in human blood,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL624082,,BAO_0000218,,
13802,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL625054,,BAO_0000218,,
13803,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL877485,,BAO_0000019,,
13804,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625055,,BAO_0000218,,
13805,10009,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625056,,BAO_0000218,,
13806,10009,In vitro oxidation of compound in presence of human plasma,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL625057,,BAO_0000218,,
13807,10009,In vitro oxidation of compound in presence of hydrogen peroxide,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625058,,BAO_0000019,,
13808,10009,In vitro oxidation of compound in presence of mouse brain homogenate,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625059,,BAO_0000218,,
13809,10009,In vitro oxidation of compound in presence of mouse liver homogenate,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629536,,BAO_0000218,,
13810,11510,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629537,,BAO_0000218,,
13811,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629538,,BAO_0000218,,
13812,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629539,,BAO_0000218,,
13813,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL874445,,BAO_0000218,,
13814,11510,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629540,,BAO_0000218,,
13815,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629541,,BAO_0000218,,
13816,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629542,,BAO_0000218,,
13817,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630243,,BAO_0000218,,
13818,11510,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630244,,BAO_0000218,,
13819,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630245,,BAO_0000218,,
13820,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630246,,BAO_0000218,,
13821,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630247,,BAO_0000218,,
13822,11510,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630248,,BAO_0000218,,
13823,13100,Biodistribution in rat blood at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630249,,BAO_0000218,178.0,
13824,13100,Biodistribution in rat blood at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630250,,BAO_0000218,178.0,
13825,13100,Biodistribution in rat blood at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630251,,BAO_0000218,178.0,
13826,13100,Biodistribution in rat blood at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630252,,BAO_0000218,178.0,
13827,13100,Biodistribution in rat blood at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL630408,,BAO_0000218,178.0,
13828,13100,Biodistribution in rat cerebellum at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630409,,BAO_0000218,2037.0,
13829,13100,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL874446,,BAO_0000218,2037.0,
13830,13100,Biodistribution in rat cerebellum at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630410,,BAO_0000218,2037.0,
13831,13100,Biodistribution in rat cerebellum at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630411,,BAO_0000218,2037.0,
13832,13100,Biodistribution in rat cerebellum at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630412,,BAO_0000218,2037.0,
13833,13100,Biodistribution in rat cerebellum at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630413,,BAO_0000218,2037.0,
13834,13100,Biodistribution in rat cerebellum at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630414,,BAO_0000218,2037.0,
13835,13100,Biodistribution in rat cerebellum at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL630415,,BAO_0000218,2037.0,
13836,13100,Biodistribution in rat cortex at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630416,,BAO_0000218,,
13837,13100,Biodistribution in rat cortex at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630417,,BAO_0000218,,
13838,13100,Biodistribution in rat cortex at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630418,,BAO_0000218,,
13839,13100,Biodistribution in rat cortex at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630419,,BAO_0000218,,
13840,13100,Biodistribution in rat cortex at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630420,,BAO_0000218,,
13841,13100,Biodistribution in rat cortex at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630421,,BAO_0000218,,
13842,13100,Biodistribution in rat cortex at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630422,,BAO_0000218,,
13843,13100,Biodistribution in rat cortex at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630423,,BAO_0000218,,
13844,13100,Biodistribution in rat heart at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630424,,BAO_0000218,948.0,
13845,13100,Biodistribution in rat heart at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630425,,BAO_0000218,948.0,
13846,13100,Biodistribution in rat heart at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL629462,,BAO_0000218,948.0,
13847,13100,Biodistribution in rat heart at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630426,,BAO_0000218,948.0,
13848,13100,Biodistribution in rat heart at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL630427,,BAO_0000218,948.0,
13849,13100,Biodistribution in rat heart at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625877,,BAO_0000218,948.0,
13850,13100,Biodistribution in rat heart at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625878,,BAO_0000218,948.0,
13851,13100,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625879,,BAO_0000218,10000000.0,
13852,13100,Biodistribution in rat hippocampus at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625880,,BAO_0000218,10000000.0,
13853,13100,Biodistribution in rat hippocampus at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625881,,BAO_0000218,10000000.0,
13854,13100,Biodistribution in rat hippocampus at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625882,,BAO_0000218,10000000.0,
13855,13100,Biodistribution in rat hippocampus at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625883,,BAO_0000218,10000000.0,
13856,13100,Biodistribution in rat kidney at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625884,,BAO_0000218,2113.0,
13857,13100,Biodistribution in rat kidney at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625885,,BAO_0000218,2113.0,
13858,13100,Biodistribution in rat kidney at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628649,,BAO_0000218,2113.0,
13859,13100,Biodistribution in rat kidney at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628650,,BAO_0000218,2113.0,
13860,13100,Biodistribution in rat kidney at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628651,,BAO_0000218,2113.0,
13861,13100,Biodistribution in rat kidney at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628652,,BAO_0000218,2113.0,
13862,13100,Biodistribution in rat kidney at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL628653,,BAO_0000218,2113.0,
13863,13100,Biodistribution in rat liver at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628654,,BAO_0000218,2107.0,
13864,13100,Biodistribution in rat liver at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL628655,,BAO_0000218,2107.0,
13865,13100,Biodistribution in rat liver at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625238,,BAO_0000218,2107.0,
13866,13100,Biodistribution in rat liver at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625239,,BAO_0000218,2107.0,
13867,13100,Biodistribution in rat liver at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625240,,BAO_0000218,2107.0,
13868,13100,Biodistribution in rat liver at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625241,,BAO_0000218,2107.0,
13869,13100,Biodistribution in rat liver at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625242,,BAO_0000218,2107.0,
13870,13100,Biodistribution in rat lung at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL874587,,BAO_0000218,2048.0,
13871,13100,Biodistribution in rat lung at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625405,,BAO_0000218,2048.0,
13872,13100,Biodistribution in rat lung at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625406,,BAO_0000218,2048.0,
13873,13100,Biodistribution in rat lung at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625407,,BAO_0000218,2048.0,
13874,13100,Biodistribution in rat lung at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625408,,BAO_0000218,2048.0,
13875,13100,Biodistribution in rat lung at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625409,,BAO_0000218,2048.0,
13876,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625410,,BAO_0000218,1515.0,
13877,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625411,,BAO_0000218,1515.0,
13878,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625412,,BAO_0000218,1515.0,
13879,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625413,,BAO_0000218,1515.0,
13880,12361,Percent of maximal contractile response to compound in rat thoracic aorta strips v,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625414,,BAO_0000218,1515.0,
13881,12361,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625415,,BAO_0000218,1515.0,
13882,12361,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,A,,,Rattus norvegicus,10116.0,,Thoracic aorta,,,50597,N,1,Intermediate,1,,CHEMBL625416,,BAO_0000218,1515.0,
13883,12712,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625417,,BAO_0000218,1088.0,
13884,7415,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL625418,,BAO_0000218,1988.0,
13885,7415,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625419,,BAO_0000218,1088.0,
13886,7415,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625420,,BAO_0000218,,
13887,7415,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626996,,BAO_0000218,,
13888,7415,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL626997,,BAO_0000218,1988.0,
13889,7415,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626998,,BAO_0000218,1088.0,
13890,7415,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626999,,BAO_0000218,,
13891,8050,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627000,,BAO_0000218,,
13892,8050,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627001,,BAO_0000218,,
13893,8050,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627002,,BAO_0000218,,
13894,8050,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627003,,BAO_0000218,,
13895,8050,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627004,,BAO_0000218,1088.0,
13896,8050,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627005,,BAO_0000218,1088.0,
13897,8050,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL874594,,BAO_0000218,1088.0,
13898,8050,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627006,,BAO_0000218,1088.0,
13899,8050,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627007,,BAO_0000218,1088.0,
13900,8050,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627884,,BAO_0000218,1088.0,
13901,8050,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627885,,BAO_0000218,1088.0,
13902,8050,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627886,,BAO_0000218,1088.0,
13903,8050,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627887,,BAO_0000218,1088.0,
13904,8050,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627888,,BAO_0000218,1088.0,
13905,8050,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL628057,,BAO_0000218,1088.0,
13906,8050,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627405,,BAO_0000218,1088.0,
13907,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627406,,BAO_0000218,1088.0,
13908,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627407,,BAO_0000218,1088.0,
13909,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627408,,BAO_0000218,1088.0,
13910,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627409,,BAO_0000218,1088.0,
13911,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL875486,,BAO_0000218,1088.0,
13912,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627410,,BAO_0000218,1088.0,
13913,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627411,,BAO_0000218,1088.0,
13914,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627412,,BAO_0000218,1088.0,
13915,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627413,,BAO_0000218,1088.0,
13916,12582,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627414,,BAO_0000218,1088.0,
13917,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627415,,BAO_0000218,1088.0,
13918,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627416,,BAO_0000218,1088.0,
13919,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627417,,BAO_0000218,1088.0,
13920,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627418,,BAO_0000218,1088.0,
13921,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627419,,BAO_0000218,1088.0,
13922,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627320,,BAO_0000218,1088.0,
13923,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627321,,BAO_0000218,1088.0,
13924,12017,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627322,,BAO_0000218,2113.0,
13925,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627323,,BAO_0000218,2113.0,
13926,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627491,,BAO_0000218,2113.0,
13927,12017,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627492,,BAO_0000218,2113.0,
13928,12017,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL627493,,BAO_0000218,2113.0,
13929,12017,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627494,,BAO_0000218,2107.0,
13930,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627495,,BAO_0000218,2107.0,
13931,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627496,,BAO_0000218,2107.0,
13932,12017,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627497,,BAO_0000218,2107.0,
13933,12017,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL627498,,BAO_0000218,2107.0,
13934,12017,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627499,,BAO_0000218,2048.0,
13935,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627500,,BAO_0000218,2048.0,
13936,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627501,,BAO_0000218,2048.0,
13937,12017,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625616,,BAO_0000218,2048.0,
13938,12017,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625617,,BAO_0000218,2048.0,
13939,12017,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625618,,BAO_0000218,2385.0,
13940,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625619,,BAO_0000218,2385.0,
13941,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625620,,BAO_0000218,2385.0,
13942,12017,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625621,,BAO_0000218,2385.0,
13943,12017,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625622,,BAO_0000218,2385.0,
13944,12017,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625788,,BAO_0000218,2106.0,
13945,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625789,,BAO_0000218,2106.0,
13946,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625790,,BAO_0000218,2106.0,
13947,12017,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625791,,BAO_0000218,2106.0,
13948,12017,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL622334,,BAO_0000218,2106.0,
13949,12017,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622335,,BAO_0000218,2046.0,
13950,12017,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622336,,BAO_0000218,2046.0,
13951,12017,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622337,,BAO_0000218,2046.0,
13952,12017,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622338,,BAO_0000218,2046.0,
13953,12017,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL622339,,BAO_0000218,2046.0,
13954,12017,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL624153,,BAO_0000218,,
13955,12017,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628430,,BAO_0000218,,
13956,12017,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628431,,BAO_0000218,,
13957,12017,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628432,,BAO_0000218,,
13958,12017,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628433,,BAO_0000218,,
13959,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL628434,,BAO_0000218,2106.0,
13960,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL626789,,BAO_0000218,2106.0,
13961,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL626790,,BAO_0000218,2106.0,
13962,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL626791,,BAO_0000218,2106.0,
13963,12017,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL626792,,BAO_0000218,2106.0,
13964,12017,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL626793,,BAO_0000218,2106.0,
13965,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627436,,BAO_0000218,,
13966,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627437,,BAO_0000218,,
13967,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627438,,BAO_0000218,,
13968,11510,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627439,,BAO_0000218,,
13969,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627440,,BAO_0000218,,
13970,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627602,,BAO_0000218,,
13971,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627603,,BAO_0000218,,
13972,11510,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627604,,BAO_0000218,,
13973,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627605,,BAO_0000218,,
13974,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627606,,BAO_0000218,,
13975,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627607,,BAO_0000218,,
13976,11510,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627608,,BAO_0000218,,
13977,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627609,,BAO_0000218,,
13978,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627610,,BAO_0000218,,
13979,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627611,,BAO_0000218,,
13980,11510,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627612,,BAO_0000218,,
13981,8362,Octanol:water partition coefficient is evaluated,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL627613,,BAO_0000100,,
13982,8257,Partition coefficient in 1-octanol/water system,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627614,,BAO_0000100,,
13983,8257,Partition coefficient in 1-octanol/water system measured using radio active compounds,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627615,,BAO_0000100,,
13984,9468,Partition coefficient in octanol/water system was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627616,,BAO_0000100,,
13985,9468,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627617,,BAO_0000100,,
13986,10568,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627618,,BAO_0000019,,
13987,10568,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627619,,BAO_0000019,,
13988,15359,Pseudo-first-order rate constant of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627620,,BAO_0000019,,
13989,15359,Pseudo-first-order rate constant with 1-min time point,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627621,,BAO_0000019,,
13990,15359,Pseudo-first-order rate constant without 1-min time point,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627622,,BAO_0000019,,
13991,10431,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627623,,BAO_0000019,,
13992,10431,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627624,,BAO_0000019,,
13993,10431,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627625,,BAO_0000019,,
13994,15704,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628523,,BAO_0000019,,
13995,15287,The alkaline hydrolysis second order rate constant(K OH) of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628524,,BAO_0000019,,
13996,7516,The efflux rate constant of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628525,,BAO_0000019,,
13997,12973,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625732,,BAO_0000019,,
13998,12973,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625733,,BAO_0000019,,
13999,12973,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625734,,BAO_0000019,,
14000,12973,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625913,,BAO_0000019,,
14001,8696,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625914,,BAO_0000019,,
14002,15052,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625915,,BAO_0000019,,
14003,15052,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625916,,BAO_0000019,,
14004,10503,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625917,,BAO_0000019,,
14005,8354,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625918,,BAO_0000019,,
14006,8354,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625919,,BAO_0000019,,
14007,8354,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625920,,BAO_0000019,,
14008,8354,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874453,,BAO_0000019,,
14009,8354,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625921,,BAO_0000019,,
14010,10503,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625922,,BAO_0000019,,
14011,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625923,,BAO_0000019,,
14012,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625924,,BAO_0000019,,
14013,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625925,,BAO_0000019,,
14014,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625926,,BAO_0000019,,
14015,13100,Biodistribution in rat lung at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL627704,,BAO_0000218,2048.0,
14016,13100,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627705,,BAO_0000218,,
14017,13100,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627706,,BAO_0000218,,
14018,13100,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627707,,BAO_0000218,,
14019,13100,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627708,,BAO_0000218,,
14020,13100,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628361,,BAO_0000218,,
14021,13100,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628362,,BAO_0000218,,
14022,13100,Biodistribution in rat striatum at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628363,,BAO_0000218,2435.0,
14023,13100,Biodistribution in rat striatum at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628364,,BAO_0000218,2435.0,
14024,13100,Biodistribution in rat striatum at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628365,,BAO_0000218,2435.0,
14025,13100,Biodistribution in rat striatum at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL874454,,BAO_0000218,2435.0,
14026,13100,Biodistribution in rat striatum at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628531,,BAO_0000218,2435.0,
14027,13100,Biodistribution in rat striatum at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628532,,BAO_0000218,2435.0,
14028,13100,Biodistribution in rat striatum at 3 hr after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628533,,BAO_0000218,2435.0,
14029,13100,Biodistribution in rat striatum at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Striatum,,,50597,N,1,Intermediate,1,,CHEMBL628534,,BAO_0000218,2435.0,
14030,13100,Biodistribution in rat thyroid at 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL628535,,BAO_0000218,2046.0,
14031,13100,Biodistribution in rat thyroid at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL628536,,BAO_0000218,2046.0,
14032,13100,Biodistribution in rat thyroid at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL628537,,BAO_0000218,2046.0,
14033,13100,Biodistribution in rat thyroid at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL628538,,BAO_0000218,2046.0,
14034,13100,Biodistribution in rat thyroid at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL628539,,BAO_0000218,2046.0,
14035,13100,Biodistribution in rat thyroid at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630297,,BAO_0000218,2046.0,
14036,13100,Biodistribution in rat thyroid at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL630298,,BAO_0000218,2046.0,
14037,13100,Biodistribution in rest of brain of rat 120 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL630299,,BAO_0000218,955.0,
14038,13100,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL628094,,BAO_0000218,955.0,
14039,13100,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL628095,,BAO_0000218,955.0,
14040,13100,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL874648,,BAO_0000218,955.0,
14041,13100,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL628096,,BAO_0000218,955.0,
14042,13100,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL628097,,BAO_0000218,955.0,
14043,13100,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL628098,,BAO_0000218,955.0,
14044,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628099,,BAO_0000019,,
14045,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628100,,BAO_0000019,,
14046,13331,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628101,,BAO_0000019,,
14047,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628102,,BAO_0000019,,
14048,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628103,,BAO_0000019,,
14049,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628104,,BAO_0000019,,
14050,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628105,,BAO_0000019,,
14051,13331,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628106,,BAO_0000019,,
14052,10086,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628107,,BAO_0000218,1088.0,
14053,10086,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,F,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL628108,,BAO_0000218,1088.0,
14054,10086,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628109,,BAO_0000218,1088.0,
14055,10086,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,F,,,,,,Urine,,,22224,U,0,Autocuration,1,,CHEMBL625299,,BAO_0000218,1088.0,
14056,10086,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625300,,BAO_0000218,1088.0,
14057,10086,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625301,,BAO_0000218,1088.0,
14058,10086,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625302,,BAO_0000218,1088.0,
14059,10086,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL874649,,BAO_0000218,1088.0,
14060,13248,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625303,,BAO_0000218,,
14061,13248,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625463,,BAO_0000218,,
14062,14527,In vitro metabolism in human liver microsomes,A,,,Homo sapiens,9606.0,,Liver,,,50587,N,1,Intermediate,1,,CHEMBL625464,,BAO_0000218,2107.0,
14063,3008,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL625465,,BAO_0000218,,
14064,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625466,,BAO_0000218,1088.0,
14065,12582,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625467,,BAO_0000218,1088.0,
14066,12582,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625468,,BAO_0000218,1088.0,
14067,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625469,,BAO_0000218,1088.0,
14068,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625470,,BAO_0000218,1088.0,
14069,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL632418,,BAO_0000218,1088.0,
14070,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627250,,BAO_0000218,1088.0,
14071,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627251,,BAO_0000218,1088.0,
14072,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627252,,BAO_0000218,1088.0,
14073,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627253,,BAO_0000218,1088.0,
14074,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627254,,BAO_0000218,1088.0,
14075,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875471,,BAO_0000218,1088.0,
14076,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627255,,BAO_0000218,1088.0,
14077,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627256,,BAO_0000218,1088.0,
14078,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627257,,BAO_0000218,1088.0,
14079,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627258,,BAO_0000218,1088.0,
14080,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627259,,BAO_0000218,1088.0,
14081,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627260,,BAO_0000218,1088.0,
14082,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623256,,BAO_0000218,1088.0,
14083,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL874413,,BAO_0000218,1088.0,
14084,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623257,,BAO_0000218,1088.0,
14085,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623258,,BAO_0000218,1088.0,
14086,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623259,,BAO_0000218,1088.0,
14087,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623260,,BAO_0000218,1088.0,
14088,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623261,,BAO_0000218,1088.0,
14089,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623262,,BAO_0000218,1088.0,
14090,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623263,,BAO_0000218,1088.0,
14091,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623264,,BAO_0000218,1088.0,
14092,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623265,,BAO_0000218,1088.0,
14093,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623266,,BAO_0000218,1088.0,
14094,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623267,,BAO_0000218,1088.0,
14095,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623268,,BAO_0000218,1088.0,
14096,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623269,,BAO_0000218,1088.0,
14097,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623270,,BAO_0000218,1088.0,
14098,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623271,,BAO_0000218,1088.0,
14099,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623272,,BAO_0000218,1088.0,
14100,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623273,,BAO_0000218,1088.0,
14101,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623274,,BAO_0000218,1088.0,
14102,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL874414,,BAO_0000218,1088.0,
14103,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623275,,BAO_0000218,1088.0,
14104,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629150,,BAO_0000218,1088.0,
14105,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623276,,BAO_0000218,1088.0,
14106,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623277,,BAO_0000218,1088.0,
14107,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623112,,BAO_0000218,1088.0,
14108,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623113,,BAO_0000218,1088.0,
14109,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623800,,BAO_0000218,1088.0,
14110,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623801,,BAO_0000218,1088.0,
14111,12017,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL623802,,BAO_0000218,2106.0,
14112,12017,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL623803,,BAO_0000218,995.0,
14113,12017,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL623970,,BAO_0000218,995.0,
14114,12017,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Uterus,,,50597,N,1,Intermediate,1,,CHEMBL623971,,BAO_0000218,995.0,
14115,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623972,,BAO_0000218,178.0,
14116,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623973,,BAO_0000218,178.0,
14117,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623974,,BAO_0000218,178.0,
14118,14045,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL623975,,BAO_0000218,178.0,
14119,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623976,,BAO_0000218,955.0,
14120,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623977,,BAO_0000218,955.0,
14121,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623978,,BAO_0000218,955.0,
14122,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL623979,,BAO_0000218,955.0,
14123,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623980,,BAO_0000218,,
14124,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL623981,,BAO_0000218,,
14125,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626278,,BAO_0000218,,
14126,14045,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626279,,BAO_0000218,,
14127,14045,Biodistribution in mice bladder plus excreted urine was determined,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626280,,BAO_0000218,,
14128,14045,"Percentage biodistribution in mouse blood, 10 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626281,,BAO_0000218,,
14129,14045,"Percentage biodistribution in mouse blood, 30 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626282,,BAO_0000218,,
14130,14045,"Percentage biodistribution in mouse blood, 5 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626283,,BAO_0000218,,
14131,14045,"Percentage biodistribution in mouse blood, 60 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626284,,BAO_0000218,,
14132,14045,"Percentage biodistribution in mouse brain, 10 minutes post injection",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626285,,BAO_0000218,955.0,
14133,14045,"Percentage biodistribution in mouse brain, 30 minutes post injection",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626286,,BAO_0000218,955.0,
14134,14045,"Percentage biodistribution in mouse brain, 5 minutes post injection",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626287,,BAO_0000218,955.0,
14135,14045,"Percentage biodistribution in mouse brain, 60 minutes post injection",A,,,Mus musculus,10090.0,,Brain,,,50594,N,1,Intermediate,1,,CHEMBL626288,,BAO_0000218,955.0,
14136,14045,"Percentage biodistribution in mouse heart, 10 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626289,,BAO_0000218,,
14137,14045,"Percentage biodistribution in mouse heart, 30 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626290,,BAO_0000218,,
14138,14045,"Percentage biodistribution in mouse heart, 5 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL626291,,BAO_0000218,,
14139,14045,"Percentage biodistribution in mouse heart, 60 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL839888,,BAO_0000218,,
14140,14045,"Percentage biodistribution in mouse intestine, 10 minutes post injection",A,,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL626292,,BAO_0000218,160.0,
14141,14045,"Percentage biodistribution in mouse intestine, 30 minutes post injection",A,,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL626293,,BAO_0000218,160.0,
14142,14045,"Percentage biodistribution in mouse intestine, 5 minutes post injection",A,,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL626294,,BAO_0000218,160.0,
14143,14045,"Percentage biodistribution in mouse intestine, 60 minutes post injection",A,,,Mus musculus,10090.0,,Intestine,,,50594,N,1,Intermediate,1,,CHEMBL626295,,BAO_0000218,160.0,
14144,14045,"Percentage biodistribution in mouse liver, 10 minutes post injection",A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627659,,BAO_0000218,2107.0,
14145,14045,"Percentage biodistribution in mouse liver, 30 minutes of post injection",A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627660,,BAO_0000218,2107.0,
14146,14045,"Percentage biodistribution in mouse liver, 5 minutes post injection",A,,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627661,,BAO_0000218,2107.0,
14147,14045,Biodistribution in mice liver at 60 minutes of post injection,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL627662,,BAO_0000218,2107.0,
14148,14045,Biodistribution in mice lungs at 10 min of post injection,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL627663,,BAO_0000218,2048.0,
14149,14045,"Percentage biodistribution in mouse lung, 30 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627664,,BAO_0000218,,
14150,14045,"Percentage biodistribution in mousee lung, 5 minutes post injection",A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL627665,,BAO_0000218,,
14151,14045,Biodistribution in mice lungs at 60 min of post injection,A,In vivo,,Mus musculus,10090.0,,Lung,,,50594,N,1,Intermediate,1,,CHEMBL627666,,BAO_0000218,2048.0,
14152,14045,Percentage biodistribution in mouse spleen,A,,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL627667,,BAO_0000218,2106.0,
14153,14045,Percentage biodistribution in mouse stomach,A,,,Mus musculus,10090.0,,Stomach,,,50594,N,1,Intermediate,1,,CHEMBL627668,,BAO_0000218,945.0,
14154,11745,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,A,,,Mus musculus,10090.0,,Urine,,,50594,N,1,Intermediate,1,,CHEMBL627669,,BAO_0000218,1088.0,
14155,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,A,In vivo,,,,,Urinary bladder,,,22224,U,0,Autocuration,1,,CHEMBL627670,,BAO_0000218,1255.0,
14156,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL627671,,BAO_0000218,178.0,
14157,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,A,In vivo,,,,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL627672,,BAO_0000218,1474.0,
14158,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627673,,BAO_0000218,,
14159,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,A,In vivo,,,,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL627674,,BAO_0000218,2113.0,
14160,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,A,In vivo,,,,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL627675,,BAO_0000218,2107.0,
14161,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,A,In vivo,,,,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL627676,,BAO_0000218,2048.0,
14162,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627677,,BAO_0000218,2385.0,
14163,8354,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627678,,BAO_0000019,,
14164,7095,Affinity for protein binding expressed as association constant in fresh rat serum,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL627679,,BAO_0000218,1977.0,
14165,12185,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627680,,BAO_0000019,,
14166,12185,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627681,,BAO_0000019,,
14167,12185,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627682,,BAO_0000019,,
14168,12185,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627683,,BAO_0000019,,
14169,12686,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627684,,BAO_0000019,,
14170,12686,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874441,,BAO_0000019,,
14171,12686,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627685,,BAO_0000019,,
14172,12686,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627686,,BAO_0000019,,
14173,8057,Apparent rate constant Koff for inactivation of dTMP synthase.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627687,,BAO_0000019,,
14174,15778,The irreversible inhibitor activity by second order rate equation.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627688,,BAO_0000019,,
14175,12375,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628038,,BAO_0000218,,
14176,12375,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628039,,BAO_0000218,,
14177,12375,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628040,,BAO_0000218,,
14178,13588,Dissociation rate calculated from the first-order equation using t1/2 value,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628041,,BAO_0000019,,
14179,15039,The compound was tested for Binding constant against DNA,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630226,,BAO_0000019,,
14180,9500,First order rate constant for cyclization of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628042,,BAO_0000019,,
14181,10014,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625232,,BAO_0000019,,
14182,10014,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625233,,BAO_0000019,,
14183,568,Hydrolysis rate constant was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625979,,BAO_0000019,,
14184,10026,Observed first order rate constant,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625980,,BAO_0000019,,
14185,10281,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625981,,BAO_0000019,,
14186,10281,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625982,,BAO_0000019,,
14187,9680,Second-order rate constant for attack on PNPA at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625983,,BAO_0000019,,
14188,13028,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625984,,BAO_0000019,,
14189,13028,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625985,,BAO_0000019,,
14190,13028,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625986,,BAO_0000019,,
14191,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625987,,BAO_0000019,,
14192,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625988,,BAO_0000019,,
14193,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625989,,BAO_0000019,,
14194,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625990,,BAO_0000019,,
14195,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625991,,BAO_0000019,,
14196,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625992,,BAO_0000019,,
14197,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625993,,BAO_0000019,,
14198,13028,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631973,,BAO_0000019,,
14199,13028,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632143,,BAO_0000019,,
14200,13028,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632144,,BAO_0000019,,
14201,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632145,,BAO_0000019,,
14202,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632146,,BAO_0000019,,
14203,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632147,,BAO_0000019,,
14204,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632148,,BAO_0000019,,
14205,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632149,,BAO_0000019,,
14206,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632150,,BAO_0000019,,
14207,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632151,,BAO_0000019,,
14208,3008,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL632152,,BAO_0000218,,
14209,4509,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL632153,,BAO_0000218,,
14210,4509,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,A,,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL632154,,BAO_0000218,,
14211,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL632155,,BAO_0000218,,
14212,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL632156,,BAO_0000218,,
14213,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL632157,,BAO_0000218,,
14214,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL632158,,BAO_0000218,,
14215,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL632159,,BAO_0000218,,
14216,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL626305,,BAO_0000218,,
14217,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL626306,,BAO_0000218,,
14218,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL626307,,BAO_0000218,,
14219,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL626308,,BAO_0000218,,
14220,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL626479,,BAO_0000218,,
14221,8613,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,A,,,Human herpesvirus 1,10298.0,,,,,50602,N,1,Intermediate,1,,CHEMBL626480,,BAO_0000218,,
14222,6021,Calculated partition coefficient (clogP) (MlogP),P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626481,,BAO_0000100,,
14223,9348,Equipotent potent ratio relative to carbachol (nicotinic activity),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626482,,BAO_0000019,,
14224,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626483,,BAO_0000218,,
14225,15592,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL626484,,BAO_0000218,,
14226,15592,Solubility at pH 7.4 in micro g/mL;NA denotes available,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626485,,BAO_0000100,,
14227,15592,Solubility at pH 7.4 in micro g/mL;NA denotes not available,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626486,,BAO_0000100,,
14228,15592,Solubility at pH 7.4 in ug/mL;NA denotes not available,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626487,,BAO_0000100,,
14229,15592,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,A,In vivo,,Canis lupus familiaris,9615.0,,Plasma,,,50588,N,1,Intermediate,1,,CHEMBL626488,,BAO_0000218,1969.0,
14230,7095,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,A,,,Rattus norvegicus,10116.0,,Serum,,,50597,N,1,Intermediate,1,,CHEMBL626489,,BAO_0000218,1977.0,
14231,16618,Area under the MAP curve measured over 5 min; ND means Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626490,,BAO_0000019,,
14232,16835,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626491,,BAO_0000100,,
14233,15284,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL626492,,BAO_0000100,,
14234,15750,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626493,,BAO_0000019,,
14235,16618,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626494,,BAO_0000218,,
14236,16618,Half life after oral tested,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626495,,BAO_0000218,,
14237,15812,Half life was determined in plasma of rat; NT indicates not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626496,,BAO_0000218,1969.0,
14238,16618,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626497,,BAO_0000218,,
14239,16618,Oral bioavailability after oral tested,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626498,,BAO_0000218,,
14240,13098,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626499,,BAO_0000218,,
14241,13098,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626500,,BAO_0000218,,
14242,15812,half life was determined in plasma of rat; NT indicates not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626501,,BAO_0000218,1969.0,
14243,15812,half life was determined in plasma of rat; NT means not tested,A,,,Rattus norvegicus,10116.0,,Plasma,,,50597,N,1,Intermediate,1,,CHEMBL626502,,BAO_0000218,1969.0,
14244,11510,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626503,,BAO_0000218,,
14245,11510,Mean sodium excretion in rats (Control/Drug treatment value); inactive,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626504,,BAO_0000218,,
14246,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626505,,BAO_0000218,,
14247,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626506,,BAO_0000218,,
14248,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626507,,BAO_0000218,,
14249,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626508,,BAO_0000218,,
14250,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626509,,BAO_0000218,,
14251,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875480,,BAO_0000218,,
14252,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626510,,BAO_0000218,,
14253,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626511,,BAO_0000218,,
14254,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL626512,,BAO_0000218,,
14255,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628208,,BAO_0000218,,
14256,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628209,,BAO_0000218,,
14257,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628210,,BAO_0000218,,
14258,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628211,,BAO_0000218,,
14259,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628212,,BAO_0000218,,
14260,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628213,,BAO_0000218,,
14261,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628214,,BAO_0000218,1088.0,
14262,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628215,,BAO_0000218,1088.0,
14263,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628216,,BAO_0000218,1088.0,
14264,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626595,,BAO_0000218,1088.0,
14265,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626596,,BAO_0000218,1088.0,
14266,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626597,,BAO_0000218,1088.0,
14267,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626598,,BAO_0000218,1088.0,
14268,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622242,,BAO_0000218,1088.0,
14269,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622243,,BAO_0000218,1088.0,
14270,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622244,,BAO_0000218,1088.0,
14271,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622245,,BAO_0000218,1088.0,
14272,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622246,,BAO_0000218,1088.0,
14273,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622247,,BAO_0000218,1088.0,
14274,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622248,,BAO_0000218,1088.0,
14275,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL877483,,BAO_0000218,1088.0,
14276,12582,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL622249,,BAO_0000218,1088.0,
14277,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622250,,BAO_0000218,1088.0,
14278,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622251,,BAO_0000218,1088.0,
14279,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622252,,BAO_0000218,1088.0,
14280,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622253,,BAO_0000218,1088.0,
14281,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622254,,BAO_0000218,1088.0,
14282,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622255,,BAO_0000218,1088.0,
14283,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622256,,BAO_0000218,1088.0,
14284,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622257,,BAO_0000218,1088.0,
14285,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622258,,BAO_0000218,1088.0,
14286,12582,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622259,,BAO_0000218,1088.0,
14287,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622927,,BAO_0000218,1088.0,
14288,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622928,,BAO_0000218,1088.0,
14289,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL622929,,BAO_0000218,1088.0,
14290,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL623182,,BAO_0000218,1088.0,
14291,12582,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL623183,,BAO_0000218,1088.0,
14292,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623184,,BAO_0000218,1088.0,
14293,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623185,,BAO_0000218,1088.0,
14294,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL877484,,BAO_0000218,1088.0,
14295,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL627274,,BAO_0000218,1088.0,
14296,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623186,,BAO_0000218,1088.0,
14297,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623187,,BAO_0000218,1088.0,
14298,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL623188,,BAO_0000218,1088.0,
14299,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628055,,BAO_0000218,1088.0,
14300,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628056,,BAO_0000218,1088.0,
14301,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628200,,BAO_0000218,1088.0,
14302,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628201,,BAO_0000218,1088.0,
14303,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628202,,BAO_0000218,1088.0,
14304,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628203,,BAO_0000218,1088.0,
14305,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628204,,BAO_0000218,1088.0,
14306,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628205,,BAO_0000218,1088.0,
14307,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628206,,BAO_0000218,1088.0,
14308,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL628207,,BAO_0000218,2367.0,
14309,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627220,,BAO_0000218,2367.0,
14310,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627221,,BAO_0000218,2385.0,
14311,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627222,,BAO_0000218,2367.0,
14312,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627223,,BAO_0000218,,
14313,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL632062,,BAO_0000218,2385.0,
14314,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,A,In vivo,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL632063,,BAO_0000218,2106.0,
14315,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,A,In vivo,,,,,Urinary bladder,,,22224,U,0,Autocuration,1,,CHEMBL632064,,BAO_0000218,1255.0,
14316,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL632065,,BAO_0000218,178.0,
14317,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,A,In vivo,,,,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL632066,,BAO_0000218,1474.0,
14318,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632067,,BAO_0000218,,
14319,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,A,In vivo,,,,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL629188,,BAO_0000218,2113.0,
14320,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,A,In vivo,,,,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL629189,,BAO_0000218,2107.0,
14321,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,A,In vivo,,,,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL629190,,BAO_0000218,2048.0,
14322,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629191,,BAO_0000218,2385.0,
14323,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL629192,,BAO_0000218,2367.0,
14324,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629193,,BAO_0000218,2385.0,
14325,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL629194,,BAO_0000218,2367.0,
14326,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629195,,BAO_0000218,,
14327,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629373,,BAO_0000218,2385.0,
14328,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,A,In vivo,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL629374,,BAO_0000218,2106.0,
14329,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL629375,,BAO_0000218,2367.0,
14330,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,A,In vivo,,,,,Urinary bladder,,,22224,U,0,Autocuration,1,,CHEMBL629376,,BAO_0000218,1255.0,
14331,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL629377,,BAO_0000218,178.0,
14332,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,A,In vivo,,,,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL629378,,BAO_0000218,1474.0,
14333,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629379,,BAO_0000218,,
14334,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,A,In vivo,,,,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL629151,,BAO_0000218,2113.0,
14335,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,A,In vivo,,,,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL629152,,BAO_0000218,2107.0,
14336,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,A,In vivo,,,,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL629153,,BAO_0000218,2048.0,
14337,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629154,,BAO_0000218,2385.0,
14338,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL629155,,BAO_0000218,2367.0,
14339,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL629156,,BAO_0000218,2367.0,
14340,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629157,,BAO_0000218,2385.0,
14341,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL629158,,BAO_0000218,2367.0,
14342,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629159,,BAO_0000218,,
14343,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629160,,BAO_0000218,2385.0,
14344,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,A,In vivo,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL629161,,BAO_0000218,2106.0,
14345,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,A,In vivo,,,,,Urinary bladder,,,22224,U,0,Autocuration,1,,CHEMBL629162,,BAO_0000218,1255.0,
14346,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL629163,,BAO_0000218,178.0,
14347,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,A,In vivo,,,,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL629164,,BAO_0000218,1474.0,
14348,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629165,,BAO_0000218,,
14349,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,A,In vivo,,,,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL629166,,BAO_0000218,2107.0,
14350,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,A,In vivo,,,,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL629167,,BAO_0000218,2048.0,
14351,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL629168,,BAO_0000218,2385.0,
14352,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629169,,BAO_0000019,,
14353,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629170,,BAO_0000019,,
14354,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631153,,BAO_0000019,,
14355,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875121,,BAO_0000019,,
14356,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631154,,BAO_0000019,,
14357,2193,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631155,,BAO_0000019,,
14358,568,Hydrolysis rate constant was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631156,,BAO_0000019,,
14359,9680,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631157,,BAO_0000019,,
14360,9680,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631158,,BAO_0000019,,
14361,9680,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631159,,BAO_0000019,,
14362,10026,Observed second order rate constant,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631160,,BAO_0000019,,
14363,10281,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631161,,BAO_0000019,,
14364,10014,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631162,,BAO_0000019,,
14365,10014,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630313,,BAO_0000019,,
14366,9680,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630314,,BAO_0000019,,
14367,9680,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630315,,BAO_0000019,,
14368,13028,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630316,,BAO_0000019,,
14369,13028,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630986,,BAO_0000019,,
14370,13028,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630987,,BAO_0000019,,
14371,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630988,,BAO_0000019,,
14372,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630989,,BAO_0000019,,
14373,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630990,,BAO_0000019,,
14374,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630991,,BAO_0000019,,
14375,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630992,,BAO_0000019,,
14376,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630993,,BAO_0000019,,
14377,13028,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630994,,BAO_0000019,,
14378,10014,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630995,,BAO_0000218,,
14379,9962,Association constant for compound at 31 degree C was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629252,,BAO_0000019,,
14380,12029,Calculated antagonist equilibrium dissociation constant of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629253,,BAO_0000019,,
14381,12029,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629944,,BAO_0000019,,
14382,10583,Dissociation constants vs LTE4 on guinea pig trachea,A,,,Cavia porcellus,10141.0,,Trachea,,,50512,N,1,Intermediate,1,,CHEMBL629945,,BAO_0000218,3126.0,
14383,568,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629946,,BAO_0000019,,
14384,568,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629947,,BAO_0000019,,
14385,568,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629948,,BAO_0000019,,
14386,568,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL856024,,BAO_0000019,,
14387,7493,Affinity constant KD value was derived from TMP,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629949,,BAO_0000019,,
14388,8371,Apparent dissociation (binding) rate constant was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629950,,BAO_0000019,,
14389,13114,Dissociation constant (KD) of the compound,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630127,,BAO_0000100,,
14390,15515,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630128,,BAO_0000100,,
14391,522,Dissociation constant from ESR titration experiments,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630129,,BAO_0000100,,
14392,13888,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630130,,BAO_0000019,,
14393,2616,Dissociation constant was evaluated.,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875234,,BAO_0000100,,
14394,3798,Dissociation constant was reported,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630131,,BAO_0000100,,
14395,8731,Dissociation constant was determined in rat pituitary cells.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630132,,BAO_0000218,,
14396,11892,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630133,,BAO_0000019,,
14397,11892,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630134,,BAO_0000019,,
14398,2582,Equilibrium dissociation constant of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630135,,BAO_0000019,,
14399,11892,Equilibrium dissociation constant was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630136,,BAO_0000019,,
14400,13396,Kinetic constant KD was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630137,,BAO_0000019,,
14401,603,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630138,,BAO_0000019,,
14402,15673,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630139,,BAO_0000019,,
14403,10368,Rate constant for hydrolysis in aqueous acetone.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630140,,BAO_0000019,,
14404,14228,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875235,,BAO_0000019,,
14405,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876439,,BAO_0000218,,
14406,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630605,,BAO_0000218,,
14407,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630606,,BAO_0000218,,
14408,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630607,,BAO_0000218,,
14409,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630608,,BAO_0000218,,
14410,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630609,,BAO_0000218,,
14411,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630610,,BAO_0000218,,
14412,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630611,,BAO_0000218,,
14413,11510,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629552,,BAO_0000218,,
14414,11510,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629733,,BAO_0000218,,
14415,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629734,,BAO_0000218,,
14416,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629735,,BAO_0000218,,
14417,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629736,,BAO_0000218,,
14418,11510,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629737,,BAO_0000218,,
14419,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629738,,BAO_0000218,,
14420,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629739,,BAO_0000218,,
14421,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629740,,BAO_0000218,,
14422,11510,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629741,,BAO_0000218,,
14423,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629742,,BAO_0000218,,
14424,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629743,,BAO_0000218,,
14425,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629744,,BAO_0000218,,
14426,11510,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629745,,BAO_0000218,,
14427,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629746,,BAO_0000218,,
14428,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629747,,BAO_0000218,,
14429,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629748,,BAO_0000218,,
14430,11510,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629749,,BAO_0000218,,
14431,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629750,,BAO_0000218,,
14432,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629751,,BAO_0000218,,
14433,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629752,,BAO_0000218,,
14434,11510,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629753,,BAO_0000218,,
14435,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629754,,BAO_0000218,,
14436,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629755,,BAO_0000218,,
14437,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629756,,BAO_0000218,,
14438,11510,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629757,,BAO_0000218,,
14439,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629758,,BAO_0000218,,
14440,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629759,,BAO_0000218,,
14441,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL629760,,BAO_0000218,,
14442,11510,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876443,,BAO_0000218,,
14443,8310,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629761,,BAO_0000218,,
14444,8310,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629762,,BAO_0000218,,
14445,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629763,,BAO_0000218,,
14446,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629764,,BAO_0000218,,
14447,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629765,,BAO_0000218,,
14448,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629766,,BAO_0000218,,
14449,8310,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629767,,BAO_0000218,,
14450,8310,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629768,,BAO_0000218,,
14451,8310,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629769,,BAO_0000218,,
14452,8310,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629770,,BAO_0000218,,
14453,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,A,,,Canis lupus familiaris,9615.0,,,,,50588,N,1,Intermediate,1,,CHEMBL629771,,BAO_0000218,,
14454,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629772,,BAO_0000218,,
14455,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL629773,,BAO_0000218,,
14456,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625455,,BAO_0000218,,
14457,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625456,,BAO_0000218,,
14458,8310,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL625457,,BAO_0000218,,
14459,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625458,,BAO_0000218,1088.0,
14460,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625459,,BAO_0000218,1088.0,
14461,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875483,,BAO_0000218,1088.0,
14462,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL634779,,BAO_0000218,1088.0,
14463,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625460,,BAO_0000218,1088.0,
14464,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626117,,BAO_0000218,1088.0,
14465,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626118,,BAO_0000218,1088.0,
14466,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628342,,BAO_0000218,1088.0,
14467,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628343,,BAO_0000218,1088.0,
14468,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628344,,BAO_0000218,1088.0,
14469,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628345,,BAO_0000218,1088.0,
14470,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628346,,BAO_0000218,1088.0,
14471,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628347,,BAO_0000218,1088.0,
14472,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628348,,BAO_0000218,1088.0,
14473,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628349,,BAO_0000218,1088.0,
14474,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875611,,BAO_0000218,1088.0,
14475,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628350,,BAO_0000218,1088.0,
14476,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628351,,BAO_0000218,1088.0,
14477,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628352,,BAO_0000218,1088.0,
14478,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628353,,BAO_0000218,1088.0,
14479,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628354,,BAO_0000218,1088.0,
14480,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626667,,BAO_0000218,1088.0,
14481,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626668,,BAO_0000218,1088.0,
14482,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626669,,BAO_0000218,1088.0,
14483,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626670,,BAO_0000218,1088.0,
14484,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626671,,BAO_0000218,1088.0,
14485,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626672,,BAO_0000218,1088.0,
14486,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626673,,BAO_0000218,1088.0,
14487,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626674,,BAO_0000218,1088.0,
14488,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626675,,BAO_0000218,1088.0,
14489,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626676,,BAO_0000218,1088.0,
14490,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626677,,BAO_0000218,1088.0,
14491,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626678,,BAO_0000218,1088.0,
14492,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626679,,BAO_0000218,1088.0,
14493,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875612,,BAO_0000218,1088.0,
14494,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626680,,BAO_0000218,1088.0,
14495,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626681,,BAO_0000218,1088.0,
14496,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626682,,BAO_0000218,1088.0,
14497,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626683,,BAO_0000218,1088.0,
14498,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626684,,BAO_0000218,1088.0,
14499,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626685,,BAO_0000218,1088.0,
14500,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626686,,BAO_0000218,1088.0,
14501,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626687,,BAO_0000218,1088.0,
14502,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624978,,BAO_0000218,1088.0,
14503,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624979,,BAO_0000218,1088.0,
14504,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624980,,BAO_0000218,1088.0,
14505,12582,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL624981,,BAO_0000218,1088.0,
14506,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL624982,,BAO_0000218,1088.0,
14507,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627564,,BAO_0000218,2367.0,
14508,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627565,,BAO_0000218,2367.0,
14509,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627566,,BAO_0000218,,
14510,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627567,,BAO_0000218,2385.0,
14511,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,A,In vivo,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL627568,,BAO_0000218,2106.0,
14512,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,A,In vivo,,,,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL627569,,BAO_0000218,2113.0,
14513,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,A,In vivo,,,,,Urinary bladder,,,22224,U,0,Autocuration,1,,CHEMBL627570,,BAO_0000218,1255.0,
14514,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,A,In vivo,,,,,Blood,,,22224,U,0,Autocuration,1,,CHEMBL627571,,BAO_0000218,178.0,
14515,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,A,In vivo,,,,,Bone element,,,22224,U,0,Autocuration,1,,CHEMBL627572,,BAO_0000218,1474.0,
14516,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627573,,BAO_0000218,,
14517,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,A,In vivo,,,,,Kidney,,,22224,U,0,Autocuration,1,,CHEMBL627574,,BAO_0000218,2113.0,
14518,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,A,In vivo,,,,,Liver,,,22224,U,0,Autocuration,1,,CHEMBL627575,,BAO_0000218,2107.0,
14519,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,A,In vivo,,,,,Lung,,,22224,U,0,Autocuration,1,,CHEMBL627576,,BAO_0000218,2048.0,
14520,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627577,,BAO_0000218,2385.0,
14521,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627578,,BAO_0000218,2367.0,
14522,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627579,,BAO_0000218,2367.0,
14523,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627580,,BAO_0000218,2385.0,
14524,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627581,,BAO_0000218,2367.0,
14525,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,A,In vivo,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627582,,BAO_0000218,,
14526,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627583,,BAO_0000218,2385.0,
14527,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,A,In vivo,,,,,Spleen,,,22224,U,0,Autocuration,1,,CHEMBL627584,,BAO_0000218,2106.0,
14528,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,A,In vivo,,,,,Prostate gland,,,22224,U,0,Autocuration,1,,CHEMBL627585,,BAO_0000218,2367.0,
14529,13257,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,A,In vivo,,,,,Muscle tissue,,,22224,U,0,Autocuration,1,,CHEMBL627586,,BAO_0000218,2385.0,
14530,15413,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627587,,BAO_0000218,,
14531,15413,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL627588,,BAO_0000218,,
14532,15413,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628250,,BAO_0000218,,
14533,15413,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628251,,BAO_0000218,,
14534,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL628252,,BAO_0000218,10000000.0,
14535,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL628253,,BAO_0000218,10000000.0,
14536,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL628254,,BAO_0000218,1898.0,
14537,15413,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL877493,,BAO_0000218,1898.0,
14538,15413,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628255,,BAO_0000218,,
14539,15413,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628256,,BAO_0000218,,
14540,15413,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL628257,,BAO_0000218,10000000.0,
14541,15413,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL628258,,BAO_0000218,1898.0,
14542,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628259,,BAO_0000218,,
14543,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628429,,BAO_0000218,,
14544,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL626862,,BAO_0000218,10000000.0,
14545,15413,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL626863,,BAO_0000218,1898.0,
14546,15413,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL625886,,BAO_0000218,2037.0,
14547,15413,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL625887,,BAO_0000218,2037.0,
14548,15413,Biodistribution of the [11C]-radiolabeled compound in rat cortex,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625888,,BAO_0000218,,
14549,15413,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625889,,BAO_0000218,,
14550,15413,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625890,,BAO_0000218,10000000.0,
14551,15413,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL625891,,BAO_0000218,10000000.0,
14552,15413,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL625892,,BAO_0000218,1898.0,
14553,15413,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL625893,,BAO_0000218,1898.0,
14554,15413,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,A,In vivo,,Rattus norvegicus,10116.0,,Cerebellum,,,50597,N,1,Intermediate,1,,CHEMBL625894,,BAO_0000218,2037.0,
14555,15413,Biodistribution of the [18F]-radiolabeled compound in rat cortex,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625895,,BAO_0000218,,
14556,12404,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625896,,BAO_0000019,,
14557,568,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625897,,BAO_0000019,,
14558,568,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625898,,BAO_0000019,,
14559,568,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL625899,,BAO_0000019,,
14560,12404,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL626124,,BAO_0000019,,
14561,7624,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,A,,,Escherichia coli,562.0,,,,,50212,N,1,Intermediate,1,,CHEMBL628500,,BAO_0000218,,
14562,7624,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL857856,,BAO_0000218,,
14563,7624,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628501,,BAO_0000218,,
14564,4643,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628502,,BAO_0000019,,
14565,11532,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628503,,BAO_0000019,,
14566,11018,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628504,,BAO_0000019,,
14567,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628505,,BAO_0000019,,
14568,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL874452,,BAO_0000019,,
14569,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628506,,BAO_0000019,,
14570,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628507,,BAO_0000019,,
14571,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628508,,BAO_0000019,,
14572,8949,Michaelis constant (KM) was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628509,,BAO_0000019,,
14573,12404,Reaction rate parameter value for phosphate with transfer with respect to ATP,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628510,,BAO_0000019,,
14574,7625,Substrate concentration for half maximal velocity was reported for rat hexokinase I,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628511,,BAO_0000019,,
14575,7625,Substrate concentration for half maximal velocity was reported for rat hexokinase II,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628512,,BAO_0000019,,
14576,7625,Substrate concentration for half maximal velocity was reported for rat hexokinase III,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628513,,BAO_0000019,,
14577,7625,Substrate concentration for half maximal velocity was reported for yeast hexokinase,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628514,,BAO_0000019,,
14578,12908,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628515,,BAO_0000019,,
14579,10368,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628516,,BAO_0000019,,
14580,13108,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628517,,BAO_0000019,,
14581,13108,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628518,,BAO_0000019,,
14582,15217,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628519,,BAO_0000019,,
14583,15217,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628520,,BAO_0000019,,
14584,10933,Binding constant was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628521,,BAO_0000019,,
14585,2363,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630443,,BAO_0000019,,
14586,2363,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630444,,BAO_0000019,,
14587,2276,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857732,,BAO_0000019,,
14588,14915,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630445,,BAO_0000100,,
14589,8847,Catalytic rate constant of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630446,,BAO_0000019,,
14590,15357,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630447,,BAO_0000019,,
14591,2869,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630448,,BAO_0000019,,
14592,3484,Catalytic rate constant against phospholipase A2 was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630449,,BAO_0000019,,
14593,1373,"Compound was evaluated for catalytic constant, Kcat",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630450,,BAO_0000019,,
14594,8142,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630451,,BAO_0000019,,
14595,14131,Kcat calculated from 0.693/T1/2,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630452,,BAO_0000019,,
14596,17269,Kcat was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630453,,BAO_0000019,,
14597,3485,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630454,,BAO_0000019,,
14598,3485,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630455,,BAO_0000019,,
14599,3485,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631487,,BAO_0000019,,
14600,5962,Kcat value was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631488,,BAO_0000019,,
14601,3133,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL876440,,BAO_0000019,,
14602,3133,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631489,,BAO_0000019,,
14603,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857742,,BAO_0000019,,
14604,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631490,,BAO_0000019,,
14605,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631491,,BAO_0000019,,
14606,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631492,,BAO_0000019,,
14607,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631493,,BAO_0000019,,
14608,4892,Kinetic parameter for rate of conversion to PABA was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631494,,BAO_0000019,,
14609,3133,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631495,,BAO_0000019,,
14610,11488,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Rattus norvegicus,10116.0,,Feces,,,50597,N,1,Intermediate,1,,CHEMBL631496,,BAO_0000218,1988.0,
14611,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631497,,BAO_0000218,1088.0,
14612,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631498,,BAO_0000218,1088.0,
14613,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629776,,BAO_0000218,1088.0,
14614,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629777,,BAO_0000218,1088.0,
14615,11488,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL629778,,BAO_0000218,1088.0,
14616,11488,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630456,,BAO_0000218,,
14617,11488,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630457,,BAO_0000218,,
14618,11488,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630458,,BAO_0000218,,
14619,11488,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630459,,BAO_0000218,,
14620,11488,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630460,,BAO_0000218,,
14621,11488,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL876550,,BAO_0000218,,
14622,11488,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630461,,BAO_0000218,,
14623,11488,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630462,,BAO_0000218,,
14624,11488,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630463,,BAO_0000218,,
14625,11488,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630464,,BAO_0000218,,
14626,11488,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630465,,BAO_0000218,,
14627,11488,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630466,,BAO_0000218,,
14628,11488,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630467,,BAO_0000218,,
14629,11488,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630633,,BAO_0000218,,
14630,11488,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630634,,BAO_0000218,,
14631,11488,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630635,,BAO_0000218,,
14632,11488,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630636,,BAO_0000218,,
14633,11488,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630637,,BAO_0000218,,
14634,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL630638,,BAO_0000218,1988.0,
14635,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL630639,,BAO_0000218,1988.0,
14636,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL630640,,BAO_0000218,1988.0,
14637,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL876551,,BAO_0000218,1988.0,
14638,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL630641,,BAO_0000218,1088.0,
14639,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL630642,,BAO_0000218,1088.0,
14640,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL630643,,BAO_0000218,1088.0,
14641,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL630644,,BAO_0000218,1088.0,
14642,7132,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL630645,,BAO_0000218,1088.0,
14643,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL625599,,BAO_0000218,1988.0,
14644,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL625600,,BAO_0000218,1988.0,
14645,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL625601,,BAO_0000218,1988.0,
14646,7132,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,,Feces,,,50592,N,1,Intermediate,1,,CHEMBL625602,,BAO_0000218,1988.0,
14647,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL627470,,BAO_0000218,1088.0,
14648,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL627471,,BAO_0000218,1088.0,
14649,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL627472,,BAO_0000218,1088.0,
14650,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL627473,,BAO_0000218,1088.0,
14651,7132,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",A,,,Oryctolagus cuniculus,9986.0,,Urine,,,50592,N,1,Intermediate,1,,CHEMBL627474,,BAO_0000218,1088.0,
14652,13925,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627475,,BAO_0000218,178.0,
14653,13925,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL627476,,BAO_0000218,178.0,
14654,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627477,,BAO_0000218,1088.0,
14655,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627478,,BAO_0000218,1088.0,
14656,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627479,,BAO_0000218,1088.0,
14657,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627480,,BAO_0000218,1088.0,
14658,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627481,,BAO_0000218,1088.0,
14659,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627482,,BAO_0000218,1088.0,
14660,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL627483,,BAO_0000218,1088.0,
14661,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL875636,,BAO_0000218,1088.0,
14662,12582,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625764,,BAO_0000218,1088.0,
14663,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625765,,BAO_0000218,1088.0,
14664,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625766,,BAO_0000218,1088.0,
14665,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625767,,BAO_0000218,1088.0,
14666,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625768,,BAO_0000218,1088.0,
14667,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625769,,BAO_0000218,1088.0,
14668,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625770,,BAO_0000218,1088.0,
14669,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625771,,BAO_0000218,1088.0,
14670,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625772,,BAO_0000218,1088.0,
14671,12582,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,A,,,Canis lupus familiaris,9615.0,,Urine,,,50588,N,1,Intermediate,1,,CHEMBL625773,,BAO_0000218,1088.0,
14672,12582,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625774,,BAO_0000218,1088.0,
14673,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625775,,BAO_0000218,1088.0,
14674,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625776,,BAO_0000218,1088.0,
14675,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625777,,BAO_0000218,1088.0,
14676,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625778,,BAO_0000218,1088.0,
14677,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625779,,BAO_0000218,1088.0,
14678,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625780,,BAO_0000218,1088.0,
14679,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL625781,,BAO_0000218,1088.0,
14680,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875637,,BAO_0000218,1088.0,
14681,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626473,,BAO_0000218,1088.0,
14682,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626474,,BAO_0000218,1088.0,
14683,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626475,,BAO_0000218,1088.0,
14684,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626476,,BAO_0000218,1088.0,
14685,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL634397,,BAO_0000218,1088.0,
14686,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL626477,,BAO_0000218,1088.0,
14687,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631069,,BAO_0000218,1088.0,
14688,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631070,,BAO_0000218,1088.0,
14689,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631071,,BAO_0000218,1088.0,
14690,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631072,,BAO_0000218,1088.0,
14691,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631073,,BAO_0000218,1088.0,
14692,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631074,,BAO_0000218,1088.0,
14693,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631075,,BAO_0000218,1088.0,
14694,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631725,,BAO_0000218,1088.0,
14695,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631726,,BAO_0000218,1088.0,
14696,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631727,,BAO_0000218,1088.0,
14697,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631728,,BAO_0000218,1088.0,
14698,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631729,,BAO_0000218,1088.0,
14699,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631730,,BAO_0000218,1088.0,
14700,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631731,,BAO_0000218,1088.0,
14701,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631910,,BAO_0000218,1088.0,
14702,15413,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,A,In vivo,,Rattus norvegicus,10116.0,,Hippocampus,,,50597,N,1,Intermediate,1,,CHEMBL631911,,BAO_0000218,10000000.0,
14703,15413,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL631912,,BAO_0000218,1898.0,
14704,15413,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,A,In vivo,,Rattus norvegicus,10116.0,,Hypothalamus,,,50597,N,1,Intermediate,1,,CHEMBL631913,,BAO_0000218,1898.0,
14705,12017,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631914,,BAO_0000218,178.0,
14706,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631915,,BAO_0000218,178.0,
14707,12017,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL875778,,BAO_0000218,178.0,
14708,12017,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631916,,BAO_0000218,178.0,
14709,12017,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631917,,BAO_0000218,178.0,
14710,12017,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631918,,BAO_0000218,178.0,
14711,12017,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631919,,BAO_0000218,178.0,
14712,12017,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631920,,BAO_0000218,178.0,
14713,12017,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631921,,BAO_0000218,178.0,
14714,12017,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631922,,BAO_0000218,178.0,
14715,12017,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL631923,,BAO_0000218,178.0,
14716,12017,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631924,,BAO_0000218,,
14717,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630234,,BAO_0000218,,
14718,12017,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630235,,BAO_0000218,,
14719,12017,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630236,,BAO_0000218,,
14720,12017,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630237,,BAO_0000218,,
14721,12017,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630238,,BAO_0000218,,
14722,12017,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630239,,BAO_0000218,,
14723,12017,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630303,,BAO_0000218,,
14724,12017,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630304,,BAO_0000218,,
14725,12017,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630305,,BAO_0000218,,
14726,12017,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630306,,BAO_0000218,2113.0,
14727,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630307,,BAO_0000218,2113.0,
14728,12017,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630308,,BAO_0000218,2113.0,
14729,12017,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL630309,,BAO_0000218,2113.0,
14730,12017,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL629309,,BAO_0000218,2113.0,
14731,12017,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL629993,,BAO_0000218,2113.0,
14732,12017,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL629994,,BAO_0000218,2113.0,
14733,12017,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL629995,,BAO_0000218,2113.0,
14734,12017,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL631993,,BAO_0000218,2113.0,
14735,12017,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL631994,,BAO_0000218,2113.0,
14736,12017,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL631995,,BAO_0000218,2113.0,
14737,12017,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631996,,BAO_0000218,2107.0,
14738,12017,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631997,,BAO_0000218,2107.0,
14739,12017,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631998,,BAO_0000218,2107.0,
14740,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631999,,BAO_0000218,2107.0,
14741,12017,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL632000,,BAO_0000218,2107.0,
14742,12017,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL632001,,BAO_0000218,2107.0,
14743,12017,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL874424,,BAO_0000218,2107.0,
14744,12017,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL632002,,BAO_0000218,2107.0,
14745,12017,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL632003,,BAO_0000218,2107.0,
14746,3133,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632004,,BAO_0000019,,
14747,2742,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632005,,BAO_0000019,,
14748,2742,Compound was tested for amidase rate in the presence of N62C screen enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632006,,BAO_0000019,,
14749,2742,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632007,,BAO_0000019,,
14750,2742,Compound was tested for amidase rate in the presence of S166C screen enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632008,,BAO_0000019,,
14751,2742,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632009,,BAO_0000019,,
14752,2742,Compound was tested for esterase rate in the presence of N62C screen enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632010,,BAO_0000019,,
14753,2742,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL857750,,BAO_0000019,,
14754,2742,Compound was tested for esterase rate in the presence of S166C screen enzyme,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632011,,BAO_0000019,,
14755,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632012,,BAO_0000019,,
14756,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632013,,BAO_0000019,,
14757,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL632014,,BAO_0000019,,
14758,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629622,,BAO_0000019,,
14759,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629623,,BAO_0000019,,
14760,2276,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629624,,BAO_0000019,,
14761,17269,Ratio of Kcat to that of Km was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629625,,BAO_0000019,,
14762,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629626,,BAO_0000019,,
14763,2276,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629627,,BAO_0000019,,
14764,15917,"Compound was evaluated for constant, Kd",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629628,,BAO_0000019,,
14765,10933,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629629,,BAO_0000019,,
14766,10933,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629630,,BAO_0000019,,
14767,14293,Dissociation Constant of compound determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL856030,,BAO_0000019,,
14768,6698,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629631,,BAO_0000019,,
14769,6698,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,B,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629632,,BAO_0000019,,
14770,4318,Dissociation constant of compound with Fructose was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629633,,BAO_0000100,,
14771,4318,Dissociation constant of compound with Fructose was determined; Not determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629634,,BAO_0000100,,
14772,4318,Dissociation constant of compound with Lactulose was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629635,,BAO_0000100,,
14773,4318,Dissociation constant of compound with Lactulose was determined; Not determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629636,,BAO_0000100,,
14774,14959,Dissociation constant of the Compound,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629637,,BAO_0000100,,
14775,5913,Dissociation constant by non-linear regression analysis,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629638,,BAO_0000100,,
14776,14218,Dissociation constant was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629639,,BAO_0000100,,
14777,10689,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629640,,BAO_0000100,,
14778,13925,Dissociation constant was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629641,,BAO_0000100,,
14779,16359,Dissociation constant was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631344,,BAO_0000100,,
14780,10944,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631345,,BAO_0000218,2385.0,
14781,11080,The dissociation constant determined by fluorescence displacement assay,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631346,,BAO_0000019,,
14782,17805,kd value surface plasmon resonance (SPR) method,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631524,,BAO_0000019,,
14783,10944,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631525,,BAO_0000218,2385.0,
14784,16645,First dissociation constant of the binding of compound to V30M TTR,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631526,,BAO_0000019,,
14785,16645,Second dissociation constant of the binding of compound to V30M TTR,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631527,,BAO_0000019,,
14786,7793,"Compound was evaluated for equilibrium constant, Ke",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631528,,BAO_0000019,,
14787,12199,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,A,,,,,,Hypothalamus,,,22224,U,0,Autocuration,1,,CHEMBL631529,,BAO_0000019,1898.0,
14788,12199,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,A,,,,,,Hypothalamus,,,22224,U,0,Autocuration,1,,CHEMBL631530,,BAO_0000019,1898.0,
14789,9680,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631531,,BAO_0000019,,
14790,9680,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631532,,BAO_0000019,,
14791,9680,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL631533,,BAO_0000019,,
14792,13758,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL876552,,BAO_0000218,,
14793,13758,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631534,,BAO_0000218,,
14794,13758,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631535,,BAO_0000218,,
14795,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631536,,BAO_0000218,,
14796,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631537,,BAO_0000218,,
14797,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631538,,BAO_0000218,,
14798,13758,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631539,,BAO_0000218,,
14799,13758,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,A,,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631540,,BAO_0000218,,
14800,14393,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625637,,BAO_0000218,,
14801,14393,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625638,,BAO_0000218,,
14802,15078,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL625639,,BAO_0000218,,
14803,13925,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625640,,BAO_0000218,955.0,
14804,13925,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625641,,BAO_0000218,955.0,
14805,13925,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625642,,BAO_0000218,948.0,
14806,13925,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625643,,BAO_0000218,948.0,
14807,13925,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625644,,BAO_0000218,2113.0,
14808,13925,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Kidney,,,50597,N,1,Intermediate,1,,CHEMBL625645,,BAO_0000218,2113.0,
14809,13925,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625646,,BAO_0000218,2107.0,
14810,13925,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625647,,BAO_0000218,2107.0,
14811,13925,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625648,,BAO_0000218,2048.0,
14812,13925,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL625649,,BAO_0000218,2048.0,
14813,13925,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625650,,BAO_0000218,2385.0,
14814,13925,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL625651,,BAO_0000218,2385.0,
14815,13925,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL625652,,BAO_0000218,14.0,
14816,13925,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Zone of skin,,,50597,N,1,Intermediate,1,,CHEMBL625653,,BAO_0000218,14.0,
14817,13925,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625654,,BAO_0000218,2106.0,
14818,13925,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL625655,,BAO_0000218,2106.0,
14819,9712,Biodistribution of Compound in rat blood after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625656,,BAO_0000218,178.0,
14820,9712,Biodistribution of Compound in rat blood after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Blood,,,50597,N,1,Intermediate,1,,CHEMBL625657,,BAO_0000218,178.0,
14821,9712,Biodistribution of Compound in rat brain after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625658,,BAO_0000218,955.0,
14822,9712,Biodistribution of Compound in rat brain after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Brain,,,50597,N,1,Intermediate,1,,CHEMBL625659,,BAO_0000218,955.0,
14823,9712,Biodistribution of Compound in rat heart after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625660,,BAO_0000218,948.0,
14824,9712,Biodistribution of Compound in rat heart after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Heart,,,50597,N,1,Intermediate,1,,CHEMBL625661,,BAO_0000218,948.0,
14825,9712,Biodistribution of Compound in rat liver after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625662,,BAO_0000218,2107.0,
14826,9712,Biodistribution of Compound in rat liver after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL625663,,BAO_0000218,2107.0,
14827,9712,Biodistribution of Compound in rat lung after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL875621,,BAO_0000218,2048.0,
14828,9712,Biodistribution of Compound in rat lung after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL628382,,BAO_0000218,2048.0,
14829,9712,Biodistribution of Compound in rat muscle after 15 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL628383,,BAO_0000218,2385.0,
14830,9712,Biodistribution of Compound in rat muscle after 2 minutes of administration,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL628384,,BAO_0000218,2385.0,
14831,13925,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628385,,BAO_0000218,,
14832,13925,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875753,,BAO_0000218,,
14833,13925,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628386,,BAO_0000218,,
14834,6941,Organ distribution in rat blood 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628387,,BAO_0000218,,
14835,6941,Organ distribution in rat blood 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628388,,BAO_0000218,,
14836,6941,Organ distribution in rat blood 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628389,,BAO_0000218,,
14837,6941,Organ distribution in rat blood 30 min after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL632756,,BAO_0000218,,
14838,6941,Organ distribution in rat brain 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628390,,BAO_0000218,,
14839,6941,Organ distribution in rat brain 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631811,,BAO_0000218,,
14840,6941,Organ distribution in rat brain 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631812,,BAO_0000218,,
14841,6941,Organ distribution in rat heart 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631813,,BAO_0000218,,
14842,6941,Organ distribution in rat heart 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631814,,BAO_0000218,,
14843,6941,Organ distribution in rat heart 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631815,,BAO_0000218,,
14844,6941,Organ distribution in rat kidney 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631816,,BAO_0000218,,
14845,6941,Organ distribution in rat kidney 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL875758,,BAO_0000218,,
14846,6941,Organ distribution in rat kidney 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631817,,BAO_0000218,,
14847,6941,Organ distribution in rat liver 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631818,,BAO_0000218,2107.0,
14848,6941,Organ distribution in rat liver 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631819,,BAO_0000218,2107.0,
14849,6941,Organ distribution in rat liver 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL631820,,BAO_0000218,2107.0,
14850,6941,Organ distribution in rat lung 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631821,,BAO_0000218,,
14851,6941,Organ distribution in rat lung 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631822,,BAO_0000218,,
14852,6941,Organ distribution in rat lung 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL631823,,BAO_0000218,,
14853,6941,Organ distribution in rat muscle 2 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631824,,BAO_0000218,2385.0,
14854,6941,Organ distribution in rat muscle 2 hr after intravenous injection,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631825,,BAO_0000218,2385.0,
14855,6941,Organ distribution in rat muscle 30 minutes after intravenous injection,A,,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631826,,BAO_0000218,2385.0,
14856,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631827,,BAO_0000218,,
14857,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631828,,BAO_0000218,,
14858,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL631829,,BAO_0000218,,
14859,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875759,,BAO_0000218,1088.0,
14860,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631830,,BAO_0000218,1088.0,
14861,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631831,,BAO_0000218,1088.0,
14862,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631832,,BAO_0000218,1088.0,
14863,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631833,,BAO_0000218,1088.0,
14864,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631834,,BAO_0000218,1088.0,
14865,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631835,,BAO_0000218,1088.0,
14866,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631836,,BAO_0000218,1088.0,
14867,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631837,,BAO_0000218,1088.0,
14868,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631838,,BAO_0000218,1088.0,
14869,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631839,,BAO_0000218,1088.0,
14870,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631840,,BAO_0000218,1088.0,
14871,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631841,,BAO_0000218,1088.0,
14872,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631842,,BAO_0000218,1088.0,
14873,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631843,,BAO_0000218,1088.0,
14874,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631844,,BAO_0000218,1088.0,
14875,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631845,,BAO_0000218,1088.0,
14876,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631846,,BAO_0000218,1088.0,
14877,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL875760,,BAO_0000218,1088.0,
14878,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL632199,,BAO_0000218,1088.0,
14879,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631847,,BAO_0000218,1088.0,
14880,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL631848,,BAO_0000218,1088.0,
14881,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628707,,BAO_0000218,1088.0,
14882,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628708,,BAO_0000218,1088.0,
14883,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628709,,BAO_0000218,1088.0,
14884,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628710,,BAO_0000218,1088.0,
14885,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628711,,BAO_0000218,1088.0,
14886,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628712,,BAO_0000218,1088.0,
14887,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628713,,BAO_0000218,1088.0,
14888,12582,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,A,,,Rattus norvegicus,10116.0,,Urine,,,50597,N,1,Intermediate,1,,CHEMBL628714,,BAO_0000218,1088.0,
14889,7415,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL628715,,BAO_0000218,,
14890,7313,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629179,,BAO_0000019,,
14891,7313,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629180,,BAO_0000019,,
14892,7313,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL875108,,BAO_0000019,,
14893,7570,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,,,,Adrenal cortex,,,22224,U,0,Autocuration,1,,CHEMBL629181,,BAO_0000019,1235.0,
14894,7570,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,A,,,,,,Adrenal cortex,,,22224,U,0,Autocuration,1,,CHEMBL629182,,BAO_0000019,1235.0,
14895,7570,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629183,,BAO_0000019,,
14896,7570,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629184,,BAO_0000019,,
14897,7570,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,,,,Adrenal cortex,,,22224,U,0,Autocuration,1,,CHEMBL629185,,BAO_0000019,1235.0,
14898,7570,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,A,,,,,,Adrenal cortex,,,22224,U,0,Autocuration,1,,CHEMBL629186,,BAO_0000019,1235.0,
14899,7570,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629187,,BAO_0000019,,
14900,7570,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629887,,BAO_0000019,,
14901,7570,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629888,,BAO_0000019,,
14902,7570,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629889,,BAO_0000019,,
14903,7570,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,A,,,,,,Adrenal cortex,,,22224,U,0,Autocuration,1,,CHEMBL629890,,BAO_0000019,1235.0,
14904,7570,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629891,,BAO_0000019,,
14905,7570,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629892,,BAO_0000019,,
14906,7570,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,A,,,,,,Adrenal cortex,,,22224,U,0,Autocuration,1,,CHEMBL629893,,BAO_0000019,1235.0,
14907,7570,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629894,,BAO_0000019,,
14908,7570,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629895,,BAO_0000019,,
14909,14122,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",A,In vivo,,Canis lupus familiaris,9615.0,,,,,22224,U,0,Autocuration,1,,CHEMBL875109,,BAO_0000218,,
14910,16449,Absolute bioavailability in male cynomolgus monkeys,A,In vivo,,Macaca fascicularis,9541.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629896,,BAO_0000218,,
14911,16449,Absolute bioavailability in maleSprague-Dawley rats,A,In vivo,,Rattus norvegicus,10116.0,,,,,22224,U,0,Autocuration,1,,CHEMBL629897,,BAO_0000218,,
14912,12017,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL629898,,BAO_0000218,2107.0,
14913,12017,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL630057,,BAO_0000218,2107.0,
14914,12017,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Liver,,,50597,N,1,Intermediate,1,,CHEMBL630058,,BAO_0000218,2107.0,
14915,12017,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630059,,BAO_0000218,2048.0,
14916,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630060,,BAO_0000218,2048.0,
14917,12017,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630061,,BAO_0000218,2048.0,
14918,12017,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630062,,BAO_0000218,2048.0,
14919,12017,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630063,,BAO_0000218,2048.0,
14920,12017,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630064,,BAO_0000218,2048.0,
14921,12017,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630065,,BAO_0000218,2048.0,
14922,12017,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630066,,BAO_0000218,2048.0,
14923,12017,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630067,,BAO_0000218,2048.0,
14924,12017,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Lung,,,50597,N,1,Intermediate,1,,CHEMBL630068,,BAO_0000218,2048.0,
14925,12017,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631113,,BAO_0000218,2385.0,
14926,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631114,,BAO_0000218,2385.0,
14927,12017,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631115,,BAO_0000218,2385.0,
14928,12017,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL631116,,BAO_0000218,2385.0,
14929,12017,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630528,,BAO_0000218,2385.0,
14930,12017,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630529,,BAO_0000218,2385.0,
14931,12017,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630530,,BAO_0000218,2385.0,
14932,12017,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630531,,BAO_0000218,2385.0,
14933,12017,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630532,,BAO_0000218,2385.0,
14934,12017,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Muscle tissue,,,50597,N,1,Intermediate,1,,CHEMBL630533,,BAO_0000218,2385.0,
14935,15045,Biodistribution in normal mice blood after 120 hr,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL630534,,BAO_0000218,178.0,
14936,15045,Biodistribution in normal mice blood after 24 hr,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL630535,,BAO_0000218,178.0,
14937,15045,Biodistribution in normal mice blood after 4 hr,A,In vivo,,Mus musculus,10090.0,,Blood,,,50594,N,1,Intermediate,1,,CHEMBL630536,,BAO_0000218,178.0,
14938,15045,Biodistribution in normal mice bone after 120 hr,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL630537,,BAO_0000218,10000001.0,
14939,15045,Biodistribution in normal mice bone after 24 hr,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL630538,,BAO_0000218,10000001.0,
14940,15045,Biodistribution in normal mice bone after 4 hr,A,In vivo,,Mus musculus,10090.0,,Bone,,,50594,N,1,Intermediate,1,,CHEMBL630539,,BAO_0000218,10000001.0,
14941,15045,Biodistribution in normal mice heart after 120 hr,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL630540,,BAO_0000218,948.0,
14942,15045,Biodistribution in normal mice heart after 24 hr,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL630541,,BAO_0000218,948.0,
14943,15045,Biodistribution in normal mice heart after 4 hr,A,In vivo,,Mus musculus,10090.0,,Heart,,,50594,N,1,Intermediate,1,,CHEMBL630542,,BAO_0000218,948.0,
14944,15045,Biodistribution in normal mice kidney after 120 hr,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL630543,,BAO_0000218,2113.0,
14945,15045,Biodistribution in normal mice kidney after 24 hr,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL630544,,BAO_0000218,2113.0,
14946,15045,Biodistribution in normal mice kidney after 4 hr,A,In vivo,,Mus musculus,10090.0,,Kidney,,,50594,N,1,Intermediate,1,,CHEMBL630545,,BAO_0000218,2113.0,
14947,15045,Biodistribution in normal mice liver after 120 hr,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL630546,,BAO_0000218,2107.0,
14948,15045,Biodistribution in normal mice liver after 24 hr,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL630547,,BAO_0000218,2107.0,
14949,15045,Biodistribution in normal mice liver after 4 hr,A,In vivo,,Mus musculus,10090.0,,Liver,,,50594,N,1,Intermediate,1,,CHEMBL630548,,BAO_0000218,2107.0,
14950,15045,Biodistribution in normal mice spleen after 120 hr,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL630549,,BAO_0000218,2106.0,
14951,15045,Biodistribution in normal mice spleen after 24 hr,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL630550,,BAO_0000218,2106.0,
14952,15045,Biodistribution in normal mice spleen after 4 hr,A,In vivo,,Mus musculus,10090.0,,Spleen,,,50594,N,1,Intermediate,1,,CHEMBL876426,,BAO_0000218,2106.0,
14953,12017,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630551,,BAO_0000218,2106.0,
14954,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630552,,BAO_0000218,2106.0,
14955,12017,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630553,,BAO_0000218,2106.0,
14956,12017,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630554,,BAO_0000218,2106.0,
14957,12017,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630555,,BAO_0000218,2106.0,
14958,12017,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630556,,BAO_0000218,2106.0,
14959,12017,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630557,,BAO_0000218,2106.0,
14960,12017,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630558,,BAO_0000218,2106.0,
14961,12017,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630559,,BAO_0000218,2106.0,
14962,12017,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Spleen,,,50597,N,1,Intermediate,1,,CHEMBL630560,,BAO_0000218,2106.0,
14963,12017,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,A,In vivo,,Rattus norvegicus,10116.0,,Thyroid gland,,,50597,N,1,Intermediate,1,,CHEMBL876427,,BAO_0000218,2046.0,
14964,14941,The Kel values in female wistar rats.,A,,,Rattus norvegicus,10116.0,,,,,50597,N,1,Intermediate,1,,CHEMBL630561,,BAO_0000218,,
14965,4646,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630562,,BAO_0000019,,
14966,8847,Hydrolysis rate constant of the compound,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL630563,,BAO_0000019,,
14967,11778,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,P,,,,,,,,,22229,U,0,Autocuration,1,,CHEMBL629673,,BAO_0000100,,
14968,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629674,,BAO_0000019,,
14969,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629675,,BAO_0000019,,
14970,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629676,,BAO_0000019,,
14971,2363,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629677,,BAO_0000019,,
14972,8371,Apparent inactivation rate constant was evaluated,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629678,,BAO_0000019,,
14973,14883,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629679,,BAO_0000019,,
14974,14883,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629680,,BAO_0000019,,
14975,4643,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629681,,BAO_0000019,,
14976,3519,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629682,,BAO_0000019,,
14977,10600,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629683,,BAO_0000019,,
14978,8501,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,F,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629684,,BAO_0000019,,
14979,8505,Dissociation constant was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629685,,BAO_0000100,,
14980,9778,Dissociation constant was determined,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629686,,BAO_0000100,,
14981,9778,Dissociation constant at pH 7.4,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL872932,,BAO_0000100,,
14982,9778,Dissociation constant in presence of 1 mM dithiothreitol,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL629687,,BAO_0000100,,
14983,13007,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL872931,,BAO_0000019,,
14984,13007,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628151,,BAO_0000019,,
14985,13007,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628152,,BAO_0000019,,
14986,13007,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628153,,BAO_0000019,,
14987,11482,Kinetic constant for aromatization of androstenedione,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628154,,BAO_0000019,,
14988,11482,Kinetic constant for aromatization of testosterone,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628155,,BAO_0000019,,
14989,2303,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628156,,BAO_0000019,,
14990,11964,Local inhibition constant was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628157,,BAO_0000019,,
14991,3140,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,A,,,Saccharomyces cerevisiae,4932.0,,,,,50347,N,1,Intermediate,1,,CHEMBL857533,,BAO_0000218,,
14992,10650,Dissociation constant value of the compound,P,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628158,,BAO_0000100,,
14993,4667,In vitro permeability through cornea without epithelium,A,,,,,,Cornea,,,22224,U,0,Autocuration,1,,CHEMBL628159,,BAO_0000019,964.0,
14994,4667,In vitro permeability through intact cornea,A,,,,,,Cornea,,,22224,U,0,Autocuration,1,,CHEMBL875616,,BAO_0000019,964.0,
14995,9199,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,A,,,Oryctolagus cuniculus,9986.0,,Cornea,,,50592,N,1,Intermediate,1,,CHEMBL628160,,BAO_0000218,964.0,
14996,11966,Rate of enzyme inactivation for the compound was determined,A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628161,,BAO_0000019,,
14997,4667,In vitro permeability through cornea without epithelium,A,,,,,,Cornea,,,22224,U,0,Autocuration,1,,CHEMBL628162,,BAO_0000019,964.0,
14998,4667,In vitro permeability through intact cornea,A,,,,,,Cornea,,,22224,U,0,Autocuration,1,,CHEMBL628163,,BAO_0000019,964.0,
14999,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628164,,BAO_0000019,,
15000,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628165,,BAO_0000019,,
15001,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628166,,BAO_0000019,,
15002,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628167,,BAO_0000019,,
15003,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628168,,BAO_0000019,,
15004,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628169,,BAO_0000019,,
15005,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628170,,BAO_0000019,,
15006,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628171,,BAO_0000019,,
15007,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627434,,BAO_0000019,,
15008,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL627435,,BAO_0000019,,
15009,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628110,,BAO_0000019,,
15010,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628111,,BAO_0000019,,
15011,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628112,,BAO_0000019,,
15012,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628260,,BAO_0000019,,
15013,8354,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",A,,,,,,,,,22224,U,0,Autocuration,1,,CHEMBL628261,,BAO_0000019,,
15014,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628262,,BAO_0000218,,
15015,14439,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Homo sapiens,9606.0,,,,,50587,N,1,Intermediate,1,,CHEMBL628263,,BAO_0000218,,
15016,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628264,,BAO_0000218,,
15017,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628265,,BAO_0000218,,
15018,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628266,,BAO_0000218,,
15019,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628267,,BAO_0000218,,
15020,14439,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628268,,BAO_0000218,,
15021,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628269,,BAO_0000218,,
15022,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628270,,BAO_0000218,,
15023,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628271,,BAO_0000218,,
15024,14439,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),A,In vivo,,Mus musculus,10090.0,,,,,50594,N,1,Intermediate,1,,CHEMBL628272,,BAO_0000218,,
